dokumendiregister.ee
OtsingAsutusedMCP
Otsing›Sotsiaalministeerium
Muu lepingAvalik

Leping

Sotsiaalministeerium · 18. detsember 2018
Viit
1.8-2/785-1
Registreeritud
18. detsember 2018
Dokumendi liik
Muu leping
Funktsioon
1.8 Finantsplaneerimine ja raamatupidamisarvestus
Sari
1.8-2 Lepingud (töövõtt ja käsundus juriidiliste isikutega, koostöölepe kulude hüvitamiseks, haldus, liising, üür-rent, kindlustus, müük, litsentsid, ost, varaline vastutus, varakasutus, andmevahetus) koos aktidega
Toimik
1.8-2/2023
Vastutaja
Ruth Paju (Sotsiaalministeerium, Kantsleri vastutusvaldkond)

Failid

  • 📎Grant Agreement-825575-EJP RD.pdf12225 KB

Sisu (failidest)

Grant Agreement number: 825575 — EJP RD — H2020-SC1-BHC-2018-2020/H2020-SC1-2018-Single-Stage-RTD H2020 Associated with MGARef. document EJP Cofund — Multi:-v5.0 Ares(2018)6091977 28/11/2018 EUROPEAN COMMISSION DIRECTORATE-GENERAL RESEARCH & INNOVATION Health Innovative and Personalised Medicine GRANT AGREEMENT NUMBER 825575 — EJP RD This Agreement (‘the Agreement’) is between the following parties: on the one part, the European Union (‘the EU’), represented by the European Commission ('the Commission'), represented for the purposes of signature of this Agreement by the Head of Unit, DIRECTORATE- GENERAL RESEARCH & INNOVATION, Health, Administration and finance, Mila BAS SANCHEZ, and on the other part, 1. ‘the coordinator’: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), established in RUE DE TOLBIAC 101, PARIS 75654, France, VAT number: FR31180036048, represented for the purposes of signing the Agreement by Regional Delegate of Inserm, Camille CHAUDONNERET and the following other beneficiaries, if they sign their ‘Accession Form’ (see Annex 3 and Article 56): 2. FONDS ZUR FÖRDERUNG DER WISSENSCHAFTLICHEN FORSCHUNG (FWF), established in SENSENGASSE 1, WIEN 1090, Austria, VAT number: ATU37675903, 3. AIT AUSTRIAN INSTITUTE OF TECHNOLOGY GMBH (AIT), established in GIEFINGGASSE 4, WIEN 1210, Austria, VAT number: ATU14703506, 4. LUDWIG BOLTZMANN GESELLSCHAFT GMBH (LBG (LBI-RUD)), established in NUSSDORFER STRASSE 64 6 STOCK, WIEN 1090, Austria, VAT number: ATU61640503, 5. FONDS NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FNRS), established in Rue d'Egmont 5, BRUXELLES 1050, Belgium, 6. FONDS VOOR WETENSCHAPPELIJK ONDERZOEK-VLAANDEREN (FWO), established in EGMONTSTRAAT 5, BRUSSEL 1000, Belgium, VAT number: BE0880212840, 7. KATHOLIEKE UNIVERSITEIT LEUVEN (KU Leuven), established in OUDE MARKT 13, LEUVEN 3000, Belgium, VAT number: BE0419052173, 1 Grant Agreement number: 825575 — EJP RD — H2020-SC1-BHC-2018-2020/H2020-SC1-2018-Single-Stage-RTD H2020 Associated with MGARef. document EJP Cofund — Multi:-v5.0 Ares(2018)6091977 28/11/2018 8. MINISTRY OF EDUCATION YOUTH AND SPORTS (MEYS), established in Karmelitska 7, Prague 118 12, Czech Republic, 9. SOTSIAALMINISTEERIUM (MOSAE), established in Suur-Ameerika 1, TALLINN 10122, Estonia, 10. SUOMEN AKATEMIA (AKA), established in HAKANIEMENRANTA 6, HELSINKI 00531, Finland, VAT number: FI02458939, 11. AGENCE NATIONALE DE LA RECHERCHE (ANR), established in 50 avenue Daumesnil, PARIS 75012, France, 12. FONDATION MALADIES RARES (FFRD), established in RUE DIDOT 96, PARIS 75014, France, 13. ASS FRANCAISE CONTRE LES MYOPATHIES (AFM), established in 47-83 47 BOULEVARD DE L'HOPITAL, INSTITUT DE MYOLO, PARIS 75013, France, VAT number: FR00775609571, 14. IMAGINE INSTITUT DES MALADIES GENETIQUES NECKER ENFANTS MALADES FONDATION (IMAGINE), established in RUE DE VAUGIRARD 156, PARIS 75015, France, 15. DEUTSCHES ZENTRUM FUER LUFT - UND RAUMFAHRT EV (DLR), established in Linder Hoehe, KOELN 51147, Germany, 16. UNIVERSITAETSKLINIKUM AACHEN (UKA), established in Pauwelsstrasse 30, AACHEN 52074, Germany, VAT number: DE813100566, 17. CHARITE - UNIVERSITAETSMEDIZIN BERLIN (CHARITE), established in Chariteplatz 1, BERLIN 10117, Germany, VAT number: DE228847810, 18. UNIVERSITAETSKLINIKUM FREIBURG (UKL-FR), established in HUGSTETTER STRASSE 49, FREIBURG 79106, Germany, VAT number: DE811506626, 19. NEMZETI KUTATASI FEJLESZTESI ES INNOVACIOS HIVATAL (NKFIH), established in KETHLY ANNA TER 1, BUDAPEST 1077, Hungary, VAT number: HU15831000, 20. THE HEALTH RESEARCH BOARD (HRB), established in LOWER BAGGOT STREET 73, DUBLIN 2, Ireland, VAT number: IE4820764P, 21. MINISTERO DELLA SALUTE (IT-MOH), established in Via Giorgio Ribotta 5, ROMA 00144, Italy, VAT number: N/A, 22. REGIONE TOSCANA (TuscReg), established in Palazzo Strozzi Sacrati - Piazza del Duomo 10, FIRENZE 50122, Italy, VAT number: IT01386030488, 23. FONDAZIONE REGIONALE PER LA RICERCA BIOMEDICA (FRRB), established in PIAZZA CITTA DI LOMBARDIA 1, MILANO 20124, Italy, VAT number: IT97608860157, 24. FONDAZIONE PER LA RICERCA FARMACOLOGICA GIANNI BENZI ONLUS (FGB), established in VIA ABATE EUSTASIO 30, VALENZANO BARI 70010, Italy, VAT number: IT06780820723, 2 Grant Agreement number: 825575 — EJP RD — H2020-SC1-BHC-2018-2020/H2020-SC1-2018-Single-Stage-RTD H2020 Associated with MGARef. document EJP Cofund — Multi:-v5.0 Ares(2018)6091977 28/11/2018 25. FONDAZIONE TELETHON (FTELE), established in VIA VARESE 16/B, ROMA 00185, Italy, VAT number: IT04879781005, 26. ISTITUTO SUPERIORE DI SANITA (ISS), established in Viale Regina Elena 299, ROMA 00161, Italy, VAT number: IT03657731000, 27. CONSORZIO PER VALUTAZIONI BIOLOGICHE E FARMACOLOGICHE (CVBF), established in VIA NICOLO PUTIGNANI 178, BARI 70122, Italy, VAT number: IT01897720189, 28. TEDDY - EUROPEAN NETWORK OF EXCELLENCE FOR PAEDIATRIC CLINICAL RESEARCH (TEDDY), established in VIA LUIGI PORTA 14, PAVIA 231261, Italy, VAT number: IT01825900184, 29. MINISTERO DELL'ISTRUZIONE, DELL'UNIVERSITA' E DELLA RICERCA (MIUR), established in Via Michele Carcani 61, ROMA 00153, Italy, VAT number: IT97429780584, 30. VALSTS IZGLITIBAS ATTISTIBAS AGENTURA (VIAA), established in VALNU IELA 1, RIGA 1050, Latvia, 31. Lietuvos mokslo taryba (LMT), established in Gedimino 3, Vilnius LT-01103, Lithuania, 32. VIESOJI ISTAIGA VILNIAUS UNIVERSITETO LIGONINE SANTAROS KLINIKOS (VUHSK), established in SANTARISKIU G 2, VILNIUS 08661, Lithuania, VAT number: LT243645610, 33. FONDS NATIONAL DE LA RECHERCHE (FNR), established in 2 AVENUE DE L'UNIVERSITE, ESCH-SUR-ALZETTE 4365, Luxembourg, VAT number: LU20686731, 34. ZORGONDERZOEK NEDERLAND ZON (ZonMw), established in Laan Van Nieuw Oost Indie 334, DEN HAAG 2593CE, Netherlands, 35. ACADEMISCH ZIEKENHUIS GRONINGEN (UMCG), established in HANZEPLEIN 1, GRONINGEN 9713 GZ, Netherlands, VAT number: NL800866393B01, 36. UNIVERSITEIT MAASTRICHT (UM), established in Minderbroedersberg 4-6, MAASTRICHT 6200 MD, Netherlands, 37. NARODOWE CENTRUM BADAN I ROZWOJU (NCBR), established in UL. NOWOGRODZKA 47A, WARSZAWA 00 695, Poland, VAT number: PL7010073777, 38. WARSZAWSKI UNIWERSYTET MEDYCZNY (MUW), established in UL. ZWIRKI I WIGURY 61, WARSZAWA 02 091, Poland, VAT number: PL5250005828, 39. GDANSKI UNIWERSYTET MEDYCZNY (MUG), established in ULICA M SKLODOWSKIEJ CURIE 3A, GDANSK 80210, Poland, 40. INSTYTUT POMNIK CENTRUM ZDROWIA DZIECKA (IPCZD), established in Aleja Dzieci Polskich 20, WARSZAWA 04730, Poland, VAT number: PL9521143675, 41. FUNDACAO PARA A CIENCIA E A TECNOLOGIA (FCT), established in AVENIDA D CARLOS I 126, LISBOA 1249 074, Portugal, VAT number: PT503904040, 3 Grant Agreement number: 825575 — EJP RD — H2020-SC1-BHC-2018-2020/H2020-SC1-2018-Single-Stage-RTD H2020 Associated with MGARef. document EJP Cofund — Multi:-v5.0 Ares(2018)6091977 28/11/2018 42. INSTITUTO NACIONAL DE SAUDE DR. RICARDO JORGE (INSA), established in AVENIDA PADRE CRUZ, LISBOA 1600 560, Portugal, VAT number: PT501427511, 43. SLOVENSKA AKADEMIA VIED (SAS), established in STEFANIKOVA 49, BRATISLAVA 814 38, Slovakia, VAT number: N/A, 44. INSTITUTO DE SALUD CARLOS III (ISCIII), established in MONFORTE DE LEMOS 5, MADRID 28029, Spain, VAT number: ESQ2827015E, 45. FUNDACIO CENTRE DE REGULACIO GENOMICA (CNAG-CRG), established in CARRER DOCTOR AIGUADER 88, BARCELONA 08003, Spain, VAT number: ESG62426937, 46. UNIVERSIDAD POLITECNICA DE MADRID (UPM), established in CALLE RAMIRO DE MAEZTU 7 EDIFICIO RECTORADO, MADRID 28040, Spain, VAT number: ESQ2818015F, 47. CONSORCIO CENTRO DE INVESTIGACION BIOMEDICA EN RED M.P. (CIBER), established in CALLE MONFORTE DE LEMOS 5, MADRID 28029, Spain, VAT number: ESG85296226, 48. VETENSKAPSRADET - SWEDISH RESEARCH COUNCIL (SRC), established in VASTRA JARNVAGSGATAN 3, STOCKHOLM 111 64, Sweden, VAT number: SE202100520801, 49. VERKET FÖR INNOVATIONSSYSTEM (VINNOVA), established in Mäster Samuelsgatan 56, STOCKHOLM 10158, Sweden, VAT number: SE202100521601, 50. UNIVERSITY OF LEICESTER (ULEIC), established in UNIVERSITY ROAD, LEICESTER LE1 7RH, United Kingdom, VAT number: GB916583894, 51. THE UNIVERSITY OF LIVERPOOL (ULIV), established in BROWNLOW HILL 765 FOUNDATION BUILDING, LIVERPOOL L69 7ZX, United Kingdom, VAT number: GB673598875, 52. UNIVERSITY OF NEWCASTLE UPON TYNE (UNEW), established in KINGS GATE, NEWCASTLE UPON TYNE NE1 7RU, United Kingdom, VAT number: GB499672470, 53. ST. ANNA KINDERKREBSFORSCHUNG (CCRI), established in ZIMMERMANNPLATZ 10, WIEN 1090, Austria, VAT number: ATU16377105, 54. ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP), established in 3 Avenue Victoria, PARIS 75004, France, VAT number: FR95267500452, 55. HOPITAUX UNIVERSITAIRES DE STRASBOURG (HUS), established in PLACE DE L HOPITAL 1, STRASBOURG CEDEX 67091, France, VAT number: FR47266700574, 56. CENTRE ANTICANCEREUX LEON BERARD (CLB), established in RUE LAENNEC 28, LYON 69373, France, 57. UNIVERSITAETSKLINIKUM HEIDELBERG (UKL-HD), established in IM NEUENHEIMER FELD 672, HEIDELBERG 69120, Germany, VAT number: DE143293939, 58. EBERHARD KARLS UNIVERSITAET TUEBINGEN (EKUT), established in GESCHWISTER-SCHOLL-PLATZ, TUEBINGEN 72074, Germany, VAT number: DE812383453, 4 Grant Agreement number: 825575 — EJP RD — H2020-SC1-BHC-2018-2020/H2020-SC1-2018-Single-Stage-RTD H2020 Associated with MGARef. document EJP Cofund — Multi:-v5.0 Ares(2018)6091977 28/11/2018 59. JOHANN WOLFGANG GOETHE-UNIVERSITATFRANKFURT AM MAIN (GUF), established in THEODOR W ADORNO PLATZ 1, FRANKFURT AM MAIN 60629, Germany, VAT number: DE114110511, 60. HELIOS DR. HORST SCHMIDT KLINIKEN WIESBADEN GMBH (HSK), established in LUDWIG ERHARD STRASSE 100, WIESBADEN 65199, Germany, VAT number: DE183092254, 61. ISTITUTO ORTOPEDICO RIZZOLI (IOR), established in VIA DI BARBIANO 1/10, BOLOGNA 40136, Italy, VAT number: IT00302030374, 62. AZIENDA OSPEDALIERO UNIVERSITARIA PISANA (AOUP), established in VIA ROMA 67, PISA 56123, Italy, VAT number: IT01310860505, 63. AZIENDA OSPEDALIERA UNIVERSITARIA SENESE (AOUS), established in STRADA DELLE SCOTTE 14, SIENA 53100, Italy, VAT number: IT00388300527, 64. ACADEMISCH ZIEKENHUIS LEIDEN (LUMC), established in ALBINUSDREEF 2, LEIDEN 2333 ZA, Netherlands, VAT number: NL003566213B01, 65. STICHTING KATHOLIEKE UNIVERSITEIT (Radboudumc), established in GEERT GROOTEPLEIN NOORD 9, NIJMEGEN 6525 EZ, Netherlands, VAT number: NL002968721B01, 66. Academisch Medisch Centrum bij de Universiteit van Amsterdam (AMC), established in MEIBERGDREEF 9, AMSTERDAM 1105AZ, Netherlands, VAT number: NL004627672B01, 67. ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM (ERASMUS MC), established in DR. MOLEWATERPLEIN 40, ROTTERDAM 3015 GD, Netherlands, VAT number: NL807181997B01, 68. SERVICIO MADRILENO DE SALUD (SERMAS), established in PLAZA CARLOS TRIAS BERTRAN 7, MADRID 28020, Spain, VAT number: ESQ2801221I, 69. THE NEWCASTLE UPON TYNE HOSPITALS NHS FOUNDATION TRUST (NUTH), established in FREEMAN HOSPITAL, HIGH HEATON, NEWCASTLE-UPON-TYNE NE7 7DN, United Kingdom, VAT number: GB654968777, 70. GREAT ORMOND STREET HOSPITAL FOR CHILDREN NATIONAL HEALTH SERVICE TRUST (GOSH), established in GREAT ORMOND STREET, LONDON WC1N 3JH, United Kingdom, VAT number: GB654922910, 71. EUROPEAN ORGANISATION FOR RESEARCH AND TREATMENT OF CANCER AISBL (EORTC), established in Avenue E. Mounier 83, Brussels 1200, Belgium, VAT number: BE0408292992, 72. INFRAFRONTIER GMBH (INFRAFRONTIER), established in INGOLSTADTER LANDSTRASSE 1, NEUHERBERG 85764, Germany, VAT number: DE291307064, 73. BIOBANKS AND BIOMOLECULAR RESOURCESRESEARCH INFRASTRUCTURE CONSORTIUM(BBMRI-ERIC) (BBMRI), established in NEUE STIFTINGTALSTRASSE 2/B/6, GRAZ 8010, Austria, VAT number: ATU68520549, 5 Grant Agreement number: 825575 — EJP RD — H2020-SC1-BHC-2018-2020/H2020-SC1-2018-Single-Stage-RTD H2020 Associated with MGARef. document EJP Cofund — Multi:-v5.0 Ares(2018)6091977 28/11/2018 74. ECRIN EUROPEAN CLINICAL RESEARCH INFRASTRUCTURE NETWORK (ECRIN), established in 5 RUE WATT, PARIS 75013, France, VAT number: FR91801933235, 75. EATRIS ERIC (EATRIS), established in DE BOELELAAN 1118, AMSTERDAM 1081 HZ, Netherlands, VAT number: NL853383054B01, 76. EUROPEAN MOLECULAR BIOLOGY LABORATORY (EMBL), established in Meyerhofstrasse 1, HEIDELBERG 69117, Germany, 77. EURORDIS - EUROPEAN ORGANISATION FOR RARE DISEASES ASSOCIATION (EURORDIS), established in RUE DIDOT 96, Paris 75014, France, 78. MINISTRY OF HEALTH (CSO-MOH), established in YIRMIYAHU 39, JERUSALEM 9101002, Israel, 79. SCHWEIZERISCHER NATIONALFONDS ZUR FORDERUNG DER WISSENSCHAFTLICHEN FORSCHUNG (SNSF), established in Wildhainweg 3, Bern 3012, Switzerland, VAT number: CH249693, 80. BLACKSWAN FOUNDATION (Blackswan), established in CHEMIN DE LA RIAZ 11, VUARRENS 1418, Switzerland, 81. TURKIYE BILIMSEL VE TEKNOLOJIK ARASTIRMA KURUMU (TUBITAK), established in Ataturk Bulvari 221, ANKARA 06100, Turkey, VAT number: TR1750003600, 82. ACIBADEM UNIVERSITESI (ACURARE), established in ICERENKOY MAH. KAYISDAGI CAD. NO/32 ATASEHIR, ISTANBUL 34752, Turkey, VAT number: TR0050521966, 83. HACETTEPE UNIVERSITESI (HUGEN), established in HACETTEPE UNIVERSITESI BEYTEPE KAMPUSU REKTORLUK BINASI, CANKAYA ANKARA 06800, Turkey, 84. CANADIAN INSTITUTES OF HEALTH RESEARCH (CIHR), established in ELGIN STREET 9TH FLOOR ADDRESS LOCATOR 4809A 160, OTTAWA ONTARIO K1T 4H8, Canada, as ‘beneficiary not receiving EU funding’ (see Article 9), 85. FONDS DE RECHERCHE DU QUEBEC - SANTE (FRQS), established in RUE SHERBROOKE OUEST 500, MONTREAL QUEBEC H3A3C6, Canada, as ‘beneficiary not receiving EU funding’ (see Article 9), 86. INSERM TRANSFERT SA (IT), established in RUE WATT 7, PARIS 75013, France, 87. GENIKI GRAMMATIA EREVNAS KAI TECHNOLOGIAS (GSRT), established in Mesogeion Avenue 14-18, ATHENS 11510, Greece, 88. DEUTSCHE FORSCHUNGSGEMEINSCHAFT (DFG), established in Kennedyallee 40, BONN 53175, Germany, VAT number: DE122276357, as ‘beneficiary not receiving EU funding’ (see Article 9), Unless otherwise specified, references to ‘beneficiary’ or ‘beneficiaries’ include the coordinator. The parties referred to above have agreed to enter into the Agreement under the terms and conditions below. 6 Grant Agreement number: 825575 — EJP RD — H2020-SC1-BHC-2018-2020/H2020-SC1-2018-Single-Stage-RTD H2020 Associated with MGARef. document EJP Cofund — Multi:-v5.0 Ares(2018)6091977 28/11/2018 By signing the Agreement or the Accession Form, the beneficiaries accept the grant and agree to implement it under their own responsibility and in accordance with the Agreement, with all the obligations and conditions it sets out. The Agreement is composed of: Terms and Conditions Annex 1 Description of the action Annex 2 Estimated budget for the action 2a Additional information on the estimated budget Annex 3 Accession Forms Annex 4 Model for the financial statements Annex 5 Model for the certificate on the financial statements Annex 6 Model for the certificate on the methodology Annex 7 Annual work plan for the next year Annex 8 Model for the statement on the use of the previous pre-financing payment 7 Grant Agreement number: 825575 — EJP RD — H2020-SC1-BHC-2018-2020/H2020-SC1-2018-Single-Stage-RTD H2020 Associated with MGARef. document EJP Cofund — Multi:-v5.0 Ares(2018)6091977 28/11/2018 TERMS AND CONDITIONS TABLE OF CONTENTS CHAPTER 1 GENERAL..............................................................................................................................................16 ARTICLE 1 — SUBJECT OF THE AGREEMENT.......................................................................................16 CHAPTER 2 ACTION................................................................................................................................................. 16 ARTICLE 2 — ACTION TO BE IMPLEMENTED ......................................................................................16 ARTICLE 3 — DURATION AND STARTING DATE OF THE ACTION....................................................16 ARTICLE 4 — ESTIMATED BUDGET AND BUDGET TRANSFERS.......................................................16 4.1 Estimated budget................................................................................................................................ 16 4.2 Budget transfers..................................................................................................................................16 CHAPTER 3 GRANT...................................................................................................................................................16 ARTICLE 5 — GRANT AMOUNT, FORM OF GRANT, REIMBURSEMENT RATES AND FORMS OF COSTS............................................................................................................................................16 5.1 Maximum grant amount..................................................................................................................... 16 5.2 Form of grant, reimbursement rates and forms of costs....................................................................16 5.3 Final grant amount — Calculation.....................................................................................................17 5.4 Revised final grant amount — Calculation....................................................................................... 19 ARTICLE 6 — ELIGIBLE AND INELIGIBLE COSTS................................................................................19 6.1 General conditions for costs to be eligible........................................................................................ 19 6.2 Specific conditions for costs to be eligible........................................................................................20 6.3 Conditions for costs of linked third parties to be eligible................................................................. 27 6.4 Conditions for in-kind contributions provided by third parties free of charge to be eligible............. 27 6.5 Ineligible costs....................................................................................................................................27 6.6 Consequences of declaration of ineligible costs................................................................................ 27 CHAPTER 4 RIGHTS AND OBLIGATIONS OF THE PARTIES........................................................................ 28 SECTION 1 RIGHTS AND OBLIGATIONS RELATED TO IMPLEMENTING THE ACTION................ 28 ARTICLE 7 — GENERAL OBLIGATION TO PROPERLY IMPLEMENT THE ACTION.........................28 7.1 General obligation to properly implement the action........................................................................ 28 7.2 Consequences of non-compliance...................................................................................................... 28 ARTICLE 8 — RESOURCES TO IMPLEMENT THE ACTION — THIRD PARTIES INVOLVED IN THE ACTION.........................................................................................................................................28 ARTICLE 9 — IMPLEMENTATION OF ACTION TASKS BY BENEFICIARIES NOT RECEIVING EU FUNDING...................................................................................................................................... 28 9.1 Rules for the implementation of action tasks by beneficiaries not receiving EU funding................. 28 8 Grant Agreement number: 825575 — EJP RD — H2020-SC1-BHC-2018-2020/H2020-SC1-2018-Single-Stage-RTD H2020 Associated with MGARef. document EJP Cofund — Multi:-v5.0 Ares(2018)6091977 28/11/2018 9.2 Consequences of non-compliance...................................................................................................... 29 ARTICLE 10 — PURCHASE OF GOODS, WORKS OR SERVICES..........................................................29 10.1 Rules for purchasing goods, works or services............................................................................... 29 10.2 Consequences of non-compliance.................................................................................................... 29 ARTICLE 11 — USE OF IN-KIND CONTRIBUTIONS PROVIDED BY THIRD PARTIES AGAINST PAYMENT..................................................................................................................................... 30 11.1 Rules for the use of in-kind contributions against payment............................................................ 30 11.2 Consequences of non-compliance.................................................................................................... 30 ARTICLE 12 — USE OF IN-KIND CONTRIBUTIONS PROVIDED BY THIRD PARTIES FREE OF CHARGE........................................................................................................................................30 12.1 Rules for the use of in-kind contributions free of charge................................................................30 12.2 Consequences of non-compliance.................................................................................................... 31 ARTICLE 13 — IMPLEMENTATION OF ACTION TASKS BY SUBCONTRACTORS............................31 13.1 Rules for subcontracting action tasks.............................................................................................. 31 13.2 Consequences of non-compliance.................................................................................................... 32 ARTICLE 14 — IMPLEMENTATION OF ACTION TASKS BY LINKED THIRD PARTIES.................... 32 14.1 Rules for calling upon linked third parties to implement part of the action.................................... 32 14.2 Consequences of non-compliance.................................................................................................... 35 ARTICLE 14a — IMPLEMENTATION OF ACTION TASKS BY INTERNATIONAL PARTNERS........... 35 ARTICLE 15 — FINANCIAL SUPPORT TO THIRD PARTIES.................................................................. 35 15.1 Rules for providing financial support to third parties......................................................................35 15.2 Financial support in the form of prizes........................................................................................... 35 15.3 Consequences of non-compliance.................................................................................................... 36 ARTICLE 16 — PROVISION OF TRANS-NATIONAL OR VIRTUAL ACCESS TO RESEARCH INFRASTRUCTURE.....................................................................................................................36 SECTION 2 RIGHTS AND OBLIGATIONS RELATED TO THE GRANT ADMINISTRATION.............. 36 ARTICLE 17 — GENERAL OBLIGATION TO INFORM............................................................................36 17.1 General obligation to provide information upon request.................................................................36 17.2 Obligation to keep information up to date and to inform about events and circumstances likely to affect the Agreement........................................................................................................................36 17.3 Consequences of non-compliance.................................................................................................... 37 ARTICLE 18 — KEEPING RECORDS — SUPPORTING DOCUMENTATION.........................................37 18.1 Obligation to keep records and other supporting documentation.................................................... 37 18.2 Consequences of non-compliance.................................................................................................... 38 ARTICLE 19 — SUBMISSION OF DELIVERABLES................................................................................. 38 19.1 Obligation to submit deliverables.................................................................................................... 38 9 Grant Agreement number: 825575 — EJP RD — H2020-SC1-BHC-2018-2020/H2020-SC1-2018-Single-Stage-RTD H2020 Associated with MGARef. document EJP Cofund — Multi:-v5.0 Ares(2018)6091977 28/11/2018 19.2 Consequences of non-compliance.................................................................................................... 39 ARTICLE 20 — REPORTING — PAYMENT REQUESTS.......................................................................... 39 20.1 Obligation to submit reports............................................................................................................ 39 20.2 Reporting periods............................................................................................................................. 39 20.2a Request for a second pre-financing payment.................................................................................39 20.3 Periodic reports — Requests for interim payments.........................................................................39 20.4 Final report — Request for payment of the balance....................................................................... 41 20.5 Information on cumulative expenditure incurred.............................................................................41 20.6 Currency for financial statements and conversion into euro........................................................... 41 20.7 Language of reports..........................................................................................................................42 20.8 Consequences of non-compliance.................................................................................................... 42 ARTICLE 21 — PAYMENTS AND PAYMENT ARRANGEMENTS...........................................................42 21.1 Payments to be made....................................................................................................................... 42 21.2 Pre-financing payment — Amount — Amount retained for the Guarantee Fund........................... 42 21.3 Interim payments — Amount — Calculation..................................................................................42 21.4 Payment of the balance — Amount — Calculation — Release of the amount retained for the Guarantee Fund................................................................................................................................ 43 21.5 Notification of amounts due.............................................................................................................44 21.6 Currency for payments..................................................................................................................... 44 21.7 Payments to the coordinator — Distribution to the beneficiaries....................................................44 21.8 Bank account for payments..............................................................................................................44 21.9 Costs of payment transfers...............................................................................................................45 21.10 Date of payment............................................................................................................................. 45 21.11 Consequences of non-compliance.................................................................................................. 45 ARTICLE 22 — CHECKS, REVIEWS, AUDITS AND INVESTIGATIONS — EXTENSION OF FINDINGS..................................................................................................................................... 45 22.1 Checks, reviews and audits by the Commission..............................................................................45 22.2 Investigations by the European Anti-Fraud Office (OLAF)............................................................47 22.3 Checks and audits by the European Court of Auditors (ECA)........................................................48 22.4 Checks, reviews, audits and investigations for international organisations..................................... 48 22.5 Consequences of findings in checks, reviews, audits and investigations — Extension of findings............................................................................................................................................. 48 22.6 Consequences of non-compliance.................................................................................................... 50 ARTICLE 23 — EVALUATION OF THE IMPACT OF THE ACTION....................................................... 50 23.1 Right to evaluate the impact of the action.......................................................................................50 23.2 Consequences of non-compliance.................................................................................................... 50 10 Grant Agreement number: 825575 — EJP RD — H2020-SC1-BHC-2018-2020/H2020-SC1-2018-Single-Stage-RTD H2020 Associated with MGARef. document EJP Cofund — Multi:-v5.0 Ares(2018)6091977 28/11/2018 SECTION 3 RIGHTS AND OBLIGATIONS RELATED TO BACKGROUND AND RESULTS................. 50 SUBSECTION 1 GENERAL............................................................................................................................ 50 ARTICLE 23a — MANAGEMENT OF INTELLECTUAL PROPERTY...................................................... 50 23a.1 Obligation to take measures to implement the Commission Recommendation on the management of intellectual property in knowledge transfer activities................................................................. 50 23a.2 Consequences of non-compliance.................................................................................................. 51 SUBSECTION 2 RIGHTS AND OBLIGATIONS RELATED TO BACKGROUND................................ 51 ARTICLE 24 — AGREEMENT ON BACKGROUND..................................................................................51 24.1 Agreement on background............................................................................................................... 51 24.2 Consequences of non-compliance.................................................................................................... 51 ARTICLE 25 — ACCESS RIGHTS TO BACKGROUND............................................................................ 51 25.1 Exercise of access rights — Waiving of access rights — No sub-licensing....................................51 25.2 Access rights for other beneficiaries, for implementing their own tasks under the action...............52 25.3 Access rights for other beneficiaries, for exploiting their own results............................................ 52 25.4 Access rights for affiliated entities.................................................................................................. 52 25.5 Access rights for third parties.......................................................................................................... 52 25.6 Consequences of non-compliance.................................................................................................... 53 SUBSECTION 3 RIGHTS AND OBLIGATIONS RELATED TO RESULTS............................................53 ARTICLE 26 — OWNERSHIP OF RESULTS...............................................................................................53 26.1 Ownership by the beneficiary that generates the results................................................................. 53 26.2 Joint ownership by several beneficiaries......................................................................................... 53 26.3 Rights of third parties (including personnel)................................................................................... 53 26.4 EU ownership, to protect results......................................................................................................54 26.5 Consequences of non-compliance.................................................................................................... 54 ARTICLE 27 — PROTECTION OF RESULTS — VISIBILITY OF EU FUNDING................................... 55 27.1 Obligation to protect the results.......................................................................................................55 27.2 EU ownership, to protect the results................................................................................................55 27.3 Information on EU funding..............................................................................................................55 27.4 Consequences of non-compliance.................................................................................................... 55 ARTICLE 28 — EXPLOITATION OF RESULTS..........................................................................................55 28.1 Obligation to exploit the results.......................................................................................................55 28.2 Results that could contribute to European or international standards — Information on EU funding..............................................................................................................................................56 28.3 Consequences of non-compliance.................................................................................................... 56 ARTICLE 29 — DISSEMINATION OF RESULTS — OPEN ACCESS — VISIBILITY OF EU FUNDING...................................................................................................................................... 56 11 Grant Agreement number: 825575 — EJP RD — H2020-SC1-BHC-2018-2020/H2020-SC1-2018-Single-Stage-RTD H2020 Associated with MGARef. document EJP Cofund — Multi:-v5.0 Ares(2018)6091977 28/11/2018 29.1 Obligation to disseminate results..................................................................................................... 56 29.2 Open access to scientific publications............................................................................................. 56 29.3 Open access to research data........................................................................................................... 57 29.4 Information on EU funding — Obligation and right to use the EU emblem ..................................58 29.5 Disclaimer excluding Commission responsibility............................................................................58 29.6 Consequences of non-compliance.................................................................................................... 58 ARTICLE 30 — TRANSFER AND LICENSING OF RESULTS.................................................................. 58 30.1 Transfer of ownership...................................................................................................................... 58 30.2 Granting licenses.............................................................................................................................. 59 30.3 Commission right to object to transfers or licensing.......................................................................59 30.4 Consequences of non-compliance.................................................................................................... 59 ARTICLE 31 — ACCESS RIGHTS TO RESULTS....................................................................................... 59 31.1 Exercise of access rights — Waiving of access rights — No sub-licensing....................................59 31.2 Access rights for other beneficiaries, for implementing their own tasks under the action...............59 31.3 Access rights for other beneficiaries, for exploiting their own results............................................ 59 31.4 Access rights of affiliated entities....................................................................................................60 31.5 Access rights for the EU institutions, bodies, offices or agencies and EU Member States..............60 31.6 Access rights for third parties.......................................................................................................... 60 31.7 Consequences of non-compliance.................................................................................................... 60 SECTION 4 OTHER RIGHTS AND OBLIGATIONS.......................................................................................60 ARTICLE 32 — RECRUITMENT AND WORKING CONDITIONS FOR RESEARCHERS..................... 60 32.1 Obligation to take measures to implement the European Charter for Researchers and Code of Conduct for the Recruitment of Researchers...................................................................................60 32.2 Consequences of non-compliance.................................................................................................... 61 ARTICLE 33 — GENDER EQUALITY.........................................................................................................61 33.1 Obligation to aim for gender equality..............................................................................................61 33.2 Consequences of non-compliance.................................................................................................... 61 ARTICLE 34 — ETHICS AND RESEARCH INTEGRITY.......................................................................... 61 34.1 Obligation to comply with ethical and research integrity principles............................................... 61 34.2 Activities raising ethical issues........................................................................................................ 62 34.3 Activities involving human embryos or human embryonic stem cells............................................62 34.4 Consequences of non-compliance.................................................................................................... 63 ARTICLE 35 — CONFLICT OF INTERESTS.............................................................................................. 63 35.1 Obligation to avoid a conflict of interests....................................................................................... 63 35.2 Consequences of non-compliance.................................................................................................... 63 12 Grant Agreement number: 825575 — EJP RD — H2020-SC1-BHC-2018-2020/H2020-SC1-2018-Single-Stage-RTD H2020 Associated with MGARef. document EJP Cofund — Multi:-v5.0 Ares(2018)6091977 28/11/2018 ARTICLE 36 — CONFIDENTIALITY...........................................................................................................63 36.1 General obligation to maintain confidentiality................................................................................ 63 36.2 Consequences of non-compliance.................................................................................................... 64 ARTICLE 37 — SECURITY-RELATED OBLIGATIONS............................................................................. 64 37.1 Results with a security recommendation......................................................................................... 64 37.2 Classified information...................................................................................................................... 64 37.3 Activities involving dual-use goods or dangerous materials and substances...................................65 37.4 Consequences of non-compliance.................................................................................................... 65 ARTICLE 38 — PROMOTING THE ACTION — VISIBILITY OF EU FUNDING....................................65 38.1 Communication activities by beneficiaries...................................................................................... 65 38.2 Communication activities by the Commission................................................................................ 66 38.3 Consequences of non-compliance.................................................................................................... 67 ARTICLE 39 — PROCESSING OF PERSONAL DATA...............................................................................67 39.1 Processing of personal data by the Commission............................................................................. 67 39.2 Processing of personal data by the beneficiaries............................................................................. 67 39.3 Consequences of non-compliance.................................................................................................... 68 ARTICLE 40 — ASSIGNMENTS OF CLAIMS FOR PAYMENT AGAINST THE COMMISSION........... 68 CHAPTER 5 DIVISION OF BENEFICIARIES’ ROLES AND RESPONSIBILITIES — RELATIONSHIP WITH COMPLEMENTARY BENEFICIARIES — RELATIONSHIP WITH PARTNERS OF A JOINT ACTION........................................................................................................................................ 68 ARTICLE 41 — DIVISION OF BENEFICIARIES’ ROLES AND RESPONSIBILITIES — RELATIONSHIP WITH COMPLEMENTARY BENEFICIARIES — RELATIONSHIP WITH PARTNERS OF A JOINT ACTION.............................................................................................68 41.1 Roles and responsibility towards the Commission.......................................................................... 68 41.2 Internal division of roles and responsibilities.................................................................................. 68 41.3 Internal arrangements between beneficiaries — Consortium agreement.........................................69 41.4 Relationship with complementary beneficiaries — Collaboration agreement.................................70 41.5 Relationship with partners of a joint action — Coordination agreement........................................ 70 CHAPTER 6 REJECTION OF COSTS — REDUCTION OF THE GRANT — RECOVERY — SANCTIONS — DAMAGES — SUSPENSION — TERMINATION — FORCE MAJEURE................................ 70 SECTION 1 REJECTION OF COSTS — REDUCTION OF THE GRANT — RECOVERY — SANCTIONS.............................................................................................................................................. 70 ARTICLE 42 — REJECTION OF INELIGIBLE COSTS.............................................................................. 70 42.1 Conditions......................................................................................................................................... 70 42.2 Ineligible costs to be rejected — Calculation — Procedure............................................................70 42.3 Effects............................................................................................................................................... 70 ARTICLE 43 — REDUCTION OF THE GRANT......................................................................................... 71 13 Grant Agreement number: 825575 — EJP RD — H2020-SC1-BHC-2018-2020/H2020-SC1-2018-Single-Stage-RTD H2020 Associated with MGARef. document EJP Cofund — Multi:-v5.0 Ares(2018)6091977 28/11/2018 43.1 Conditions......................................................................................................................................... 71 43.2 Amount to be reduced — Calculation — Procedure.......................................................................71 43.3 Effects............................................................................................................................................... 72 ARTICLE 44 — RECOVERY OF UNDUE AMOUNTS............................................................................... 72 44.1 Amount to be recovered — Calculation — Procedure....................................................................72 ARTICLE 45 — ADMINISTRATIVE SANCTIONS..................................................................................... 76 SECTION 2 LIABILITY FOR DAMAGES.........................................................................................................76 ARTICLE 46 — LIABILITY FOR DAMAGES.............................................................................................76 46.1 Liability of the Commission............................................................................................................ 76 46.2 Liability of the beneficiaries............................................................................................................ 76 SECTION 3 SUSPENSION AND TERMINATION............................................................................................76 ARTICLE 47 — SUSPENSION OF PAYMENT DEADLINE....................................................................... 76 47.1 Conditions......................................................................................................................................... 76 47.2 Procedure.......................................................................................................................................... 77 ARTICLE 48 — SUSPENSION OF PAYMENTS.......................................................................................... 77 48.1 Conditions......................................................................................................................................... 77 48.2 Procedure.......................................................................................................................................... 78 ARTICLE 49 — SUSPENSION OF THE ACTION IMPLEMENTATION................................................... 78 49.1 Suspension of the action implementation, by the beneficiaries.......................................................78 49.2 Suspension of the action implementation, by the Commission....................................................... 79 ARTICLE 50 — TERMINATION OF THE AGREEMENT OR OF THE PARTICIPATION OF ONE OR MORE BENEFICIARIES..............................................................................................................80 50.1 Termination of the Agreement, by the beneficiaries........................................................................80 50.2 Termination of the participation of one or more beneficiaries, by the beneficiaries........................81 50.3 Termination of the Agreement or the participation of one or more beneficiaries, by the Commission...................................................................................................................................... 83 SECTION 4 FORCE MAJEURE.......................................................................................................................... 87 ARTICLE 51 — FORCE MAJEURE.............................................................................................................. 87 CHAPTER 7 FINAL PROVISIONS...........................................................................................................................88 ARTICLE 52 — COMMUNICATION BETWEEN THE PARTIES...............................................................88 52.1 Form and means of communication.................................................................................................88 52.2 Date of communication.................................................................................................................... 88 52.3 Addresses for communication.......................................................................................................... 89 ARTICLE 53 — INTERPRETATION OF THE AGREEMENT.....................................................................89 53.1 Precedence of the Terms and Conditions over the Annexes............................................................89 53.2 Privileges and immunities................................................................................................................ 89 14 Grant Agreement number: 825575 — EJP RD — H2020-SC1-BHC-2018-2020/H2020-SC1-2018-Single-Stage-RTD H2020 Associated with MGARef. document EJP Cofund — Multi:-v5.0 Ares(2018)6091977 28/11/2018 ARTICLE 54 — CALCULATION OF PERIODS, DATES AND DEADLINES........................................... 89 ARTICLE 55 — AMENDMENTS TO THE AGREEMENT......................................................................... 89 55.1 Conditions......................................................................................................................................... 89 55.2 Procedure.......................................................................................................................................... 90 ARTICLE 56 — ACCESSION TO THE AGREEMENT............................................................................... 90 56.1 Accession of the beneficiaries mentioned in the Preamble............................................................. 90 56.2 Addition of new beneficiaries.......................................................................................................... 91 ARTICLE 57 — APPLICABLE LAW AND SETTLEMENT OF DISPUTES.............................................. 91 57.1 Applicable law..................................................................................................................................91 57.2 Dispute settlement............................................................................................................................ 91 ARTICLE 58 — ENTRY INTO FORCE OF THE AGREEMENT................................................................ 92 15 Grant Agreement number: 825575 — EJP RD — H2020-SC1-BHC-2018-2020/H2020-SC1-2018-Single-Stage-RTD H2020 Associated with MGARef. document EJP Cofund — Multi:-v5.0 Ares(2018)6091977 28/11/2018 CHAPTER 1 GENERAL ARTICLE 1 — SUBJECT OF THE AGREEMENT This Agreement sets out the rights and obligations and the terms and conditions applicable to the grant awarded to the beneficiaries for implementing the action set out in Chapter 2. CHAPTER 2 ACTION ARTICLE 2 — ACTION TO BE IMPLEMENTED The grant is awarded for the action entitled ‘European Joint Programme on Rare Diseases’ — ‘EJP RD’ (‘action’), as described in Annex 1. ARTICLE 3 — DURATION AND STARTING DATE OF THE ACTION The duration of the action will be 60 months as of 1 January 2019 (‘starting date of the action’). ARTICLE 4 — ESTIMATED BUDGET AND BUDGET TRANSFERS 4.1 Estimated budget The ‘estimated budget’ for the action is set out in Annex 2. It contains the estimated eligible costs and the forms of costs, broken down by beneficiary (and linked third party) and budget category (see Articles 5, 6, and 14). It also shows the estimated costs of the beneficiaries not receiving EU funding (see Article 9). 4.2 Budget transfers The estimated budget breakdown indicated in Annex 2 may be adjusted — without an amendment (see Article 55) — by transfers of amounts between beneficiaries, budget categories and/or forms of costs set out in Annex 2, if the action is implemented as described in Annex 1. However, the beneficiaries may not add costs relating to subcontracts not provided for in Annex 1, unless such additional subcontracts are approved by an amendment or in accordance with Article 13. CHAPTER 3 GRANT ARTICLE 5 — GRANT AMOUNT, FORM OF GRANT, REIMBURSEMENT RATES AND FORMS OF COSTS 5.1 Maximum grant amount The ‘maximum grant amount’ is EUR 55 073 831.17 (fifty five million seventy three thousand eight hundred and thirty one EURO and seventeen eurocents). 5.2 Form of grant, reimbursement rates and forms of costs 16 Grant Agreement number: 825575 — EJP RD — H2020-SC1-BHC-2018-2020/H2020-SC1-2018-Single-Stage-RTD H2020 Associated with MGARef. document EJP Cofund — Multi:-v5.0 Ares(2018)6091977 28/11/2018 The grant reimburses 70% of the action's eligible costs (see Article 6) (‘reimbursement of eligible costs grant’) (see Annex 2). The estimated eligible costs of the action are EUR 94 516 062.29 (ninety four million five hundred and sixteen thousand sixty two EURO and twenty nine eurocents). Eligible costs (see Article 6) must be declared under the following forms ('forms of costs'): (a) for direct personnel costs: - as actually incurred costs (‘actual costs’) or - on the basis of an amount per unit calculated by the beneficiary in accordance with its usual cost accounting practices (‘unit costs’). Personnel costs for SME owners or beneficiaries that are natural persons not receiving a salary (see Article 6.2, Points A.4 and A.5) must be declared on the basis of the amount per unit set out in Annex 2a (unit costs); (b) for direct costs for subcontracting: as actually incurred costs (actual costs); (c) for direct costs of providing financial support to third parties: as actually incurred costs (actual costs); (d) for other direct costs: - for costs of internally invoiced goods and services: on the basis of an amount per unit calculated by the beneficiary in accordance with its usual cost accounting practices (‘unit costs’); - for all other costs: as actually incurred costs (actual costs); (e) for indirect costs: on the basis of a flat-rate applied as set out in Article 6.2, Point E (‘flat-rate costs’); (f) specific cost category(ies): not applicable. 5.3 Final grant amount — Calculation The ‘final grant amount’ depends on the actual extent to which the action is implemented in accordance with the Agreement’s terms and conditions. This amount is calculated by the Commission — when the payment of the balance is made (see Article 21.4) — in the following steps: Step 1 — Application of the reimbursement rates to the eligible costs Step 2 — Limit to the maximum grant amount Step 3 — Reduction due to the no-profit rule Step 4 — Reduction due to substantial errors, irregularities or fraud or serious breach of obligations 17 Grant Agreement number: 825575 — EJP RD — H2020-SC1-BHC-2018-2020/H2020-SC1-2018-Single-Stage-RTD H2020 Associated with MGARef. document EJP Cofund — Multi:-v5.0 Ares(2018)6091977 28/11/2018 5.3.1 Step 1 — Application of the reimbursement rates to the eligible costs The reimbursement rate(s) (see Article 5.2) are applied to the eligible costs (actual costs, unit costs and flat-rate costs; see Article 6) declared by the beneficiaries and linked third parties (see Article 20) and approved by the Commission (see Article 21). 5.3.2 Step 2 — Limit to the maximum grant amount If the amount obtained following Step 1 is higher than the maximum grant amount set out in Article 5.1, it will be limited to the latter. 5.3.3 Step 3 — Reduction due to the no-profit rule The grant must not produce a profit. ‘Profit’ means the surplus of the amount obtained following Steps 1 and 2 plus the action’s total receipts, over the action’s total eligible costs. The ‘action’s total eligible costs’ are the consolidated total eligible costs approved by the Commission. The ‘action’s total receipts’ are the consolidated total receipts generated during its duration (see Article 3). The following are considered receipts: (a) income generated by the action; if the income is generated from selling equipment or other assets purchased under the Agreement, the receipt is up to the amount declared as eligible under the Agreement; (b) financial contributions given by third parties to the beneficiary or to a linked third party specifically to be used for the action, and (c) in-kind contributions provided by third parties free of charge and specifically to be used for the action, if they have been declared as eligible costs. The following are however not considered receipts: (a) income generated by exploiting the action’s results (see Article 28); (b) financial contributions by third parties, if they may be used to cover costs other than the eligible costs (see Article 6); (c) financial contributions by third parties with no obligation to repay any amount unused at the end of the period set out in Article 3. If there is a profit, it will be deducted from the amount obtained following Steps 1 and 2. 5.3.4 Step 4 — Reduction due to substantial errors, irregularities or fraud or serious breach of obligations — Reduced grant amount — Calculation If the grant is reduced (see Article 43), the Commission will calculate the reduced grant amount by deducting the amount of the reduction (calculated in proportion to the seriousness of the errors, 18 Grant Agreement number: 825575 — EJP RD — H2020-SC1-BHC-2018-2020/H2020-SC1-2018-Single-Stage-RTD H2020 Associated with MGARef. document EJP Cofund — Multi:-v5.0 Ares(2018)6091977 28/11/2018 irregularities or fraud or breach of obligations, in accordance with Article 43.2) from the maximum grant amount set out in Article 5.1. The final grant amount will be the lower of the following two: - the amount obtained following Steps 1 to 3 or - the reduced grant amount following Step 4. 5.4 Revised final grant amount — Calculation If — after the payment of the balance (in particular, after checks, reviews, audits or investigations; see Article 22) — the Commission rejects costs (see Article 42) or reduces the grant (see Article 43), it will calculate the ‘revised final grant amount’ for the beneficiary concerned by the findings. This amount is calculated by the Commission on the basis of the findings, as follows: - in case of rejection of costs: by applying the reimbursement rate to the revised eligible costs approved by the Commission for the beneficiary concerned; - in case of reduction of the grant: by calculating the concerned beneficiary’s share in the grant amount reduced in proportion to the seriousness of the errors, irregularities or fraud or breach of obligations (see Article 43.2). In case of rejection of costs and reduction of the grant, the revised final grant amount for the beneficiary concerned will be the lower of the two amounts above. ARTICLE 6 — ELIGIBLE AND INELIGIBLE COSTS 6.1 General conditions for costs to be eligible ‘Eligible costs’ are costs that meet the following criteria: (a) for actual costs: (i) they must be actually incurred by the beneficiary; (ii) they must be incurred in the period set out in Article 3, with the exception of costs relating to the submission of the periodic report for the last reporting period and the final report (see Article 20); (iii) they must be indicated in the estimated budget set out in Annex 2; (iv) they must be incurred in connection with the action as described in Annex 1 and necessary for its implementation; (v) they must be identifiable and verifiable, in particular recorded in the beneficiary’s accounts in accordance with the accounting standards applicable in the country where the beneficiary is established and with the beneficiary’s usual cost accounting practices; (vi) they must comply with the applicable national law on taxes, labour and social security, and 19 Grant Agreement number: 825575 — EJP RD — H2020-SC1-BHC-2018-2020/H2020-SC1-2018-Single-Stage-RTD H2020 Associated with MGARef. document EJP Cofund — Multi:-v5.0 Ares(2018)6091977 28/11/2018 (vii) they must be reasonable, justified and must comply with the principle of sound financial management, in particular regarding economy and efficiency; (b) for unit costs: (i) they must be calculated as follows: {amounts per unit set out in Annex 2a or calculated by the beneficiary in accordance with its usual cost accounting practices (see Article 6.2, Point A and Article 6.2.D.5) multiplied by the number of actual units}; (ii) the number of actual units must comply with the following conditions: - the units must be actually used or produced in the period set out in Article 3; - the units must be necessary for implementing the action or produced by it, and - the number of units must be identifiable and verifiable, in particular supported by records and documentation (see Article 18); (c) for flat-rate costs: (i) they must be calculated by applying the flat-rate set out in Annex 2, and (ii) the costs (actual costs or unit costs) to which the flat-rate is applied must comply with the conditions for eligibility set out in this Article. 6.2 Specific conditions for costs to be eligible Costs are eligible if they comply with the general conditions (see above) and the specific conditions set out below for each of the following budget categories: A. direct personnel costs; B. direct costs of subcontracting; C. direct costs of providing financial support to third parties; D. other direct costs; E. indirect costs; F. not applicable. ‘Direct costs’ are costs that are directly linked to the action implementation and can therefore be attributed to it directly. They must not include any indirect costs (see Point E below). ‘Indirect costs’ are costs that are not directly linked to the action implementation and therefore cannot be attributed directly to it. A. Direct personnel costs Types of eligible personnel costs 20 Grant Agreement number: 825575 — EJP RD — H2020-SC1-BHC-2018-2020/H2020-SC1-2018-Single-Stage-RTD H2020 Associated with MGARef. document EJP Cofund — Multi:-v5.0 Ares(2018)6091977 28/11/2018 A.1 Personnel costs are eligible, if they are related to personnel working for the beneficiary under an employment contract (or equivalent appointing act) and assigned to the action (‘costs for employees (or equivalent)’). They must be limited to salaries (including during parental leave), social security contributions, taxes and other costs included in the remuneration, if they arise from national law or the employment contract (or equivalent appointing act). Beneficiaries that are non-profit legal entities1 may also declare as personnel costs additional remuneration for personnel assigned to the action (including payments on the basis of supplementary contracts regardless of their nature), if: (a) it is part of the beneficiary’s usual remuneration practices and is paid in a consistent manner whenever the same kind of work or expertise is required; (b) the criteria used to calculate the supplementary payments are objective and generally applied by the beneficiary, regardless of the source of funding used. ‘Additional remuneration’ means any part of the remuneration which exceeds what the person would be paid for time worked in projects funded by national schemes. Additional remuneration for personnel assigned to the action is eligible up to the following amount: (a) if the person works full time and exclusively on the action during the full year: up to EUR 8 000; (b) if the person works exclusively on the action but not full-time or not for the full year: up to the corresponding pro-rata amount of EUR 8 000, or (c) if the person does not work exclusively on the action: up to a pro-rata amount calculated as follows: {{EUR 8 000 divided by the number of annual productive hours (see below)}, multiplied by the number of hours that the person has worked on the action during the year}. A.2 The costs for natural persons working under a direct contract with the beneficiary other than an employment contract are eligible personnel costs, if: (a) the person works under conditions similar to those of an employee (in particular regarding the way the work is organised, the tasks that are performed and the premises where they are performed); (b) the result of the work carried out belongs to the beneficiary (unless exceptionally agreed otherwise), and 1 For the definition, see Article 2.1(14) of Regulation (EU) No 1290/2013 of the European Parliament and of the Council of 11 December 2013 laying down the rules for the participation and dissemination in “Horizon 2020 – the Framework Programme for Research and Innovation (2014-2020)” (‘Rules for Participation Regulation No 1290/2013’) (OJ L 347, 20.12.2013 p.81): ‘non-profit legal entity’ means a legal entity which by its legal form is non-profit-making or which has a legal or statutory obligation not to distribute profits to its shareholders or individual members. 21 Grant Agreement number: 825575 — EJP RD — H2020-SC1-BHC-2018-2020/H2020-SC1-2018-Single-Stage-RTD H2020 Associated with MGARef. document EJP Cofund — Multi:-v5.0 Ares(2018)6091977 28/11/2018 (c) the costs are not significantly different from those for personnel performing similar tasks under an employment contract with the beneficiary. A.3 The costs of personnel seconded by a third party against payment are eligible personnel costs, if the conditions in Article 11.1 are met. A.4 Costs of owners of beneficiaries that are small and medium-sized enterprises (‘SME owners’) who are working on the action and who do not receive a salary are eligible personnel costs, if they correspond to the amount per unit set out in Annex 2a multiplied by the number of actual hours worked on the action. A.5 Costs of ‘beneficiaries that are natural persons’ not receiving a salary are eligible personnel costs, if they correspond to the amount per unit set out in Annex 2a multiplied by the number of actual hours worked on the action. Calculation Personnel costs must be calculated by the beneficiaries as follows: {{hourly rate multiplied by the number of actual hours worked on the action}, plus for non-profit legal entities: additional remuneration to personnel assigned to the action under the conditions set out above (Point A.1)}. The number of actual hours declared for a person must be identifiable and verifiable (see Article 18). The total number of hours declared in EU or Euratom grants, for a person for a year, cannot be higher than the annual productive hours used for the calculations of the hourly rate. Therefore, the maximum number of hours that can be declared for the grant are: {the number of annual productive hours for the year (see below) minus total number of hours declared by the beneficiary, for that person for that year, for other EU or Euratom grants} The ‘hourly rate’ is one of the following: (a) for personnel costs declared as actual costs (i.e. budget categories A.1, A.2 and A.3): the hourly rate is calculated per full financial year, as follows: {actual annual personnel costs (excluding additional remuneration) for the person divided by number of annual productive hours}. using the personnel costs and the number of productive hours for each full financial year covered by the reporting period concerned. If a financial year is not closed at the end of the 22 Grant Agreement number: 825575 — EJP RD — H2020-SC1-BHC-2018-2020/H2020-SC1-2018-Single-Stage-RTD H2020 Associated with MGARef. document EJP Cofund — Multi:-v5.0 Ares(2018)6091977 28/11/2018 reporting period, the beneficiaries must use the hourly rate of the last closed financial year available. For the ‘number of annual productive hours’, the beneficiaries may choose one of the following: (i) ‘fixed number of hours’: 1 720 hours for persons working full time (or corresponding pro-rata for persons not working full time); (ii) ‘individual annual productive hours’: the total number of hours worked by the person in the year for the beneficiary, calculated as follows: {annual workable hours of the person (according to the employment contract, applicable collective labour agreement or national law) plus overtime worked minus absences (such as sick leave and special leave)}. ‘Annual workable hours’ means the period during which the personnel must be working, at the employer’s disposal and carrying out his/her activity or duties under the employment contract, applicable collective labour agreement or national working time legislation. If the contract (or applicable collective labour agreement or national working time legislation) does not allow to determine the annual workable hours, this option cannot be used; (iii) ‘standard annual productive hours’: the ‘standard number of annual hours’ generally applied by the beneficiary for its personnel in accordance with its usual cost accounting practices. This number must be at least 90% of the ‘standard annual workable hours’. If there is no applicable reference for the standard annual workable hours, this option cannot be used. For all options, the actual time spent on parental leave by a person assigned to the action may be deducted from the number of annual productive hours. As an alternative, beneficiaries may calculate the hourly rate per month, as follows: {actual monthly personnel cost (excluding additional remuneration) for the person divided by {number of annual productive hours / 12}} using the personnel costs for each month and (one twelfth of) the annual productive hours calculated according to either option (i) or (iii) above, i.e.: - fixed number of hours or - standard annual productive hours. 23 Grant Agreement number: 825575 — EJP RD — H2020-SC1-BHC-2018-2020/H2020-SC1-2018-Single-Stage-RTD H2020 Associated with MGARef. document EJP Cofund — Multi:-v5.0 Ares(2018)6091977 28/11/2018 Time spent on parental leave may not be deducted when calculating the hourly rate per month. However, beneficiaries may declare personnel costs incurred in periods of parental leave in proportion to the time the person worked on the action in that financial year. If parts of a basic remuneration are generated over a period longer than a month, the beneficiaries may include only the share which is generated in the month (irrespectively of the amount actually paid for that month). Each beneficiary must use only one option (per full financial year or per month) during each full financial year; (b) for personnel costs declared on the basis of unit costs (i.e. budget categories A.1, A.2, A.4 and A.5): the hourly rate is one of the following: (i) for SME owners or beneficiaries that are natural persons: the hourly rate set out in Annex 2a (see Points A.4 and A.5 above), or (ii) for personnel costs declared on the basis of the beneficiary’s usual cost accounting practices: the hourly rate calculated by the beneficiary in accordance with its usual cost accounting practices, if: - the cost accounting practices used are applied in a consistent manner, based on objective criteria, regardless of the source of funding; - the hourly rate is calculated using the actual personnel costs recorded in the beneficiary’s accounts, excluding any ineligible cost or costs included in other budget categories. The actual personnel costs may be adjusted by the beneficiary on the basis of budgeted or estimated elements. Those elements must be relevant for calculating the personnel costs, reasonable and correspond to objective and verifiable information; and - the hourly rate is calculated using the number of annual productive hours (see above). B. Direct costs of subcontracting (including related duties, taxes and charges such as non- deductible value added tax (VAT) paid by the beneficiary) are eligible if the conditions in Article 13.1.1 are met. C. Direct costs of providing financial support to third parties C.1 Direct costs of providing financial support are eligible if the conditions set out in Article 15.1.1 are met. D. Other direct costs D.1 Travel costs and related subsistence allowances (including related duties, taxes and charges such as non-deductible value added tax (VAT) paid by the beneficiary) are eligible if they are in line with the beneficiary’s usual practices on travel. 24 Grant Agreement number: 825575 — EJP RD — H2020-SC1-BHC-2018-2020/H2020-SC1-2018-Single-Stage-RTD H2020 Associated with MGARef. document EJP Cofund — Multi:-v5.0 Ares(2018)6091977 28/11/2018 D.2 The depreciation costs of equipment, infrastructure or other assets (new or second-hand) as recorded in the beneficiary’s accounts are eligible, if they were purchased in accordance with Article 10.1.1 and written off in accordance with international accounting standards and the beneficiary’s usual accounting practices. The costs of renting or leasing equipment, infrastructure or other assets (including related duties, taxes and charges such as non-deductible value added tax (VAT) paid by the beneficiary) are also eligible, if they do not exceed the depreciation costs of similar equipment, infrastructure or assets and do not include any financing fees. The costs of equipment, infrastructure or other assets contributed in-kind against payment are eligible, if they do not exceed the depreciation costs of similar equipment, infrastructure or assets, do not include any financing fees and if the conditions in Article 11.1 are met. The only portion of the costs that will be taken into account is that which corresponds to the duration of the action and rate of actual use for the purposes of the action. D.3 Costs of other goods and services (including related duties, taxes and charges such as non- deductible value added tax (VAT) paid by the beneficiary) are eligible, if they are: (a) purchased specifically for the action and in accordance with Article 10.1.1 or (b) contributed in kind against payment and in accordance with Article 11.1. Such goods and services include, for instance, consumables and supplies, dissemination (including open access), protection of results, certificates on the financial statements (if they are required by the Agreement), certificates on the methodology, translations and publications. D.4 Capitalised and operating costs of ‘large research infrastructure’2 directly used for the action are eligible, if: (a) the value of the large research infrastructure represents at least 75% of the total fixed assets (at historical value in its last closed balance sheet before the date of the signature of the Agreement or as determined on the basis of the rental and leasing costs of the research infrastructure3); (b) the beneficiary’s methodology for declaring the costs for large research infrastructure has been positively assessed by the Commission (‘ex-ante assessment’); (c) the beneficiary declares as direct eligible costs only the portion which corresponds to the duration of the action and the rate of actual use for the purposes of the action, and 2 ‘Large research infrastructure’ means research infrastructure of a total value of at least EUR 20 million, for a beneficiary, calculated as the sum of historical asset values of each individual research infrastructure of that beneficiary, as they appear in its last closed balance sheet before the date of the signature of the Agreement or as determined on the basis of the rental and leasing costs of the research infrastructure. 3 For the definition see Article 2(6) of the H2020 Framework Programme Regulation No 1291/2013: ‘Research infrastructure’ are facilities, resources and services that are used by the research communities to conduct research and foster innovation in their fields. Where relevant, they may be used beyond research, e.g. for education or public services. They include: major scientific equipment (or sets of instruments); knowledge-based resources such as collections, archives or scientific data; e-infrastructures such as data and computing systems and communication networks; and any other infrastructure of a unique nature essential to achieve excellence in research and innovation. Such infrastructures may be ‘single-sited’, ‘virtual’ or ‘distributed’. 25 Grant Agreement number: 825575 — EJP RD — H2020-SC1-BHC-2018-2020/H2020-SC1-2018-Single-Stage-RTD H2020 Associated with MGARef. document EJP Cofund — Multi:-v5.0 Ares(2018)6091977 28/11/2018 (d) they comply with the conditions as further detailed in the annotations to the H2020 grant agreements. D.5 Costs of internally invoiced goods and services directly used for the action are eligible, if: (a) they are declared on the basis of a unit cost calculated in accordance with the beneficiary’s usual cost accounting practices; (b) the cost accounting practices used are applied in a consistent manner, based on objective criteria, regardless of the source of funding; (c) the unit cost is calculated using the actual costs for the good or service recorded in the beneficiary’s accounts, excluding any ineligible cost or costs included in other budget categories. The actual costs may be adjusted by the beneficiary on the basis of budgeted or estimated elements. Those elements must be relevant for calculating the costs, reasonable and correspond to objective and verifiable information; (d) the unit cost excludes any costs of items which are not directly linked to the production of the invoiced goods or service. ‘Internally invoiced goods and services’ means goods or services which are provided by the beneficiary directly for the action and which the beneficiary values on the basis of its usual cost accounting practices. E. Indirect costs Indirect costs are eligible if they are declared on the basis of the flat-rate of 25% of the eligible direct costs (see Article 5.2 and Points A to D above), from which are excluded: (a) costs of subcontracting and (b) costs of in-kind contributions provided by third parties which are not used on the beneficiary’s premises and (c) costs of providing financial support to third parties; (d) not applicable. Beneficiaries receiving an operating grant4 financed by the EU or Euratom budget cannot declare indirect costs for the period covered by the operating grant, unless they can demonstrate that the operating grant does not cover any costs of the action. F. Specific cost category(ies) 4 For the definition, see Article 121(1)(b) of Regulation (EU, Euratom) No 966/2012 of the European Parliament and of the Council of 25 October 2012 on the financial rules applicable to the general budget of the Union and repealing Council Regulation (EC, Euratom) No 1605/2002 (‘Financial Regulation No 966/2012’) (OJ L 218, 26.10.2012, p.1): ‘operating grant’ means direct financial contribution, by way of donation, from the budget in order to finance the functioning of a body which pursues an aim of general EU interest or has an objective forming part of and supporting an EU policy. 26 Grant Agreement number: 825575 — EJP RD — H2020-SC1-BHC-2018-2020/H2020-SC1-2018-Single-Stage-RTD H2020 Associated with MGARef. document EJP Cofund — Multi:-v5.0 Ares(2018)6091977 28/11/2018 Not applicable 6.3 Conditions for costs of linked third parties to be eligible Costs incurred by linked third parties are eligible if they fulfil — mutatis mutandis — the general and specific conditions for eligibility set out in this Article (Article 6.1 and 6.2) and Article 14.1.1. 6.4 Conditions for in-kind contributions provided by third parties free of charge to be eligible In-kind contributions provided free of charge are eligible direct costs (for the beneficiary or linked third party), if the costs incurred by the third party fulfil — mutatis mutandis — the general and specific conditions for eligibility set out in this Article (Article 6.1 and 6.2) and Article 12.1. 6.5 Ineligible costs ‘Ineligible costs’ are: (a) costs that do not comply with the conditions set out above (Article 6.1 to 6.4), in particular: (i) costs related to return on capital; (ii) debt and debt service charges; (iii) provisions for future losses or debts; (iv) interest owed; (v) doubtful debts; (vi) currency exchange losses; (vii) bank costs charged by the beneficiary’s bank for transfers from the Commission; (viii) excessive or reckless expenditure; (ix) deductible VAT; (x) costs incurred during suspension of the implementation of the action (see Article 49); (b) costs declared under another EU or Euratom grant (including grants awarded by a Member State and financed by the EU or Euratom budget and grants awarded by bodies other than the Commission for the purpose of implementing the EU or Euratom budget); in particular, indirect costs if the beneficiary is already receiving an operating grant financed by the EU or Euratom budget in the same period, unless it can demonstrate that the operating grant does not cover any costs of the action. 6.6 Consequences of declaration of ineligible costs Declared costs that are ineligible will be rejected (see Article 42). This may also lead to any of the other measures described in Chapter 6. 27 Grant Agreement number: 825575 — EJP RD — H2020-SC1-BHC-2018-2020/H2020-SC1-2018-Single-Stage-RTD H2020 Associated with MGARef. document EJP Cofund — Multi:-v5.0 Ares(2018)6091977 28/11/2018 CHAPTER 4 RIGHTS AND OBLIGATIONS OF THE PARTIES SECTION 1 RIGHTS AND OBLIGATIONS RELATED TO IMPLEMENTING THE ACTION ARTICLE 7 — GENERAL OBLIGATION TO PROPERLY IMPLEMENT THE ACTION 7.1 General obligation to properly implement the action The beneficiaries must implement the action as described in Annex 1 and in compliance with the provisions of the Agreement and all legal obligations under applicable EU, international and national law. 7.2 Consequences of non-compliance If a beneficiary breaches any of its obligations under this Article, the grant may be reduced (see Article 43). Such breaches may also lead to any of the other measures described in Chapter 6. ARTICLE 8 — RESOURCES TO IMPLEMENT THE ACTION — THIRD PARTIES INVOLVED IN THE ACTION The beneficiaries must have the appropriate resources to implement the action. If it is necessary to implement the action, the beneficiaries may: - purchase goods, works and services (see Article 10); - use in-kind contributions provided by third parties against payment (see Article 11); - use in-kind contributions provided by third parties free of charge (see Article 12); - call upon subcontractors to implement action tasks described in Annex 1 (see Article 13); - call upon linked third parties to implement action tasks described in Annex 1 (see Article 14); - call upon international partners to implement action tasks described in Annex 1 (see Article 14a). In these cases, the beneficiaries retain sole responsibility towards the Commission and the other beneficiaries for implementing the action. ARTICLE 9 — IMPLEMENTATION OF ACTION TASKS BY BENEFICIARIES NOT RECEIVING EU FUNDING 9.1 Rules for the implementation of action tasks by beneficiaries not receiving EU funding Beneficiaries that (‘beneficiaries not receiving EU funding’) must implement the action tasks attributed to them in Annex 1 in accordance with Article 7.1. 28 Grant Agreement number: 825575 — EJP RD — H2020-SC1-BHC-2018-2020/H2020-SC1-2018-Single-Stage-RTD H2020 Associated with MGARef. document EJP Cofund — Multi:-v5.0 Ares(2018)6091977 28/11/2018 Their costs are estimated in Annex 2 but: - will not be reimbursed and - will not be taken into account for the calculation of the grant (see Articles 5.2, 5.3 and 5.4, and 21). Chapter 3, Articles 10 to 15, 18.1.2, 20.3(b), 20.4(b), 20.6, 21, 23a, 26.4, 27.2, 28.1, 28.2, 30.3, 31.5, 40, 42, 43, 44, 47 and 48 do not apply to these beneficiaries. They will not be subject to financial checks, reviews and audits under Article 22. Beneficiaries not receiving EU funding may provide in-kind contributions to another beneficiary. In this case, they will be considered as a third party for the purpose of Articles 11 and 12. 9.2 Consequences of non-compliance If a beneficiary not receiving EU funding breaches any of its obligations under this Article, its participation in the Agreement may be terminated (see Article 50). Such breaches may also lead to any of the other measures described in Chapter 6 that are applicable to it. ARTICLE 10 — PURCHASE OF GOODS, WORKS OR SERVICES 10.1 Rules for purchasing goods, works or services 10.1.1 If necessary to implement the action, the beneficiaries may purchase goods, works or services. The beneficiaries must make such purchases ensuring the best value for money or, if appropriate, the lowest price. In doing so, they must avoid any conflict of interests (see Article 35). The beneficiaries must ensure that the Commission, the European Court of Auditors (ECA) and the European Anti-Fraud Office (OLAF) can exercise their rights under Articles 22 and 23 also towards their contractors. 10.1.2 Beneficiaries that are ‘contracting authorities’ within the meaning of Directive 2004/18/EC5 (or 2014/24/EU6) or ‘contracting entities’ within the meaning of Directive 2004/17/EC7 (or 2014/25/EU8) must comply with the applicable national law on public procurement. 10.2 Consequences of non-compliance 5 Directive 2004/18/EC of the European Parliament and of the Council of 31 March 2004 on the coordination of procedures for the award of public work contracts, public supply contracts and public service contracts (OJ L 134, 30.04.2004, p. 114). 6 Directive 2014/24/EU of the European Parliament and of the Council of 26 February 2014 on public procurement and repealing Directive 2004/18/EC. (OJ L 94, 28.03.2014, p. 65). 7 Directive 2004/17/EC of the European Parliament and of the Council of 31 March 2004 coordinating the procurement procedures of entities operating in the water, energy, transport and postal services sectors (OJ L 134, 30.04.2004, p. 1) 8 Directive 2014/25/EU of the European Parliament and of the Council of 26 February 2014 on procurement by entities operating in the water, energy, transport and postal services sectors and repealing Directive 2004/17/EC (OJ L 94, 28.03.2014, p. 243). 29 Grant Agreement number: 825575 — EJP RD — H2020-SC1-BHC-2018-2020/H2020-SC1-2018-Single-Stage-RTD H2020 Associated with MGARef. document EJP Cofund — Multi:-v5.0 Ares(2018)6091977 28/11/2018 If a beneficiary breaches any of its obligations under Article 10.1.1, the costs related to the contract concerned will be ineligible (see Article 6) and will be rejected (see Article 42). If a beneficiary breaches any of its obligations under Article 10.1.2, the grant may be reduced (see Article 43). Such breaches may also lead to any of the other measures described in Chapter 6. ARTICLE 11 — USE OF IN-KIND CONTRIBUTIONS PROVIDED BY THIRD PARTIES AGAINST PAYMENT 11.1 Rules for the use of in-kind contributions against payment If necessary to implement the action, the beneficiaries may use in-kind contributions provided by third parties against payment. The beneficiaries may declare costs related to the payment of in-kind contributions as eligible (see Article 6.1 and 6.2), up to the third parties’ costs for the seconded persons, contributed equipment, infrastructure or other assets or other contributed goods and services. The third parties and their contributions must be set out in Annex 1. The Commission may however approve in-kind contributions not set out in Annex 1 without amendment (see Article 55), if: - they are specifically justified in the periodic technical report and - their use does not entail changes to the Agreement which would call into question the decision awarding the grant or breach the principle of equal treatment of applicants. The beneficiaries must ensure that the Commission, the European Court of Auditors (ECA) and the European Anti-Fraud Office (OLAF) can exercise their rights under Articles 22 and 23 also towards the third parties. 11.2 Consequences of non-compliance If a beneficiary breaches any of its obligations under this Article, the costs related to the payment of the in-kind contribution will be ineligible (see Article 6) and will be rejected (see Article 42). Such breaches may also lead to any of the other measures described in Chapter 6. ARTICLE 12 — USE OF IN-KIND CONTRIBUTIONS PROVIDED BY THIRD PARTIES FREE OF CHARGE 12.1 Rules for the use of in-kind contributions free of charge If necessary to implement the action, the beneficiaries may use in-kind contributions provided by third parties free of charge. The beneficiaries may declare costs incurred by the third parties for the seconded persons, contributed equipment, infrastructure or other assets or other contributed goods and services as eligible in accordance with Article 6.4. 30 Grant Agreement number: 825575 — EJP RD — H2020-SC1-BHC-2018-2020/H2020-SC1-2018-Single-Stage-RTD H2020 Associated with MGARef. document EJP Cofund — Multi:-v5.0 Ares(2018)6091977 28/11/2018 The third parties and their contributions must be set out in Annex 1. The Commission may however approve in-kind contributions not set out in Annex 1 without amendment (see Article 55), if: - they are specifically justified in the periodic technical report and - their use does not entail changes to the Agreement which would call into question the decision awarding the grant or breach the principle of equal treatment of applicants. The beneficiaries must ensure that the Commission, the European Court of Auditors (ECA) and the European Anti-Fraud Office (OLAF) can exercise their rights under Articles 22 and 23 also towards the third parties. 12.2 Consequences of non-compliance If a beneficiary breaches any of its obligations under this Article, the costs incurred by the third parties related to the in-kind contribution will be ineligible (see Article 6) and will be rejected (see Article 42). Such breaches may also lead to any of the other measures described in Chapter 6. ARTICLE 13 — IMPLEMENTATION OF ACTION TASKS BY SUBCONTRACTORS 13.1 Rules for subcontracting action tasks 13.1.1 If necessary to implement the action, the beneficiaries may award subcontracts covering the implementation of certain action tasks described in Annex 1. Subcontracting may cover only a limited part of the action. The beneficiaries must award the subcontracts ensuring the best value for money or, if appropriate, the lowest price. In doing so, they must avoid any conflict of interests (see Article 35). The tasks to be implemented and the estimated cost for each subcontract must be set out in Annex 1 and the total estimated costs of subcontracting per beneficiary must be set out in Annex 2. The Commission may however approve subcontracts not set out in Annex 1 and 2 without amendment (see Article 55), if: - they are specifically justified in the periodic technical report and - they do not entail changes to the Agreement which would call into question the decision awarding the grant or breach the principle of equal treatment of applicants. The beneficiaries must ensure that the Commission, the European Court of Auditors (ECA) and the European Anti-Fraud Office (OLAF) can exercise their rights under Articles 22 and 23 also towards their subcontractors. 13.1.2 The beneficiaries must ensure that their obligations under Articles 35, 36, 38 and 46 also apply to the subcontractors. Beneficiaries that are ‘contracting authorities’ within the meaning of Directive 2004/18/EC (or 2014/24/EU) or ‘contracting entities’ within the meaning of Directive 2004/17/EC (or 2014/25/EU) must comply with the applicable national law on public procurement. 31 Grant Agreement number: 825575 — EJP RD — H2020-SC1-BHC-2018-2020/H2020-SC1-2018-Single-Stage-RTD H2020 Associated with MGARef. document EJP Cofund — Multi:-v5.0 Ares(2018)6091977 28/11/2018 13.2 Consequences of non-compliance If a beneficiary breaches any of its obligations under Article 13.1.1, the costs related to the subcontract concerned will be ineligible (see Article 6) and will be rejected (see Article 42). If a beneficiary breaches any of its obligations under Article 13.1.2, the grant may be reduced (see Article 43). Such breaches may also lead to any of the other measures described in Chapter 6. ARTICLE 14 — IMPLEMENTATION OF ACTION TASKS BY LINKED THIRD PARTIES 14.1 Rules for calling upon linked third parties to implement part of the action 14.1.1 The following affiliated entities10 and third parties with a legal link to a beneficiary11 (‘linked third parties’) may implement the action tasks attributed to them in Annex 1: - INSTITUT ZA MOLEKULARNU GENETIKU I GENETICKO INZENJERSTVO (IMGGE), affiliated or linked to INSERM - STOCKHOLMS LANS LANDSTING (KI), affiliated or linked to INSERM - UNIVERZITETNI KLINICNI CENTER LJUBLJANA (UMCL-UKCL), affiliated or linked to INSERM - Department of Health (PHE), affiliated or linked to INSERM - MEDICAL RESEARCH INFRASTRUCTURE DEVELOPMENT AND HEALTH SERVICES FUND BY THE SHEBA MEDICAL CENTER (SHEBA), affiliated or linked to INSERM - RINNEKOTI SAATIO (Rinnekoti), affiliated or linked to INSERM - KLINIKA ZA DJECJE BOLESTI ZAGREB (KDBZ), affiliated or linked to INSERM - TARTU ULIKOOL (UT), affiliated or linked to INSERM 10 For the definition see Article 2.1(2) Rules for Participation Regulation No 1290/2013: ‘affiliated entity’ means any legal entity that is: - under the direct or indirect control of a participant, or - under the same direct or indirect control as the participant, or - directly or indirectly controlling a participant. ‘Control’ may take any of the following forms: (a) the direct or indirect holding of more than 50% of the nominal value of the issued share capital in the legal entity concerned, or of a majority of the voting rights of the shareholders or associates of that entity; (b) the direct or indirect holding, in fact or in law, of decision-making powers in the legal entity concerned. However the following relationships between legal entities shall not in themselves be deemed to constitute controlling relationships: (a) the same public investment corporation, institutional investor or venture-capital company has a direct or indirect holding of more than 50% of the nominal value of the issued share capital or a majority of voting rights of the shareholders or associates; (b) the legal entities concerned are owned or supervised by the same public body. 11 ‘Third party with a legal link to a beneficiary’ is any legal entity which has a legal link to the beneficiary implying collaboration that is not limited to the action. 32 Grant Agreement number: 825575 — EJP RD — H2020-SC1-BHC-2018-2020/H2020-SC1-2018-Single-Stage-RTD H2020 Associated with MGARef. document EJP Cofund — Multi:-v5.0 Ares(2018)6091977 28/11/2018 - MEDIZINISCHE HOCHSCHULE HANNOVER (MHH), affiliated or linked to INSERM - OSPEDALE PEDIATRICO BAMBINO GESU (OPBG), affiliated or linked to INSERM - Ministry for Health - Government of Malta (DHIR), affiliated or linked to INSERM - GEORGIAN FOUNDATION FOR GENETIC AND RARE DISEASES (GERAD), affiliated or linked to INSERM - BULGARIAN ASSOCIATION FOR PROMOTION OF EDUCATION AND SCIENCE (BAPES), affiliated or linked to INSERM - UNIVERZITA KARLOVA (CUNI), affiliated or linked to INSERM - HEALTH SERVICE EXECUTIVE HSE (HSE), affiliated or linked to INSERM - LES HOPITAUX UNIVERSITAIRES DE GENEVE (HUG), affiliated or linked to INSERM - OSLO UNIVERSITETSSYKEHUS HF (OUS-HF), affiliated or linked to INSERM - BERNU KLINISKA UNIVERSITATES SLIMNICA VALSTS SIA (CCUH), affiliated or linked to INSERM - UNIVERSITE D'AIX MARSEILLE (AMU), affiliated or linked to INSERM - Center of Medical Genetics and Primary Health Care (CMG), affiliated or linked to INSERM - MEDIZINISCHE UNIVERSITAET WIEN (MUW-AT), affiliated or linked to INSERM - SCIENSANO (Sciensano), affiliated or linked to INSERM - UNIVERSITATEA DE MEDICINA SI FARMACIE GRIGORE T.POPA IASI (UMF), affiliated or linked to INSERM - AGENZIA PER LA PROMOZIONE DELLA RICERCA EUROPEA (APRE), affiliated or linked to IT-MOH - FUNDACIO SANT JOAN DE DEU (FSJD), affiliated or linked to TEDDY - UNIVERSITE LYON 1 CLAUDE BERNARD (UCBL), affiliated or linked to CLB - Universitaetsklinikum Tuebingen (UKT), affiliated or linked to EKUT - KLINIKUM DER JOHANN WOLFGANG VON GOETHE UNIVERSITAET (UKF), affiliated or linked to GUF - MANCHESTER UNIVERSITY NHS FOUNDATION TRUST (MFT NHS TRUST), affiliated or linked to AOUS - CENTRE HOSPITALIER REG UNIVERSITAIRE DIJON (CHU DIJON), affiliated or linked to AOUS - UNIVERSITY OF GLASGOW (UoG), affiliated or linked to LUMC 33 Grant Agreement number: 825575 — EJP RD — H2020-SC1-BHC-2018-2020/H2020-SC1-2018-Single-Stage-RTD H2020 Associated with MGARef. document EJP Cofund — Multi:-v5.0 Ares(2018)6091977 28/11/2018 - UNIVERSITATSKLINIKUM SCHLESWIG-HOLSTEIN (UKSH), affiliated or linked to LUMC - INSTITUT CURIE (IC), affiliated or linked to Radboudumc - STOCKHOLMS LANS LANDSTING (KUH), affiliated or linked to Radboudumc - MANCHESTER UNIVERSITY NHS FOUNDATION TRUST (MFT), affiliated or linked to Radboudumc - TERVEYDEN JA HYVINVOINNIN LAITOS (THL), affiliated or linked to BBMRI - MEDIZINISCHE UNIVERSITAT GRAZ (MUG), affiliated or linked to BBMRI - CENTRO DI RICERCA, SVILUPPO E STUDI SUPERIORI IN SARDEGNA SOCIETÀ A RESPONSABILITÀ LIMITATA (CRS4), affiliated or linked to BBMRI - KLINIKUM RECHTS DER ISAR DER TECHNISCHEN UNIVERSITAT MUNCHEN (TUM), affiliated or linked to BBMRI - UNIVERSITETET I OSLO (UiO), affiliated or linked to EATRIS - FUNDACIO HOSPITAL UNIVERSITARI VALL D'HEBRON - INSTITUT DE RECERCA (VHIR), affiliated or linked to EATRIS - UPPSALA UNIVERSITET (UU (ELIXIR-SE)), affiliated or linked to EMBL - THE UNIVERSITY OF MANCHESTER (UNIMAN), affiliated or linked to EMBL - UNIVERZA V LJUBLJANI (UL (ELIXIR-SI)), affiliated or linked to EMBL - CSC-TIETEEN TIETOTEKNIIKAN KESKUS OY (CSC (ELIXIR-FI)), affiliated or linked to EMBL - BARCELONA SUPERCOMPUTING CENTER - CENTRO NACIONAL DE SUPERCOMPUTACION (BSC (ELIXIR-ES)), affiliated or linked to EMBL - DANMARKS TEKNISKE UNIVERSITET (DTU (ELIXIR-DK)), affiliated or linked to EMBL - CONSIGLIO NAZIONALE DELLE RICERCHE (CNR (ELIXIR-IT)), affiliated or linked to EMBL - STICHTING DTL PROJECTS (DTL-Projects), affiliated or linked to EMBL - THE CHANCELLOR MASTERS AND SCHOLARS OF THE UNIVERSITY OF CAMBRIDGE (UCAM), affiliated or linked to EMBL - SIB INSTITUT SUISSE DE BIOINFORMATIQUE (SIB (ELIXIR-CH)), affiliated or linked to EMBL - Masarykova univerzita (MU-CERIT-SC), affiliated or linked to EMBL The linked third parties may declare as eligible the costs they incur for implementing the action tasks in accordance with Article 6.3. 34 Grant Agreement number: 825575 — EJP RD — H2020-SC1-BHC-2018-2020/H2020-SC1-2018-Single-Stage-RTD H2020 Associated with MGARef. document EJP Cofund — Multi:-v5.0 Ares(2018)6091977 28/11/2018 The beneficiaries must ensure that the Commission, the European Court of Auditors (ECA) and the European Anti-Fraud Office (OLAF) can exercise their rights under Articles 22 and 23 also towards their linked third parties. 14.1.2 The beneficiaries must ensure that their obligations under Articles 18, 20, 35, 36 and 38 also apply to their linked third parties. 14.2 Consequences of non-compliance If any obligation under Article 14.1.1 is breached, the costs of the linked third party will be ineligible (see Article 6) and will be rejected (see Article 42). If any obligation under Article 14.1.2 is breached, the grant may be reduced (see Article 43). Such breaches may also lead to any of the other measures described in Chapter 6. ARTICLE 14a — IMPLEMENTATION OF ACTION TASKS BY INTERNATIONAL PARTNERS Not applicable ARTICLE 15 — FINANCIAL SUPPORT TO THIRD PARTIES 15.1 Rules for providing financial support to third parties 15.1.1 The beneficiaries must provide financial support in accordance with the conditions set out in Annex 1. At a minimum, these conditions must include: (a) the maximum amount of financial support for each third party. The maximum amount may not exceed EUR 60 000 for each third party, unless it is necessary to achieve the objectives of the action as described in Annex 1; (b) the criteria for calculating the exact amount of the financial support; (c) the different types of activity that qualify for financial support, on the basis of a closed list; (d) the persons or categories of persons that may receive financial support, and (e) the criteria for giving financial support. The beneficiaries must ensure that the Commission, the European Court of Auditors (ECA) and the European Anti-Fraud Office (OLAF) can exercise their rights under Articles 22 and 23 also towards the third parties receiving financial support. 15.1.2 The beneficiaries must ensure that their obligations under Articles 35, 36, 38 and 46 also apply to the third parties receiving financial support. 15.2 Financial support in the form of prizes 35 Grant Agreement number: 825575 — EJP RD — H2020-SC1-BHC-2018-2020/H2020-SC1-2018-Single-Stage-RTD H2020 Associated with MGARef. document EJP Cofund — Multi:-v5.0 Ares(2018)6091977 28/11/2018 Not applicable 15.3 Consequences of non-compliance If a beneficiary breaches any of its obligations under Articles 15.1.1 or 15.2.1, the costs related to the financial support or prize will be ineligible (see Article 6) and will be rejected (see Article 42). If a beneficiary breaches any of its obligations under Articles 15.1.2 or 15.2.2, the grant may be reduced (see Article 43). Such breaches may also lead to any of the other measures described in Chapter 6. ARTICLE 16 — PROVISION OF TRANS-NATIONAL OR VIRTUAL ACCESS TO RESEARCH INFRASTRUCTURE Not applicable SECTION 2 RIGHTS AND OBLIGATIONS RELATED TO THE GRANT ADMINISTRATION ARTICLE 17 — GENERAL OBLIGATION TO INFORM 17.1 General obligation to provide information upon request The beneficiaries must provide — during implementation of the action or afterwards and in accordance with Article 41.2 — any information requested in order to verify eligibility of the costs, proper implementation of the action and compliance with any other obligation under the Agreement. 17.2 Obligation to keep information up to date and to inform about events and circumstances likely to affect the Agreement Each beneficiary must keep information stored in the Participant Portal Beneficiary Register (via the electronic exchange system; see Article 52) up to date, in particular, its name, address, legal representatives, legal form and organisation type. Each beneficiary must immediately inform the coordinator — which must immediately inform the Commission and the other beneficiaries — of any of the following: (a) events which are likely to affect significantly or delay the implementation of the action or the EU's financial interests, in particular: (i) changes in its legal, financial, technical, organisational or ownership situation or those of its linked third parties and (ii) changes in the name, address, legal form, organisation type of its linked third parties; (b) circumstances affecting: (i) the decision to award the grant or (ii) compliance with requirements under the Agreement. 36 Grant Agreement number: 825575 — EJP RD — H2020-SC1-BHC-2018-2020/H2020-SC1-2018-Single-Stage-RTD H2020 Associated with MGARef. document EJP Cofund — Multi:-v5.0 Ares(2018)6091977 28/11/2018 17.3 Consequences of non-compliance If a beneficiary breaches any of its obligations under this Article, the grant may be reduced (see Article 43). Such breaches may also lead to any of the other measures described in Chapter 6. ARTICLE 18 — KEEPING RECORDS — SUPPORTING DOCUMENTATION 18.1 Obligation to keep records and other supporting documentation The beneficiaries must — for a period of five years after the payment of the balance — keep records and other supporting documentation in order to prove the proper implementation of the action and the costs they declare as eligible. They must make them available upon request (see Article 17) or in the context of checks, reviews, audits or investigations (see Article 22). If there are on-going checks, reviews, audits, investigations, litigation or other pursuits of claims under the Agreement (including the extension of findings; see Article 22), the beneficiaries must keep the records and other supporting documentation until the end of these procedures. The beneficiaries must keep the original documents. Digital and digitalised documents are considered originals if they are authorised by the applicable national law. The Commission may accept non- original documents if it considers that they offer a comparable level of assurance. 18.1.1 Records and other supporting documentation on the scientific and technical implementation The beneficiaries must keep records and other supporting documentation on scientific and technical implementation of the action in line with the accepted standards in the respective field. 18.1.2 Records and other documentation to support the costs declared The beneficiaries must keep the records and documentation supporting the costs declared, in particular the following: (a) for actual costs: adequate records and other supporting documentation to prove the costs declared, such as contracts, subcontracts, invoices and accounting records. In addition, the beneficiaries' usual cost accounting practices and internal control procedures must enable direct reconciliation between the amounts declared, the amounts recorded in their accounts and the amounts stated in the supporting documentation; (b) for unit costs: adequate records and other supporting documentation to prove the number of units declared. Beneficiaries do not need to identify the actual eligible costs covered or to keep or provide supporting documentation (such as accounting statements) to prove the amount per unit. In addition, for unit costs calculated in accordance with the beneficiary's usual cost accounting practices, the beneficiaries must keep adequate records and documentation to prove that the cost accounting practices used comply with the conditions set out in Article 6.2. 37 Grant Agreement number: 825575 — EJP RD — H2020-SC1-BHC-2018-2020/H2020-SC1-2018-Single-Stage-RTD H2020 Associated with MGARef. document EJP Cofund — Multi:-v5.0 Ares(2018)6091977 28/11/2018 The beneficiaries and linked third parties may submit to the Commission, for approval, a certificate (drawn up in accordance with Annex 6) stating that their usual cost accounting practices comply with these conditions (‘certificate on the methodology’). If the certificate is approved, costs declared in line with this methodology will not be challenged subsequently, unless the beneficiaries have concealed information for the purpose of the approval. (c) for flat-rate costs: adequate records and other supporting documentation to prove the eligibility of the costs to which the flat-rate is applied. The beneficiaries do not need to identify the costs covered or provide supporting documentation (such as accounting statements) to prove the amount declared at a flat-rate. In addition, for personnel costs (declared as actual costs or on the basis of unit costs), the beneficiaries must keep time records for the number of hours declared. The time records must be in writing and approved by the persons working on the action and their supervisors, at least monthly. In the absence of reliable time records of the hours worked on the action, the Commission may accept alternative evidence supporting the number of hours declared, if it considers that it offers an adequate level of assurance. As an exception, for persons working exclusively on the action, there is no need to keep time records, if the beneficiary signs a declaration confirming that the persons concerned have worked exclusively on the action. For costs declared by linked third parties (see Article 14), it is the beneficiary that must keep the originals of the financial statements and the certificates on the financial statements of the linked third parties. 18.2 Consequences of non-compliance If a beneficiary breaches any of its obligations under this Article, costs insufficiently substantiated will be ineligible (see Article 6) and will be rejected (see Article 42), and the grant may be reduced (see Article 43). Such breaches may also lead to any of the other measures described in Chapter 6. ARTICLE 19 — SUBMISSION OF DELIVERABLES 19.1 Obligation to submit deliverables The coordinator must submit: - 90 days before the end of each reporting period: (a) the ‘annual work plan for the next year’ (see Annex 7), for approval by the Commission and (b) a summary progress report on the activities carried out during the on-going reporting period. This report must show how the activities proposed in the annual work plan for the next year ensure continuity with the work already carried out. 38 Grant Agreement number: 825575 — EJP RD — H2020-SC1-BHC-2018-2020/H2020-SC1-2018-Single-Stage-RTD H2020 Associated with MGARef. document EJP Cofund — Multi:-v5.0 Ares(2018)6091977 28/11/2018 If the Commission considers that the annual work plan for the next year does not comply with Annex 1, the coordinator must submit a revised version within 30 days from receiving formal notification. If the Commission considers that the revised annual work plan for the next year still does not comply with Annex 1, it may terminate the Agreement (see Article 50.3). - the other ‘deliverables’ identified in Annex 1, in accordance with the timing and conditions set out in it. 19.2 Consequences of non-compliance If the coordinator breaches any of its obligations under this Article, the Commission may apply any of the measures described in Chapter 6. ARTICLE 20 — REPORTING — PAYMENT REQUESTS 20.1 Obligation to submit reports The coordinator must submit to the Commission (see Article 52) the technical and financial reports set out in this Article. These reports include the requests for payment and must be drawn up using the forms and templates provided in the electronic exchange system (see Article 52). 20.2 Reporting periods The action is divided into the following ‘reporting periods’: - RP1: from month 1 to month 12 - RP2: from month 13 to month 24 - RP3: from month 25 to month 36 - RP4: from month 37 to month 48 - RP5: from month 49 to month 60 20.2a Request for a second pre-financing payment Not applicable 20.3 Periodic reports — Requests for interim payments The coordinator must submit a periodic report within 60 days following the end of each reporting period. The periodic report must include the following: (a) a ‘periodic technical report’ containing: (i) an explanation of the work carried out by the beneficiaries; (ii) an overview of the progress towards the objectives of the action, including milestones and deliverables identified in Annex 1 and the annual work plan for the year (see Annex 7). 39 Grant Agreement number: 825575 — EJP RD — H2020-SC1-BHC-2018-2020/H2020-SC1-2018-Single-Stage-RTD H2020 Associated with MGARef. document EJP Cofund — Multi:-v5.0 Ares(2018)6091977 28/11/2018 This report must include explanations justifying the differences between work expected to be carried out in accordance with Annex 1 and the annual work plan for the year (see Annex 7) and that actually carried out. The report must also detail the exploitation and dissemination of the results and — if required in Annex 1 — an updated ‘plan for the exploitation and dissemination of the results’; The report must indicate the communication activities. (iii) a summary for publication by the Commission; (iv) the answers to the ‘questionnaire’, covering issues related to the action implementation and the economic and societal impact, notably in the context of the Horizon 2020 key performance indicators and the Horizon 2020 monitoring requirements; (b) a ‘periodic financial report’ containing: (i) an ‘individual financial statement’ (see Annex 4) from each beneficiary and from each linked third party, for the reporting period concerned. The individual financial statement must detail the eligible costs (actual costs, unit costs and flat-rate costs; see Article 6) for each budget category (see Annex 2). The beneficiaries and linked third parties must declare all eligible costs, even if — for actual costs, unit costs and flat-rate costs — they exceed the amounts indicated in the estimated budget (see Annex 2). Amounts which are not declared in the individual financial statement will not be taken into account by the Commission. If an individual financial statement is not submitted for a reporting period, it may be included in the periodic financial report for the next reporting period. The individual financial statements of the last reporting period must also detail the receipts of the action (see Article 5.3.3). Each beneficiary and each linked third party must certify that: - the information provided is full, reliable and true; - the costs declared are eligible (see Article 6); - the costs can be substantiated by adequate records and supporting documentation (see Article 18) that will be produced upon request (see Article 17) or in the context of checks, reviews, audits and investigations (see Article 22), and - for the last reporting period: that all the receipts have been declared (see Article 5.3.3); (ii) an explanation of the use of resources and the information on subcontracting (see Article 13) and in-kind contributions provided by third parties (see Articles 11 and 12) from each beneficiary and from each linked third party, for the reporting period concerned; 40 Grant Agreement number: 825575 — EJP RD — H2020-SC1-BHC-2018-2020/H2020-SC1-2018-Single-Stage-RTD H2020 Associated with MGARef. document EJP Cofund — Multi:-v5.0 Ares(2018)6091977 28/11/2018 (iii) Not applicable; (iv) a ‘periodic summary financial statement’, created automatically by the electronic exchange system, consolidating the individual financial statements for the reporting period concerned and including — except for the last reporting period — the request for interim payment. 20.4 Final report — Request for payment of the balance In addition to the periodic report for the last reporting period, the coordinator must submit the final report within 60 days following the end of the last reporting period. The final report must include the following: (a) a ‘final technical report’ with a summary for publication containing: (i) an overview of the results and their exploitation and dissemination; (ii) the conclusions on the action, and (iii) the socio-economic impact of the action; (b) a ‘final financial report’ containing: (i) a ‘final summary financial statement’, created automatically by the electronic exchange system, consolidating the individual financial statements for all reporting periods and including the request for payment of the balance and (ii) a ‘certificate on the financial statements’ (drawn up in accordance with Annex 5) for each beneficiary and for each linked third party, if it requests a total contribution of EUR 325 000 or more, as reimbursement of actual costs and unit costs calculated on the basis of its usual cost accounting practices (see Article 5.2 and Article 6.2). 20.5 Information on cumulative expenditure incurred Not applicable 20.6 Currency for financial statements and conversion into euro Financial statements must be drafted in euro. Beneficiaries and linked third parties with accounting established in a currency other than the euro must convert the costs recorded in their accounts into euro, at the average of the daily exchange rates published in the C series of the Official Journal of the European Union, calculated over the corresponding reporting period. If no daily euro exchange rate is published in the Official Journal of the European Union for the currency in question, they must be converted at the average of the monthly accounting rates published on the Commission’s website, calculated over the corresponding reporting period. Beneficiaries and linked third parties with accounting established in euro must convert costs incurred in another currency into euro according to their usual accounting practices. 41 Grant Agreement number: 825575 — EJP RD — H2020-SC1-BHC-2018-2020/H2020-SC1-2018-Single-Stage-RTD H2020 Associated with MGARef. document EJP Cofund — Multi:-v5.0 Ares(2018)6091977 28/11/2018 20.7 Language of reports All reports (technical and financial reports, including financial statements) must be submitted in the language of the Agreement. 20.8 Consequences of non-compliance If the reports submitted do not comply with this Article, the Commission may suspend the payment deadline (see Article 47) and apply any of the other measures described in Chapter 6. If the coordinator breaches its obligation to submit the reports and if it fails to comply with this obligation within 30 days following a written reminder, the Commission may terminate the Agreement (see Article 50) or apply any of the other measures described in Chapter 6. ARTICLE 21 — PAYMENTS AND PAYMENT ARRANGEMENTS 21.1 Payments to be made The following payments will be made to the coordinator: - a pre-financing payment; - one or more interim payments, on the basis of the request(s) for interim payment (see Article 20), and - one payment of the balance, on the basis of the request for payment of the balance (see Article 20). 21.2 Pre-financing payment — Amount — Amount retained for the Guarantee Fund The aim of the pre-financing is to provide the beneficiaries with a float. It remains the property of the EU until the payment of the balance. The Commission will — within 30 days, either from the entry into force of the Agreement (see Article 58) or from 10 days before the starting date of the action (see Article 3), whichever is the latest — make a pre-financing payment to the coordinator of EUR 17 628 693.44 (seventeen million six hundred and twenty eight thousand six hundred and ninety three EURO and forty four eurocents), except if Article 48 applies. From this amount, an amount of EUR 2 753 691.56 (two million seven hundred and fifty three thousand six hundred and ninety one EURO and fifty six eurocents), corresponding to 5% of the maximum grant amount (see Article 5.1), is retained by the Commission and transferred into the ‘Guarantee Fund’. 21.3 Interim payments — Amount — Calculation Interim payments reimburse the eligible costs incurred for the implementation of the action during the corresponding reporting periods. The Commission will pay to the coordinator the amount due as interim payment within 90 days from receiving the periodic report (see Article 20.3), except if Articles 47 or 48 apply. 42 Grant Agreement number: 825575 — EJP RD — H2020-SC1-BHC-2018-2020/H2020-SC1-2018-Single-Stage-RTD H2020 Associated with MGARef. document EJP Cofund — Multi:-v5.0 Ares(2018)6091977 28/11/2018 Payment is subject to the approval of the periodic report. Its approval does not imply recognition of the compliance, authenticity, completeness or correctness of its content. The amount due as interim payment is calculated by the Commission in the following steps: Step 1 – Application of the reimbursement rates Step 2 – Limit to 90% of the maximum grant amount 21.3.1 Step 1 — Application of the reimbursement rates The reimbursement rate(s) (see Article 5.2) are applied to the eligible costs (actual costs, unit costs and flat-rate costs; see Article 6) declared by the beneficiaries and the linked third parties (see Article 20) and approved by the Commission (see above) for the concerned reporting period. 21.3.2 Step 2 — Limit to 90% of the maximum grant amount The total amount of pre-financing and interim payments must not exceed 90% of the maximum grant amount set out in Article 5.1. The maximum amount for the interim payment will be calculated as follows: {90% of the maximum grant amount (see Article 5.1) minus {pre-financing and previous interim payments}}. 21.4 Payment of the balance — Amount — Calculation — Release of the amount retained for the Guarantee Fund The payment of the balance reimburses the remaining part of the eligible costs incurred by the beneficiaries for the implementation of the action. If the total amount of earlier payments is greater than the final grant amount (see Article 5.3), the payment of the balance takes the form of a recovery (see Article 44). If the total amount of earlier payments is lower than the final grant amount, the Commission will pay the balance within 90 days from receiving the final report (see Article 20.4), except if Articles 47 or 48 apply. Payment is subject to the approval of the final report. Its approval does not imply recognition of the compliance, authenticity, completeness or correctness of its content. The amount due as the balance is calculated by the Commission by deducting the total amount of pre-financing and interim payments (if any) already made, from the final grant amount determined in accordance with Article 5.3: {final grant amount (see Article 5.3) minus {pre-financing and interim payments (if any) made}}. 43 Grant Agreement number: 825575 — EJP RD — H2020-SC1-BHC-2018-2020/H2020-SC1-2018-Single-Stage-RTD H2020 Associated with MGARef. document EJP Cofund — Multi:-v5.0 Ares(2018)6091977 28/11/2018 At the payment of the balance, the amount retained for the Guarantee Fund (see above) will be released and: - if the balance is positive: the amount released will be paid in full to the coordinator together with the amount due as the balance; - if the balance is negative (payment of the balance taking the form of recovery): it will be deducted from the amount released (see Article 44.1.2). If the resulting amount: - is positive, it will be paid to the coordinator - is negative, it will be recovered. The amount to be paid may however be offset — without the beneficiaries’ consent — against any other amount owed by a beneficiary to the Commission or an executive agency (under the EU or Euratom budget), up to the maximum EU contribution indicated, for that beneficiary, in the estimated budget (see Annex 2). 21.5 Notification of amounts due When making payments, the Commission will formally notify to the coordinator the amount due, specifying whether it concerns a interim payment or the payment of the balance. For the payment of the balance, the notification will also specify the final grant amount. In the case of reduction of the grant or recovery of undue amounts, the notification will be preceded by the contradictory procedure set out in Articles 43 and 44. 21.6 Currency for payments The Commission will make all payments in euro. 21.7 Payments to the coordinator — Distribution to the beneficiaries Payments will be made to the coordinator. Payments to the coordinator will discharge the Commission from its payment obligation. The coordinator must distribute the payments between the beneficiaries without unjustified delay. Pre-financing may however be distributed only: (a) if the minimum number of beneficiaries set out in the call for proposals has acceded to the Agreement (see Article 56) and (b) to beneficiaries that have acceded to the Agreement (see Article 56). 21.8 Bank account for payments All payments will be made to the following bank account: 44 Grant Agreement number: 825575 — EJP RD — H2020-SC1-BHC-2018-2020/H2020-SC1-2018-Single-Stage-RTD H2020 Associated with MGARef. document EJP Cofund — Multi:-v5.0 Ares(2018)6091977 28/11/2018 Name of bank: TRESOR PUBLIC Full name of the account holder: ACS INSERM PARIS VI ST ANTOINE IBAN code: FR7610071750000000100523686 21.9 Costs of payment transfers The cost of the payment transfers is borne as follows: - the Commission bears the cost of transfers charged by its bank; - the beneficiary bears the cost of transfers charged by its bank; - the party causing a repetition of a transfer bears all costs of the repeated transfer. 21.10 Date of payment Payments by the Commission are considered to have been carried out on the date when they are debited to its account. 21.11 Consequences of non-compliance 21.11.1 If the Commission does not pay within the payment deadlines (see above), the beneficiaries are entitled to late-payment interest at the rate applied by the European Central Bank (ECB) for its main refinancing operations in euros (‘reference rate’), plus three and a half points. The reference rate is the rate in force on the first day of the month in which the payment deadline expires, as published in the C series of the Official Journal of the European Union. If the late-payment interest is lower than or equal to EUR 200, it will be paid to the coordinator only upon request submitted within two months of receiving the late payment. Late-payment interest is not due if all beneficiaries are EU Member States (including regional and local government authorities or other public bodies acting on behalf of a Member State for the purpose of this Agreement). Suspension of the payment deadline or payments (see Articles 47 and 48) will not be considered as late payment. Late-payment interest covers the period running from the day following the due date for payment (see above), up to and including the date of payment. Late-payment interest is not considered for the purposes of calculating the final grant amount. 21.11.2 If the coordinator breaches any of its obligations under this Article, the grant may be reduced (see Article 43) and the Agreement or the participation of the coordinator may be terminated (see Article 50). Such breaches may also lead to any of the other measures described in Chapter 6. ARTICLE 22 — CHECKS, REVIEWS, AUDITS AND INVESTIGATIONS — EXTENSION OF FINDINGS 22.1 Checks, reviews and audits by the Commission 45 Grant Agreement number: 825575 — EJP RD — H2020-SC1-BHC-2018-2020/H2020-SC1-2018-Single-Stage-RTD H2020 Associated with MGARef. document EJP Cofund — Multi:-v5.0 Ares(2018)6091977 28/11/2018 22.1.1 Right to carry out checks The Commission will — during the implementation of the action or afterwards — check the proper implementation of the action and compliance with the obligations under the Agreement, including assessing deliverables and reports. For this purpose the Commission may be assisted by external persons or bodies. The Commission may also request additional information in accordance with Article 17. The Commission may request beneficiaries to provide such information to it directly. Information provided must be accurate, precise and complete and in the format requested, including electronic format. 22.1.2 Right to carry out reviews The Commission may — during the implementation of the action or afterwards — carry out reviews on the proper implementation of the action (including assessment of deliverables and reports), compliance with the obligations under the Agreement and continued scientific or technological relevance of the action. Reviews may be started up to two years after the payment of the balance. They will be formally notified to the coordinator or beneficiary concerned and will be considered to have started on the date of the formal notification. If the review is carried out on a third party (see Articles 10 to 16), the beneficiary concerned must inform the third party. The Commission may carry out reviews directly (using its own staff) or indirectly (using external persons or bodies appointed to do so). It will inform the coordinator or beneficiary concerned of the identity of the external persons or bodies. They have the right to object to the appointment on grounds of commercial confidentiality. The coordinator or beneficiary concerned must provide — within the deadline requested — any information and data in addition to deliverables and reports already submitted (including information on the use of resources). The Commission may request beneficiaries to provide such information to it directly. The coordinator or beneficiary concerned may be requested to participate in meetings, including with external experts. For on-the-spot reviews, the beneficiaries must allow access to their sites and premises, including to external persons or bodies, and must ensure that information requested is readily available. Information provided must be accurate, precise and complete and in the format requested, including electronic format. On the basis of the review findings, a ‘review report’ will be drawn up. The Commission will formally notify the review report to the coordinator or beneficiary concerned, which has 30 days to formally notify observations (‘contradictory review procedure’). Reviews (including review reports) are in the language of the Agreement. 46 Grant Agreement number: 825575 — EJP RD — H2020-SC1-BHC-2018-2020/H2020-SC1-2018-Single-Stage-RTD H2020 Associated with MGARef. document EJP Cofund — Multi:-v5.0 Ares(2018)6091977 28/11/2018 22.1.3 Right to carry out audits The Commission may — during the implementation of the action or afterwards — carry out audits on the proper implementation of the action and compliance with the obligations under the Agreement. Audits may be started up to two years after the payment of the balance. They will be formally notified to the coordinator or beneficiary concerned and will be considered to have started on the date of the formal notification. If the audit is carried out on a third party (see Articles 10 to 16), the beneficiary concerned must inform the third party. The Commission may carry out audits directly (using its own staff) or indirectly (using external persons or bodies appointed to do so). It will inform the coordinator or beneficiary concerned of the identity of the external persons or bodies. They have the right to object to the appointment on grounds of commercial confidentiality. The coordinator or beneficiary concerned must provide — within the deadline requested — any information (including complete accounts, individual salary statements or other personal data) to verify compliance with the Agreement. The Commission may request beneficiaries to provide such information to it directly. For on-the-spot audits, the beneficiaries must allow access to their sites and premises, including to external persons or bodies, and must ensure that information requested is readily available. Information provided must be accurate, precise and complete and in the format requested, including electronic format. On the basis of the audit findings, a ‘draft audit report’ will be drawn up. The Commission will formally notify the draft audit report to the coordinator or beneficiary concerned, which has 30 days to formally notify observations (‘contradictory audit procedure’). This period may be extended by the Commission in justified cases. The ‘final audit report’ will take into account observations by the coordinator or beneficiary concerned. The report will be formally notified to it. Audits (including audit reports) are in the language of the Agreement. The Commission may also access the beneficiaries’ statutory records for the periodical assessment of unit costs or flat-rate amounts. 22.2 Investigations by the European Anti-Fraud Office (OLAF) Under Regulations No 883/201313 and No 2185/9614 (and in accordance with their provisions and 13 Regulation (EU, Euratom) No 883/2013 of the European Parliament and of the Council of 11 September 2013 concerning investigations conducted by the European Anti-Fraud Office (OLAF) and repealing Regulation (EC) No 1073/1999 of the European Parliament and of the Council and Council Regulation (Euratom) No 1074/1999 (OJ L 248, 18.09.2013, p. 1). 14 Council Regulation (Euratom, EC) No 2185/1996 of 11 November 1996 concerning on-the-spot checks and inspections carried out by the Commission in order to protect the European Communities' financial interests against fraud and other irregularities (OJ L 292, 15.11.1996, p. 2). 47 Grant Agreement number: 825575 — EJP RD — H2020-SC1-BHC-2018-2020/H2020-SC1-2018-Single-Stage-RTD H2020 Associated with MGARef. document EJP Cofund — Multi:-v5.0 Ares(2018)6091977 28/11/2018 procedures), the European Anti-Fraud Office (OLAF) may — at any moment during implementation of the action or afterwards — carry out investigations, including on-the-spot checks and inspections, to establish whether there has been fraud, corruption or any other illegal activity affecting the financial interests of the EU. 22.3 Checks and audits by the European Court of Auditors (ECA) Under Article 287 of the Treaty on the Functioning of the European Union (TFEU) and Article 161 of the Financial Regulation No 966/201215, the European Court of Auditors (ECA) may — at any moment during implementation of the action or afterwards — carry out audits. The ECA has the right of access for the purpose of checks and audits. 22.4 Checks, reviews, audits and investigations for international organisations In conformity with its financial regulations, the European Union, including the European Anti-Fraud Office (OLAF) and the European Court of Auditors (ECA), may undertake, including on the spot, checks, reviews, audits and investigations. This Article will be applied in accordance with any specific agreement concluded in this respect by the international organisation and the European Union. 22.5 Consequences of findings in checks, reviews, audits and investigations — Extension of findings 22.5.1 Findings in this grant Findings in checks, reviews, audits or investigations carried out in the context of this grant may lead to the rejection of ineligible costs (see Article 42), reduction of the grant (see Article 43), recovery of undue amounts (see Article 44) or to any of the other measures described in Chapter 6. Rejection of costs or reduction of the grant after the payment of the balance will lead to a revised final grant amount (see Article 5.4). Findings in checks, reviews, audits or investigations may lead to a request for amendment for the modification of Annex 1 (see Article 55). Checks, reviews, audits or investigations that find systemic or recurrent errors, irregularities, fraud or breach of obligations may also lead to consequences in other EU or Euratom grants awarded under similar conditions (‘extension of findings from this grant to other grants’). Moreover, findings arising from an OLAF investigation may lead to criminal prosecution under national law. 22.5.2 Findings in other grants The Commission may extend findings from other grants to this grant (‘extension of findings from other grants to this grant’), if: 15 Regulation (EU, Euratom) No 966/2012 of the European Parliament and of the Council of 25 October 2012 on the financial rules applicable to the general budget of the Union and repealing Council Regulation (EC, Euratom) No 1605/2002 (OJ L 298, 26.10.2012, p. 1). 48 Grant Agreement number: 825575 — EJP RD — H2020-SC1-BHC-2018-2020/H2020-SC1-2018-Single-Stage-RTD H2020 Associated with MGARef. document EJP Cofund — Multi:-v5.0 Ares(2018)6091977 28/11/2018 (a) the beneficiary concerned is found, in other EU or Euratom grants awarded under similar conditions, to have committed systemic or recurrent errors, irregularities, fraud or breach of obligations that have a material impact on this grant and (b) those findings are formally notified to the beneficiary concerned — together with the list of grants affected by the findings — no later than two years after the payment of the balance of this grant. The extension of findings may lead to the rejection of costs (see Article 42), reduction of the grant (see Article 43), recovery of undue amounts (see Article 44), suspension of payments (see Article 48), suspension of the action implementation (see Article 49) or termination (see Article 50). 22.5.3 Procedure The Commission will formally notify the beneficiary concerned the systemic or recurrent errors and its intention to extend these audit findings, together with the list of grants affected. 22.5.3.1 If the findings concern eligibility of costs: the formal notification will include: (a) an invitation to submit observations on the list of grants affected by the findings; (b) the request to submit revised financial statements for all grants affected; (c) the correction rate for extrapolation established by the Commission on the basis of the systemic or recurrent errors, to calculate the amounts to be rejected if the beneficiary concerned: (i) considers that the submission of revised financial statements is not possible or practicable or (ii) does not submit revised financial statements. The beneficiary concerned has 90 days from receiving notification to submit observations, revised financial statements or to propose a duly substantiated alternative correction method. This period may be extended by the Commission in justified cases. The Commission may then start a rejection procedure in accordance with Article 42, on the basis of: - the revised financial statements, if approved; - the proposed alternative correction method, if accepted or - the initially notified correction rate for extrapolation, if it does not receive any observations or revised financial statements, does not accept the observations or the proposed alternative correction method or does not approve the revised financial statements. 22.5.3.2 If the findings concern substantial errors, irregularities or fraud or serious breach of obligations: the formal notification will include: (a) an invitation to submit observations on the list of grants affected by the findings and (b) the flat-rate the Commission intends to apply according to the principle of proportionality. 49 Grant Agreement number: 825575 — EJP RD — H2020-SC1-BHC-2018-2020/H2020-SC1-2018-Single-Stage-RTD H2020 Associated with MGARef. document EJP Cofund — Multi:-v5.0 Ares(2018)6091977 28/11/2018 The beneficiary concerned has 90 days from receiving notification to submit observations or to propose a duly substantiated alternative flat-rate. The Commission may then start a reduction procedure in accordance with Article 43, on the basis of: - the proposed alternative flat-rate, if accepted or - the initially notified flat-rate, if it does not receive any observations or does not accept the observations or the proposed alternative flat-rate. 22.6 Consequences of non-compliance If a beneficiary breaches any of its obligations under this Article, any insufficiently substantiated costs will be ineligible (see Article 6) and will be rejected (see Article 42). Such breaches may also lead to any of the other measures described in Chapter 6. ARTICLE 23 — EVALUATION OF THE IMPACT OF THE ACTION 23.1 Right to evaluate the impact of the action The Commission may carry out interim and final evaluations of the impact of the action measured against the objective of the EU programme. Evaluations may be started during implementation of the action and up to five years after the payment of the balance. The evaluation is considered to start on the date of the formal notification to the coordinator or beneficiaries. The Commission may make these evaluations directly (using its own staff) or indirectly (using external bodies or persons it has authorised to do so). The coordinator or beneficiaries must provide any information relevant to evaluate the impact of the action, including information in electronic format. 23.2 Consequences of non-compliance If a beneficiary breaches any of its obligations under this Article, the Commission may apply the measures described in Chapter 6. SECTION 3 RIGHTS AND OBLIGATIONS RELATED TO BACKGROUND AND RESULTS SUBSECTION 1 GENERAL ARTICLE 23a — MANAGEMENT OF INTELLECTUAL PROPERTY 23a.1 Obligation to take measures to implement the Commission Recommendation on the management of intellectual property in knowledge transfer activities 50 Grant Agreement number: 825575 — EJP RD — H2020-SC1-BHC-2018-2020/H2020-SC1-2018-Single-Stage-RTD H2020 Associated with MGARef. document EJP Cofund — Multi:-v5.0 Ares(2018)6091977 28/11/2018 Beneficiaries that are universities or other public research organisations must take measures to implement the principles set out in Points 1 and 2 of the Code of Practice annexed to the Commission Recommendation on the management of intellectual property in knowledge transfer activities16. This does not change the obligations set out in Subsections 2 and 3 of this Section. The beneficiaries must ensure that researchers and third parties involved in the action are aware of them. 23a.2 Consequences of non-compliance If a beneficiary breaches its obligations under this Article, the Commission may apply any of the measures described in Chapter 6. SUBSECTION 2 RIGHTS AND OBLIGATIONS RELATED TO BACKGROUND ARTICLE 24 — AGREEMENT ON BACKGROUND 24.1 Agreement on background The beneficiaries must identify and agree (in writing) on the background for the action (‘agreement on background’). ‘Background’ means any data, know-how or information — whatever its form or nature (tangible or intangible), including any rights such as intellectual property rights — that: (a) is held by the beneficiaries before they acceded to the Agreement, and (b) is needed to implement the action or exploit the results. 24.2 Consequences of non-compliance If a beneficiary breaches any of its obligations under this Article, the grant may be reduced (see Article 43). Such breaches may also lead to any of the other measures described in Chapter 6. ARTICLE 25 — ACCESS RIGHTS TO BACKGROUND 25.1 Exercise of access rights — Waiving of access rights — No sub-licensing To exercise access rights, this must first be requested in writing (‘request for access’). ‘Access rights’ means rights to use results or background under the terms and conditions laid down in this Agreement. Waivers of access rights are not valid unless in writing. 16 Commission Recommendation C(2008) 1329 of 10.4.2008 on the management of intellectual property in knowledge transfer activities and the Code of Practice for universities and other public research institutions attached to this recommendation. 51 Grant Agreement number: 825575 — EJP RD — H2020-SC1-BHC-2018-2020/H2020-SC1-2018-Single-Stage-RTD H2020 Associated with MGARef. document EJP Cofund — Multi:-v5.0 Ares(2018)6091977 28/11/2018 Unless agreed otherwise, access rights do not include the right to sub-license. 25.2 Access rights for other beneficiaries, for implementing their own tasks under the action The beneficiaries must give each other access — on a royalty-free basis — to background needed to implement their own tasks under the action, unless the beneficiary that holds the background has — before acceding to the Agreement —: (a) informed the other beneficiaries that access to its background is subject to legal restrictions or limits, including those imposed by the rights of third parties (including personnel), or (b) agreed with the other beneficiaries that access would not be on a royalty-free basis. 25.3 Access rights for other beneficiaries, for exploiting their own results The beneficiaries must give each other access — under fair and reasonable conditions — to background needed for exploiting their own results, unless the beneficiary that holds the background has — before acceding to the Agreement — informed the other beneficiaries that access to its background is subject to legal restrictions or limits, including those imposed by the rights of third parties (including personnel). ‘Fair and reasonable conditions’ means appropriate conditions, including possible financial terms or royalty-free conditions, taking into account the specific circumstances of the request for access, for example the actual or potential value of the results or background to which access is requested and/or the scope, duration or other characteristics of the exploitation envisaged. Requests for access may be made — unless agreed otherwise — up to one year after the period set out in Article 3. 25.4 Access rights for affiliated entities Unless otherwise agreed in the consortium agreement, access to background must also be given — under fair and reasonable conditions (see above; Article 25.3) and unless it is subject to legal restrictions or limits, including those imposed by the rights of third parties (including personnel) — to affiliated entities17 established in an EU Member State or ‘associated country’18, if this is needed to exploit the results generated by the beneficiaries to which they are affiliated. Unless agreed otherwise (see above; Article 25.1), the affiliated entity concerned must make the request directly to the beneficiary that holds the background. Requests for access may be made — unless agreed otherwise — up to one year after the period set out in Article 3. 25.5 Access rights for third parties Not applicable 17 For the definition, see ‘affiliated entity’ footnote (Article 14.1). 18 For the definition, see Article 2.1(3) of the Rules for Participation Regulation No 1290/2013: ‘associated country’ means a third country which is party to an international agreement with the Union, as identified in Article 7 of Horizon 2020 Framework Programme Regulation No 1291/2013. Article 7 sets out the conditions for association of non-EU countries to Horizon 2020. 52 Grant Agreement number: 825575 — EJP RD — H2020-SC1-BHC-2018-2020/H2020-SC1-2018-Single-Stage-RTD H2020 Associated with MGARef. document EJP Cofund — Multi:-v5.0 Ares(2018)6091977 28/11/2018 25.6 Consequences of non-compliance If a beneficiary breaches any of its obligations under this Article, the grant may be reduced (see Article 43). Such breaches may also lead to any of the other measures described in Chapter 6. SUBSECTION 3 RIGHTS AND OBLIGATIONS RELATED TO RESULTS ARTICLE 26 — OWNERSHIP OF RESULTS 26.1 Ownership by the beneficiary that generates the results Results are owned by the beneficiary that generates them. ‘Results’ means any (tangible or intangible) output of the action such as data, knowledge or information — whatever its form or nature, whether it can be protected or not — that is generated in the action, as well as any rights attached to it, including intellectual property rights. 26.2 Joint ownership by several beneficiaries Two or more beneficiaries own results jointly if: (a) they have jointly generated them and (b) it is not possible to: (i) establish the respective contribution of each beneficiary, or (ii) separate them for the purpose of applying for, obtaining or maintaining their protection (see Article 27). The joint owners must agree (in writing) on the allocation and terms of exercise of their joint ownership (‘joint ownership agreement’), to ensure compliance with their obligations under this Agreement. Unless otherwise agreed in the joint ownership agreement, each joint owner may grant non-exclusive licences to third parties to exploit jointly-owned results (without any right to sub-license), if the other joint owners are given: (a) at least 45 days advance notice and (b) fair and reasonable compensation. Once the results have been generated, joint owners may agree (in writing) to apply another regime than joint ownership (such as, for instance, transfer to a single owner (see Article 30) with access rights for the others). 26.3 Rights of third parties (including personnel) If third parties (including personnel) may claim rights to the results, the beneficiary concerned must ensure that it complies with its obligations under the Agreement. 53 Grant Agreement number: 825575 — EJP RD — H2020-SC1-BHC-2018-2020/H2020-SC1-2018-Single-Stage-RTD H2020 Associated with MGARef. document EJP Cofund — Multi:-v5.0 Ares(2018)6091977 28/11/2018 If a third party generates results, the beneficiary concerned must obtain all necessary rights (transfer, licences or other) from the third party, in order to be able to respect its obligations as if those results were generated by the beneficiary itself. If obtaining the rights is impossible, the beneficiary must refrain from using the third party to generate the results. 26.4 EU ownership, to protect results 26.4.1 The EU may — with the consent of the beneficiary concerned — assume ownership of results to protect them, if a beneficiary intends — up to four years after the period set out in Article 3 — to disseminate its results without protecting them, except in any of the following cases: (a) the lack of protection is because protecting the results is not possible, reasonable or justified (given the circumstances); (b) the lack of protection is because there is a lack of potential for commercial or industrial exploitation, or (c) the beneficiary intends to transfer the results to another beneficiary or third party established in an EU Member State or associated country, which will protect them. Before the results are disseminated and unless any of the cases above under Points (a), (b) or (c) applies, the beneficiary must formally notify the Commission and at the same time inform it of any reasons for refusing consent. The beneficiary may refuse consent only if it can show that its legitimate interests would suffer significant harm. If the Commission decides to assume ownership, it will formally notify the beneficiary concerned within 45 days of receiving notification. No dissemination relating to these results may take place before the end of this period or, if the Commission takes a positive decision, until it has taken the necessary steps to protect the results. 26.4.2 The EU may — with the consent of the beneficiary concerned — assume ownership of results to protect them, if a beneficiary intends — up to four years after the period set out in Article 3 — to stop protecting them or not to seek an extension of protection, except in any of the following cases: (a) the protection is stopped because of a lack of potential for commercial or industrial exploitation; (b) an extension would not be justified given the circumstances. A beneficiary that intends to stop protecting results or not seek an extension must — unless any of the cases above under Points (a) or (b) applies — formally notify the Commission at least 60 days before the protection lapses or its extension is no longer possible and at the same time inform it of any reasons for refusing consent. The beneficiary may refuse consent only if it can show that its legitimate interests would suffer significant harm. If the Commission decides to assume ownership, it will formally notify the beneficiary concerned within 45 days of receiving notification. 26.5 Consequences of non-compliance 54 Grant Agreement number: 825575 — EJP RD — H2020-SC1-BHC-2018-2020/H2020-SC1-2018-Single-Stage-RTD H2020 Associated with MGARef. document EJP Cofund — Multi:-v5.0 Ares(2018)6091977 28/11/2018 If a beneficiary breaches any of its obligations under this Article, the grant may be reduced (see Article 43). Such breaches may also lead to the any of the other measures described in Chapter 6. ARTICLE 27 — PROTECTION OF RESULTS — VISIBILITY OF EU FUNDING 27.1 Obligation to protect the results Each beneficiary must examine the possibility of protecting its results and must adequately protect them — for an appropriate period and with appropriate territorial coverage — if: (a) the results can reasonably be expected to be commercially or industrially exploited and (b) protecting them is possible, reasonable and justified (given the circumstances). When deciding on protection, the beneficiary must consider its own legitimate interests and the legitimate interests (especially commercial) of the other beneficiaries. 27.2 EU ownership, to protect the results If a beneficiary intends not to protect its results, to stop protecting them or not seek an extension of protection, the EU may — under certain conditions (see Article 26.4) — assume ownership to ensure their (continued) protection. 27.3 Information on EU funding Applications for protection of results (including patent applications) filed by or on behalf of a beneficiary must — unless the Commission requests or agrees otherwise or unless it is impossible — include the following: “The project leading to this application has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 825575”. 27.4 Consequences of non-compliance If a beneficiary breaches any of its obligations under this Article, the grant may be reduced (see Article 43). Such a breach may also lead to any of the other measures described in Chapter 6. ARTICLE 28 — EXPLOITATION OF RESULTS 28.1 Obligation to exploit the results Each beneficiary must — up to four years after the period set out in Article 3 — take measures aiming to ensure ‘exploitation’ of its results (either directly or indirectly, in particular through transfer or licensing; see Article 30) by: (a) using them in further research activities (outside the action); (b) developing, creating or marketing a product or process; 55 Grant Agreement number: 825575 — EJP RD — H2020-SC1-BHC-2018-2020/H2020-SC1-2018-Single-Stage-RTD H2020 Associated with MGARef. document EJP Cofund — Multi:-v5.0 Ares(2018)6091977 28/11/2018 (c) creating and providing a service, or (d) using them in standardisation activities. This does not change the security obligations in Article 37, which still apply. 28.2 Results that could contribute to European or international standards — Information on EU funding If results are incorporated in a standard, the beneficiary concerned must — unless the Commission requests or agrees otherwise or unless it is impossible — ask the standardisation body to include the following statement in (information related to) the standard: “Results incorporated in this standard received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 825575”. 28.3 Consequences of non-compliance If a beneficiary breaches any of its obligations under this Article, the grant may be reduced in accordance with Article 43. Such a breach may also lead to any of the other measures described in Chapter 6. ARTICLE 29 — DISSEMINATION OF RESULTS — OPEN ACCESS — VISIBILITY OF EU FUNDING 29.1 Obligation to disseminate results Unless it goes against their legitimate interests, each beneficiary must — as soon as possible — ‘disseminate’ its results by disclosing them to the public by appropriate means (other than those resulting from protecting or exploiting the results), including in scientific publications (in any medium). This does not change the obligation to protect results in Article 27, the confidentiality obligations in Article 36, the security obligations in Article 37 or the obligations to protect personal data in Article 39, all of which still apply. A beneficiary that intends to disseminate its results must give advance notice to the other beneficiaries of — unless agreed otherwise — at least 45 days, together with sufficient information on the results it will disseminate. Any other beneficiary may object within — unless agreed otherwise — 30 days of receiving notification, if it can show that its legitimate interests in relation to the results or background would be significantly harmed. In such cases, the dissemination may not take place unless appropriate steps are taken to safeguard these legitimate interests. If a beneficiary intends not to protect its results, it may — under certain conditions (see Article 26.4.1) — need to formally notify the Commission before dissemination takes place. 29.2 Open access to scientific publications 56 Grant Agreement number: 825575 — EJP RD — H2020-SC1-BHC-2018-2020/H2020-SC1-2018-Single-Stage-RTD H2020 Associated with MGARef. document EJP Cofund — Multi:-v5.0 Ares(2018)6091977 28/11/2018 Each beneficiary must ensure open access (free of charge online access for any user) to all peer-reviewed scientific publications relating to its results. In particular, it must: (a) as soon as possible and at the latest on publication, deposit a machine-readable electronic copy of the published version or final peer-reviewed manuscript accepted for publication in a repository for scientific publications; Moreover, the beneficiary must aim to deposit at the same time the research data needed to validate the results presented in the deposited scientific publications. (b) ensure open access to the deposited publication — via the repository — at the latest: (i) on publication, if an electronic version is available for free via the publisher, or (ii) within six months of publication (twelve months for publications in the social sciences and humanities) in any other case. (c) ensure open access — via the repository — to the bibliographic metadata that identify the deposited publication. The bibliographic metadata must be in a standard format and must include all of the following: - the terms “European Union (EU)” and “Horizon 2020”; - the name of the action, acronym and grant number; - the publication date, and length of embargo period if applicable, and - a persistent identifier. 29.3 Open access to research data Regarding the digital research data generated in the action (‘data’), the beneficiaries must: (a) deposit in a research data repository and take measures to make it possible for third parties to access, mine, exploit, reproduce and disseminate — free of charge for any user — the following: (i) the data, including associated metadata, needed to validate the results presented in scientific publications, as soon as possible; (ii) other data, including associated metadata, as specified and within the deadlines laid down in the ‘data management plan’ (see Annex 1); (b) provide information — via the repository — about tools and instruments at the disposal of the beneficiaries and necessary for validating the results (and — where possible — provide the tools and instruments themselves). This does not change the obligation to protect results in Article 27, the confidentiality obligations in Article 36, the security obligations in Article 37 or the obligations to protect personal data in Article 39, all of which still apply. 57 Grant Agreement number: 825575 — EJP RD — H2020-SC1-BHC-2018-2020/H2020-SC1-2018-Single-Stage-RTD H2020 Associated with MGARef. document EJP Cofund — Multi:-v5.0 Ares(2018)6091977 28/11/2018 As an exception, the beneficiaries do not have to ensure open access to specific parts of their research data under Point (a)(i) and (iii), if the achievement of the action's main objective (as described in Annex 1) would be jeopardised by making those specific parts of the research data openly accessible. In this case, the data management plan must contain the reasons for not giving access. 29.4 Information on EU funding — Obligation and right to use the EU emblem Unless the Commission requests or agrees otherwise or unless it is impossible, any dissemination of results (in any form, including electronic) must: (a) display the EU emblem and (b) include the following text: “This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 825575”. When displayed together with another logo, the EU emblem must have appropriate prominence. For the purposes of their obligations under this Article, the beneficiaries may use the EU emblem without first obtaining approval from the Commission. This does not however give them the right to exclusive use. Moreover, they may not appropriate the EU emblem or any similar trademark or logo, either by registration or by any other means. 29.5 Disclaimer excluding Commission responsibility Any dissemination of results must indicate that it reflects only the author's view and that the Commission is not responsible for any use that may be made of the information it contains. 29.6 Consequences of non-compliance If a beneficiary breaches any of its obligations under this Article, the grant may be reduced (see Article 43). Such a breach may also lead to any of the other measures described in Chapter 6. ARTICLE 30 — TRANSFER AND LICENSING OF RESULTS 30.1 Transfer of ownership Each beneficiary may transfer ownership of its results. It must however ensure that its obligations under Articles 26.2, 26.4, 27, 28, 29, 30 and 31 also apply to the new owner and that this owner has the obligation to pass them on in any subsequent transfer. This does not change the security obligations in Article 37, which still apply. Unless agreed otherwise (in writing) for specifically-identified third parties or unless impossible under applicable EU and national laws on mergers and acquisitions, a beneficiary that intends to transfer ownership of results must give at least 45 days advance notice (or less if agreed in writing) to the 58 Grant Agreement number: 825575 — EJP RD — H2020-SC1-BHC-2018-2020/H2020-SC1-2018-Single-Stage-RTD H2020 Associated with MGARef. document EJP Cofund — Multi:-v5.0 Ares(2018)6091977 28/11/2018 other beneficiaries that still have (or still may request) access rights to the results. This notification must include sufficient information on the new owner to enable any beneficiary concerned to assess the effects on its access rights. Unless agreed otherwise (in writing) for specifically-identified third parties, any other beneficiary may object within 30 days of receiving notification (or less if agreed in writing), if it can show that the transfer would adversely affect its access rights. In this case, the transfer may not take place until agreement has been reached between the beneficiaries concerned. 30.2 Granting licenses Each beneficiary may grant licences to its results (or otherwise give the right to exploit them), if: (a) this does not impede the access rights under Article 31 and (b) not applicable. In addition to Points (a) and (b), exclusive licences for results may be granted only if all the other beneficiaries concerned have waived their access rights (see Article 31.1). This does not change the dissemination obligations in Article 29 or security obligations in Article 37, which still apply. 30.3 Commission right to object to transfers or licensing Not applicable 30.4 Consequences of non-compliance If a beneficiary breaches any of its obligations under this Article, the grant may be reduced (see Article 43). Such a breach may also lead to any of the other measures described in Chapter 6. ARTICLE 31 — ACCESS RIGHTS TO RESULTS 31.1 Exercise of access rights — Waiving of access rights — No sub-licensing The conditions set out in Article 25.1 apply. The obligations set out in this Article do not change the security obligations in Article 37, which still apply. 31.2 Access rights for other beneficiaries, for implementing their own tasks under the action The beneficiaries must give each other access — on a royalty-free basis — to results needed for implementing their own tasks under the action. 31.3 Access rights for other beneficiaries, for exploiting their own results The beneficiaries must give each other — under fair and reasonable conditions (see Article 25.3) — access to results needed for exploiting their own results. 59 Grant Agreement number: 825575 — EJP RD — H2020-SC1-BHC-2018-2020/H2020-SC1-2018-Single-Stage-RTD H2020 Associated with MGARef. document EJP Cofund — Multi:-v5.0 Ares(2018)6091977 28/11/2018 Requests for access may be made — unless agreed otherwise — up to one year after the period set out in Article 3. 31.4 Access rights of affiliated entities Unless agreed otherwise in the consortium agreement, access to results must also be given — under fair and reasonable conditions (Article 25.3) — to affiliated entities established in an EU Member State or associated country, if this is needed for those entities to exploit the results generated by the beneficiaries to which they are affiliated. Unless agreed otherwise (see above; Article 31.1), the affiliated entity concerned must make any such request directly to the beneficiary that owns the results. Requests for access may be made — unless agreed otherwise — up to one year after the period set out in Article 3. 31.5 Access rights for the EU institutions, bodies, offices or agencies and EU Member States The beneficiaries must give access to their results — on a royalty-free basis — to EU institutions, bodies, offices or agencies, for developing, implementing or monitoring EU policies or programmes. Such access rights are limited to non-commercial and non-competitive use. This does not change the right to use any material, document or information received from the beneficiaries for communication and publicising activities (see Article 38.2). 31.6 Access rights for third parties Not applicable 31.7 Consequences of non-compliance If a beneficiary breaches any of its obligations under this Article, the grant may be reduced (see Article 43). Such breaches may also lead to any of the other measures described in Chapter 6. SECTION 4 OTHER RIGHTS AND OBLIGATIONS ARTICLE 32 — RECRUITMENT AND WORKING CONDITIONS FOR RESEARCHERS 32.1 Obligation to take measures to implement the European Charter for Researchers and Code of Conduct for the Recruitment of Researchers The beneficiaries must take all measures to implement the principles set out in the Commission Recommendation on the European Charter for Researchers and the Code of Conduct for the Recruitment of Researchers20, in particular regarding: 20 Commission Recommendation 2005/251/EC of 11 March 2005 on the European Charter for Researchers and on a Code of Conduct for the Recruitment of Researchers (OJ L 75, 22.3.2005, p. 67). 60 Grant Agreement number: 825575 — EJP RD — H2020-SC1-BHC-2018-2020/H2020-SC1-2018-Single-Stage-RTD H2020 Associated with MGARef. document EJP Cofund — Multi:-v5.0 Ares(2018)6091977 28/11/2018 - working conditions; - transparent recruitment processes based on merit, and - career development. The beneficiaries must ensure that researchers and third parties involved in the action are aware of them. 32.2 Consequences of non-compliance If a beneficiary breaches its obligations under this Article, the Commission may apply any of the measures described in Chapter 6. ARTICLE 33 — GENDER EQUALITY 33.1 Obligation to aim for gender equality The beneficiaries must take all measures to promote equal opportunities between men and women in the implementation of the action. They must aim, to the extent possible, for a gender balance at all levels of personnel assigned to the action, including at supervisory and managerial level. 33.2 Consequences of non-compliance If a beneficiary breaches its obligations under this Article, the Commission may apply any of the measures described in Chapter 6. ARTICLE 34 — ETHICS AND RESEARCH INTEGRITY 34.1 Obligation to comply with ethical and research integrity principles The beneficiaries must carry out the action in compliance with: (a) ethical principles (including the highest standards of research integrity) and (b) applicable international, EU and national law. Funding will not be granted for activities carried out outside the EU if they are prohibited in all Member States or for activities which destroy human embryos (for example, for obtaining stem cells). The beneficiaries must ensure that the activities under the action have an exclusive focus on civil applications. The beneficiaries must ensure that the activities under the action do not: (a) aim at human cloning for reproductive purposes; (b) intend to modify the genetic heritage of human beings which could make such changes heritable (with the exception of research relating to cancer treatment of the gonads, which may be financed), or 61 Grant Agreement number: 825575 — EJP RD — H2020-SC1-BHC-2018-2020/H2020-SC1-2018-Single-Stage-RTD H2020 Associated with MGARef. document EJP Cofund — Multi:-v5.0 Ares(2018)6091977 28/11/2018 (c) intend to create human embryos solely for the purpose of research or for the purpose of stem cell procurement, including by means of somatic cell nuclear transfer. In addition, the beneficiaries must respect the fundamental principle of research integrity — as set out, for instance, in the European Code of Conduct for Research Integrity21. This implies compliance with the following fundamental principles: - reliability in ensuring the quality of research reflected in the design, the methodology, the analysis and the use of resources; - honesty in developing, undertaking, reviewing, reporting and communicating research in a transparent, fair and unbiased way; - respect for colleagues, research participants, society, ecosystems, cultural heritage and the environment; - accountability for the research from idea to publication, for its management and organisation, for training, supervision and mentoring, and for its wider impacts and means that beneficiaries must ensure that persons carrying out research tasks follow the good research practices and refrain from the research integrity violations described in this Code. This does not change the other obligations under this Agreement or obligations under applicable international, EU or national law, all of which still apply. 34.2 Activities raising ethical issues Activities raising ethical issues must comply with the ‘ethics requirements’ set out as deliverables in Annex 1. Before the beginning of an activity raising an ethical issue, each beneficiary must have obtained: (a) any ethics committee opinion required under national law and (b) any notification or authorisation for activities raising ethical issues required under national and/or European law needed for implementing the action tasks in question. The documents must be kept on file and be submitted upon request by the coordinator to the Commission (see Article 52). If they are not in English, they must be submitted together with an English summary, which shows that the action tasks in question are covered and includes the conclusions of the committee or authority concerned (if available). 34.3 Activities involving human embryos or human embryonic stem cells Activities involving research on human embryos or human embryonic stem cells may be carried out, in addition to Article 34.1, only if: 21 European Code of Conduct for Research Integrity of ALLEA (All European Academies) http://ec.europa.eu/research/participants/data/ref/h2020/other/hi/h2020-ethics_code-of-conduct_en.pdf 62 Grant Agreement number: 825575 — EJP RD — H2020-SC1-BHC-2018-2020/H2020-SC1-2018-Single-Stage-RTD H2020 Associated with MGARef. document EJP Cofund — Multi:-v5.0 Ares(2018)6091977 28/11/2018 - they are set out in Annex 1 or - the coordinator has obtained explicit approval (in writing) from the Commission (see Article 52). 34.4 Consequences of non-compliance If a beneficiary breaches any of its obligations under this Article, the grant may be reduced (see Article 43) and the Agreement or participation of the beneficiary may be terminated (see Article 50). Such breaches may also lead to any of the other measures described in Chapter 6. ARTICLE 35 — CONFLICT OF INTERESTS 35.1 Obligation to avoid a conflict of interests The beneficiaries must take all measures to prevent any situation where the impartial and objective implementation of the action is compromised for reasons involving economic interest, political or national affinity, family or emotional ties or any other shared interest (‘conflict of interests’). They must formally notify to the Commission without delay any situation constituting or likely to lead to a conflict of interests and immediately take all the necessary steps to rectify this situation. The Commission may verify that the measures taken are appropriate and may require additional measures to be taken by a specified deadline. 35.2 Consequences of non-compliance If a beneficiary breaches any of its obligations under this Article, the grant may be reduced (see Article 43) and the Agreement or participation of the beneficiary may be terminated (see Article 50). Such breaches may also lead to any of the other measures described in Chapter 6. ARTICLE 36 — CONFIDENTIALITY 36.1 General obligation to maintain confidentiality During implementation of the action and for four years after the period set out in Article 3, the parties must keep confidential any data, documents or other material (in any form) that is identified as confidential at the time it is disclosed (‘confidential information’). If a beneficiary requests, the Commission may agree to keep such information confidential for an additional period beyond the initial four years. If information has been identified as confidential only orally, it will be considered to be confidential only if this is confirmed in writing within 15 days of the oral disclosure. Unless otherwise agreed between the parties, they may use confidential information only to implement the Agreement. The beneficiaries may disclose confidential information to their personnel or third parties involved in the action only if they: 63 Grant Agreement number: 825575 — EJP RD — H2020-SC1-BHC-2018-2020/H2020-SC1-2018-Single-Stage-RTD H2020 Associated with MGARef. document EJP Cofund — Multi:-v5.0 Ares(2018)6091977 28/11/2018 (a) need to know to implement the Agreement and (b) are bound by an obligation of confidentiality. This does not change the security obligations in Article 37, which still apply. The Commission may disclose confidential information to its staff, other EU institutions and bodies. It may disclose confidential information to third parties, if: (a) this is necessary to implement the Agreement or safeguard the EU's financial interests and (b) the recipients of the information are bound by an obligation of confidentiality. Under the conditions set out in Article 4 of the Rules for Participation Regulation No 1290/201322, the Commission must moreover make available information on the results to other EU institutions, bodies, offices or agencies as well as Member States or associated countries. The confidentiality obligations no longer apply if: (a) the disclosing party agrees to release the other party; (b) the information was already known by the recipient or is given to him without obligation of confidentiality by a third party that was not bound by any obligation of confidentiality; (c) the recipient proves that the information was developed without the use of confidential information; (d) the information becomes generally and publicly available, without breaching any confidentiality obligation, or (e) the disclosure of the information is required by EU or national law. 36.2 Consequences of non-compliance If a beneficiary breaches any of its obligations under this Article, the grant may be reduced (see Article 43). Such breaches may also lead to any of the other measures described in Chapter 6. ARTICLE 37 — SECURITY-RELATED OBLIGATIONS 37.1 Results with a security recommendation Not applicable 37.2 Classified information Not applicable 22 Regulation (EU) No 1290/2013 of the European Parliament and of the Council of 11 December 2013 laying down the rules for participation and dissemination in "Horizon 2020 - the Framework Programme for Research and Innovation (2014-2020)" (OJ L 347, 20.12.2013 p.81). 64 Grant Agreement number: 825575 — EJP RD — H2020-SC1-BHC-2018-2020/H2020-SC1-2018-Single-Stage-RTD H2020 Associated with MGARef. document EJP Cofund — Multi:-v5.0 Ares(2018)6091977 28/11/2018 37.3 Activities involving dual-use goods or dangerous materials and substances Not applicable 37.4 Consequences of non-compliance Not applicable ARTICLE 38 — PROMOTING THE ACTION — VISIBILITY OF EU FUNDING 38.1 Communication activities by beneficiaries 38.1.1 Obligation to promote the action and its results The beneficiaries must promote the action and its results, by providing targeted information to multiple audiences (including the media and the public) in a strategic and effective manner. This does not change the dissemination obligations in Article 29, the confidentiality obligations in Article 36 or the security obligations in Article 37, all of which still apply. Before engaging in a communication activity expected to have a major media impact, the beneficiaries must inform the Commission (see Article 52). 38.1.2 Information on EU funding — Obligation and right to use the EU emblem Unless the Commission requests or agrees otherwise or unless it is impossible, any communication activity related to the action (including in electronic form, via social media, etc.) and any infrastructure, equipment and major results funded by the grant must: (a) display the EU emblem and (b) include the following text: For communication activities: “This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 825575”. For infrastructure, equipment and major results: “This [infrastructure][equipment][insert type of result] is part of a project that has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 825575”. When displayed together with another logo, the EU emblem must have appropriate prominence. For the purposes of their obligations under this Article, the beneficiaries may use the EU emblem without first obtaining approval from the Commission. This does not, however, give them the right to exclusive use. Moreover, they may not appropriate the EU emblem or any similar trademark or logo, either by registration or by any other means. 38.1.3 Disclaimer excluding Commission responsibility 65 Grant Agreement number: 825575 — EJP RD — H2020-SC1-BHC-2018-2020/H2020-SC1-2018-Single-Stage-RTD H2020 Associated with MGARef. document EJP Cofund — Multi:-v5.0 Ares(2018)6091977 28/11/2018 Any communication activity related to the action must indicate that it reflects only the author's view and that the Commission is not responsible for any use that may be made of the information it contains. 38.2 Communication activities by the Commission 38.2.1 Right to use beneficiaries’ materials, documents or information The Commission may use, for its communication and publicising activities, information relating to the action, documents notably summaries for publication and public deliverables as well as any other material, such as pictures or audio-visual material received from any beneficiary (including in electronic form). This does not change the confidentiality obligations in Article 36 and the security obligations in Article 37, all of which still apply. If the Commission’s use of these materials, documents or information would risk compromising legitimate interests, the beneficiary concerned may request the Commission not to use it (see Article 52). The right to use a beneficiary’s materials, documents and information includes: (a) use for its own purposes (in particular, making them available to persons working for the Commission or any other EU institution, body, office or agency or body or institutions in EU Member States; and copying or reproducing them in whole or in part, in unlimited numbers); (b) distribution to the public (in particular, publication as hard copies and in electronic or digital format, publication on the internet, as a downloadable or non-downloadable file, broadcasting by any channel, public display or presentation, communicating through press information services, or inclusion in widely accessible databases or indexes); (c) editing or redrafting for communication and publicising activities (including shortening, summarising, inserting other elements (such as meta-data, legends, other graphic, visual, audio or text elements), extracting parts (e.g. audio or video files), dividing into parts, use in a compilation); (d) translation; (e) giving access in response to individual requests under Regulation No 1049/200124, without the right to reproduce or exploit; (f) storage in paper, electronic or other form; (g) archiving, in line with applicable document-management rules, and (h) the right to authorise third parties to act on its behalf or sub-license the modes of use set out in Points (b), (c), (d) and (f) to third parties if needed for the communication and publicising activities of the Commission. If the right of use is subject to rights of a third party (including personnel of the beneficiary), the 24 Regulation (EC) No 1049/2001 of the European Parliament and of the Council of 30 May 2001 regarding public access to European Parliament, Council and Commission documents, OJ L 145, 31.5.2001, p. 43. 66 Grant Agreement number: 825575 — EJP RD — H2020-SC1-BHC-2018-2020/H2020-SC1-2018-Single-Stage-RTD H2020 Associated with MGARef. document EJP Cofund — Multi:-v5.0 Ares(2018)6091977 28/11/2018 beneficiary must ensure that it complies with its obligations under this Agreement (in particular, by obtaining the necessary approval from the third parties concerned). Where applicable (and if provided by the beneficiaries), the Commission will insert the following information: “© – [year] – [name of the copyright owner]. All rights reserved. Licensed to the European Union (EU) under conditions.” 38.3 Consequences of non-compliance If a beneficiary breaches any of its obligations under this Article, the grant may be reduced (see Article 43). Such breaches may also lead to any of the other measures described in Chapter 6. ARTICLE 39 — PROCESSING OF PERSONAL DATA 39.1 Processing of personal data by the Commission Any personal data under the Agreement will be processed by the Commission under Regulation No 45/200125 and according to the ‘notifications of the processing operations’ to the Data Protection Officer (DPO) of the Commission (publicly accessible in the DPO register). Such data will be processed by the ‘data controller’ of the Commission for the purposes of implementing, managing and monitoring the Agreement or protecting the financial interests of the EU or Euratom (including checks, reviews, audits and investigations; see Article 22). The persons whose personal data are processed have the right to access and correct their own personal data. For this purpose, they must send any queries about the processing of their personal data to the data controller, via the contact point indicated in the privacy statement(s) that are published on the Commission websites. They also have the right to have recourse at any time to the European Data Protection Supervisor (EDPS). 39.2 Processing of personal data by the beneficiaries The beneficiaries must process personal data under the Agreement in compliance with applicable EU and national law on data protection (including authorisations or notification requirements). The beneficiaries may grant their personnel access only to data that is strictly necessary for implementing, managing and monitoring the Agreement. The beneficiaries must inform the personnel whose personal data are collected and processed by the Commission. For this purpose, they must provide them with the privacy statement(s) (see above), before transmitting their data to the Commission. 25 Regulation (EC) No 45/2001 of the European Parliament and of the Council of 18 December 2000 on the protection of individuals with regard to the processing of personal data by the Community institutions and bodies and on the free movement of such data (OJ L 8, 12.01.2001, p. 1). 67 Grant Agreement number: 825575 — EJP RD — H2020-SC1-BHC-2018-2020/H2020-SC1-2018-Single-Stage-RTD H2020 Associated with MGARef. document EJP Cofund — Multi:-v5.0 Ares(2018)6091977 28/11/2018 39.3 Consequences of non-compliance If a beneficiary breaches any of its obligations under Article 39.2, the Commission may apply any of the measures described in Chapter 6. ARTICLE 40 — ASSIGNMENTS OF CLAIMS FOR PAYMENT AGAINST THE COMMISSION The beneficiaries may not assign any of their claims for payment against the Commission to any third party, except if approved by the Commission on the basis of a reasoned, written request by the coordinator (on behalf of the beneficiary concerned). If the Commission has not accepted the assignment or the terms of it are not observed, the assignment will have no effect on it. In no circumstances will an assignment release the beneficiaries from their obligations towards the Commission. CHAPTER 5 DIVISION OF BENEFICIARIES’ ROLES AND RESPONSIBILITIES — RELATIONSHIP WITH COMPLEMENTARY BENEFICIARIES — RELATIONSHIP WITH PARTNERS OF A JOINT ACTION ARTICLE 41 — DIVISION OF BENEFICIARIES’ ROLES AND RESPONSIBILITIES — RELATIONSHIP WITH COMPLEMENTARY BENEFICIARIES — RELATIONSHIP WITH PARTNERS OF A JOINT ACTION 41.1 Roles and responsibility towards the Commission The beneficiaries have full responsibility for implementing the action and complying with the Agreement. The beneficiaries are jointly and severally liable for the technical implementation of the action as described in Annex 1. If a beneficiary fails to implement its part of the action, the other beneficiaries become responsible for implementing this part (without being entitled to any additional EU funding for doing so), unless the Commission expressly relieves them of this obligation. The financial responsibility of each beneficiary is governed by Article 44. 41.2 Internal division of roles and responsibilities The internal roles and responsibilities of the beneficiaries are divided as follows: (a) Each beneficiary must: (i) keep information stored in the Participant Portal Beneficiary Register (via the electronic exchange system) up to date (see Article 17); (ii) inform the coordinator immediately of any events or circumstances likely to affect significantly or delay the implementation of the action (see Article 17); 68 Grant Agreement number: 825575 — EJP RD — H2020-SC1-BHC-2018-2020/H2020-SC1-2018-Single-Stage-RTD H2020 Associated with MGARef. document EJP Cofund — Multi:-v5.0 Ares(2018)6091977 28/11/2018 (iii) submit to the coordinator in good time: - individual financial statements for itself and its linked third parties and, if required, certificates on the financial statements (see Article 20); - the data needed to draw up the technical reports (see Article 20); - ethics committee opinions and notifications or authorisations for activities raising ethical issues (see Article 34); - any other documents or information required by the Commission under the Agreement, unless the Agreement requires the beneficiary to submit this information directly to the Commission. (b) The coordinator must: (i) monitor that the action is implemented properly (see Article 7); (ii) act as the intermediary for all communications between the beneficiaries and the Commission (in particular, providing the Commission with the information described in Article 17), unless the Agreement specifies otherwise; (iii) request and review any documents or information required by the Commission and verify their completeness and correctness before passing them on to the Commission; (iv) submit the deliverables and reports to the Commission (see Articles 19 and 20); (v) ensure that all payments are made to the other beneficiaries without unjustified delay (see Article 21); (vi) inform the Commission of the amounts paid to each beneficiary, when required under the Agreement (see Articles 44 and 50) or requested by the Commission. The coordinator may not delegate or subcontract the above-mentioned tasks to any other beneficiary or third party (including linked third parties). 41.3 Internal arrangements between beneficiaries — Consortium agreement The beneficiaries must have internal arrangements regarding their operation and co-ordination to ensure that the action is implemented properly. These internal arrangements must be set out in a written ‘consortium agreement’ between the beneficiaries, which may cover: - internal organisation of the consortium; - management of access to the electronic exchange system; - distribution of EU funding; - additional rules on rights and obligations related to background and results (including whether access rights remain or not, if a beneficiary is in breach of its obligations) (see Section 3 of Chapter 4); 69 Grant Agreement number: 825575 — EJP RD — H2020-SC1-BHC-2018-2020/H2020-SC1-2018-Single-Stage-RTD H2020 Associated with MGARef. document EJP Cofund — Multi:-v5.0 Ares(2018)6091977 28/11/2018 - settlement of internal disputes; - liability, indemnification and confidentiality arrangements between the beneficiaries. The consortium agreement must not contain any provision contrary to the Agreement. 41.4 Relationship with complementary beneficiaries — Collaboration agreement Not applicable 41.5 Relationship with partners of a joint action — Coordination agreement Not applicable CHAPTER 6 REJECTION OF COSTS — REDUCTION OF THE GRANT — RECOVERY — SANCTIONS — DAMAGES — SUSPENSION — TERMINATION — FORCE MAJEURE SECTION 1 REJECTION OF COSTS — REDUCTION OF THE GRANT — RECOVERY — SANCTIONS ARTICLE 42 — REJECTION OF INELIGIBLE COSTS 42.1 Conditions The Commission will — after termination of the participation of a beneficiary, at the time of an interim payment, at the payment of the balance or afterwards — reject any costs which are ineligible (see Article 6), in particular following checks, reviews, audits or investigations (see Article 22). The rejection may also be based on the extension of findings from other grants to this grant (see Article 22.5.2). 42.2 Ineligible costs to be rejected — Calculation — Procedure Ineligible costs will be rejected in full. If the rejection of costs does not lead to a recovery (see Article 44), the Commission will formally notify the coordinator or beneficiary concerned of the rejection of costs, the amounts and the reasons why (if applicable, together with the notification of amounts due; see Article 21.5). The coordinator or beneficiary concerned may — within 30 days of receiving notification — formally notify the Commission of its disagreement and the reasons why. If the rejection of costs leads to a recovery, the Commission will follow the contradictory procedure with pre-information letter set out in Article 44. 42.3 Effects If the Commission rejects costs at the time of an interim payment or the payment of the balance, it will deduct them from the total eligible costs declared, for the action, in the periodic or final summary 70 Grant Agreement number: 825575 — EJP RD — H2020-SC1-BHC-2018-2020/H2020-SC1-2018-Single-Stage-RTD H2020 Associated with MGARef. document EJP Cofund — Multi:-v5.0 Ares(2018)6091977 28/11/2018 financial statement (see Articles 20.3 and 20.4). It will then calculate the interim payment or payment of the balance as set out in Articles 21.3 or 21.4. If the Commission rejects costs after termination of the participation of a beneficiary, it will deduct them from the costs declared by the beneficiary in the termination report and include the rejection in the calculation after termination (see Article 50.2 and 50.3). If the Commission — after an interim payment but before the payment of the balance — rejects costs declared in a periodic summary financial statement, it will deduct them from the total eligible costs declared, for the action, in the next periodic summary financial statement or in the final summary financial statement. It will then calculate the interim payment or payment of the balance as set out in Articles 21.3 or 21.4. If the Commission rejects costs after the payment of the balance, it will deduct the amount rejected from the total eligible costs declared, by the beneficiary, in the final summary financial statement. It will then calculate the revised final grant amount as set out in Article 5.4. ARTICLE 43 — REDUCTION OF THE GRANT 43.1 Conditions The Commission may — after termination of the participation of a beneficiary, at the payment of the balance or afterwards — reduce the grant, if : (a) a beneficiary (or a natural person who has the power to represent or take decisions on its behalf) has committed: (i) substantial errors, irregularities or fraud or (ii) serious breach of obligations under the Agreement or during the award procedure (including improper implementation of the action, submission of false information, failure to provide requested information, breach of ethical principles) or (b) a beneficiary (or a natural person who has the power to represent or take decision on its behalf) has committed — in other EU or Euratom grants awarded to it under similar conditions — systemic or recurrent errors, irregularities, fraud or serious breach of obligations that have a material impact on this grant (extension of findings from other grants to this grant; see Article 22.5.2). 43.2 Amount to be reduced — Calculation — Procedure The amount of the reduction will be proportionate to the seriousness of the errors, irregularities or fraud or breach of obligations. Before reduction of the grant, the Commission will formally notify a ‘pre-information letter’ to the coordinator or beneficiary concerned: - informing it of its intention to reduce the grant, the amount it intends to reduce and the reasons why and - inviting it to submit observations within 30 days of receiving notification 71 Grant Agreement number: 825575 — EJP RD — H2020-SC1-BHC-2018-2020/H2020-SC1-2018-Single-Stage-RTD H2020 Associated with MGARef. document EJP Cofund — Multi:-v5.0 Ares(2018)6091977 28/11/2018 If the Commission does not receive any observations or decides to pursue reduction despite the observations it has received, it will formally notify confirmation of the reduction (if applicable, together with the notification of amounts due; see Article 21). 43.3 Effects If the Commission reduces the grant after termination of the participation of a beneficiary, it will calculate the reduced grant amount for that beneficiary and then determine the amount due to that beneficiary (see Article 50.2 and 50.3). If the Commission reduces the grant at the time of the payment of the balance, it will calculate the reduced grant amount for the action and then determine the amount due as payment of the balance (see Articles 5.3.4 and 21.4). If the Commission reduces the grant after the payment of the balance, it will calculate the revised final grant amount for the beneficiary concerned (see Article 5.4). If the revised final grant amount for the beneficiary concerned is lower than its share of the final grant amount, the Commission will recover the difference (see Article 44). ARTICLE 44 — RECOVERY OF UNDUE AMOUNTS 44.1 Amount to be recovered — Calculation — Procedure The Commission will — after termination of the participation of a beneficiary, at the payment of the balance or afterwards — claim back any amount that was paid, but is not due under the Agreement. Each beneficiary’s financial responsibility in case of recovery is limited to its own debt (including undue amounts paid by the Commission for costs declared by its linked third parties), except for the amount retained for the Guarantee Fund (see Article 21.4). 44.1.1 Recovery after termination of a beneficiary’s participation If recovery takes place after termination of a beneficiary’s participation (including the coordinator), the Commission will claim back the undue amount from the beneficiary concerned, by formally notifying it a debit note (see Article 50.2 and 50.3). This note will specify the amount to be recovered, the terms and the date for payment. If payment is not made by the date specified in the debit note, the Commission will recover the amount: (a) by ‘offsetting’ it — without the beneficiary’s consent — against any amounts owed to the beneficiary concerned by the Commission or an executive agency (from the EU or Euratom budget). In exceptional circumstances, to safeguard the EU’s financial interests, the Commission may offset before the payment date specified in the debit note; (b) not applicable; (c) by taking legal action (see Article 57) or by adopting an enforceable decision under 72 Grant Agreement number: 825575 — EJP RD — H2020-SC1-BHC-2018-2020/H2020-SC1-2018-Single-Stage-RTD H2020 Associated with MGARef. document EJP Cofund — Multi:-v5.0 Ares(2018)6091977 28/11/2018 Article 299 of the Treaty on the Functioning of the EU (TFEU) and Article 79(2) of the Financial regulation No 966/2012. If payment is not made by the date specified in the debit note, the amount to be recovered (see above) will be increased by late-payment interest at the rate set out in Article 21.11, from the day following the payment date in the debit note, up to and including the date the Commission receives full payment of the amount. Partial payments will be first credited against expenses, charges and late-payment interest and then against the principal. Bank charges incurred in the recovery process will be borne by the beneficiary, unless Directive 2007/64/EC26 applies. 44.1.2 Recovery at payment of the balance If the payment of the balance takes the form of a recovery (see Article 21.4), the Commission will formally notify a ‘pre-information letter’ to the coordinator: - informing it of its intention to recover, the amount due as the balance and the reasons why; - specifying that it intends to deduct the amount to be recovered from the amount retained for the Guarantee Fund; - requesting the coordinator to submit a report on the distribution of payments to the beneficiaries within 30 days of receiving notification, and - inviting the coordinator to submit observations within 30 days of receiving notification. If no observations are submitted or the Commission decides to pursue recovery despite the observations it has received, it will confirm recovery (together with the notification of amounts due; see Article 21.5) and: - pay the difference between the amount to be recovered and the amount retained for the Guarantee Fund, if the difference is positive or - formally notify to the coordinator a debit note for the difference between the amount to be recovered and the amount retained for the Guarantee Fund, if the difference is negative. This note will also specify the terms and the date for payment. If the coordinator does not repay the Commission by the date in the debit note and has not submitted the report on the distribution of payments: the Commission will recover the amount set out in the debit note from the coordinator (see below). If the coordinator does not repay the Commission by the date in the debit note, but has submitted the report on the distribution of payments: the Commission will: (a) identify the beneficiaries for which the amount calculated as follows is negative: 26 Directive 2007/64/EC of the European Parliament and of the Council of 13 November 2007 on payment services in the internal market amending Directives 97/7/EC, 2002/65/EC, 2005/60/EC and 2006/48/EC and repealing Directive 97/5/EC (OJ L 319, 05.12.2007, p. 1). 73 Grant Agreement number: 825575 — EJP RD — H2020-SC1-BHC-2018-2020/H2020-SC1-2018-Single-Stage-RTD H2020 Associated with MGARef. document EJP Cofund — Multi:-v5.0 Ares(2018)6091977 28/11/2018 {{{{beneficiary’s costs declared in the final summary financial statement and approved by the Commission multiplied by the reimbursement rate set out in Article 5.2 for the beneficiary concerned plus its linked third parties’ costs declared in the final summary financial statement and approved by the Commission multiplied by the reimbursement rate set out in Article 5.2 for each linked third party concerned} divided by the EU contribution for the action calculated according to Article 5.3.1} multiplied by } the final grant amount (see Article 5.3) , minus {pre-financing and interim payments received by the beneficiary} . } (b) formally notify to each beneficiary identified according to point (a) a debit note specifying the terms and date for payment. The amount of the debit note is calculated as follows: {{amount calculated according to point (a) for the beneficiary concerned divided by the sum of the amounts calculated according to point (a) for all the beneficiaries identified according to point (a)} multiplied by the amount set out in the debit note formally notified to the coordinator}. If payment is not made by the date specified in the debit note, the Commission will recover the amount: (a) by offsetting it — without the beneficiary’s consent — against any amounts owed to the beneficiary concerned by the Commission or an executive agency (from the EU or Euratom budget). In exceptional circumstances, to safeguard the EU’s financial interests, the Commission may offset before the payment date specified in the debit note; (b) by drawing on the Guarantee Fund. The Commission will formally notify the beneficiary concerned the debit note on behalf of the Guarantee Fund and recover the amount: (i) not applicable; (ii) by taking legal action (see Article 57) or by adopting an enforceable decision under Article 299 of the Treaty on the Functioning of the EU (TFEU) and Article 79(2) of the Financial Regulation No 966/2012. If payment is not made by the date in the debit note, the amount to be recovered (see above) will be increased by late-payment interest at the rate set out in Article 21.11, from the day following the 74 Grant Agreement number: 825575 — EJP RD — H2020-SC1-BHC-2018-2020/H2020-SC1-2018-Single-Stage-RTD H2020 Associated with MGARef. document EJP Cofund — Multi:-v5.0 Ares(2018)6091977 28/11/2018 payment date in the debit note, up to and including the date the Commission receives full payment of the amount. Partial payments will be first credited against expenses, charges and late-payment interest and then against the principal. Bank charges incurred in the recovery process will be borne by the beneficiary, unless Directive 2007/64/EC applies. 44.1.3 Recovery of amounts after payment of the balance If, for a beneficiary, the revised final grant amount (see Article 5.4) is lower than its share of the final grant amount, it must repay the difference to the Commission. The beneficiary’s share of the final grant amount is calculated as follows: {{{beneficiary’s costs declared in the final summary financial statement and approved by the Commission multiplied by the reimbursement rate set out in Article 5.2 for the beneficiary concerned plus its linked third parties’ costs declared in the final summary financial statement and approved by the Commission multiplied by the reimbursement rate set out in Article 5.2 for each linked third party concerned} divided by the EU contribution for the action calculated according to Article 5.3.1} multiplied by } the final grant amount (see Article 5.3) . If the coordinator has not distributed amounts received (see Article 21.7), the Commission will also recover these amounts. The Commission will formally notify a pre-information letter to the beneficiary concerned: - informing it of its intention to recover, the due amount and the reasons why and - inviting it to submit observations within 30 days of receiving notification. If no observations are submitted or the Commission decides to pursue recovery despite the observations it has received, it will confirm the amount to be recovered and formally notify to the beneficiary concerned a debit note. This note will also specify the terms and the date for payment. If payment is not made by the date specified in the debit note, the Commission will recover the amount: (a) by offsetting it — without the beneficiary’s consent — against any amounts owed to the beneficiary concerned by the Commission or an executive agency (from the EU or Euratom budget). In exceptional circumstances, to safeguard the EU’s financial interests, the Commission may offset before the payment date specified in the debit note; 75 Grant Agreement number: 825575 — EJP RD — H2020-SC1-BHC-2018-2020/H2020-SC1-2018-Single-Stage-RTD H2020 Associated with MGARef. document EJP Cofund — Multi:-v5.0 Ares(2018)6091977 28/11/2018 (b) by drawing on the Guarantee Fund. The Commission will formally notify the beneficiary concerned the debit note on behalf of the Guarantee Fund and recover the amount: (i) not applicable; (ii) by taking legal action (see Article 57) or by adopting an enforceable decision under Article 299 of the Treaty on the Functioning of the EU (TFEU) and Article 79(2) of the Financial Regulation No 966/2012. If payment is not made by the date in the debit note, the amount to be recovered (see above) will be increased by late-payment interest at the rate set out in Article 21.11, from the day following the date for payment in the debit note, up to and including the date the Commission receives full payment of the amount. Partial payments will be first credited against expenses, charges and late-payment interest and then against the principal. Bank charges incurred in the recovery process will be borne by the beneficiary, unless Directive 2007/64/EC applies. ARTICLE 45 — ADMINISTRATIVE SANCTIONS In addition to contractual measures, the Commission may also adopt administrative sanctions under Articles 106 and 131(4) of the Financial Regulation No 966/2012 (i.e. exclusion from future procurement contracts, grants, prizes and expert contracts and/or financial penalties). SECTION 2 LIABILITY FOR DAMAGES ARTICLE 46 — LIABILITY FOR DAMAGES 46.1 Liability of the Commission The Commission cannot be held liable for any damage caused to the beneficiaries or to third parties as a consequence of implementing the Agreement, including for gross negligence. The Commission cannot be held liable for any damage caused by any of the beneficiaries or third parties involved in the action, as a consequence of implementing the Agreement. 46.2 Liability of the beneficiaries Except in case of force majeure (see Article 51), the beneficiaries must compensate the Commission for any damage it sustains as a result of the implementation of the action or because the action was not implemented in full compliance with the Agreement. SECTION 3 SUSPENSION AND TERMINATION ARTICLE 47 — SUSPENSION OF PAYMENT DEADLINE 47.1 Conditions 76 Grant Agreement number: 825575 — EJP RD — H2020-SC1-BHC-2018-2020/H2020-SC1-2018-Single-Stage-RTD H2020 Associated with MGARef. document EJP Cofund — Multi:-v5.0 Ares(2018)6091977 28/11/2018 The Commission may — at any moment — suspend the payment deadline (see Article 21.2 to 21.4) if a request for payment (see Article 20) cannot be approved because: (a) it does not comply with the provisions of the Agreement (see Article 20); (b) the technical or financial reports have not been submitted or are not complete or additional information is needed, or (c) there is doubt about the eligibility of the costs declared in the financial statements and additional checks, reviews, audits or investigations are necessary. 47.2 Procedure The Commission will formally notify the coordinator of the suspension and the reasons why. The suspension will take effect the day notification is sent by the Commission (see Article 52). If the conditions for suspending the payment deadline are no longer met, the suspension will be lifted — and the remaining period will resume. If the suspension exceeds two months, the coordinator may request the Commission if the suspension will continue. If the payment deadline has been suspended due to the non-compliance of the technical or financial reports (see Article 20) and the revised report or statement is not submitted or was submitted but is also rejected, the Commission may also terminate the Agreement or the participation of the beneficiary (see Article 50.3.1(l)). ARTICLE 48 — SUSPENSION OF PAYMENTS 48.1 Conditions The Commission may — at any moment — suspend payments, in whole or in part and interim payments or the payment of the balance for one or more beneficiaries, if: (a) a beneficiary (or a natural person who has the power to represent or take decision on its behalf) has committed or is suspected of having committed: (i) substantial errors, irregularities or fraud or (ii) serious breach of obligations under the Agreement or during the award procedure (including improper implementation of the action, submission of false information, failure to provide required information, breach of ethical principles) or (b) a beneficiary (or a natural person who has the power to represent or take decision on its behalf) has committed — in other EU or Euratom grants awarded to it under similar conditions — systemic or recurrent errors, irregularities, fraud or serious breach of obligations that have a material impact on this grant (extension of findings from other grants to this grant; see Article 22.5.2). If payments are suspended for one or more beneficiaries, the Commission will make partial payment(s) for the part(s) not suspended. If suspension concerns the payment of the balance, — once suspension 77 Grant Agreement number: 825575 — EJP RD — H2020-SC1-BHC-2018-2020/H2020-SC1-2018-Single-Stage-RTD H2020 Associated with MGARef. document EJP Cofund — Multi:-v5.0 Ares(2018)6091977 28/11/2018 is lifted — the payment or the recovery of the amount(s) concerned will be considered the payment of the balance that closes the action. 48.2 Procedure Before suspending payments, the Commission will formally notify the coordinator or beneficiary concerned: - informing it of its intention to suspend payments and the reasons why and - inviting it to submit observations within 30 days of receiving notification. If the Commission does not receive observations or decides to pursue the procedure despite the observations it has received, it will formally notify confirmation of the suspension. Otherwise, it will formally notify that the suspension procedure is not continued. The suspension will take effect the day the confirmation notification is sent by the Commission. If the conditions for resuming payments are met, the suspension will be lifted. The Commission will formally notify the coordinator or beneficiary concerned. During the suspension, the periodic report(s) for all reporting periods except the last one (see Article 20.3), must not contain any individual financial statements from the beneficiary concerned and its linked third parties. The coordinator must include them in the next periodic report after the suspension is lifted or — if suspension is not lifted before the end of the action — in the last periodic report. The beneficiaries may suspend implementation of the action (see Article 49.1) or terminate the Agreement or the participation of the beneficiary concerned (see Article 50.1 and 50.2). ARTICLE 49 — SUSPENSION OF THE ACTION IMPLEMENTATION 49.1 Suspension of the action implementation, by the beneficiaries 49.1.1 Conditions The beneficiaries may suspend implementation of the action or any part of it, if exceptional circumstances — in particular force majeure (see Article 51) — make implementation impossible or excessively difficult. 49.1.2 Procedure The coordinator must immediately formally notify to the Commission the suspension (see Article 52), stating: - the reasons why and - the expected date of resumption. The suspension will take effect the day this notification is received by the Commission. Once circumstances allow for implementation to resume, the coordinator must immediately formally 78 Grant Agreement number: 825575 — EJP RD — H2020-SC1-BHC-2018-2020/H2020-SC1-2018-Single-Stage-RTD H2020 Associated with MGARef. document EJP Cofund — Multi:-v5.0 Ares(2018)6091977 28/11/2018 notify the Commission and request an amendment of the Agreement to set the date on which the action will be resumed, extend the duration of the action and make other changes necessary to adapt the action to the new situation (see Article 55) — unless the Agreement or the participation of a beneficiary has been terminated (see Article 50). The suspension will be lifted with effect from the resumption date set out in the amendment. This date may be before the date on which the amendment enters into force. Costs incurred during suspension of the action implementation are not eligible (see Article 6). 49.2 Suspension of the action implementation, by the Commission 49.2.1 Conditions The Commission may suspend implementation of the action or any part of it, if: (a) a beneficiary (or a natural person who has the power to represent or take decisions on its behalf) has committed or is suspected of having committed: (i) substantial errors, irregularities or fraud or (ii) serious breach of obligations under the Agreement or during the award procedure (including improper implementation of the action, submission of false information, failure to provide required information, breach of ethical principles); (b) a beneficiary (or a natural person who has the power to represent or take decisions on its behalf) has committed — in other EU or Euratom grants awarded to it under similar conditions — systemic or recurrent errors, irregularities, fraud or serious breach of obligations that have a material impact on this grant (extension of findings from other grants to this grant; see Article 22.5.2), or (c) the action is suspected of having lost its scientific or technological relevance. 49.2.2 Procedure Before suspending implementation of the action, the Commission will formally notify the coordinator or beneficiary concerned: - informing it of its intention to suspend the implementation and the reasons why and - inviting it to submit observations within 30 days of receiving notification. If the Commission does not receive observations or decides to pursue the procedure despite the observations it has received, it will formally notify confirmation of the suspension. Otherwise, it will formally notify that the procedure is not continued. The suspension will take effect five days after confirmation notification is received (or on a later date specified in the notification). It will be lifted if the conditions for resuming implementation of the action are met. The coordinator or beneficiary concerned will be formally notified of the lifting and the Agreement will be amended to set the date on which the action will be resumed, extend the duration of the action 79 Grant Agreement number: 825575 — EJP RD — H2020-SC1-BHC-2018-2020/H2020-SC1-2018-Single-Stage-RTD H2020 Associated with MGARef. document EJP Cofund — Multi:-v5.0 Ares(2018)6091977 28/11/2018 and make other changes necessary to adapt the action to the new situation (see Article 55) — unless the Agreement has already been terminated (see Article 50). The suspension will be lifted with effect from the resumption date set out in the amendment. This date may be before the date on which the amendment enters into force. Costs incurred during suspension are not eligible (see Article 6). The beneficiaries may not claim damages due to suspension by the Commission (see Article 46). Suspension of the action implementation does not affect the Commission’s right to terminate the Agreement or participation of a beneficiary (see Article 50), reduce the grant or recover amounts unduly paid (see Articles 43 and 44). ARTICLE 50 — TERMINATION OF THE AGREEMENT OR OF THE PARTICIPATION OF ONE OR MORE BENEFICIARIES 50.1 Termination of the Agreement, by the beneficiaries 50.1.1 Conditions and procedure The beneficiaries may terminate the Agreement. The coordinator must formally notify termination to the Commission (see Article 52), stating: - the reasons why and - the date the termination will take effect. This date must be after the notification. If no reasons are given or if the Commission considers the reasons do not justify termination, the Agreement will be considered to have been ‘terminated improperly’. The termination will take effect on the day specified in the notification. 50.1.2 Effects The coordinator must — within 60 days from when termination takes effect — submit: (i) a periodic report (for the open reporting period until termination; see Article 20.3) and (ii) the final report (see Article 20.4). If the Commission does not receive the reports within the deadline (see above), only costs which are included in an approved periodic report will be taken into account. The Commission will calculate the final grant amount (see Article 5.3) and the balance (see Article 21.4) on the basis of the reports submitted. Only costs incurred until termination are eligible (see Article 6). Costs relating to contracts due for execution only after termination are not eligible. Improper termination may lead to a reduction of the grant (see Article 43). After termination, the beneficiaries’ obligations (in particular Articles 20, 22, 23, Section 3 of Chapter 4, 36, 37, 38, 40, 42, 43 and 44) continue to apply. 80 Grant Agreement number: 825575 — EJP RD — H2020-SC1-BHC-2018-2020/H2020-SC1-2018-Single-Stage-RTD H2020 Associated with MGARef. document EJP Cofund — Multi:-v5.0 Ares(2018)6091977 28/11/2018 50.2 Termination of the participation of one or more beneficiaries, by the beneficiaries 50.2.1 Conditions and procedure The participation of one or more beneficiaries may be terminated by the coordinator, on request of the beneficiary concerned or on behalf of the other beneficiaries. The coordinator must formally notify termination to the Commission (see Article 52) and inform the beneficiary concerned. If the coordinator’s participation is terminated without its agreement, the formal notification must be done by another beneficiary (acting on behalf of the other beneficiaries). The notification must include: - the reasons why; - the opinion of the beneficiary concerned (or proof that this opinion has been requested in writing); - the date the termination takes effect. This date must be after the notification, and - a request for amendment (see Article 55), with a proposal for reallocation of the tasks and the estimated budget of the beneficiary concerned (see Annexes 1 and 2) and, if necessary, the addition of one or more new beneficiaries (see Article 56). If termination takes effect after the period set out in Article 3, no request for amendment must be included unless the beneficiary concerned is the coordinator. In this case, the request for amendment must propose a new coordinator. If this information is not given or if the Commission considers that the reasons do not justify termination, the participation will be considered to have been terminated improperly. The termination will take effect on the day specified in the notification. 50.2.2 Effects The coordinator must — within 30 days from when termination takes effect — submit: (i) a report on the distribution of payments to the beneficiary concerned and (ii) if termination takes effect during the period set out in Article 3, a ‘termination report’ from the beneficiary concerned, for the open reporting period until termination, containing an overview of the progress of the work, an overview of the use of resources, the individual financial statement and, if applicable, the certificate on the financial statement (see Articles 20.3 and 20.4). The information in the termination report must also be included in the periodic report for the next reporting period (see Article 20.3). If the request for amendment is rejected by the Commission (because it calls into question the decision awarding the grant or breaches the principle of equal treatment of applicants), the Agreement may be terminated according to Article 50.3.1(c). 81 Grant Agreement number: 825575 — EJP RD — H2020-SC1-BHC-2018-2020/H2020-SC1-2018-Single-Stage-RTD H2020 Associated with MGARef. document EJP Cofund — Multi:-v5.0 Ares(2018)6091977 28/11/2018 If the request for amendment is accepted by the Commission, the Agreement is amended to introduce the necessary changes (see Article 55). The Commission will — on the basis of the periodic reports, the termination report and the report on the distribution of payments — calculate the amount which is due to the beneficiary and if the (pre-financing and interim) payments received by the beneficiary exceed this amount. The amount which is due is calculated in the following steps: Step 1 — Application of the reimbursement rate to the eligible costs The grant amount for the beneficiary is calculated by applying the reimbursement rate(s) to the total eligible costs declared by the beneficiary and its linked third parties in the termination report and approved by the Commission. Only costs incurred by the beneficiary concerned until termination takes effect are eligible (see Article 6). Costs relating to contracts due for execution only after termination are not eligible. Step 2 — Reduction due to substantial errors, irregularities or fraud or serious breach of obligations In case of a reduction (see Article 43), the Commission will calculate the reduced grant amount for the beneficiary by deducting the amount of the reduction (calculated in proportion to the seriousness of the errors, irregularities or fraud or breach of obligations, in accordance with Article 43.2) from the grant amount for the beneficiary. If the payments received exceed the amounts due: - if termination takes effect during the period set out in Article 3 and the request for amendment is accepted, the beneficiary concerned must repay to the coordinator the amount unduly received. The Commission will formally notify the amount unduly received and request the beneficiary concerned to repay it to the coordinator within 30 days of receiving notification. If it does not repay the coordinator, the Commission will draw upon the Guarantee Fund to pay the coordinator and then notify a debit note on behalf of the Guarantee Fund to the beneficiary concerned (see Article 44); - in all other cases, in particular if termination takes effect after the period set out in Article 3, the Commission will formally notify a debit note to the beneficiary concerned. If payment is not made by the date in the debit note, the Guarantee Fund will pay to the Commission the amount due and the Commission will notify a debit note on behalf of the Guarantee Fund to the beneficiary concerned (see Article 44); - if the beneficiary concerned is the former coordinator, it must repay the new coordinator according to the procedure above, unless: - termination takes effect after an interim payment and - the former coordinator has not distributed amounts received as pre-financing or interim payments (see Article 21.7). 82 Grant Agreement number: 825575 — EJP RD — H2020-SC1-BHC-2018-2020/H2020-SC1-2018-Single-Stage-RTD H2020 Associated with MGARef. document EJP Cofund — Multi:-v5.0 Ares(2018)6091977 28/11/2018 In this case, the Commission will formally notify a debit note to the former coordinator. If payment is not made by the date in the debit note, the Guarantee Fund will pay to the Commission the amount due. The Commission will then pay the new coordinator and notify a debit note on behalf of the Guarantee Fund to the former coordinator (see Article 44). If the payments received do not exceed the amounts due: amounts owed to the beneficiary concerned will be included in the next interim or final payment. If the Commission does not receive the termination report within the deadline (see above), only costs included in an approved periodic report will be taken into account. If the Commission does not receive the report on the distribution of payments within the deadline (see above), it will consider that: - the coordinator did not distribute any payment to the beneficiary concerned and that - the beneficiary concerned must not repay any amount to the coordinator. Improper termination may lead to a reduction of the grant (see Article 43) or termination of the Agreement (see Article 50). After termination, the concerned beneficiary’s obligations (in particular Articles 20, 22, 23, Section 3 of Chapter 4, 36, 37, 38, 40, 42, 43 and 44) continue to apply. 50.3 Termination of the Agreement or the participation of one or more beneficiaries, by the Commission 50.3.1 Conditions The Commission may terminate the Agreement or the participation of one or more beneficiaries, if: (a) one or more beneficiaries do not accede to the Agreement (see Article 56); (b) a change to their legal, financial, technical, organisational or ownership situation (or those of its linked third parties) is likely to substantially affect or delay the implementation of the action or calls into question the decision to award the grant; (c) following termination of participation for one or more beneficiaries (see above), the necessary changes to the Agreement would call into question the decision awarding the grant or breach the principle of equal treatment of applicants (see Article 55); (d) implementation of the action is prevented by force majeure (see Article 51) or suspended by the coordinator (see Article 49.1) and either: (i) resumption is impossible, or (ii) the necessary changes to the Agreement would call into question the decision awarding the grant or breach the principle of equal treatment of applicants; (e) a beneficiary is declared bankrupt, being wound up, having its affairs administered by the courts, has entered into an arrangement with creditors, has suspended business activities, or is subject to any other similar proceedings or procedures under national law; 83 Grant Agreement number: 825575 — EJP RD — H2020-SC1-BHC-2018-2020/H2020-SC1-2018-Single-Stage-RTD H2020 Associated with MGARef. document EJP Cofund — Multi:-v5.0 Ares(2018)6091977 28/11/2018 (f) a beneficiary (or a natural person who has the power to represent or take decisions on its behalf) has been found guilty of professional misconduct, proven by any means; (g) a beneficiary does not comply with the applicable national law on taxes and social security; (h) the action has lost scientific or technological relevance; (i) not applicable; (j) not applicable; (k) a beneficiary (or a natural person who has the power to represent or take decisions on its behalf) has committed fraud, corruption, or is involved in a criminal organisation, money laundering or any other illegal activity; (l) a beneficiary (or a natural person who has the power to represent or take decisions on its behalf) has committed: (i) substantial errors, irregularities or fraud or (ii) serious breach of obligations under the Agreement or during the award procedure (including improper implementation of the action, submission of false information, failure to provide required information, breach of ethical principles); (m) a beneficiary (or a natural person who has the power to represent or take decisions on its behalf) has committed — in other EU or Euratom grants awarded to it under similar conditions — systemic or recurrent errors, irregularities, fraud or serious breach of obligations that have a material impact on this grant (extension of findings from other grants to this grant; see Article 22.5.2); (n) despite a specific request by the Commission, a beneficiary does not request — through the coordinator — an amendment to the Agreement to end the participation of one of its linked third parties or international partners that is in one of the situations under points (e), (f), (g), (k), (l) or (m) and to reallocate its tasks. 50.3.2 Procedure Before terminating the Agreement or participation of one or more beneficiaries, the Commission will formally notify the coordinator or beneficiary concerned: - informing it of its intention to terminate and the reasons why and - inviting it, within 30 days of receiving notification, to submit observations and — in case of Point (l.ii) above — to inform the Commission of the measures to ensure compliance with the obligations under the Agreement. If the Commission does not receive observations or decides to pursue the procedure despite the observations it has received, it will formally notify to the coordinator or beneficiary concerned confirmation of the termination and the date it will take effect. Otherwise, it will formally notify that the procedure is not continued. The termination will take effect: 84 Grant Agreement number: 825575 — EJP RD — H2020-SC1-BHC-2018-2020/H2020-SC1-2018-Single-Stage-RTD H2020 Associated with MGARef. document EJP Cofund — Multi:-v5.0 Ares(2018)6091977 28/11/2018 - for terminations under Points (b), (c), (e), (g), (h), (j), (l.ii) and (n) above: on the day specified in the notification of the confirmation (see above); - for terminations under Points (a), (d), (f), (i), (k), (l.i) and (m) above: on the day after the notification of the confirmation is received. 50.3.3 Effects (a) for termination of the Agreement: The coordinator must — within 60 days from when termination takes effect — submit: (i) a periodic report (for the last open reporting period until termination; see Article 20.3) and (ii) a final report (see Article 20.4). If the Agreement is terminated for breach of the obligation to submit reports (see Articles 20.8 and 50.3.1(l)), the coordinator may not submit any reports after termination. If the Commission does not receive the reports within the deadline (see above), only costs which are included in an approved periodic report will be taken into account. The Commission will calculate the final grant amount (see Article 5.3) and the balance (see Article 21.4) on the basis of the reports submitted. Only costs incurred until termination takes effect are eligible (see Article 6). Costs relating to contracts due for execution only after termination are not eligible. This does not affect the Commission’s right to reduce the grant (see Article 43) or to impose administrative sanctions (Article 45). The beneficiaries may not claim damages due to termination by the Commission (see Article 46). After termination, the beneficiaries’ obligations (in particular Articles 20, 22, 23, Section 3 of Chapter 4, 36, 37, 38, 40, 42, 43 and 44) continue to apply. (b) for termination of the participation of one or more beneficiaries: The coordinator must — within 60 days from when termination takes effect — submit: (i) a report on the distribution of payments to the beneficiary concerned; (ii) a request for amendment (see Article 55), with a proposal for reallocation of the tasks and estimated budget of the beneficiary concerned (see Annexes 1 and 2) and, if necessary, the addition of one or more new beneficiaries (see Article 56). If termination is notified after the period set out in Article 3, no request for amendment must be submitted unless the beneficiary concerned is the coordinator. In this case the request for amendment must propose a new coordinator, and (iii) if termination takes effect during the period set out in Article 3, a termination report from the beneficiary concerned, for the open reporting period until termination, containing an overview of the progress of the work, an overview of the use of resources, 85 Grant Agreement number: 825575 — EJP RD — H2020-SC1-BHC-2018-2020/H2020-SC1-2018-Single-Stage-RTD H2020 Associated with MGARef. document EJP Cofund — Multi:-v5.0 Ares(2018)6091977 28/11/2018 the individual financial statement and, if applicable, the certificate on the financial statement (see Article 20). The information in the termination report must also be included in the periodic report for the next reporting period (see Article 20.3). If the request for amendment is rejected by the Commission (because it calls into question the decision awarding the grant or breaches the principle of equal treatment of applicants), the Agreement may be terminated according to Article 50.3.1(c). If the request for amendment is accepted by the Commission, the Agreement is amended to introduce the necessary changes (see Article 55). The Commission will — on the basis of the periodic reports, the termination report and the report on the distribution of payments — calculate the amount which is due to the beneficiary and if the (pre-financing and interim) payments received by the beneficiary exceed this amount. The amount which is due is calculated in the following steps: Step 1 — Application of the reimbursement rate to the eligible costs The grant amount for the beneficiary is calculated by applying the reimbursement rate(s) to the total eligible costs declared by the beneficiary and its linked third parties in the termination report and approved by the Commission. Only costs incurred by the beneficiary concerned until termination takes effect are eligible (see Article 6). Costs relating to contracts due for execution only after termination are not eligible. Step 2 — Reduction due to substantial errors, irregularities or fraud or serious breach of obligations In case of a reduction (see Article 43), the Commission will calculate the reduced grant amount for the beneficiary by deducting the amount of the reduction (calculated in proportion to the seriousness of the errors, irregularities or fraud or breach of obligations, in accordance with Article 43.2) from the grant amount for the beneficiary. If the payments received exceed the amounts due: - if termination takes effect during the period set out in Article 3 and the request for amendment is accepted, the beneficiary concerned must repay to the coordinator the amount unduly received. The Commission will formally notify the amount unduly received and request the beneficiary concerned to repay it to the coordinator within 30 days of receiving notification. If it does not repay the coordinator, the Commission will draw upon the Guarantee Fund to pay the coordinator and then notify a debit note on behalf of the Guarantee Fund to the beneficiary concerned (see Article 44); - in all other cases, in particular if termination takes effect after the period set out in Article 3, the Commission will formally notify a debit note to the beneficiary concerned. If payment is not made by the date in the debit note, the Guarantee Fund 86 Grant Agreement number: 825575 — EJP RD — H2020-SC1-BHC-2018-2020/H2020-SC1-2018-Single-Stage-RTD H2020 Associated with MGARef. document EJP Cofund — Multi:-v5.0 Ares(2018)6091977 28/11/2018 will pay to the Commission the amount due and the Commission will notify a debit note on behalf of the Guarantee Fund to the beneficiary concerned (see Article 44); - if the beneficiary concerned is the former coordinator, it must repay the new coordinator according to the procedure above, unless: - termination takes effect after an interim payment and - the former coordinator has not distributed amounts received as pre-financing or interim payments (see Article 21.7). In this case, the Commission will formally notify a debit note to the former coordinator. If payment is not made by the date in the debit note, the Guarantee Fund will pay to the Commission the amount due. The Commission will then pay the new coordinator and notify a debit note on behalf of the Guarantee Fund to the former coordinator (see Article 44). If the payments received do not exceed the amounts due: amounts owed to the beneficiary concerned will be included in the next interim or final payment. If the Commission does not receive the termination report within the deadline (see above), only costs included in an approved periodic report will be taken into account. If the Commission does not receive the report on the distribution of payments within the deadline (see above), it will consider that: - the coordinator did not distribute any payment to the beneficiary concerned and that - the beneficiary concerned must not repay any amount to the coordinator. After termination, the concerned beneficiary’s obligations (in particular Articles 20, 22, 23, Section 3 of Chapter 4, 36, 37, 38, 40, 42, 43 and 44) continue to apply. SECTION 4 FORCE MAJEURE ARTICLE 51 — FORCE MAJEURE ‘Force majeure’ means any situation or event that: - prevents either party from fulfilling their obligations under the Agreement, - was unforeseeable, exceptional situation and beyond the parties’ control, - was not due to error or negligence on their part (or on the part of third parties involved in the action), and - proves to be inevitable in spite of exercising all due diligence. The following cannot be invoked as force majeure: - any default of a service, defect in equipment or material or delays in making them available, unless they stem directly from a relevant case of force majeure, 87 Grant Agreement number: 825575 — EJP RD — H2020-SC1-BHC-2018-2020/H2020-SC1-2018-Single-Stage-RTD H2020 Associated with MGARef. document EJP Cofund — Multi:-v5.0 Ares(2018)6091977 28/11/2018 - labour disputes or strikes, or - financial difficulties. Any situation constituting force majeure must be formally notified to the other party without delay, stating the nature, likely duration and foreseeable effects. The parties must immediately take all the necessary steps to limit any damage due to force majeure and do their best to resume implementation of the action as soon as possible. The party prevented by force majeure from fulfilling its obligations under the Agreement cannot be considered in breach of them. CHAPTER 7 FINAL PROVISIONS ARTICLE 52 — COMMUNICATION BETWEEN THE PARTIES 52.1 Form and means of communication Communication under the Agreement (information, requests, submissions, ‘formal notifications’, etc.) must: - be made in writing and - bear the number of the Agreement. All communication must be made through the Participant Portal electronic exchange system and using the forms and templates provided there. If — after the payment of the balance — the Commission finds that a formal notification was not accessed, a second formal notification will be made by registered post with proof of delivery (‘formal notification on paper’). Deadlines will be calculated from the moment of the second notification. Communications in the electronic exchange system must be made by persons authorised according to the Participant Portal Terms & Conditions. For naming the authorised persons, each beneficiary must have designated — before the signature of this Agreement — a ‘legal entity appointed representative (LEAR)’. The role and tasks of the LEAR are stipulated in his/her appointment letter (see Participant Portal Terms & Conditions). If the electronic exchange system is temporarily unavailable, instructions will be given on the Commission website. 52.2 Date of communication Communications are considered to have been made when they are sent by the sending party (i.e. on the date and time they are sent through the electronic exchange system). Formal notifications through the electronic exchange system are considered to have been made when they are received by the receiving party (i.e. on the date and time of acceptance by the receiving party, as indicated by the time stamp). A formal notification that has not been accepted within 10 days after sending is considered to have been accepted. 88 Grant Agreement number: 825575 — EJP RD — H2020-SC1-BHC-2018-2020/H2020-SC1-2018-Single-Stage-RTD H2020 Associated with MGARef. document EJP Cofund — Multi:-v5.0 Ares(2018)6091977 28/11/2018 Formal notifications on paper sent by registered post with proof of delivery (only after the payment of the balance) are considered to have been made on either: - the delivery date registered by the postal service or - the deadline for collection at the post office. If the electronic exchange system is temporarily unavailable, the sending party cannot be considered in breach of its obligation to send a communication within a specified deadline. 52.3 Addresses for communication The electronic exchange system must be accessed via the following URL: https://ec.europa.eu/research/participants/portal/desktop/en/projects/ The Commission will formally notify the coordinator and beneficiaries in advance any changes to this URL. Formal notifications on paper (only after the payment of the balance) addressed to the Commission must be sent to the official mailing address indicated on the Commission’s website. Formal notifications on paper (only after the payment of the balance) addressed to the beneficiaries must be sent to their legal address as specified in the Participant Portal Beneficiary Register. ARTICLE 53 — INTERPRETATION OF THE AGREEMENT 53.1 Precedence of the Terms and Conditions over the Annexes The provisions in the Terms and Conditions of the Agreement take precedence over its Annexes. Annex 2 takes precedence over Annex 1. 53.2 Privileges and immunities Nothing in the Agreement may be interpreted as a waiver of any privileges or immunities accorded to the EUROPEAN MOLECULAR BIOLOGY LABORATORY by its constituent documents or international law. ARTICLE 54 — CALCULATION OF PERIODS, DATES AND DEADLINES In accordance with Regulation No 1182/7127, periods expressed in days, months or years are calculated from the moment the triggering event occurs. The day during which that event occurs is not considered as falling within the period. ARTICLE 55 — AMENDMENTS TO THE AGREEMENT 55.1 Conditions 27 Regulation (EEC, Euratom) No 1182/71 of the Council of 3 June 1971 determining the rules applicable to periods, dates and time-limits (OJ L 124, 8.6.1971, p. 1). 89 Grant Agreement number: 825575 — EJP RD — H2020-SC1-BHC-2018-2020/H2020-SC1-2018-Single-Stage-RTD H2020 Associated with MGARef. document EJP Cofund — Multi:-v5.0 Ares(2018)6091977 28/11/2018 The Agreement may be amended, unless the amendment entails changes to the Agreement which would call into question the decision awarding the grant or breach the principle of equal treatment of applicants. Amendments may be requested by any of the parties. 55.2 Procedure The party requesting an amendment must submit a request for amendment signed in the electronic exchange system (see Article 52). The coordinator submits and receives requests for amendment on behalf of the beneficiaries (see Annex 3). If a change of coordinator is requested without its agreement, the submission must be done by another beneficiary (acting on behalf of the other beneficiaries). The request for amendment must include: - the reasons why; - the appropriate supporting documents, and - for a change of coordinator without its agreement: the opinion of the coordinator (or proof that this opinion has been requested in writing). The Commission may request additional information. If the party receiving the request agrees, it must sign the amendment in the electronic exchange system within 45 days of receiving notification (or any additional information the Commission has requested). If it does not agree, it must formally notify its disagreement within the same deadline. The deadline may be extended, if necessary for the assessment of the request. If no notification is received within the deadline, the request is considered to have been rejected An amendment enters into force on the day of the signature of the receiving party. An amendment takes effect on the date agreed by the parties or, in the absence of such an agreement, on the date on which the amendment enters into force. ARTICLE 56 — ACCESSION TO THE AGREEMENT 56.1 Accession of the beneficiaries mentioned in the Preamble The other beneficiaries must accede to the Agreement by signing the Accession Form (see Annex 3) in the electronic exchange system (see Article 52) within 30 days after its entry into force (see Article 58). They will assume the rights and obligations under the Agreement with effect from the date of its entry into force (see Article 58). If a beneficiary does not accede to the Agreement within the above deadline, the coordinator must — within 30 days — request an amendment to make any changes necessary to ensure proper 90 Grant Agreement number: 825575 — EJP RD — H2020-SC1-BHC-2018-2020/H2020-SC1-2018-Single-Stage-RTD H2020 Associated with MGARef. document EJP Cofund — Multi:-v5.0 Ares(2018)6091977 28/11/2018 implementation of the action. This does not affect the Commission’s right to terminate the Agreement (see Article 50). 56.2 Addition of new beneficiaries In justified cases, the beneficiaries may request the addition of a new beneficiary. For this purpose, the coordinator must submit a request for amendment in accordance with Article 55. It must include an Accession Form (see Annex 3) signed by the new beneficiary in the electronic exchange system (see Article 52). New beneficiaries must assume the rights and obligations under the Agreement with effect from the date of their accession specified in the Accession Form (see Annex 3). ARTICLE 57 — APPLICABLE LAW AND SETTLEMENT OF DISPUTES 57.1 Applicable law The Agreement is governed by the applicable EU law, supplemented if necessary by the law of Belgium. As an exception, the Agreement is governed by a different applicable law for the following beneficiaries: - EUROPEAN MOLECULAR BIOLOGY LABORATORY: by the general principles governing the law of international organisations and the rules of general international law 57.2 Dispute settlement If a dispute concerning the interpretation, application or validity of the Agreement cannot be settled amicably, the General Court — or, on appeal, the Court of Justice of the European Union — has sole jurisdiction. Such actions must be brought under Article 272 of the Treaty on the Functioning of the EU (TFEU). As an exception, if such a dispute is between the Commission and MINISTRY OF HEALTH, SCHWEIZERISCHER NATIONALFONDS ZUR FORDERUNG DER WISSENSCHAFTLICHEN FORSCHUNG, BLACKSWAN FOUNDATION, TURKIYE BILIMSEL VE TEKNOLOJIK ARASTIRMA KURUMU, ACIBADEM UNIVERSITESI, HACETTEPE UNIVERSITESI, CANADIAN INSTITUTES OF HEALTH RESEARCH, FONDS DE RECHERCHE DU QUEBEC - SANTE, the competent Belgian courts have sole jurisdiction. As an exception, for the following beneficiaries: - EUROPEAN MOLECULAR BIOLOGY LABORATORY such disputes must — if they cannot be settled amicably — be referred to arbitration. Each party must formally notify to the other party its intention of resorting to arbitration and the identity of the arbitrator. The Permanent Court of Arbitration Optional Rules for Arbitration Involving International Organisations and States in force at the date of entry into force of the Agreement will apply. The appointing authority will be the Secretary-General of the Permanent Court of Arbitration following a written request submitted by either party. The arbitration proceedings must take place in Brussels 91 Grant Agreement number: 825575 — EJP RD — H2020-SC1-BHC-2018-2020/H2020-SC1-2018-Single-Stage-RTD H2020 Associated with MGARef. document EJP Cofund — Multi:-v5.0 Ares(2018)6091977 28/11/2018 and the language used in the arbitral proceedings will be English. The arbitral award will be binding on all parties and will not be subject to appeal. If a dispute concerns administrative sanctions, offsetting or an enforceable decision under Article 299 TFEU (see Articles 44, 45 and 46), the beneficiaries must bring action before the General Court — or, on appeal, the Court of Justice of the European Union — under Article 263 TFEU. ARTICLE 58 — ENTRY INTO FORCE OF THE AGREEMENT The Agreement will enter into force on the day of signature by the Commission or the coordinator, depending on which is later. SIGNATURES For the coordinator For the Commission [--TGSMark#signature-999997833_75_210--] [--TGSMark#signature-service_75_210--] Camille CHAUDONNERET with ECAS id nchaucmi signed Signed by Mila BAS SANCHEZ with ECAS id bassami as in the Participant Portal on 13/12/2018 at 02:13:21 an authorised representative on 13-12-2018 10:52:06 (transaction id SigId-95714- (transaction id SigId-101288- 7hpKIXbkMLMEP1K4BMAs5GcXMhBPsoHKapJcH8tPzl2 gGMrPJ5dlhgIczNLmKraWszOBb7NazPXa7tccKKhUPl3y 2AsRo8gJzzICO0dxlNDv5S7onKFuWJjTzg6oQ90XvMiW- nFzmnoKFc5bZNYquLMuP4ZAydwD0DBhopHTXG5hgn8- PHslUMVSXYCzVB2usIRhDj- PHslUMVSXYCzVB2usIRhDj- uQbPV0VdXOPxlSRwnfYHxXzHg5pMwzUzh8qdQY9zre4 iuJAhXWlZU3WKBBF1g04CCvelUhgIyxGKpKsaACx4zY) y). Timestamp by third party at Thu Dec 13 10:52:10 CET 2018 Thu Dec 13 02:13:30 CET 2018 92 Associated with document Ref. Ares(2018)6091977 - 28/11/2018 EUROPEAN COMMISSION DIRECTORATE-GENERAL RESEARCH & INNOVATION Innovative and Personalised Medicine ANNEX 1 (part A) COFUND (European Joint Programme) NUMBER — 825575 — EJP RD Associated with document Ref. Ares(2018)6091977 - 28/11/2018 Table of Contents 1.1. The project summary................................................................................................................................. 3 1.2. The list of beneficiaries..............................................................................................................................4 1.3. Workplan Tables - Detailed implementation..............................................................................................8 1.3.1. WT1 List of work packages........................................................................................................... 8 1.3.2. WT2 List of deliverables.............................................................................................................. 10 1.3.3. WT3 Work package descriptions................................................................................................. 34 Work package 1......................................................................................................................... 34 Work package 2......................................................................................................................... 43 Work package 3......................................................................................................................... 50 Work package 4......................................................................................................................... 54 Work package 5......................................................................................................................... 61 Work package 6......................................................................................................................... 65 Work package 7......................................................................................................................... 71 Work package 8......................................................................................................................... 74 Work package 9......................................................................................................................... 77 Work package 10....................................................................................................................... 82 Work package 11....................................................................................................................... 87 Work package 12....................................................................................................................... 95 Work package 13..................................................................................................................... 100 Work package 14..................................................................................................................... 104 Work package 15..................................................................................................................... 109 Work package 16..................................................................................................................... 113 Work package 17..................................................................................................................... 117 Work package 18..................................................................................................................... 120 Work package 19..................................................................................................................... 123 Work package 20..................................................................................................................... 128 Work package 21..................................................................................................................... 133 1.3.4. WT4 List of milestones.............................................................................................................. 137 1.3.5. WT5 Critical Implementation risks and mitigation actions......................................................... 143 1.3.6 WT6 Summary of project effort in person-months......................................................................149 1.3.7. WT7 Tentative schedule of project reviews...............................................................................161 Associated with document Ref. Ares(2018)6091977 - 28/11/2018 1.1. The project summary Project Number 1 825575 Project Acronym 2 EJP RD One form per project General information Project title 3 European Joint Programme on Rare Diseases Starting date 4 01/01/2019 Duration in months 5 60 Call (part) identifier 6 H2020-SC1-2018-Single-Stage-RTD SC1-BHC-04-2018 Topic Rare Disease European Joint Programme Cofund Fixed EC Keywords Health sciences rare diseases, funding, data, omics, shared access, FAIR, patients, training, Free keywords empowerment, translation, public-private partnerships, innovative methodologies for clinical studies Abstract 7 As recognized by the Council Recommendation 2009/C 151/02, rare diseases (RD) are a prime example of a research area that can strongly profit from coordination on a European and international scale. RD research should be improved to overcome fragmentation, leading to efficacious use of data and resources, faster scientific progress and competitiveness, and most importantly to decrease unnecessary hardship and prolonged suffering of RD patients. In the specific context of the massive generation, need for reuse and efficient interpretation of data, introduction of omics into care practice and the structuration of RD care centers in European Reference Networks, it appears crucial and timely to maximize the potential of already funded tools and programmes by supporting them further, scaling up, linking, and most importantly, adapting them to the needs of end-users through implementation tests in real settings. Such a concerted effort is necessary to develop a sustainable ecosystem allowing a virtuous circle between RD care, research and medical innovation. To achieve this goal, the European Joint Programme on RD (EJP RD) has two major objectives: (i) To improve the integration, the efficacy, the production and the social impact of research on RD through the development, demonstration and promotion of Europe/world-wide sharing of research and clinical data, materials, processes, knowledge and know-how; (ii) To implement and further develop an efficient model of financial support for all types of research on RD (fundamental, clinical, epidemiological, social, economic, health service) coupled with accelerated exploitation of research results for benefit of patients. To this end, the EJP RD actions will be organized within four major Pillars assisted by the central coordination: (P1): Funding of research; (P2): Coordinated access to data and services; (P3) Capacity building; (P4): Accelerated translation of research projects and improvement outcomes of clinical studies. Page 3 of 161 Associated with document Ref. Ares(2018)6091977 - 28/11/2018 1.2. List of Beneficiaries Project Number 1 825575 Project Acronym 2 EJP RD List of Beneficiaries Project Project No Name Short name Country entry exit month8 month INSTITUT NATIONAL DE LA SANTE ET 1 INSERM France 1 60 DE LA RECHERCHE MEDICALE FONDS ZUR FÖRDERUNG DER 2 FWF Austria 1 60 WISSENSCHAFTLICHEN FORSCHUNG AIT AUSTRIAN INSTITUTE OF 3 AIT Austria 1 60 TECHNOLOGY GMBH LUDWIG BOLTZMANN GESELLSCHAFT 4 LBG (LBI-RUD) Austria 1 60 GMBH FONDS NATIONAL DE LA RECHERCHE 5 FNRS Belgium 1 60 SCIENTIFIQUE FONDS VOOR WETENSCHAPPELIJK 6 FWO Belgium 1 60 ONDERZOEK-VLAANDEREN 7 KATHOLIEKE UNIVERSITEIT LEUVEN KU Leuven Belgium 1 60 MINISTRY OF EDUCATION YOUTH AND 8 MEYS Czech Republic 1 60 SPORTS 9 SOTSIAALMINISTEERIUM MOSAE Estonia 1 60 10 SUOMEN AKATEMIA AKA Finland 1 60 AGENCE NATIONALE DE LA 11 ANR France 1 60 RECHERCHE 12 FONDATION MALADIES RARES FFRD France 1 60 ASS FRANCAISE CONTRE LES 13 AFM France 1 60 MYOPATHIES IMAGINE INSTITUT DES MALADIES 14 GENETIQUES NECKER ENFANTS IMAGINE France 1 60 MALADES FONDATION DEUTSCHES ZENTRUM FUER LUFT - 15 DLR Germany 1 60 UND RAUMFAHRT EV 16 UNIVERSITAETSKLINIKUM AACHEN UKA Germany 1 60 CHARITE - UNIVERSITAETSMEDIZIN 17 CHARITE Germany 1 60 BERLIN 18 UNIVERSITAETSKLINIKUM FREIBURG UKL-FR Germany 1 60 NEMZETI KUTATASI FEJLESZTESI ES 19 NKFIH Hungary 1 60 INNOVACIOS HIVATAL 20 THE HEALTH RESEARCH BOARD HRB Ireland 1 60 21 MINISTERO DELLA SALUTE IT-MOH Italy 1 60 22 REGIONE TOSCANA TuscReg Italy 1 60 FONDAZIONE REGIONALE PER LA 23 FRRB Italy 1 60 RICERCA BIOMEDICA Page 4 of 161 Associated with document Ref. Ares(2018)6091977 - 28/11/2018 1.2. List of Beneficiaries Project Project No Name Short name Country entry exit month8 month FONDAZIONE PER LA RICERCA 24 FARMACOLOGICA GIANNI BENZI FGB Italy 1 60 ONLUS 25 FONDAZIONE TELETHON FTELE Italy 1 60 26 ISTITUTO SUPERIORE DI SANITA ISS Italy 1 60 CONSORZIO PER VALUTAZIONI 27 CVBF Italy 1 60 BIOLOGICHE E FARMACOLOGICHE TEDDY - EUROPEAN NETWORK 28 OF EXCELLENCE FOR PAEDIATRIC TEDDY Italy 1 60 CLINICAL RESEARCH MINISTERO DELL'ISTRUZIONE, 29 MIUR Italy 1 60 DELL'UNIVERSITA' E DELLA RICERCA VALSTS IZGLITIBAS ATTISTIBAS 30 VIAA Latvia 1 60 AGENTURA 31 Lietuvos mokslo taryba LMT Lithuania 1 60 VIESOJI ISTAIGA VILNIAUS 32 UNIVERSITETO LIGONINE SANTAROS VUHSK Lithuania 1 60 KLINIKOS 33 FONDS NATIONAL DE LA RECHERCHE FNR Luxembourg 1 60 34 ZORGONDERZOEK NEDERLAND ZON ZonMw Netherlands 1 60 ACADEMISCH ZIEKENHUIS 35 UMCG Netherlands 1 60 GRONINGEN 36 UNIVERSITEIT MAASTRICHT UM Netherlands 1 60 NARODOWE CENTRUM BADAN I 37 NCBR Poland 1 60 ROZWOJU WARSZAWSKI UNIWERSYTET 38 MUW Poland 1 60 MEDYCZNY 39 GDANSKI UNIWERSYTET MEDYCZNY MUG Poland 1 60 INSTYTUT POMNIK CENTRUM 40 IPCZD Poland 1 60 ZDROWIA DZIECKA FUNDACAO PARA A CIENCIA E A 41 FCT Portugal 1 60 TECNOLOGIA INSTITUTO NACIONAL DE SAUDE DR. 42 INSA Portugal 1 60 RICARDO JORGE 43 SLOVENSKA AKADEMIA VIED SAS Slovakia 1 60 44 INSTITUTO DE SALUD CARLOS III ISCIII Spain 1 60 FUNDACIO CENTRE DE REGULACIO 45 CNAG-CRG Spain 1 60 GENOMICA UNIVERSIDAD POLITECNICA DE 46 UPM Spain 1 60 MADRID Page 5 of 161 Associated with document Ref. Ares(2018)6091977 - 28/11/2018 1.2. List of Beneficiaries Project Project No Name Short name Country entry exit month8 month CONSORCIO CENTRO DE 47 INVESTIGACION BIOMEDICA EN RED CIBER Spain 1 60 M.P. VETENSKAPSRADET - SWEDISH 48 SRC Sweden 1 60 RESEARCH COUNCIL 49 VERKET FÖR INNOVATIONSSYSTEM VINNOVA Sweden 1 60 50 UNIVERSITY OF LEICESTER ULEIC United Kingdom 1 60 51 THE UNIVERSITY OF LIVERPOOL ULIV United Kingdom 1 60 UNIVERSITY OF NEWCASTLE UPON 52 UNEW United Kingdom 1 60 TYNE 53 ST. ANNA KINDERKREBSFORSCHUNG CCRI Austria 1 60 ASSISTANCE PUBLIQUE - HOPITAUX DE 54 AP-HP France 1 60 PARIS HOPITAUX UNIVERSITAIRES DE 55 HUS France 1 60 STRASBOURG CENTRE ANTICANCEREUX LEON 56 CLB France 1 60 BERARD UNIVERSITAETSKLINIKUM 57 UKL-HD Germany 1 60 HEIDELBERG EBERHARD KARLS UNIVERSITAET 58 EKUT Germany 1 60 TUEBINGEN JOHANN WOLFGANG GOETHE- 59 GUF Germany 1 60 UNIVERSITATFRANKFURT AM MAIN HELIOS DR. HORST SCHMIDT 60 HSK Germany 1 60 KLINIKEN WIESBADEN GMBH 61 ISTITUTO ORTOPEDICO RIZZOLI IOR Italy 1 60 AZIENDA OSPEDALIERO 62 AOUP Italy 1 60 UNIVERSITARIA PISANA AZIENDA OSPEDALIERA 63 AOUS Italy 1 60 UNIVERSITARIA SENESE 64 ACADEMISCH ZIEKENHUIS LEIDEN LUMC Netherlands 1 60 STICHTING KATHOLIEKE 65 Radboudumc Netherlands 1 60 UNIVERSITEIT Academisch Medisch Centrum bij de 66 AMC Netherlands 1 60 Universiteit van Amsterdam ERASMUS UNIVERSITAIR MEDISCH 67 ERASMUS MC Netherlands 1 60 CENTRUM ROTTERDAM 68 SERVICIO MADRILENO DE SALUD SERMAS Spain 1 60 THE NEWCASTLE UPON TYNE 69 NUTH United Kingdom 1 60 HOSPITALS NHS FOUNDATION TRUST Page 6 of 161 Associated with document Ref. Ares(2018)6091977 - 28/11/2018 1.2. List of Beneficiaries Project Project No Name Short name Country entry exit month8 month GREAT ORMOND STREET HOSPITAL 70 FOR CHILDREN NATIONAL HEALTH GOSH United Kingdom 1 60 SERVICE TRUST EUROPEAN ORGANISATION FOR 71 RESEARCH AND TREATMENT OF EORTC Belgium 1 60 CANCER AISBL 72 INFRAFRONTIER GMBH INFRAFRONTIER Germany 1 60 BIOBANKS AND BIOMOLECULAR RESOURCESRESEARCH 73 BBMRI Austria 1 60 INFRASTRUCTURE CONSORTIUM(BBMRI-ERIC) ECRIN EUROPEAN CLINICAL 74 RESEARCH INFRASTRUCTURE ECRIN France 1 60 NETWORK 75 EATRIS ERIC EATRIS Netherlands 1 60 EUROPEAN MOLECULAR BIOLOGY 76 EMBL Germany 1 60 LABORATORY EURORDIS - EUROPEAN 77 ORGANISATION FOR RARE DISEASES EURORDIS France 1 60 ASSOCIATION 78 MINISTRY OF HEALTH CSO-MOH Israel 1 60 SCHWEIZERISCHER NATIONALFONDS 79 ZUR FORDERUNG DER SNSF Switzerland 1 60 WISSENSCHAFTLICHEN FORSCHUNG 80 BLACKSWAN FOUNDATION Blackswan Switzerland 1 60 TURKIYE BILIMSEL VE TEKNOLOJIK 81 TUBITAK Turkey 1 60 ARASTIRMA KURUMU 82 ACIBADEM UNIVERSITESI ACURARE Turkey 1 60 83 HACETTEPE UNIVERSITESI HUGEN Turkey 1 60 CANADIAN INSTITUTES OF HEALTH 84 CIHR Canada 1 60 RESEARCH FONDS DE RECHERCHE DU QUEBEC - 85 FRQS Canada 1 60 SANTE 86 INSERM TRANSFERT SA IT France 1 60 GENIKI GRAMMATIA EREVNAS KAI 87 GSRT Greece 1 60 TECHNOLOGIAS DEUTSCHE 88 DFG Germany 1 60 FORSCHUNGSGEMEINSCHAFT Page 7 of 161 Associated with document Ref. Ares(2018)6091977 - 28/11/2018 1.3. Workplan Tables - Detailed implementation 1.3.1. WT1 List of work packages WP Person- Start End WP Title Lead beneficiary10 Number9 months11 month12 month13 WP1 Coordination and management 1 - INSERM 470.00 1 60 Integrative research and innovation WP2 44 - ISCIII 64.00 1 60 strategy Sustainability strategy and business WP3 1 - INSERM 65.00 1 60 plan Ethical, regulatory, legal and IPR WP4 24 - FGB 63.00 1 60 framework of the EJP RD WP5 Communication & dissemination 1 - INSERM 89.00 1 60 Joint Transnational Calls for WP6 15 - DLR 133.60 1 60 collaborative research projects Networking to share knowledge on WP7 34 - ZonMw 21.40 1 60 rare diseases WP8 Rare Disease Research Challenges 12 - FFRD 25.00 1 60 WP9 Monitoring of funded projects 78 - CSO-MOH 25.00 1 60 User-driven strategic planning and WP10 transversal activities for Pillar 2 data 1 - INSERM 118.60 1 60 ecosystem Common virtual platform for WP11 discoverable data and resources for 1 - INSERM 1,330.70 1 60 RD research Enabling sustainable FAIRness and WP12 Federation at the record level for RD 50 - ULEIC 1,254.41 1 60 data, patients and samples Enabling multidisciplinary, WP13 holistic approaches for rare disease 36 - UM 297.90 1 60 diagnostics and therapeutics Training on data management & WP14 26 - ISS 185.00 1 60 quality Capacity building and training of WP15 patients and researchers in Rare 77 - EURORDIS 117.40 1 60 Disease research and processes WP16 Online Academic education course 12 - FFRD 92.50 1 60 ERN RD training and support WP17 58 - EKUT 63.00 1 60 programme Development and adaptation of WP18 32 - VUHSK 12.00 24 60 training activities Facilitating partnerships and WP19 accelerating translation for higher 75 - EATRIS 208.00 1 60 patient impact Accelerating the validation, use WP20 54 - AP-HP 251.00 1 60 and development of innovative Page 8 of 161 Associated with document Ref. Ares(2018)6091977 - 28/11/2018 1.3. Workplan Tables - Detailed implementation WP Person- Start End WP Title Lead beneficiary10 Number9 months11 month12 month13 methodologies tailored for clinical trials in RDs WP21 Ethics requirements 1 - INSERM N/A 1 60 Total 4,886.51 Page 9 of 161 Associated with document Ref. Ares(2018)6091977 - 28/11/2018 1.3.2. WT2 list of deliverables Due Deliverable WP Dissemination Deliverable Title Lead beneficiary Type 15 Date (in Number14 number9 level16 months)17 Report from the Kick- D1.1 WP1 1 - INSERM Report Public 2 off meeting Confidential, only for members Helpdesk directory of of the consortium D1.2 WP1 1 - INSERM Report 3 people and services (including the Commission Services) First report from the face-to-face ExCom D1.3 WP1 1 - INSERM Report Public 7 and Policy Board meeting Second report from the face-to-face ExCom D1.4 WP1 1 - INSERM Report Public 19 and Policy Board meeting Third report from the face-to-face ExCom D1.5 WP1 1 - INSERM Report Public 31 and Policy Board meeting Fourth report from the face-to-face ExCom D1.6 WP1 1 - INSERM Report Public 43 and Policy Board meeting Fifth report from the face-to-face ExCom D1.7 WP1 1 - INSERM Report Public 55 and Policy Board meeting Confidential, only for members First Summary Progress of the consortium D1.8 Report and Annual WP1 1 - INSERM Report 9 (including the Work Plan Commission Services) Confidential, only for members Second Summary of the consortium D1.9 Progress Report and WP1 1 - INSERM Report 21 (including the Annual Work Plan Commission Services) Confidential, only for members Third Summary of the consortium D1.10 Progress Report and WP1 1 - INSERM Report 33 (including the Annual Work Plan Commission Services) Page 10 of 161 Associated with document Ref. Ares(2018)6091977 - 28/11/2018 Due Deliverable WP Dissemination Deliverable Title Lead beneficiary Type15 Date (in Number14 number9 level16 months)17 Confidential, only for members Fourth Summary of the consortium D1.11 Progress Report and WP1 1 - INSERM Report 45 (including the Annual Work Plan Commission Services) Confidential, only for members Fifth Summary of the consortium D1.12 Progress Report and WP1 1 - INSERM Report 57 (including the Annual Work Plan Commission Services) Confidential, only for members First Technical and of the consortium D1.13 WP1 1 - INSERM Report 15 Financial Report (including the Commission Services) Confidential, only for members Second Technical and of the consortium D1.14 WP1 1 - INSERM Report 27 Financial Report (including the Commission Services) Confidential, only for members Third Technical and of the consortium D1.15 WP1 1 - INSERM Report 39 Financial Report (including the Commission Services) Confidential, only for members Fourth Technical and of the consortium D1.16 WP1 1 - INSERM Report 51 Financial Report (including the Commission Services) Confidential, only for members Fifth Technical and of the consortium D1.17 WP1 1 - INSERM Report 60 Financial Report (including the Commission Services) Confidential, only for members Monitoring activities of the consortium D1.18 WP1 51 - ULIV Report 2 handbook (including the Commission Services) First EJP RD Confidential, D1.19 WP1 27 - CVBF Report 12 Monitoring Report only for members Page 11 of 161 Associated with document Ref. Ares(2018)6091977 - 28/11/2018 Due Deliverable WP Dissemination Deliverable Title Lead beneficiary Type15 Date (in Number14 number9 level16 months)17 of the consortium (including the Commission Services) Confidential, only for members Second EJP RD of the consortium D1.20 WP1 27 - CVBF Report 24 Monitoring Report (including the Commission Services) Confidential, only for members Third EJP RD of the consortium D1.21 WP1 27 - CVBF Report 36 Monitoring Report (including the Commission Services) Confidential, only for members Fourth EJP RD of the consortium D1.22 WP1 27 - CVBF Report 48 Monitoring Report (including the Commission Services) Confidential, only for members Fifth EJP RD of the consortium D1.23 WP1 27 - CVBF Report 60 Monitoring Report (including the Commission Services) Initial Data D1.24 WP1 1 - INSERM Report Public 6 Management Plan ORDP: Updated Data Open D1.25 WP1 1 - INSERM Public 6 Management Plan Research Data Pilot Final list of D2.1 WP2 27 - CVBF Report Public 5 prioritization criteria Prioritization scheme D2.2 including decision- WP2 27 - CVBF Report Public 5 making process Confidential, First Summary only for members document on mapped of the consortium D2.3 WP2 44 - ISCIII Report 5 research and innovation (including the needs Commission Services) Second Summary Confidential, document on mapped only for members D2.4 WP2 44 - ISCIII Report 17 research and innovation of the consortium needs (including the Page 12 of 161 Associated with document Ref. Ares(2018)6091977 - 28/11/2018 Due Deliverable WP Dissemination Deliverable Title Lead beneficiary Type15 Date (in Number14 number9 level16 months)17 Commission Services) Confidential, Third Summary only for members document on mapped of the consortium D2.5 WP2 44 - ISCIII Report 29 research and innovation (including the needs Commission Services) Confidential, Fourth Summary only for members document on mapped of the consortium D2.6 WP2 44 - ISCIII Report 41 research and innovation (including the needs Commission Services) Confidential, Fifth Summary only for members document on mapped of the consortium D2.7 WP2 44 - ISCIII Report 53 research and innovation (including the needs Commission Services) D2.8 First Scoping paper WP2 26 - ISS Report Public 7 D2.9 Second Scoping paper WP2 26 - ISS Report Public 19 D2.10 Third Scoping paper WP2 26 - ISS Report Public 31 D2.11 Fourth Scoping paper WP2 38 - MUW Report Public 43 D2.12 Fifth Scoping paper WP2 38 - MUW Report Public 55 Confidential, only for members First List of refined JTC of the consortium D2.13 WP2 44 - ISCIII Report 7 topics (including the Commission Services) Confidential, only for members Second List of refined of the consortium D2.14 WP2 44 - ISCIII Report 19 JTC topics (including the Commission Services) Confidential, only for members Third List of refined of the consortium D2.15 WP2 11 - ANR Report 31 JTC topics (including the Commission Services) First List of research D2.16 and innovation needs WP2 1 - INSERM Report Public 6 requiring medium- or Page 13 of 161 Associated with document Ref. Ares(2018)6091977 - 28/11/2018 Due Deliverable WP Dissemination Deliverable Title Lead beneficiary Type15 Date (in Number14 number9 level16 months)17 long-term approach and related Task Forces Second List of research and innovation needs D2.17 requiring medium- or WP2 1 - INSERM Report Public 18 long-term approach and related Task Forces Third List of research and innovation needs D2.18 requiring medium- or WP2 1 - INSERM Report Public 30 long-term approach and related Task Forces Fourth List of research and innovation needs D2.19 requiring medium- or WP2 1 - INSERM Report Public 42 long-term approach and related Task Forces Fifth List of research and innovation needs D2.20 requiring medium- or WP2 1 - INSERM Report Public 54 long-term approach and related Task Forces First Analysis of national state of play D2.21 WP2 26 - ISS Report Public 9 and alignment process with EJP RD Second Analysis of national state of play D2.22 WP2 26 - ISS Report Public 21 and alignment process with EJP RD Third Analysis of national state of play D2.23 WP2 26 - ISS Report Public 32 and alignment process with EJP RD Fourth Analysis of national state of play D2.24 WP2 26 - ISS Report Public 55 and alignment process with EJP RD First Report from D2.25 strategic workshop with WP2 26 - ISS Report Public 34 national policy makers Second Report from D2.26 strategic workshop with WP2 38 - MUW Report Public 58 national policy makers Dynamic catalogue of D3.1 EJP-RD sustainable WP3 1 - INSERM Report Public 36 resources including Page 14 of 161 Associated with document Ref. Ares(2018)6091977 - 28/11/2018 Due Deliverable WP Dissemination Deliverable Title Lead beneficiary Type15 Date (in Number14 number9 level16 months)17 Service Roadmap Database Confidential, Study cases only for members of innovative of the consortium D3.2 sustainability solutions WP3 1 - INSERM Report 36 (including the for specific EJP RD Commission outcomes Services) Confidential, Analysis of structures, only for members business models of the consortium D3.3 and required WP3 75 - EATRIS Report 42 (including the complementarity from Commission other relevant initiatives Services) Confidential, First Proposal of only for members structure, governance of the consortium D3.4 and financial model and WP3 44 - ISCIII Report 46 (including the global sustainability Commission roadmap Services) Confidential, Second Proposal of only for members structure, governance of the consortium D3.5 and financial model and WP3 44 - ISCIII Report 54 (including the global sustainability Commission roadmap Services) Confidential, only for members of the consortium D4.1 First AREB report WP4 24 - FGB Report 6 (including the Commission Services) Confidential, only for members First Periodic AREB of the consortium D4.2 WP4 24 - FGB Report 19 report (including the Commission Services) Confidential, only for members Second Periodic AREB of the consortium D4.3 WP4 24 - FGB Report 31 report (including the Commission Services) Confidential, only for members Third Periodic AREB of the consortium D4.4 WP4 24 - FGB Report 43 report (including the Commission Services) Page 15 of 161 Associated with document Ref. Ares(2018)6091977 - 28/11/2018 Due Deliverable WP Dissemination Deliverable Title Lead beneficiary Type15 Date (in Number14 number9 level16 months)17 Confidential, only for members Fourth Periodic AREB of the consortium D4.5 WP4 24 - FGB Report 55 report (including the Commission Services) Set of template D4.6 agreements for EJP RD WP4 25 - FTELE Report Public 6 website Confidential, only for members First Periodic IPR of the consortium D4.7 report (based on WP4 25 - FTELE Report 6 (including the ExCom inputs) Commission Services) Confidential, only for members Second Periodic of the consortium D4.8 IPR report (based on WP4 25 - FTELE Report 18 (including the ExCom inputs) Commission Services) Confidential, only for members Third Periodic IPR of the consortium D4.9 report (based on WP4 25 - FTELE Report 24 (including the ExCom inputs) Commission Services) Confidential, only for members Fourth Periodic IPR of the consortium D4.10 report (based on WP4 25 - FTELE Report 24 (including the ExCom inputs) Commission Services) Confidential, only for members Fifth Periodic IPR of the consortium D4.11 report (based on WP4 25 - FTELE Report 30 (including the ExCom inputs) Commission Services) Confidential, only for members Sixth Periodic IPR of the consortium D4.12 report (based on WP4 25 - FTELE Report 36 (including the ExCom inputs) Commission Services) Confidential, Seventh Periodic only for members D4.13 IPR report (based on WP4 25 - FTELE Report 42 of the consortium ExCom inputs) (including the Page 16 of 161 Associated with document Ref. Ares(2018)6091977 - 28/11/2018 Due Deliverable WP Dissemination Deliverable Title Lead beneficiary Type15 Date (in Number14 number9 level16 months)17 Commission Services) Confidential, only for members Eighth Periodic IPR of the consortium D4.14 report (based on WP4 25 - FTELE Report 48 (including the ExCom inputs) Commission Services) Confidential, only for members Ninth Periodic IPR of the consortium D4.15 report (based on WP4 25 - FTELE Report 54 (including the ExCom inputs) Commission Services) Confidential, only for members Tenth and final Periodic of the consortium D4.16 IPR report (based on WP4 25 - FTELE Report 60 (including the ExCom inputs) Commission Services) Confidential, only for members First IPR support of the consortium D4.17 WP4 25 - FTELE Report 6 (monitoring) report (including the Commission Services) Confidential, only for members Second IPR support of the consortium D4.18 WP4 25 - FTELE Report 12 (monitoring) report (including the Commission Services) Confidential, only for members Third IPR support of the consortium D4.19 WP4 25 - FTELE Report 18 (monitoring) report (including the Commission Services) Confidential, only for members Fourth IPR support of the consortium D4.20 WP4 25 - FTELE Report 24 (monitoring) report (including the Commission Services) Confidential, only for members Fifth IPR support of the consortium D4.21 WP4 25 - FTELE Report 30 (monitoring) report (including the Commission Services) Page 17 of 161 Associated with document Ref. Ares(2018)6091977 - 28/11/2018 Due Deliverable WP Dissemination Deliverable Title Lead beneficiary Type15 Date (in Number14 number9 level16 months)17 Confidential, only for members Sixth IPR support of the consortium D4.22 WP4 25 - FTELE Report 36 (monitoring) report (including the Commission Services) Confidential, only for members Seventh IPR support of the consortium D4.23 WP4 25 - FTELE Report 42 (monitoring) report (including the Commission Services) Confidential, only for members Eighth IPR support of the consortium D4.24 WP4 25 - FTELE Report 48 (monitoring) report (including the Commission Services) Confidential, only for members Ninth IPR support of the consortium D4.25 WP4 25 - FTELE Report 54 (monitoring) report (including the Commission Services) Confidential, only for members Tenth and final IPR of the consortium D4.26 support (monitoring) WP4 25 - FTELE Report 60 (including the report Commission Services) Websites, D5.1 EJP RD website WP5 1 - INSERM patents Public 2 filling, etc. Websites, D5.2 EJP RD Newsletter WP5 1 - INSERM patents Public 2 filling, etc. First RE(ACT) D5.3 WP5 80 - Blackswan Report Public 16 Congress report Second RE(ACT) D5.4 WP5 80 - Blackswan Report Public 30 Congress report Third RE(ACT) D5.5 WP5 80 - Blackswan Report Public 54 Congress report First Confidential Confidential, Call documents: only for members memorandum of of the consortium D6.1 WP6 15 - DLR Report 1 understanding, (including the governance Commission of the call and Services) Page 18 of 161 Associated with document Ref. Ares(2018)6091977 - 28/11/2018 Due Deliverable WP Dissemination Deliverable Title Lead beneficiary Type15 Date (in Number14 number9 level16 months)17 evaluation document JTC2019-2022 Second Confidential Call documents: Confidential, memorandum of only for members understanding, of the consortium D6.2 WP6 11 - ANR Report 11 governance (including the of the call and Commission evaluation document Services) JTC2019-2022 Third Confidential Call documents: Confidential, memorandum of only for members understanding, of the consortium D6.3 WP6 12 - FFRD Report 23 governance (including the of the call and Commission evaluation document Services) JTC2019-2022 Fourth Confidential Call documents: Confidential, memorandum of only for members understanding, of the consortium D6.4 WP6 44 - ISCIII Report 35 governance (including the of the call and Commission evaluation document Services) JTC2019-2022 First Public Call documents JTC2019-2022: call D6.5 WP6 15 - DLR Report Public 1 text, guidelines for applicants, proposal templates Second Public Call documents JTC2019-2022: call D6.6 WP6 11 - ANR Report Public 11 text, guidelines for applicants, proposal templates Third Public Call documents JTC2019-2022: call D6.7 WP6 12 - FFRD Report Public 23 text, guidelines for applicants, proposal templates Fourth Public Call documents JTC2019-2022: call D6.8 WP6 44 - ISCIII Report Public 35 text, guidelines for applicants, proposal templates Page 19 of 161 Associated with document Ref. Ares(2018)6091977 - 28/11/2018 Due Deliverable WP Dissemination Deliverable Title Lead beneficiary Type15 Date (in Number14 number9 level16 months)17 Confidential, only for members First Joint selection list of the consortium D6.9 of the projects to be WP6 15 - DLR Report 10 (including the funded JTC2019-2022 Commission Services) Confidential, only for members Second Joint selection of the consortium D6.10 list of the projects to be WP6 11 - ANR Report 22 (including the funded JTC2019-2022 Commission Services) Confidential, only for members Third Joint selection of the consortium D6.11 list of the projects to be WP6 12 - FFRD Report 24 (including the funded JTC2019-2022 Commission Services) Confidential, only for members Fourth Joint selection of the consortium D6.12 list of the projects to be WP6 44 - ISCIII Report 46 (including the funded JTC2019-2022 Commission Services) Confidential Call Confidential, document for only for members Evaluation Committee of the consortium D7.1 WP7 34 - ZonMw Report 7 for Networking scheme (including the including set of criteria Commission for evaluation Services) Public Call document D7.2 WP7 34 - ZonMw Report Public 7 for Networking scheme First List of D7.3 funded networks in WP7 34 - ZonMw Report Public 21 Networking scheme Second List of D7.4 funded networks in WP7 34 - ZonMw Report Public 54 Networking scheme Confidential, First Confidential only for members Observers’ report on of the consortium D7.5 the evaluation of sets WP7 34 - ZonMw Report 12 (including the of applications for the Commission Networking scheme Services) Second Confidential Confidential, Observers’ report on only for members D7.6 the evaluation of sets WP7 34 - ZonMw Report 30 of the consortium of applications for the (including the Networking scheme Page 20 of 161 Associated with document Ref. Ares(2018)6091977 - 28/11/2018 Due Deliverable WP Dissemination Deliverable Title Lead beneficiary Type15 Date (in Number14 number9 level16 months)17 Commission Services) Confidential, only for members Report on multi- of the consortium D8.1 WP8 77 - EURORDIS Report 8 stakeholder workshops (including the Commission Services) Call documents for D8.2 WP8 12 - FFRD Report Public 13 validation List of first phase D8.3 WP8 12 - FFRD Report Public 21 projects financed Confidential, only for members List of second phase of the consortium D8.4 WP8 12 - FFRD Report 43 projects financed (including the Commission Services) Confidential, Refined list of only for members indicators for of the consortium D9.1 WP9 78 - CSO-MOH Report 5 monitoring of JTC (including the funded project Commission Services) Confidential, First Year report on only for members progress assessment of of the consortium D9.2 WP9 78 - CSO-MOH Report 28 JTC 2019, 2020 and (including the 2021 projects Commission Services) Confidential, Second Yearly reports only for members on progress assessment of the consortium D9.3 WP9 78 - CSO-MOH Report 40 of JTC 2019, 2020 and (including the 2021 projects Commission Services) Confidential, Third Yearly reports only for members on progress assessment of the consortium D9.4 WP9 78 - CSO-MOH Report 52 of JTC 2019, 2020 and (including the 2021 projects Commission Services) First Final assessment Confidential, report of E-Rare-3 only for members JTC 2016, JTC 2017, of the consortium D9.5 WP9 78 - CSO-MOH Report 35 JTC 2018 projects and (including the the EJP RD JTC 2019 Commission projects Services) Page 21 of 161 Associated with document Ref. Ares(2018)6091977 - 28/11/2018 Due Deliverable WP Dissemination Deliverable Title Lead beneficiary Type15 Date (in Number14 number9 level16 months)17 Second Final Confidential, assessment report of only for members E-Rare-3 JTC 2016, of the consortium D9.6 WP9 78 - CSO-MOH Report 47 JTC 2017, JTC 2018 (including the projects and the EJP Commission RD JTC 2019 projects Services) Third Final assessment Confidential, report of E-Rare-3 only for members JTC 2016, JTC 2017, of the consortium D9.7 WP9 78 - CSO-MOH Report 59 JTC 2018 projects and (including the the EJP RD JTC 2019 Commission projects Services) Confidential, only for members List of indicators of the consortium D9.8 for monitoring of WP9 78 - CSO-MOH Report 7 (including the Networking grants Commission Services) First Report on the assessment of results of Confidential, a 1st, 2nd and 3rd set only for members of funded Networking of the consortium D9.9 WP9 78 - CSO-MOH Report 24 events and a final (including the general report on all Commission funded Networking Services) events Second Report on the assessment of results of Confidential, a 1st, 2nd and 3rd set only for members of funded Networking of the consortium D9.10 WP9 78 - CSO-MOH Report 39 events and a final (including the general report on all Commission funded Networking Services) events Third Report on the assessment of results of Confidential, a 1st, 2nd and 3rd set only for members of funded Networking of the consortium D9.11 WP9 78 - CSO-MOH Report 59 events and a final (including the general report on all Commission funded Networking Services) events Confidential, only for members List of indicators for of the consortium D9.12 WP9 78 - CSO-MOH Report 21 RD funded challenges (including the Commission Services) Page 22 of 161 Associated with document Ref. Ares(2018)6091977 - 28/11/2018 Due Deliverable WP Dissemination Deliverable Title Lead beneficiary Type15 Date (in Number14 number9 level16 months)17 Confidential, only for members Report on the of the consortium D9.13 assessment of 1st phase WP9 78 - CSO-MOH Report 39 (including the results of the challenges Commission Services) Confidential, Report on the only for members assessment of 2nd of the consortium D9.14 WP9 78 - CSO-MOH Report 54 phase results of the (including the challenges Commission Services) First Annual strategic report and Action plan for Pillar 2, including: Systematic surveys D10.1 reports, QMS of Pillar WP10 1 - INSERM Report Public 9 2 description, GDPR compliance report and sustainability planning reporting Second Annual strategic report and Action plan for Pillar 2, including: Systematic D10.2 surveys reports, QMS WP10 1 - INSERM Report Public 21 of Pillar 2 description, GDPR compliance report and sustainability planning reporting Third Annual strategic report and Action plan for Pillar 2, including: Systematic surveys D10.3 reports, QMS of Pillar WP10 1 - INSERM Report Public 33 2 description, GDPR compliance report and sustainability planning reporting Fourth Annual strategic report and Action plan for Pillar 2, including: Systematic surveys D10.4 reports, QMS of Pillar WP10 1 - INSERM Report Public 45 2 description, GDPR compliance report and sustainability planning reporting Page 23 of 161 Associated with document Ref. Ares(2018)6091977 - 28/11/2018 Due Deliverable WP Dissemination Deliverable Title Lead beneficiary Type15 Date (in Number14 number9 level16 months)17 Report on the State D10.5 of the Art of existing WP10 1 - INSERM Report Public 9 resources First Ontological model D11.1 WP11 76 - EMBL Other Public 12 of resources metadata Second Ontological D11.2 model of resources WP11 76 - EMBL Other Public 24 metadata Third Ontological D11.3 model of resources WP11 76 - EMBL Other Public 36 metadata Fourth Ontological D11.4 model of resources WP11 76 - EMBL Other Public 48 metadata Fifth Ontological model D11.5 WP11 76 - EMBL Other Public 60 of resources metadata Virtual platform of RD Websites, resources annotated D11.6 WP11 1 - INSERM patents Public 12 with EJP ontological filling, etc. model First update Virtual platform of RD Websites, D11.7 resources annotated WP11 1 - INSERM patents Public 24 with EJP ontological filling, etc. model Second update Virtual platform of RD Websites, D11.8 resources annotated WP11 1 - INSERM patents Public 36 with EJP ontological filling, etc. model Third update Virtual platform of RD Websites, D11.9 resources annotated WP11 1 - INSERM patents Public 48 with EJP ontological filling, etc. model Fourth update Virtual platform of RD Websites, D11.10 resources annotated WP11 1 - INSERM patents Public 60 with EJP ontological filling, etc. model First version of Additional facilities integrated to resources regarding data D11.11 WP11 76 - EMBL Other Public 12 deposition and access, including user guidelines and documentation Page 24 of 161 Associated with document Ref. Ares(2018)6091977 - 28/11/2018 Due Deliverable WP Dissemination Deliverable Title Lead beneficiary Type15 Date (in Number14 number9 level16 months)17 Second version Additional facilities integrated to resources regarding data D11.12 WP11 76 - EMBL Other Public 24 deposition and access, including user guidelines and documentation Third version Additional facilities integrated to resources regarding data D11.13 WP11 76 - EMBL Other Public 36 deposition and access, including user guidelines and documentation Fourth version Additional facilities integrated to resources regarding data D11.14 WP11 76 - EMBL Other Public 48 deposition and access, including user guidelines and documentation Fifth version Additional facilities integrated to resources regarding D11.15 data deposition and WP11 76 - EMBL Other Public 60 access, including user guidelines and documentation First Report on processed genome- phenome datasets and multi-omics use cases D11.16 analysed, including WP11 45 - CNAG-CRG Report Public 12 description of new cloud and online analysis functionalities and tools Second Report on processed genome- phenome datasets and multi-omics use cases D11.17 analysed, including WP11 45 - CNAG-CRG Report Public 24 description of new cloud and online analysis functionalities and tools Third Report on D11.18 WP11 45 - CNAG-CRG Report Public 36 processed genome- Page 25 of 161 Associated with document Ref. Ares(2018)6091977 - 28/11/2018 Due Deliverable WP Dissemination Deliverable Title Lead beneficiary Type15 Date (in Number14 number9 level16 months)17 phenome datasets and multi-omics use cases analysed, including description of new cloud and online analysis functionalities and tools Fourth Report on processed genome- phenome datasets and multi-omics use cases D11.19 analysed, including WP11 45 - CNAG-CRG Report Public 48 description of new cloud and online analysis functionalities and tools Fifth Report on processed genome- phenome datasets and multi-omics use cases D11.20 analysed, including WP11 45 - CNAG-CRG Report Public 60 description of new cloud and online analysis functionalities and tools Report on core set D12.1 of unified FAIR data WP12 50 - ULEIC Report Public 18 standards First Report on core set of FAIR software tools and on extended D12.2 WP12 3 - AIT Report Public 30 set of unified FAIR data standards, applied in EJP RD Second Report on core set of FAIR software tools and on extended D12.3 WP12 3 - AIT Report Public 48 set of unified FAIR data standards, applied in EJP RD Report on extended set of FAIR software tools, applied in D12.4 EJP,including overview WP12 64 - LUMC Report Public 60 of FAIRification guidelines for RD data managers Collection of 20 D13.1 curated (sub)Portal on WP13 36 - UM Report Public 36 WikiPathways Page 26 of 161 Associated with document Ref. Ares(2018)6091977 - 28/11/2018 Due Deliverable WP Dissemination Deliverable Title Lead beneficiary Type15 Date (in Number14 number9 level16 months)17 Completed pathway analysis workflow (data analysis including both D13.2 WP13 36 - UM Report Public 48 types of genetic variant linking and network creation) Completed network analysis workflow (active node detection, lifestyle factor network D13.3 WP13 36 - UM Report Public 54 evaluation and extended network analysis for drugs and toxic compounds) First Report of Orphanet nomenclature D14.1 WP14 1 - INSERM Report Public 14 training for trainers and national trainings Second Report of Orphanet nomenclature D14.2 WP14 1 - INSERM Report Public 60 training for trainers and national trainings First Report on course on interpretation of D14.3 WP14 7 - KU Leuven Report Public 12 genetic variants and quality standards Second Report on course on interpretation D14.4 WP14 7 - KU Leuven Report Public 60 of genetic variants and quality standards First Report on D14.5 International course on WP14 26 - ISS Report Public 24 undiagnosed diseases Second Report on D14.6 International course on WP14 26 - ISS Report Public 60 undiagnosed diseases First Report on sample D14.7 data management WP14 25 - FTELE Report Public 12 training workshops Second Report on sample data D14.8 WP14 25 - FTELE Report Public 60 management training workshops First Report on International course on D14.9 Rare Disease Registries WP14 26 - ISS Report Public 12 and FAIRification of data at source Page 27 of 161 Associated with document Ref. Ares(2018)6091977 - 28/11/2018 Due Deliverable WP Dissemination Deliverable Title Lead beneficiary Type15 Date (in Number14 number9 level16 months)17 Second Report on International course on D14.10 Rare Disease Registries WP14 26 - ISS Report Public 60 and FAIRification of data at source First Report on D15.1 WP15 77 - EURORDIS Report Public 12 ExPRESS Second Report on D15.2 WP15 77 - EURORDIS Report Public 60 ExPRESS First Report on training of patient representatives on D15.3 WP15 77 - EURORDIS Report Public 24 scientific innovation and translational research in RD Second Report on training of patient representatives on D15.4 WP15 77 - EURORDIS Report Public 60 scientific innovation and translational research in RD First Report on D15.5 EURORDIS’ WP15 77 - EURORDIS Report Public 12 Leadership Programme Second Report D15.6 on EURORDIS’ WP15 77 - EURORDIS Report Public 48 Leadership Programme Training plan for D15.7 paediatric patients’ in WP15 28 - TEDDY Report Public 30 the EJP Report on paediatric D15.8 patients’ experts WP15 28 - TEDDY Report Public 60 training courses Draft content of the D16.1 WP16 12 - FFRD Report Public 9 online academic course Content of the first 5 D16.2 WP16 12 - FFRD Other Public 24 online modules Content of the full D16.3 WP16 12 - FFRD Other Public 48 online course Confidential, only for members First Impact assessment of the consortium D16.4 of the online academic WP16 76 - EMBL Report 36 (including the course Commission Services) Page 28 of 161 Associated with document Ref. Ares(2018)6091977 - 28/11/2018 Due Deliverable WP Dissemination Deliverable Title Lead beneficiary Type15 Date (in Number14 number9 level16 months)17 Confidential, only for members Second Impact of the consortium D16.5 assessment of the WP16 76 - EMBL Report 60 (including the online academic course Commission Services) Results of survey on preferences, needs and D17.1 WP17 64 - LUMC Report Public 4 resources from the ERNs ecosystem EJP RD ERN training D17.2 WP17 57 - UKL-HD Report Public 7 programmes First Annual report D17.3 on implementation of WP17 58 - EKUT Report Public 13 training programs Second Annual reports D17.4 on implementation of WP17 58 - EKUT Report Public 60 training programs Final report on evaluation and adaptation of training programmes according D18.1 WP18 32 - VUHSK Report Public 60 to EJP RD progress of work, specific needs of EU13 countries and ERN developing needs Confidential, First Periodic report on only for members mentoring and technical of the consortium D19.1 WP19 75 - EATRIS Report 24 support for translational (including the research projects Commission Services) Confidential, Second Periodic report only for members on mentoring and of the consortium D19.2 technical support for WP19 75 - EATRIS Report 42 (including the translational research Commission projects Services) Confidential, Third Periodic report on only for members mentoring and technical of the consortium D19.3 WP19 75 - EATRIS Report 60 support for translational (including the research projects Commission Services) Confidential, Final report on follow- only for members D19.4 on funding and WP19 25 - FTELE Report 60 of the consortium exploitation (including the Page 29 of 161 Associated with document Ref. Ares(2018)6091977 - 28/11/2018 Due Deliverable WP Dissemination Deliverable Title Lead beneficiary Type15 Date (in Number14 number9 level16 months)17 Commission Services) User satisfaction and Confidential, feasibility report on only for members Facilitating partnerships of the consortium D19.5 WP19 59 - GUF Report 48 and accelerating (including the translation for higher Commission patient impact Services) Confidential, only for members Roadmap for EU of the consortium D19.6 investment platform for WP19 25 - FTELE Report 36 (including the RDs Commission Services) Confidential, only for members Terms of Reference of of the consortium D20.1 clinical studies support WP20 74 - ECRIN Report 6 (including the office Commission Services) Confidential, only for members First Report on the of the consortium D20.2 assessment of the WP20 74 - ECRIN Report 36 (including the support office activity Commission Services) Confidential, only for members Second Report on of the consortium D20.3 the assessment of the WP20 74 - ECRIN Report 48 (including the support office activity Commission Services) Confidential, only for members Third Report on the of the consortium D20.4 assessment of the WP20 74 - ECRIN Report 60 (including the support office activity Commission Services) Confidential, First Report on only for members options for long-term of the consortium D20.5 WP20 74 - ECRIN Report 48 sustainability of the (including the support office Commission Services) Confidential, Second Report on only for members options for long-term of the consortium D20.6 WP20 74 - ECRIN Report 60 sustainability of the (including the support office Commission Services) Page 30 of 161 Associated with document Ref. Ares(2018)6091977 - 28/11/2018 Due Deliverable WP Dissemination Deliverable Title Lead beneficiary Type15 Date (in Number14 number9 level16 months)17 Confidential, only for members List of topics for of the consortium D20.7 demonstration projects WP20 61 - IOR Report 6 (including the call Commission Services) Final Report of funded D20.8 WP20 16 - UKA Report Public 50 demonstration projects Final Report of funded D20.9 new methodology WP20 16 - UKA Report Public 58 projects Summary Report of D20.10 WP20 54 - AP-HP Report Public 60 Task Force Group Confidential, only for members of the consortium D21.1 A - Requirement No. 1 WP21 1 - INSERM Ethics 12 (including the Commission Services) Confidential, only for members NEC - Requirement No. of the consortium D21.2 WP21 1 - INSERM Ethics 12 2 (including the Commission Services) Confidential, only for members GEN - Requirement of the consortium D21.3 WP21 1 - INSERM Ethics 12 No. 3 (including the Commission Services) Confidential, only for members of the consortium D21.4 H - Requirement No. 4 WP21 1 - INSERM Ethics 12 (including the Commission Services) Confidential, only for members of the consortium D21.5 H - Requirement No. 5 WP21 1 - INSERM Ethics 12 (including the Commission Services) Confidential, only for members of the consortium D21.6 H - Requirement No. 6 WP21 1 - INSERM Ethics 12 (including the Commission Services) Page 31 of 161 Associated with document Ref. Ares(2018)6091977 - 28/11/2018 Due Deliverable WP Dissemination Deliverable Title Lead beneficiary Type15 Date (in Number14 number9 level16 months)17 Confidential, only for members of the consortium D21.7 H - Requirement No. 7 WP21 1 - INSERM Ethics 12 (including the Commission Services) Confidential, only for members of the consortium D21.8 H - Requirement No. 8 WP21 1 - INSERM Ethics 12 (including the Commission Services) Confidential, only for members of the consortium D21.9 H - Requirement No. 9 WP21 1 - INSERM Ethics 12 (including the Commission Services) Confidential, only for members POPD - Requirement of the consortium D21.10 WP21 1 - INSERM Ethics 12 No. 10 (including the Commission Services) Confidential, only for members POPD - Requirement of the consortium D21.11 WP21 1 - INSERM Ethics 12 No. 11 (including the Commission Services) Confidential, only for members POPD - Requirement of the consortium D21.12 WP21 1 - INSERM Ethics 12 No. 12 (including the Commission Services) Confidential, only for members POPD - Requirement of the consortium D21.13 WP21 1 - INSERM Ethics 12 No. 13 (including the Commission Services) Confidential, only for members GEN - Requirement of the consortium D21.14 WP21 1 - INSERM Ethics 12 No. 14 (including the Commission Services) GEN - Requirement Confidential, D21.15 WP21 1 - INSERM Ethics 12 No. 15 only for members Page 32 of 161 Associated with document Ref. Ares(2018)6091977 - 28/11/2018 Due Deliverable WP Dissemination Deliverable Title Lead beneficiary Type15 Date (in Number14 number9 level16 months)17 of the consortium (including the Commission Services) Page 33 of 161 Associated with document Ref. Ares(2018)6091977 - 28/11/2018 1.3.3. WT3 Work package descriptions Work package number 9 WP1 Lead beneficiary 10 1 - INSERM Work package title Coordination and management Start month 1 End month 60 Objectives ● Carry out the overall management of the initiative (capture, guide and lead all work related to the 5-year programme and the annual work plans); ● Oversee and organize project-related meetings, including meetings of the General Assembly, Executive Committee, Policy Board, ad hoc Scientific Board(s) and IRDiRC; ● Execute Scientific Secretariat of IRDiRC; ● Ensure appropriate financial administration (budgeting, planning, accounting); ● Report to the European Commission (including annual reports, annual summary progress reports, annual work plans and deliverables); ● Ensure efficient internal communication (with help of dedicated tools); ● Ensure effective dialogue and coordination with project partners to assess progress and challenges in implementing the annual work plans; ● Develop and implement the EJP RD Helpdesk; ● Ensure efficient decision making and manage conflicts in accordance with the rules set-out in the consortium agreement; ● Implement the risk management strategy; ● Develop and implement the monitoring of the EJP RD activities ● Carry efforts to expand EJP RD consortium to new countries Description of work and role of partners WP1 - Coordination and management [Months: 1-60] INSERM, DLR, CVBF, VUHSK, ZonMw, ULIV, AP-HP, UKL-HD, EATRIS, EMBL, EURORDIS Task 1.1: Implementation and responsibilities of the coordination office (M1-M60) TL: INSERM (Coo) The Coordination Office based at INSERM will consist of the coordinator, two senior and two junior project managers, communication officer, financial officer and assistant. The CO will be central point and carry out the day-to-day operational management by supporting EJP RD partners. It will be the primary contact for the EJP RD partners, Policy Board, IRDiRC, European Commission, and other interested parties. The CO will be responsible for an efficient management of overall contractual obligations. It will ensure compliance by Beneficiaries with their obligations under the Grant Agreement and Consortium Agreement in terms of administrative, legal and financial management. It will monitor timely preparation and submission of the Deliverables to the European Commission, and coordinate preparation and submission to the EC of the periodic Annual Progress Reports, Annual Work Plans, technical and financial reports and Final Report. It will manage and coordinate any legal obligation such as Amendments to the Grant Agreement when required. SubTask 1.1.1: Scientific Secretariat of IRDiRC (M1-M60) STL: INSERM (Coo) The Scientific Secretariat (SciSec) of IRDiRC will be secured by EJP RD Project Managers seconded by the Communication and Financial Officers. The integration of the SciSec in the EJP RD coordination is crucial as it guarantees tight connection between EJP RD and IRDiRC necessary for common strategy, harmonized efforts and critical position of Europe within IRDiRC Consortium. SciSec acts in service of and in response to the needs/requests of the IRDiRC. The SciSec will provide support to the IRDiRC bodies (Consortium Assembly, Constituent Committees, Scientific Committees, Operating Committee), manage the logistics of the meetings and reporting. It will ensure a liaison between the EJP RD and IRDiRC members and Task Forces and other IRDiRC-specific Activities (see also WP2) to optimize the complementarity and the coherence of their specific activities contributing to the common goals. SubTask 1.1.2: Central Helpdesk (M1-M60) STL: INSERM (Coo), Participants: Operating Group (INSERM (Orpha), DLR, UKL-HD, APHP, VUHSK, ZonMw, EURORDIS, EATRIS); ULiv Page 34 of 161 Associated with document Ref. Ares(2018)6091977 - 28/11/2018 The proposed central Helpdesk will be the single-entry point for any inquiry related to the actions and services proposed within the EJP RD. From the start, it will be managed by one of the EJP RD project managers that will be responsible for providing of rapid response or re-directing the demand to the expert groups of a specific Pillar or connected projects (in order to avoid duplication of efforts). It will function through the EJP RD website where contact information will be provided. The project managers will be responsible for the registration and analysis of all incoming queries that will be classified based on the “key” agreed with Helpdesk support groups formed by dedicated pillars’ members. The goal is to monitor the incoming demands and adapt the service according to the needs. An analysis of incoming requests will be performed every 3 months in connection to Task 1.3. A directory of people and services available within and outside the EJP RD (via connected partners) will be created for the need of efficient management of demands and in support for the Helpdesk. The Helpdesk will have close working relationships with similar elements of other initiatives like C4C project or involved infrastructures in order to manage cross-referrals between initiatives. Task 1.2: Coordination & support within and across pillars (M1-M60) TL: INSERM (Coo), Participants: Operating Group (INSERM (Orpha), DLR, UKL-HD, APHP, VUHSK, ZonMw, EURORDIS, EATRIS) In order to coordinate the support and swift communication within and across pillars, the pillar leaders together with coordinator and project managers will form the Operating Group (OG). The OG is already a functioning body that has gained experience, cohesion and efficacy during the preparation phase. Regular (twice a month) conference calls will ensure close follow up of activities, continuous alignment and adequate reactivity in case of urgent situations and risk management. The OG will participate in the preparation of the Executive Committee meetings and will be the driving force for the elaboration of the Annual Work Plans (see also 1.2.1). The Pillar leaders will coordinate the activities of WPs within their Pillars, will reflect on progress and engage in a collective brainstorming on future directions and visions for the EJP RD. They will identify possible bottlenecks and report them to the CO. While the OG will be the operative body, the Executive Committee (ExCom composed of the Coordinator, project officer, Pillar leaders, patients and ERN representatives and all WP leaders) will be the forum to discuss details of the EJP RD progress, annual work plans and related resource utilization. The ExCom will meet by conference call every month in the first year and every two months in the following years of the project. It will also hold one face-to-face meeting per year: at M6, jointly with the Policy Board (see 3.2) in order to discuss the priorities and work on the development of the Annual Work Plan to be presented at the start of M9 at the Governance Board meeting. SubTask 1.2.1: Development of Annual Progress Report and Annual Work Plans (M1-M60) STL: INSERM (Coo), Participants: Operating Group (INSERM (Orpha), DLR, UK- HD, APHP, VUHSK, ZonMw, EURORDIS, EATRIS); ALL WP leaders The development of the Annual Progress Report and Annual Work Plan will follow a structured process managed by the Executive Committee: ● Each pillar will be responsible to capture outcomes and reflect them in the summary progress reports documenting proposals and ideas, including input to the monitoring of EJP RD activities. These annual progress reports will be drafted by each WP leader and compiled by the respective Pillar leaders. The CO jointly with relevant leaders of transversal WPs will follow the same procedure; ● The CO will be responsible for the collation of the single summary progress reports to be complemented by the outcomes of the monitoring and progress against established Key Performance Indicators captured within Task 1.3. The final draft of the full Annual Progress Report will be presented to the Governing Board for validation before sending to the Commission; ● At the same time the ExCom will be asked to propose tasks and deliverables based on the internal consultation of WPs and in line with their implementation status. This will include update of the budgetary plan and proposition of the redistribution of funds and new responsibilities. The collated draft will be discussed at the ExCom face-to-face meeting (M6) and updated based on the inputs from the Policy Board and prioritization procedure. As for the Annual Progress Report, the finalized version of Annual Plan will be presented for validation to the Governing Board (M9) before sending to the Commission; ● The Annual Work Plan and Annual Progress Report will be complementary: the report will show how the activities proposed in the annual work plan for the next year provide continuity with completed and ongoing work. The Commission will thus be informed regarding project progress and compliance with commitments. SubTask 1.2.2: Organization of EJP RD governance meetings (M1-M60) STL: INSERM (Coo) The CO will prepare and organize meetings of the Governing Board (once a year, M9/M21/M33/M45/M57), the highest- decision making body (see also section 3.2), to approve the organization, work programme, the Annual Work Plan of the following year, the structure and information flow and the political outcome of the EJP RD. The Governing Board shall consist of one representative per participating country, one representative of ERNs, one representative of participating EU infrastructures, 1 patient organization representative (EURORDIS), one representative of Orphanet and one representative of other non-profit organizations. It will be up to each participating country/type of beneficiary Page 35 of 161 Associated with document Ref. Ares(2018)6091977 - 28/11/2018 to decide on the nomination procedure for their representative. Back-to-back to GB meeting, the CO will organize meetings of the whole EJP RD Consortium (M9/M21/M33/M45/M57), to present yearly progress, oversee the needs within the pillars (and respective work packages) and to ensure the efficient implementation of recommendations and/ or decisions taken by the Governing Board, the Executive Committee and the Policy Board. Finally, INSERM will support WP2 leaders in organization of the Policy Board meetings (once a year, M6/M18/M30/M42/M54). All meetings planned during the project will be held in different countries to raise visibility and encourage commitment. Joint or back-to-back organization of these events with workshops or Task Forces planned in different WP will be privileged in order to reduce the costs. SubTask 1.2.3: EJP RD internal communication (M1-M60) STL: INSERM (Coo) Beside regular conference calls and meetings of the OG and ExCom, the whole EJP RD Consortium will meet at least once a year, while each of the Pillars will follow its specific agenda according to planned activities. Due to the size of the Consortium, direct communication (on regular basis) will be ensured through a dedicated internal monthly newsletter including “EJP RD Actions Updates”. The internal Newsletter will summarize important timelines (conference calls, activity reports, deliverables etc.) as well as specific events outside the consortium of high importance for partners. An Intranet secured platform will be established for the exchange and deposit of project related documents accessible to all partners. SubTask 1.2.4: Initiating new partnerships (M1-M60) STL : INSERM (Coo) The EJP RD consortium includes 85 partners (and their linked third parties) from 33 countries. However, not all EU countries or several members of IRDiRC are involved in the project. To maximize the impact of the programme, the EJP RD coordination and partners will continue efforts to initiate new, long-term partnerships. This will be achieved through the promotion of the EJP RD at different occasions (dedicated communication support will be deployed) and the support of Pillar leaders as ambassadors of the programme will be key. IRDiRC members will be encouraged to get involved and different modes of implication will be proposed: from “soft” collaboration to full engagement. Finally, the official meetings of Policy Board, Programme Commitee meetings of the European Commission or events initiated by the rotating presidency of the Council of the EU will be explored and used to speak for EJP RD and initiate new collaborations. Task 1.3: Monitoring of the EJP RD activities and achievements (M1-M60) TL: CVBF, Participants: ELIXIR, ULiv The aim of this task is to evaluate the quality of the EJP RD activities and the achievement of the expected project goals. The identification of KPIs and suitable metrics to monitor the impact of EJP RD activities not otherwise monitored within specific Pillars represents the first step of this task. The monitoring activities will include collecting and analyzing relevant documents (reports from Helpdesk and Pillars) to measure the performance and evaluate if the expected targets are reached. The results of the monitoring activities highlighting strengths and weaknesses of the EJP will be delivered to the coordination bodies for the adaptation of the strategy, integration in the annual reports and work plans, and to support risk management. SubTask 1.2.4: Initiating new partnerships (M1-M60) STL : INSERM (Coo) The EJP RD consortium includes 85 partners (and their linked third parties) from 33 countries. However, not all EU countries or several members of IRDiRC are involved in the project. To maximize the impact of the programme, the EJP RD coordination and partners will continue efforts to initiate new, long-term partnerships. This will be achieved through the promotion of the EJP RD at different occasions (dedicated communication support will be deployed) and the support of Pillar leaders as ambassadors of the programme will be key. IRDiRC members will be encouraged to get involved and different modes of implication will be proposed: from “soft” collaboration to full engagement. Finally, the official meetings of Policy Board, Programme Commitee meetings of the European Commission or events initiated by the rotating presidency of the Council of the EU will be explored and used to speak for EJP RD and initiate new collaborations. SubTask 1.3.1: Identification of key performance indicators (M1-M60) STL: ULiv; Participants: Operating Group (INSERM [Coo & Orpha], DLR, UKL-HD, APHP, VUHSK, ZonMw, EURORDIS, EATRIS); CVBF, ELIXIR Upon definition of the key processes to be monitored the related KPIs, the metrics and the methodology for the monitoring of the project activities will be defined. The OG will participate to this subtask. To ensure an adequate quality standard, the EJP RD activities will be monitored and evaluated considering three perspectives: (i) internal to the EJP; (ii) the RD community; (iii) interfaces between the EJP and the broader health research community. The KPIs and metrics will be defined (and adapted) on the basis of: (i) overall and yearly objectives of the EJP RD; (ii) timeline of the milestones and deliverables; (iii) list of monitored procedures. Page 36 of 161 Associated with document Ref. Ares(2018)6091977 - 28/11/2018 Criteria which will be considered for the KPIs definition are: 1) all activities will be directed towards sustainability and 5 years strategy; 2) all performance indicators will be SMART and context specific; 3) limited in number and scope. The deliverable 1.7 “Monitoring activities Handbook” will contain: (i) the list of KPIs used for the monitoring of the EJP RD as a whole; (ii) the list of other performance indicators used within specific Pillars/WPs; (iii) the process to alert EJP to risks and issues (including mechanisms and timelines for escalation from Task to WP to Pillar to Coordination). EJP RD performance will be evaluated in term of compliance with: (i) standards for all monitored activities; (ii) user experience and assessment; (iii) review of “exceptions” when services do not meet standards. A workshop will be organized at month 2 with the ExCom, in order to approve the final list of proposed KPIs and related metrics, handbook of monitored procedures and methodology for the monitoring. The Monitoring Activities Handbook will be available by the end of Month 3. Since it may be necessary to revise and adapt KPIs and metrics during the project, in this workshop the responsible(s) for KPIs and metrics revision will be designated. KPIs and metrics revision and approval will be performed yearly at months 14, 26, 38 and 50 during the annual meeting or the coordinating board ExecCom meeting. A detailed description of the monitoring methods and procedures, together with the specific roles and competencies, i.e., who does what and how, will be included in the Handbook. SubTask 1.3.2: Implementation of the monitoring process (M1-M60) STL: CVBF, Participant: ULiv The monitoring will be performed continuously and reported every 12 months (12-24-36-48-60) in period deliverables called Monitoring Reports. The monitoring reports will serve to: (i) assess the quality and specificity of performed activities; (ii) adjust the quality and specificity of planned activities; (iii) integrate the results of the monitoring in the up scaling model and sustainability beyond the EJP RD; (iv) disseminate the EJP RD results. The first Monitoring Report will be produced in the 1st AWP at Month 12 and will be used to monitor and assess the project progresses and to promptly identify issues which need corrective actions. Also, interim internal reports at month will be provided at month 6, 18, 30, 42, and 54 and will be used for drafting the Annual Work Plans at months 9, 21, 33, 45 and 57, respectively. Task 1.4: Data management plan (M1-M60) TL: INSERM, Participants: Operating Group (INSERM [Coo & Orpha], DLR, UKL-HD, APHP, VUHSK, ZonMw, EURORDIS, EATRIS); (Pillar 2 WPLs) As stated in the section 2.2.4 data management is one of the major activities of the EJP RD Pillar 2 and thus Pillar 2 can be assimilated as DMP itself. All data activities will follow Open Research Data principles (which conform to FAIR data principles), and comply with the GDPR and existing ethical and legal expectations for healthcare, research and patient data. Nevertheless, it will be important to describe how data management will be extended and tackled under other Pillars. That is why, EJP RD decided to deliver concise DMP at M6 taking the advantage of top-level experts of Pillar 2. This initial DMP will be updated in line with Pillar 2 developments and its revised version will be delivered at M42. Special attention will be given to the compliance with all regulatory and ethical aspects. Thus, the DMP will be developed under the supervision of the Ethics Advisor and in collaboration AREB. Participation per Partner Partner number and short name WP1 effort 1 - INSERM 403.00 15 - DLR 6.00 27 - CVBF 16.00 32 - VUHSK 6.00 34 - ZonMw 6.00 51 - ULIV 8.00 54 - AP-HP 6.00 57 - UKL-HD 6.00 75 - EATRIS 6.00 76 - EMBL 0.00 Page 37 of 161 Associated with document Ref. Ares(2018)6091977 - 28/11/2018 Partner number and short name WP1 effort DTL-Projects 1.00 77 - EURORDIS 6.00 Total 470.00 List of deliverables Due Deliverable Deliverable Title Lead beneficiary Type15 Dissemination level16 Date (in Number14 months)17 Report from the Kick-off D1.1 1 - INSERM Report Public 2 meeting Confidential, only for members of the Helpdesk directory of D1.2 1 - INSERM Report consortium (including 3 people and services the Commission Services) First report from the D1.3 face-to-face ExCom and 1 - INSERM Report Public 7 Policy Board meeting Second report from the D1.4 face-to-face ExCom and 1 - INSERM Report Public 19 Policy Board meeting Third report from the D1.5 face-to-face ExCom and 1 - INSERM Report Public 31 Policy Board meeting Fourth report from the D1.6 face-to-face ExCom and 1 - INSERM Report Public 43 Policy Board meeting Fifth report from the D1.7 face-to-face ExCom and 1 - INSERM Report Public 55 Policy Board meeting Confidential, only First Summary Progress for members of the D1.8 Report and Annual Work 1 - INSERM Report consortium (including 9 Plan the Commission Services) Confidential, only Second Summary for members of the D1.9 Progress Report and 1 - INSERM Report consortium (including 21 Annual Work Plan the Commission Services) Confidential, only Third Summary Progress for members of the D1.10 Report and Annual Work 1 - INSERM Report consortium (including 33 Plan the Commission Services) Page 38 of 161 Associated with document Ref. Ares(2018)6091977 - 28/11/2018 List of deliverables Due Deliverable Deliverable Title Lead beneficiary Type 15 Dissemination level 16 Date (in Number14 months)17 Confidential, only Fourth Summary for members of the D1.11 Progress Report and 1 - INSERM Report consortium (including 45 Annual Work Plan the Commission Services) Confidential, only Fifth Summary Progress for members of the D1.12 Report and Annual Work 1 - INSERM Report consortium (including 57 Plan the Commission Services) Confidential, only for members of the First Technical and D1.13 1 - INSERM Report consortium (including 15 Financial Report the Commission Services) Confidential, only for members of the Second Technical and D1.14 1 - INSERM Report consortium (including 27 Financial Report the Commission Services) Confidential, only for members of the Third Technical and D1.15 1 - INSERM Report consortium (including 39 Financial Report the Commission Services) Confidential, only for members of the Fourth Technical and D1.16 1 - INSERM Report consortium (including 51 Financial Report the Commission Services) Confidential, only for members of the Fifth Technical and D1.17 1 - INSERM Report consortium (including 60 Financial Report the Commission Services) Confidential, only for members of the Monitoring activities D1.18 51 - ULIV Report consortium (including 2 handbook the Commission Services) Confidential, only for members of the First EJP RD Monitoring D1.19 27 - CVBF Report consortium (including 12 Report the Commission Services) Second EJP RD Confidential, only D1.20 27 - CVBF Report 24 Monitoring Report for members of the Page 39 of 161 Associated with document Ref. Ares(2018)6091977 - 28/11/2018 List of deliverables Due Deliverable Deliverable Title Lead beneficiary Type 15 Dissemination level 16 Date (in Number14 months)17 consortium (including the Commission Services) Confidential, only for members of the Third EJP RD D1.21 27 - CVBF Report consortium (including 36 Monitoring Report the Commission Services) Confidential, only for members of the Fourth EJP RD D1.22 27 - CVBF Report consortium (including 48 Monitoring Report the Commission Services) Confidential, only for members of the Fifth EJP RD Monitoring D1.23 27 - CVBF Report consortium (including 60 Report the Commission Services) Initial Data Management D1.24 1 - INSERM Report Public 6 Plan ORDP: Open Updated Data D1.25 1 - INSERM Research Public 6 Management Plan Data Pilot Description of deliverables D1.1: Report from the Kick-off meeting (M2) D1.2: Helpdesk directory of people and services (M3) D1.3, D1.4, D1.5, D1.6 and D1.7: Report from the face-to-face ExCom and Policy Board meeting (M7, M19, M31, M43, M55) D1.8, D1.9, D1.10, D1.11 and D1.12: Summary Progress Report and Annual Work Plan (M9, 21, 33, 45, 57) D1.13, D1.14, D1.15, D1.16 and D1.17: Technical and Financial Report (M15, 27, 39, 51, 63) D1.18: Monitoring activities handbook (M3) D1.19, D1.20, D1.21, D1.22 and D1.23: EJP RD Monitoring Report (M12, 24, 36, 48, 60) D1.24: Initial Data Management Plan (M6) D1.25: Updated DMP (M42) D1.1 : Report from the Kick-off meeting [2] Report from the Kick-off meeting D1.2 : Helpdesk directory of people and services [3] Helpdesk directory of people and services D1.3 : First report from the face-to-face ExCom and Policy Board meeting [7] Report from the face-to-face ExCom and Policy Board meeting due at M7 D1.4 : Second report from the face-to-face ExCom and Policy Board meeting [19] Report from the face-to-face ExCom and Policy Board meeting due at M19 D1.5 : Third report from the face-to-face ExCom and Policy Board meeting [31] Report from the face-to-face ExCom and Policy Board meeting due at Month 31 Page 40 of 161 Associated with document Ref. Ares(2018)6091977 - 28/11/2018 D1.6 : Fourth report from the face-to-face ExCom and Policy Board meeting [43] Report from the face-to-face ExCom and Policy Board meeting due at Month 43 D1.7 : Fifth report from the face-to-face ExCom and Policy Board meeting [55] Report from the face-to-face ExCom and Policy Board meeting due at month 55 D1.8 : First Summary Progress Report and Annual Work Plan [9] Summary Progress Report and Annual Work Plan due at Month 9 D1.9 : Second Summary Progress Report and Annual Work Plan [21] Summary Progress Report and Annual Work Plan due at month 21 D1.10 : Third Summary Progress Report and Annual Work Plan [33] Summary Progress Report and Annual Work Plan due at month 33 D1.11 : Fourth Summary Progress Report and Annual Work Plan [45] Summary Progress Report and Annual Work Plan due at month 45 D1.12 : Fifth Summary Progress Report and Annual Work Plan [57] Summary Progress Report and Annual Work Plan due at month 57 D1.13 : First Technical and Financial Report [15] Technical and Financial Report due at month 15 D1.14 : Second Technical and Financial Report [27] Technical and Financial Report due at month 27 D1.15 : Third Technical and Financial Report [39] Technical and Financial Report due at month 39 D1.16 : Fourth Technical and Financial Report [51] Technical and Financial Report due at month 51 D1.17 : Fifth Technical and Financial Report [60] Technical and Financial Report due at month 63 D1.18 : Monitoring activities handbook [2] Other lead beneficiaries: ELIXIR (76) and CVBF (27) Monitoring activities handbook D1.19 : First EJP RD Monitoring Report [12] EJP RD Monitoring Report due at month 12 D1.20 : Second EJP RD Monitoring Report [24] EJP RD Monitoring Report due at month 24 D1.21 : Third EJP RD Monitoring Report [36] EJP RD Monitoring Report due at month 36 D1.22 : Fourth EJP RD Monitoring Report [48] EJP RD Monitoring Report due at month 48 D1.23 : Fifth EJP RD Monitoring Report [60] EJP RD Monitoring Report due at month 60 D1.24 : Initial Data Management Plan [6] Initial Data Management Plan D1.25 : Updated Data Management Plan [6] Updated Data Management Plan including the Open Data Research Pilot information on how EJP RD will faciliatate the access to data and resources Page 41 of 161 Associated with document Ref. Ares(2018)6091977 - 28/11/2018 Schedule of relevant Milestones Due Milestone Milestone title Lead beneficiary Date (in Means of verification number18 months) Coordination & governance Minutes of the 1st Operating MS1 1 - INSERM 1 structures established Group conference call MS2 Helpdesk entry point set up 1 - INSERM 3 Website MS3 Policy Board established 1 - INSERM 3 List of Policy Board Members Page 42 of 161 Associated with document Ref. Ares(2018)6091977 - 28/11/2018 Work package number 9 WP2 Lead beneficiary 10 44 - ISCIII Work package title Integrative research and innovation strategy Start month 1 End month 60 Objectives This WP focuses on the development of EJP RD research and innovation strategy in connection to all related stakeholders. Specific objectives are: ● To map the needs for RD research and innovation; ● To define the prioritization model for the EJP RD actions as part of the annual planning and in connection to WP3 (Sustainability) and WP4 (Ethical, Regulatory, Legal and IPR framework); ● To prioritize topics for the joint transnational calls (JTCs) to be implemented within Pillar; ● To feed the medium and long-term RD research and innovation strategy in collaboration with IRDiRC; ● To prepare a Scoping Paper to be promoted (and implemented) by the national mirror groups and within the current and forthcoming EC Framework Programme. Description of work and role of partners WP2 - Integrative research and innovation strategy [Months: 1-60] ISCIII, INSERM, ANR, DLR, IT-MOH, FTELE, ISS, CVBF, VUHSK, ZonMw, MUW, AP-HP, UKL-HD, EATRIS, EURORDIS Other lead beneficiary: ISS (26) Task 2.1: Prioritization scheme for EJP RD actions (M1-M36) TL: CVBF, FTELE; Participants: ISCIII, ISS The prioritization scheme will be based on a set of criteria and procedure defining the decision-making process, by which to order mapped needs and actions that contribute to the EJP RD objectives or that stand in need of further exploration. The identified criteria will encompass scientific evidence aspects, demands of the RD community, regulatory and societal concerns and take into account financial and technical feasibility. The criteria will be defined based on the input collected (through a survey) from RD stakeholders representing research community, ERNs, patients and policy makers. The ExCom will endorse the prioritization criteria and will submit the prioritization scheme for the input and validation of the Governing Board to be finally adopted by the Policy Board during its first face-to-face meeting. Task 2.2 Mapping the research and innovation needs (M1-M48) TL: ISCIII, ISS, Participants: Operating Group (INSERM [Coo & Orpha], DLR, IT MoH, UKL-HD, APHP, VUHSK, ZonMw, EURORDIS, EATRIS); DTL-Projects (ELIXIR-NL); MUW The aim of this task is to identify and regularly update the research and innovation needs that will feed the EJP RD Annual Plans and contribute to the development of the long-term strategy of the EJP RD. This mapping exercise will include inputs from different type of stakeholders going beyond the EJP RD beneficiaries and their Linked Third parties: ● Internal input from the EJP RD (Operating Group); ● National and EU needs represented by the EJP RD Policy Board and in connection to national mirror groups; ● Yearly analysis of the state of play of funded research and drug development, overlaps and trends at international level (based on data collected in Pillar 2, WP11, Task 11.2); ● International research strategy developed by the International Rare Diseases Research Consortium (IRDiRC) and represented by its scientific and constitutive committees. Taking into account the overall objective of the EJP RD is to establish a sustainable structure for support of RD research and innovation, the mapping shall expand beyond mere scientific requisites and encompass other connected domains comprising: (i) Diagnosis & healthcare; (ii) Regulatory & ethics (including the open data & science issues); (iii) EU competitiveness & innovation. The inputs will be collected from all stakeholders on a yearly basis within the first trimester of every year. A summary document will be generated and sent to the Policy Board and ExCom as basis for prioritization exercise. The Policy Board will meet once a year (month 6) to deliberate, prioritize (according to prioritization scheme developed under Task 2.1) and issue recommendations to the EJP RD ExCom on the actions to implement within subsequent Annual Work Plan and the ones that require medium and longer-term investigation. In addition to informing Annual Work Plan, the outcomes of the mapping and prioritization will be reformulated in the form of Scoping Paper (prepared by the Task 2.2 leaders with help of CO) to be transmitted to the leaders of Task 2.3, 2.4 and 2.5 for complementary actions. Page 43 of 161 Associated with document Ref. Ares(2018)6091977 - 28/11/2018 Task 2.3: Scientific programming of joint transnational calls (M1-M36) TL: ISCIII, ANR, Participants: DLR, FFRD, IT MoH The joint transnational calls (JTCs) to be implemented within Pillar 1 represent important resource of both funding and research capacity. Firstly, because their goal is to integrate national investments into RD research under single, common programme; secondly, because funded research projects not only advance knowledge, diagnosis and therapy development for RDs in general, but also should significantly contribute to the development, improvement and demonstration of the EJP RD infrastructure, tools and methodologies. Thus, programming of research topics for JTCs will be treated with particular attention. The above-mentioned mapping and prioritization exercise will serve as basis to produce JTC topics table that will be submitted for further refinement by the specific ad hoc Scientific Advisory Board called on the demand of Pillar 1 Call Steering Committee(s). As result, a list of maximum 3 detailed topics will be produced. Particular attention will be made to avoid any COI of Research Performing Organizations participating in the EJP RD and that would be eligible to apply to JTCs. That is why, the final decision on topics will be taken independently by the Board of Funders, in agreement with the established call rules and national prerogatives (see Pillar 1 WP6). Task 2.4: Management of the medium, longer-term research strategy questions and dedicated linkage with Task Forces of IRDiRC (M1 – M60) TL: INSERM (Coo), Participants: Operating Group (INSERM (Orpha), DLR, UKL-HD, APHP, VUHSK, ZonMw, EURORDIS, EATRIS); ISCIII, ISS At present each of the IRDiRC Scientific (Diagnostics, Interdisciplinary, Therapies) or Constituent (Funders, Patients Advocacy, Companies) Committees has the possibility to seize upon specific RD research need or bottleneck and propose a Task Force aiming at issuing recommendations or concrete actions to overcome the identified obstacle. The majority of EJP RD countries and the European Commission are also members of IRDiRC and participate actively in different committees. Furthermore, the Chair and Vice-Chair of IRDiRC will be members of EJP RD Policy Board. Such strong connection is a mutual advantage and will prevent duplication of efforts. Thus, any research strategic question or need identified by the Policy Board as requiring medium or longer-term approach (Task 2.2) will be studied in relation to the ongoing or future Task Forces planned within IRDiRC activities. Whenever an issue recognized by Policy Board either of national or EU-specific nature, a dedicated, IRDiRC-independent Task Force(s) will be proposed. The setting up of a Task Force will follow well-established scheme proposed by IRDiRC, composed of the following steps: (i) Analysis and preparation of background document; (ii) Call for experts to constitute TF working group; (iii) Establishment of TF work plan; (iv) Up to 6 months of work including regular conference calls; (v) Production of final recommendations and/or roadmap to be followed by the engaged stakeholders (enquirers); (vi) Dissemination. Any other issue with identified synergy to IRDiRC TF will be integrated and treated jointly. Finally, needs/questions of international wingspan, not yet treated by IRDiRC will be proposed as subjects for new collective Task Forces. The EJP RD Coordination office (including IRDiRC SciSec) will be responsible for the management of the TF. Task 2.5: Translation/impact of prioritization on national and EU strategies (M6 – M60) TL: ISS, MUW, Participants: EURORDIS, FTELE, ISCIII, IT MoH It is expected that the European dimension of the EJP RD and involvement of the Policy Board should have impact both ways - on the activities of the EJP RD itself but also on the undertakings at national and EU level. Thus, the T2.2 Scoping Paper will be promoted by the national mirror groups and within the current and forthcoming EC Framework Programme. In addition, the Task leaders will be responsible for collection of information from EU Member States (via a survey targeting national mirror groups) on the EJP RD relevant/complementary actions performed at national level. Specific focus will be made on EU-13 countries in respect to their specific needs, obstacles and advancements. A report analyzing national alignment with EJP RD will be produced annually and presented at the occasion of the Policy Board & ExCom meetings. In addition, two Strategic Workshops with relevant policy stakeholders will be organized (M33, M57). Participation per Partner Partner number and short name WP2 effort 1 - INSERM 13.00 11 - ANR 2.00 15 - DLR 1.00 21 - IT-MOH 2.00 25 - FTELE 1.00 Page 44 of 161 Associated with document Ref. Ares(2018)6091977 - 28/11/2018 Partner number and short name WP2 effort 26 - ISS 18.00 27 - CVBF 1.00 32 - VUHSK 1.00 34 - ZonMw 1.00 38 - MUW 4.00 44 - ISCIII 16.00 54 - AP-HP 1.00 57 - UKL-HD 1.00 75 - EATRIS 1.00 77 - EURORDIS 1.00 Total 64.00 List of deliverables Due Deliverable Deliverable Title Lead beneficiary Type15 Dissemination level16 Date (in Number14 months)17 Final list of prioritization D2.1 27 - CVBF Report Public 5 criteria Prioritization scheme D2.2 including decision- 27 - CVBF Report Public 5 making process Confidential, only First Summary document for members of the D2.3 on mapped research and 44 - ISCIII Report consortium (including 5 innovation needs the Commission Services) Confidential, only Second Summary for members of the document on mapped D2.4 44 - ISCIII Report consortium (including 17 research and innovation the Commission needs Services) Confidential, only Third Summary for members of the document on mapped D2.5 44 - ISCIII Report consortium (including 29 research and innovation the Commission needs Services) Confidential, only Fourth Summary for members of the document on mapped D2.6 44 - ISCIII Report consortium (including 41 research and innovation the Commission needs Services) Fifth Summary document Confidential, only D2.7 on mapped research and 44 - ISCIII Report for members of the 53 innovation needs consortium (including Page 45 of 161 Associated with document Ref. Ares(2018)6091977 - 28/11/2018 List of deliverables Due Deliverable Deliverable Title Lead beneficiary Type 15 Dissemination level 16 Date (in Number14 months)17 the Commission Services) D2.8 First Scoping paper 26 - ISS Report Public 7 D2.9 Second Scoping paper 26 - ISS Report Public 19 D2.10 Third Scoping paper 26 - ISS Report Public 31 D2.11 Fourth Scoping paper 38 - MUW Report Public 43 D2.12 Fifth Scoping paper 38 - MUW Report Public 55 Confidential, only for members of the First List of refined JTC D2.13 44 - ISCIII Report consortium (including 7 topics the Commission Services) Confidential, only for members of the Second List of refined D2.14 44 - ISCIII Report consortium (including 19 JTC topics the Commission Services) Confidential, only for members of the Third List of refined JTC D2.15 11 - ANR Report consortium (including 31 topics the Commission Services) First List of research and innovation needs D2.16 requiring medium- or 1 - INSERM Report Public 6 long-term approach and related Task Forces Second List of research and innovation needs D2.17 requiring medium- or 1 - INSERM Report Public 18 long-term approach and related Task Forces Third List of research and innovation needs D2.18 requiring medium- or 1 - INSERM Report Public 30 long-term approach and related Task Forces Fourth List of research and innovation needs D2.19 requiring medium- or 1 - INSERM Report Public 42 long-term approach and related Task Forces Fifth List of research D2.20 and innovation needs 1 - INSERM Report Public 54 requiring medium- or Page 46 of 161 Associated with document Ref. Ares(2018)6091977 - 28/11/2018 List of deliverables Due Deliverable Deliverable Title Lead beneficiary Type 15 Dissemination level 16 Date (in Number14 months)17 long-term approach and related Task Forces First Analysis of national state of play and D2.21 26 - ISS Report Public 9 alignment process with EJP RD Second Analysis of national state of play and D2.22 26 - ISS Report Public 21 alignment process with EJP RD Third Analysis of national state of play and D2.23 26 - ISS Report Public 32 alignment process with EJP RD Fourth Analysis of national state of play and D2.24 26 - ISS Report Public 55 alignment process with EJP RD First Report from D2.25 strategic workshop with 26 - ISS Report Public 34 national policy makers Second Report from D2.26 strategic workshop with 38 - MUW Report Public 58 national policy makers Description of deliverables D26: Final list of prioritization criteria (M5) D27: Prioritization scheme including decision-making process (M5) D28, D29, D30, D31 and D32: Summary document on mapped research and innovation needs (M5, 17, 29, 41, 53) D33, D34, D35, D36 and D37: Scoping paper (M7, M19, M31, M42, M54) D38, D39 and D40: List of refined JTC topics (M7, M19, M31) D41, D42, D43, D44 and D45: List of research and innovation needs requiring medium- or long-term approach and related Task Forces (M7, M18, M30, M42, M54) D46, D47; D48 and D49: Analysis of national state of play and alignment process with EJP RD (M9, M21, M32, M55) D50 and D51: Report from strategic workshop with national policy makers (M34, M58) D2.1 : Final list of prioritization criteria [5] Other lead beneficiary FTELE (25) Final list of prioritization criteria D2.2 : Prioritization scheme including decision-making process [5] Other lead beneficiary FTELE (25) Prioritization scheme including decision-making process D2.3 : First Summary document on mapped research and innovation needs [5] Other lead beneficiary ISS (26) Summary document on mapped research and innovation needs D2.4 : Second Summary document on mapped research and innovation needs [17] Other lead beneficiary ISS (26) Summary document on mapped research and innovation needs D2.5 : Third Summary document on mapped research and innovation needs [29] Page 47 of 161 Associated with document Ref. Ares(2018)6091977 - 28/11/2018 Other lead beneficiary ISS (26) Summary document on mapped research and innovation needs due at month 29 D2.6 : Fourth Summary document on mapped research and innovation needs [41] Other lead beneficiary ISS (26) Summary document on mapped research and innovation needs due at month 41 D2.7 : Fifth Summary document on mapped research and innovation needs [53] Other lead beneficiary ISS (26) Summary document on mapped research and innovation needs due at month 53 D2.8 : First Scoping paper [7] Other lead beneficiaries: ISCIII (44) and INSERM (1) Scoping paper due at Month 7 D2.9 : Second Scoping paper [19] Other lead beneficiaries ISCIII (44) and INSERM (1) Scoping paper due at month 19 D2.10 : Third Scoping paper [31] Other lead beneficiaries ISCIII (44) and INSERM (1) Scoping paper due at month 31 D2.11 : Fourth Scoping paper [43] Other lead beneficiaries: ISCIII (44) and INSERM (1) Scoping paper due at month 43 D2.12 : Fifth Scoping paper [55] Other lead beneficiaries ISCIII (44) and INSERM (1) Scoping paper due at month 55 D2.13 : First List of refined JTC topics [7] Other lead beneficiary ANR (11) List of refined JTC topics due at month 7 D2.14 : Second List of refined JTC topics [19] Other lead beneficiary ANR (11) List of refined JTC topics due at month 19 D2.15 : Third List of refined JTC topics [31] Other lead beneficiary ANR (11) List of refined JTC topics due at month 31 D2.16 : First List of research and innovation needs requiring medium- or long-term approach and related Task Forces [6] List of research and innovation needs requiring medium- or long-term approach and related Task Forces due at month 6 D2.17 : Second List of research and innovation needs requiring medium- or long-term approach and related Task Forces [18] List of research and innovation needs requiring medium- or long-term approach and related Task Forces due at month 18 D2.18 : Third List of research and innovation needs requiring medium- or long-term approach and related Task Forces [30] List of research and innovation needs requiring medium- or long-term approach and related Task Forces due at month 30 D2.19 : Fourth List of research and innovation needs requiring medium- or long-term approach and related Task Forces [42] List of research and innovation needs requiring medium- or long-term approach and related Task Forces due at month 42 D2.20 : Fifth List of research and innovation needs requiring medium- or long-term approach and related Task Forces [54] List of research and innovation needs requiring medium- or long-term approach and related Task Forces due at month 54 D2.21 : First Analysis of national state of play and alignment process with EJP RD [9] Other lead beneficiary MUW (38) Analysis of national state of play and alignment process with EJP RD due at Month 9 D2.22 : Second Analysis of national state of play and alignment process with EJP RD [21] Page 48 of 161 Associated with document Ref. Ares(2018)6091977 - 28/11/2018 Other lead beneficiary MUW (38) Analysis of national state of play and alignment process with EJP RD due at month 21 D2.23 : Third Analysis of national state of play and alignment process with EJP RD [32] Other lead beneficiary MUW (38) Analysis of national state of play and alignment process with EJP RD due at month 32 D2.24 : Fourth Analysis of national state of play and alignment process with EJP RD [55] Other lead beneficiary MUW (38) Analysis of national state of play and alignment process with EJP RD due at month 55 D2.25 : First Report from strategic workshop with national policy makers [34] Other lead beneficiary MUW (38) Report from strategic workshop with national policy makers due at month 34 D2.26 : Second Report from strategic workshop with national policy makers [58] Other lead beneficiary MUW (38) Report from strategic workshop with national policy makers due at month 58 Schedule of relevant Milestones Due Milestone Milestone title Lead beneficiary Date (in Means of verification number18 months) Survey on prioritization MS4 27 - CVBF 3 Survey document criteria set up and launched Prioritization scheme and Minutes of the ExCom and MS5 list of criteria validated by 44 - ISCIII 6 Policy Board meeting ExCom and Policy Board Page 49 of 161 Associated with document Ref. Ares(2018)6091977 - 28/11/2018 Work package number 9 WP3 Lead beneficiary 10 1 - INSERM Work package title Sustainability strategy and business plan Start month 1 End month 60 Objectives The objective of WP3 is to prepare, and implement the EJP RD sustainability strategy in collaboration with the EJP-RD boards, Pillars and relevant WP/Task leaders. The strategy will identify routes to sustainability and develop relevant action plans. Specific objectives: ● Identify elements of the EJP RD that are potentially sustainable by integrating information from the monitoring of EJP activities (WP1) with feedback from targeted end-user groups and key stakeholders including entities that will provide the resources for sustainability (ex. EU Member States); ● Identify potential sustainability models, including both ‘classic’ and innovative approaches to fund-raising activities, business models and legal status of on-going European infrastructures and initiatives; ● Initiate efforts to promote the sustainable activities of the EJP-RD; ● In collaboration with WP4 (Ethical, regulatory & legal framework) formulate recommendations for the governance of the organization(s) that will succeed EJP RD with a particular focus on intellectual property and access issues; ● Develop the sustainability roadmap of the EJP RD. WP3 will ensure liaison with other strategic initiatives working on global sustainability issues (e.g. RDA, EOSC, EC- funded e-Infrastructures, ESFRI Forum and its Health and Food Strategic Working Group, relevant H2020 projects and other international initiatives) in view of aligning strategic sustainability activities and exploiting synergies. Description of work and role of partners WP3 - Sustainability strategy and business plan [Months: 1-60] INSERM, DLR, VUHSK, ZonMw, ISCIII, ULIV, AP-HP, UKL-HD, EATRIS, EMBL, EURORDIS Other lead beneficiaries: EATRIS (75) and ISCIII (44) WP Methodology Sustainability strategy encompasses several important aspects that will be addressed in this WP: (i) identification of value propositions that emerge from EJP RD activities, taking into account effective segmentation of capabilities and markets and the needs of resource holders; (ii) developing business plans for the activities of EJP RD that are sustainable, including identification of necessary resources; (iii) scoping legal and governance issues relating to sustainability. The experience and lessons learnt from the performance of E-RARE, RD-Connect, Orphanet, ERNs and other initiatives indicate that long term sustainability is a serious issue necessary to be tackled by the EJP RD as early as possible. Consultation with internal and external stakeholders will be essential to ensure that the approach to sustainability is appropriate and that sustainability is considered throughout the programme. Task 3.1: Service roadmap: alignment of the needs, expectations and engagement of the different RD research stakeholders in Europe with respect to EJP RD sustainability (M1 – M36) TL: INSERM (RaDiCo), ISCIII, Participants: ULiv, DTL-Projects, Operating Group (INSERM [Coo & Orpha], DLR, UKL-HD, APHP, VUHSK, ZonMw, EURORDIS, EATRIS) In close collaboration with the OG and transversal WPs 2 & 5, this task aims to integrate and maintain the information collected on needs, expectations and possible contributions of: (i) National Programme Owners (PO) and Programme Managers (PM) (Subtask 3.1.1 led by ISCIII) and (ii) other stakeholders (Subtask 3.1.2 led by INSERM-RaDiCo) to define in a standard format value propositions that can drive sustainability perspectives. In a 360° perspective matrix- based approach, the stakeholders will be segmented into specific subgroups (funders and public authorities, patients, researchers and learned societies, care givers, industry) taking into account their needs, expectations and possible contributions (including long term financial and/or in-kind commitment). This task will develop value propositions for “viable” activities that will be prioritized via Task 3.2 and by stakeholders with resources that can sustain them. Task 3.2: Preparation of the sustainable EJP-RD services catalogue, supporting the EJP-RD dissemination and communication activities (M12 – M36) TL: INSERM (RaDiCo), EATRIS, Participants: ISCIII, ULiv, DTL-Projects Based on the results of Task 3.1 together with subsequent internal monitoring of EJP RD performance (WP1, Task 1.3), inputs from Pillars and Transversal WPs, and clear user demand, a catalogue of services will be compiled by WP3 and disseminated by WP5. The dissemination will include participation at dedicated events or channeling information Page 50 of 161 Associated with document Ref. Ares(2018)6091977 - 28/11/2018 to the ESFRI infrastructures, funding agencies and governmental bodies about the ‘catalogue’ and EJP RD plans and successes. In addition, WP3 will support EJP RD components seeking resources to develop study cases of innovative sustainability solutions. Task 3.3: Preparation of the EJP-RD sustainability plan with business plan (M1 – M42) TL: EATRIS, ISCIII, Participants: INSERM (RaDiCo), ULiv, DTL-Projects The task will consist of benchmarking of sustainability strategies that exist in the EU research fields, such as European ESFRI landmark research infrastructures and projects in the ESFRI Roadmap, European and national research data hubs (e.g. EOSC / EDI), public and private institutes, foundations across the globe, with strong interconnections and involvements of NGOs, private partners and public bodies. The results will be assessed, with high potential benchmark strategies collated for possible use in the EJP sustainability roadmap. Then, the specific ecosystem in which the EJP RD will operate will be evaluated: current state, target users, relevant unique value within-project take-up, post-project take-up, financial aspects, and competitive analysis. The evaluation of the ecosystem will identify the expectations and requirements of the member states (and other sources of sustainable resources) regarding: (i) expected benefits and willingness to pay; (ii) constraints on operational structure, legal model, IP and other governance issues. The potential sustainability models identified will be submitted to a SWOT analysis including their structure and governance differences, budgetary needs, legal and tax-related environments, and the identification of potential financing sources and their possible consequences on competing or synergistic interests. The sustainability cases will be based on a business case with strategy of clients and combination of financial sources, including: national funds for availability of e-Infrastructures, public funds and research grants, regional resource sharing and collaboration via Memorandum of Understanding, public-private partnerships and exploration of pay-per-use and in-kind business models. Sustainability models will be targeted to segments of resource holders. Finally, the most relevant sustainability models will be selected with its business case, taking into account prioritization information from the EJP RD sustainable service catalogue produced by Task 3.2, and presented to the EJP RD Governance and the stakeholders. The models will include the following criteria: (i) open-access versus controlled availability of the EJP RD deliverables and outcomes in line with European Open Science Cloud and European Data Infrastructure, (ii) design of services that enable researchers to make the most of the EJP outcomes (iii) ensuring the possibility for accession of new members/contributors interested in joining, (iv) identification of cash flow between the actors, (v) pricing of services, (vi) financial viability and (vii) buy- in by the stakeholders. The selected sustainability models should include the Beneficiaries having contributed to the considered deliverables and PO, PM and other key stakeholders that are involved in RD research (and beyond). A first list of the relevant models addressing sustainability for key stakeholders will be delivered. This list will be published for a public consultation. Following it, a refined list will be delivered to inform the Task 3.4. Task 3.4: Sustainability roadmap (M36-M60) TL: ISCIII, EATRIS, Participants: INSERM (RaDiCo), ULiv, DTL-Projects This task will build on Tasks 3.1 – 3.3 to define the final sustainability roadmap for the EJP RD with all milestones to be reached in order to roll out and implement the selected model to ensure sustainability of the integrated RD research infrastructure at both EU and national levels. Upon the preferences and requirements expressed by Member States a proposal with SWOT produced in T3.3 and future KPIs will be drafted and presented to Members States for adoption after the EJP RD ends. A first version of the sustainability roadmap will be prepared and defined at M46. The roadmap will be finalized at M54 with final decision after an iterative process taking into account associated deliverable completion and evaluation by other WPs. Participation per Partner Partner number and short name WP3 effort 1 - INSERM 26.00 15 - DLR 1.00 32 - VUHSK 1.00 34 - ZonMw 1.00 44 - ISCIII 13.00 51 - ULIV 3.00 54 - AP-HP 1.00 57 - UKL-HD 1.00 Page 51 of 161 Associated with document Ref. Ares(2018)6091977 - 28/11/2018 Partner number and short name WP3 effort 75 - EATRIS 14.00 76 - EMBL 0.00 DTL-Projects 3.00 77 - EURORDIS 1.00 Total 65.00 List of deliverables Due Deliverable Deliverable Title Lead beneficiary Type 15 Dissemination level 16 Date (in Number14 months)17 Dynamic catalogue of EJP-RD sustainable D3.1 resources including 1 - INSERM Report Public 36 Service Roadmap Database Confidential, only Study cases of innovative for members of the sustainability solutions D3.2 1 - INSERM Report consortium (including 36 for specific EJP RD the Commission outcomes Services) Analysis of structures, Confidential, only business models and for members of the D3.3 required complementarity 75 - EATRIS Report consortium (including 42 from other relevant the Commission initiatives Services) First Proposal of Confidential, only structure, governance for members of the D3.4 and financial model and 44 - ISCIII Report consortium (including 46 global sustainability the Commission roadmap Services) Second Proposal of Confidential, only structure, governance for members of the D3.5 and financial model and 44 - ISCIII Report consortium (including 54 global sustainability the Commission roadmap Services) Description of deliverables D52: Dynamic catalogue of EJP-RD sustainable resources including Service Roadmap Database (M36) D53: Study cases of innovative sustainability solutions for specific EJP RD outcomes (M36) D54: Analysis of structures, business models and required complementarity from other relevant initiatives (M42) D55 and D56: Proposal of structure, governance and financial model and global sustainability roadmap (M46, M54) D3.1 : Dynamic catalogue of EJP-RD sustainable resources including Service Roadmap Database [36] Dynamic catalogue of EJP-RD sustainable resources including Service Roadmap Database Lead beneficiary INSERM (RADICO) D3.2 : Study cases of innovative sustainability solutions for specific EJP RD outcomes [36] Page 52 of 161 Associated with document Ref. Ares(2018)6091977 - 28/11/2018 Study cases of innovative sustainability solutions for specific EJP RD outcomes Lead beneficiary ISNERM (RADICO) D3.3 : Analysis of structures, business models and required complementarity from other relevant initiatives [42] Other lead beneficiary: EATRIS (75) Analysis of structures, business models and required complementarity from other relevant initiatives D3.4 : First Proposal of structure, governance and financial model and global sustainability roadmap [46] Other lead beneficiary EATRIS (75) Proposal of structure, governance and financial model and global sustainability roadmap due at month 46 D3.5 : Second Proposal of structure, governance and financial model and global sustainability roadmap [54] Other lead beneficiary (EATRIS (75) Proposal of structure, governance and financial model and global sustainability roadmap due at month 54 Schedule of relevant Milestones Due Milestone Milestone title Lead beneficiary Date (in Means of verification number18 months) Survey to national mirror MS6 groups established and 26 - ISS 5 Survey document launched Proposed model approved by Suitable structure and the EJP-RD Governance and MS7 sustainability model for the 75 - EATRIS 42 MS according to decision- EJP RD proposed making procedures Final Business model and Final proposal for decision on MS8 44 - ISCIII 54 sustainability plan for the sustainability roadmap adoption Page 53 of 161 Associated with document Ref. Ares(2018)6091977 - 28/11/2018 Work package number 9 WP4 Lead beneficiary 10 24 - FGB Work package title Ethical, regulatory, legal and IPR framework of the EJP RD Start month 1 End month 60 Objectives This WP aims at providing all Pillars with the proper strategy to address ethical, regulatory (including GDPR), legal and Intellectual Property Right (IPR) issues, and at ensuring that relevant rules are complied with within the course of the EJP for RD. The specific objectives include: ● Setting up an ‘Advisory Regulatory Ethics Board’; ● Advising on the regulatory procedures and ethical provisions to perform regulatory-compliant research and data collection and to protect patient rights; ● Coordinating activities related to IPR issues of the EJP for RD as a whole. This will allow EJP RD to perform not only ethically-sounded but also regulatory-compliant multi-national research. Description of work and role of partners WP4 - Ethical, regulatory, legal and IPR framework of the EJP RD [Months: 1-60] FGB, INSERM, DLR, FTELE, CVBF, VUHSK, ZonMw, AP-HP, UKL-HD, BBMRI, ECRIN, EATRIS, EMBL, EURORDIS Other WP lead beneficiaries: FTELE (25) Task 4.1. Advice and monitoring ethical/regulatory issues within EJP RD. (M1-M60) TL: INSERM With the aim to comply with the European ethical and legal frameworks, an independent expert will be appointed as an “Ethics Advisor”. He/she will be in charge of advising on and monitoring ethical/legal/regulatory issues of the EJP RD, of the Data Management Plan as well as of the projects founded within EJP RD to ensure that the ethics management of the projects are carried out within the H2020 framework. He/she will closely work with the EJP RD operating group and the Advisory Regulatory Ethics Board’ (AREB) that will be set up (see Task 4.2). Task 4.2 Managing ethical and regulatory issues (M1-M60) TL: FGB, Participants: BBMRI, ECRIN, ELIXIR, CVBF, INSERM, Operating Group (INSERM [Coo& Orpha], DLR, UKL-HD, APHP, VUHSK, ZonMw, EURORDIS, EATRIS) In order to ensure compliance of the project and its activities with ethical and regulatory requirements, a project ‘Advisory Regulatory Ethics Board’ (AREB) will be set up. It will be composed of internal EJP RD ethics/regulatory/ legal experts, including members with recognised expertise from involved European RIs. It will ensure compliance with all international and European relevant rules and ethical norms, including but not limited to fundamental and patients’ rights, data management, protection and confidentiality, of the EJP RD as well as of the projects founded within EJP RD. In particular, the AREB will be in charge of overseeing ethical issues and regulatory procedures envisaged in the EJP RD four Pillars and by assisting partners. Specifically, the AREB will: ● Collaborate with Pillar 1 to ensure that the Joint Transnational Calls for collaborative research projects will include all relevant requirements in the call text and guidelines for applicants; ● Verify that the collaborative research projects funded in Pillar 1 as well as pilot project/proof of concept foreseen in Pillars 2 and 4 activities are regulatory- and ethically-compliant and that they will properly address patient rights and the necessary regulatory procedures, e.g. ethical approval, authorisation from competent authorities, regulatory advice from EMA or national agencies (Scientific Advice/Protocol Assistance, EMA qualification opinion, certification of ATMP quality etc.), Paediatric Investigation Plan (PIP) or waiver, pharmacovigilance obligations; ● Ensure that data handling carried out in Pillars 2 and 4 and projects funded in Pillar 1 comply with GDPR and national laws, including requirement for special declarations or authorisations; ● Inform and update EJP RD consortium partners on the advancements, changes and news from the regulatory, ethical and legal framework during the yearly EJP RD Consortium meetings; ● Support EJP RD partners with ethical and legal advice whenever requested; ● Provide recommendations in case of detection of possible gap in the regulatory/ethical/legal framework to be applied in multi-national biomedical research in the context of the EJP RD; ● Ensure that the H2020 framework for ethics is fully applied to the planned subsidiary projects, and the ethics management of these should be carried out within the H2020 framework. Page 54 of 161 Associated with document Ref. Ares(2018)6091977 - 28/11/2018 A dialogue with the EMA and its committees as well as the national competent authorities will be established. Whenever relevant, other regulatory agencies/authorities will be addressed as well, e.g. Food and Drug Administration (FDA, US) and Japanese Ministry of Health, Labour and Welfare (MHLW) and Pharmaceuticals and Medical Devices Agency (PMDA). Task 4.3. Managing legal and IPR issues (M1-M60) TL: FTELE, Participant: FGB, BBMRI Considering the high number of partners in the EJP RD consortium and the variety of planned activities, a one-size- fits-all approach cannot be adopted. The Task Leader (TL) will therefore manage case by case the requests from EJP RD beneficiaries and proactively monitor the IP relevant issues throughout the whole project duration. The IP support report will serve as input to the Monitoring (Task 1.3) of the EJP RD activities and outcomes. Every six months, the TL will interview the ExCom in order to: ● Collect emerging needs on IP issues in every WP; ● Identify the activities more likely to produce results that are expected to be commercially or industrially exploitable and therefore needs IP protection; ● Keep track of the IP generated by each of the WPs, in particular in terms of copyrighted softwares or training materials and patents (if any) and feed the WP3 Sustainability strategy. Moreover, the TL will: ● Collect and archive any new or updated declaration on background IP by EJP-RD beneficiaries; ● Upon request, facilitate the contact and the negotiation between the Technology Transfer Offices and/or legal departments of the relevant beneficiaries in case of joint ownership of the results; ● Make available, through the EJP RD website, a set of legal templates for Inter Institutional Agreements, Data Transfer Agreement and Material Transfer Agreement compliant with EU rules, Grant Agreement and Consortium Agreement provisions; ● Upon request, support EJP RD beneficiaries in the use and adaptation to their specific needs of the above mentioned templates. Participation per Partner Partner number and short name WP4 effort 1 - INSERM 14.00 15 - DLR 1.00 24 - FGB 20.00 25 - FTELE 16.00 27 - CVBF 1.00 32 - VUHSK 1.00 34 - ZonMw 1.00 54 - AP-HP 1.00 57 - UKL-HD 1.00 73 - BBMRI 1.00 74 - ECRIN 1.00 75 - EATRIS 2.00 76 - EMBL 0.00 DTL-Projects 1.00 77 - EURORDIS 2.00 Total 63.00 Page 55 of 161 Associated with document Ref. Ares(2018)6091977 - 28/11/2018 List of deliverables Due Deliverable Deliverable Title Lead beneficiary Type 15 Dissemination level 16 Date (in Number14 months)17 Confidential, only for members of the D4.1 First AREB report 24 - FGB Report consortium (including 6 the Commission Services) Confidential, only for members of the First Periodic AREB D4.2 24 - FGB Report consortium (including 19 report the Commission Services) Confidential, only for members of the Second Periodic AREB D4.3 24 - FGB Report consortium (including 31 report the Commission Services) Confidential, only for members of the Third Periodic AREB D4.4 24 - FGB Report consortium (including 43 report the Commission Services) Confidential, only for members of the Fourth Periodic AREB D4.5 24 - FGB Report consortium (including 55 report the Commission Services) Set of template D4.6 agreements for EJP RD 25 - FTELE Report Public 6 website Confidential, only for members of the First Periodic IPR report D4.7 25 - FTELE Report consortium (including 6 (based on ExCom inputs) the Commission Services) Confidential, only Second Periodic IPR for members of the D4.8 report (based on ExCom 25 - FTELE Report consortium (including 18 inputs) the Commission Services) Confidential, only for members of the Third Periodic IPR report D4.9 25 - FTELE Report consortium (including 24 (based on ExCom inputs) the Commission Services) Fourth Periodic IPR Confidential, only D4.10 report (based on ExCom 25 - FTELE Report for members of the 24 inputs) consortium (including Page 56 of 161 Associated with document Ref. Ares(2018)6091977 - 28/11/2018 List of deliverables Due Deliverable Deliverable Title Lead beneficiary Type 15 Dissemination level 16 Date (in Number14 months)17 the Commission Services) Confidential, only for members of the Fifth Periodic IPR report D4.11 25 - FTELE Report consortium (including 30 (based on ExCom inputs) the Commission Services) Confidential, only for members of the Sixth Periodic IPR report D4.12 25 - FTELE Report consortium (including 36 (based on ExCom inputs) the Commission Services) Confidential, only Seventh Periodic IPR for members of the D4.13 report (based on ExCom 25 - FTELE Report consortium (including 42 inputs) the Commission Services) Confidential, only Eighth Periodic IPR for members of the D4.14 report (based on ExCom 25 - FTELE Report consortium (including 48 inputs) the Commission Services) Confidential, only for members of the Ninth Periodic IPR report D4.15 25 - FTELE Report consortium (including 54 (based on ExCom inputs) the Commission Services) Confidential, only Tenth and final Periodic for members of the D4.16 IPR report (based on 25 - FTELE Report consortium (including 60 ExCom inputs) the Commission Services) Confidential, only for members of the First IPR support D4.17 25 - FTELE Report consortium (including 6 (monitoring) report the Commission Services) Confidential, only for members of the Second IPR support D4.18 25 - FTELE Report consortium (including 12 (monitoring) report the Commission Services) Confidential, only for members of the Third IPR support D4.19 25 - FTELE Report consortium (including 18 (monitoring) report the Commission Services) Page 57 of 161 Associated with document Ref. Ares(2018)6091977 - 28/11/2018 List of deliverables Due Deliverable Deliverable Title Lead beneficiary Type 15 Dissemination level 16 Date (in Number14 months)17 Confidential, only for members of the Fourth IPR support D4.20 25 - FTELE Report consortium (including 24 (monitoring) report the Commission Services) Confidential, only for members of the Fifth IPR support D4.21 25 - FTELE Report consortium (including 30 (monitoring) report the Commission Services) Confidential, only for members of the Sixth IPR support D4.22 25 - FTELE Report consortium (including 36 (monitoring) report the Commission Services) Confidential, only for members of the Seventh IPR support D4.23 25 - FTELE Report consortium (including 42 (monitoring) report the Commission Services) Confidential, only for members of the Eighth IPR support D4.24 25 - FTELE Report consortium (including 48 (monitoring) report the Commission Services) Confidential, only for members of the Ninth IPR support D4.25 25 - FTELE Report consortium (including 54 (monitoring) report the Commission Services) Confidential, only Tenth and final IPR for members of the D4.26 support (monitoring) 25 - FTELE Report consortium (including 60 report the Commission Services) Description of deliverables D57 First AREB report (M6) D58, D59, D60 and D61 Periodic AREB report (M19, M31, M43, M55) D62 Set of template agreements for EJP RD website (M6) D63 to D72 Periodic IPR report (based on ExCom inputs) (M6, 12, 18, 24, 30, 36, 42, 48, 54, 60) D73 to D82 IPR support (monitoring) report (M6, M12, 18, 24, 30, 36, 42, 48, 54, 60). D4.1 : First AREB report [6] First AREB report D4.2 : First Periodic AREB report [19] Periodic AREB report due at month 19 Page 58 of 161 Associated with document Ref. Ares(2018)6091977 - 28/11/2018 D4.3 : Second Periodic AREB report [31] Periodic AREB report due at month 31 D4.4 : Third Periodic AREB report [43] Periodic AREB report due at month 43 D4.5 : Fourth Periodic AREB report [55] Periodic AREB report due at month 55 D4.6 : Set of template agreements for EJP RD website [6] Set of template agreements for EJP RD website D4.7 : First Periodic IPR report (based on ExCom inputs) [6] Periodic IPR report (based on ExCom inputs) due at month 6 D4.8 : Second Periodic IPR report (based on ExCom inputs) [18] Periodic IPR report (based on ExCom inputs) due at month 18 D4.9 : Third Periodic IPR report (based on ExCom inputs) [24] Periodic IPR report (based on ExCom inputs) due at month 24 D4.10 : Fourth Periodic IPR report (based on ExCom inputs) [24] Periodic IPR report (based on ExCom inputs) due at month 24 D4.11 : Fifth Periodic IPR report (based on ExCom inputs) [30] Periodic IPR report (based on ExCom inputs) due at month 30 D4.12 : Sixth Periodic IPR report (based on ExCom inputs) [36] Periodic IPR report (based on ExCom inputs) due at month 36 D4.13 : Seventh Periodic IPR report (based on ExCom inputs) [42] Periodic IPR report (based on ExCom inputs) due at month 42 D4.14 : Eighth Periodic IPR report (based on ExCom inputs) [48] Periodic IPR report (based on ExCom inputs) due at month 48 D4.15 : Ninth Periodic IPR report (based on ExCom inputs) [54] Periodic IPR report (based on ExCom inputs) due at month 54 D4.16 : Tenth and final Periodic IPR report (based on ExCom inputs) [60] Final Periodic IPR report (based on ExCom inputs) due at month 60 D4.17 : First IPR support (monitoring) report [6] IPR support (monitoring) report due at month 6 D4.18 : Second IPR support (monitoring) report [12] IPR support (monitoring) report due at month 12 D4.19 : Third IPR support (monitoring) report [18] IPR support (monitoring) report due at month 18 D4.20 : Fourth IPR support (monitoring) report [24] IPR support (monitoring) report due at month 24 D4.21 : Fifth IPR support (monitoring) report [30] IPR support (monitoring) report due at month 30 D4.22 : Sixth IPR support (monitoring) report [36] IPR support (monitoring) report due at month 36 D4.23 : Seventh IPR support (monitoring) report [42] IPR support (monitoring) report due at month 42 D4.24 : Eighth IPR support (monitoring) report [48] Page 59 of 161 Associated with document Ref. Ares(2018)6091977 - 28/11/2018 IPR support (monitoring) report due at month 48 D4.25 : Ninth IPR support (monitoring) report [54] IPR support (monitoring) report due at month 54 D4.26 : Tenth and final IPR support (monitoring) report [60] Final IPR support (monitoring) report due at month 60 Schedule of relevant Milestones Due Milestone Milestone title Lead beneficiary Date (in Means of verification number18 months) MS9 AREB set up 24 - FGB 5 List of AREB members 1st Annual AREB meeting MS10 24 - FGB 6 Meeting minutes held 2nd Annual AREB meeting MS11 24 - FGB 18 Meeting minutes held 3rd Annual AREB meeting MS12 24 - FGB 30 Meeting minutes held 4th Annual AREB meeting MS13 24 - FGB 42 Meeting minutes held Set of template agreements Availability on-line (EJP RD MS14 for IPR issues available to the 25 - FTELE 7 website) community Page 60 of 161 Associated with document Ref. Ares(2018)6091977 - 28/11/2018 Work package number 9 WP5 Lead beneficiary 10 1 - INSERM Work package title Communication & dissemination Start month 1 End month 60 Objectives ● Prepare and support the communication and dissemination strategy for the EJP RD as a whole and taking into account the needs of each Pillar and transversal WPs ● Effectively communicate on activities of each Pillar/WP to a wide range of stakeholders and potential users in a coherent, targeted and timely manner; ● Actively disseminate outputs from all work packages through a wide range of channels and tailored activities to target audiences; ● Promote the initiative and ensure awareness by establishing dialogues with key stakeholders and potential partners at national and EU level. Description of work and role of partners WP5 - Communication & dissemination [Months: 1-60] INSERM, DLR, TEDDY, VUHSK, ZonMw, ULIV, AP-HP, UKL-HD, EATRIS, EURORDIS, Blackswan Task 5.1: EJP RD external communication & dissemination of results (M1-M60) TL: INSERM (Coo), Participants: Operating Group (INSERM (Orpha), EURORDIS, DLR, UKL-HD, APHP, VUHSK, EATRIS, ZonMw), BLACKSWAN Subtask 5.1.1: Implementation of the EJP RD communication strategy (M1-M60) STL: INSERM (Coo), Participants: Operating Group (INSERM (Orpha), EURORDIS, DLR, UKL-HD, APHP, VUHSK, EATRIS, ZonMw) The operational day-to-day management of the communication & dissemination will be ensured by the Communication Manager (CM) who will be part of the Coordination Office. The CM will collaborate closely with the Operating Group to provide the interface between the partners participating in different pillars/WPs, collect their needs and provide suitable communication and dissemination means to design communication actions targeted for the different audiences. The CM will be responsible for the timely aggregation of items requiring communication/dissemination actions and propose implementation, in line with the communication and dissemination plan provided in the proposal, and taking advantage of the centrally provided tools (website, broadcast media, scientific support from project managers) coupled with the extensive capacity and international coverage of the EJP RD partners (see also Task 5.2). The strategy will be adapted to the type of stakeholders: general public, patients, policy makers and research community. The initially proposed frequency and formats will be agreed and validated by the Executive Committee with the possibility of revision whenever deemed necessary. Impact of communication and dissemination activities will be assessed during the course of the project via the Task 1.3 (Monitoring). Dissemination activities will be tracked and evaluated regularly based on the criteria determined in the Communication and Dissemination Plan to ensure an efficient impact and European-added value. Subtask 5.1.2: Communication and dissemination tools (M1-M60) STL: INSERM (Coo), Participants: BLACKSWAN EJP RD website: the website will be established at the start of the project (M2). It will be a central tool to communicate, disseminate the results but also serve as a single entry point for the EJP RD Helpdesk (see Subtask 1.1.2). The website will be developed and maintained by INSERM under the responsibility of Coordination Unit and Communication Manager in particular. The website will constantly updated and will feature individual pages dedicated to specific activities developed within each Pillar and transversal WPs as well as sections focusing on promotion of relevant news and activities of other EJP RD related initiatives. It will also encompass user-friendly interface for the EJP RD Helpdesk. Newsletters: Project newsletters and flash news will be produced and disseminated through various listing of stakeholders. The service used will be MailChimp, which has several reporting features such as download/access statistics and breaking down the subscribers by country, age and gender etc. The newsletters will also be published on the website. Social media pack: The social media like Facebook, Twitter or LinkedIn are now part of the regular communication and dissemination panoply. They will be also included in the EJP RD communication strategy. Special attention will be given to the regular follow up and appropriate management (including privacy policy) of these tools to be subsumed under duties of the CM. Page 61 of 161 Associated with document Ref. Ares(2018)6091977 - 28/11/2018 Printed communication materials: leaflets, brochures presenting the goals and activities of the EJP RD for the distribution during meetings and workshops; generic posters with the intention to reflect the status of the project and to support the presentations at events and meetings. Whenever possible these communication materials will be translated into the national languages of the EJP RD partner in order to facilitate and increase awareness. Broadcast media: The audio and video support will be available to cover EJP RD events, interviews and preparation of dedicated content (ex. general public, young patients, to feature new tools, etc.). EJP RD will pro-actively engage with EC specific (e.g., Horizon Magazine, Cordis) and international media. Scientific writing support: The experience gathered by the SciSec of IRDiRC (see also Task 1.1.1) showed that centralized support for writing of reports, drafting of papers and preparation of scientific contents increases the efficiency of the communication and dissemination of outputs produced by numerous Task Forces, workshops and working groups. This model will be also implemented in the EJP RD. The scientific writing support will be provided by the CM and EJP RD project managers. This core group may be reinforced on an ad hoc basis by experts mobilized from among EJP RD partners. Scientific Congresses: The EJP RD intends to continue the collaboration initiated by E-Rare and IRDiRC with BlackSwan Foundation to support and further expand RE(ACT) Congress. In addition, collaboration with other relevant events like ECRD, ICORD, UDNI or ESHG congresses will be used to strengthen the dissemination capacity and exploit the potential of these events to promote excellent research financed by Pillar 1 (and previously by E-Rare), outcomes of other Pillars and provide stimulating environment for RD community. Joint targeted workshops fostering promotion and collaboration with relevant stakeholders (regulatory bodies, patients or private investors) will be also organized at these occasions. Subtask 5.1.3: Support of communication and dissemination activities of IRDiRC (M1-M60) STL: INSERM At present the communication and dissemination support of IRDiRC is ensured by its Scientific Secretariat. It includes the maintenance and regular updates of the IRDiRC website, the development of a monthly newsletter, updates on social media and development of suitable written content and organization of IRDiRC Congress. Since IRDiRC SciSec will be integrative part of the EJP RD Coordination office, these activities and dedicated to IRDiRC communication tools will be maintained (along with other responsibilities of the SciSec) and supported by Communication and project Managers. Yearly communication and dissemination plan specific to IRDiRC will be presented at the IRDiRC Consortium Assembly. Task 5.2: Integrating EJP-RD communication and dissemination strategies with the strategies of involved stakeholders (M1-M60) TL: INSERM(Orphanet LTPs), Participants: EURORDIS, TEDDY, ULiv The EJP RD gathers 85 partners from 32 EU, associated and non-European countries. Many involved beneficiaries represent networks or projects that cover multitude of stakeholders like research communities (alliances, learned societies), healthcare providers, patients (including young patients) or policy-makers (ministries, ethics and data protection authorities, HTA). Thus, the internal potential of EJP RD partners should not be neglected, as it will serve to vehicle unified information and multiply the communication and dissemination capacity of the EJP RD at regional and national level. For this Task the Orphanet and EURORDIS networks already implemented in all of the EJP RD countries will be used to link with national RD stakeholders and support EJP RD communication & dissemination efforts. The TEDDY and C4C networks (ULiv), specifically dedicated to pediatric clinical research and having large experience in communication to young patients will second EURORDIS and Orphanet. Finally, national networks of collaborators (including voluntary helpers) will assist in adapting and translating the EJP RD newsletter, specific reports or publication in national languages to reach wider public. Participation per Partner Partner number and short name WP5 effort 1 - INSERM 68.00 15 - DLR 1.00 28 - TEDDY 1.00 32 - VUHSK 1.00 34 - ZonMw 1.00 51 - ULIV 1.00 Page 62 of 161 Associated with document Ref. Ares(2018)6091977 - 28/11/2018 Partner number and short name WP5 effort 54 - AP-HP 1.00 57 - UKL-HD 1.00 75 - EATRIS 1.00 77 - EURORDIS 1.00 80 - Blackswan 12.00 Total 89.00 List of deliverables Due Deliverable Deliverable Title Lead beneficiary Type15 Dissemination level16 Date (in Number14 months)17 Websites, D5.1 EJP RD website 1 - INSERM patents Public 2 filling, etc. Websites, D5.2 EJP RD Newsletter 1 - INSERM patents Public 2 filling, etc. First RE(ACT) Congress D5.3 80 - Blackswan Report Public 16 report Second RE(ACT) D5.4 80 - Blackswan Report Public 30 Congress report Third RE(ACT) D5.5 80 - Blackswan Report Public 54 Congress report Description of deliverables D83: EJP RD website (M2) D84: EJP RD Newsletter (M2) D85, D86 and D87: RE(ACT) Congress report (M16, M30, M54) D5.1 : EJP RD website [2] EJP RD website D5.2 : EJP RD Newsletter [2] EJP RD Newsletter D5.3 : First RE(ACT) Congress report [16] First RE(ACT) Congress report due at M16 D5.4 : Second RE(ACT) Congress report [30] Second RE(ACT) Congress report due at Month 30 D5.5 : Third RE(ACT) Congress report [54] Third RE(ACT) Congress report due at month 54 Page 63 of 161 Associated with document Ref. Ares(2018)6091977 - 28/11/2018 Schedule of relevant Milestones Due Milestone Milestone title Lead beneficiary Date (in Means of verification number18 months) EJP RD social media pack set Relevant social media MS15 1 - INSERM 2 up and running accounts Decision on the organization Minutes of the relevant MS16 of the RE(ACT) 2020 1 - INSERM 4 ExCom conference call congress Decision on the organization Minutes of the relevant MS17 of the RE(ACT) 2022 1 - INSERM 18 ExCom conference call congress Decision on the organization Minutes of the relevant MS18 of the RE(ACT) 2024 1 - INSERM 42 ExCom conference call congress Target countries and List of target countries and MS19 voluntary helpers for 1 - INSERM 2 voluntary helpers translated Newsletter agreed Page 64 of 161 Associated with document Ref. Ares(2018)6091977 - 28/11/2018 Work package number 9 WP6 Lead beneficiary 10 15 - DLR Work package title Joint Transnational Calls for collaborative research projects Start month 1 End month 60 Objectives The funding of transnational collaborative research is critical to enhance the cooperation between scientists working on rare diseases across Europe and beyond, and thus reduce the fragmentation of research in this field. Therefore, the central Pillar 1 activity is providing financial support to third parties. WP1 will foster the implementation of four joint transnational calls for research projects combining national/regional funding and EC co-funding. Transnational calls including basic, translational, clinical, social and health economic research topics will be included in the overall research agenda for the five years of the EJP RD. The first two calls should have broad topics to enable the widest participation of funding organizations. It is expected that at least 60 Mio € will be spent to research projects in the four calls. Specific objectives are: Implementation of four joint transnational calls for research projects combining national/regional funding and EC co- funding which include the tasks: ● Topic selection ● Preparation of the call and establishment of the joint call secretariat ● Evaluation of the joint call and funding decision ● Quality management of call procedures Description of work and role of partners WP6 - Joint Transnational Calls for collaborative research projects [Months: 1-60] DLR, FWF, FNRS, MOSAE, AKA, ANR, FFRD, NKFIH, HRB, IT-MOH, TuscReg, FRRB, MIUR, LMT, FNR, ZonMw, NCBR, FCT, SAS, ISCIII, SRC, VINNOVA, EURORDIS, CSO-MOH, SNSF, TUBITAK, GSRT, DFG The Joint Transnational Calls (JTCs) will be implemented using the “virtual common pot” funding mode. This means that national/regional funding will be made available through national/regional funding organisations according to their own regulations. In addition, in two Joint Transnational Calls the EC will also provide funding that will maximize the number of selected projects that can be funded. Each country/region will fund only their own national/regional component of the transnational research project. Funding from the EC will be distributed through the national/regional funding agencies. The participation in each call will be negotiated between the EJP Pillar 1 funding agency partners on the basis of their possible funding commitments, taking into account the principle of variable geometry (i.e. that each partner decides to join one, several or all planned calls on the basis of their political and financial possibilities and commitments). Moreover, funding bodies (agencies, patient organizations, charities) not belonging to the EJP RD will also have the possibility to support the calls and provide additional funding. The representatives of the participating funding agencies in a joint call will constitute the call steering committee (CSC), which is in charge of deciding on the final topic (based on inputs from Task 2.3) selection and the specific design of the joint call. The CSC will also be the monitoring body for all actions taken by the acting joint call secretariat (JCS). The implementation of transnational research funding will be streamlined according to the lessons learned in the previous E-Rare JTCs and will be built on the established procedures and underlying documents. Due to the yearly overlapping of the joint calls the JCS responsibility will be shared between four partners (DLR-PT, Germany; ANR, France; FFRD, France; ISCIII, Spain) in order to distribute the workload and ensure good practice. Three partners have experience in managing joint transnational calls in several ERA-Nets, including E-Rare, or other transnational initiatives. Most importantly, the incorporation of the joint transnational calls within the broader EJP RD ecosystem provides a unique opportunity for synergies between the individual research projects (Pillar 1) and the supporting resources and tools (Pillars 2-4) since successful research projects will be supported by and will make use of the methodologies, tools and resources made available through Pillars 2-4 (strong recommendations on Data Management Plan, use of Pillar 2 Virtual Platform and links to other relevant activities of the EJP RD will be explicit). Task 6.1 1st co-funded Joint Transnational Call (JTC 2019) (M1-M12) TL: DLR; Participants: all participants in the call Subtask 6.1.1 Topic selection and eligibility criteria (M1) TL: DLR; Participants: all partners joining the call Page 65 of 161 Associated with document Ref. Ares(2018)6091977 - 28/11/2018 As indicated above the topics of co-funded calls will be broad topics to enable the widest participation of funding organizations. The call will focus on implementing IRDiRC objectives. Special consideration will be given to avoid duplication with Horizon 2020 calls in the area of rare diseases. The final formulation of the topics will be undertaken by the CSC pending approval by the EC Project Officer. Subtask 6.1.2 Preparation of the call and establishment of the joint call secretariat (M1-M2) STL: DLR; Participants: all partners joining the call The task leader will be responsible for drafting and finalizing all necessary documents: Memorandum of Understanding, Call text, Governance and evaluation procedures, Guidelines for applicants and Proposal templates. Previous versions of these documents already established within E-Rare-3 ERA-Net and validated by the Commission, will efficiently be used as templates. In addition, the task leader will set up the JCS. The JCS will act as central support to the applicants regarding all aspects of proposal drafting and submission. Finally, each participating funding organization will establish its national contact point. Potential applicants will be strongly encouraged to contact their national representative for advice on national rules and regulations, including eligibility and financial budget regulations. The call for proposals will be published on the EJP RD website and by the national funding organizations via their national publishing routines such as websites, newsletters, press announcements. The publishing instruments of the EC like the Participant Portal and ERA-LEARN will be used as well. If feasible and necessary, a call pre-announcement will be published to maximize the early mobilization of the rare diseases research community. The EC will be duly notified of the call and its content at least 30 days before the expected date of publication. The call will be opened for the submission of proposals for at least 60 days. Subtask 6.1.3 Evaluation of the joint call (M1-M10) STL: DLR; Participants: all partners joining the call The evaluation will be implemented in a two-step procedure according to the Horizon 2020 rules. The eligible applications will first undergo national eligibility check and then be submitted to the transnational peer review Scientific Evaluation Committee (SEC) composed of independent expert scientists chosen for their scientific, technical and/or disease-specific expertise, as well as patient representatives. The Committee will be as far as possible gender and geographically balanced, including experts from countries participating and not participating in the call, experienced (i.e. previous SEC members) as well as new members. Reviewers will be carefully selected with regard to any potential conflict of interest. Each pre-proposal will be reviewed by two SEC members with expertise in line with the proposal. The full proposals will be reviewed by at least five independent experts: two (remote) external specialists of the disease and/or approach and three members of the previously established SEC. In addition, an independent expert will be invited as official observer to the second SEC meeting to assess the conformity of the general implementation of the joint call and specifically the proper implementation of the international peer review and establishment of the ranking list of transnational projects. The evaluation and selection process will ensure that the H2020 framework for ethics is fully applied to the funded projects. The assessment of the observer will be provided in a report to the European Commission. Subtask 6.1.4: Funding decision (M10-M12) STL: DLR; Participants: all partners joining the call The CSC will take its final funding decision based strictly on the scientific recommendation of the SEC (ranking list). As many full proposals as possible with a clear funding recommendation will be funded, taking into account the available budget. Each eligible applicant will be funded by the organization of the country from which the applicants have applied and according to the national administrative regulations (virtual common pot model). The final distribution of the EC contribution will be discussed and agreed by the CSC in order to maximize the number of high quality proposals to be funded by filling funding gaps and/or topping up the national contributions (mixed model). This will be done in accordance to the general criteria fixed in advance to the launch of the call to avoid the underestimation of national budgets and to permit a balanced distribution of the EC contribution in line with the national funding. If proposals have identical scores, the proposals coming from participating Member States or associated countries with still available funding will be given precedence, in order to further maximize the number of selected projects. The joint selection list of projects to be funded will be communicated to the EC. The applicants will be informed about the final funding decision and the national negotiations will commence. The final funding list will be prepared by the JCS and provided to WP5 for publication on the EJP RD website and Newsletter, the relevant EC portals as well as the IRDiRC webpage. Subtask 6.1.5 Quality management of call procedures (M1-M12) STL: DLR; Participants: all partners joining the call The practicability of administrative and operational mechanisms used for implementation of calls, peer review, funding of projects and scientific follow up will be monitored by the JCS with feedback from all participating stakeholders. The lessons learned will feed the call design and implementation of the next joint calls. Thus, the evolution of robust and functional administrative and operational practices will be facilitated and continual process improvement will be implemented. Results of this quality management process will be incorporated in the lessons learned reports for individual calls and presented to the CSC. In addition, detailed statistics and information of the submitted, pre-selected, recommended and funded proposals will be collected and made available on the demand of the European Commission. Page 66 of 161 Associated with document Ref. Ares(2018)6091977 - 28/11/2018 Task 6.2 – 6.4 Joint Transnational Calls 2020-22 TL: DLR In general, the description of work for the other calls is analogous to the first call described above. Lessons learned from the first call and strategic input from the other work packages will be taken into account for all the steps included in these calls. Identification of topics for subsequent calls (2020 – 2022) will be based on the procedure described in the transversal strategy WP and will include multi-stakeholder input from the rare disease community inside and outside the EJP as well as IRDiRC and lessons learned from previous E-Rare calls. Each time the topics and call procedures will be submitted in advance to the EC for validation. Task 6.2 2nd co-funded Joint Transnational Call (JTC 2020) (M4-M24) TL: ANR; Participants: all participants in the call Task 6.3 3rd Joint Transnational Call (JTC 2021) not co-funded by the EC (M16-M36) TL: FFRD; Participants: all partners joining the call Task 6.4 4th Joint Transnational Call (JTC 2022) not co-funded by the EC (M28-M48) TL: ISCIII; Participants: all partners joining the call Participation per Partner Partner number and short name WP6 effort 2 - FWF 3.00 5 - FNRS 3.00 9 - MOSAE 3.00 10 - AKA 3.00 11 - ANR 15.40 12 - FFRD 12.40 15 - DLR 21.40 19 - NKFIH 3.00 20 - HRB 3.00 21 - IT-MOH 3.00 22 - TuscReg 3.00 23 - FRRB 3.00 29 - MIUR 3.00 31 - LMT 3.00 33 - FNR 3.00 34 - ZonMw 3.00 37 - NCBR 3.00 41 - FCT 3.00 43 - SAS 3.00 44 - ISCIII 12.40 48 - SRC 3.00 49 - VINNOVA 3.00 77 - EURORDIS 3.00 78 - CSO-MOH 3.00 79 - SNSF 3.00 Page 67 of 161 Associated with document Ref. Ares(2018)6091977 - 28/11/2018 Partner number and short name WP6 effort 81 - TUBITAK 3.00 87 - GSRT 3.00 88 - DFG 3.00 Total 133.60 List of deliverables Due Deliverable Deliverable Title Lead beneficiary Type15 Dissemination level16 Date (in Number14 months)17 First Confidential Call documents: Confidential, only memorandum of for members of the D6.1 understanding, 15 - DLR Report consortium (including 1 governance of the call the Commission and evaluation document Services) JTC2019-2022 Second Confidential Call documents: Confidential, only memorandum of for members of the D6.2 understanding, 11 - ANR Report consortium (including 11 governance of the call the Commission and evaluation document Services) JTC2019-2022 Third Confidential Call documents: Confidential, only memorandum of for members of the D6.3 understanding, 12 - FFRD Report consortium (including 23 governance of the call the Commission and evaluation document Services) JTC2019-2022 Fourth Confidential Call documents: Confidential, only memorandum of for members of the D6.4 understanding, 44 - ISCIII Report consortium (including 35 governance of the call the Commission and evaluation document Services) JTC2019-2022 First Public Call documents D6.5 JTC2019-2022: call text, 15 - DLR Report Public 1 guidelines for applicants, proposal templates Second Public Call documents D6.6 JTC2019-2022: call text, 11 - ANR Report Public 11 guidelines for applicants, proposal templates Page 68 of 161 Associated with document Ref. Ares(2018)6091977 - 28/11/2018 List of deliverables Due Deliverable Deliverable Title Lead beneficiary Type 15 Dissemination level 16 Date (in Number14 months)17 Third Public Call documents D6.7 JTC2019-2022: call text, 12 - FFRD Report Public 23 guidelines for applicants, proposal templates Fourth Public Call documents D6.8 JTC2019-2022: call text, 44 - ISCIII Report Public 35 guidelines for applicants, proposal templates Confidential, only First Joint selection list for members of the D6.9 of the projects to be 15 - DLR Report consortium (including 10 funded JTC2019-2022 the Commission Services) Confidential, only Second Joint selection for members of the D6.10 list of the projects to be 11 - ANR Report consortium (including 22 funded JTC2019-2022 the Commission Services) Confidential, only Third Joint selection for members of the D6.11 list of the projects to be 12 - FFRD Report consortium (including 24 funded JTC2019-2022 the Commission Services) Confidential, only Fourth Joint selection for members of the D6.12 list of the projects to be 44 - ISCIII Report consortium (including 46 funded JTC2019-2022 the Commission Services) Description of deliverables D88 to D91: Confidential Call documents: memorandum of understanding, governance of the call and evaluation document JTC2019-2022 (M1, M11, M23, M35) D92 to D95: Public Call documents JTC2019-2022: call text, guidelines for applicants, proposal templates (M1, M11, M23, M35) D96 to D99: Joint selection list of the projects to be funded JTC2019-2022 (M10, M22, M24, M46) D6.1 : First Confidential Call documents: memorandum of understanding, governance of the call and evaluation document JTC2019-2022 [1] Other lead beneficiaries: ANR (11), FFRD (12), ISCIII (44) Confidential Call documents: memorandum of understanding, governance of the call and evaluation document JTC2019-2022 due at month 1 D6.2 : Second Confidential Call documents: memorandum of understanding, governance of the call and evaluation document JTC2019-2022 [11] Other lead beneficiaries: ANR (11), FFRD (12) and ISCIII (44) Confidential Call documents: memorandum of understanding, governance of the call and evaluation document JTC2019-2022 due at month 11 D6.3 : Third Confidential Call documents: memorandum of understanding, governance of the call and evaluation document JTC2019-2022 [23] Page 69 of 161 Associated with document Ref. Ares(2018)6091977 - 28/11/2018 Other lead beneficiaries: ANR (11), FFRD (12) and ISCIII (44) Confidential Call documents: memorandum of understanding, governance of the call and evaluation document JTC2019-2022 due at month 23 D6.4 : Fourth Confidential Call documents: memorandum of understanding, governance of the call and evaluation document JTC2019-2022 [35] Other lead beneficiaries: ANR (11), FFRD (12) and ISCIII (44) Confidential Call documents: memorandum of understanding, governance of the call and evaluation document JTC2019-2022 due at month 35 D6.5 : First Public Call documents JTC2019-2022: call text, guidelines for applicants, proposal templates [1] Other lead beneficiaries: ANR (11), FFRD (12) and ISCIII (44) Public Call documents JTC2019-2022: call text, guidelines for applicants, proposal templates due at month 1 D6.6 : Second Public Call documents JTC2019-2022: call text, guidelines for applicants, proposal templates [11] Other lead beneficiaries: ANR (11), FFRD (12) and ISCIII (44) Public Call documents JTC2019-2022: call text, guidelines for applicants, proposal templates due at month 11 D6.7 : Third Public Call documents JTC2019-2022: call text, guidelines for applicants, proposal templates [23] Other lead beneficiaries: ANR (11), FFRD (12) and ISCIII (44) Public Call documents JTC2019-2022: call text, guidelines for applicants, proposal templates due at mont 23 D6.8 : Fourth Public Call documents JTC2019-2022: call text, guidelines for applicants, proposal templates [35] Other lead beneficiaries ANR (11), FFRD (12) and ISCIII (44) Public Call documents JTC2019-2022: call text, guidelines for applicants, proposal templates due at month 35 D6.9 : First Joint selection list of the projects to be funded JTC2019-2022 [10] Other lead beneficiaries: ANR (11), FFRD (12) and ISCIII (44) Joint selection list of the projects to be funded JTC2019-2022 due at month 10 D6.10 : Second Joint selection list of the projects to be funded JTC2019-2022 [22] Other lead beneficiaries: ANR (11), FFRD (12) and ISCIII (44) Joint selection list of the projects to be funded JTC2019-2022 due at month 22 D6.11 : Third Joint selection list of the projects to be funded JTC2019-2022 [24] Other lead beneficiaries: ANR (11), FFRD (12) and ISCIII (44) Joint selection list of the projects to be funded JTC2019-2022 due at month 24 D6.12 : Fourth Joint selection list of the projects to be funded JTC2019-2022 [46] Other lead beneficiaries: ANR (11), FFRD (12) and ISCIII (44) Joint selection list of the projects to be funded JTC2019-2022 due at month 46 Schedule of relevant Milestones Due Milestone Milestone title Lead beneficiary Date (in Means of verification number18 months) Page 70 of 161 Associated with document Ref. Ares(2018)6091977 - 28/11/2018 Work package number 9 WP7 Lead beneficiary 10 34 - ZonMw Work package title Networking to share knowledge on rare diseases Start month 1 End month 60 Objectives The main objective of this work package is to encourage sharing of knowledge on rare diseases of clinicians, (biomedical) scientists and patient (organization[s]) by implementing a Networking support scheme. The scheme will provide financial support to third parties for fostering organization of workshops or conferences to support new research networks or strengthening existing research networks, to enable exchange of knowledge. It is expected that these new or improved networks may lead to future collaborative research efforts, e.g. by applying to research funding within the EJP RD (e.g. Joint Transnational Calls), to COST actions or Marie Skłodowska-Curie Actions (mobility and training calls). A budget of 2 M€ is foreseen to finance about 70 networking grants. Specific objectives are: ● Establishment of the Networking scheme ● Early assessment of the Networking scheme and further improvement Description of work and role of partners WP7 - Networking to share knowledge on rare diseases [Months: 1-60] ZonMw, VIAA, SRC, EURORDIS, CSO-MOH, TUBITAK Task 7.1: Development of the Networking scheme (M1-M7) TL: CSO-MoH, ZonMw, Participants: CIHR, TUBITAK The experience of several countries (e.g. Netherlands or France) shows that networking schemes developed at national scale are of added value and generate positive results . Taking the example of these initiatives, the EJP RD proposes to implement the support for networking at European/international level. Financial support will be provided through competitive calls to foster networking of rare disease stakeholders to (list not exhaustive): • Share existing knowledge on a specific (group of) rare disease(s) or on cohorts of undiagnosed patients that are suspected of suffering from a rare disease/rare diseases; • Improve the knowledge on rare disease(s); • Encourage further innovation and research, e.g. by preparing an application for another networking grant, training grant or research grant in an EC or other international programme; • Share knowledge and best practices on data sharing (Pillar 2) and /or to promote novel/validated methodological approaches for clinical research (including clinical trials) (Pillar 4). It is expected that networks of researchers/clinicians and patient organizations from countries involved in the EJP RD will be eligible to apply. The consortia should include beneficiaries from at least three different eligible countries at the time of application. Additional partners, from countries not involved in the EJP RD, may be also part of the consortium, depending on the scope of the networking event. However, they will not be eligible to directly receive funds. There will be no limitation in the number of participants. Nonetheless, the maximum grant amount will be limited to 30 000 € for each funded networking event. Documents for the application and evaluation procedure will be developed within the first semester of the EJP RD and will be submitted for validation of the EC before opening of the call. The call will be published widely through the same channels as the Joint Transnational Calls (WP6). Task 7.2: Application and evaluation of proposals for the Networking Scheme (M7-M60) TL: ZonMw, Participants: CSO-MOH, EURORDIS, VIAA, SRC, TUBITAK An existing electronic submission system provided by one of the involved participants will be chosen and modified to the needs of the Networking scheme. The application system will be open permanently, but the proposals will be collected every three months for evaluation by a Committee of independent experts issued from funding agencies and EURORDIS. The dates of collection of the proposals for each evaluation session as well as changes will be clearly communicated to interested applicants. Applicants may apply for a budget for a networking event more than once. The principal investigator will receive the funding on behalf of the consortium and will be the responsible person for the internal management of the consortium. The budget has to be spent within a year after receiving the grant. Funded applicants will be bound to communicate the dates and information on the organized event at least two months in advance for the dissemination purposes by the EJP RD (WP5). In addition, the funded applicants will have to deliver Page 71 of 161 Associated with document Ref. Ares(2018)6091977 - 28/11/2018 a final (public) report after the meeting. These reports will be monitored and assessed (Pillar 1 Task WP9.2) and used for dissemination and communication purposes (WP5). The evaluation procedure will respect Horizon 2020 rules and evaluation criteria (excellence, impact & quality and efficiency of implementation). Proposals will be ranked according to the evaluation results. It is expected that about 15 projects will be granted per year. An independent expert will be invited as official observer to the evaluation session after the first subsidy round and after the fifth subsidy round (see Task 7.3) to assess the conformity of the general implementation of the Networking scheme and establishment of the ranking list of transnational networks. The assessments of the observer will be provided in a report to the European Commission. The management of grants will be ensured by ZonMw that will be responsible for collection of the applications at each deadline, supporting the Evaluation Committee and communication with the applicants, including sending the budget for the meetings to the granted applicants. The ZonMw grant terms and conditions will be applied for the management of the grants. Task 7.3 Early assessment of the Networking scheme (M21-M24) TL: CSO-MOH, ZonMw; Participants: CIHR, TUBITAK After four subsidy rounds the Networking scheme will be assessed to analyze whether it meets its objectives. This will be done in collaboration with WP1 Task 1.3 (Monitoring). In addition, “lessons learned” from the quarterly implementation and evaluation process will serve for improvement of next rounds Participation per Partner Partner number and short name WP7 effort 30 - VIAA 1.00 34 - ZonMw 13.20 48 - SRC 1.00 77 - EURORDIS 1.00 78 - CSO-MOH 3.20 81 - TUBITAK 2.00 Total 21.40 List of deliverables Due Deliverable Deliverable Title Lead beneficiary Type 15 Dissemination level 16 Date (in Number14 months)17 Confidential Call Confidential, only document for Evaluation for members of the Committee for D7.1 34 - ZonMw Report consortium (including 7 Networking scheme the Commission including set of criteria Services) for evaluation Public Call document for D7.2 34 - ZonMw Report Public 7 Networking scheme First List of funded D7.3 networks in Networking 34 - ZonMw Report Public 21 scheme Second List of funded D7.4 networks in Networking 34 - ZonMw Report Public 54 scheme Page 72 of 161 Associated with document Ref. Ares(2018)6091977 - 28/11/2018 List of deliverables Due Deliverable Deliverable Title Lead beneficiary Type 15 Dissemination level 16 Date (in Number14 months)17 First Confidential Confidential, only Observers’ report on for members of the D7.5 the evaluation of sets 34 - ZonMw Report consortium (including 12 of applications for the the Commission Networking scheme Services) Second Confidential Confidential, only Observers’ report on for members of the D7.6 the evaluation of sets 34 - ZonMw Report consortium (including 30 of applications for the the Commission Networking scheme Services) Description of deliverables D100: Confidential Call documents for Evaluation Committee for Networking scheme, including set of criteria for evaluation (M7) D101: Public Call document for Networking scheme (M7) D102 and D103: List of funded networks in Networking scheme (M21, M54) D104 and D105: Confidential Observers’ report on the evaluation of sets of applications for the Networking scheme (M12, M30) D7.1 : Confidential Call document for Evaluation Committee for Networking scheme including set of criteria for evaluation [7] Confidential Call document for Evaluation Committee for Networking scheme including set of criteria for evaluation D7.2 : Public Call document for Networking scheme [7] Other lead beneficiary: CSO/MOH (78) Public Call document for Networking scheme D7.3 : First List of funded networks in Networking scheme [21] List of funded networks in Networking scheme due at month 21 D7.4 : Second List of funded networks in Networking scheme [54] List of funded networks in Networking scheme due at month 54 D7.5 : First Confidential Observers’ report on the evaluation of sets of applications for the Networking scheme [12] Confidential Observers’ report on the evaluation of sets of applications for the Networking scheme due at month 12 D7.6 : Second Confidential Observers’ report on the evaluation of sets of applications for the Networking scheme [30] Confidential Observers’ report on the evaluation of sets of applications for the Networking scheme due at month 30 Schedule of relevant Milestones Due Milestone Milestone title Lead beneficiary Date (in Means of verification number18 months) Public Call document on Implementation of MS20 34 - ZonMw 7 website and announcement of Networking scheme the first round Page 73 of 161 Associated with document Ref. Ares(2018)6091977 - 28/11/2018 Work package number 9 WP8 Lead beneficiary 10 12 - FFRD Work package title Rare Disease Research Challenges Start month 1 End month 60 Objectives Main objectives: ● To solve specific Rare Disease Research (RDR) Challenges in the field of therapeutic development. ● To facilitate collaboration between academia and industry. Description of work and role of partners WP8 - Rare Disease Research Challenges [Months: 1-60] FFRD, DLR, ZonMw, EATRIS, EURORDIS Task 8.1: Development of the scheme (M1-M8) TL: EURORDIS; Participants: FFRD, DLR, ZonMw, EATRIS, AFM The RDR Challenges will be created based on the successful examples of other funding opportunities such as the challenge-driven innovation scheme of Vinnova (https://www.vinnova.se/en/m/challenge-driven-innovation/) and UK Crack-IT scheme (https://crackit.org.uk/crack-it-challenges) The goal is to set up an innovative, rapid and efficient call for projects involving both industry and academia and with strong incentive for all participants: facilitated pathway for academics to exploit their research and access to scientific and technological innovations emerging from academic research for industry. The concept of the RDR Challenge will need to be fit for the rare diseases field. This will be addressed in 2 multi-stakeholder workshops gathering experienced/interested funders, experts in public-private partnerships from Pillar 4, industry representatives and independent scientific experts. Industry representatives will be drawn from the EURORDIS Round Table of Companies (ERTC; http://www.eurordis.org/ertc consisting of about 70 private companies), the companies that are members of IRDiRC and/or EFPIA. Special attention will be given to alleviate risks of lengthy negotiations about intellectual property rights, economical use of the results and safeguarding utilization, for example by developing a model cooperation agreement. IP developed within the project will be the property of the contractor (Challenge winner) and its sub-contractors. This WP will be closely connected to the Pillar 4 efforts aiming at public-private collaborations. It is expected that industry will provide input by co-funding and/or in-kind contributions to the projects. Task 8.2: Identification of challenges (M9-M12) TL: FFRD; Participants: EURORDIS, DLR, ZonMw, EATRIS, AFM A multidisciplinary stakeholder committee including industry participants will be established to propose the Challenges solvable in a short time period of 18 months with a possible 12-month extension.The final choice of challenges will be based on predefined criteria e.g. viability, impact and time to impact, commercial potential/potential for uptake of the technology, alignment with external activities, risk of Challenge not being solved, added value for RD community. The Challenges that meet the criteria will be approved by the multidisciplinary stakeholder committee for use in the call. The final chosen challenge(s) will be used to develop call documents. Task 8.3: The call for projects, eligibility criteria and evaluation (M13-M56) TL: FFRD; Participants: EURORDIS, DLR, ZonMw, EATRIS, AFM The opening of the RDR Challenges is foreseen for Year 2. As specified above the scheme will be refined and proposed for validation of the Commission within Annual Work Plan for Y2. However, general principles and eligibility criteria are presented below: The RDR Challenges scheme foresees selection and funding of projects in a 4-stage process: (i) selection of most promising proofs of concept (POCs) responding to the proposed challenge(s); (ii) funding of POCs for maximum of 18 months; (iii) evaluation of results of funded POCs and selection of projects passing to the second stage; (iv) funding of selected projects for additional 12 months to finalize the challenge. All projects should involve the sponsor as co- investor from the start. The expected co-funding from sponsors should be of at least 30%. Financial support to third parties will be provided to academia and SMEs from countries participating in the EJP RD. Since each application will have to involve the sponsor, EJP RD will organize a face-to-face networking meeting for academia, SMEs and industry to initiate formation of future consortia in advance of the opening of the call. The evaluation process will follow Horizon 2020 rules and criteria (Excellence, Impact, Quality and efficiency of implementation). Projects will be assessed by a multidisciplinary Review Panel composed of independent experts. Special attention will be given that the expertise of the review panel matches the challenges that will be addressed. Page 74 of 161 Associated with document Ref. Ares(2018)6091977 - 28/11/2018 The two-stage selection process will be done by the same Review Panel.The projects will be financed based on the established ranking list. Task 8.4: Management of the funding resources, establishment of contracts and distribution of funding to selected projects (M17-M50) TL: FFRD The maximum grant amount for the phase 1 POCs will be of 150 000 € and for the 2nd phase of 100 000 € The administrative and legal action necessary for the distribution of the funding to the successful applicants of the call will be performed by FFRD. The contractual obligations applied will be the ones of Horizon 2020 and will take into account the necessary regulations including the required ethical, legal and data protection approvals. Participation per Partner Partner number and short name WP8 effort 12 - FFRD 16.50 15 - DLR 1.50 34 - ZonMw 1.50 75 - EATRIS 1.50 77 - EURORDIS 4.00 Total 25.00 List of deliverables Due Deliverable Deliverable Title Lead beneficiary Type15 Dissemination level16 Date (in Number14 months)17 Confidential, only for members of the Report on multi- D8.1 77 - EURORDIS Report consortium (including 8 stakeholder workshops the Commission Services) Call documents for D8.2 12 - FFRD Report Public 13 validation List of first phase D8.3 12 - FFRD Report Public 21 projects financed Confidential, only for members of the List of second phase D8.4 12 - FFRD Report consortium (including 43 projects financed the Commission Services) Description of deliverables D106: Report on multi-stakeholder workshops for RDR Challenges (M8) D107: Call documents for RDR Challenge scheme for validation (M13) D108: List of first phase challenge projects financed (M21) D109: List of second phase challenge projects financed (M43) D8.1 : Report on multi-stakeholder workshops [8] Report on multi-stakeholder workshops D8.2 : Call documents for validation [13] Page 75 of 161 Associated with document Ref. Ares(2018)6091977 - 28/11/2018 Call documents for validation D8.3 : List of first phase projects financed [21] List of first phase projects financed D8.4 : List of second phase projects financed [43] List of second phase projects financed Schedule of relevant Milestones Due Milestone Milestone title Lead beneficiary Date (in Means of verification number18 months) Multi-stakeholder workshops Report from RDR Challenges MS21 to set-up RDR Challenges 77 - EURORDIS 8 workshops scheme Page 76 of 161 Associated with document Ref. Ares(2018)6091977 - 28/11/2018 Work package number 9 WP9 Lead beneficiary 10 78 - CSO-MOH Work package title Monitoring of funded projects Start month 1 End month 60 Objectives The proposed subsidy schemes, granted projects and granted networks in Pillar 1 and the previous E-Rare projects have to be monitored for progress and results of Pillar 1 funding schemes. Monitoring of the results of the different granted projects is necessary to measure their outcomes and ensure an adequate use of resources. The results of the monitoring will be communicated to the coordination and communication office for further dissemination in the transversal activities within the EJP and for dissemination outside the EJP. In addition, there will be a close collaboration with Pillar 4 to enhance the translational development of the funded project results from WP1. Description of work and role of partners WP9 - Monitoring of funded projects [Months: 1-60] CSO-MOH, FNRS, FFRD Task 9.1 Monitoring of Joint Transnational Calls for collaborative research projects (M1-M60) TL: CSO-MoH, DLR; Participants: FNRS, FCT, FFRD, ANR, ISCIII, EATRIS, and all partners participating in the monitored calls participate with 100% in kind personnel contribution for this activity) All funded projects of WP6 will be required to complete an on-line questionnaire for monitoring annual progress and a final report at the end of the funding period. The results of the projects follow-up and assessment will be presented to the EJP RD funding partners every year. In addition, the coordinators and/or national/regional group leaders will be asked to present the results of their projects at a mid-term monitoring meeting. In this midterm meeting, experts will be invited to evaluate the progress of the funded projects. Representatives of the funding agencies will participate in the meetings as well. Subtask 9.1.1 Definition/Update of the indicators for ex-post evaluation of funded projects in each call (M1-M60) STL: CSO-MoH, Participants: FNRS; DLR, FCT, FFRD, ANR, ISCIII, EATRIS, and all partners participating in the monitored calls participate with 100% in kind personnel contribution for this activity Within the frame of E-Rare-3 a list of indicators was developed and applied to design the template for periodic and final reports of funded projects. This set indicators will serve to establish and refine indicators for the EJP funded projects and will need to be adapted to the specificities of the different call topics. The selected indicators will be embedded in the design of the online reporting forms to be used in the follow-up and monitoring activities. Some examples include: number of project-related publications, patents, new employees, established collaborations, etc. Subtask 9.1.2 Adaptation of the monitoring tool for follow-up and assessment of funded projects (M1-M60) STL: FNRS The aim of this task is to adapt the online tool for reporting, monitoring, and assessment of all funded projects that was developed in E-Rare-3. It will enable an easy collection and management of the reports of funded projects. Subtask 9.1.3 Follow-up, monitoring and assessment of funded projects in WP6, including organization of mid-term monitoring meetings for each Call (M1-M60) STL: CSO-MoH, Participants: FCT, DLR, ANR, FFRD, ISCIII and all partners participating in the monitored calls participate with 100% in kind personnel contribution for this activity This task aims at both evaluating the progress and assessing the outputs of granted projects. It will be carried out in close collaboration with the co-funded call secretariats (WP6). The funded projects will be followed up and monitored through brief online annual progress reports and a final report at the end of the funding period. The results of the WP6 projects follow up and assessment will be analyzed by the STL and the summary of this analysis will be presented to the WP6 partners every year. These results will also be available for analysis in the P4 innovation support activities. Relevant outputs (e.g. publications, patents etc.) will be communicated through the central dissemination activities. In addition, mid-term monitoring meetings will be set up for each call. Subtask 9.1.4 Assessment of E-Rare 3 Joint Call Funding programme (M1-M48) STL: CSO-MoH, Participants: FCT, ANR, ISCIII, ZonMw and all partners participating in the monitored calls participate with 100% in kind personnel contribution for this activity Analogous to subtask 9.1.3, the monitoring of projects funded in the E-Rare calls of 2017 and 2018 will be continued and completed in this task. Task 9.2 Monitoring of networking grants to share knowledge on rare diseases (M1-M60) TL: CSO-MoH, ZonMw; Participants: FNRS, SRC, TUBITAK, VIAA, EURORDIS. Page 77 of 161 Associated with document Ref. Ares(2018)6091977 - 28/11/2018 The granted applicants of all funded networking grants in P1WP7 will have to complete a short, standardized report after the meeting has taken place. These reports will be monitored and also used for dissemination purposes (WP5 - Communication and Dissemination). The report format will be customized using indicators (developed in Subtask 9.2.1) and a specific on-line reporting form on an existing monitoring tool (adapted in subtask 9.2.2). The monitoring team (consisting of the Task 9.2 leaders) will contact the granted applicant directly for information delivery and reporting requests. Subtask 9.2.1 Definition of indicators for ex-post evaluation of funded networking events (M1-M7) STL: CSO-MoH, ZonMw; Participants: FNR,. SRC, TUBITAK, VIAA, EURORDIS The monitoring team will define indicators for the ex-post evaluation of funded networking grants with help of the Evaluation Committee that evaluates the applications of the networking scheme (Task 7.2). Subtask 9.2.2 Adaptation of monitoring tool for follow-up and assessment of funded networking events (M1-M7) STL: FNRS For each call, a reporting template will be developed to be implemented within online existing monitoring tool. These templates will facilitate the collection of the reports of the funded projects, their analysis and subsequent reporting. Subtask 9.2.3 Assessment of the funded networking events (M13-M60) STL: CSO-MoH, ZonMw Follow-up, analysis and assessments of results of the networking grants and communication of the results to the EJP RD management for dissemination. This monitoring of the results of the networking grants will regularly take place: a report on the assessment of the first set of funded meetings will be written after four subsidy rounds for the early assessment of the networking scheme (Task 7.3). Subsequently, two midterm monitoring reports will be written on the assessment of the results of the second and third set of funded meetings and a final monitoring report. Task 9.3. Monitoring of Rare Disease Research Challenge (M17-M56) TL: CSO-MoH, FFRD; Participants: FNRS, EURORDIS, DLR, ZonMw, EATRIS, AFM participate with 100% in kind personnel contribution for this activity The granted applicants of the Rare Disease Challenges in WP8 will have to complete a report after finalizing the two stages of the project. The report format will be customized using relevant indicators (to be established). In addition, the achievement of defined milestones will be closely monitored. The monitoring team will contact directly the granted applicants for information delivery and reporting request. The reports will be used to facilitate the uptake, implementation or further development of the solutions by industry or other stakeholders. Participation per Partner Partner number and short name WP9 effort 5 - FNRS 4.00 12 - FFRD 1.00 78 - CSO-MOH 20.00 Total 25.00 List of deliverables Due Deliverable Deliverable Title Lead beneficiary Type 15 Dissemination level 16 Date (in Number14 months)17 Confidential, only Refined list of indicators for members of the D9.1 for monitoring of JTC 78 - CSO-MOH Report consortium (including 5 funded project the Commission Services) Confidential, only First Year report on D9.2 78 - CSO-MOH Report for members of the 28 progress assessment of consortium (including Page 78 of 161 Associated with document Ref. Ares(2018)6091977 - 28/11/2018 List of deliverables Due Deliverable Deliverable Title Lead beneficiary Type 15 Dissemination level 16 Date (in Number14 months)17 JTC 2019, 2020 and 2021 the Commission projects Services) Confidential, only Second Yearly reports on for members of the progress assessment of D9.3 78 - CSO-MOH Report consortium (including 40 JTC 2019, 2020 and 2021 the Commission projects Services) Confidential, only Third Yearly reports on for members of the progress assessment of D9.4 78 - CSO-MOH Report consortium (including 52 JTC 2019, 2020 and 2021 the Commission projects Services) First Final assessment Confidential, only report of E-Rare-3 for members of the JTC 2016, JTC 2017, D9.5 78 - CSO-MOH Report consortium (including 35 JTC 2018 projects and the Commission the EJP RD JTC 2019 Services) projects Second Final assessment Confidential, only report of E-Rare-3 for members of the JTC 2016, JTC 2017, D9.6 78 - CSO-MOH Report consortium (including 47 JTC 2018 projects and the Commission the EJP RD JTC 2019 Services) projects Third Final assessment Confidential, only report of E-Rare-3 for members of the JTC 2016, JTC 2017, D9.7 78 - CSO-MOH Report consortium (including 59 JTC 2018 projects and the Commission the EJP RD JTC 2019 Services) projects Confidential, only List of indicators for members of the D9.8 for monitoring of 78 - CSO-MOH Report consortium (including 7 Networking grants the Commission Services) First Report on the assessment of results of Confidential, only a 1st, 2nd and 3rd set for members of the D9.9 of funded Networking 78 - CSO-MOH Report consortium (including 24 events and a final general the Commission report on all funded Services) Networking events Second Report on the Confidential, only assessment of results of for members of the D9.10 a 1st, 2nd and 3rd set 78 - CSO-MOH Report consortium (including 39 of funded Networking the Commission events and a final general Services) Page 79 of 161 Associated with document Ref. Ares(2018)6091977 - 28/11/2018 List of deliverables Due Deliverable Deliverable Title Lead beneficiary Type 15 Dissemination level 16 Date (in Number14 months)17 report on all funded Networking events Third Report on the assessment of results of Confidential, only a 1st, 2nd and 3rd set for members of the D9.11 of funded Networking 78 - CSO-MOH Report consortium (including 59 events and a final general the Commission report on all funded Services) Networking events Confidential, only for members of the List of indicators for RD D9.12 78 - CSO-MOH Report consortium (including 21 funded challenges the Commission Services) Confidential, only Report on the assessment for members of the D9.13 of 1st phase results of the 78 - CSO-MOH Report consortium (including 39 challenges the Commission Services) Confidential, only Report on the assessment for members of the D9.14 of 2nd phase results of 78 - CSO-MOH Report consortium (including 54 the challenges the Commission Services) Description of deliverables D110: Refined list of indicators for monitoring of JTC funded project (M5) D111 to D113: Yearly reports on progress assessment of JTC 2019, 2020 and 2021 projects (M28, M40, M52) D114 to D116: Final assessment report of E-Rare-3 JTC 2016, JTC 2017, JTC 2018 projects and the EJP RD JTC 2019 projects (M35, M47, M59) D117: List of indicators for monitoring of Networking grants (M7) D118 to D120: Reports on the assessment of results of a 1st, 2nd and 3rd set of funded Networking events and a final general report on all funded Networking events (M24, M39, M59) D121: List of indicators for RD funded Challenges (M21) D122: Report on the assessment of 1st phase results of the RD challenges (M39) D123: Report on the assessment of 2nd phase results of the RD challenges (M54) D9.1 : Refined list of indicators for monitoring of JTC funded project [5] Refined list of indicators for monitoring of JTC funded project D9.2 : First Year report on progress assessment of JTC 2019, 2020 and 2021 projects [28] Yearly reports on progress assessment of JTC 2019, 2020 and 2021 projects due at month 28 D9.3 : Second Yearly reports on progress assessment of JTC 2019, 2020 and 2021 projects [40] Yearly reports on progress assessment of JTC 2019, 2020 and 2021 projects due at month 40 D9.4 : Third Yearly reports on progress assessment of JTC 2019, 2020 and 2021 projects [52] Yearly reports on progress assessment of JTC 2019, 2020 and 2021 projects due at month 52 D9.5 : First Final assessment report of E-Rare-3 JTC 2016, JTC 2017, JTC 2018 projects and the EJP RD JTC 2019 projects [35] Page 80 of 161 Associated with document Ref. Ares(2018)6091977 - 28/11/2018 First Final assessment report of E-Rare-3 JTC 2016, JTC 2017, JTC 2018 projects and the EJP RD JTC 2019 projects due at month 35 D9.6 : Second Final assessment report of E-Rare-3 JTC 2016, JTC 2017, JTC 2018 projects and the EJP RD JTC 2019 projects [47] Second Final assessment report of E-Rare-3 JTC 2016, JTC 2017, JTC 2018 projects and the EJP RD JTC 2019 projects due at month 47 D9.7 : Third Final assessment report of E-Rare-3 JTC 2016, JTC 2017, JTC 2018 projects and the EJP RD JTC 2019 projects [59] Final assessment report of E-Rare-3 JTC 2016, JTC 2017, JTC 2018 projects and the EJP RD JTC 2019 projects at month 59 D9.8 : List of indicators for monitoring of Networking grants [7] Other lead beneficiary: ZonMW (34) List of indicators for monitoring of Networking grants D9.9 : First Report on the assessment of results of a 1st, 2nd and 3rd set of funded Networking events and a final general report on all funded Networking events [24] Other lead beneficiary: ZonMW (34) Reports on the assessment of results of a 1st, 2nd and 3rd set of funded Networking events and a final general report on all funded Networking events due at month 24 D9.10 : Second Report on the assessment of results of a 1st, 2nd and 3rd set of funded Networking events and a final general report on all funded Networking events [39] Other lead beneficiary: ZonMW (34) Second Report on the assessment of results of a 1st, 2nd and 3rd set of funded Networking events and a final general report on all funded Networking events due at month 39 D9.11 : Third Report on the assessment of results of a 1st, 2nd and 3rd set of funded Networking events and a final general report on all funded Networking events [59] Other lead beneficiary: ZonMW (34) Third Report on the assessment of results of a 1st, 2nd and 3rd set of funded Networking events and a final general report on all funded Networking events due at month 59 D9.12 : List of indicators for RD funded challenges [21] List of indicators for RD funded challenges D9.13 : Report on the assessment of 1st phase results of the challenges [39] Other lead beneficiary FFRD (12) Report on the assessment of 1st phase results of the challenges D9.14 : Report on the assessment of 2nd phase results of the challenges [54] Other lead beneficiary: FFRD (12) Report on the assessment of 2nd phase results of the challenges Schedule of relevant Milestones Due Milestone Milestone title Lead beneficiary Date (in Means of verification number18 months) Adapted monitoring tool Link to monitoring tool MS22 implemented for collaborative 5 - FNRS 9 released to granted applicants research projects Adapted monitoring tool Link to monitoring tool MS23 implemented for Networking 5 - FNRS 9 released to granted applicants grants Final reports of Rare disease MS24 challenge projects delivered 78 - CSO-MOH 54 Final reports to monitoring tool Page 81 of 161 Associated with document Ref. Ares(2018)6091977 - 28/11/2018 Work package number 9 WP10 Lead beneficiary 10 1 - INSERM Work package title User-driven strategic planning and transversal activities for Pillar 2 data ecosystem Start month 1 End month 60 Objectives The overall objective of this WP is to provide a unifying coordination effort that places users, not least ERNs, in a central strategic position in Pillar 2. Research Infrastructures (RIs) will be key in addressing quality and sustainability/upscaling challenges. WP10 will have special importance in optimising the activities and the quality of work conducted by WP11 (about metadata and centralised data resources), WP12 (about record level and federated solutions), and WP13 (about filling gaps in data and analysis methods regarding heterogeneous RD data). This WP will thus help Pillar 2 to build and iteratively test the desired Virtual Platform (VP) for efficient deposition, discoverability, access, and advanced use of RD data, samples, patients, tools and resources. EJP RD will thereby progressively reduce fragmentation of effort, accelerate scientific progress, shorten the diagnostic odyssey, and expand treatment possibilities. Specific objectives include: ● Continuously track the utility of Pillar 2 outputs compared to RD community needs ● Iteratively refine a strategic plan guiding Pillar 2 activities to meet real-world needs ● Establish and apply quality management and GDPR compliance by design for WP11/12/13 operations ● Evaluate models to sustain and scale-up the use of the virtual platform and FAIRification support services Description of work and role of partners WP10 - User-driven strategic planning and transversal activities for Pillar 2 data ecosystem [Months: 1-60] INSERM, FTELE, ISS, UM, INSA, CNAG-CRG, ULEIC, UKL-HD, LUMC, BBMRI, EMBL WP Methodology WP10 will base its work on methodologies that consult and empower the relevant RD communities, in particular ERNs. Actions will be ongoing, but based around annual cycles of tracking progress and needs in parallel (via TCs, surveys, interviews, virtual platform impact and quality assessments, etc), with a final bringing together of all these aspects in an large community retreat, to produce guidance on prioritizations and adjustments for the following year. Annual retreats will also entail field-testing of developed systems, by working on specific use-cases proposed by ERNs and by Pillar 4 partners. Hence listening, distilling and strategic planning are core elements of this WP. Task 10.1: Convene yearly retreats leading to Pillar 2 annual strategic plans (M1-M60) TL:INSERM (Orph) [STLs: ISS, INSERM (Orph), ULEIC] Other: [contribute to annual retreat, design and draft annual strategic plan] All ERNs, CNAG-CRG, LUMC, UM, UKL-HD This Task will ensure that the direction of developments in WP11 and WP12 are iteratively adjusted to meet the needs of the RD community. Additionally, and critically, in the first two years of the project, the goal will also be to identify and ensure prioritisation of work towards proof of principle demonstrators to validate the core functionalities that Pillar 2 seeks to create, and to prioritize proof-of-concept studies to be performed in WP13 allowing for integrative systems biology approaches for rare diseases. Based on the lessons learned during the continuous monitoring of pillar 2 WPs, and on the feedback from the community provided in Task 10.2, as well as on the needs and expectations of the ERNs community, back-and-forth discussions will be organized between the users and builders of Pillar 2, so that gaps, risks and opportunities can be agreed and specific actions triggered. This will occur via a transparent and inclusive process, with ERNs in the driving seat for making these decisions (as main users of the data and resource ecosystem created in Pillar 2). The mechanism will involve two activities, both occurring once per year: Subtask 10.1.1 (“Whole-RD-community annual retreat”) will take place over approximately 3 days each May, involve 24 ERNs plus Pillar 2 WPs contributors and Pillar 4 representatives, and be open to others who wish to attend (space allowing); and Subtask 10.1.2 (“Annual strategic plan for Pillar 2”) whereby a multi-stakeholder strategy board will refine the Pillar 2 workplan, guided by recommendations from the annual retreat, as well on the analysis of the state of the art of resources that already exist, to be put into action by WP leaders. The updated Pillar 2 workplan will itself contribute to the EJP RD Annual workplan (Coordination WP2). In addition, annual retreats will include field-testing exercises, by organizing use case based, end-users live tests of the virtual platform functionalities in order to adjust developments and to monitor usefulness. Task 10.2: Coordinating Pillar 2 Work Packages outputs and aligning to RD community needs (M1-M60) TL: ULEIC [STL: FTELE, CNAG-CRG] Other: [conduct surveys/interviews, contribute to TCs and surveys/interviews] All ERNs, INSERM (Orph), LUMC, UM, INSA, UKL-HD Page 82 of 161 Associated with document Ref. Ares(2018)6091977 - 28/11/2018 This Task will gather and summarize the information needed to simultaneously assess Pillar 2 WPs outputs against RD community needs. Specifically, we will undertake Subtask 10.2.1 (”Bi-monthly TCs and reports with WPs leaders”), leading to regular progress reports that are properly documented and made promptly available to the EJP consortium. In parallel, to expose and track the evolving needs of the RD community, we will undertake Subtask 10.2.2 (”Community surveys and structured interviews”) on a continual basis throughout the project, focused on technical, scientific and strategic requirements and how the outputs of Pillar 2 are or are not serving the community. ERNs will be centrally involved in advising, designing and responding to these activities, as well as Pillar 4 partners, in order to ensure Pillar 2 activities are optimised to enable innovation. Task 10.3: Coordination of technical GDPR implementation (M1-M60) TL: BBMRI, ELIXI;, Other: [explore and advise re GDPR] INSERM (RaDiCo), CNAG-CRG, LUMC, ULEIC In collaboration with all the Pillar 2 contributors and according to the EJP policy established in Transversal WP4, this task will identify and document personal data processing, including legal basis and technical and organizational safeguards implemented. Methodology will be developed for risk assessment, including assistance with DPIA to the extent needed. The task will provide technical guidance to WP11, WP12 and WP13 to ensure consistent implementation of security and privacy by design in the software and services delivered by Pillar 2. Task 10.4: Quality oversight (M1-M60) TL: BBMRI, ELIXIR; Other: [establish & deploy formalised quality policy] All ERNs, INSERM (RaDiCo), INSERM (Orph), CNAG-CRG, LUMC, ULEIC This task will analyze processes and services delivered within Pillar 2 and propose a quality management system (QMS) to assist with complying with user requirements and to ensure quality of services delivered. Specific aspects include documenting user requirements, software design and development (including software development best practice ), operation of services. The FitSM lightweight IT service management standard will be assessed for this purpose, as it has been already used in EOSCpilot and EOSC-hub projects. The QMS will define performance indicators and monitor them in regular improvement cycles. The code developed within the project will undergo peer review in order to provide feedback to developers. Task 10.5: Sustainability and scaling up (M1-M60) TL: DTL-Projects (ELIXIR-NL), Other: [design sustainability options] ELIXIR, FTELE, INSERM (RaDiCo), INSERM (Orph), BBMRI, CNAG-CRG, LUMC, ISS, ULEIC This task will investigate financing models to sustain and scale up the development and use of the virtual platform (VP) and its support services, in close collaboration with sustainability experts in the EJP RD transversal WP3, the RIs, the European Open Science Cloud project (EOSC), experts associated with RDA, and the international GO FAIR offices (currently in the Netherlands, Germany, and France, with an RD implementation network starting in 2018). This task will explore needs, opportunities and methods for sustaining and scaling up each VP component and service judged to be useful by the EJP RD community, and map this to a financing model matrix developed by Transversal WP3. By eliciting real costs of the VP activities, selected models will be simulated and evaluated with sustainability experts, potential payers (e.g. funders, ERN HCPs, patient organizations), and suppliers (e.g. SMEs). Participation per Partner Partner number and short name WP10 effort 1 - INSERM 13.40 25 - FTELE 25.10 26 - ISS 6.00 36 - UM 1.10 42 - INSA 1.10 45 - CNAG-CRG 5.70 50 - ULEIC 13.50 57 - UKL-HD 0.50 64 - LUMC 5.20 73 - BBMRI 23.10 Page 83 of 161 Associated with document Ref. Ares(2018)6091977 - 28/11/2018 Partner number and short name WP10 effort 76 - EMBL 0.00 DTL-Projects 23.90 Total 118.60 List of deliverables Due Deliverable Deliverable Title Lead beneficiary Type15 Dissemination level16 Date (in Number14 months)17 First Annual strategic report and Action plan for Pillar 2, including: Systematic surveys D10.1 reports, QMS of Pillar 1 - INSERM Report Public 9 2 description, GDPR compliance report and sustainability planning reporting Second Annual strategic report and Action plan for Pillar 2, including: Systematic surveys D10.2 reports, QMS of Pillar 1 - INSERM Report Public 21 2 description, GDPR compliance report and sustainability planning reporting Third Annual strategic report and Action plan for Pillar 2, including: Systematic surveys D10.3 reports, QMS of Pillar 1 - INSERM Report Public 33 2 description, GDPR compliance report and sustainability planning reporting Fourth Annual strategic report and Action plan for Pillar 2, including: Systematic surveys D10.4 reports, QMS of Pillar 1 - INSERM Report Public 45 2 description, GDPR compliance report and sustainability planning reporting Report on the State of the D10.5 1 - INSERM Report Public 9 Art of existing resources Description of deliverables Page 84 of 161 Associated with document Ref. Ares(2018)6091977 - 28/11/2018 D124 to D127: Annual strategic report and Action plan for Pillar 2, including: Systematic surveys reports, QMS of Pillar 2 description, GDPR compliance report and sustainability planning reporting (M9, updates M21,M33, 45) D10.1 : First Annual strategic report and Action plan for Pillar 2, including: Systematic surveys reports, QMS of Pillar 2 description, GDPR compliance report and sustainability planning reporting [9] Annual strategic report and Action plan for Pillar 2, including: Systematic surveys reports, QMS of Pillar 2 description, GDPR compliance report and sustainability planning reporting due at M9 D10.2 : Second Annual strategic report and Action plan for Pillar 2, including: Systematic surveys reports, QMS of Pillar 2 description, GDPR compliance report and sustainability planning reporting [21] Annual strategic report and Action plan for Pillar 2, including: Systematic surveys reports, QMS of Pillar 2 description, GDPR compliance report and sustainability planning reporting update at month 21 D10.3 : Third Annual strategic report and Action plan for Pillar 2, including: Systematic surveys reports, QMS of Pillar 2 description, GDPR compliance report and sustainability planning reporting [33] Annual strategic report and Action plan for Pillar 2, including: Systematic surveys reports, QMS of Pillar 2 description, GDPR compliance report and sustainability planning reporting update at month 33 D10.4 : Fourth Annual strategic report and Action plan for Pillar 2, including: Systematic surveys reports, QMS of Pillar 2 description, GDPR compliance report and sustainability planning reporting [45] Annual strategic report and Action plan for Pillar 2, including: Systematic surveys reports, QMS of Pillar 2 description, GDPR compliance report and sustainability planning reporting update at month 45 D10.5 : Report on the State of the Art of existing resources [9] Report on the State of the Art of existing resources Schedule of relevant Milestones Due Milestone Milestone title Lead beneficiary Date (in Means of verification number18 months) Annual meeting involving all ERNs, Pillar 2 WPs co- leaders, WP10 partners 1st Annual retreat of Pillar 2 MS25 1 - INSERM 6 and Pillar 4 representative completed organized and achieved, including background documents Annual meeting involving all ERNs, Pillar 2 WPs co- leaders, WP10 partners 2nd Annual retreat of Pillar 2 MS26 1 - INSERM 18 and Pillar 4 representative completed organized and achieved, including background documents Annual meeting involving all ERNs, Pillar 2 WPs co- leaders, WP10 partners 3rd Annual retreat of Pillar 2 MS27 1 - INSERM 30 and Pillar 4 representative completed organized and achieved, including background documents Annual meeting involving 4th Annual retreat of Pillar 2 all ERNs, Pillar 2 WPs co- MS28 1 - INSERM 42 completed leaders, WP10 partners and Pillar 4 representative Page 85 of 161 Associated with document Ref. Ares(2018)6091977 - 28/11/2018 Schedule of relevant Milestones Due Milestone Milestone title Lead beneficiary Date (in Means of verification number18 months) organized and achieved, including background documents Annual meeting involving all ERNs, Pillar 2 WPs co- leaders, WP10 partners 5th Annual retreat of Pillar 2 MS29 1 - INSERM 54 and Pillar 4 representative completed organized and achieved, including background documents Pillar 2 WP10: Online MS30 1st End-users surveys done 50 - ULEIC 5 surveys developed, sent and results analyzed. Pillar 2 WP10 : Online MS31 2nd End-users surveys done 50 - ULEIC 17 surveys developed, sent and results analyzed. Pillar 2 WP10 : Online MS32 3rd End-users surveys done 50 - ULEIC 29 surveys developed, sent and results analyzed. Pillar 2 WP10: Online MS33 4th End-users surveys done 50 - ULEIC 41 surveys developed, sent and results analyzed. Pillar 2 WP10: Online MS34 5th End-users surveys done 50 - ULEIC 53 surveys developed, sent and results analyzed. Financing models for Matrix and support document sustaining and scaling listing the appropriateness up FAIRification support of financing models for MS35 65 - Radboudumc 18 services assessed with sustaining and scaling up sustainability experts and RD virtual platform components community stakeholders and support services Simulations of financing models for sustaining and scaling up FAIRification Results of the simulations MS36 support services executed and 65 - Radboudumc 48 of financing models for evaluated with sustainability FAIRification services listed experts and RD community stakeholders Page 86 of 161 Associated with document Ref. Ares(2018)6091977 - 28/11/2018 Work package number 9 WP11 Lead beneficiary 10 1 - INSERM Work package title Common virtual platform for discoverable data and resources for RD research Start month 1 End month 60 Objectives The overall objectives of this WP are i) to build a comprehensive, FAIR-compliant virtual platform describing resources (including registries, biobanks, research infrastructures, genome-phenome repositories, methods, standards, etc) allowing for these resources to be findable online via a central access point and ii) to provide researchers the means to deposit, share and analyse phenotypic, genomic and multi-omics data building on and scaling up existing resources. The specific objectives of this WP are: ● To produce an ontological model to represent fine-grained metadata describing existing and future resources relevant for RD research. ● To build a comprehensive suite of catalogs based on this ontological model to allow queries through a central facility. ● To facilitate data generated from RD research to be deposited in existing repositories by improving their capacity, interoperability, privacy protection, and security compliance. ● To facilitate user access to resources by adopting a common Authentication and Authorization Interface (AAI) ● To improve and scale up genomic, phenomic and multi-omics analysis, integration and sharing capabilities Description of work and role of partners WP11 - Common virtual platform for discoverable data and resources for RD research [Months: 1-60] INSERM, AIT, LBG (LBI-RUD), CHARITE, UKL-FR, FTELE, ISS, VUHSK, UMCG, UM, IPCZD, ISCIII, CNAG-CRG, UPM, CIBER, ULEIC, CCRI, UKL-HD, GUF, HSK, LUMC, Radboudumc, AMC, INFRAFRONTIER, BBMRI, EMBL, ACURARE Other lead beneficiary: CNAG (45) Methodology WP11 will build on and scale up existing catalogs (Orphanet, BBMRI, RD-Connect Biobank and Registry Finder, JRC’s ERDRI and ELIXIR bio.tools) to develop a comprehensive suite of catalogs using standardized metadata and utilizing existing recommended ontologies (i.e. Orphanet rare disease ontology (ORDO), Human Phenotype Ontology (HPO). It will allow registries, biobanks, data repositories, and other resources and tools to be findable by queries in terms of disease, genes, phenotypes, sample types, and other data element types. Queries may expand to federated queries at data record-level through the FAIRIfication process of WP12. This centralized metadata system will be FAIR compliant. Furthermore, WP11 will improve, adapt, scale up and document existing RD data deposition and analysis resources (such as the RD-Connect GPAP and Sample Catalogue, DECIPHER, INFRAFRONTIER, hPSCreg, Cellosaurus, EGA, Metabolights or Pride), and make them findable through the EJP virtual platform, to serve researchers’ deposition and analysis needs (i.e. for the projects funded in Pillar 1, Solve-RD and others). Access will be simplified by adopting a common Authentication and Authorization Infrastructure (AAI), and a system to link anonymised data from the same patient in different projects will be deployed via Privacy Preserving Record Linkage (PPRL). Functionality of resources will be expanded by improving their usability. Additional experimental data issued from WP4 will be included. Task 11.1: Metadata and ontological model definition for cataloging resources for RD research (M1-M60) TL: EMBL-EBI, GUF [STL: SIB (ELIXIR-CH), GUF, AMC] Other: [metadata definition and modelisation] JRC, INSERM(Orph), BBMRI, UMCG, UPM, LUMC, ULEIC, Charité, ACU/ACURARE, UM, ISCIII, CIBER Subtask 11.1.1: A set of metadata will be defined to describe each RD resource to be included in the virtual platform following prioritization provided by WP10. This set of metadata will be based on, and expand, metadata already developed by Orphanet, BBMR-ERIC (for biobanks), RD-Connect (for registries and biobanks), and JRC’s ERDRI (European Rare Disease Registry Infrastructure, including the registries Central Metadata Repository and the European Directory of Registries). Schemas such as MIABIS (biobanks), and Bioschema.org, and standard ontologies (Orphanet Rare Disease Ontology ORDO, Human Phenotype Ontology HPO, OBIB) and standard nomenclatures (HGNC, Uniprot/neXtProt, Cellosaurus etc) will be used to improve interoperability. This will provide a unified way to describe a range of includable resources in the centralized suite of catalogs built in Task 11.2. Accessibility metadata will be included based on ADA-M tool as well as provenance information about the metadata itself. These metadata will serve as a starting point for metadata description at record level in WP12. Metadata will be organized as application ontology integrated with other standard ontologies (Subtask 11.1.2). Resources to be included will be prioritized following WP10 Page 87 of 161 Associated with document Ref. Ares(2018)6091977 - 28/11/2018 strategic decisions, and the model will be updated and extended every year in order to include new resources (subtask 11.1.3). Prioritized resources will be financially supported to provide their metadata. Task 11.2: FAIR-compliant virtual platform for discovery of RD resources (M1-M60) TL: INSERM(Orph) [STL: INSERM(Orph), UMCG, DTU (ELIXIR-DK), BSC (ELIXIR-ES), GUF] Other: [integration and extension of catalogs and development of central query point] JRC, BBMRI, CNAG-CRG, UPM, LUMC, UM, CIBER, VUHSK, IPCZD (CMHI), ULEIC A database of RD-specific expert resources is already maintained by Orphanet by the collection, manual curation and quality control of expert centres (including ERNs), diagnostic tests, patient organizations, infrastructures, registries and databases and RD research projects and clinical trials and orphan drugs in 35 countries. These are described with a set of metadata and organized around the elements of ORDO, which allows these resources to be findable by disease and by gene. Task 11.2 aims at building a virtual platform using and expanding this catalog based on the metadata model developed in Task 11.1, integrating it with catalogs already developed by BBMRI-ERIC and RD-Connect for biobanks and registries (using MOLGENIS) and JRC’s ERDRI (for registries), and ensuring manual curation, quality and updates (subtask 11.2.1). In order to provide analytical data to inform the research strategic agenda elaborated by Transversal WP2, an international RD specific database of research projects, clinical trials and developing therapies will be enriched by national data and by IRDiRC members (subtask 11.2.2). To make relevant RD analysis tools and methods discoverable, the ELIXIR's bio.tools catalogue will continue its adaptation for the RD community initiated in EXCELERATE (subtask 11.2.3). The virtual platform built in Task 11.2 will be optimized to allow queries using the underlying ontological model. Query facilities will provided online and to the EJP-RD helpdesk (Subtask 11.2.4). Task 11.3: Data deposition and access to data infrastructures for RD research (M1-M60) TL: EMBL-EBI [STL: CSC (ELIXIR-FI), MU-CERIT-SC (ELIXIR-CZ), ELIXIR, BSC (ELIXIR-ES), UU (ELIXIR-SE), INSERM (RaDiCo), AIT] Other: [develop and document secure linked data deposition and access capabilities] INFRAFRONTIER, UKL-HD (ERKnet), APHP (PaedCan), LUMC(Endo-ERN), GUF(ERN-Lung), HSK (MetabERN), FTELE, UMCG, BBMRI, CNAG-CRG, GUF, Charité, INSERM (AMU), ISCIII, ISS, UKLFR, CIBER, ULEIC, WTSI (Associated partner) Task 11.3 aims to serve the needs for depositing, integrating and storing quality controlled (meta)data produced by the EJP and the overall RD community building on existing resources including registries (JRC-ERDRI, RD- Connect Registry and Biobank Finder, known also as IDcards), patient cohorts (RadiCo, BBMRI-ERIC Directory), biobanks (RD-Connect Sample Catalogue, RD-Connect Registry and Biobank Finder, BBMRI-ERIC Directory), cell lines (hPSCreg, Cellosaurus), mouse models (INFRAFRONTIER), raw omics data (EGA, Pride, MetaboLights) and genome-phenome platforms (DECIPHER, RD-Connect GPAP). Subtask 11.3.1 will support resources by improving and/or expanding their deposition and access mechanisms (Application Programming Interfaces, APIs, and Graphical User Interfaces, GUIs) and deploying mechanisms to ensure quality of datasets, evaluating GDPR compliance and implementing transparency measures and means to monitor data re-usability following Pillar 2 Task 10.3 guidance. BBMRI-ERIC Negotiator, used for implementing access pipeline for biobanks and registries will be extended to support resources integrated in WP12. The LifeScience AAI (converging from ELIXIR and BBMRI-ERIC Authorization and Authentication Infrastructure), enabling users to access several resources using the same credential while controlling access permissions, will be implemented (subtask 11.3.2). To overcome issues associated with patient identification and duplication, subtask 11.3.3. will deploy a GDPR compliant PPRL (Privacy Preserving Record Linkage) solution based on EUPID, aligned with the proposals from the joint GA4GH/IRDiRC PPRL working group. General and resource specific documentation and guidelines including user registration, data deposition, data access, data security, policies, transparency, incentives for data submitters and usage of ontologies and standards will be published online via EJP RD website (subtask 11.3.4). Task 11.4: Provision of RD analysis and data sharing capabilities through online resources (M1-M60) TL: CNAG-CRG [STL: UMCG, CNAG-CRG, BSC (ELIXIR-ES), SIB (ELIXIR-CH), EMBL-EBI, CSC (ELIXIR- FI), UU (ELIXIR-SE), LBG (LBI-RUD)] Other: [phenotype, genotype and multi-omics integrated analysis facilities ] LUMC (Endo-ERN), FTELE, INSERM (RaDiCo), BBMRI, RUMC, LUMC, INSERM (AMU), ISS, UM, ACU/ ACURARE, ISCIII, CIBER, UKLFR, WTSI, (Associated partner) To contribute to the achievement of the IRDiRC diagnostics goals and provide analysis and data sharing capabilities to the EJP platform, task 11.4 will support and upscale user friendly software and tools for the analysis of omics data together with rich standardised clinical and phenotypic data. To create a comprehensive suite of online analysis tools, they will be made compatible with the models developed in T11.1, included in T11.2 and linked to key resources from T11.3. The capacity to identify causative genetic variants and discover new pathogenic genes will be provided by building on the online RD-Connect genome-phenome analysis platform (GPAP) (subtask 11.4.1). The GPAP is a recognised IRDiRC resource that provides secure user-friendly deposition, access, analysis and interpretation of/to integrated genotype (whole genomes, exomes and panels) and standardised phenotype information. The GPAP will play a central role in the Solve-RD project. In subtask 11.4.2, methods and tools for integrative bioinformatics analysis will be developed and implemented in alignment with WP13, including user-friendly interfaces for easy access and Page 88 of 161 Associated with document Ref. Ares(2018)6091977 - 28/11/2018 interactive analysis. This collaborative, integrated analysis of multi-omics data will be provided to projects funded in Pillar 1 generating multi-omics datasets and to WP13 selected use cases, being leveraging also on the multi-omics datasets generated within Solve-RD. Furthermore, a pilot cloud computing capability will be piloted for custom analyses from funded projects in Pillar 1 (subtask 11.4.3). Main raw omics data resources such as the EGA or MetaboLights will be connected building on the developments from Solve-RD. Newly developed analysis methods and tools will be integrated or linked to in the analysis systems following a user-driven prioritisation, and improvements on the usability of the resources will be made according to the EJP and ERN needs (subtask 11.4.4). Participation per Partner Partner number and short name WP11 effort 1 - INSERM 431.40 3 - AIT 26.80 4 - LBG (LBI-RUD) 22.30 17 - CHARITE 31.30 18 - UKL-FR 17.40 25 - FTELE 9.90 26 - ISS 6.80 32 - VUHSK 5.00 35 - UMCG 74.00 36 - UM 11.00 40 - IPCZD 10.00 44 - ISCIII 9.90 45 - CNAG-CRG 181.70 46 - UPM 10.60 47 - CIBER 14.70 50 - ULEIC 12.60 53 - CCRI 5.00 57 - UKL-HD 2.80 59 - GUF 76.80 60 - HSK 3.90 64 - LUMC 42.10 65 - Radboudumc 10.70 66 - AMC 5.70 72 - INFRAFRONTIER 39.00 73 - BBMRI 65.80 76 - EMBL 0.00 DTL-Projects 194.10 82 - ACURARE 9.40 Total 1,330.70 Page 89 of 161 Associated with document Ref. Ares(2018)6091977 - 28/11/2018 List of deliverables Due Deliverable Deliverable Title Lead beneficiary Type 15 Dissemination level 16 Date (in Number14 months)17 First Ontological model D11.1 76 - EMBL Other Public 12 of resources metadata Second Ontological D11.2 model of resources 76 - EMBL Other Public 24 metadata Third Ontological model D11.3 76 - EMBL Other Public 36 of resources metadata Fourth Ontological D11.4 model of resources 76 - EMBL Other Public 48 metadata Fifth Ontological model D11.5 76 - EMBL Other Public 60 of resources metadata Virtual platform of RD Websites, D11.6 resources annotated with 1 - INSERM patents Public 12 EJP ontological model filling, etc. First update Virtual Websites, platform of RD resources D11.7 1 - INSERM patents Public 24 annotated with EJP filling, etc. ontological model Second update Virtual Websites, platform of RD resources D11.8 1 - INSERM patents Public 36 annotated with EJP filling, etc. ontological model Third update Virtual Websites, platform of RD resources D11.9 1 - INSERM patents Public 48 annotated with EJP filling, etc. ontological model Fourth update Virtual Websites, platform of RD resources D11.10 1 - INSERM patents Public 60 annotated with EJP filling, etc. ontological model First version of Additional facilities integrated to resources D11.11 regarding data deposition 76 - EMBL Other Public 12 and access, including user guidelines and documentation Second version Additional facilities integrated to resources D11.12 regarding data deposition 76 - EMBL Other Public 24 and access, including user guidelines and documentation Page 90 of 161 Associated with document Ref. Ares(2018)6091977 - 28/11/2018 List of deliverables Due Deliverable Deliverable Title Lead beneficiary Type 15 Dissemination level 16 Date (in Number14 months)17 Third version Additional facilities integrated to resources regarding data D11.13 76 - EMBL Other Public 36 deposition and access, including user guidelines and documentation Fourth version Additional facilities integrated to resources D11.14 regarding data deposition 76 - EMBL Other Public 48 and access, including user guidelines and documentation Fifth version Additional facilities integrated to resources regarding data D11.15 76 - EMBL Other Public 60 deposition and access, including user guidelines and documentation First Report on processed genome-phenome datasets and multi-omics use cases analysed, D11.16 45 - CNAG-CRG Report Public 12 including description of new cloud and online analysis functionalities and tools Second Report on processed genome- phenome datasets and multi-omics use cases D11.17 45 - CNAG-CRG Report Public 24 analysed, including description of new cloud and online analysis functionalities and tools Third Report on processed genome- phenome datasets and multi-omics use cases D11.18 45 - CNAG-CRG Report Public 36 analysed, including description of new cloud and online analysis functionalities and tools Fourth Report on processed genome- phenome datasets and D11.19 45 - CNAG-CRG Report Public 48 multi-omics use cases analysed, including description of new cloud Page 91 of 161 Associated with document Ref. Ares(2018)6091977 - 28/11/2018 List of deliverables Due Deliverable Deliverable Title Lead beneficiary Type 15 Dissemination level 16 Date (in Number14 months)17 and online analysis functionalities and tools Fifth Report on processed genome-phenome datasets and multi-omics use cases analysed, D11.20 45 - CNAG-CRG Report Public 60 including description of new cloud and online analysis functionalities and tools Description of deliverables D128 to D132: Ontological model of resources metadata (M12, 24, 36, 48, 60) D133 to D137: Virtual platform of RD resources annotated with EJP ontological model and updated regularly (M12, 24, 36, 48, 60) D138 to D142: Additional facilities integrated to resources regarding data deposition and access, including User guidelines and documentation for data deposition and access (M12, M24, M36, M48, M60) D143 to D147: Report on processed genome-phenome datasets and multi-omics use cases analysed, including Description of new cloud and online analysis functionalities and tools (M12, M24, M36, M48, M60) D11.1 : First Ontological model of resources metadata [12] First Ontological model of resources metadata due at mont 12 D11.2 : Second Ontological model of resources metadata [24] Second Ontological model of resources metadata due at month 24 D11.3 : Third Ontological model of resources metadata [36] Third Ontological model of resources metadata due at month 36 D11.4 : Fourth Ontological model of resources metadata [48] Fourth Ontological model of resources metadata due at month 48 D11.5 : Fifth Ontological model of resources metadata [60] Fifth Ontological model of resources metadata due at month 60 D11.6 : Virtual platform of RD resources annotated with EJP ontological model [12] First version of the Virtual platform of RD resources annotated with EJP ontological model due at month 12 D11.7 : First update Virtual platform of RD resources annotated with EJP ontological model [24] First update of the Virtual platform of RD resources annotated with EJP ontological model due at month 24 D11.8 : Second update Virtual platform of RD resources annotated with EJP ontological model [36] Second update of the Virtual platform of RD resources annotated with EJP ontological model due at month 36 D11.9 : Third update Virtual platform of RD resources annotated with EJP ontological model [48] Third update of the Virtual platform of RD resources annotated with EJP ontological model due at month 48 D11.10 : Fourth update Virtual platform of RD resources annotated with EJP ontological model [60] Fourth update of the Virtual platform of RD resources annotated with EJP ontological model due at month 60 D11.11 : First version of Additional facilities integrated to resources regarding data deposition and access, including user guidelines and documentation [12] Other lead beneficiary ELIXIR (76) First version of Additional facilities integrated to resources regarding data deposition and access, including user guidelines and documentation due at month 12 Page 92 of 161 Associated with document Ref. Ares(2018)6091977 - 28/11/2018 D11.12 : Second version Additional facilities integrated to resources regarding data deposition and access, including user guidelines and documentation [24] Other lead beneficiary: ELIXIR (76) Second version of Additional facilities integrated to resources regarding data deposition and access, including user guidelines and documentation due at month 24 D11.13 : Third version Additional facilities integrated to resources regarding data deposition and access, including user guidelines and documentation [36] Other lead beneficiary: ELIXIR (76) Third version of Additional facilities integrated to resources regarding data deposition and access, including user guidelines and documentation due at month 36 D11.14 : Fourth version Additional facilities integrated to resources regarding data deposition and access, including user guidelines and documentation [48] Other lead beneficiary: ELIXIR (76) Fourth version of the Additional facilities integrated to resources regarding data deposition and access, including user guidelines and documentation due at month 48 D11.15 : Fifth version Additional facilities integrated to resources regarding data deposition and access, including user guidelines and documentation [60] Other lead beneficiary: ELIXIR (76) Fifth version of the Additional facilities integrated to resources regarding data deposition and access, including user guidelines and documentation due at month 60 D11.16 : First Report on processed genome-phenome datasets and multi-omics use cases analysed, including description of new cloud and online analysis functionalities and tools [12] Other lead beneficiary UMCG (35) First Report on processed genome-phenome datasets and multi-omics use cases analysed, including description of new cloud and online analysis functionalities and tools due at month 12 D11.17 : Second Report on processed genome-phenome datasets and multi-omics use cases analysed, including description of new cloud and online analysis functionalities and tools [24] Other lead beneficiary UMCG (35) Second Report on processed genome-phenome datasets and multi-omics use cases analysed, including description of new cloud and online analysis functionalities and tools due at month 24 D11.18 : Third Report on processed genome-phenome datasets and multi-omics use cases analysed, including description of new cloud and online analysis functionalities and tools [36] Other lead beneficiary: UMCG (35) Third Report on processed genome-phenome datasets and multi-omics use cases analysed, including description of new cloud and online analysis functionalities and tools due at month 36 D11.19 : Fourth Report on processed genome-phenome datasets and multi-omics use cases analysed, including description of new cloud and online analysis functionalities and tools [48] Other lead beneficiary: UMCG (35) Fourth Report on processed genome-phenome datasets and multi-omics use cases analysed, including description of new cloud and online analysis functionalities and tools due at month 48 D11.20 : Fifth Report on processed genome-phenome datasets and multi-omics use cases analysed, including description of new cloud and online analysis functionalities and tools [60] Other lead beneficiary: UMCG (35) Fifth Report on processed genome-phenome datasets and multi-omics use cases analysed, including description of new cloud and online analysis functionalities and tools due at month 60 Schedule of relevant Milestones Due Milestone Milestone title Lead beneficiary Date (in Means of verification number18 months) First Metadata sets of Prioritized resources having MS37 identified and prioritized 76 - EMBL 9 validated metadata sets resources Second Metadata sets of Prioritized resources having MS38 identified and prioritized 76 - EMBL 21 validated metadata sets resources updated at month 21 Page 93 of 161 Associated with document Ref. Ares(2018)6091977 - 28/11/2018 Schedule of relevant Milestones Due Milestone Milestone title Lead beneficiary Date (in Means of verification number18 months) Third Metadata sets of Prioritized resources having MS39 identified and prioritized 76 - EMBL 33 validated metadata sets resources updated at month 33 Fourth Metadata sets of Prioritized resources having MS40 identified and prioritized 76 - EMBL 45 validated metadata sets resources updated at month 45 Fifth Metadata sets of Prioritized resources having MS41 identified and prioritized 76 - EMBL 57 validated metadata sets resources updated at month 57 Common AAI integrated in 3 3 resources integrated with MS42 76 - EMBL 24 resources LifeScience/ELIXIR AAI PPRL available to link data PPRL in production for 3 MS43 76 - EMBL 36 between at least 3 projects/ projects/resources resources Pilot cloud computing infrastructure available for MS44 Pilot cloud deployed 45 - CNAG-CRG 24 deploying workflows at UCMG and BSC(ELIXIR-SI) Page 94 of 161 Associated with document Ref. Ares(2018)6091977 - 28/11/2018 Work package number 9 WP12 Lead beneficiary 10 50 - ULEIC Enabling sustainable FAIRness and Federation at the record level for RD data, patients Work package title and samples Start month 1 End month 60 Objectives This WP will ensure the availability of standards, inter-operable tools, and networks of expert support for biological, clinical and preclinical data, samples, and patient information, to create maximal utility as per the FAIR paradigm. Specific objectives of this WP are: ● To identify, refine and expose core standards for dataset interoperability, asset (data, sample, subject) discovery, and responsible data sharing (via Task 12.1), concentrating on data level rather than resource level information, guided by the needs of EJPRD stakeholders from pillar 1 and 4, including ERNs towards the overall EJPRD objectives. ● To improve and deploy open-source tools, by multi-site teams, made maximally interoperable and compliant with EJPRD agreed standards, to enable RD data to be made FAIR in practice (via Task 12.2). ● To coordinate and deploy broad expertise and practical support for data ‘FAIRification’, including options for data hosting and brokering (via Task 12.3), with a path towards a self-propagating and self-sustaining ecosystem for provisioning of FAIR data stewardship. Description of work and role of partners WP12 - Enabling sustainable FAIRness and Federation at the record level for RD data, patients and samples [Months: 1-60] ULEIC, INSERM, AIT, CHARITE, FTELE, UMCG, UM, MUW, ISCIII, CNAG-CRG, UPM, CIBER, UKL-HD, GUF, LUMC, Radboudumc, AMC, BBMRI, EMBL, ACURARE Other lead beneficiary: LUMC (64) To progressively ‘FAIRify’ RD resources at the record-level to support innovative basic, translational and clinical research, our efforts will synergise with and extend those of WP11 (which has a resource level focus) and WP13 (which has a data integration focus) – with guidance from WP10. The approach assumes that RD research data, samples and clinical information gathered from patients will typically be distributed, heterogeneous and sensitive. By joint research, development, services and sharing of expertise we will enhance and apply extant capabilities to support RD data custodians, biobanks, and registries. Relevant standards will be identified and refined for WP12 by a community wide effort (Task 12.1), existing software will be improved to stress interoperability and functionalities needed by WP12 (Task 12.2), and expertise for practical FAIRification support and FAIR data hosting services for EJP RD projects will be leveraged via user workshops and engagement (Task 12.3) – whilst reflecting users’ needs back to Tasks 12.1 & 12.2, and maturing everything towards a sustainable model. Task 12.1: Compare and align core interoperability standards of relevance (M1-M60) TL: ULEIC [STLs: BBMRI, UMCG, LUMC, AMC, ULEIC] Other: [TC/Workshop attendance, info gathering, design/ testing] UKL-HD (ERK-net), JRC, INSERM (Orph), EMBL-EBI, CSC (ELIXIR-FI), SIB (ELIXIR-CH), UPM, UM, ACU/ACURARE, INSERM (RaDiCo), GUF, AIT, FTELE, Charité, ISCIII, MUW, CIBER This task will underpin the Virtual Platform by defining the standards required to maximise interoperability and federation potential. This will span RD genotype-phenotype databases, RD biobanks, RD patient registries, ERN networks, and ultimately (as guided by WP13) extend to clinical and digital health data, PROM information, natural history and environmental data. The aim is not to invent new standards. Instead, we will engage a broad community of stakeholders to jointly survey the standards that already exist, establish how/where they are being used, and thereby define overlaps, conflicts and gaps that exist. We will then establish what is needed to map and translate between alternatives, and devise refinements and extensions as necessary. Undertaking this work along with the existing producers and users of today’s most relevant standards, and publishing our results (along with Transversal WP5), will ensure they are accepted and employed by the field’s practitioners (who will have been involved in their creation). To this end, we will arrange regular teleconferences and workshops between teams that presently develop or use standards in this space, and encourage external groups to join in. Key external partners would be IRDiRC, ELIXIR, BBMRI, Solve-RD and GA4GH, which have overlapping membership with EJP. Topic priorities will be guided by WP12 tool developments (Task 12.2) and FAIRification activities (Task 12.3), and by WPs 10, 11 and 13. Task 12.1 will be adaptive, but organised around five domains, each having its own expert leadership team coordinating subgroups on specific standards: “Metadata and data models” (Subtask 12.1.1) to provide syntactic and semantic targets that Page 95 of 161 Associated with document Ref. Ares(2018)6091977 - 28/11/2018 FAIRification procedures would target to improve Findability and Interoperability, beyond the resource-level models of WP11; “Federation architectures and network registers” (Subtask 12.1.2) to underpin a growing federated arrangement of RD resources; “Automated Accessibility and Reusability elements” (Subtask 12.1.3), not least machine-readable consent & use conditions, governance policies, patient/sample/data identifiers, and anonymization methods; “Query languages and data exchange formats” (Subtask 12.1.4) to provide a 'lingua franca' for databases and data discovery platforms to translate from and to, so that they can (with suitable permissions) interpret and respond to mutual queries and promote Findability and Interoperability; and “Ontologies & semantics for record-level clinical and preclinical information” (Subtask 12.1.5), to steadily improve our ability to feed complex medical data into the research world. Task 12.2: Multi-team software development to enable the FAIR ecosystem (M1-M60) TL: AIT [STL: BBMRI, GUF, AIT, ULEIC] Other: [developers and service providers] JRC, INSERM (Orph), UMCG, CNAG-CRG, UPM, LUMC, AMC, MUW, FTELE, INSERM (AMU), RUMC A wide array of technologies and capabilities are needed to make RD datasets and resources FAIR, and so in Task 12.2 we will work with RD communities to improve existing Open Source software. The goal will be to enhance their utility, their interoperability and their compatibility with standards defined by Task 12.1, driven by priorities defined in WP10. We will use these tools in Task 12.3, assist the community in adopting them, and thereby validate them and inform iteratively cycles of further optimisation. Task 12.2 activities will be guided by tool users and by feedback at annual retreats organised by WP10. More specifically, we will start each cycle of tool development by first defining an unmet need, and assess the effectiveness of the developed software by evaluating its ability to address the targeted need - all in conjunction with real-world users. The work will also be undertaken by multi-team efforts, addressing four key topics, namely: “Semantic and syntactic harmonisation of data records” (Subtask 12.2.1) which is a core need when making datasets, samples and patients precisely Findable and maximally Interoperable; “Data extraction, obfuscation, anonymisation and disclosure control” (Subtask 12.2.2) to appropriately manage the confidentiality of sensitive patient- level data; “Metadata-level, data-level and sample-level discovery support” (Subtask 12.2.3) which extends the resource level Findability work of WP11 and includes new approaches to RD patient matchmaking that give the person making the query more influence over what constitutes a real match; and “Management of consent and data use conditions, plus automated access control (Subtask 12.2.4) to ensure data discovery and sharing are made more efficient and more responsibly conducted. Awareness of and access to these tools will be facilitates in conjunction with the main EJP RD Helpdesk. Task 12.3: Combining expertise for practical FAIRification support (M1-M60) TL: LUMC [STLs: UMCG, LUMC, AMC, ULEIC] Other: [TC/Expertise gathering, hosting services, FAIR Services] INSERM (Orph), CNAG-CRG, INSERM (RaDiCo), BBMRI, EMBL-EBI, SIB (ELIXIR-CH), INSERM (AMU), Charité, UPM, RUMC, ISS Widespread implementation of FAIR data principles requires interdisciplinary collaboration and practical support to ensure a good flow of standards, technologies and capabilities out to the community. Developing guidelines, protocols, and support services to aid the RD community with practical implementation of FAIR data principles is the goal of Task 12.3. Specifically, Subtask 12.3.1 (“Coordinating teams of experts”) will organise online and face-to-face meetings to engage dispersed experts and integrate RD infrastructural activities with bodies such as IRDiRC, GA4GH, ELIXIR and BBMRI. A liaison program will involve early-career representatives of EJPRD stakeholders in developing FAIR infrastructure and best data stewardship practices. Subtask 12.3.2 (“Brokered hosting service”) will establish a data hosting service to support data discovery in FAIRification efforts. This will include new forms of RD patient matchmaking for use within networks of authorised users, and place the queryer in full control of the matching criteria. Subtask 12.3.3 (“FAIR data stewardship service”) entails practical FAIRification activities. Dedicated FAIR data stewards, engaged via Subtask 12.3.1 will work with stakeholders to implement standards (Task 12.1) and tools (Task 12.2) to make selected data more FAIR compliant, in order to solve real-world problems from pillars 1 and 4 and external users. Formalised, objective FAIR metrics will be used to monitor progress. Each FAIRification undertaking will address a different set of challenges and different cross-resource questions to ensure that FAIRification guidelines, standards and tools cover a sufficient range of practical applications of the EJPRD. The FAIRification process and reusable artefacts, such as an application ontology, will be documented and shared with the wider RD community, and fed into the training program of Pillar 3. The actual total costs of FAIRification in practice will be analysed as input for developing financial models for a sustainable FAIRification service for the RD community (Task 10.5). Participation per Partner Partner number and short name WP12 effort 1 - INSERM 47.90 Page 96 of 161 Associated with document Ref. Ares(2018)6091977 - 28/11/2018 Partner number and short name WP12 effort 3 - AIT 106.50 17 - CHARITE 9.00 25 - FTELE 36.60 35 - UMCG 162.40 36 - UM 2.50 38 - MUW 11.70 44 - ISCIII 2.51 45 - CNAG-CRG 11.00 46 - UPM 54.80 47 - CIBER 2.90 50 - ULEIC 193.90 57 - UKL-HD 2.80 59 - GUF 121.50 64 - LUMC 151.60 65 - Radboudumc 32.90 66 - AMC 94.30 73 - BBMRI 180.80 76 - EMBL 25.90 82 - ACURARE 2.90 Total 1,254.41 List of deliverables Due Deliverable Deliverable Title Lead beneficiary Type15 Dissemination level16 Date (in Number14 months)17 Report on core set D12.1 of unified FAIR data 50 - ULEIC Report Public 18 standards First Report on core set of FAIR software tools and on extended D12.2 3 - AIT Report Public 30 set of unified FAIR data standards, applied in EJP RD Second Report on core set of FAIR software tools and on extended D12.3 3 - AIT Report Public 48 set of unified FAIR data standards, applied in EJP RD Page 97 of 161 Associated with document Ref. Ares(2018)6091977 - 28/11/2018 List of deliverables Due Deliverable Deliverable Title Lead beneficiary Type 15 Dissemination level 16 Date (in Number14 months)17 Report on extended set of FAIR software tools, applied in D12.4 EJP,including overview 64 - LUMC Report Public 60 of FAIRification guidelines for RD data managers Description of deliverables D148: Report on core set of unified FAIR data standards (M18) D149 and D150: Report on core set of FAIR software tools and on extended set of unified FAIR data standards, applied in EJP RD, available (M30, M48) D151: Report on extended set of FAIR software tools, applied in EJP RD, including overview of FAIRification guidelines for RD data managers (M60) D12.1 : Report on core set of unified FAIR data standards [18] Report on core set of unified FAIR data standards D12.2 : First Report on core set of FAIR software tools and on extended set of unified FAIR data standards, applied in EJP RD [30] First Report on core set of FAIR software tools and on extended set of unified FAIR data standards, applied in EJP RD due at month 30 D12.3 : Second Report on core set of FAIR software tools and on extended set of unified FAIR data standards, applied in EJP RD [48] Second Report on core set of FAIR software tools and on extended set of unified FAIR data standards, applied in EJP RD due at month 48 D12.4 : Report on extended set of FAIR software tools, applied in EJP,including overview of FAIRification guidelines for RD data managers [60] Other lead beneficiary: LUMC (64) Report on extended set of FAIR software tools, applied in EJP,including overview of FAIRification guidelines for RD data managers Schedule of relevant Milestones Due Milestone Milestone title Lead beneficiary Date (in Means of verification number18 months) Core standards teams Lists of teams and target MS45 assembled and working 50 - ULEIC 12 standards in place, plus shared actively document storage Multi-team software Lists of teams and target goals MS46 collaborations working on 50 - ULEIC 18 and standards in place agreed goals and standards Communication established List of experts and between experts and stakeholders in place, plus MS47 stakeholder representatives 64 - LUMC 12 means of communication and involved in practical shared document storage FAIRification support Page 98 of 161 Associated with document Ref. Ares(2018)6091977 - 28/11/2018 Schedule of relevant Milestones Due Milestone Milestone title Lead beneficiary Date (in Means of verification number18 months) First update FAIRification Guidelines document updated MS48 guidelines for RD data 64 - LUMC 6 by the latest FAIRification managers experiences at month 6 Second update FAIRification Guidelines document updated MS49 guidelines for RD data 64 - LUMC 30 by the latest FAIRification managers experiences at month 30 Third update FAIRification Guidelines document updated MS50 guidelines for RD data 64 - LUMC 42 by the latest FAIRification managers experiences Guidelines document updated Fourth update FAIRification by the latest FAIRification MS51 guidelines for RD data 64 - LUMC 54 experiences updated at month managers 54 Page 99 of 161 Associated with document Ref. Ares(2018)6091977 - 28/11/2018 Work package number 9 WP13 Lead beneficiary 10 36 - UM Enabling multidisciplinary, holistic approaches for rare disease diagnostics and Work package title therapeutics Start month 1 End month 60 Objectives Extend the virtual platform with workflows that allow holistic research based on rare disease data and biological knowledge. Fill gaps in technologies identified in previously performed explorative studies and perform proof of principle studies to evaluate the results and improve and optimise the approach. Thereby, improve the understanding of the etiology and progression or rare diseases and support the discovery of biomarkers and the identification of druggable pathways and targets, and allow the study of disease modifiers such as nutrition, and metabolism (exercise) aspects of lifestyle and exposure to toxicants. Provide content for training in pillar 3 to make these new workflows available for the community. Description of work and role of partners WP13 - Enabling multidisciplinary, holistic approaches for rare disease diagnostics and therapeutics [Months: 1-60] UM, INSERM, LBG (LBI-RUD), UKL-FR, ISS, UMCG, ISCIII, CNAG-CRG, UKL-HD, EKUT, LUMC, Radboudumc, EMBL, ACURARE Other lead beneficiary: UKL-HD (57) Methodology: The approach will include the following steps: (i) Knowledge structuring based on text and data mining and expert curation; (ii) creation of technical links for integration (database ID linksets, FAIR format conversions from repository data to tool ready data, links between biological entities (e.g. gene variants and their effects); (iii) create disease specific pathways and networks with flexible data representations based on i and ii; (iv) Allow extension of these networks with relevant regulatory information (e.g. transcription factors and miRNAs) and evaluation for intrinsic lifestyle factors (e.g. micronutrient targets) and epigenetic factors and allow extension with external environmental factors like chemical exposure (toxicology) and allow subsequent active node analysis to evaluate these; (v) Create complete workflows. As part of the whole process continuously perform small proof of principle studies that help to drive the work forward, help show the relevance of what is done and help identify problems with the effectiveness of what is being done and to adapt that to the next level. Basically implementing an agile approach as known in software development for this WP. Some of the outcomes of WP13 will be applied and tested within the collaborative analyses of multi-omics datasets performed in WP11 task 11.4.2 on existing data, data provided by the ERNs and data generated from Pillar 1 funded projects and the Solve-RD project. Work with Pillar 3 to develop training, especially on creating pathways, using the pathways, networks and complete workflows for discovery of diagnostic and therapeutic activities and for inference of lifestyle and environmental factors. Task 13.1: Fill a number of pre identified gaps to allow integrative systems biology approaches for rare diseases (M1- M60) TL: UM, LUMC, [STLs: LUMC, RUMC, UM, INSERM (AMU), ISS Other: EKUT, ACU/ACURARE, EMBL-EBI, SIB (ELIXIR-CH), UMCG, CNAG-CRG, UK-LFR, ISCIII, LBG/LBI-RUD (mentioned at the end of subtasks they are involved in, subtask leaders in bold) Subtask 13.1.1: Pathways created and expert curated. Build a knowledge base of relevant rare diseases biological pathways for the existing pathway portal available on WikiPathways. Select relevant diseases in collaboration with ERNs (via WP10) and Solve-RD. For diseases where pathways that can be used by analytical tools are not yet available, use literature review including FAIR text-mining predictive methods, data mining and expert input from ERNs and FAIR to identify disease-relevant genes and use the knowledge available in neXtProt and other resources, e.g. protein-protein interactions, co-expression, co-localisation, etc. to create a network structure. Annotate those network structures and make them available for integrated omics analysis in pathway and network tools and in BioPax ontology based pathway RDF format contributed to the Open PHACTS platform and WikiData. (UM, LUMC, ACU/ACURARE; M1-36) Subtask 13.1.2 Mapping to genes: Allow gene directed mapping of rare disease gene variants to genes (and then to pathways) based on mappings available in external resources. Update mapping databases and allow access to a location- based gene mapping service. Work with WP11/12 to get interoperable gene variant descriptions (correct identifiers including genome locations) that allow these mappings to be used, use genomics platform annotation pipeline from RD- connect. (UM, LUMC; M1-36; develop, updates 1-60) Page 100 of 161 Associated with document Ref. Ares(2018)6091977 - 28/11/2018 Subtask 13.1.3 Mapping (combinations) of variants to function: Mapping of (combinations of) variants to functional gene regulatory sequences and protein domains operationalized for the rare disease community and allow use of that to evaluate edges (interactions and reactions in pathways), linking this to the edgetic concept. (RUMC, LUMC, CNAG- CRG, EMBL-EBI, SIB(ELIXIR-CH); M1-60) Subtask 13.1.4 Link to external FAIR data: Leverage on the data generated by Solve-RD and the funded projects in Pillar 1 and work with WP11/12 to allow integration, and thereby analysis, of FAIRified experimental multi-omics data with knowledge based pathways and networks derived from FAIRified external data sources (e.g. using ELIXIR core repositories and resources respectively), and using the fact that it was already linked to FAIR genotype and phenotype data within the RD-Connect platform, provide specific scripts/tools. (RUMC, LUMC, CNAG-CRG, UMCG, UM, EKUT; M13-60) Subtask 13.1.5 Network repository: For a limited number of diseases create evaluated and documented networks and deposit in the network repository NDEX (for analysis in Cytoscape). (UM, LUMC; M37-60) Subtask 13.1.6 Environmental lifestyle: Allow network analysis to discover identify possibly relevant environmental factors (such as exercise and nutrition including factors affecting epigenetics) from multi-omics networks. (INSERM- AMU, RUMC, UM; M19-60) Subtask 13.1.7 Treatment drugs: Allow and describe network analysis and single pathway approaches to compare rare diseases with to known treatable diseases and to add drugs to networks and explore sub paths using network directionality for target selection using methods that will be developed in collaboration with external EFPIA partners. (LUMC, UM, UK-LFR, M1-36) Subtask 13.1.8 Environmental toxicology: Allow and describe network enrichment analysis and single pathway approaches and connect environmental (toxicology based) data via the OpenRiskNet and eNanomapper APIs, thereby allowing links between (epi)genetics and exposure. (ISS, UM, ISCIII; M1-48) Subtask 13.1.9 Workflow leading to understanding of disease mechanisms and diagnosis: Describe workflow for (multi)omics data analysis finding (sub)pathways, building networks and describing basic network analysis (up to finding affected sub pathways and active nodes and thereby diagnostic biomarker (Subtasks 1 to 4) and extended workflows for Subtasks 6, 7 and 8. (UM, INSERM-AMU, LBG/LBI-RUD, LUMC, RUMC; M25-60) Subtask 13.1.10 Link to Adverse Outcome Pathway approach: Harmonize the rare disease pathways (from 1) to be linked with events that occur in Adverse Outcome Pathways (AOPs) created by the EUToxRisk flagship project as made available on the OECD AOPWiki. (LUMC, ISS, UM; M13-36) Task 13.2: Organise proof of principle studies to identify efficacy of the work done and identify remaining (including new) gaps (M1-M60) TL: RUMC Other: LUMC (data linking), UM (integrating 4,1 tasks, network building, extension and evaluation), ACU/ ACURARE (active sub-paths and effects thereon for MS2) The proof of principle studies form an essential element in the agile approach for the pathway and workflow development in task 13.1. They steer the pathway selection in task 13.1.1 and set targets for the other 13.1 tasks. The developed elements are continually tested in these studies and where possible improved. The topics for the studies will be selected based on the strategic annual plan established in WP10 together with ERNs and with the participation of Solve-RD and EuRenOmics. With their input we will identify relevant resources and select the pathways that need to be developed. We expect to carry out 5 rare disease related proof of principle studies for relevant parts of the WP work plan. The first study will help select and create datasets to link and analyse and pathways to be developed and in the second study we will use these pathways to analyse omics data. In a third study we will evaluate advanced omics analysis: evaluate genetics mappings and protein structure effects. These will contribute to MS1.The final two studies will evaluate nutritional lifestyle effects in disease networks and links between disease network and toxicology data and will contribute to MS2. A second group of studies, possibly for different diseases, will aim at research questions relevant for multi-omics linkage to known drug targets, lifestyle nutrition and metabolism (exercise) relations and to environmental toxicology resources for MS13.2. All studies will combine data FAIRified in WP12, in part selected for this purpose, with the pathways from task 13.1.1 leading to the selection of enriched pathways which are then combined in networks, we will then use the 13.1 subtasks to define the workflow to answer research questions and we will identify gaps in available technology. The operational, tested, workflows, tools and pathway- and mapping data that result after the pilot studies will be integrated in the Pillar 2 virtual platform and will form the basis for tutorial development with pillar 3. After having conducted these studies, the remaining gaps will be reported to the strategic research agenda transversal activity, for possible implementation in research calls through Pillar 1. Participation per Partner Page 101 of 161 Associated with document Ref. Ares(2018)6091977 - 28/11/2018 Partner number and short name WP13 effort 1 - INSERM 17.30 4 - LBG (LBI-RUD) 0.70 18 - UKL-FR 5.60 26 - ISS 12.20 35 - UMCG 3.60 36 - UM 88.40 44 - ISCIII 5.00 45 - CNAG-CRG 6.60 57 - UKL-HD 5.60 58 - EKUT 3.10 64 - LUMC 63.70 65 - Radboudumc 54.80 76 - EMBL 2.80 82 - ACURARE 28.50 Total 297.90 List of deliverables Due Deliverable Deliverable Title Lead beneficiary Type 15 Dissemination level 16 Date (in Number14 months)17 Collection of 20 D13.1 curated (sub)Portal on 36 - UM Report Public 36 WikiPathways Completed pathway analysis workflow (data analysis including both D13.2 36 - UM Report Public 48 types of genetic variant linking and network creation) Completed network analysis workflow (active node detection, lifestyle D13.3 factor network evaluation 36 - UM Report Public 54 and extended network analysis for drugs and toxic compounds) Description of deliverables D152: Collection of 20 curated pathways in (sub)portal on WikiPathways (M36) D153: Completed pathway analysis workflow (data analysis including both types of genetic variant linking and network creation) (M48) D154: Completed network analysis workflow (active node detection, lifestyle factor network evaluation and extended network analysis for drugs and toxic compounds) (M54) Page 102 of 161 Associated with document Ref. Ares(2018)6091977 - 28/11/2018 D13.1 : Collection of 20 curated (sub)Portal on WikiPathways [36] Collection of 20 curated (sub)Portal on WikiPathways D13.2 : Completed pathway analysis workflow (data analysis including both types of genetic variant linking and network creation) [48] Completed pathway analysis workflow (data analysis including both types of genetic variant linking and network creation) D13.3 : Completed network analysis workflow (active node detection, lifestyle factor network evaluation and extended network analysis for drugs and toxic compounds) [54] Completed network analysis workflow (active node detection, lifestyle factor network evaluation and extended network analysis for drugs and toxic compounds) Schedule of relevant Milestones Due Milestone Milestone title Lead beneficiary Date (in Means of verification number18 months) D153 (D13.2) workflow used in proof of concepts study Peer reviewed paper or report MS52 evaluated and improved, 36 - UM 48 in BioRXiv. Plus plans on with project plans for future GitHub updates and release scheme. D13.3 workflow used in proof of concepts study evaluated Peer reviewed paper or report MS53 and improved, with project 36 - UM 60 in BioRXiv. Plus plans on plans for future updates and GitHub release scheme Page 103 of 161 Associated with document Ref. Ares(2018)6091977 - 28/11/2018 Work package number 9 WP14 Lead beneficiary 10 26 - ISS Work package title Training on data management & quality Start month 1 End month 60 Objectives The main objectives of WP14 are to decrease RD data fragmentation and increase data quality through training activities on data management & quality which will raise the level of capacities and help data sharing and networking within the RD community. The training activities of WP14 will focus on (i) Standardization of rare disease data; (ii) Standards and quality in genetic testing; (iii) Strategies to foster solutions of undiagnosed rare disease cases; (iv) Biological rare disease sample data management, and sharing; (v) Establishment and long term sustainability of International, FAIR and high quality rare disease registries and (vi) Learn components and interoperability tools of the European Rare Diseases Registry Infrastructure Description of work and role of partners WP14 - Training on data management & quality [Months: 1-60] ISS, INSERM, LBG (LBI-RUD), KU Leuven, IMAGINE, CHARITE, FTELE, VUHSK, UMCG, MUG, IPCZD, ISCIII, CNAG-CRG, EKUT, HSK, IOR, LUMC, AMC, BBMRI, EMBL, EURORDIS, ACURARE, HUGEN Methodology WP14 will achieve the objectives through (i) the integration and implementation of existing and successful training activities and (ii) development of new specific trainings to address all objectives. This will ensure appropriate coverage of relevant aspects on data management & quality under a joint programme for meaningful interaction and comprehensive training across RD community in Europe. Task 14.1: Training on the Orphanet nomenclature and RD ontologies for RD research (M1-M60) TL: INSERM (Orph), Participants: LUMC, LBG (LBI-RUD), MUW An Orphanet nominated training manager will develop a novel training module on the Orphanet nomenclature and RD ontologies for RD research for clinicians and scientists. This work will be done in collaboration with a scientific committee. The novel course will be translated and adapted to country-specific needs by the Orphanet Network teams, in order to organise ‘National trainings’ in their national languages (free for participants). The training manager will also organise a 'Training for Trainers' which will be dispensed to the Orphanet Network teams, enabling them to acquire efficient training techniques and thus in turn dispense effective ‘National trainings’ in their country. Participation in this training will help clinicians and researchers to exploit the full potential of the Orphanet database integrated data through ORDO and Orphanet nomenclature use thus enabling them to generate additional knowledge in their field. Task 14.2: Standards and quality of genetics/genomics data in laboratory and clinical research practice (M1-M60) TL: KULeuven, Participants: EKUT, ACU/ACURARE, ISS, IPCZD (CMHI), CNAG-CRG, INSERM (AMU), UMCG ‘Next generation sequencing’ (NGS) generates overwhelming amounts of data. Clinical and basic researchers are increasingly confronted with the complexity of genomic data. It is of importance to provide training on the interpretation of genetic variants and quality standards. Courses for scientists, bio-informaticians and clinicians with an interest in genomic technologies and applications will be developed. The aim is to teach participants about the evaluation of the pathogenic nature and clinical significance of genetic variants, on the criteria that have to be set to the NGS analysis pipelines and on the use of international databases. The course will build on expertise gained by EuroGentest and help in the translation of research tools to diagnostic applications (in line with the IRDiRC objectives). The impact is on the quality and reliability of NGS results, obtained through rare disease research. Over the years, the course content will shift to total genome interpretation, which will entail novel disease molecular mechanisms. Annual 3-day residential training courses typically host 20 participants and will travel across Europe (KULeuven, EKUT, ACU/ACURARE, ISS and IPCZD (CHMI)). Task 14.3: Training on strategies to foster solutions of undiagnosed rare disease cases (M12-M60) TL: ISS, Participants: EKUT, LBG (LBI-RUD), ACU/ACURARE, ISCIII, INSERM (AMU), FTELE, UMCG, IMAGINE, CNAG-CRG, IPCZD (CMHI) This task will implement a new 3-day residential training course that will provide newly-developed strategies and tools based on phenotypic and molecular analysis to foster solutions for undiagnosed rare disease cases for researchers and clinicians. The course will be organised and hosted in ISS in close collaboration with task partners, “Solve-RD”, and the Undiagnosed Network International (UDNI). The course will guide participants on novel molecular strategies, functional analysis, integrative multi-omics interpretation and clinical utility (EKUT, linked with Pillar 3 Task 14.1, and with Pillar 2 WP13). In particular, a selected number of cases will be presented (in rotation by the following partners LBG Page 104 of 161 Associated with document Ref. Ares(2018)6091977 - 28/11/2018 (LBI-RUD), EKUT, ACU/ACURARE, ISCIII, IMAGINE, UMCG, FTELE, INSERM (AMU). Moreover participants during the course will learn how to use tools such as the RD-Connect genome-phenome analysis platform (CNAG- CRG and linked with Pillar 2 WP11) and other bio-informatic resources (INSERM-AMU). Participants at the end of the course will be better equipped with specific knowledge enabling them to solve undiagnosed cases. Task 14.4: Training for biobanks and researchers/clinicians on sample data management (M1-M60) TL: FTELE; Participants: UMCG, BBMRI, CHARITE, ISCIII, MUG, HUGEN (HACETTEPE), VUHSK Biological samples from RD patients are precious resources for research. Due to their intrinsic rarity, these samples are often dispersed in multiple biobanks and are difficult to locate. Moreover, samples collected by researchers within projects are often not available for reuse or processed with adequate standards. Such practices do not facilitate research reproducibility and are not in the best interest of the patients. Biobanks have begun to share RD datasets to centralised sample catalogues (e.g. RD-Connect, EuroBioBank) to facilitate access, and support the change towards best practice with their special position interfacing patients, clinicians and researchers. However, RD samples and associated data pose particular management challenges for their high variety of data types (e.g. disease names, genetic variants, phenotypes, clinical data), as well as balancing the need to share while preserving privacy and rights of patients. The goals of this task are to train (subtask 14.4.1) researchers/clinicians on how to use biobanks to support their projects for sample management, and (subtask 14.4.2) to train biobank staff how to share and link individual RD samples and data, using existing platforms and standards developed by Pillar 2. The latest ethical and legal requirements including privacy/data protection provisions will be covered (linked with Transversal activities in WP4). Two annual workshops (developed by FTELE, BBMRI, UMCG, CHARITE), rotating in different locations including EU-13 countries, will be organised (ISCIII, MUG, HUGEN (HACETTEPE), VUHSK). Task 14.5: Training on rare disease registries and FAIRification of data at the source (M1-M60) TL: ISS; Participants: LUMC (also for Endo-ERN); Bond-ERN (IOR), Metab-ERN (HK) EURORDIS, ISCIII, LUMC, INSERM (RaDiCo); UMCG, DTL-Projects (ELIXIR-NL), CNR (ELIXIR -IT), AMC Since 2013 this course has been organised and hosted in ISS with the collaboration and support of key partners including RD-Connect, ELIXIR, LUMC, and EURORDIS. The enhanced and expanded course provided by this task will be an annual residential training course for the establishment of Findable, Accessible, Interoperable, and Reusable, for humans and computers, (FAIR) Rare Disease (RD) registries. The course, organised and hosted in ISS in close collaboration with task partners, is open to the international researcher community, patients, registry curators, database managers, healthcare professionals and students and takes place over 5 days split into two main parts. In the first 3 days, participants learn (a) what resources are needed for the establishment / maintenance of a high-quality registry; (b) the features of successful strategies to ensure (i) long-time sustainability of the registry, (ii) including quality, (iii) legal and ethical issues in compliance with the EU General Data Protection Regulation, and (iv) FAIR principles (most of the speakers from task partners). The final two days of the course are a hands-on tutorial (Bring Your Own Data, BYOD) where the attendees work with IT-Trainers and use a set of light-weight tools to make use cases FAIR (mainly from LUMC, and ELIXIR, link with Pillar 2 WP12 in particular task 12.3). Use cases are brought by task partners (ENDO-ERN, BOND- ERN and METAB-ERN) and in part by participants. Task 14.6: Training on the European Rare Diseases Registry Infrastructure (ERDRI) (M1-M60) TL: JRC; Participants: INSERM (Orph), AIT; Other (external collaborators for JRC) UMC Frankfurt, University of Mainz The task will be in accordance to the JRC's contribution to Pillar 2 WP11 and WP12. Accordingly, the JRC and its partners for this task will provide trainings to all interested stakeholders on the ERDRI components and other interoperability tools including the Central Metadata Repository: structure, functioning, access by registries, implementation (JRC and UMC Frankfurt); the European Directory of Registries: structure, functioning, access by registries, implementation (JRC and University of Mainz); the implementation of the Set of Common Data Elements for Rare Disease Registration (JRC) and linked element sources (codification, ontologies - Orphanet) and the EUPID Pseudonymisation tool for RD registries : functioning, access, implementation (JRC and AIT). Participation per Partner Partner number and short name WP14 effort 1 - INSERM 28.00 4 - LBG (LBI-RUD) 2.00 7 - KU Leuven 12.00 14 - IMAGINE 2.00 Page 105 of 161 Associated with document Ref. Ares(2018)6091977 - 28/11/2018 Partner number and short name WP14 effort 17 - CHARITE 8.00 25 - FTELE 27.00 26 - ISS 43.00 32 - VUHSK 1.00 35 - UMCG 10.00 39 - MUG 1.00 40 - IPCZD 4.00 44 - ISCIII 6.00 45 - CNAG-CRG 1.00 58 - EKUT 7.00 60 - HSK 2.00 61 - IOR 2.00 64 - LUMC 7.00 66 - AMC 1.00 73 - BBMRI 5.00 76 - EMBL 0.00 CNR (ELIXIR-IT) 3.00 DTL-Projects 4.00 77 - EURORDIS 3.00 82 - ACURARE 5.00 83 - HUGEN 1.00 Total 185.00 List of deliverables Due Deliverable Deliverable Title Lead beneficiary Type15 Dissemination level16 Date (in Number14 months)17 First Report of Orphanet nomenclature training D14.1 1 - INSERM Report Public 14 for trainers and national trainings Second Report of Orphanet nomenclature D14.2 1 - INSERM Report Public 60 training for trainers and national trainings First Report on course on interpretation of genetic D14.3 7 - KU Leuven Report Public 12 variants and quality standards Page 106 of 161 Associated with document Ref. Ares(2018)6091977 - 28/11/2018 List of deliverables Due Deliverable Deliverable Title Lead beneficiary Type 15 Dissemination level 16 Date (in Number14 months)17 Second Report on course on interpretation of D14.4 7 - KU Leuven Report Public 60 genetic variants and quality standards First Report on D14.5 International course on 26 - ISS Report Public 24 undiagnosed diseases Second Report on D14.6 International course on 26 - ISS Report Public 60 undiagnosed diseases First Report on sample D14.7 data management 25 - FTELE Report Public 12 training workshops Second Report on D14.8 sample data management 25 - FTELE Report Public 60 training workshops First Report on International course on D14.9 Rare Disease Registries 26 - ISS Report Public 12 and FAIRification of data at source Second Report on International course on D14.10 Rare Disease Registries 26 - ISS Report Public 60 and FAIRification of data at source Description of deliverables D155 and D156: Reports of Orphanet nomenclature training for trainers and national trainings (M14 and M60) D157 and D158: Report on course on interpretation of genetic variants and quality standards (M12 and M60) D159 and D160: Report on International course on undiagnosed diseases (M24 and M60) D161 and D162: Report on sample data management training workshops (M12 and M60) D163 and D164: Report on International course on Rare Disease Registries and FAIRification of data at source (M12 and M60) D14.1 : First Report of Orphanet nomenclature training for trainers and national trainings [14] First Report of Orphanet nomenclature training for trainers and national trainings due at month 14 D14.2 : Second Report of Orphanet nomenclature training for trainers and national trainings [60] Second Report of Orphanet nomenclature training for trainers and national trainings due at month 60 D14.3 : First Report on course on interpretation of genetic variants and quality standards [12] First Report on course on interpretation of genetic variants and quality standards due at month 12 D14.4 : Second Report on course on interpretation of genetic variants and quality standards [60] Second Report on course on interpretation of genetic variants and quality standards due at month 60 D14.5 : First Report on International course on undiagnosed diseases [24] First Report on International course on undiagnosed diseases due at month 24 Page 107 of 161 Associated with document Ref. Ares(2018)6091977 - 28/11/2018 D14.6 : Second Report on International course on undiagnosed diseases [60] Second Report on International course on undiagnosed diseases due at month 60 D14.7 : First Report on sample data management training workshops [12] First Report on sample data management training workshops due at month 12 D14.8 : Second Report on sample data management training workshops [60] Second Report on sample data management training workshops due at month 60 D14.9 : First Report on International course on Rare Disease Registries and FAIRification of data at source [12] First Report on International course on Rare Disease Registries and FAIRification of data at source due at month 12 D14.10 : Second Report on International course on Rare Disease Registries and FAIRification of data at source [60] Second Report on International course on Rare Disease Registries and FAIRification of data at source due at month 60 Schedule of relevant Milestones Due Milestone Milestone title Lead beneficiary Date (in Means of verification number18 months) Report of scientific committee Orphanet training content MS54 1 - INSERM 10 meeting validated and defined available Definition of the training MS55 Training Roadmap established 26 - ISS 1 schedule Page 108 of 161 Associated with document Ref. Ares(2018)6091977 - 28/11/2018 Work package number 9 WP15 Lead beneficiary 10 77 - EURORDIS Capacity building and training of patients and researchers in Rare Disease research and Work package title processes Start month 1 End month 60 Objectives The overall objective of this WP is to address one key component of the EJP on RD that is to improve RD research and innovation and to enhance the uptake of research results by building the capacity of the patient community and other key stakeholders. The specific objectives of this WP include: ● Gaining an understanding of therapeutic development and regulatory processes for medicinal products in the field of rare diseases for patients and researchers; ● Providing the knowledge and skills required for patients to become legitimate collaborators in RD scientific & translational research hence enabling the implementation of the strategy supported by the EJP on education of patients; ● Empowering the patient community and specifically patient representatives in their roles as equal, valued, and efficient partners in research and scientific project / ERNs governance bodies; ● Applying appropriate methods in the empowerment process of the paediatric patients to provide them with knowledge, skills and educational comprehensive tools covering some of the main knowledge gaps related to the paediatric developmental specificities. Description of work and role of partners WP15 - Capacity building and training of patients and researchers in Rare Disease research and processes [Months: 1-60] EURORDIS, IMAGINE, ISS, TEDDY, MUG, ACURARE Methodology This WP will apply a blended approach to deliver the existing and new training activities (e-learning and face to face for T15.1, T15.2 and T15.3) open and free to all participants that will be integrated within the EURORDIS Open Academy . The T15.4 will develop gamified training material adapted to the paediatric target audience and deliver its course via short workshops in year 4 and 5 organised in synergy with the TEDDY Network, FSJD and the IMI2-funded project C4C (i.e. Conect4Children). Task 15.1: ExPRESS Expert Patients and Researchers EURORDIS Summer School (M1-M60) TL: EURORDIS, Participant: LUMC One of the ultimate aims of research is to bring innovative, life-transforming therapeutic options to patients who are also taking on ever increasing roles in advocating for medicines development, equal access to treatments across Europe and ensuring that medical information is clear, accurate and comprehensible. ExPRESS Expert Patients and Researchers EURORDIS Summer School (ExPRESS) is an annual training programme organised by EURORDIS. The face-to-face course trains 45 expert patients and 15 researchers annually as part of an intensive 4.5-day course held in Barcelona. It was demonstrated that joint training of patients and researchers is of great benefit for both type of stakeholders helping to raise awareness and sharpen advocacy skills and gain an understanding of therapeutic development and regulatory processes for medicinal products in the field of rare diseases. Joint training enable both stakeholders to become more active in this ecosystem. This task will support the human resources necessary to organize, develop and carry out all activities as well as the operational support needed to ensure participation of researchers. The EJP for RD’s contribution is being requested pro-rata thus leveraging on complementary and diverse sources of funding raised by EURORDIS. Task 15.2: Training for patient advocates on scientific innovation and translational research aspects in rare diseases (M12-M60) TL: EURORDIS; Participant: IMAGINE This task will enable further development of a new 5-day annual residential training workshop for 30 patient representatives, focused on scientific innovation and translational research organised by EURORDIS since 2018. The programme will introduce trainees to translational research, genetics, the latest advances in diagnostic tools and pathways including those developed within the large European project called Solve-RD, disease model systems, data (collection, sharing, and protection), patient-reported outcomes and the use of novel technologies in the context of rare diseases research. Training will be delivered by experts in research coming from academia and industry, along with patient groups who will provide case studies in successful research engagement. The course will also provide Page 109 of 161 Associated with document Ref. Ares(2018)6091977 - 28/11/2018 information on research funding in the EU, research funding strategies for patient groups and corporate collaborations. The course will take place at the Imagine Institute for Genetic Diseases in Paris which will enable daily on site visits to relevant laboratories and interactive discussion between research teams and participants. This task will support the development of the programme in line with scientific breakthrough in RD research and implementation of the course from Y2 (2020) to Y5 (2023) of the EJP (the 2018 and 2019 editions are funded through Solve-RD). Task 15.3: Training for patient representatives and advocates on leadership and communication skills (M1-M48) TL: EURORDIS; Participants: ISS, ACU/ACURARE and MUG This task uses a unique strategy of engagement and integration of patients at all levels of leadership, design, training, coaching and communication. The brand new Leadership Programme aims to provide patient representatives including but not limited to members of the European Patient Advocacy Groups (ePAGs) involved in the 24 European Reference Networks with a comprehensive overview of working processes involved in various advisory, management and steering research committees, governance processes and terminology, fostering meaningful communication, cooperation, and coordination strategies and helping patient representatives carefully consider strategic health and research advocacy processes, roles, and responsibilities. The EURORDIS leadership programme will be developed and implemented for the first time within the course of the EJP and will combine 4 modules (Personal Impact, Building Partnerships, Leadership Style and Knowledge Generation) that will help nurture individual personal authority to better act on behalf of others, influence decisions and set the strategic direction within ERNs and European-wide disease specific and infrastructure research initiatives and projects. This task will support the development of the annual face-to-face 2 days training programme for 30 participants. The location will be rotating each year between France (EURORDIS), Italy (ISS), Turkey (ACU/ACURARE) and Poland (MUG). Task 15.4: Educational materials and activities for paediatric patients (M25-M60) TL: TEDDY & LTP (FSJD); Participant: EURORDIS Due to the paediatric specific developmental characteristics, specifically tailored methods should be applied to the training and empowerment process of paediatric patients. The activities undertaken in this task will be conducted based on the experience carried out within the FP6 TEDDY Network of Excellence coordinated by CVBF, as further developed in the context of the Category 1 Enpr-EMA member “TEDDY Network of Excellence for Paediatric Clinical Trial”. There will also be relevant links and synergies with the ongoing H2020 project EPTRI European Paediatric Translational Research Infrastructure, coordinated by CVBF, the H2020 project PEDCRIN Paediatric Clinical Research Infrastructure Network coordinated by ECRIN and with the IMI2 C4C project. These are both collaborative projects, in which ad hoc actions for paediatric patients’ empowerment are foreseen, involving also Foundation Sant Joan de Deu (FSJD). The planned activities include short workshops in collaboration with EURORDIS and the eYPAGnet (the European Young Persons' Advisory Group network) for 15 patients’ representatives focusing on the following areas: (i) Genetic / rare disease characteristics and evolution; (ii) Role for paediatric patients and relevance of clinical and translational research (including patients’ engagement in clinical trials, the consent issue, the patient-reported outcomes in the context of paediatric rare diseases); (iii) Orphan Medicinal Products availability and access for paediatric patients on the EU market, pharmacovigilance and off-label use in paediatric setting. The Face to Face ‘paediatric patient experts training course’ will start in year 3 and will be hosted in Italy (TEDDY), Spain (JSJD) and France (EURORDIS). Participation per Partner Partner number and short name WP15 effort 14 - IMAGINE 0.40 26 - ISS 2.00 28 - TEDDY 22.00 39 - MUG 2.00 77 - EURORDIS 89.00 82 - ACURARE 2.00 Total 117.40 Page 110 of 161 Associated with document Ref. Ares(2018)6091977 - 28/11/2018 List of deliverables Due Deliverable Deliverable Title Lead beneficiary Type 15 Dissemination level 16 Date (in Number14 months)17 D15.1 First Report on ExPRESS 77 - EURORDIS Report Public 12 Second Report on D15.2 77 - EURORDIS Report Public 60 ExPRESS First Report on training of patient representatives D15.3 on scientific innovation 77 - EURORDIS Report Public 24 and translational research in RD Second Report on training of patient representatives on D15.4 77 - EURORDIS Report Public 60 scientific innovation and translational research in RD First Report on D15.5 EURORDIS’ Leadership 77 - EURORDIS Report Public 12 Programme Second Report on D15.6 EURORDIS’ Leadership 77 - EURORDIS Report Public 48 Programme Training plan for D15.7 paediatric patients’ in the 28 - TEDDY Report Public 30 EJP Report on paediatric D15.8 patients’ experts training 28 - TEDDY Report Public 60 courses Description of deliverables D165 and D166: Report on ExPRESS (M12 and M60) D167 and D168: Report on training of patient representatives on scientific innovation and translational research in RD (M24 and M60) D169 and D170: Report on EURORDIS’ Leadership Programme (M12 and M48) D171: Training plan for paediatric patients’ in the EJP (M30) D172: Report on paediatric patients’ experts training courses (M60) D15.1 : First Report on ExPRESS [12] First Report on ExPRESS EURORDIS Summer School due at month 12 D15.2 : Second Report on ExPRESS [60] Second Report on ExPRESS EURORDIS Summer School due at month 60 D15.3 : First Report on training of patient representatives on scientific innovation and translational research in RD [24] First Report on training of patient representatives on scientific innovation and translational research in RD due at month 24 D15.4 : Second Report on training of patient representatives on scientific innovation and translational research in RD [60] Page 111 of 161 Associated with document Ref. Ares(2018)6091977 - 28/11/2018 Second Report on training of patient representatives on scientific innovation and translational research in RD due at month 60 D15.5 : First Report on EURORDIS’ Leadership Programme [12] First Report on EURORDIS’ Leadership Programme due at month 12 D15.6 : Second Report on EURORDIS’ Leadership Programme [48] Second Report on EURORDIS’ Leadership Programme due at month 48 D15.7 : Training plan for paediatric patients’ in the EJP [30] Other beneficiary: FSJD Training plan for paediatric patients’ in the EJP D15.8 : Report on paediatric patients’ experts training courses [60] Other beneficiary: FSJD Report on paediatric patients’ experts training courses Schedule of relevant Milestones Due Milestone Milestone title Lead beneficiary Date (in Means of verification number18 months) Page 112 of 161 Associated with document Ref. Ares(2018)6091977 - 28/11/2018 Work package number 9 WP16 Lead beneficiary 10 12 - FFRD Work package title Online Academic education course Start month 1 End month 60 Objectives Most of the currently available trainings and courses are either focusing on a group of RD, a specific technology or developed for a national/university audience. The overall objective of this WP is to provide a EU-wide streamlined education programme on RD research to all interested stakeholders via an e-learning established service provider that will combine both certificated courses and MOOC. The modules of the e-learning course will be created and/or adapted from existing/available content together with top-tier RD experts. Education being part of the future activities to be developed by ERNs, this WP will also provide complimentary access to the e-learning platform facilities, as well as visibility to the research training activities and educational material developed by the ERNs and other relevant clinical networks. Educational material developed within the online academic education course is focussed on the transversal aspects across RDs and is non-redundant with that of the ERNs. The specific objectives of this WP are to: ● Ensure a thorough EU-wide benchmark and assessment of RD academic trainings and e-learning courses in order to prevent any duplication of existing content and favour relevant adaptation and inclusion of existing courses in the future EJP-RD online course; ● Develop a comprehensive, high-quality e-learning course, both available to an academic audience but also to a wider public in coordination with a professional service provider; ● Closely monitor the impact of the course in order to implement the relevant modifications throughout the EJP-RD lifetime and ensure its widest impact. Description of work and role of partners WP16 - Online Academic education course [Months: 1-60] FFRD, INSERM, FGB, VUHSK, ISCIII, AP-HP, UKL-HD, AOUS, Radboudumc, SERMAS, NUTH, GOSH, EATRIS, EMBL, EURORDIS Task 16.1: Assess the needs, target audience, main topics of the academic education course (M1-M6), TL: FFRD; Participants: SERMAS (ERN TransplantChild), RUMC (LTP-Curie Institute for ERN GENTURIS), VUHSK, NUTH (EURO-NMD), EURORDIS, UKL-HD (ERN ERKNet), GOSH (LTP-HCL for ERN EpiCARE), APHP (for MetabERN and Endo-ERN) This task will be performed through a thorough benchmark of existing RD academic courses at EU level by i) building on the outcome of task 17.1 in Pillar 3 regarding ERNs needs and ii) working with other relevant stakeholders (EU Universities, Patients’ Organizations, Learned Societies, EU Infrastructures, Industry stakeholders having developed trainings on RD, etc.). Aside the content, the benchmark will also include targeted audiences of the current available courses as well as experts and lecturers involved in those courses. As far as possible shareable feedbacks from lecturers, students, developers and providers of the courses will be collected. This benchmark will enable to identify gaps and specific needs as well as the main topics to address with the most relevant lecturers to involve. Priority areas of training will be identified in order to implement the course in the most relevant way. Task 16.2: Developing the online course (M6-M48), TL: FFRD, Participants: ISCIII, EURORDIS, VUHSK, AOUS (LTP-CHU Dijon for ERN ITHACA), RUMC (LTP- Curie Institute for ERN GENTURIS), SERMAS (ERN TransplantChild), Inserm (Orph), Inserm (AMU), EATRIS, NUTH (ERN EURO-NMD), UKL-HD (ERN ERKNet), GOSH (LTP-HCL for ERN EpiCARE), APHP (for ERN MetabERN and Endo-ERN), FGB, UU (ELIXIR-SI), FutureLearn (subcontractor) Subtask 16.2.1: Format, technical issues, status, and accreditation STL: FFRD, Participant: FutureLearn (subcontractor) The most suitable format and options/tools for the course will be discussed in close coordination with the e-learning platform provider and the coordinators of the modules. European Credit Transfer System eligibility (ECTS) will be sought, as it will be an incentive to target students more specifically. Based on existing e-learning courses, the envisioned length for each module of the course would be 10 to 15 hours, over two to five weeks. The most-suited number of sessions/year/modules will also be defined, with a minimum of one session/year/module. Based on the success of each module, they could be run as many times a year as relevant with no added-fee. The selected e-learning platform is totally scalable and enables to adapt content for different audiences and to provide in parallel free-MOOC open to Page 113 of 161 Associated with document Ref. Ares(2018)6091977 - 28/11/2018 everyone and programme certification for enrolled students/learners. The partners will rely on a renowned e-learning platform with track record working with EU projects and top-ranked EU Universities together with a strong expertise in Health. The platform will help promote the course and disseminate it, in close coordination with WP5. The platform will be actively involved in managing lecturers of the different modules. Practical issues such as filming, e-tutoring, collaborative learning, virtual classroom will be further defined in collaboration with coordinators of the modules and the lecturers whilst keeping within the service provider contract. Subtask 16.2.2: Identify and work with relevant European universities, learned societies and other institutions to develop the content of the academic course STL: FFRD, Participants: ISCIII, EURORDIS, VUHSK, AOUS (LTP-CHU Dijon for ERN ITHACA), RUMC (LTP- Curie Institute for ERN GENTURIS), SERMAS (ERN TransplantChild), Inserm (Orph), Inserm (AMU), EATRIS, NUTH (for ERN EURO-NMD), UKL-HD (ERN ERKNet), GOSH (LTP-HCL for ERN EpiCARE), APHP (ERN MetabERN andENDO-ERN), FGB, UU (ELIXIR-SI),FutureLearn (subcontractor) Top-tier EU RD experts will be involved in the definition of the course content together with the most relevant lecturers. 10 to 12 modules have been envisioned but will be challenged by task 16.1 outputs. Each module will be built in close collaboration with two co-coordinators (objectives, content, e-learning options, lecturers, detailed programme, evaluation options, etc.). Co-coordinators of the modules are bringing diverse expertise that will enrich the approach: eight ERNs, Universities, Research Institutes (VUHSK, ISCIII, Inserm-AMU, Inserm-ORPHANET), Patients’ Organisations (EURORDIS), EU Infrastructures (EATRIS, ELIXIR, Charities (FFRD, FGB). Modules will be launched progressively: five modules would be implemented by M24, five more by M36 and the rest of them by M48, with the full course running by the end of M48 with several sessions per year per module. The modules to be launched at first will be selected based on task 16.1 outputs. The list of coordinators will also be enriched based on task 16.1 outputs. Modules will encompass a wide variety of subjects taking into consideration a bench-to-bedside approach. Whenever possible and relevant, a three-fold perspective will be followed including patients’ testimonies, clinicians’ perspective and researchers’ expertise. The course will be developed with the ability to link and flag ERN own research e-learning training activities. Access to the e-learning platform facilities to ERNs will also be facilitated. Task 16.3: Follow-up, assessment and monitoring of the e-learning course (M18-M60) TL: UCAM (ELIXIR-UK), UMAN (ELIXIR-UK), Participants: FFRD and FutureLearn ( subcontractor) A close and regular follow-up will be necessary to adapt the online course and ensure its effectiveness. Assessment will encompass both qualitative and quantitative and a strategy for the uptake of suggested improvements to the course itself. Evaluation activities to be performed in this task will be developed in collaboration and shared with transversal WP1 (task 1.3: Monitoring of the EJP RD activities). Objectivity will also be ensured with the task 16.3 leader not being involved in the development of the course’s content. Subtask 16.3.1 Quantitative assessment STL: UCAM (ELIXIR-UK), UMAN (ELIXIR-UK, Participant: FutureLearn (subcontractor) The quantitative follow-up and monitoring will be ensured by the e-learning platform as part of its basic contract (no extra fee). The platform will be capturing, in real time, demographic data (e.g. gender, geographic distribution, age, carrier stage, etc.) as well as students’ performance. De-identified raw data would need further interpretation that will be handled by ELIXIR-UK. Subtask 16.3.2 Follow-up of the assessment, feedback of coordinators/lecturers/attendees STL: UCAM (ELIXIR-UK), UMAN (ELIXIR-UK) Students’ assessment and evaluation will be defined in collaboration with coordinators and lecturers and will allow for a measure of training quality and impact. Metrics and Key Performance Indicators (KPIs) developed by ELIXIR will be used in order to adopt and refine a common benchmark mechanism for the different modules. This will be done in close collaboration with WP1/Task 1.3 and WP5. The application of a common feedback collection approach across all modules’ coordinators and lecturers will guarantee that the same core data will be gathered, allowing for an easy comparison between modules. This will provide not only a benchmarking process for training providers to use but also the ability (through the collection of appropriate metrics and KPIs) to determine the quality and impact of the training being delivered. A combination of short and long-term post-course feedback surveys will be fostered to measure the quality (short term) and impact (long term) of the course. This will be done in close links with WP1 and WP3 of the EJP RD transversal activities. Subtask 16.3.3 Monitoring/adaptation of the course STL: FFRD The modules of the course will be adapted in the subsequent sessions for a given module taken into consideration impact assessment studies. The e-learning platform enabling to run modules separately, improvements could be brought module/module and in a very flexible way. The adaptation of the course will be done in close collaboration with the modules co-coordinators and lecturers. Page 114 of 161 Associated with document Ref. Ares(2018)6091977 - 28/11/2018 Participation per Partner Partner number and short name WP16 effort 1 - INSERM 2.50 12 - FFRD 47.00 24 - FGB 1.00 32 - VUHSK 4.00 44 - ISCIII 3.50 54 - AP-HP 4.50 57 - UKL-HD 1.50 63 - AOUS 1.00 65 - Radboudumc 1.50 68 - SERMAS 1.50 69 - NUTH 1.50 70 - GOSH 1.50 75 - EATRIS 3.50 76 - EMBL 0.00 UU (ELIXIR-SE) 1.00 UNIMAN 6.00 UCAM 8.00 77 - EURORDIS 3.00 Total 92.50 List of deliverables Due Deliverable Deliverable Title Lead beneficiary Type 15 Dissemination level 16 Date (in Number14 months)17 Draft content of the D16.1 12 - FFRD Report Public 9 online academic course Content of the first 5 D16.2 12 - FFRD Other Public 24 online modules Content of the full online D16.3 12 - FFRD Other Public 48 course Confidential, only First Impact assessment for members of the D16.4 of the online academic 76 - EMBL Report consortium (including 36 course the Commission Services) Second Impact Confidential, only D16.5 assessment of the online 76 - EMBL Report for members of the 60 academic course consortium (including Page 115 of 161 Associated with document Ref. Ares(2018)6091977 - 28/11/2018 List of deliverables Due Deliverable Deliverable Title Lead beneficiary Type 15 Dissemination level 16 Date (in Number14 months)17 the Commission Services) Description of deliverables D173: Draft content of the online academic course (M9) D174: Content of the first 5 online modules (M24) D175: Content of the full online course (M48) D176 and D177: Impact assessment of the course (M36 and M60) D16.1 : Draft content of the online academic course [9] Draft content of the online academic course D16.2 : Content of the first 5 online modules [24] Content of the first 5 online modules D16.3 : Content of the full online course [48] Content of the full online course D16.4 : First Impact assessment of the online academic course [36] First Impact assessment of the online academic course Lead beneficiary: UCAM (ELIXIR-UK) D16.5 : Second Impact assessment of the online academic course [60] Second Impact assessment of the online academic course due at month 60 Lead beneficiary: UCAM (ELIXIR-UK) Schedule of relevant Milestones Due Milestone Milestone title Lead beneficiary Date (in Means of verification number18 months) Overview/benchmark Draft content course for MS56 of online courses on RD 12 - FFRD 9 the academic online course completed available Follow-up with the service Technical platform developed provider closely monitored MS57 and ready for online academic 12 - FFRD 18 and tracked through regular course deployment calls/emails Course accreditations Official feedbacks from MS58 obtained for the RD online 12 - FFRD 18 relevant organisations academic course First 5 modules of the RD 5 modules available online MS59 online academic course 12 - FFRD 24 and accessible to an EU-wide developed audience 12 modules available online Full online course available MS60 12 - FFRD 48 and accessible to an EU-wide online audience Page 116 of 161 Associated with document Ref. Ares(2018)6091977 - 28/11/2018 Work package number 9 WP17 Lead beneficiary 10 58 - EKUT Work package title ERN RD training and support programme Start month 1 End month 60 Objectives The overall objective of this WP is to deliver research training programs for the European Reference Networks (ERNs) focusing on cross-cutting and over-arching research themes. The specific objectives of this WP are: ● To map and assess the existing landscape of the training programs in the ERN training networks in terms of needs, target groups, formats, contents, and existing resources regarding cross-cutting and overarching research themes ● To develop and deliver tailored research training activities that will be periodically adjusted to current needs to support RD research in the formed ERN training groups ● To accredit the training activities across Europe. Description of work and role of partners WP17 - ERN RD training and support programme [Months: 1-60] EKUT, UKL-HD, LUMC, Radboudumc Methodology In order to implement training programs that provide a cross-ERN added value, the 24 ERNs will be divided into four training groups according to research topics that are shared by the ERNs of each group. The following training groups have been formed: • Group 1 “Neuro” will integrate: ERN-RND (coordination), EURO-NMD, EpiCare, ERN-Eye, ERN-CRANIO, and ERN-ITHACA, • Group 2 “Neoplasm and Malformation” will integrate: GENTURIS, EURACAN, PaedCan, ReCONNECT, EuroBlood Net, ERN RITA, and ERNICA. • Group 3 “Organs” will integrate: ERKNet, Rare-Liver, TransplantChild, Guard-Heart, ERN Lung, and ERN eUrogen, • Group 4 “Systemic” will integrate: Endo-ERN, METABERN, VASCERN, ERN Skin and BOND. These training groups represent the very first integration of ERNs on operational level. The ERN coordinators belonging to the respective groups will jointly introduce a decision-making process to decide on and review funded training activities. Matter of factly, the WP will coordinate its activities with the established ERN CG Working Group on guidelines, education and training. By date, there has not been coordination activities of this group as regards ERN training activities meaning that this WP will act as the main driver. Task 17.1: Mapping to collect information on preferences, needs and resources from the ERNs ecosystem (M1-M3) TL: LUMC, Participants: UKL-HD, EKUT, RUMC The goal of this online survey is for the first time to gather and assess information on cross-cutting and overarching research training interests, activities and themes to feed into the development of research training programs to be delivered in the ERN training groups. Four ERN training groups have been formed based common research topics. Such a mapping has not been done yet and will provide novel data as well as the basis for implementing the ERN training groups. Information and data have been collected by some ERNs with a focus on ERN specific content, although not in a coordinated fashion across ERNs. These data might nevertheless serve as a starting point. Research training needs and added value, target groups, formats, contents and existing resources will be taken into account when implementing a structured survey. The survey will contain overarching questions and questions tailored to the respective ERN groups. The results will also inform Pillar 3 Task 16.1 specifically regarding ERN training needs. Task 17.2: Development of training programs for the ERN training networks based on the results of survey, (M4-M6) TL: UKL-HD, Participants: EKUT, LUMC, RUMC; This task will develop bespoke training programs for the ERN groups based on the results of the survey performed in task 1 focusing on identified cross-cutting and overarching research topics. We will use focus group meetings to develop and consent on the training programs. Focus groups will be composed of ERN coordinators, ERN training leads and ePAG representatives. The output of the focus groups that is the consented training program will be delivered through task 17.3. Such training programs present a level of integration not yet achieved on operational level between the existing ERNs. So far ERNs have operationally focused on their respective networks. Task 17.3: Deliver training programs through the ERN training networks, (M7-M60) TL: EKUT, Participants: UKL-HD, RUMC, LUMC Page 117 of 161 Associated with document Ref. Ares(2018)6091977 - 28/11/2018 Based on the training programs produced in task 17.2, the ERN training groups will be planning, organizing and delivering research training activities. Based on the identified cross-cutting and overarching themes task forces will be formed that are composed of the ERN clinicians and researcher that are experts in the respective theme. Notably, no such cross-cutting ERN task forces on operational level exist yet and will thus bring about a new level of collaboration of the ERNs. The task forces will develop fitting training activities that might comprise formats like fellow exchange, clinical workshops, and further formats to be determined through the mapping exercise. Fellow exchanges might focus on performance of (i) small bilateral research projects linking partners from different ERNs through using cutting-edge methodologies and approaches and/or (ii) training of novel research methodologies that provide added value beyond the single ERN level. Clinical workshops will be directed towards multidisciplinary multi-disciplinary research themes that might have the potential to play a disruptive role in medical practise such as big data based care, tissue engineering and stem cell technologies as well as mind-machine interface. Primary addressees of the training activities are healthcare professionals from ERNs interested or active in research. Task 17.4 Accreditation of training activities, (M7-M60) TL: EKUT, Participants: UKL-HD, LUMC, RUMC The objectives of this task will be to seek the recognition of the training activities to be accredited by respective accreditation organisations such as the European Union of Medical Specialists (UEMS) to allow the participants to get CME accredited training activities recognised in their respective home countries. Participation per Partner Partner number and short name WP17 effort 57 - UKL-HD 15.00 58 - EKUT 18.00 64 - LUMC 15.00 65 - Radboudumc 15.00 Total 63.00 List of deliverables Due Deliverable Deliverable Title Lead beneficiary Type 15 Dissemination level 16 Date (in Number14 months)17 Results of survey on preferences, needs and D17.1 64 - LUMC Report Public 4 resources from the ERNs ecosystem EJP RD ERN training D17.2 57 - UKL-HD Report Public 7 programmes First Annual report D17.3 on implementation of 58 - EKUT Report Public 13 training programs Second Annual reports D17.4 on implementation of 58 - EKUT Report Public 60 training programs Description of deliverables D178: Results of survey on preferences, needs and resources from the ERNs ecosystem (M4) D179: EJP RD ERN training programmes (M7) D180 and D181: Periodic reports on implementation of training programs (M13 and M60) Page 118 of 161 Associated with document Ref. Ares(2018)6091977 - 28/11/2018 D17.1 : Results of survey on preferences, needs and resources from the ERNs ecosystem [4] Results of survey on preferences, needs and resources from the ERNs ecosystem D17.2 : EJP RD ERN training programmes [7] EJP RD ERN training programmes D17.3 : First Annual report on implementation of training programs [13] First Annual reports on implementation of training programs due at month 13 D17.4 : Second Annual reports on implementation of training programs [60] Second Annual reports on implementation of training programs due at month 60 Schedule of relevant Milestones Due Milestone Milestone title Lead beneficiary Date (in Means of verification number18 months) Consent by respective ERN MS61 ERN training groups formed 58 - EKUT 1 coordinators Training programs of ERN Confirmed research training MS62 58 - EKUT 6 training groups consented programs for ERN groups Page 119 of 161 Associated with document Ref. Ares(2018)6091977 - 28/11/2018 Work package number 9 WP18 Lead beneficiary 10 32 - VUHSK Work package title Development and adaptation of training activities Start month 24 End month 60 Objectives The overall objective of this WP is to ensure that capacity building activities within Pillar 3 address the developing education and training needs in RD research of key stakeholders (including clinicians, researchers, patient representatives, but also paramedical sector), across different EU countries. Fostering the constant flow of knowledge and know-how, arising from the activities of Pillars 2 and 4 and reaching out to RD research community as a whole will enhance usage of best practices and standards in RD research. These activities will be done in close collaboration and shared with WP1 Task1.3. These activities will decrease fragmentation of RD research education and training activities across universities, countries, infrastructures, and networks (such as ERNs). The specific objectives of this WP include: ● Adaptation of capacity building activities according to progress of work in Pillar 2 and Pillar 4; ● Adaptation of capacity building activities according to specific needs of EU-13 countries; ● Adaptation of capacity building activities according to specific ERN training and support needs (closely linked to the work of WP17 of Pillar 3 and WP20 of Pillar 4). Description of work and role of partners WP18 - Development and adaptation of training activities [Months: 24-60] VUHSK, FFRD, FTELE, ISS, IPCZD, EKUT, EURORDIS Other co-lead beneficiaries: IPCZ (40) and EURORDIS (77) Methodology Careful evaluation of different information sources on RD education and training needs will be performed including evaluation of Pillar 3 training users and developers’ experience surveys, self-assessments and reports. Internal (Pillar 1, 2 and 4 leaders, ERNs, EURORDIS) and external sources such as the Association of Medical Schools in Europe and European Union of Medical Specialists, will be consulted for the identification of areas for further development required to address specific emerging needs of the rare disease community (VUHSK, EURORDIS, ISS, FTELE, FFRD, EKUT). In addition, particular attention will be given to the specific adaptation of training activities for EU-13 countries (IPCZD (CHMI), VUHSK, UU (ELIXIR-SI)) with the aims of enhancing EU-13 inclusion into RD communities. Reports of identified gaps and needs will be shared with WP1 Task 1.3 and WP2 Task 2.2 for prioritization and annual planning and with WP5 for dissemination purposes. Task 18.1: Evaluation of developing needs according to progress of work in Pillars 2 and 4 and relevant adaptation of training activities (M24-M60) TL: EURORDIS and FFRD, Participants: EKUT, ISS, VUHSK, FTELE; Task 18.1 will work in synergy with the Operating Group and the Executive Committee (EURORDIS, VUHSK) to review progress, report and identify training areas in need of further development and/or not previously addressed within Pillar 3. For example, close attention will be given to ensure continuous relevance and alignment of training topics and areas of Pillar 3 WP14 (ISS), WP15 (EURORDIS) and WP16 (FFRD) with progress of work in WP10 and WP13 of Pillar 2 (ISS, FTELE, EKUT). Furthermore, it is envisaged that a new training activity will be developed to provide capacity building of the different stakeholders on the use of the common platform to be developed under WP11 of Pillar 2. Task 18.2: Evaluation of strategic priorities and development of existing training activities according to specific needs of EU-13 countries, (M24-M60) TL: IPCZD (CHMI) and VUHSK, Participants: EURORDIS, FFRD, EKUT, ISS, UU (ELIXIR-SI); Currently, EU-13 countries still lag behind in RD research and their wider participation is hindered by challenges such as lack of RD research and training funding and economic constraints for attending international conferences/workshops. Task 18.2 will provide the driving force to make available wider possibilities of education and training to participants from EU-13 (including rotation of courses and fellowships for EU-13 participants), hence contributing to their wider, more active and consistent participation in RD research. Additional efforts to disseminate the free on-line academic courses (WP16) within EU-13 countries will be made to increase visibility and accessibility of these resources. Task 18.2 co-leaders (IPCZD (CHMI) and VUHSK) supported by Pillar 3 leaders and partners (EURORDIS, ISS, FTELE, FFRD, EKUT, Univ of Ljubljana) will carefully evaluate strategic priorities in capacity building needs of EU-13 countries and Page 120 of 161 Associated with document Ref. Ares(2018)6091977 - 28/11/2018 will transfer their assessment to WP1 Task 1.3 and WP2 Task 2.2 for prioritization and annual planning and to WP5 for dissemination purposes. Task 18.3: Evaluation of developing ERN training and support needs and adaptation of training activities in WP17, (M24-M60) TL: EKUT, Participants: EURORDIS, VUHSK, FFRD Task 18.3 will work in synergy with WP17 of Pillar 3 (EKUT) and WP19, Task 19.2 of Pillar 4 to adapt ERN training and support programmes to the emerging and developing needs of ERNs including but not limited to training in methodologies for clinical trials (WP20 of Pillar 4). The 4 core training networks composed of representatives from all ERNs in WP17 will ensure relevance of the adaptation across rare diseases and facilitate implementation of the new methodologies in the different ERNs. Participation per Partner Partner number and short name WP18 effort 12 - FFRD 1.00 25 - FTELE 1.00 26 - ISS 1.00 32 - VUHSK 4.00 40 - IPCZD 2.00 58 - EKUT 1.00 77 - EURORDIS 2.00 Total 12.00 List of deliverables Due Deliverable Deliverable Title Lead beneficiary Type15 Dissemination level16 Date (in Number14 months)17 Final report on evaluation and adaptation of training programmes according D18.1 to EJP RD progress of 32 - VUHSK Report Public 60 work, specific needs of EU13 countries and ERN developing needs Description of deliverables D182: Final report on evaluation and adaptation of training programmes according to Pillar 2 and 3 progress of work, specific needs of EU-13 countries and developing needs of ERNs (M60) D18.1 : Final report on evaluation and adaptation of training programmes according to EJP RD progress of work, specific needs of EU13 countries and ERN developing needs [60] Other lead beneficiaries: EURORDIS (77), IPCZD (40) and EKUT (58) Final report on evaluation and adaptation of training programmes according to EJP RD progress of work, specific needs of EU13 countries and ERN developing needs Page 121 of 161 Associated with document Ref. Ares(2018)6091977 - 28/11/2018 Schedule of relevant Milestones Due Milestone Milestone title Lead beneficiary Date (in Means of verification number18 months) Page 122 of 161 Associated with document Ref. Ares(2018)6091977 - 28/11/2018 Work package number 9 WP19 Lead beneficiary 10 75 - EATRIS Work package title Facilitating partnerships and accelerating translation for higher patient impact Start month 1 End month 60 Objectives The overall aim of this work package is to provide researchers the mix of competences (drug/diagnostic development, regulatory, methodological, pre-clinical and clinical development, IPR) needed to support rigorous translational research, to secure follow-on funding and find partners for the development of new treatments and diagnostics for rare diseases. To move a research project across all the compulsory steps that lead to market authorization and reimbursement, and remove the well-known difficulties, a multitude of different actions and different sets of competencies are necessary. This WP will support the RD community to more effectively translate high quality research into high impact interventions for the RD patient community, by creating a bridge between basic research and medical innovation, otherwise known as the “bench to bed-side” approach. The specific objectives are: ● Empower researchers to conduct rigorous translational research by providing self-help resources and active project mentoring and technical support; ● Improve the uptake of successful research projects towards clinical implementation with active exploitation and follow-on funding support; ● Improve efficiency and outcomes of translational research, and develop novel funding concept to reduce the ‘valley of death’ funding gap. Description of work and role of partners WP19 - Facilitating partnerships and accelerating translation for higher patient impact [Months: 1-60] EATRIS, FFRD, FGB, FTELE, CVBF, UNEW, CCRI, CLB, GUF, HSK, HUGEN Other lead beneficiary: FTELE (25) Task 19.1: Accelerating translation TL: CVBF, EATRIS, Participants: FTELE, UNEW, GUF (ERN LUNG), CCRI (PAEDCAN) Subtask 19.1.1: Innovation Management Toolbox (M1-M60) In this task, a toolbox will be established as an online virtual library that provides self-help resources that will be openly accessible to the RD research community, and will be utilised by the WP partners and Innovation Managers to implement documents and guidance for projects supported here. This library will be accessible through the virtual platform in Pillar 2. Via electronic surveys of the ERN and basic research community conducted by ERNLUNG, the pressing needs for self-help resources and templates will be ascertained, to drive the population of the library. The toolbox will include technical guidance (such as target validation techniques, use of molecular imaging for drug development, and - drawing upon the work done in other pillars, especially Pillar 2 - patient confidentiality and data handling, animal welfare, biorepositories, plus intellectual property management and contract templates), a project management manual, and regulatory guidance. Many of these materials have already been created in other contexts and will be available after collation. Particular attention to the Paediatric Regulation will be given by CVBF and a handbook will be created by UNEW, to develop an ‘ACT’ (Advisory Committee on Therapeutics) model for Rare Diseases, based on the successful TACT model in the muscular dystrophy field. WP19 will make this library accessible through the Central Helpdesk and Virtual Platform of the EJP RD. It will also provide guidance to Pillar 2 on special requirements for translational/ clinical research. Subtask 19.1.2: Assessment of translational research projects (M1-M54) All projects selected for funding through Pillar 1 and ongoing projects from E-Rare-3 will be analyzed to establish the development stage of the project and the likely product classification of the concept. In so doing, the future developmental needs should be confirmed including the regulatory pathway (in collaboration with the regulatory transversal WP4). This analysis will be undertaken by FTELE and EATRIS, and Paediatric projects will be assessed by CVBF, all of which are expert organizations in innovation management and translational research, and comprise experts with basic science, product development, regulatory, commercial and intellectual property expertise. Projects eligible for IM support are: ● Translational research projects funded in Pillar 1; ● Successful RDR Challenge projects from WP8 of Pillar 1; Page 123 of 161 Associated with document Ref. Ares(2018)6091977 - 28/11/2018 ● Ongoing projects (with 2 years or more still to run at time of application) from E-RARE 3 that request support and are identified as translational. Subtask 19.1.3: Real-time mentoring and technical support for translational research projects (M1-M60) All projects that are translational will be offered the support of a dedicated Innovation Manager (IM) that will utilise the innovation management toolbox (T 19.1) and the extensive networks of the partners in the EJP RD. These networks include those of the ESFRI infrastructures (BBRMI, ECRIN, EATRIS, ELIXIR), the ERNs, global partners in and outside of IRDiRC (especially those with drug, medtech and diagnostics development expertise, such as NIH NCATS, CDRD, LifeArc, AFM Telethon, FTELE), and the paediatric research community through CVBF-EPTRI. Projects will be supported until IM capacity is exhausted and so will be on a first-come-first-serve basis. The assigned Innovation Manager will be the permanent contact point for the supported project, granting access to expertise, facilities and tools. From M1 IM will build a pool of mentors by approaching individuals to request involvement. The mentors enrolled in WP19 will be from industry and regulatory organisations, providing excellent contact between research, industry and regulatory sectors. Consenting experts will be added to a database and will sign a mentoring agreement to establish the rules of engagement. Experts subsequently recruited into support of specific projects will mentor team in a longitudinal, distance format, via regular conference call meetings and occasional face-to-face as needed, and will verify the achievement of milestones, advise on further steps and issue recommendations on technical progress, in order to maximise the project’s potential of success and further development towards the clinic. Finally, on ad hoc basis, the IM and mentors will provide guidance to Pillar 2 on special requirements for translational/clinical research if demanded. Task 19.2: Support in exploitation and follow-on funding (M1-M60) TL:FTELE; Participants: EATRIS, CVBF, FFRD, FGB, HUGEN (HACETTEPE), CLB (ERN-EURACAN), HSK (MetabERN), AFM This task is aimed at providing support and guidance to projects approaching the end of EJP RD funding, in particular on the definition and implementation of a development and exploitation plan. Activities in this task are accessible to principal investigators: ● Funded through the transnational calls of Pillar 1 and that have been indicated as candidates to receive IM support in subtask 19.1.3 ● Originated from the PoC challenges in P1WP8 ● Funded through E-Rare calls upon request and with minimum technology readiness level (TRL) 4. Subtask 19.2.1: Assessing the potential of projects (M1-M54) The aim of this sub-task is to provide Pillar 1 translational projects and those from PoC RDR Challenges approaching their term, the opportunity to discuss envisaged next steps with a panel of experts in drug development, IP and business development, potentially including also relevant experts in the specific disease area (ERNs). Special attention will be paid in selecting the experts for the assessment panel in order to avoid any conflict of interest. The aim of this assessment is to identify the best strategy to bring the projects forward in development depending on the data obtained, TRL reached and expertise required to further development. Subtask 19.2.2: Development and exploitation plan (M3-M60) Based on the assessment conducted in the subtask above, PIs will receive support in the definition of a suitable plan to implement the identified strategy, potentially using a limited part of the remaining funding to cover initial development activities. The plan will encompass: ● Research activities mainly aimed at validating data obtained in the project ● IP strategy ● Definition of the unmet need filled by the project (analysis of the disease field, epidemiology, available treatments/ diagnostics, main players) ● Sustainability plan (follow on funding, partnership with industry, company creation). Subtask 19.2.3: Follow-on funding (M5-M60) In order to implement the plan defined above, in the cases where further funding is needed to reach proof of concept, support in identifying suitable funding opportunities (either through public or private funding) and guidance in preparing the application will be provided through the expertise in technology transfer, pre-clinical and clinical development as well as in regulatory affairs. Subtask 19.2.4: Partnering support (M6-M60) This task will support projects that meet the requirements to be uptaken by companies/investors for the achievement of their development plan. FTELE has established over the years a number of partnerships with commercial partners that have allowed to bring one advanced therapy to patients (i.e. Strimvelis, approved by EMA in 2016) and to support clinical trials for 5 genetic diseases. This expertise, combined with that of the other partners in the task, will be made available to PIs to support them in approaching companies. In addition to the identification of the best candidate partners, a guide to the preparation of appropriate project presentations (both confidential and non-confidential) will be provided, including layout models. Task 19.3: Evaluation of Innovation Management and exploitation support tasks (M44-M48) Page 124 of 161 Associated with document Ref. Ares(2018)6091977 - 28/11/2018 TL: GUF (ERN-LUNG) On the basis of surveys and - if needed - interviews of users of the services provided in T19.1-T19.4, ERN-LUNG will assess the user satisfaction and added value of both services and the library. A report will be created utilizing the Transversal Sustainability matrix provided by WP3, to inform sustainability planning and monitoring Task 1.3. Task 19.4: Roadmap for a European investment platform for RD (M2-M44) TL: FTELE, EATRIS Expanding on specific examples of novel investment platforms in RD and elsewhere, this task will assess feasibility and define a roadmap for the creation of a pan-European funding platform with a focus on RDs, to optimize the path to the patent and sustain the important innovation activities of the EJP RD. The roadmap will feed the sustainability strategy of the EJP RD as a whole performed in WP3. Participation per Partner Partner number and short name WP19 effort 12 - FFRD 7.00 24 - FGB 12.00 25 - FTELE 74.00 27 - CVBF 28.00 52 - UNEW 10.00 53 - CCRI 3.00 56 - CLB 2.00 59 - GUF 5.00 60 - HSK 3.00 75 - EATRIS 53.00 83 - HUGEN 11.00 Total 208.00 List of deliverables Due Deliverable Deliverable Title Lead beneficiary Type 15 Dissemination level 16 Date (in Number14 months)17 Confidential, only First Periodic report on for members of the mentoring and technical D19.1 75 - EATRIS Report consortium (including 24 support for translational the Commission research projects Services) Second Periodic report Confidential, only on mentoring and for members of the D19.2 technical support for 75 - EATRIS Report consortium (including 42 translational research the Commission projects Services) Third Periodic report on Confidential, only mentoring and technical D19.3 75 - EATRIS Report for members of the 60 support for translational consortium (including research projects Page 125 of 161 Associated with document Ref. Ares(2018)6091977 - 28/11/2018 List of deliverables Due Deliverable Deliverable Title Lead beneficiary Type 15 Dissemination level 16 Date (in Number14 months)17 the Commission Services) Confidential, only for members of the Final report on follow-on D19.4 25 - FTELE Report consortium (including 60 funding and exploitation the Commission Services) User satisfaction and Confidential, only feasibility report on for members of the Facilitating partnerships D19.5 59 - GUF Report consortium (including 48 and accelerating the Commission translation for higher Services) patient impact Confidential, only Roadmap for EU for members of the D19.6 investment platform for 25 - FTELE Report consortium (including 36 RDs the Commission Services) Description of deliverables D183 to D185: Periodic reports on mentoring and technical support for translational research projects (M24, M42, M60) D186: Final report on follow-on funding and exploitation (M 60) D187: User satisfaction and feasibility report (M48) D188: Roadmap for EU investment platform for RDs (M36) D19.1 : First Periodic report on mentoring and technical support for translational research projects [24] Other lead beneficiary: CVBF (27) First Periodic report on mentoring and technical support for translational research projects due at month 24 D19.2 : Second Periodic report on mentoring and technical support for translational research projects [42] Other lead beneficiary: CVBF (27) First Periodic report on mentoring and technical support for translational research projects due at month 42 D19.3 : Third Periodic report on mentoring and technical support for translational research projects [60] Other lead beneficiary: CVBF (27) Third Periodic report on mentoring and technical support for translational research projects due at month 60 D19.4 : Final report on follow-on funding and exploitation [60] Other lead beneficiary: FGB (24) Final report on follow-on funding and exploitation D19.5 : User satisfaction and feasibility report on Facilitating partnerships and accelerating translation for higher patient impact [48] User satisfaction and feasibility report on Facilitating partnerships and accelerating translation for higher patient impact D19.6 : Roadmap for EU investment platform for RDs [36] Other lead beneficiary: EATRIS (75) Roadmap for EU investment platform for RDs Page 126 of 161 Associated with document Ref. Ares(2018)6091977 - 28/11/2018 Schedule of relevant Milestones Due Milestone Milestone title Lead beneficiary Date (in Means of verification number18 months) Innovation Management MS63 75 - EATRIS 8 Toolbox available on website Toolbox openly accessible User satisfaction survey Internal report on collected MS64 75 - EATRIS 46 completed survey results Benchmarking of investment Internal report on MS65 75 - EATRIS 30 platform models completed benchmarking Page 127 of 161 Associated with document Ref. Ares(2018)6091977 - 28/11/2018 Work package number 9 WP20 Lead beneficiary 10 54 - AP-HP Accelerating the validation, use and development of innovative methodologies tailored Work package title for clinical trials in RDs Start month 1 End month 60 Objectives The overall objective of this WP is to foster the development of innovative methodologies tailored for clinical studies in RDs. The specific objectives are to map the best methodologies for clinical studies in RDs and to validate innovative and promising design and analysis methodologies for therapy evaluation in some specific rare diseases. This WP will support ERNs to use the most adapted methodologies improving clinical trial studies in RDs. Moreover innovative design and analysis methodologies in RD areas should be developed in fields with unmet need in order to fill the gaps. Once validated, agreed and accepted by all stakeholders, the innovative methodologies will foster the achievement of IRDiRC goals. Description of work and role of partners WP20 - Accelerating the validation, use and development of innovative methodologies tailored for clinical trials in RDs [Months: 1-60] AP-HP, UKA, CCRI, UKL-HD, HSK, IOR, SERMAS, GOSH, ECRIN Other lead beneficiaries: UKA (16) and HSK (60) Task 20.1: Task Force Group (M1-M60) TL: UKA, APHP, HSK (Metab-ERN), Participants: UKA, APHP, CCRI (Ped-Can), IOR (ERN-Bond), UKL-HD (ERKnet), GOSH (EPICARE), ECRIN, EURORDIS, ULiv, AFM The main activities within the WP20 will be coordinated and monitored by a Task Force Group (TFG) of experts which will be established during the first month of the EJP RD project (subtask 20.1.1) and represented by the WP leaders with additional scientific, clinical and methodological experts and representative(s) of patients from EURORDIS. The TFG will be responsible for review of the existing state-of-the-art methodologies at European and international levels in specific topics related to clinical trials in rare diseases. Whenever needed the TFG will expand its capacity by including additional experts from ERNs and other external specialists covering different disciplines. The TFG will review the standard of clinical studies methodology usable in RD research and deliver the roadmap of available methodologies promising to gain efficiency for a given RD or a group of RDs. The duties of the TFG will include: (i) coordination of activities within WP20; (ii) identification of promising areas for the demonstration projects and innovative methodology projects; (iii) preparation of detailed internal call (topic) description for internal call for demonstration projects and innovative methodology projects (Tasks 20.3 & 20.4); (iv) writing of the final report summarizing main results of the WP20 including recommendations roadmap. The Group will start the work by a concise knowledge interchange and identification of highly promising areas for validation of recent promising methodologies and areas in need of further innovation. The TFG will be responsible for the monitoring of the progress of the projects and annual progress reports will serve as input to the EJP RD Annual Progress Report. The TFG will also identify the items/findings ready for dissemination to the RD community through Transversal WP5 but also through the clinical trials support office with ECRIN (task 20.2) and through training activities of WPs 15 and 16. The main results of the WP20 of the TFG roadmap will be disseminated via a peer review publications, e.g. summarized in a “Points to Consider” paper by the regulators (EMA, etc.). Task 20.2: Support in design and planning of RD clinical studies (M1-M60) TL: ECRIN, Participants: APHP (ERN-Skin), SERMAS (ERN Child Transplant) To support the RD/ERN clinical investigators in the preparation of clinical studies for the development of new treatments, for drug or device repurposing, or for diagnostic studies a support office will be set up (task 20.2.1). The support office will benefit from the current ECRIN organization reinforced by a dedicated RD clinical manager who will be the permanent contact point for the ERN clinical investigators and partners, collecting information on the projects, organizing and facilitating their access to the specific expertise and ensuring timely delivery of support. The (ECRIN) RD clinical manager will be supported by the (ECRIN) Clinical Operation Manager and medical expert(s). The support will include design and methodological aspects of the study and statistical methodology adapted to the small sample size. The office will offer support to ERN investigators to plan trials testing new treatments or new strategies for the benefit of the patients. Beside ECRIN specialists, it will include two representatives of ERNs, and a methodology expert (from the TFG). Additional experts from the TFG will provide specific input upon request. A “Terms of Reference” document will describe the mission, composition and activities of the support office, and the Page 128 of 161 Associated with document Ref. Ares(2018)6091977 - 28/11/2018 eligibility of the investigators requesting support (first restricted to members of ERNs, then expanded to the Pillar 1 calls or projects on clinical studies). The support office will meet through teleconferences, inviting the investigators to present and discuss their project proposals. For each project, the office will propose a spectrum of support in the planning of clinical studies on RDs including: (i) the site and country selection; (ii) patient recruitment strategies; (iii) information on regulatory and ethical aspects; (iv) informed consent and insurance requirements on the management of samples and IMP; (v) recommendations on monitoring plan, on data management, sharing and analysis; (vi) support on cost evaluation; (vii) recommendations on consortium and study management and governance; (viii) recommendations on contracting, together with risk assessment and mitigation. Further design aspects will include recommendations on the choice the most efficient study design, the choice of primary endpoint, the comparator, inclusion and exclusion criteria, and on all aspects of the statistical methodology of the study. The requests and nature of support provided will be recorded for evaluation of efficiency (Task 1.3) and incoming needs towards the reinforcement of the capacity of ERNs to initiate and conduct clinical studies, independently of industry sponsors. Task 20.3: Demonstration projects on existing statistical methodologies to improve RD clinical trials (M9-M48) TL: IOR (ERN BOND); GOSH (EPICARE), Participants: APHP, UKA By M9 WP20 will organize call for 6 demonstration projects. This will be done with support from Pillar 1 chosen partner to ensure transparent and efficient call implementation and evaluation process. Recent developments suggest that traditional methodologies do not result in cost effective and efficient trials supporting RD research as needed. A major source of innovative methodologies are recently published by IDeAl , asterix and InSPiRe . However, validation of these new methodologies is still missing. Thus, the overall aim of the 6 small scale demonstration projects will be to validate in practical settings the existing, most recently presented innovative methodologies, in practil settings to provide necessary proofs of their efficacy and thereby raise awareness and usage of these methodologies. The demonstration will be based on existing RD data or running co-funded pilot studies (with industry or private partners) to proof the feasibility for possible use of these methods. The main source for these data will be completed clinical trials data of ERNs. As result, the investigation will show the benefit of these innovative methodologies for therapy evaluation in RD and thereby foster better treatment evaluation with efficient analysis techniques. Taking into account, that the various design aspects, like definition of endpoints, trial layout, randomization techniques and power calculation are related to analysis techniques, the result of this task will be pivotal in influencing design and implementation of clinical trials in RD at large scale. The progress and results of the demonstration projects will be followed and referred to the TFG during the monthly meetings. Finally, these results will be communicated to Pillar 4, Task 20.2, to Pillar 3 WP18 and to the communication manager of the EJP RD. It is expected that with the launch of the call in M9 demonstrators should start in month 15 with 30 months (2.5 years) working period. Thus, the final results of these validation projects will be expected at M45. Task 20.4: Projects on innovative methodologies to improve RD clinical trials in limited populations (M12-M56) TL: CCRI (PAEDCan) & HSK (Metab ERN), Participants: APHP, UKA Recently, the IRDiRC Task Force for ‘Small population Clinical Trials’ tackled the issue of optimization and improvement of commonly adopted approaches to reach agreement between the different stakeholders on appropriate small population studies. Based on the inputs from this Task Force, the TFG together with other relevant experts will identify the most promising areas of research on missing methodologies to close the gaps in clinical studies on limited populations. The internal call will be organized similarly to the one on demonstrators, with the input from the TFG on the detailed call text and factual implementation by partners (from Pillar 1) possessing expertise in launching, implementing and evaluating call for projects. The proposed areas for innovative methodology projects will include: From the clinical perspectives: ● Finding more appropriate endpoints for clinical studies in RDs which allow assessing clinically meaningful responses as PCOMs ● Validation of possible composite end points and surrogates ● Capture in the cohorts of natural history studies efficacy and important safety information through life span. And from statistical methodologies perspectives: ● Level of evidence assessment associated with randomization in limited populations ● Efficient designing and analysis of bridging studies for RD ● Pharmacometric modeling for design and analysis in limited populations The involvement of clinicians, patients and methodologists will be considered as the best configuration to meaningful results to customized methodological development of clinical studies matching the patients need (and not only focusing on testing of a given therapy). The internal call for the innovative methodology projects will be launched in month 12 and will start in month 18 with the 36-month working period. Thus the results are expected by M54. Page 129 of 161 Associated with document Ref. Ares(2018)6091977 - 28/11/2018 Participation per Partner Partner number and short name WP20 effort 16 - UKA 59.00 53 - CCRI 10.00 54 - AP-HP 68.00 57 - UKL-HD 4.00 60 - HSK 17.00 61 - IOR 6.00 68 - SERMAS 4.00 70 - GOSH 6.00 74 - ECRIN 77.00 Total 251.00 List of deliverables Due Deliverable Deliverable Title Lead beneficiary Type15 Dissemination level16 Date (in Number14 months)17 Confidential, only Terms of Reference of for members of the D20.1 clinical studies support 74 - ECRIN Report consortium (including 6 office the Commission Services) Confidential, only First Report on the for members of the D20.2 assessment of the support 74 - ECRIN Report consortium (including 36 office activity the Commission Services) Confidential, only Second Report on the for members of the D20.3 assessment of the support 74 - ECRIN Report consortium (including 48 office activity the Commission Services) Confidential, only Third Report on the for members of the D20.4 assessment of the support 74 - ECRIN Report consortium (including 60 office activity the Commission Services) Confidential, only First Report on for members of the options for long-term D20.5 74 - ECRIN Report consortium (including 48 sustainability of the the Commission support office Services) Confidential, only Second Report on D20.6 74 - ECRIN Report for members of the 60 options for long-term consortium (including Page 130 of 161 Associated with document Ref. Ares(2018)6091977 - 28/11/2018 List of deliverables Due Deliverable Deliverable Title Lead beneficiary Type 15 Dissemination level 16 Date (in Number14 months)17 sustainability of the the Commission support office Services) Confidential, only List of topics for for members of the D20.7 demonstration projects 61 - IOR Report consortium (including 6 call the Commission Services) Final Report of funded D20.8 16 - UKA Report Public 50 demonstration projects Final Report of funded D20.9 new methodology 16 - UKA Report Public 58 projects Summary Report of Task D20.10 54 - AP-HP Report Public 60 Force Group Description of deliverables D189: “Terms of Reference” for clinical studies support office group (M6) D190 to D192: Report on the assessment of the support office activity (M36, M48, M60) D193 and D194: Report on options for long-term sustainability of the support office (M48 and M60) D195: List of topics for demonstration projects call (M6) D196: Final Report of funded Demonstration Projects’ (M50) D197: Final Report of funded methodology Projects (M58 D198: Summary Report of TFG (M60) D20.1 : Terms of Reference of clinical studies support office [6] Terms of Reference of clinical studies support office D20.2 : First Report on the assessment of the support office activity [36] First Report on the assessment of the support office activity due at month 36 D20.3 : Second Report on the assessment of the support office activity [48] Second Report on the assessment of the support office activity due at month 48 D20.4 : Third Report on the assessment of the support office activity [60] Third Report on the assessment of the support office activity due at month 60 D20.5 : First Report on options for long-term sustainability of the support office [48] First Report on options for long-term sustainability of the support office due at month 48 D20.6 : Second Report on options for long-term sustainability of the support office [60] Second Report on options for long-term sustainability of the support office due at month 60 D20.7 : List of topics for demonstration projects call [6] Other lead beneficiary AP-HP (54) List of topics for demonstration projects call D20.8 : Final Report of funded demonstration projects [50] Other lead beneficiaries: AP-HP (54), IOR (61) and GOSH (70) Final Report of funded demonstration projects D20.9 : Final Report of funded new methodology projects [58] Other lead beneficiaries: AP-HP (54), CCRI (10) and HSK (60) Final Report of funded new methodology projects D20.10 : Summary Report of Task Force Group [60] Page 131 of 161 Associated with document Ref. Ares(2018)6091977 - 28/11/2018 Other lead beneficiary: AP-HP (54) Summary Report of the Task Force Group Schedule of relevant Milestones Due Milestone Milestone title Lead beneficiary Date (in Means of verification number18 months) MS66 Task Force Group set up 16 - UKA 1 Task Force Appointment list 6 demonstration of MS67 methodologies projects 61 - IOR 15 List of demonstration projects launched 6 innovative methodologies MS68 53 - CCRI 18 List of innovative projects projects launched Report about Kick-off of Clinical trials support office MS69 54 - AP-HP 3 clinical trials office support established group Page 132 of 161 Associated with document Ref. Ares(2018)6091977 - 28/11/2018 Work package number 9 WP21 Lead beneficiary 10 1 - INSERM Work package title Ethics requirements Start month 1 End month 60 Objectives The objective is to ensure compliance with the 'ethics requirements' set out in this work package. Description of work and role of partners WP21 - Ethics requirements [Months: 1-60] INSERM This work package sets out the 'ethics requirements' that the project must comply with. List of deliverables Due Deliverable Deliverable Title Lead beneficiary Type15 Dissemination level16 Date (in Number14 months)17 Confidential, only for members of the D21.1 A - Requirement No. 1 1 - INSERM Ethics consortium (including 12 the Commission Services) Confidential, only for members of the NEC - Requirement No. D21.2 1 - INSERM Ethics consortium (including 12 2 the Commission Services) Confidential, only for members of the GEN - Requirement No. D21.3 1 - INSERM Ethics consortium (including 12 3 the Commission Services) Confidential, only for members of the D21.4 H - Requirement No. 4 1 - INSERM Ethics consortium (including 12 the Commission Services) Confidential, only for members of the D21.5 H - Requirement No. 5 1 - INSERM Ethics consortium (including 12 the Commission Services) Confidential, only for members of the D21.6 H - Requirement No. 6 1 - INSERM Ethics consortium (including 12 the Commission Services) Page 133 of 161 Associated with document Ref. Ares(2018)6091977 - 28/11/2018 List of deliverables Due Deliverable Deliverable Title Lead beneficiary Type 15 Dissemination level 16 Date (in Number14 months)17 Confidential, only for members of the D21.7 H - Requirement No. 7 1 - INSERM Ethics consortium (including 12 the Commission Services) Confidential, only for members of the D21.8 H - Requirement No. 8 1 - INSERM Ethics consortium (including 12 the Commission Services) Confidential, only for members of the D21.9 H - Requirement No. 9 1 - INSERM Ethics consortium (including 12 the Commission Services) Confidential, only for members of the POPD - Requirement No. D21.10 1 - INSERM Ethics consortium (including 12 10 the Commission Services) Confidential, only for members of the POPD - Requirement No. D21.11 1 - INSERM Ethics consortium (including 12 11 the Commission Services) Confidential, only for members of the POPD - Requirement No. D21.12 1 - INSERM Ethics consortium (including 12 12 the Commission Services) Confidential, only for members of the POPD - Requirement No. D21.13 1 - INSERM Ethics consortium (including 12 13 the Commission Services) Confidential, only for members of the GEN - Requirement No. D21.14 1 - INSERM Ethics consortium (including 12 14 the Commission Services) Confidential, only for members of the GEN - Requirement No. D21.15 1 - INSERM Ethics consortium (including 12 15 the Commission Services) Description of deliverables Page 134 of 161 Associated with document Ref. Ares(2018)6091977 - 28/11/2018 The 'ethics requirements' that the project must comply with are included as deliverables in this work package. D21.1 : A - Requirement No. 1 [12] 5.4. The applicant must provide a general guidance on Directive 2010/63/EU, the nature of the experiments, the procedures to ensure the welfare of the animals, the principle of the three Rs will be applied, and training requirement for researchers, whenever animal research is involved 5.7. The applicant must clarify whether non-human primates will be involved in this study and justify their inclusion in the research. D21.2 : NEC - Requirement No. 2 [12] 6.1. A statement with the applicant's commitment not to transfer any personal data/material from or to the EU before obtaining the relevant authorisations must be provided. 6.2. The applicant must confirm that the ethical standards and guidelines of Horizon2020 will be rigorously applied, regardless of the country in which the research is carried out. 6.4. The applicant must provide details on the material which will be imported to/exported from EU and adequate authorisation must be provided. D21.3 : GEN - Requirement No. 3 [12] 12.2. An Ethics Board (AREB WP4) is to be established which must include the relevant independent expertise to monitor the ethical concerns of this project. A periodic report from the Ethics Board must be submitted. D21.4 : H - Requirement No. 4 [12] 2.1. Details on the procedures and criteria that will be used to identify/recruit research participants must be provided. D21.5 : H - Requirement No. 5 [12] 2.2. Detailed information on the informed consent procedures that will be implemented for the participants must be provided. D21.6 : H - Requirement No. 6 [12] 2.3. Templates of the informed consent forms and information sheet must be provided. They have to be in the language and terms understandable by the participants. D21.7 : H - Requirement No. 7 [12] 2.4. The applicant must clarify whether children and/or adults unable to give informed consent will be involved and, if so, justification for their participation must be provided. D21.8 : H - Requirement No. 8 [12] 2.5. The applicant must clarify how consent/assent will be ensured in case children and/or adults unable to give informed consent are involved. D21.9 : H - Requirement No. 9 [12] 2.11. Copies of ethics approvals for the research with humans must be submitted. D21.10 : POPD - Requirement No. 10 [12] 4.1. The applicant must check if a declaration on compliance and/or authorisation is required under national law for collecting and processing personal data as described in the proposal. If yes, the declaration on compliance and/or authorisation must be [kept on file (to be specified in the grant agreement)] [submitted as a deliverable]. D21.11 : POPD - Requirement No. 11 [12] 4.2. If no declaration on compliance or authorisation is required under the applicable national law, a statement from the designated Data Protection Officer that all personal data collection and processing will be carried out according to EU and national legislation must be [kept on file (to be specified in the grant agreement)] [submitted as a deliverable]. D21.12 : POPD - Requirement No. 12 [12] 4.4. Detailed information on the procedures for data collection, storage, protection, retention, and destruction, and confirmation that they comply with national and EU legislation must be [included in the grant agreement before signature] [kept on file (to be specified in the grant agreement)] [submitted as a deliverable]. D21.13 : POPD - Requirement No. 13 [12] 4.9. In case of further processing of previously collected personal data, relevant authorisations must be [kept on file (to be specified in the grant agreement)] [submitted as a deliverable]. D21.14 : GEN - Requirement No. 14 [12] Page 135 of 161 Associated with document Ref. Ares(2018)6091977 - 28/11/2018 12.1. An Ethics Advisor with the relevant independent expertise to monitor the ethical concerns in this project must be appointed. A periodic report from the Ethics Advisor must be submitted. D21.15 : GEN - Requirement No. 15 [12] 12.1. An Ethics Advisor with the relevant independent expertise to monitor the ethical concerns in this project must be appointed. A periodic report from the Ethics Advisor must be submitted. 12.2. An Ethics Board must be established which includes the relevant independent expertise to monitor the ethics concerns of this project. A periodic report from the Ethics Board must be submitted. The Ethics Board should make sure the H2020 framework for ethics is fully applied to the planned subsidiary projects, and the ethics management of these should be carried out within the H2020 framework. Schedule of relevant Milestones Due Milestone Milestone title Lead beneficiary Date (in Means of verification number18 months) Page 136 of 161 Associated with document Ref. Ares(2018)6091977 - 28/11/2018 1.3.4. WT4 List of milestones Due Milestone WP Milestone title Lead beneficiary Date (in Means of verification number18 number9 months)17 Coordination & Minutes of the 1st Operating MS1 governance structures WP1 1 - INSERM 1 Group conference call established Helpdesk entry point MS2 WP1 1 - INSERM 3 Website set up Policy Board MS3 WP1 1 - INSERM 3 List of Policy Board Members established Survey on prioritization MS4 criteria set up and WP2 27 - CVBF 3 Survey document launched Prioritization scheme and list of criteria Minutes of the ExCom and MS5 WP2 44 - ISCIII 6 validated by ExCom Policy Board meeting and Policy Board Survey to national mirror groups MS6 WP3 26 - ISS 5 Survey document established and launched Proposed model approved by Suitable structure and the EJP-RD Governance and MS7 sustainability model for WP3 75 - EATRIS 42 MS according to decision- the EJP RD proposed making procedures Final proposal for Final Business model and MS8 decision on the WP3 44 - ISCIII 54 sustainability plan for sustainability roadmap adoption MS9 AREB set up WP4 24 - FGB 5 List of AREB members 1st Annual AREB MS10 WP4 24 - FGB 6 Meeting minutes meeting held 2nd Annual AREB MS11 WP4 24 - FGB 18 Meeting minutes meeting held 3rd Annual AREB MS12 WP4 24 - FGB 30 Meeting minutes meeting held 4th Annual AREB MS13 WP4 24 - FGB 42 Meeting minutes meeting held Set of template agreements for IPR Availability on-line (EJP RD MS14 WP4 25 - FTELE 7 issues available to the website) community EJP RD social media Relevant social media MS15 WP5 1 - INSERM 2 pack set up and running accounts Decision on the organization of the Minutes of the relevant MS16 WP5 1 - INSERM 4 RE(ACT) 2020 ExCom conference call congress Page 137 of 161 Associated with document Ref. Ares(2018)6091977 - 28/11/2018 Due Milestone WP Milestone title Lead beneficiary Date (in Means of verification number18 number9 months)17 Decision on the organization of the Minutes of the relevant MS17 WP5 1 - INSERM 18 RE(ACT) 2022 ExCom conference call congress Decision on the organization of the Minutes of the relevant MS18 WP5 1 - INSERM 42 RE(ACT) 2024 ExCom conference call congress Target countries and voluntary helpers for List of target countries and MS19 WP5 1 - INSERM 2 translated Newsletter voluntary helpers agreed Public Call document on Implementation of MS20 WP7 34 - ZonMw 7 website and announcement of Networking scheme the first round Multi-stakeholder workshops to set- Report from RDR Challenges MS21 WP8 77 - EURORDIS 8 up RDR Challenges workshops scheme Adapted monitoring tool implemented for Link to monitoring tool MS22 WP9 5 - FNRS 9 collaborative research released to granted applicants projects Adapted monitoring Link to monitoring tool MS23 tool implemented for WP9 5 - FNRS 9 released to granted applicants Networking grants Final reports of Rare disease challenge MS24 WP9 78 - CSO-MOH 54 Final reports projects delivered to monitoring tool Annual meeting involving all ERNs, Pillar 2 WPs co- leaders, WP10 partners 1st Annual retreat of MS25 WP10 1 - INSERM 6 and Pillar 4 representative Pillar 2 completed organized and achieved, including background documents Annual meeting involving all ERNs, Pillar 2 WPs co- leaders, WP10 partners 2nd Annual retreat of MS26 WP10 1 - INSERM 18 and Pillar 4 representative Pillar 2 completed organized and achieved, including background documents Annual meeting involving 3rd Annual retreat of all ERNs, Pillar 2 WPs co- MS27 WP10 1 - INSERM 30 Pillar 2 completed leaders, WP10 partners and Pillar 4 representative Page 138 of 161 Associated with document Ref. Ares(2018)6091977 - 28/11/2018 Due Milestone WP Milestone title Lead beneficiary Date (in Means of verification number18 number9 months)17 organized and achieved, including background documents Annual meeting involving all ERNs, Pillar 2 WPs co- leaders, WP10 partners 4th Annual retreat of MS28 WP10 1 - INSERM 42 and Pillar 4 representative Pillar 2 completed organized and achieved, including background documents Annual meeting involving all ERNs, Pillar 2 WPs co- leaders, WP10 partners 5th Annual retreat of MS29 WP10 1 - INSERM 54 and Pillar 4 representative Pillar 2 completed organized and achieved, including background documents Pillar 2 WP10: Online 1st End-users surveys MS30 WP10 50 - ULEIC 5 surveys developed, sent and done results analyzed. Pillar 2 WP10 : Online 2nd End-users surveys MS31 WP10 50 - ULEIC 17 surveys developed, sent and done results analyzed. Pillar 2 WP10 : Online 3rd End-users surveys MS32 WP10 50 - ULEIC 29 surveys developed, sent and done results analyzed. Pillar 2 WP10: Online 4th End-users surveys MS33 WP10 50 - ULEIC 41 surveys developed, sent and done results analyzed. Pillar 2 WP10: Online 5th End-users surveys MS34 WP10 50 - ULEIC 53 surveys developed, sent and done results analyzed. Financing models for sustaining and scaling Matrix and support document up FAIRification listing the appropriateness support services of financing models for MS35 WP10 65 - Radboudumc 18 assessed with sustaining and scaling up sustainability experts virtual platform components and RD community and support services stakeholders Simulations of financing models for sustaining Results of the simulations and scaling up MS36 WP10 65 - Radboudumc 48 of financing models for FAIRification support FAIRification services listed services executed and evaluated with sustainability experts Page 139 of 161 Associated with document Ref. Ares(2018)6091977 - 28/11/2018 Due Milestone WP Milestone title Lead beneficiary Date (in Means of verification number18 number9 months)17 and RD community stakeholders First Metadata sets Prioritized resources having MS37 of identified and WP11 76 - EMBL 9 validated metadata sets prioritized resources Second Metadata Prioritized resources having MS38 sets of identified and WP11 76 - EMBL 21 validated metadata sets prioritized resources updated at month 21 Third Metadata sets Prioritized resources having MS39 of identified and WP11 76 - EMBL 33 validated metadata sets prioritized resources updated at month 33 Fourth Metadata Prioritized resources having MS40 sets of identified and WP11 76 - EMBL 45 validated metadata sets prioritized resources updated at month 45 Fifth Metadata sets Prioritized resources having MS41 of identified and WP11 76 - EMBL 57 validated metadata sets prioritized resources updated at month 57 Common AAI 3 resources integrated with MS42 integrated in 3 WP11 76 - EMBL 24 LifeScience/ELIXIR AAI resources PPRL available to link data PPRL in production for MS43 WP11 76 - EMBL 36 between at least 3 projects/ 3 projects/resources resources Pilot cloud computing infrastructure available for MS44 Pilot cloud deployed WP11 45 - CNAG-CRG 24 deploying workflows at UCMG and BSC(ELIXIR-SI) Core standards teams Lists of teams and target MS45 assembled and working WP12 50 - ULEIC 12 standards in place, plus actively shared document storage Multi-team software collaborations working Lists of teams and target goals MS46 WP12 50 - ULEIC 18 on agreed goals and and standards in place standards Communication established between List of experts and experts and stakeholder stakeholders in place, plus MS47 WP12 64 - LUMC 12 representatives means of communication and involved in practical shared document storage FAIRification support First update Guidelines document updated FAIRification MS48 WP12 64 - LUMC 6 by the latest FAIRification guidelines for RD data experiences at month 6 managers Guidelines document updated Second update MS49 WP12 64 - LUMC 30 by the latest FAIRification FAIRification experiences at month 30 Page 140 of 161 Associated with document Ref. Ares(2018)6091977 - 28/11/2018 Due Milestone WP Milestone title Lead beneficiary Date (in Means of verification number18 number9 months)17 guidelines for RD data managers Third update Guidelines document updated FAIRification MS50 WP12 64 - LUMC 42 by the latest FAIRification guidelines for RD data experiences managers Fourth update Guidelines document updated FAIRification by the latest FAIRification MS51 WP12 64 - LUMC 54 guidelines for RD data experiences updated at month managers 54 D153 (D13.2) workflow used in proof of concepts Peer reviewed paper or report MS52 study evaluated and WP13 36 - UM 48 in BioRXiv. Plus plans on improved, with project GitHub plans for future updates and release scheme. D13.3 workflow used in proof of concepts Peer reviewed paper or report study evaluated and MS53 WP13 36 - UM 60 in BioRXiv. Plus plans on improved, with project GitHub plans for future updates and release scheme Report of scientific Orphanet training MS54 WP14 1 - INSERM 10 committee meeting validated content defined and available Training Roadmap Definition of the training MS55 WP14 26 - ISS 1 established schedule Overview/benchmark Draft content course for MS56 of online courses on WP16 12 - FFRD 9 the academic online course RD completed available Technical platform Follow-up with the service developed and ready provider closely monitored MS57 WP16 12 - FFRD 18 for online academic and tracked through regular course deployment calls/emails Course accreditations Official feedbacks from MS58 obtained for the RD WP16 12 - FFRD 18 relevant organisations online academic course First 5 modules of the 5 modules available online MS59 RD online academic WP16 12 - FFRD 24 and accessible to an EU-wide course developed audience 12 modules available online Full online course MS60 WP16 12 - FFRD 48 and accessible to an EU-wide available online audience ERN training groups Consent by respective ERN MS61 WP17 58 - EKUT 1 formed coordinators Page 141 of 161 Associated with document Ref. Ares(2018)6091977 - 28/11/2018 Due Milestone WP Milestone title Lead beneficiary Date (in Means of verification number18 number9 months)17 Training programs of Confirmed research training MS62 ERN training groups WP17 58 - EKUT 6 programs for ERN groups consented Innovation MS63 Management Toolbox WP19 75 - EATRIS 8 Toolbox available on website openly accessible User satisfaction survey Internal report on collected MS64 WP19 75 - EATRIS 46 completed survey results Benchmarking of Internal report on MS65 investment platform WP19 75 - EATRIS 30 benchmarking models completed Task Force Group set MS66 WP20 16 - UKA 1 Task Force Appointment list up 6 demonstration of MS67 methodologies projects WP20 61 - IOR 15 List of demonstration projects launched 6 innovative MS68 methodologies projects WP20 53 - CCRI 18 List of innovative projects launched Report about Kick-off of Clinical trials support MS69 WP20 54 - AP-HP 3 clinical trials office support office established group Page 142 of 161 Associated with document Ref. Ares(2018)6091977 - 28/11/2018 1.3.5. WT5 Critical Implementation risks and mitigation actions Risk Description of risk WP Number Proposed risk-mitigation measures number ● High quality of the coordination team with Incapacity or departure of 1 WP1 possibility of interim by one of the Pillar leaders ● coordinator Strong commitment of the Coordinator Underestimation of ● Close follow up of the work progress (regular workload to be shared by meetings, detailed management plan) ● Possibility 2 project managers between WP1 to receive temporary support from IRDiRC Coordination office and members during rush periods IRDiRC SciSec ● The plan for 5 years already in place ● Strategy, Delay in delivery of Annual prioritization and monitoring procedures well 3 Work Plan and Annual WP1 organized ● Close follow up of the yearly agenda Progress Report by Pillar and WP leaders ● Most partners’ institutions are experiences and equipped with internal financial accounting 4 Misuse of resources WP1 and auditing office ● The Coordination financial officer will advise and partners in preparation of financial documents when necessary ● Detailed business plan prepared before launch Financial bottleneck due of the project including 15% risk of budget to underestimation of loss ● Financial management issues set up in 5 contribution capacity of WP1 Consortium Agreement ● Emergency mitigation partner(s) and/or withdrawal procedure set up – possibility to adjust the work of major partner plan and align budget ● Efficient management strategy put in place, with Failure to adapt to events reactive Operating Group ● Careful monitoring 6 WP1 (opportunities, threats, risks) process put in place to be able to react on time and adapt ● EJP RD partners are highly committed to the Programme and will contribute actively to the strategy development ● The analysis that will be provided by Orphanet/UBER Research is a good Difficulty in collection of 7 WP2 alternative that demands a limited effort from the input from stakeholders stakeholders and shall provide detailed overview of the funded previous and ongoing research and capture the overlaps and trends to be used as recommendations for prioritization Special attention will be put to differentiate Generalization in the between the needs in EU countries with a higher 8 WP2 definition of needs or lower development of national research plans on RD Special attention will be put to establish a Generalization in the prioritization scheme of actions, taking into 9 prioritization scheme for WP2 account the needs in countries with less developed actions national research plans on RD Insufficient coordination • Criteria and process of prioritization agreed 10 of priorities / unresolved WP2 at the start of the project and validated by conflicts about strategy GB • Possibility to call for Policy Board Page 143 of 161 Associated with document Ref. Ares(2018)6091977 - 28/11/2018 Risk Description of risk WP Number Proposed risk-mitigation measures number recommendations • Flexibility of Annual Work Plans ● Participation of the RPOs in the prioritization Difficulty in the management process will be separated from the topic choice of the Conflict of Interest of that will be reserved to funding bodies ● 11 WP2 EJP RD research performing Necessary scientific support for the detailed organizations (RPOs) definition of the topics will be ensure by the ad hoc Advisory Boards called by the funders IRDiRC SciSec being part of the EJP RD Coo Office will ensure strong connection with IRDiRC Problem of the alignment In addition, many EJP RD partners are members 12 between EJP RD proposed WP2 of IRDiRC and therefore can help in alignment. TF and IRDiRC TF Finally, IRDiRC chair and VC will be part of the EJP RD Policy Board to further strengthen the collaboration ● Participation of countries will be ensured at Low participation of some multiple levels: Policy Board, Governing Board countries in collecting state and Mirror Groups ● The majority of EJP RD of play information and in countries is represented in the programme by 13 WP2 the process for translation of more that one beneficiary and reflects well prioritization on national and different type of beneficiaries (RFOs, RPOs, EU strategies ERN, infrastructures, etc.), which guarantees good potential of translation at national level Incomplete/poor quality ● Provide guidance and templates to WP leaders information on added value for sustainability/user demand reporting ● 14 WP3 of services and resources, Perform independent assessment of value of creates misinformed roadmap services Difficult to achieve ● Monitor external risk factors related to sustainable collaboration sustainability ● Update Sustainability Roadmap as between the service 15 WP3 living document ● Give specific attention to other providers and the associated initiatives for agreements on equitable principles communities beyond the and realistic planning for adoption project ● WP dedicated to sustainability planned ● Sustainability activities tackled from the start of Failure to prepare for the project ● Good knowledge of beneficiaries, 16 WP3 sustainability their capacities and weaknesses ● Important commitment of Member States and direct contact and dialogue ensured via the Policy Board AREB will include the necessary expertise to cover the different topics of the regulatory and ethical framework. To this aim, members with AREB unable to respond to 17 WP4 recognized expertise and the relevant European the needs of the consortium RIs will join the board. Furthermore, EMA and national competent authorities will be addressed if necessary Inputs and feedback from ● AREB will participate whenever necessary in pillars to verify that the the OG conference calls and will be in contact 18 WP4 projects and activities will with the CO for routine updates ● AREB will be regulatory- and ethically- collaborate closely with Pillar 1 Joint Call Page 144 of 161 Associated with document Ref. Ares(2018)6091977 - 28/11/2018 Risk Description of risk WP Number Proposed risk-mitigation measures number compliant not delivered to Secretariats during the period of call preparation AREB and contractualization of projects Ethical, regulatory and legal documentation collated and Awareness raising at meetings, conferences and 19 made available through the WP4 via transversal WP5 and Pillar 3 EJP RD is not used by the community Ensure awareness and understanding of the Few/no requests for support 20 WP4 support and of its value with support from OG and from EJP RD beneficiaries WP leaders ● Strong commitment of BF and EJP RD to collaborate supported by long-lasting Breach of collaboration with collaboration history and congress reputation ● Blackswan Foundation and/ Possibility to partner with other organizations 21 or impossible to organize WP5 like ESHG or EURORDIS (ECRD Congress) ● RE(ACT) congress due to Support from EJP RD Communication Manager low budget or interest to BF team for communication and partnership search ● Earmarking adequate national budgets in line National financial with national research capacity and costs ● Post- bottlenecks for funding evaluation negotiations on increasing national 22 WP6 joint transnational research budget and/or budget negotiations with applicants projects ● Use of EC co-funding to adjust national budget shortcomings Incentives will be set up to facilitate the use of Lack of contributions Pillar 2 components. Also the projects will be and utilization of Pillar 2 informed regularly about the possibilities of 23 WP6 components by Pillar 1 use of P2 components. Finally, they will also research projects be encouraged to participate in Pillar 3 WP 14 trainings on data management and quality. Low number of applications After four subsidy rounds an early evaluation of 24 WP7 for Networking scheme the scheme is foreseen No challenges are brought Multi-stakeholder workshops, consisting of up that can be solved up to representatives of industry, academia and patient the stage of proof of concept 25 WP8 organisations will be organised to discuss within the projected time potential challenges and the chosen time period frame of 18 months with a for proof of concept of solutions possible 12-month extension ● Potential access to some 70 companies No interest from who are ERTC (EURORDIS Round Table of 26 pharmaceutical companies in WP8 Companies)members confronted with specific the project hurdles in rare diseases ● Effort also be made to attract industry in Pillar 4 Approved challenges at A face-to-face networking meeting for academia, 27 risk of not finding relevant WP8 SMEs and industry will be organized to speed up applicants collaboration and increase quality of applications. A two-stage process makes it possible to put Selected projects don’t get additional resources at month 18 on the projects 28 expected results with the risk WP8 which would have been best developed during the of challenge not being solved first period. Moreover, in case the phase one has Page 145 of 161 Associated with document Ref. Ares(2018)6091977 - 28/11/2018 Risk Description of risk WP Number Proposed risk-mitigation measures number taken some delay in starting, a 5-month window is scheduled between the completion of the second phase and the closing of the EJP at year 5. Routine procedure of messages and reminders will be implemented in collaboration with call Missing / incomplete secretariats and respective funding agencies. 29 reporting by coordinators of WP9 Several funding agencies will only sent the final projects funded within WP6 payment after receiving the final report of their national research group. A routine procedure of messages and reminders will be implemented in collaboration with the Missing / incomplete Networking scheme Secretariat. The applicants 30 reporting by coordinators of WP9 will receive 80% of the grant before the meeting. Networking scheme grants The final payment of 20% will be sent by ZonMw after receiving the report. Maintain constant dialog with the ERNs ERNs not involved in the Research group through Pillar 2 co-leader (ERN 31 WP10 Pillar 2 strategy coordinator) and incentivisation to bring their use cases and research questions Annual retreats and other means of regular contact 32 Poor WP10 surveys feedback WP10 will be also used to generate user’s feedback Regular communication (TCs, workshops) will 33 WPs divergent developments WP10 maintain the alignment between both parallel WPs Engage at least 2 partners in the metadata model Failure to deliver metadata 34 WP11 development and extend a metadata model already model to the virtual platform in place Failure to deliver single Engage at least 2 partners in the query point 35 coordinated query point to WP11 development and extend a catalog already in place resources Research projects automated Replace by manual collection and curation by 36 database subcontractor WP11 Orphanet network teams failure Provide support and expertise to encourage Common AAI not deployed resources to adopt common AAI to be 37 WP11 in all resources recommended as deposition platform by the EJP RD Resources for some of the virtual platform Resources for some of the virtual platform 38 infrastructures not sufficient WP11 infrastructures not sufficient to serve high EJP to serve high EJP community community needs needs Failure to deliver suitable Engage many partners and external groups, 39 standards recommended for WP12 already developing and using relevant standards software to be based upon Failure to deliver support Engage at least two 2 software teams per topic, 40 software for making data WP12 working together and to WP12 standards FAIR Page 146 of 161 Associated with document Ref. Ares(2018)6091977 - 28/11/2018 Risk Description of risk WP Number Proposed risk-mitigation measures number Funded projects in Pillar 1, Solve-RD and other Few Multi-omics datasets not 41 WP13 already producing multi-omics data: provide available for analysis analysis to the data producers All ERNs engaged in driving and testing the VP; WP13 providing and promoting re-use by Slow adoption of the EJP ERNs; strong communication through WP5 and 42 RD Virtual platform (VP) WP10 trainings provided through WP14 achieving facilities by the community a large outreach of the RD community; new trainings proposed through WP18 on the use and value of the VP. If such difficulties are encountered, the position Problem in recruiting a could be considered as full time for 2.5 years 43 half time position training WP14 in order to develop the training modules and manager organize the first round of national trainings Availability of experts/ Enlarge recruitment base for teachers, link to 44 teachers for each of the 3 WP14 national societies via EuroGentest courses ● Extension of deadline for registration and increased dissemination. Pre-workshop questionnaires sent do potential participants to Insufficient number of partly guide workshop content; Promotion through 45 WP14 participants ERNs, biobanks, etc. ● Increase dissemination in coordination with relevant WP/task leaders in EJP + adjust format and content based on feedbacks received Insufficient number of use A number of use cases to be used for this purpose 46 cases, databases for the WP14 already available course Incomplete implementation ● Post workshop follow-up (3 months, 6 months, of workshop guidelines by etc.) with all workshop participants to get 47 workshop participants once WP14 feedback. ● Common roadblocks should be they return to their home addressed in future workshops to enable working institutions solutions Decrease of co-funding 48 supporting the overall WP15 Decrease the number of participants participation of patients Decrease or loss of the in- kind support of Imagine Alternative on-site venues and on-site visits 49 WP15 Institute that provides the provided by other EJP RD Partners venue and on-site visits Increase dissemination in coordination with Course not engaging 50 WP16 relevant WP/task leaders in EJP + adjust format sufficient number of students and content based on feedbacks received Not all ERNs commit to Formation of training groups with committing 51 WP17 ERN training Networks ERNs Funding not sufficient to Given the size and scope of the ERNs all ERN 52 deliver training programs of WP17 training groups will significantly contribute sufficient scope additional training resources Page 147 of 161 Associated with document Ref. Ares(2018)6091977 - 28/11/2018 Risk Description of risk WP Number Proposed risk-mitigation measures number Training needs for Pillar Close monitoring ensured through transversal 53 2 platform users not fully WP18 activities and link with Pillar 2 defined in time Funding not sufficient to Maximizing resources allocated to training 54 adapt training programs of WP18 activities in WP14-WP17 to enable adaptation sufficient scope Awareness raising at meetings, conferences and The online resources are not 55 WP19 via transversal WP communication and education utilized by the community of Pillar 3 Few/no project teams request Ensure awareness and understanding of the 56 support of Innovation WP19 support and the value of mentoring Manager (IM) Few projects reach stage of ● Support project teams via IM to ensure max need for exploitation, few/no 57 WP19 chance of technical success ● Ensure max projects request exploitation awareness of support available support Delay of implementation of The TFG will implement the support office with 58 WP20 clinical study support office another member of the ECRIN network Delay in demonstration or The TFG will select the next best demonstration 59 WP20 methodological project start project of applicant list A rule will be defined by the TFG that each Project not finished in due 60 WP20 beneficiary will provide sufficient funding for time finishing the project Deviation from expected Tight monitoring of the research progress by the 61 WP20 research progress TFG will minimize the risk Tight monitoring of the research progress will minimize the risk of delay. In case of an Deliverable are delayed or 62 WP20 unachievable deliverable the TFG will develop a cannot be achieved solution in agreement with the EJP coordinator taking care of the success of the project Page 148 of 161 Associated with document Ref. Ares(2018)6091977 - 28/11/2018 1.3.6. WT6 Summary of project effort in person-months WP1 WP2 WP3 WP4 WP5 WP6 WP7 WP8 WP9 WP10 WP11 WP12 WP13 WP14 WP15 WP16 WP17 WP18 WP19 1 - INSERM 403 13 26 14 68 0 0 0 0 13.40 431.40 47.90 17.30 28 0 2.50 0 0 0 · IMGGE 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 · KI 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 · UMCL-UKCL 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 · PHE 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 · SHEBA 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 · Rinnekoti 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 · KDBZ 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 · UT 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 · MHH 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 · OPBG 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 · DHIR 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 · GERAD 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 · BAPES 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 · CUNI 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 · HSE 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 · HUG 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 · OUS-HF 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 · CCUH 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 · AMU 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 · CMG 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 · MUW-AT 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 · Sciensano 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 · UMF 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Page 149 of 161 Associated with document Ref. Ares(2018)6091977 - 28/11/2018 WP1 WP2 WP3 WP4 WP5 WP6 WP7 WP8 WP9 WP10 WP11 WP12 WP13 WP14 WP15 WP16 WP17 WP18 WP19 2 - FWF 0 0 0 0 0 3 0 0 0 0 0 0 0 0 0 0 0 0 0 3 - AIT 0 0 0 0 0 0 0 0 0 0 26.80 106.50 0 0 0 0 0 0 0 4 - LBG (LBI- 0 0 0 0 0 0 0 0 0 0 22.30 0 0.70 2 0 0 0 0 0 RUD) 5 - FNRS 0 0 0 0 0 3 0 0 4 0 0 0 0 0 0 0 0 0 0 6 - FWO 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 7 - KU Leuven 0 0 0 0 0 0 0 0 0 0 0 0 0 12 0 0 0 0 0 8 - MEYS 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 9 - MOSAE 0 0 0 0 0 3 0 0 0 0 0 0 0 0 0 0 0 0 0 10 - AKA 0 0 0 0 0 3 0 0 0 0 0 0 0 0 0 0 0 0 0 11 - ANR 0 2 0 0 0 15.40 0 0 0 0 0 0 0 0 0 0 0 0 0 12 - FFRD 0 0 0 0 0 12.40 0 16.50 1 0 0 0 0 0 0 47 0 1 7 13 - AFM 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 14 - IMAGINE 0 0 0 0 0 0 0 0 0 0 0 0 0 2 0.40 0 0 0 0 15 - DLR 6 1 1 1 1 21.40 0 1.50 0 0 0 0 0 0 0 0 0 0 0 16 - UKA 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 17 - CHARITE 0 0 0 0 0 0 0 0 0 0 31.30 9 0 8 0 0 0 0 0 18 - UKL-FR 0 0 0 0 0 0 0 0 0 0 17.40 0 5.60 0 0 0 0 0 0 19 - NKFIH 0 0 0 0 0 3 0 0 0 0 0 0 0 0 0 0 0 0 0 20 - HRB 0 0 0 0 0 3 0 0 0 0 0 0 0 0 0 0 0 0 0 21 - IT-MOH 0 2 0 0 0 3 0 0 0 0 0 0 0 0 0 0 0 0 0 · APRE 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 22 - TuscReg 0 0 0 0 0 3 0 0 0 0 0 0 0 0 0 0 0 0 0 23 - FRRB 0 0 0 0 0 3 0 0 0 0 0 0 0 0 0 0 0 0 0 24 - FGB 0 0 0 20 0 0 0 0 0 0 0 0 0 0 0 1 0 0 12 25 - FTELE 0 1 0 16 0 0 0 0 0 25.10 9.90 36.60 0 27 0 0 0 1 74 26 - ISS 0 18 0 0 0 0 0 0 0 6 6.80 0 12.20 43 2 0 0 1 0 Page 150 of 161 Associated with document Ref. Ares(2018)6091977 - 28/11/2018 WP1 WP2 WP3 WP4 WP5 WP6 WP7 WP8 WP9 WP10 WP11 WP12 WP13 WP14 WP15 WP16 WP17 WP18 WP19 27 - CVBF 16 1 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 28 28 - TEDDY 0 0 0 0 1 0 0 0 0 0 0 0 0 0 22 0 0 0 0 · FSJD 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 29 - MIUR 0 0 0 0 0 3 0 0 0 0 0 0 0 0 0 0 0 0 0 30 - VIAA 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 31 - LMT 0 0 0 0 0 3 0 0 0 0 0 0 0 0 0 0 0 0 0 32 - VUHSK 6 1 1 1 1 0 0 0 0 0 5 0 0 1 0 4 0 4 0 33 - FNR 0 0 0 0 0 3 0 0 0 0 0 0 0 0 0 0 0 0 0 34 - ZonMw 6 1 1 1 1 3 13.20 1.50 0 0 0 0 0 0 0 0 0 0 0 35 - UMCG 0 0 0 0 0 0 0 0 0 0 74 162.40 3.60 10 0 0 0 0 0 36 - UM 0 0 0 0 0 0 0 0 0 1.10 11 2.50 88.40 0 0 0 0 0 0 37 - NCBR 0 0 0 0 0 3 0 0 0 0 0 0 0 0 0 0 0 0 0 38 - MUW 0 4 0 0 0 0 0 0 0 0 0 11.70 0 0 0 0 0 0 0 39 - MUG 0 0 0 0 0 0 0 0 0 0 0 0 0 1 2 0 0 0 0 40 - IPCZD 0 0 0 0 0 0 0 0 0 0 10 0 0 4 0 0 0 2 0 41 - FCT 0 0 0 0 0 3 0 0 0 0 0 0 0 0 0 0 0 0 0 42 - INSA 0 0 0 0 0 0 0 0 0 1.10 0 0 0 0 0 0 0 0 0 43 - SAS 0 0 0 0 0 3 0 0 0 0 0 0 0 0 0 0 0 0 0 44 - ISCIII 0 16 13 0 0 12.40 0 0 0 0 9.90 2.51 5 6 0 3.50 0 0 0 45 - CNAG-CRG 0 0 0 0 0 0 0 0 0 5.70 181.70 11 6.60 1 0 0 0 0 0 46 - UPM 0 0 0 0 0 0 0 0 0 0 10.60 54.80 0 0 0 0 0 0 0 47 - CIBER 0 0 0 0 0 0 0 0 0 0 14.70 2.90 0 0 0 0 0 0 0 48 - SRC 0 0 0 0 0 3 1 0 0 0 0 0 0 0 0 0 0 0 0 49 - VINNOVA 0 0 0 0 0 3 0 0 0 0 0 0 0 0 0 0 0 0 0 50 - ULEIC 0 0 0 0 0 0 0 0 0 13.50 12.60 193.90 0 0 0 0 0 0 0 51 - ULIV 8 0 3 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Page 151 of 161 Associated with document Ref. Ares(2018)6091977 - 28/11/2018 WP1 WP2 WP3 WP4 WP5 WP6 WP7 WP8 WP9 WP10 WP11 WP12 WP13 WP14 WP15 WP16 WP17 WP18 WP19 52 - UNEW 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 10 53 - CCRI 0 0 0 0 0 0 0 0 0 0 5 0 0 0 0 0 0 0 3 54 - AP-HP 6 1 1 1 1 0 0 0 0 0 0 0 0 0 0 4.50 0 0 0 55 - HUS 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 56 - CLB 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 2 · UCBL 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 57 - UKL-HD 6 1 1 1 1 0 0 0 0 0.50 2.80 2.80 5.60 0 0 1.50 15 0 0 58 - EKUT 0 0 0 0 0 0 0 0 0 0 0 0 3.10 7 0 0 18 1 0 · UKT 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 59 - GUF 0 0 0 0 0 0 0 0 0 0 76.80 121.50 0 0 0 0 0 0 5 · UKF 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 60 - HSK 0 0 0 0 0 0 0 0 0 0 3.90 0 0 2 0 0 0 0 3 61 - IOR 0 0 0 0 0 0 0 0 0 0 0 0 0 2 0 0 0 0 0 62 - AOUP 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 63 - AOUS 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 · MFT NHS 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 TRUST · CHU DIJON 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 64 - LUMC 0 0 0 0 0 0 0 0 0 5.20 42.10 151.60 63.70 7 0 0 15 0 0 · UoG 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 · UKSH 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 65 - Radboudumc 0 0 0 0 0 0 0 0 0 0 10.70 32.90 54.80 0 0 1.50 15 0 0 · IC 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 · KUH 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 · MFT 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 66 - AMC 0 0 0 0 0 0 0 0 0 0 5.70 94.30 0 1 0 0 0 0 0 Page 152 of 161 Associated with document Ref. Ares(2018)6091977 - 28/11/2018 WP1 WP2 WP3 WP4 WP5 WP6 WP7 WP8 WP9 WP10 WP11 WP12 WP13 WP14 WP15 WP16 WP17 WP18 WP19 67 - ERASMUS 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 MC 68 - SERMAS 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1.50 0 0 0 69 - NUTH 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1.50 0 0 0 70 - GOSH 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1.50 0 0 0 71 - EORTC 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 72 - 0 0 0 0 0 0 0 0 0 0 39 0 0 0 0 0 0 0 0 INFRAFRONTIER 73 - BBMRI 0 0 0 1 0 0 0 0 0 23.10 65.80 180.80 0 5 0 0 0 0 0 · THL 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 · MUG 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 · CRS4 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 · TUM 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 74 - ECRIN 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 75 - EATRIS 6 1 14 2 1 0 0 1.50 0 0 0 0 0 0 0 3.50 0 0 53 · UiO 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 · VHIR 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 76 - EMBL 0 0 0 0 0 0 0 0 0 0 0 25.90 2.80 0 0 0 0 0 0 · UU (ELIXIR- 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 SE) · UNIMAN 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 6 0 0 0 · UL (ELIXIR-SI) 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 · CSC (ELIXIR- 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 FI) · BSC (ELIXIR- 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 ES) · DTU (ELIXIR- 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 DK) Page 153 of 161 Associated with document Ref. Ares(2018)6091977 - 28/11/2018 WP1 WP2 WP3 WP4 WP5 WP6 WP7 WP8 WP9 WP10 WP11 WP12 WP13 WP14 WP15 WP16 WP17 WP18 WP19 · CNR (ELIXIR- 0 0 0 0 0 0 0 0 0 0 0 0 0 3 0 0 0 0 0 IT) · DTL-Projects 1 0 3 1 0 0 0 0 0 23.90 194.10 0 0 4 0 0 0 0 0 · UCAM 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 8 0 0 0 · SIB (ELIXIR- 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 CH) · MU-CERIT-SC 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 77 - EURORDIS 6 1 1 2 1 3 1 4 0 0 0 0 0 3 89 3 0 2 0 78 - CSO-MOH 0 0 0 0 0 3 3.20 0 20 0 0 0 0 0 0 0 0 0 0 79 - SNSF 0 0 0 0 0 3 0 0 0 0 0 0 0 0 0 0 0 0 0 80 - Blackswan 0 0 0 0 12 0 0 0 0 0 0 0 0 0 0 0 0 0 0 81 - TUBITAK 0 0 0 0 0 3 2 0 0 0 0 0 0 0 0 0 0 0 0 82 - ACURARE 0 0 0 0 0 0 0 0 0 0 9.40 2.90 28.50 5 2 0 0 0 0 83 - HUGEN 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 11 84 - CIHR 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 85 - FRQS 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 86 - IT 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 87 - GSRT 0 0 0 0 0 3 0 0 0 0 0 0 0 0 0 0 0 0 0 88 - DFG 0 0 0 0 0 3 0 0 0 0 0 0 0 0 0 0 0 0 0 Total Person/ 470 64 65 63 89 133.60 21.40 25 25 118.60 1330.70 1254.41 297.90 185 117.40 92.50 63 12 208 Months Page 154 of 161 Associated with document Ref. Ares(2018)6091977 - 28/11/2018 WP20 WP21 Total Person/Months per Participant 1 - INSERM 0 1064.50 · IMGGE 0 0 0 · KI 0 0 0 · UMCL-UKCL 0 0 0 · PHE 0 0 0 · SHEBA 0 0 0 · Rinnekoti 0 0 0 · KDBZ 0 0 0 · UT 0 0 0 · MHH 0 0 0 · OPBG 0 0 0 · DHIR 0 0 0 · GERAD 0 0 0 · BAPES 0 0 0 · CUNI 0 0 0 · HSE 0 0 0 · HUG 0 0 0 · OUS-HF 0 0 0 · CCUH 0 0 0 · AMU 0 0 0 · CMG 0 0 0 · MUW-AT 0 0 0 · Sciensano 0 0 0 · UMF 0 0 0 2 - FWF 0 3 3 - AIT 0 133.30 Page 155 of 161 Associated with document Ref. Ares(2018)6091977 - 28/11/2018 WP20 WP21 Total Person/Months per Participant 4 - LBG (LBI-RUD) 0 25 5 - FNRS 0 7 6 - FWO 0 0 7 - KU Leuven 0 12 8 - MEYS 0 0 9 - MOSAE 0 3 10 - AKA 0 3 11 - ANR 0 17.40 12 - FFRD 0 84.90 13 - AFM 0 0 14 - IMAGINE 0 2.40 15 - DLR 0 32.90 16 - UKA 59 59 17 - CHARITE 0 48.30 18 - UKL-FR 0 23 19 - NKFIH 0 3 20 - HRB 0 3 21 - IT-MOH 0 5 · APRE 0 0 0 22 - TuscReg 0 3 23 - FRRB 0 3 24 - FGB 0 33 25 - FTELE 0 190.60 26 - ISS 0 89 27 - CVBF 0 46 28 - TEDDY 0 23 Page 156 of 161 Associated with document Ref. Ares(2018)6091977 - 28/11/2018 WP20 WP21 Total Person/Months per Participant · FSJD 0 0 0 29 - MIUR 0 3 30 - VIAA 0 1 31 - LMT 0 3 32 - VUHSK 0 24 33 - FNR 0 3 34 - ZonMw 0 27.70 35 - UMCG 0 250 36 - UM 0 103 37 - NCBR 0 3 38 - MUW 0 15.70 39 - MUG 0 3 40 - IPCZD 0 16 41 - FCT 0 3 42 - INSA 0 1.10 43 - SAS 0 3 44 - ISCIII 0 68.31 45 - CNAG-CRG 0 206.00 46 - UPM 0 65.40 47 - CIBER 0 17.60 48 - SRC 0 4 49 - VINNOVA 0 3 50 - ULEIC 0 220 51 - ULIV 0 12 52 - UNEW 0 10 53 - CCRI 10 18 Page 157 of 161 Associated with document Ref. Ares(2018)6091977 - 28/11/2018 WP20 WP21 Total Person/Months per Participant 54 - AP-HP 68 82.50 55 - HUS 0 0 56 - CLB 0 2 · UCBL 0 0 0 57 - UKL-HD 4 42.20 58 - EKUT 0 29.10 · UKT 0 0 0 59 - GUF 0 203.30 · UKF 0 0 0 60 - HSK 17 25.90 61 - IOR 6 8 62 - AOUP 0 0 63 - AOUS 0 1 · MFT NHS TRUST 0 0 0 · CHU DIJON 0 0 0 64 - LUMC 0 284.60 · UoG 0 0 0 · UKSH 0 0 0 65 - Radboudumc 0 114.90 · IC 0 0 0 · KUH 0 0 0 · MFT 0 0 0 66 - AMC 0 101 67 - ERASMUS MC 0 0 68 - SERMAS 4 5.50 69 - NUTH 0 1.50 Page 158 of 161 Associated with document Ref. Ares(2018)6091977 - 28/11/2018 WP20 WP21 Total Person/Months per Participant 70 - GOSH 6 7.50 71 - EORTC 0 0 72 - INFRAFRONTIER 0 39 73 - BBMRI 0 275.70 · THL 0 0 0 · MUG 0 0 0 · CRS4 0 0 0 · TUM 0 0 0 74 - ECRIN 77 78 75 - EATRIS 0 82 · UiO 0 0 0 · VHIR 0 0 0 76 - EMBL 0 28.70 · UU (ELIXIR-SE) 0 0 1 · UNIMAN 0 0 6 · UL (ELIXIR-SI) 0 0 0 · CSC (ELIXIR-FI) 0 0 0 · BSC (ELIXIR-ES) 0 0 0 · DTU (ELIXIR-DK) 0 0 0 · CNR (ELIXIR-IT) 0 0 3 · DTL-Projects 0 0 227 · UCAM 0 0 8 · SIB (ELIXIR-CH) 0 0 0 · MU-CERIT-SC 0 0 0 77 - EURORDIS 0 116 78 - CSO-MOH 0 26.20 Page 159 of 161 Associated with document Ref. Ares(2018)6091977 - 28/11/2018 WP20 WP21 Total Person/Months per Participant 79 - SNSF 0 3 80 - Blackswan 0 12 81 - TUBITAK 0 5 82 - ACURARE 0 47.80 83 - HUGEN 0 12 84 - CIHR 0 0 85 - FRQS 0 0 86 - IT 0 0 87 - GSRT 0 3 88 - DFG 0 3 Total Person/Months 251 4886.51 Page 160 of 161 Associated with document Ref. Ares(2018)6091977 - 28/11/2018 1.3.7. WT7 Tentative schedule of project reviews Review Tentative Planned venue Comments, if any number 19 timing of review RV1 25 Remote Mid term Page 161 of 161 Associated with document Ref. Ares(2018)6091977 - 28/11/2018 1. Project number The project number has been assigned by the Commission as the unique identifier for your project. It cannot be changed. The project number should appear on each page of the grant agreement preparation documents (part A and part B) to prevent errors during its handling. 2. Project acronym Use the project acronym as given in the submitted proposal. It can generally not be changed. The same acronym should appear on each page of the grant agreement preparation documents (part A and part B) to prevent errors during its handling. 3. Project title Use the title (preferably no longer than 200 characters) as indicated in the submitted proposal. Minor corrections are possible if agreed during the preparation of the grant agreement. 4. Starting date Unless a specific (fixed) starting date is duly justified and agreed upon during the preparation of the Grant Agreement, the project will start on the first day of the month following the entry into force of the Grant Agreement (NB : entry into force = signature by the Commission). Please note that if a fixed starting date is used, you will be required to provide a written justification. 5. Duration Insert the duration of the project in full months. 6. Call (part) identifier The Call (part) identifier is the reference number given in the call or part of the call you were addressing, as indicated in the publication of the call in the Official Journal of the European Union. You have to use the identifier given by the Commission in the letter inviting to prepare the grant agreement. 7. Abstract 8. Project Entry Month The month at which the participant joined the consortium, month 1 marking the start date of the project, and all other start dates being relative to this start date. 9. Work Package number Work package number: WP1, WP2, WP3, ..., WPn 10. Lead beneficiary This must be one of the beneficiaries in the grant (not a third party) - Number of the beneficiary leading the work in this work package 11. Person-months per work package The total number of person-months allocated to each work package. 12. Start month Relative start date for the work in the specific work packages, month 1 marking the start date of the project, and all other start dates being relative to this start date. 13. End month Relative end date, month 1 marking the start date of the project, and all end dates being relative to this start date. 14. Deliverable number Deliverable numbers: D1 - Dn 15. Type Please indicate the type of the deliverable using one of the following codes: R Document, report DEM Demonstrator, pilot, prototype DEC Websites, patent fillings, videos, etc. OTHER ETHICS Ethics requirement ORDP Open Research Data Pilot 16. Dissemination level Associated with document Ref. Ares(2018)6091977 - 28/11/2018 Please indicate the dissemination level using one of the following codes: PU Public CO Confidential, only for members of the consortium (including the Commission Services) EU-RES Classified Information: RESTREINT UE (Commission Decision 2005/444/EC) EU-CON Classified Information: CONFIDENTIEL UE (Commission Decision 2005/444/EC) EU-SEC Classified Information: SECRET UE (Commission Decision 2005/444/EC) 17. Delivery date for Deliverable Month in which the deliverables will be available, month 1 marking the start date of the project, and all delivery dates being relative to this start date. 18. Milestone number Milestone number:MS1, MS2, ..., MSn 19. Review number Review number: RV1, RV2, ..., RVn 20. Installation Number Number progressively the installations of a same infrastructure. An installation is a part of an infrastructure that could be used independently from the rest. 21. Installation country Code of the country where the installation is located or IO if the access provider (the beneficiary or linked third party) is an international organization, an ERIC or a similar legal entity. 22. Type of access VA if virtual access, TA-uc if trans-national access with access costs declared on the basis of unit cost, TA-ac if trans-national access with access costs declared as actual costs, and TA-cb if trans-national access with access costs declared as a combination of actual costs and costs on the basis of unit cost. 23. Access costs Cost of the access provided under the project. For virtual access fill only the second column. For trans-national access fill one of the two columns or both according to the way access costs are declared. Trans-national access costs on the basis of unit cost will result from the unit cost by the quantity of access to be provided. Associated with document Ref. Ares(2018)6091977 - 28/11/2018 HISTORY OF CHANGES nVer DateDD Changes 2.0 Annex 1 Part A Annex 1 Part B 08.09.2018 The tables 3.1a, 3.1 b, 3.1c, 3.2a, 3.2b, 3.4a were removed 08.09.2018 The History of changes table was added 08.09.2018 The table of content was updated 08.09.2018 The number, acronym and specification Part B was added in the footer 08.09.2018 In response to the ESR comment a short description on expansion of the EJP RD to new countries was added on Page 6. Furthermore, a new “Subtask:1.2.4: Initiating new partnerships” was added to WP1. 08.09.2018 In response to the ESR comment a paragraph dedicated to the EU13 countries was added on Page 35 in the section EJP RD “Consortium as a whole”. 08.09.2018 In response to the ESR comment an explanation on the estimated number of trainees and capacity building enhancement was added under paragraph “Pillar 3” on page 9. In addition, a paragraph was added under IMPACT section “Specific impact 6: Follow the policies and contribute to the objectives of the International Rare Diseases Research Consortium (IRDiRC)” for Pillar 4 anticipated results on page 16. 08.09.2018 In response to the ESR comment the representative of EuropaBio was added to the Policy Board composition on page 33. An explanation on the involvement of private stakeholders (industry and venture capitals) was added in the paragraph “The route to exploitation of EJP RD results at policy and industrial levels” on page 35. A short paragraph explaining the composition of mentoring support boards was added in the WP19 under subtask 19.1.3. 08.09.2018 In response to the ESR comment the description of the Operating Group on page 32 was modified. In addition, an explanation on the voting rules to avoid silencing of minority opinion was added on page 29 under the “Governing Board” paragraph. In addition, the governance structure figure on page 30 was modified in order to better reflect the origin of the Operating Group (as part of the ExCom). 08.09.2018 In response to the ESR comment extended explanation on the budget and PM share was added on page 37. 08.09.2018 In response to the ESR comment a new deliverable D10.2 “Report on the State of the Art of existing resources” (M9) was added to the WP10. 26.09.2018 A table specifying the status of each of the beneficiaries (Programme Owner, Programme Manager or Other) was added under 4.1 (Participants) on page 45 26.09.2018 The table 3.4 b was updated – the numbers of beneficiaries were added. 27. 09.2018 The Gantt chart was removed as not manageable (readable) after the update of all Milestones in Part A 27.09.2018 The AWP was updated: Gantt chart, numbers of deliverables for each action, Subtask 1.2.4 was added to Action 1. 02.11.2018 The description of all Linked Third Parties was updated. The following LTPs were removed: Partner 54 (APHP) – all LTPs were removed; Partner 70 (GOSH) – all LTPs were removed; Partner 83 (HUGEN) – HT-TTM LTP was removed. 02.11.2018 The description of Financial support to third parties was updated. The details on maximum amounts of financial support and criteria for determining exact amount were added. Details of open calls were provided. 02.11.2018 3 new beneficiaries were added: N°86 (Inserm Transfert – IT) will assist the coordination of INSERM to comply with INSERM internal rules and support INSERM in development of new collaborations related to EJP RD during the lifetime of the project. N°87 (GSRT, Greece) - funding body, will provide 1 M€ for the Pillar 1 co-funded call but from structural costs, so their contribution will not be accounted for the EC reimbursement. N°88 (DFG, Germany) - funding body, will provide 3 M€ for the Pillar 1 co-funded call but does not want to claim any EC 825575 – EJP RD – Part B 1 reimbursement. The participation ofAssociated DFG is crucial as it doubles with document the German budget Ref. Ares(2018)6091977 - 28/11/2018 for JTC 2019 call. 02.11.2018 Section 5 – Ethics was updated according to the comments of Ethics experts review. 13.11.2018 Section 4 – the explanation of the COI avoidance for INSERM and ISCIII was added. 13.11.2018 The participation of Ethics Advisor was updated in WP1 and WP4. 13.11.2018 Section 5 – Ethics was updated according to the comment of EC Project Officer. 13.11.2018 The information on the subject of beneficiaries to the jurisdiction of Belgain courts was updated. 13.11.2018 The information on the LTP of partner N°56 (CLB) was added in the table. 13.11.2018 The use of in kind contributions provided by third parties was updated according to the requirements sent by the Ec Financial and administrative officer. 825575 – EJP RD – Part B 2 Associated with document Ref. Ares(2018)6091977 - 28/11/2018 HISTORY OF CHANGES ........................................................................................................................................... 1 1. EXCELLENCE ........................................................................................................................................................ 6 1.1 Rare Diseases burden in Europe ............................................................................................................................. 6 1.2 Efforts deployed by the European Union and Member States so far ..................................................................... 6 1.3 Key policy recommendations ................................................................................................................................. 7 1.4 Major challenges to overcome................................................................................................................................ 7 1.5 Objectives of the European Joint Programme on Rare Diseases ........................................................................... 8 1.6. Relation to the work programme ........................................................................................................................... 8 1.7. Concept and methodology ..................................................................................................................................... 9 1.8 Ambition 14 2. IMPACT 15 2.1 Expected impacts .................................................................................................................................................. 15 2.1.1. Barriers / obstacles........................................................................................................................................... 20 2.1.2. Framework conditions ...................................................................................................................................... 21 2.2 Measures to maximize impact .............................................................................................................................. 21 2.2.1 Dissemination and exploitation of results ......................................................................................................... 21 2.2.2 Communication activities .................................................................................................................................. 22 2.2.3 Data Management Plan...................................................................................................................................... 22 2.2.4 Dissemination and communication Plan ........................................................................................................... 22 3. IMPLEMENTATION ............................................................................................................................................ 30 3.2. Management structure, milestones and procedures ............................................................................................. 32 3.3: Consortium as a whole ........................................................................................................................................ 37 3.4: Resources to be committed.................................................................................................................................. 39 Table 3.4a: Summary of staff effort (per participants and per WP) ........................................................................... 40 Table 3.4b: ‘Other direct cost’ items (travel, equipment, other goods and services, large research infrastructures) 41 4.1. Participants (applicants) ...................................................................................................................................... 45 01-INSERM (A) ......................................................................................................................................................... 48 01-INSERM (B) ......................................................................................................................................................... 50 01-INSERM (C) ......................................................................................................................................................... 52 01-INSERM (D) ......................................................................................................................................................... 56 02-FWF....................................................................................................................................................................... 58 03-AIT ........................................................................................................................................................................ 59 04-LBG ....................................................................................................................................................................... 61 05-FNRS ..................................................................................................................................................................... 63 06-FWO ...................................................................................................................................................................... 64 07-KU LEUVEN ........................................................................................................................................................ 64 08-MEYS .................................................................................................................................................................... 67 09-MOSAE ................................................................................................................................................................. 68 10-AKA ...................................................................................................................................................................... 69 11-ANR ...................................................................................................................................................................... 69 12-FFRD ..................................................................................................................................................................... 71 13-AFM ...................................................................................................................................................................... 73 14-IMAGINE ............................................................................................................................................................. 74 15-DLR ....................................................................................................................................................................... 75 16-UKA ...................................................................................................................................................................... 77 17-CHARITE ............................................................................................................................................................. 78 18-UKLFR .................................................................................................................................................................. 80 825575 – EJP RD – Part B 3 19-NKFIH................................................................................................................................................................... Associated with document Ref. Ares(2018)6091977 - 28/11/2018 82 20-HRB....................................................................................................................................................................... 84 21-IT MOH ................................................................................................................................................................. 85 22-TUSCREG............................................................................................................................................................. 86 23-FRRB..................................................................................................................................................................... 88 24-FGB ....................................................................................................................................................................... 90 25-FTELE ................................................................................................................................................................... 92 26-ISS ......................................................................................................................................................................... 94 27-CVBF .................................................................................................................................................................... 97 28-TEDDY ............................................................................................................................................................... 100 29-MIUR .................................................................................................................................................................. 104 30-VIAA ................................................................................................................................................................... 105 31-LMT .................................................................................................................................................................... 106 32-VUHSK ............................................................................................................................................................... 106 33-FNR ..................................................................................................................................................................... 108 34-ZONMW ............................................................................................................................................................. 109 35-UMCG ................................................................................................................................................................. 110 36-UM ...................................................................................................................................................................... 113 37-NCBR .................................................................................................................................................................. 114 38-MUW................................................................................................................................................................... 115 39-MUG ................................................................................................................................................................... 117 40-IPCZD ................................................................................................................................................................. 119 41-FCT ..................................................................................................................................................................... 122 42-INSA ................................................................................................................................................................... 123 43-SAS ..................................................................................................................................................................... 125 44-ISCIII................................................................................................................................................................... 126 45-CNAG-CRG ........................................................................................................................................................ 131 46-UPM .................................................................................................................................................................... 133 47-CIBER ................................................................................................................................................................. 135 48-SRC ..................................................................................................................................................................... 137 49-VINNOVA .......................................................................................................................................................... 137 50-ULEIC ................................................................................................................................................................. 138 51-ULIV ................................................................................................................................................................... 140 52-UNEW ................................................................................................................................................................. 141 53-CCRI ................................................................................................................................................................... 143 54-APHP (A) ............................................................................................................................................................ 145 54-APHP (B) ............................................................................................................................................................ 146 54-APHP (C) ............................................................................................................................................................ 148 54-APHP (D) ............................................................................................................................................................ 150 54-APHP (E) ............................................................................................................................................................ 153 825575 – EJP RD – Part B 4 54-APHP (F) ............................................................................................................................................................. Associated with document Ref. Ares(2018)6091977 - 28/11/2018 155 54-APHP (G) ............................................................................................................................................................ 155 55-HUS ..................................................................................................................................................................... 157 56-CLB ..................................................................................................................................................................... 159 57-UKL-HD ............................................................................................................................................................. 161 58-EKUT .................................................................................................................................................................. 162 59-GUF ..................................................................................................................................................................... 164 60-HSK ..................................................................................................................................................................... 165 61-IOR ...................................................................................................................................................................... 166 62-AOUP .................................................................................................................................................................. 169 63-AOUS .................................................................................................................................................................. 172 64-LUMC ................................................................................................................................................................. 174 65-RABOUDUMC ................................................................................................................................................... 180 66-AMC .................................................................................................................................................................... 184 67-ERASMUS MC ................................................................................................................................................... 187 68-SERMAS ............................................................................................................................................................. 188 69-NUTH .................................................................................................................................................................. 190 70-GOSH .................................................................................................................................................................. 192 71-EORTC ................................................................................................................................................................ 194 72-INFRAFRONTIER ............................................................................................................................................. 196 73-BBMRI ................................................................................................................................................................ 197 74-ECRIN/PEDCRIN............................................................................................................................................... 199 75-EATRIS ............................................................................................................................................................... 201 76-ELIXIR ................................................................................................................................................................ 203 77-EURORDIS ......................................................................................................................................................... 208 78-CSO-MOH .......................................................................................................................................................... 210 79-SNSF ................................................................................................................................................................... 210 80-BLACKSWAN ................................................................................................................................................... 211 81-TUBITAK ........................................................................................................................................................... 212 82-ACU/ACURARE ................................................................................................................................................ 213 83-HUGEN ............................................................................................................................................................... 215 84-CIHR ................................................................................................................................................................... 217 85-FRQS ................................................................................................................................................................... 218 86-IT ......................................................................................................................................................................... 219 87-GSRT................................................................................................................................................................... 220 88-DFG ..................................................................................................................................................................... 223 4.2. Third parties involved in the project (including use of third party resources) ................................. 224 4.3: Financial support to third parties ....................................................................................................................... 254 SECTION 5: ETHICS AND SECURITY ................................................................................................................... 272 5.1 Ethics ................................................................................................................................................. 272 5.2 SECURITY ....................................................................................................................................................... 279 825575 – EJP RD – Part B 5 Associated with document Ref. Ares(2018)6091977 - 28/11/2018 1. EXCELLENCE 1.1 Rare Diseases burden in Europe Rare Diseases (RDs) are life threatening or chronically debilitating conditions from which fewer than five affected persons per 10,000 citizens in the European Union (EU) suffer. It is estimated that 6,000-8,000 different RDs exist, affecting between 6% and 8% of the population in the course of their lives. Many RDs manifest in childhood, affect patient’s life-long and are not curable with current interventions or medications, resulting in high medical need and immense costs for health care system, society and families. Whereas the rarity of each disease, the extreme variability of the clinical manifestation, the common affection of different organs, and the lack of broad recognition of RDs would call for clustering of expertise, research on RD remains scarce and scattered in different research and care organizations throughout the EU. This translates into delayed diagnosis, few medicinal products and difficult access to care. That is why RDs are a prime example of a research area that can strongly profit from coordination on a European and international scale. This was recognized in the Council Recommendation of June 8, 2009 on an action in the field of RD (2009/C 151/02), which specifically emphasized that the coordination of Community, national and regional programmes for RD research should be improved. 1.2 Efforts deployed by the European Union and Member States so far Between 2007 and 2017 the European Commission (EC) invested over 874 M€1 in research on RD. The European Commission has supported not only key actions to produce data necessary to improve identification and knowledge on RD under the form of large multinational scientific projects but also strategic and coordination initiatives to provide recommendations on specific areas to support and guide Member States policies on RD. In particular, the EC has supported the International RD Research Consortium (IRDiRC2), a global consortium of funders and organizations (including patient organizations) involved in RD research to address RD grand challenges through collaborative actions such as establishing and providing access to harmonized data and samples, performing the molecular and clinical characterization of RDs, boosting translational, preclinical and clinical research, and streamlining ethical and regulatory procedures. The ambitious goal to deliver 200 new therapies for RDs by 2020 has already been met and means for RD diagnosis have greatly improved since IRDiRC was founded. IRDiRCs new vision is to provide diagnosis for most RD patients within a year of first sub-specialty medical consultation and 1000 new therapies by 2027. The EC supports several associated projects like RD-Connect3, a global infrastructure project that links up omics databases, registries, biobanks and clinical bioinformatics data used in RD research into a central resource for researchers worldwide or RareBestPractices4, which is a platform to improve the management of RD patients by disseminating trustworthy guidelines globally, identifying and prioritizing RD research needs and facilitating timely, effective and efficient translation of research results into patient oriented strategy on the clinical as well as the public health level. Finally, the European Rare Diseases Registries Infrastructure (ERDRI) being developed by the DG Joint Research Centre (JRC) in collaboration with DG SANTE will promote and support European-level solutions ensuring interoperability for registries established at the European, national and/or regional level. It will provide a source of information on rare disease patient data with a large transnational coverage. Part of the EC’s comprehensive approach to tackle the RD burden in Europe is to co-finance projects and actions with Member States. An example is the Rare Diseases Joint Action5 (continuation of EUCERD Joint Action initiated in 2011) that has the general objectives to (i) support further development and sustainability of the Orphanet6 database on RD (the biggest repository of information about RD globally co-funded by the EC since 2000), (ii) contribute to solutions to ensure an appropriate codification of RD in health information systems; (iii) continue implementation of the priorities identified in the 2009 Council Recommendation and the 2008 Commission Communication on RD, and (iv) support the work of the Commission Expert Group on Rare Diseases7 by gathering expertise and producing data necessary to its action. An additional important initiative for research on and healthcare for RD is the current development of European Reference Networks8 (ERNs) in which specialists in various disciplines in different countries in Europe join their 1 Communicated by the EC for FP7 and H2020 2014-2015 2 http://www.irdirc.org 3 http://www.irdirc.org 2 rd-connect.eu/ 4 rd-connect.eu/ 3 www.rarebestpractices.eu/ 5 www.rarebestpractices.eu/ 4 www.rd-action.eu 6 www.rd-action.eu 5 www.orpha.net/ 7 www.orpha.net/ 6 http://ec.europa.eu/health/rare_diseases/expert_group_en 7 http://ec.europa.eu/health/rare_diseases/expert_group_en 8 http://ec.europa.eu/health/ern/policy/index_en.htm 825575 – EJP RD – Part B 6 efforts to treat RD that require highly specialized healthcare and a concentration Associated ofRef. with document knowledge and resources. Ares(2018)6091977 - 28/11/2018 Although their primary goal is the development of cross-border health care, ERNs have often evolved from European research networks and their outstanding gathering of expertise has the potential, in the future, to support and facilitate translational research in areas such as quality assurance mechanisms for laboratory testing; development of good practice guidelines for diagnosis and care; natural history studies; support to cross-national clinical trials; registries; etc. The landscape cannot be complete without mentioning important efforts of Member States that integrate on one hand direct research funding and on the other support for medical infrastructures providing services to the research community. Since at present, only few European countries fund research on RD through specific dedicated programmes, the funding of transnational collaborative research is the most effective joint activity to enhance the cooperation between scientists working on RD in Europe and beyond, and thus reducing fragmentation of research in this field. The E-Rare, ERA-Net for Research Programmes on Rare Diseases9, was established in 2006 to link responsible funding organizations and ministries that combine the scarce resources for research and thus enable the participation of many researchers to transnational projects via Joint Transnational Calls (JTCs). At the start of E-Rare-1 in 2006 the consortium consisted of eight countries and extended in the following years. Today, E-Rare-3 is a network of twenty-eight partners – public bodies, ministries and research funding organizations – from twenty countries: Member States (Austria, Belgium, Czech Republic, Finland, France, Germany, Greece, Hungary, Italy, Latvia, Poland, Portugal, Romania, Spain, The Netherlands), three Associate States (Switzerland, Israel and Turkey) and two non-European countries (Canada and Japan). In addition E-Rare is member of IRDiRC and strongly contributes to its objectives. RD research also benefits from several biomedical and life sciences European Research Infrastructures such as BBMRI, ELIXIR, EU-Openscreen, Eatris, or Infrafrontier and ECRIN, which were developed in the past years through collaborative efforts of Member States. Although not specific for RDs, these infrastructures aim at development of services facilitating researchers access to resources and knowledge and to contribute to sharing of data and avoiding duplication of efforts. Finally, Rare disease research can take full advantage of cutting-edge data- focused initiatives in current European policy, including the European Open Science Cloud (EOSC)10, which aims to accelerate and support the current transition to more effective Open Science and Open Innovation in the Digital Single Market and to enable trusted access to services, systems and the re-use of shared scientific data across disciplinary, social and geographical borders. The very rarity of RD means that the field has a vast amount to gain from opening up and reuse of research data, and tapping into such major flagship initiatives will help maximize gains for the RD community as early adopters of these cutting edge data stewardship initiatives. 1.3 Key policy recommendations In 2017 report “Rare Diseases - a major unmet medical need”11 the European Commission pinpoints five key policy recommendations: ● Support integration and networking among EU research, patient and healthcare organisations; ● Adapt implementation of regulatory requirements, especially for clinical trials in rare diseases; ● Develop legally and ethically robust agreements for collecting and exchanging health and genetic data; ● Support health technology assessment, standards and evidence-base for guiding public health policy; ● Collaborate globally through the International Rare Diseases Research Consortium (IRDiRC) to accelerate research on improving the lives of patients with rare diseases. These recommendations, together with identified challenges are the main driving force of the EJP RD. 1.4 Major challenges to overcome Despite significant developments in the RD field over the past years, several challenges still remain. To achieve an integrated strategy for RD research and care there is a need for: ● Sustainable and interoperable organization with established, accepted standards to govern the collection, organisation, sharing and reuse of (health) data and resources that are currently fragmented and/or duplicated (information or samples, omics data, registries and cohorts, national history studies, biobanks, ontologies, inventories, the ethical framework, trial readiness). This includes advanced data sharing and linkage mechanism according to FAIR (Findable, Accessible, Interoperable, Reusable); ● Structured connection of research efforts with European Reference Networks (ERNs). These networks should be well placed to show how standards and tools supported by European infrastructures or developed by the RD community can be efficiently implemented and integrated into healthcare while improving the equity of 9 www.e-rare.eu 10 http://ec.europa.eu/research/openscience/index.cfm?pg=open-science-cloud 11 https://ec.europa.eu/info/sites/info/files/rarediseases_p4p-report_2017.pdf 825575 – EJP RD – Part B 7 healthcare provision across the EU on rare diseases, and to improve HTA Associated methodologies with document so that they can Ref. Ares(2018)6091977 also - 28/11/2018 be fully applied specifically to interventions addressing rare diseases; ● High quality research to identify novel disease mechanisms and to lump diseases based on common pathways; ● Enhanced uptake of research results for translation into tangible outcomes for better health and effective transfer of exploitable results to SMEs and relevant industry sectors, in particular for drug development or repurposing, humanized models, preclinical trials, biomarker development, patient trial readiness and clinical trials; ● Centralized planning and coordination that takes the overall responsibility and disposes necessary means to support the needs of the RD community and reach a greater level of integration, including in EU-13 countries and ensures active and broad participation of European and international research stakeholders in IRDiRC activities and the wide uptake of collaborative results; ● Systematic implication of patient organizations in the design of research and care programming and actions at national and regional levels; ● Effective interaction and training across RD community at all different levels (researchers, practitioners and patients). 1.5 Objectives of the European Joint Programme on Rare Diseases RD research in Europe can be improved to overcome fragmentation, leading to efficacious use of data and resources, faster scientific progress and increase of competitiveness, and most importantly to decrease unnecessary hardship and prolonged suffering of RD patients. In the specific context of the massive generation and need for reuse and efficient interpretation of data, introduction of omics into care practice and the ongoing structuration of RD care centers in European Reference Networks, it appears crucial and timely to maximize the potential of already funded tools, projects and programmes by supporting them further, scaling them up, linking them together, and most importantly, adapting them to the needs of end-users through implementation tests in real settings. Such a concerted effort is necessary to develop a sustainable ecosystem allowing a virtuous circle between RD care, research and medical innovation. To achieve this goal, the European Joint Programme on RD will have two major objectives: • To improve the integration, the efficacy, the production and the social impact of research on RD through the development, demonstration and promotion of Europe-wide and even world-wide sharing of research and clinical data, materials, processes, knowledge and know-how; • To implement and further develop an efficient model of financial support for all types of research on RD (fundamental, clinical, epidemiological, social, economic, health service) coupled with accelerated exploitation of research results for benefit of patients. Figure 1. The EJP RD concept 1.6. Relation to the work programme The proposed joint programme of activities ranging from research to coordination and networking activities, including training, demonstration and dissemination activities will be structured along five main components ensuring the implementation of a comprehensive and cohesive research and innovation bench to bedside pipeline, fully in line with the Work Programme call SC1-BHC-04-2018 “Rare Disease European Joint Programme Cofund”: 825575 – EJP RD – Part B 8 ● Pillar 1 “funding collaborative research on RD” will foster jointAssociated transnational calls Ref. with document for Ares(2018)6091977 collaborative research - 28/11/2018 projects resulting in financial support to third parties encompassing various aspects of rare diseases. In addition, the financial support actions will be extended to the Networking Scheme (to encourage sharing of knowledge on rare diseases between clinicians, (biomedical) scientists and patient organizations) and the Rare Disease Research Challenges (innovative funding scheme to foster private-public partnerships and multi- stakeholder collaborations). All calls will be implemented according to standards and good practice of Horizon 2020 including international peer review, Horizon 2020 evaluation criteria, proposal selection following the ranking list etc.; ● Pillar 2 “innovative coordinated access to data and services for transformative RD research” aiming at rationalized, optimized and increased potential of existing resources and services, will develop a FAIR virtual platform for RD information encompassing research data, samples, tools and standards to support and accelerate rare diseases research. The usefulness of the developed tools and their upscaling will be ensured through the direct links with funded research projects (Pillar 1) and new connections across the rare diseases community in particular with European Reference Networks (ERNs). In addition, pilot and proof-of-concept projects will be put in place to enable multidisciplinary, holistic approaches for rare disease diagnostics and therapeutics and fostering creation of complete diseases pathways; ● Pillar 3 “capacity building and empowerment” will be raising the level of knowledge and know-how within the RD research and care community, including through ERNs and RD patient representatives and advocates. To this end, a comprehensive programme of training courses will tackle areas such as research data management, orphan drug development, HTA & regulatory processes, scientific innovation & translational research, best practice guidelines and ERN cross-cutting themes & needs. Activities will involve large groups of stakeholders including adult and paediatric patients. Furthermore, training courses will be developed and adapted to address the specific needs of EU13 countries and to provide capacity building of the different stakeholders on the use of the common platform developed within Pillar 2. Finally, Pillar 3 aims at first-in- Europe online academic course to provide an EU-wide streamlined education programme on RD research to all interested stakeholders; ● Pillar 4 concentrates on“ accelerating the translation of high potential projects and improving outcomes of clinical studies in small populations”. By creating a bridge between basic research and medical innovation, otherwise known as the “bench to bedside” approach, this pillar aims to support the RD community to more effectively translate high quality research into high impact interventions for the RD patient community. To demonstrate its efficiency, research projects funded through Pillar 1 and previously by E-Rare will be selected for their translational potential and specifically supported and guided throughout this process. In addition, Pillar 4 will foster the development of innovative methodologies tailored for clinical studies in RDs by specifically supporting ERNs to use the most adapted methodologies improving trial studies in RDs. Demonstration studies will be funded to validate existing and most recently presented innovative methodologies as well as most promising new statistical methodologies; ● Finally, the strategic coordination and management of the EJP RD will constitute the foundation linking all the Pillars together, enabling cross-communication, prioritisation and alignment between different activities. It will encompass annual programming including gap-analysis and identification of research priorities and policy questions in demand for evidence generation, as well as monitoring of the outcome of the EJP RD. Close linkage with IRDiRC will be ensured by integration of the IRDiRC Secretariat in the EJP RD Coordination Office. A specific WP will be dedicated to provide all Pillars with the proper strategy to address ethical, regulatory, legal and Intellectual Property Right (IPR) issues, and will ensure that relevant rules are complied with within the course of the project. Finally, exploitation of EJP RD results, its innovative potential and sustainability will be key aspects, tackled from the start and throughout the course of the programme. 1.7. Concept and methodology The linked approaches and complementary strategic orientation of the four core pillars together with that of the coordination and transversal activities create an overall comprehensive and cohesive structure that will deliver and ensure implementation of the wide range of jointly related activities bridging the gaps and adding value to existing resources and initiatives. The schematic concept of EJP RD is presented in Figure 2. 825575 – EJP RD – Part B 9 Associated with document Ref. Ares(2018)6091977 - 28/11/2018 Figure 2. Structure of the EJP RD (coordination, transversal activities and four pillars) COORDINATION AND TRANSVERSAL ACTIVITIES: The EJP RD will be based on the concerted action of 88 beneficiaries and their linked third parties from 24 European (AT, BE, CZ, DE, ES, EE, FI, FR, HU, IE, IT, NL, NO, LT, LV, LU, PL, PT, RO, SE, SK, SV, UK), 4 associated (AM, CH, IL, TK) and 1 non-EU country (CA). In addition institutions from Japan and Australia will participate as “associated partners or “observers”. EJP RD will strive for further inclusion and “openness” at all levels including funding opportunities, Virtual Platform of resources and services, trainings and translation and innovation services. RD stakeholders from all countries involved in the EJP RD will be eligible to profit from offered support and the Virtual Platform will be constructed as fully open source for the benefit of the whole RD community. The EJP RD will be structured around centralised coordination and management, which will focus not only on active and efficient support of the EJP RD partners and planned activities but also will allow necessary overarching governance and implementation of transversal actions that require convergent approach, like communication, EJP RD research and innovation strategy, tackling of ethical, legal and regulatory issues, exploitation of results and IPR and closely related sustainability plan. Furthermore, direct collaboration with Policy Board of relevant high-level stakeholders (ministries, EC directorates, industry, regulatory agencies and European infrastructures forum) will ensure decisive alignment of national and European strategies and policies. Finally, despite the fact that the process of integration of Member States in the EJP RD covered an almost 2 year period in advance of the application, not all EU countries decided to get involved. However, the efforts on expansion of the EJP RD consortium will be pursued by the coordination to ensure meaningful involvement of new partners. PILLAR 1: COLLABORATIVE RESEARCH FUNDING Notwithstanding the important progress in the Rare Diseases (RD) field, many aspects remain without solutions. The need for fundamental, translational, clinical, social and health services research and most efficient modes of fostering them are therefore still topical. The interdisciplinary cooperative approaches to be addressed through national and EC programmes should be promoted. Since at present, only few European countries fund research on RD through specific dedicated programmes, the funding of transnational collaborative research is the most effective joint activity to enhance the cooperation between scientists working on RD in Europe and beyond, and thus reducing fragmentation of research in this field. Pillar 1 will be based on the strong previous collaboration and reputation of the E-Rare ERA-Net. The activities of E-Rare demonstrated that continuous cooperation of funding organizations, particularly for the implementation of joint transnational calls, influences the alignment of processes, funding procedures and timelines in addition to the gained common knowledge. The high number of proposals received in response to the calls of E-Rare highlights the great potential and diversity of the European RD research community and the need for funding of collaborative projects. The ex-post analysis of projects financed between 2007 and 2011 showed that all of them were able to achieve critical mass of resources necessary to complete their goals. In addition, the consortia demonstrated intensive exchange of samples as well as creation of databases, biobanks, or registries. These “infrastructures” were created either from scratch or by pooling the existing, but disconnected sources. The transnational collaboration within projects translated also through the training and exchange of personnel. Finally, the number of joint 825575 – EJP RD – Part B 10 publications also confirmed this success: 525 peer review articles were published Associated byRef. with document 37Ares(2018)6091977 consortia with -a28/11/2018 mean impact factor of 7.32 (range from 0.5 to 59). This confirms that joint research funding and support of RD research is considered as “stimulator” of transnational, enduring partnerships and should be further developed. However, some weaknesses were also pointed out, namely (i) insufficient level of interactions between different types of stakeholders (not only scientists) for the benefit of RD research and (ii) lack of commitment from private investors and industry. Pillar 1 will engage 29 funding bodies from 22 countries and will be open for further integration of new partners. At the moment of submission of this proposal the commitment to two first joint transnational calls reached 37 M€. Further engagement of at least 20 M€ for calls 2021-22 is also planned. Most importantly Pillar 1 takes into account lessons and recommendations learned during previous (E-Rare) years. Therefore, the proposed funding support will be extended beyond joint transnational calls and will encompass the Networking scheme (2 M€) and the Rare Diseases Research Challenges (1.5 M€ of public funding), the latter targeting public-private partnerships. Foreseen funding activities will not only strengthen rare diseases research but also increase its exploitation potential by implementing innovative mechanism of public-private support. Pillar 1 will also expand the collaboration potential beyond the national and EU borders by enabling RD networks and events including partners from and outside EJP RD participating countries. PILLAR 2: INNOVATIVE COORDINATED ACCESS TO DATA AND SERVICES FOR TRANSFORMATIVE RARE DISEASE RESEARCH Despite the significant resources already in place (knowledge bases, databases, registries and infrastructures), the fragmentation and duplication of effort and resources in relation to data, information or samples persist, making efficient and timely use of these resources in RD research challenging. In order to overcome these bottlenecks Pillar 2 will create a sustainable and interoperable ecosystem of resources (the EJP RD virtual platform), coupled to robust standards, tools and procedures that will infuse FAIR principles into advanced and secure forms of data discovery, linkage and sharing. It will allow flexible, real-time access to data (under suitably controlled conditions), with supporting tools and services that serve the ultimate goal of increasing the efficiency and efficacy of RD research. Driven by concrete use-cases and needs arising from the RD clinical and research community, it will provide the means to harmonise and standardise the way RD relevant data, samples and tools are made findable, accessible, interoperable and re-usable, and the means to query the progressively increasing number of resources and repositories connected to the EJP RD virtual platform through a central facility. The EJP RD Pillar 2 will establish a stronger and broader collaboration between the RD community and European Research Infrastructures and global consortia than ever before. This will have major mutual benefit and impact. On one hand RD research, supported by highly motivated patient representatives and ERNs, presents an exemplar challenge and opportunity for research infrastructures to create common solutions and stimulate collaboration. On the other hand, progress in RD research depends on the strongest possible infrastructure to address its needs towards efficient information retrieval and analysis across its distributed data resources. The increased capacity of infrastructures and their seamless integration with RD community will ultimately translate to higher innovation potential and benefit for patients. To that point, Pillar 2 will develop three parallel and complementary axes of work, all three governed by consistent quality, regulations and compliance with agreed standards requirements. Moreover, all axes will be driven by research and clinical user community, ensuring that Virtual Platform is built for and adopted by this community. The axes are: • Centralized metadata repository describing pre-existing resources (including catalogs, data repositories, tools and infrastructures12) with RD-specific semantic standards and metadata that conforms to an ontological, machine-readable model that also encompasses consent and data use conditions. This will make resources Findable, and their Accessibility conditions to be known. Furthermore, it will provide guidance and services to produce, store and share phenotype-genotype data for researchers, as well as standards for data processing, generation and deposition of multi-omics data, relevant for RD. More importantly, the involvement of key partner resources to normalise their metadata models, and to harmonise data deposition is already secured; • Federated ecosystem of FAIR-at-the-source resources, in order to enable data discovery, sharing and analysis down to the record level. This axis of work organizes partnering with target resources to make them FAIR compliant, as well as the required interdisciplinary collaboration between RD experts and data experts. Beyond achieving FAIRification of resources in the VP, Pillar 2 will offer to the RD community at large the means and support, including training, to enlarge the scope of the federated ecosystem, by building a sustainable FAIRification service. 12 Catalogs: Orphanet, BBMRI, ERDRI, ELIXIR’s bio.tools; Data repositories: ERNs’ registries, biobanks, RD-Connect’s GPAP; Infrastructures: INFRAFRONTIER, ECRIN, are examples of those. 825575 – EJP RD – Part B 11 • Extension of the virtual platform with workflows that allow Associated holistic research based with document Ref.on rare disease data Ares(2018)6091977 and - 28/11/2018 biological knowledge, by filling gaps in data on disease modifiers such as nutrition and metabolism, aspects of lifestyle and exposure to toxicants with the final aim to improve the understanding of the etiology and progression or rare diseases and to support the discovery of biomarkers and the identification of druggable pathways and targets. This axis of work requires exploitation of previously performed explorative studies and the conduction of proof of principle studies specific for RD. It will be based on important collaboration between European Research Networks and top-level research teams excelling in data mining and interpretation. Relevant connection to Solve-RD project will be also ensured. PILLAR 3: CAPACITY BUILDING & EMPOWERMENT Critical to ensuring equity and optimizing outcomes for people living with rare diseases is integrating RD activities under a common joint education & training programme to raise the level of knowledge and build capacity within the RD community. This is what Pillar 3 of the EJP RD is aiming to achieve by working closely and collaboratively with 45 partners including RD patient representatives (e.g. ePAGs involved in ERNs and young RD patient representatives), several ERNs, academics, researchers, clinical scientists, European Networks (e.g. Orphanet) and European research infrastructures (e.g. BBMRI, ELIXIR). The pooling of existing resources, training initiatives, relevant expertise and experience in RD trainings from the different partners within the central place of the EJP RD will meaningfully facilitate the engagement of the RD community with regulatory bodies, the private sector and the biomedical industry in order to fast-track access and provide diagnosis to unsolved cases as well as facilitate clinical trials and boost drug development of RD therapies. Patient-centered health service is increasingly recognized as a priority in medicines R&D and is a founding principle of the common values in European Union Health Systems, spanning from research to healthcare. In order to build and reinforce partnerships between patients and researchers, current practices need to evolve. This holistic approach will ultimately deliver the improved outcomes for patients and the health system. The key success factor for patient researcher partnerships is building the capability of researchers to engage meaningfully with patients, maintain transparency and build trust thus empowering them to contribute proactively with researchers and help inform research objectives. Consequently, a crucial element for sustainable research and the translation of new knowledge into the health system is to invest in capacity building for effective engagement among all stakeholders. Through this investment, significant opportunities will be created that will enhance the research and innovation capability among all stakeholders, thus enabling effective, patient centered outcomes that address RD patient needs and can be readily adopted within healthcare systems. Pillar 3 will concentrate its activities on developing and delivering a seamless flow of training programmes on key aspects relevant for rare disease research across the RD community. Existing training courses will be expanded further and new ones developed to adequately suit the needs of the RD research community with a specific attention to the needs of ERNs and EU13 countries. Pillar 3 has secured an essential and key asset which is represented by the inclusion of the major players in the European RD landscape as EJP RD partners responsible for developing and updating the training courses according to emerging needs from the community. The methodology chosen consists of a blended approach of face-to-face courses ranging from short 1 or 2-day workshops to 3 or 5 days residential training and a comprehensive EU-wide online academic RD research training programme. All training courses will be open to all and offered free of charge to interested participants. Researchers funded through Pillar 1 funding schemes and Pillar4- supported researchers and clinicians with specific issues (e.g. IP, regulatory, etc.) will be encouraged to apply and register for the training activities. In addition, 10 to 15% of selected participants will be offered travel and accommodation fellowships enabling a more equitable level of participation among less wealthy EU countries. Successful applicants will be selected using an eligibility matrix including a scoring system based on pre-identified criteria which will be adapted along the course of the EJP RD. Furthermore, several training courses will be changing location each year, hosted by EJP partners based in different countries to ensure wide participation across Europe. Within Pillar 3, the face-to-face capacity building activities plan to train around 1,500 participants over the course of the EJP [WP14:1006 trainees including WP14.1: 23x12=276; WP14.2: 20x5=100; WP14.3: 30x4=120; WP14.4:310; WP14.5: 40x5=200); WP15=335 including WP15.1: 10x5=50; WP15.2: 30x4=120; WP15.3: 30x4=120; WP15.4: 15x3=45; WP17:72 trainees; WP18: 80 trainees]. It is important to highlight that this estimation does not take into account the online academic course within WP16, which has the potential to train an unlimited number of interested stakeholders in the long term. Furthermore, WP15 also includes pre-training online modules which will grow in content over the years and will be open access to anyone interested in the topics addressed, in particular but not restricted to, rare disease patient representatives. Finally, the ambition and mission of Pillar 3 is capacity building of all RD stakeholders and as such many trained participants will be able in turn to transfer to knowledge and skills gained through the EJP to their own networks with a potential downstream impact of inestimable value. Thus, the EJP RD represents the unique opportunity to showcase all the relevant education and empowerment activities for RD research under one umbrella. 825575 – EJP RD – Part B 12 PILLAR 4: ACCELERATING THE TRANSLATION OF HIGH Associated with POTENTIAL PROJECTS- 28/11/2018 document Ref. Ares(2018)6091977 AND IMPROVING OUTCOMES OF CLINICAL STUDIES IN SMALL POPULATIONS The improvement of outcomes in translational and clinical research by providing on one hand suitable support, mentoring, expertise and improved industrial uptake and on the other hand direct innovative methodologies for RD clinical studies is one of the main goals of the EJP RD. This will be achieved with Pillar 4, which aims to structure a long-term sustainable strategy for improving pipeline productivity and translational research capacities on therapies of RDs working closely with ERNs and other actors in the RD community. There are two main areas in need of urgent attention in the development pathway. Firstly, due to the historical lack of academic incentives, expertise and funding opportunities to perform translational research in all but a handful of RDs combined with large pharmaceutical industry’s retreat from performing early translation (due to the biological complexity and high failure rates), there is a substantial gap that slows or even prevents good science from being efficiently translated into effective interventions for society. Secondly, clinical development of novel interventions for rare diseases is particularly challenging, as they are complex and heterogeneous with lack of suitable patient cohorts, incomplete understanding of outcome measures and natural history. In addition, the small size of many ultra-rare disease populations make pivotal clinical trials difficult and at the same time commercially less viable despite the incentives for the development of therapies for RDs. Improving the development pathway for rare diseases through an integrated development methodology with innovative clinical trial design and statistical analysis methods will help encourage more successful development of life changing drugs for more rare diseases. To achieve these goals Pillar 4 will promulgate three hallmarks of sounds translational research, namely mindset, professional management, and mentoring. This will be achieved through a combination of self-help resources and active in- project support from diverse fields, such as product development, regulatory and commercial. To do so, the expertise of several partners (EATRIS, FTELE, ECRIN, ERNs), will be utilised. An active mentoring programme coordinated by an Innovation Manager assigned to project teams, investigators and funders of Pillar 1 will benefit from active guidance and input into design, development and help in the execution of cutting edge translational and clinical studies. In addition, in close connection with RDR Challenges Pillar 4 will support high potential projects to find resources and expertise of private and for-profit funders and developers, in order to complete the development pathway to the patient. In Europe, several cases show that, despite the limited size of the market, the field of rare diseases is attractive to investors. On the basis of recent examples in Italy, the Netherlands and France, the Pillar 4 will create a roadmap for innovation funding in RD, utilizing blended investment modes that will feed also sustainability strategy. Acceleration of arrival of new therapeutic options to patients passes also by more efficient and reliable clinical studies. Pillar 4 is particularly well armed to tackle this issue as it gathers the capacity and expertise of the European Reference Networks strengthened by know-how of ECRIN and high-level methodologists from IDeAl project. This will be done at three levels: (i) through identification of already existing but not sufficiently used highest methodological standard for clinical trials in RDs and their direct promotion via the powerful network of ERNs and other relevant EJP RD partners; (ii) via demonstrators projects focusing on validation of recently developed methodologies for design and analysis of clinical trials and finally (iii) via design of innovative methodologies in parts of clinical design that were not adequately addressed until now (e.g. more appropriate endpoints allowing better assessment of clinically meaningful responses as PCOMs; validation of composite end points and surrogates; capture in the cohorts of natural history studies efficacy and important safety information through life span; evidence assessment associated with randomization in limited populations; pharmacometric modeling, extrapolation modelling). Pillar 4 will collaborate closely with Pillar 2 to exploit existing data and to deliver validated or new methodological standards to enhance the panel of tools for RD community. Finally, the involvement of funds from the private sector (pharma, SMEs, start ups) and the promotion of rare disease therapies as the future of personalized medicine based on particular characteristics of each individual or each small group of individuals will be extensively addressed in this Pillar. Gender/sex aspects: EJP-RD will respect the gender equality and work to keep on a gender balance throughout the project. Sex and gender are captured in the EJP RD project at three levels: In the project management and governance: The gender representation of the partners’ involved at the EJP-RD is well balanced (M/F=52/42). Attention will be taken to keep gender balance in the governance structures (Governing Board and Policy Board) as well as Advisory Ethics, Regulatory & Legal Board. With regards to conduct of research: gender perspective will be integrated in all EJP RD activities in support of gender justice, based on the recognition that a systematic approach to gender in research enhances quality and excellence. All partners, and the consortium as an entity, are committed to recruiting collaborators to the program or training activities without bias of race or gender. Furthermore, gender will be one of the indicators for the assessment of the funded projects in the calls of Pillar 1 and in the pilot projects of Pillar 2 and 4. Special attention will be paid to ensure that extra effort will be performed to try and recruit more women researchers in these 825575 – EJP RD – Part B 13 projects, and to avoid the loss of women scientists during the transition between Associated junior with document and Ref. higher positions. Ares(2018)6091977 The - 28/11/2018 equality will be also applied to the trainings offered by Pillar 3. Sex and gender aspects in research activities to be performed: Most rare diseases do not discriminate between males and females. Even for the X-linked diseases that seem to affect mainly males there is more and more evidence that also female carriers may suffer from these conditions. However, sex/gender aspects will be taken into account whenever considered relevant, e.g. (i) in Pillar 1 funded projects; (ii) in Pillar 2 with respect to influence of gender on disease mechanisms being taking into account together with environmental factors in POCs (WP13), as well as gender being represented in metadata describing data collection (WP11&12); (iii) in Pillar 2 for the development of tools of virtual platform that will serve research community; (iv) in Pillar 4 (WP20) demonstration and innovation projects for innovative methodologies to improve outcomes of clinical studies, where sex and gender are crucial elements for natural history registries, PCOMs, etc. 1.8 Ambition The European Joint Programme Cofund is a supreme instrument to grant high-level strategic organization and performance of research activities in an organized and transversal manner. EJP RD will maximize the potential of this European tool, by expanding the panel and potential of involved stakeholders. The commonly involved Programme Owners (ministries) and Programme Managers (Research Performing Organizations) will be accompanied for the first time by funders (Research Funding Organizations), European Research Infrastructures, European Reference Networks, patient organizations, education institutions, and will reach regulatory bodies and private sector. This will ensure the necessary level of integration and unique strategy to efficiently tackle societal challenges specific and relevant for the field of rare diseases. The overarching ambition of the EJP RD is to establish an urgently needed comprehensive strategy covering research, data, tools and clinics leading to optimization and exploitation of results, higher and timely diagnostic rates, faster drug discovery at reduced costs, improved patients’ care, empowering all stakeholders as well as giving Europe a leading role in the field of RD in the coming years. To do so, rare diseases need efficient research paths from patient to “product” (product being standardized diagnostic guidelines, methodological and technology approaches, biomarkers, tools, medicines or devices). Thus, the EJP RD will formalise the development “value chain” for RD in terms of diagnosis and therapies. All stakeholders will have access to a seamless pipeline from patient needs to effective intervention through relevant resources. The current state of the organization of the path from patient to product and respective EJP RD elements are summarised in Figure 3.. In this path, the first step is to identify relevant patients and populations. The second step is to gather information about them. Information gathering involves clinical information, phenotyping and genotyping, but also information beyond the exome (which is integrated through the deployment of multiple –omic technologies). The third step is to extract actionable insights from the information. Then useful insights are harnessed to develop products that are subsequently evaluated. At each step in the value chain there are three key determinants of a success: (i) input (access to facilities); (ii) resources (capability and capacity of staff, equipment and facilities); (iii) outputs and connections to the next step. Currently, for RDs, this value chain is fragmented which leads to gaps, delays, inefficiencies and diseconomies of scale. It also causes significant barriers to entry for the RD patients, researchers and funders. Finally, the challenges are magnified by the dispersed nature of rare diseases patients and expertise. Figure 3: Current generic value chain for RD “product” development. 825575 – EJP RD – Part B 14 The EJP RD will develop innovative services through a combination of: (i) Associated withimprovement of existing components document Ref. Ares(2018)6091977 - 28/11/2018 of the value chain (and their adaptation to RD when needed – mainly working with small populations and large effects); (ii) integration through developing a systematic approach to inputs and outputs to each service that improves the accessibility of all services to the RD community. Improvement and integration will be driven by funding projects, pilots and by supporting stakeholders at each step of the value chain. The experience of these projects and pilots will promote changes to the services used during RD products development and the connections between services. The future state is shown in Figure 4. Figure 4: Impact of EJP RD on value chain for RD “product” development. Therefore, the work done by EJP RD will promote consistent links that facilitate collaboration. In addition, these linkages will reduce the risks arising from dispersal and fragmentation providing a robust platform for judgments about funding allocation by research funders and third sector organizations (such as patient organizations funding research). The EJP RD will lead directly to at least 165 projects (transnational, networking, RDR challenges, POCs, demonstrators) that will each push forward the state of the art in their respective topic areas. More fundamentally, these projects will provide proof-of-concept for the joined-up approach that EJP RD will champion. This work will a) reduce barriers to entry for all contributors to the value chain; b) reduce the costs of collaboration; c) increase the benefits gained at each step of the value chain by focusing methodologies on the needs of RD. EJP-RD will increase the value of investment through a combination of shortened timelines, targeted collaborations and optimised methods. This will provide a step change in the value of work on RD product development and increase the productivity of existing investment in RD. It will build a comprehensive research environment. It will also attract new funding because of the increased likelihood of good returns on investment. Thus, the EJP RD 360° approach will be a true game changer in a way RD is conducted so as to allow realistic achievement of IRDiRC new ambitious goals. 2. IMPACT 2.1 Expected impacts EJP RD will contribute to: Overall impact: Improved alignment of national/regional activities and policies in RD Rare diseases are capital example where pooling of expertise and resources together with coordination of national and European efforts are game changers. Despite significant efforts employed so far, RD research in Europe can be further improved, to overcome fragmentation, leading to efficacious use of data and resources, faster scientific progress and increase of competitiveness, and most importantly to decrease unnecessary hardship and prolonged suffering of RD patients. To that extent, EJP RD will be the first initiative gathering over ninety partners (and their 825575 – EJP RD – Part B 15 Associated with document Ref. Ares(2018)6091977 - 28/11/2018 networks, e.g. only the ERNs by themselves cover 900 healthcare units from near all EU Member States) from 32 countries representing key stakeholders in RD field. The strength of the EJP RD consortium lies not only in the number and diversity of its partners but also in its capacity to exploit the existing elements, detect their weaknesses, improve, innovate and deliver novel more efficient solutions. To efficiently transcribe EJP RD activities and outcomes at regional, national, EU and international levels the EJP RD already involved and will maintain strong connection with relevant policy makers. The governance, research & innovation strategy and prioritization process will be organized around the Policy Board gathering ministries of research & health, relevant EC directorates and other key high-level stakeholders (see section 3.2). In addition, each country will be urged to put in place National Mirror Group (NMG) bringing national partners participating directly in the EJP RD and additional actors of the RD field. The NMDs will be central in identifying, discussing and bringing the national needs to the upper level. Each country will speak with united and single voice. This will be also reflected in the EJP RD Governing Board where each country will possess one vote (in the name of all national stakeholders). The same rule will apply to the EU Research Infrastructures, Patient Organizations, ERNs and charities. Once again EJP RD will capitalize on already existing seminal configurations (e.g. at national level around National Plans for Rare Diseases; for EU research infrastructures within CORBEL project; for ERNs within ERN Board of Coordinators, etc.) and reinforce their (gathering) potential through the EJP RD governance. Such explicit organization fortified by extraordinary commitment of EJP RD partners and RD community in general will be the key to successful alignment of regional/national and EU activities and policies in the field of rare diseases. Specific impact 1: Improve lives of rare disease patients by providing new and optimised treatment options and diagnostic tools for these diseases The contribution of the EJP RD to the improvement of lives of RD patients by providing new and optimised treatment options and diagnostic tools will be achieved as a sum of efforts provided within different pillars and transversal activities strengthened by the central coordination and close linkage with relevant policy stakeholders to translate these efforts at regional, national and EU levels. New and optimised treatment options and diagnostic tools can only emerge from well-organized, coordinated science that includes basic, translational, clinical, social and health economic research. These different types of research will be financed and closely monitored in Pillar 1 thereby accelerating development of diagnostic tools and treatments. Pillar 2 aims at removing obstacles, for both humans and computers, to finding, accessing under well defined conditions, analysing and reusing data across the many resources that are relevant for clinical and biological research on rare diseases. The power of Pillar 2 virtual platform will lie in enabling RD data and tool providers to make their data as usable as possible through FAIR principles. RD researchers and experts will be able to find and exploit most relevant data and tools more rapidly to perform advanced and reproducible analysis allowing better understanding of RD causes, mechanisms and determinants, which will improve ways to diagnose and to treat RD. The successful delivery and implementation of Pillar 3 training courses will result in the systematic implication of patient representatives in the design of research, treatment strategies and developments, as well as care programming and actions at European, national and regional levels. By creating an end-to-end pipeline of support and expertise for RD research, Pillar 4’s focus on translating excellent science into effective interventions for RD patients will maximise the patient impact of the EJP RD efforts. By ensuring access to expertise, facilities and funding, the complexities to translation will be ameliorated, while the efforts to develop, demonstrate and disseminate improved clinical study methodologies with a support desk available will substantially improve our ability to develop valuable interventions for small populations and enhance the involvement of ERNs in clinical studies. Specific impact 2: Decrease fragmentation of rare diseases expertise and research resources Through the participation of 87 partners including policy makers, funders, research organizations, ERNs, infrastructures and patients from 32 countries, EJP RD programme is unique in achieving centralised critical mass of expertise and research resources from Europe and beyond. 825575 – EJP RD – Part B 16 Associated with document Ref. Ares(2018)6091977 - 28/11/2018 The long standing collaboration (2006 – 2019) of funding agencies in EU member, associated and non-EU states in the ERA-Net E-Rare resulted in ten Joint Transnational Calls funding 117 projects including 556 research teams. Each of these projects proved the capacity to achieve critical mass in pooling resources (data, samples, expertise and patients) to perform high quality research. At least 77% of these projects established long-lasting collaborations, often extended to other research groups and countries. Progressive joining of new countries allowed pooling of national resources and better coordination of research programmes on rare diseases. EJP RD goes beyond E-Rare by integrating of 11 new agencies (total of 29 covering 22 countries) and expanding further the power of international collaboration of funders to support and encourage excellent (national/regional) research groups to collaborate transnationally in the area of rare diseases. Thus, activities of Pillar 1 will be major leverage action to decrease fragmentation and increase potential of expertise and research resources. All Pillar 2 activities focus on centralization and uniform access to resources and expertise. The Virtual Platform of Pillar 2 will provide a single access point to find and query resources through the most important catalogues for RD (e.g. Orphanet, biobank and patient registry catalogues) and tools (customized ELIXIR bio.tools). It will create an ecosystem of RD resources that are FAIR from resource level down to data element level and encompass interoperable solutions for centralised but also decentralised resources. For the first time research resources: data, infrastructures and tools will be accessible in an integrated way. In addition, Pillar 2 will be working through networks of experts from and across different disciplines to address a specific bottleneck (e.g. an interoperability standards, adoption of FAIR principles for particular health data sets). Pillar 3 will provide the training opportunities to a large panel of RD stakeholders: researchers, healthcare providers and patients, thereby contributing to strengthening knowledge and creating new experts. In addition, it will decrease the fragmentation by structuring the organization and access to already available and relevant trainings for the RD community in Europe. Multi-disciplinary, multi-sector collaboration is a hallmark of the Pillar 4 approach, and thus will bring together experts from basic research, product development, ESFRI infrastructures, ERNs, regulatory science, financing and more, and make these available to EJP RD and E-RARE projects to maximise their chance to reach the patient. In so doing, not only European but global level efforts to bring people together RD community will occur. Moreover, P4 brings together clinical and methodological experts from around the world to drive the improvement of clinical study design for small populations and enhance the development of clinical studies for very rare diseases. Specific impact 3: Increase the EU's capacity to innovate in the field of rare diseases The EJP RD programme combines massive amount of expertise and capacity not only through its direct partners but also through hundreds of rare disease researchers that will be financed in the joint transnational projects. This increases the opportunities for innovation and for translation into improved diagnostic tools and new or optimized treatments. In addition, the discoveries brought by RD field may serve and be expanded to other medical domains, as the underlying disease mechanisms may also be useful for improved diagnostic and therapeutic solutions for more common diseases. All funding activities of Pillar 1 foster the increase of research and knowledge capacity for rare diseases in Europe. The dedicated Rare Disease Challenge funding scheme will specifically aim at removing general obstacles for innovation in the field of therapeutic research in rare diseases by bringing together public and private stakeholders (academia, SMEs, industry and funders). In addition, the support provided from Pillar 4 to detect exploitation potential in funded projects of Pillar 1 and subsequent accompanying of these projects through translation to clinic steps will contribute to the increase of innovation and competitiveness potential of EU. Pillar 2 will support the increase of EU’s capacity to innovate at different levels: (i) it will maximize the potential of already existing, EU funded facilities and tools, both RD-specific and broader ones (RD-Connect, Orphanet, HPO, ELIXIR, BBMRI, EATRIS, INFRAFRONTIER, etc.) by supporting them further, scaling them up, linking them together and fully tuning them to the needs of end-users; (ii) it will set mechanisms to continuous integration of new data elements, standards and tools so as to provide European research with a unique ecosystem that will efficiently translate research into better care and medical innovation; (iii) by working hand in hand with the European Reference Networks it will bring a unique opportunity to efficiently link healthcare and research opening the road to diagnostics innovation; (iv) furthermore, as omics becomes more prevalent in clinical practice Pillar 2 will develop novel tools and pathways for comprehensive interpretation of data and setting of standards thereby accelerating means to tackle undiagnosed diseases. 825575 – EJP RD – Part B 17 Associated with document Ref. Ares(2018)6091977 - 28/11/2018 Providing state-of-the-art education and bringing together different type of stakeholders will enhance the innovation potential of the RD community. In addition, empowering patients and promoting patients’ centered approaches brings attention back to their needs, helps in focusing on relevant priorities and thereby accelerates the process of innovation. In addition, Pillar 3 itself will be source of innovation in training and education field by creating the first EU e-learning academic education programme on RD. EJP RD is structured specifically to improve innovation, and Pillar 4 creates the bridge from basic research to the clinic and back, in the bench-to-bedside-and-back approach. By both supporting the best projects to get to the patient more effectively, and working on some longstanding bottlenecks, such as methodological challenges in design and analysis of clinical studies of small populations, and access to proof-of-concept funding for preclinical projects, this pillar will allow immediate systemic improvement to Europe’s ability to innovate in RD and accelerate the reach for therapies. Specific impact 4: Improve healthcare systems' capacity to take up research results The EJP RD pipeline translated by its interlocked Pillars and transversal activities fosters effective and efficient implementation of research and innovation outcomes in the daily life of rare disease patients. The participation and strong involvement of the European Reference Networks, linking centres of expertise and professionals in different countries, will be the key element to improve the uptake of research results into health care. The funding of socio-economic and health care/health services related projects in Pillar 1 (WP6) will facilitate a better understanding of the real life problems and possible solutions for better uptake of research results in the general practice. In addition, the expected exchange of knowledge facilitated through the Networking schemes (WP7) and close connections between researchers, doctors and patients will also lead to an increased uptake of research results by providing the space to share diagnostic practices and guidelines, put more light on research results and innovative solutions and strengthen the collaborations by different stakeholders. The Pillar 2 strategy is based on giving the European Reference Networks a leading role in driving the way VP is built, with the ultimate aim to accelerate the take up of research results in clinical practice for the benefit of patients. ERNs will ensure the usability and the usefulness of the VP by continuously testing it against real-life use cases, by bringing research questions and establishing, together with Pillar 2 partners, sustainable mechanisms for ensuring a virtuous cycle between care and research. The translation from research to healthcare cannot be done without relevant education. Pillar 3 will train on how research results can be exploited in other settings like diagnosis, drug development, etc. It will also provide dedicated trainings developed by and targeted to ERNs, thus closely connecting the needs of healthcare providers and research. Pillar 4 is dedicated to patient-centrism, and in so doing will ensure that all projects traversing the chasm between lab and clinic are designed for optimal patient uptake. This will be achieved by ensuring strong technical, product development, regulatory, HTA and funding support is available, so that projects are structured with patient uptake at their heart, and can benefit from follow-on funding to get them closer to the patient. Moreover, the methodological work being done to improve statistical methods for small populations will allow clinical uptake for interventions designed for rare diseases, thereby also improving ability to implement results into the clinic. The involvement of ERNs and of patients group will be a key factor for this implementation. Specific impact 5: Reinforce the EU's role as a global leader for rare diseases The EJP RD is exemplary to the world in bringing together the various expertise on research and innovation of rare diseases from so many institutions, clinicians, researchers and patient organisations in one programme to investigate and implement the results into the life of rare disease patients in Europe and beyond. The joint funding activity of Pillar 1 bringing 23 countries and the European Commission is key to speed up rare diseases research in Europe. The joint effort leveraging national funding resources in addition to the EC funding capacity is estimated at more than 60M € for 5 years. The variety of proposed funding schemes fostering transnational research, Networks and Rare Disease Challenges will be essential to enhance excellence and thus European leadership in the field of rare diseases. 825575 – EJP RD – Part B 18 Associated with document Ref. Ares(2018)6091977 - 28/11/2018 European Pillar 2 partners are already leading global endeavours (Orphanet, HPO, FAIR data principles and metrics) or are deeply involved in global initiatives (IRDiRC, MME, Beacon, GA4GH). Consolidating their efforts into the Pillar 2 work will maximize their impact and constitute an unprecedented resource that will establish a new paradigm for conducting research in the RD field, and could be a model for other domains. Europe will demonstrate that synergizing efforts by building a structuring long-lasting ecosystem of data and resources across domains (healthcare and research) but also linking national and transnational levels has a direct impact in clinically applicable discovery and innovation. As for the other EJP RD elements, the strength of Pillar 3 is based on bringing together yet fragmented but already existing EU capacities and organizing them in a coherent and efficient RD training and education landscape. Furthermore, the EU potential will be expanded by seizing and creation of novel, first-in-class trainings. The highly multi-disciplinary, outcome-oriented approach to the EJP RD in general, and specifically in Pillar 4, will augment Europe’s world class output in RD research and development. The outstanding outputs to be expected from the efforts in Pillars 1,2 and 3 will create a rich seedbed of knowledge, which will supported by Pillar 4 on the long journey from publication to patient. P4’s combination of active support to today’s projects, combined with a systematic tackling of serious systemic roadblocks to innovation, will cement Europe’s lead in RD research and innovation. Specific impact 6: Follow the policies and contribute to the objectives of the International Rare Diseases Research Consortium (IRDiRC) The organization of the EJP RD consortium reflects well the organization of IRDiRC by bringing under single umbrella funders, research performing institutions, healthcare providers, patients and linking to industry. In addition, the majority of EJP RD partners are also members of IRDiRC. This will not only allow but also accelerate the follow up of IRDiRC policies and contribution to its objectives. Furthermore, constant connection to IRDiRC will be maintained by the integration of IRDiRC chair and vice chair in the EJP RD Policy Board, incorporation of IRDiRC Scientific Secretariat in the EJP RD Coordination Office, implementation of joint Task Forces and participation of rare diseases experts and other EJP RD members in IRDiRC scientific and constituent committees. The large part of funders involved in the EJP RD are members of IRDiRC. Funding bodies participate either with “individual” status or through the “E-Rare group of funders” that joined IRDiRC in 2012 and were strongly involved in determining the vision and goals of IRDiRC for the period 2017-2027. The support to IRDiRC policies and objectives is already translated through introduction of IRDiRC recommendations in guidelines for researchers as well as implementation of joint transnational calls targeting topics identified by IRDiRC as of most importance. This will be continued and further expanded within Pillar 1 activities. The Pillar 2 main goal is to provide access to data and services to allow better research towards diagnostics as well as new and more effective therapies for rare diseases. Thus, the overall Pillar 2 was designed towards IRDiRC 2017 – 2027 goals, namely (i) provision of a diagnosis within one year to all patients coming to medical attention with a suspected rare disease if their disorder is known in the medical literature or integrating of all currently undiagnosable individuals into a globally coordinated diagnostic and research pipeline and (ii) to develop 1000 therapies. These new IRDiRC goals can only be achieved with fundamental changes to the way science is conducted, shared, and applied to the care of rare disease patients. By creating an innovative VP and by putting in place mechanisms for constant improvement and continuous integration of new data, standards and resources, Pillar 2 realizes the commitment of Europe to catalyse those qualitative changes. Based on real-life use cases and needs brought by ERNs, Pillar 2 will help generating new knowledge on disease mechanisms towards better diagnosis and identification of druggable targets and disease modifiers to be used in research, by bringing together data and resources (expanding beyond RD), so as to take the best advantage of the most cutting-edge research across domains. Although IRDiRC recommendations do not target specifically education and training activities, its overarching and specific goals will be followed within Pillar 3. This will include for example raising awareness of complexity in diagnostics of unsolved patients with RD in the healthcare system or enhanced uptake of research results for translation into tangible outcomes, diagnosis and therapy development. With a central aim of IRDiRC being therapies and diagnostics, the patient-centric approach to Pillar 4 will directly contribute to its goals. A key focus of the activities in Pillar 4 is to improve and accelerate the productivity of 825575 – EJP RD – Part B 19 Associated with document Ref. Ares(2018)6091977 - 28/11/2018 translational and clinical research, which represents the critical path of new diagnostics and therapies to clinical implementation. The pillar will seek to address systemic weaknesses in the current development pathway by (among others) accelerating the validation and dissemination of high potential (statistical) methodologies tailored for small patient populations and proposing new approaches dedicated for RD. In so doing, the EJP RD will push for faster uptake of novel methodologies that have been shown to have utility for clinical rare disease R&D. In addition, the vast pool of resources, expertise and projects that will be created by EJP RD will be supported by P4 to take the outstanding discoveries and bring them towards the patient in form of a novel product. The outcomes in translational research will be improved by creating tailored mentoring boards for each applied research project funded in the EJP and E-RARE 3 funding programmes, the research community will avail of expert support in fields that are critical to success, including preclinical studies, product development, manufacturing, implementation of the trials regulatory affairs, and more. Such a mentoring system will be unique in Europe, and serve to improve outputs and increase cross-sectoral collaboration through organic public-private interaction. Finally, further leveraging other funding sources (by supporting researchers in defining follow-on financing opportunities) as well as creating a roadmap for a future innovation fund in Europe, the systemic funding deficiency in R&D in Europe will be partially addressed. Hereby individual projects will be more immune to the stop-start dysfunction of public financing, while providing access to expert support in innovation. Other substantial impact(s): Contribution to the European Open Science Cloud EJP RD will increase its impact by actively contributing to the European Open Science Cloud (EOSC) by: (i) supporting the EOSC in its stated desire to apply FAIR Principles (in league with the GO FAIR network), given that establishing FAIR Rare Disease data is a cornerstone of the EJP RD (Pillar 2 WP12); (ii) aligning with EOSC on the respective data plus software quality assurance approaches and the data governance principles (Pillar 2 WP10); (iii) developing the EJP RD data Virtual Platform to be a multi-tenant federated architecture able to support a plurality of service providers and service consumers, as needed for EOSC (Pillar 2 WP11); and (iv) exploring cross-fertilising sustainability models for the life science ecosystem with EJP RD being the leader on rare diseases aspects of this ecosystem (Pillar 2 WPs10 & 12, transversal WP3). In particular, this work will begin with EJP RD building on the previous European investments into the EOSC, e.g., by utilizing outcomes of EOSCpilot and EOSC-hub projects. Outcomes of these projects, such as policies for dealing with sensitive data or common metadata models and guidelines, will be adopted and promoted to help their expansion on European scale within the communities relevant to EJP RD. 2.1.1. Barriers / obstacles The key barriers to achieving the expected impacts are the dispersal of patients and fragmentation of expertise. Overcoming dispersal of patients involves interacting with relevant umbrella organisations at national (National Alliances for Rare Diseases existing in most EU countries and members of EURORDIS) and European level (European Federations for specific Rare Diseases, also members of EURORDIS) which can then interact with their members reaching a large number of individuals. However, each interaction could provide an obstacle to the work of the EJP RD because of the need to address specific anxieties, concerns, and institutional processes. Hospitals that provide care for people with RD may derive a number of benefits from working in isolation (tangible revenue streams, intangible reputational benefits). These obstacles will be balanced against the direct benefits of collaboration to patients and hospitals. RD cannot be addressed locally and the European patient advocacy groups that participate in the EJP RD will reinforce this message as appropriate. The improved value chain for RD product development developed by EJP RD will provide the trusted environment that allows individual institutions and persons to realise the benefits of collaboration. In the long-term, improved treatments will reduce the overall costs to society of RDs and will promote the reputations of hospitals that provide innovative treatments. Overcoming fragmentation of expertise involves obtaining buy-in, and institutional approval, from researchers and their host organizations. Obtaining buy-in could prove to be an obstacle because of competing opportunities and perceptions about the low value of RD research. The work done by EJP RD to improve the efficiency and effectiveness of RD research will redress the balance in favour of RD research. Institutional approval for research is equally difficult for RD and other types of research: all EJP RD participants are extremely skilled in seeking institutional approvals and will be further supported by dedicated services developed under the EJP RD. These barriers and obstacles are unlikely to have a material effect on the ability of EJP RD to achieve impact because a critical mass of collaborating individuals, advocacy groups, hospitals, and academic organizations already exists. The uncertainty about achievement relates to the scale and breadth of success beyond the groups that are already committed. Direct investment of 25 countries through funded calls in Pillar 1 will promote scale and 825575 – EJP RD – Part B 20 breadth of involvement. Progress will be monitored in WP1 Task 1.3.with Associated The Operating document Group and Executive Ref. Ares(2018)6091977 - 28/11/2018 Committee will have sufficient information to identify and address deficiencies. 2.1.2. Framework conditions A number of regulatory frameworks are relevant and will be addressed comprehensively: information governance (WP1, WP4 & Pillar 2); research conduct (WP4, WP19); transfer of biological material (WP4) and data (GDPR); national divergence (WP1). The regulatory context is relatively stable so that direct work on these topics is likely to lead to predictable achievement of the expected impacts. Many relevant standards are missing or incomplete but will be developed as needed, with full participation of EJP RD and its members in all similar initiatives. The standards environment is established and key players are included in the consortium (Orphanet, Human Phenotype Ontology -HPO-, FAIR principles conceivers) so that effort in this domain is highly likely to lead to the anticipated impacts. Public acceptance of the need for research in RD may vary. Past efforts of the RD community have increased the visibility of research and acceptance of the specific features of RD in many European countries. There is a risk that this growing acceptance will stall and that countries without RD programmes do not develop them or that member states with RD programmes will not support continued growth of those programmes. This risk would only be material to the impact of the EJP RD programme if public acceptance is reduced: this is highly unlikely. A subtler risk is the possibility that collaboration about RDs reduces the likelihood of public donations because of less direct emotional impact arising from reduced awareness of individual cases. This risk is already well-managed by umbrella groups such as EURORDIS or Telethon advocacy organizations and this know-how can be further shared. All of these risks to public acceptance of RD research and the specific actions of the EJP RD are actively mitigated by efforts made by EJP RD participants in parallel to EJP RD. Acceptance of research and methods by RD patients and their families will not change. Workforce considerations relate to the number of researchers involved in RD; the skills-mix of those researchers and the lack of support for collaboration in academic settings (that can reduce the drivers and incentives for academics to collaborate in the way proposed by this application). At present, the workforce is not a rate-limiting step in the RD product development value chain. As the current rate-limiting steps of dispersal of patients and fragmentation of expertise are addressed during the EJP RD, the skills-mix will become more important, particularly the adaptation of generic skills to the needs of RD research. The programme is designed to promote appropriate skills through Pillar 3 but also through the dedicated incentives within Pillar 1 joint transnational calls and Networking scheme. The number of researchers and the involvement of academic institutions will be increased by the increased flow of projects prompted by the EJP RD actions and organizational legacy provided by the EJP RD. The clearer relationship between effort and reward provided by improvements in the RD product development value chain is likely to improve the return on investment for individual researchers (as career pathways become more obvious) and for academic institutions (as the number and value of collaborative projects increase). Thus, attention to supply and demand elements of workforce management will promote the success of the EJP RD. The only way that workforce considerations could reduce impact would be a general reduction in the scientific workforce. This possibility is highly unlikely and the effects of a general reduction in the scientific workforce would be mitigated for RDs by the effects on supply and demand outline here. Finance of follow-up steps is directly addressed in Pillar 4, WP19. This will be directly facilitated by work to reduce costs and increase benefits. Finally, cooperation of other links in the value chain is built into the EJP RD through the extensive partnerships that beneficiaries are involved in. The EJP RD value chain starts with diagnosed patients and ends with evaluated products. Before the EJP RD value chain starts, patients are diagnosed and given clinical care. The ERNs are positioned to improve diagnosis and clinical management and will embed their work in the EJP RD. Products developed by the EJP RD value chain are fed into health care systems. ERNs will do this at the level of clinical management. EJP RD participants from national funding agencies and policy organizations will provide links to relevant national intersectoral networks. 2.2 Measures to maximize impact 2.2.1 Dissemination and exploitation of results The dissemination of outputs (new knowledge, tools, services, trainings, etc.) and achievements obtained by the EJP RD program is essential for the visibility, outreach, impact and sustainability beyond the five year of the programme. The plan on dissemination and exploitation of results is designed to maximize the impact and serves three goals: (i) increase awareness on the EJP RD in order to involve more partner countries in joining EJP RD activities resulting in a substantial contribution to the overall goals of IRDiRC and inducing changes in the RD landscape at regional/national/EU and international level; (ii) to increase knowledge on and understanding of rare diseases, accelerate diagnosis and therapy development; and, finally (iii) to engage key stakeholders to support a 825575 – EJP RD – Part B 21 sustainability scenario for EJP RD ecosystem as a whole and for individual “products”. Associated with TheAres(2018)6091977 document Ref. results of EJP RD will - 28/11/2018 be disseminated at different levels by means specifically tailored to the needs of the targeted audience. On one hand the consortium will take advantage of its extensive network of partners, their powerful outreach and excellent reputation, on the other hand it will develop new instruments that will serve to increase the impact. The dissemination plan is presented in the table below. 2.2.2 Communication activities Strengthening the communication and interactions between different stakeholders is essential to raise awareness on the importance and benefits of rare diseases research. EJP RD communication activities will include such elements as workshops/briefings to stakeholders, webinars, educational sessions with patients, practitioners and/or policy makers or scientific meetings. The communication tools will comprehend portals, newsletters, networking platforms, official reports and strategic publications, videos and social media. In order to multiply the impact special attention will be given to encourage consortia financed through Pillar 1 to organize open events to disseminate their results and knowledge as well a mandatory publication in open access journals. Scientific congresses will be organized [RE(ACT) & IRDiRC] and dedicated RD sessions will be put in place in collaboration with other European or international congresses (ESHG, ECRD, DIA BIO, etc.). 2.2.3 Data Management Plan EJP RD will contribute to the European Open Science Cloud and data management will be dealt with extensively. All data activities will follow Open Research Data principles (which conform to FAIR data principles), and comply with the GDPR and existing ethical and legal expectations for healthcare, research and patient data. Whenever possible, datasets managed by EJP RD will have no access restrictions, though more sensitive data will be provisioned in a responsible and secure manner such that discovery, access and use (analysis and linking) will be controlled based on reasonable regulatory conditions, all of which will be fully transparent. Processes for requesting data will be maximally streamlined and progressively automated. A clear commitment to the above principles will be included in the Consortium Agreement. It is important to underline that the whole of Pillar 2 relates to professional IT and RD data management, emphasizing Open data and FAIR data principles, by means of an advanced Virtual Platform (VP). Pillar 2 will provide the technology, standards, access/analysis capabilities, utility/quality assurance and GDPR guidelines for local, hosted and centralised data management. All of this shall be coordinated by Pillar 2 WP10, with monitoring and strategic guidance provided by the RD research and healthcare community. More details are provided in Pillar 2 description of the Implementation and Annual Work Plan parts. Ongoing data management in the EJP RD will be a shared responsibility. All data-related activities (existing, new and derived data) will exploit and align with the data management systems provided by Pillar 2. In Pillar 1 this pertains to the projects that are financed within joint transnational calls. In Pillar 4 this applies to generated and derived data that supports translational research. In Pillar 3, in close collaboration with Pillar 2, it is relevant to educating data custodians, stewards and users about how to apply best data management practices and how to use the Pillar 2 VP. Finally, the EJP RD extends its data management ambition to long term data support through its sustainability and scaling-up activities (transversal WP3 and Pillar 2). 2.2.4 Dissemination and communication Plan Table 1. Dissemination and communication plan including expected effects of planned activities 825575 – EJP RD – Part B 22 Associated with document Ref. Ares(2018)6091977 - 28/11/2018 EJP RD planned Expected effects of dissemination Target Audience Means of dissemination and WP Date Activity/Outputs and communication communication tools INTERNAL COMMUNICATION EJP RD internal ● EJP RD partners informed of all ● EJP RD partners ● Monthly internal NL including EJP RD 1 Continuous communication actions on time Action Updates ● Timely delivery of expected ● Regular conference calls outputs by partners ● Consortium assembly meetings EXTERNAL DISSEMINATION & COMMUNICATION Central Helpdesk ● Timely communication between ● All stakeholders ● Website Continuous providers of RD research ● Multimedia marketing campaigns targeted Every year services and consumers of at users of RD research services research services SRIA ● National and EU needs and ● Ministries of Research & Health ● Policy Board meetings 2 Every year recommendations well captured ● Relevant EU directorates (DG RTD, ● Annual SRIA Scoping paper & M33, M57 ● EJP RD annual priorities Santé, Connect) ● State of play of funded research and drug for strategic defined by Transparent ● IRDiRC development, overlaps and trends at workshops decision-making process ● ESFRI representatives international level report ● Alignment and enhancement of ● Regulatory authorities ● SoA of Member States activities related to national, EU and international ● Patient Organisations the EJP RD RD research activities (funding, ● National Mirror Groups ● Strategic workshops targeted to EU13 and support to sharing of data and EU15 needs & interactions resources, training, accelerated exploitation of research results) Medium and long-term ● Joint (with IRDiRC) ● Research and health policy makers ● Publication of outcomes on IRDiRC and 2 Continuous strategy - Task Forces identification of gaps and ● Research funders EJP RD websites bottlenecks in RD research → ● Industry ● Targeted reports or/and publications in peer alignment of strategies ● Patient(s)/Organisations review journals ● Adoption and endorsement of ● RD researchers ● Presentation at relevant workshops and TF recommendations conferences ● Integration of relevant elements in the EJP RD activities (e.g. trainings) 825575 – EJP RD – Part B 23 Management of EJP ● Implementation of EJP RD ● EJP RD partners ● Presentation of ethics, regulatory Associated 4 Every -year & legal Ref. Ares(2018)6091977 with document or 28/11/2018 RD ethics, regulatory activities in line with ethical, ● RD stakeholders at large updates to partners Continuous & legal issues regulatory and legal guidelines ● Regulatory agencies ● Dissemination via dedicated Flash News or ● Establishment of efficient NL dialogue with regulatory ● Short update reports to be published at EJP agencies RD website and redistributed to relevant ● Become an “information stakeholders for further dissemination reference” for legal, ethical and regulatory issues in RD field EJP RD service ● Detection and promotion of ● Researchers on rare diseases ● EJP RD website and Helpdesk 3 M24-M36 then catalogue useful services complying with ● ERNs / care givers ● Dedicated events continuous interoperability objectives in ● Patients’ organizations ● Channeling to ESFRI, funding bodies, RD research activities ● SMEs and industry (pharma, medical governmental bodies ● Increased interest and adhesion devices, ICT) of the research community / end ● Public funders and authorities users, ● Other funders ● Public and private support to ● Learned societies sustain most acclaimed services ● Regulators Sustainability roadmap ● Action in engaging key ● Policy makers ● Business plan 3 From M24 stakeholders ● Ministries ● Reports on innovative sustainability ● Program owners and managers solutions & sustainability models ● European Commission ● EJP-RD service catalogue ● SMEs and industry ● EJP RD dedicated strategic reports ● Foundations and learned societies ● Meetings with Policy Board ● Patients’ organizations Funded research ● Critical mass of ● Clinicians and heads of reference centers ● OA publications 6 Continous projects data/samples/patients achieved ● Researchers on rare diseases ● EJP RD and IRDiRC websites ● Increased knowledge on and ● Technology platforms ● EJP RD and partner organizations understanding of rare diseases ● European infrastructures Newsletter ● Improved diagnosis ● Patients organizations ● Scientific meetings and congresses ● Accelerated therapy ● SMEs and industry (RE(ACT), IRDiRC Congress, ECRD, development ● Program owners and managers ESHG) ● Data sharing and networking ● European Commission ● Targeted workshops (also at national level) ● Input for EJP RD virtual ● All other rare diseases related initiatives ● Pillar 3 trainings platform ● General public ● RE(ACT) platform ● Contribution to the objectives of ● EJP RD public reports and brochures IRDiRC ● EC Cordis & ERA-LEARN Networking projects ● New RD networks ● RD researchers & clinicians ● Networking events publicized on EJP RD 7 Continuous ● Increased collaboration of RD ● Patients website, Newsletter and through partner from Y2 825575 – EJP RD – Part B 24 researchers, clinicians and ● European Reference Networks organizations channels Associated with document Ref. Ares(2018)6091977 - 28/11/2018 patients ● Healthcare providers ● Reports from organized events published ● Increased sharing of knowledge on EJP RD website, Newsletter on undiagnosed patients ● OA publications (when relevant) ● Expanded geographical coverage (e.g. networks covering more EU13 countries or new collaboration with Africa, South America, etc.) RDR Challenge ● Effective academia-industry ● Industry/pharmaceutical ● ERTC specific communication 8 Case by case projects collaboration companies/SMEs (EURORDIS) basis (from ● Outputs with patenting, IP ● Venture capitals ● EFPIA website M36) potential ● Academic RD researchers ● IRDiRC website and Newsletter ● New (technology) solutions ● Creation of valuable know-how ● POCs Virtual Platform for ● Increased visibility of resources ● RD researchers and clinicians (including ● EJP RD website and Helpdesk 11 & Starting from federated FAIR data ● Resources and FAIRdata P1 funded projects) ● EJP RD and related partners newsletter 12 M12 and resources (record level) findable at a ● ERNs and national reference ● Scientific OA publications & central point centers/hospitals ● Strategic reports 13 ● Increased interoperability ● Patients ● IRDiRC Recognized resource label between resources ● Policy makers/ministries ● Inclusion in dedicated trainings ● Accelerated access to data and ● Funders ● Congresses and workshops resources ● Industry (EFPIA) ● Recommendations on use in calls for ● Integration in national and EU ● SMEs (EUCOPE) projects of Pillar 1 recommendations (e.g. RD ● EJP RD Sustainability Roadmap national plans) ● EJP RD catalogue of services ● EOSC RD analysis tools and ● Improved usability of ● RD researchers and clinicians (including ● EJP RD website and Helpdesk 11 & Starting from data sharing genomics/phenomics/multi- P1 funded projects) ● EJP RD and related partners newsletter 13 M12 capabilities omics data deposition and ● Systems Biologists and Data scientists ● Scientific OA publications (pathway analysis resources ● ERNs and national reference ● Strategic reports portal will start ● Facilitated and secure centers/hospitals ● Guidelines and recommendations month 1) deposition of data ● Policy makers ● IRDiRC Recognized resource label ● Higher number of submissions ● Funders ● Inclusion in dedicated trainings ● Higher number of accessible ● Industry (including pharma) ● Congresses and workshops datasets for research ● Recommendations on use in calls for ● Faster identification of projects of Pillar 1 causative genes and variants ● EJP RD catalogue of services ● Accelerated diagnosis including ● Presentations and workshops in ELIXIR undiagnosed or misinterpreted SME events cases ● Tutorials on pathway creation and multi- 825575 – EJP RD – Part B 25 ● Increased EU innovation omics workflows(with pillarwith Associated 3) document Ref. Ares(2018)6091977 - 28/11/2018 capacity ● Pathway portal on WikiPathways ● Better disease mechanism ● Network deposition on NDEX descriptions (on pathway portal) ● New ideas for drug targets and drug repositioning Organisation of data ● Good flow of standards, ● RD researchers and clinicians ● EJP RD website and Helpdesk 12 & Starting from stewarding technologies and capabilities ● Research institutes and hospitals ● IRDiRC Recognized resource label 14 M1 collaborations, between infrastructures, data ● Infrastructures ● Guidelines and protocols advocacy, and self-help experts and RD experts ● Funders ● OA publications networks for practical ● Emergence of self-helping data ● Policy makers ● Webinars FAIRification support stewarding networks within the ● Industry ● Trainings RD community ● Tailored service support ● Increased awareness and better ● Collaboration with international expert FAIR data stewardship groups (e.g. organised through IRDiRC, capacity planning by RD ELIXIR, GA4GH, BBMRI-ERIC, EOSC, resource managers GO FAIR, NIH, OHDSI, etc.) ● Model for FAIRification ● Recommendations for FAIR data support as a service by and for stewardship in Data Management plans in the RD community, including calls for projects of Pillar 1 public-private-partnership ● EJP RD Sustainability Roadmap ● Project-based and on-site engagement with exemplar stakeholders to seed FAIRification capacity in RD networks (e.g. ERNs) ● Online communication channels, telephone conferencing, and workshops for FAIR experts and interdisciplinary communication ● Support for advocacy and networking by stakeholder data stewards at EJPRD meetings and international conferences for RD Innovative holistic ● Reduced product attrition ● RD researchers and clinicians ● EJP RD website and Helpdesk 13 From M36 and approaches for rare ● More rapid completion of ● Research institutes and hospitals ● EJP RD and related partners newsletter then continous diseases diagnosis and product development ● Infrastructures ● Scientific OA publications therapeutics ● Funders ● Strategic reports ● Policy makers ● IRDiRC Recognized resource label ● Industry (EFPIA) ● Inclusion in dedicated trainings ● SMEs (EUCOPE) ● Congresses and workshops ● Recommendations on use in calls for projects of Pillar 1 825575 – EJP RD – Part B 26 ● EJP RD Sustainability Roadmap Associated with document Ref. Ares(2018)6091977 - 28/11/2018 Training on data ● All potential participants ● Academic researchers and clinicians ● EJP RD website and Helpdesk 14 Every year management and interested in training course(s) ● Biobank managers ● EJP RD and related partners websites & quality informed in time for registration ● Laboratory scientists & technicians newsletter ● Clinical geneticists ● Universities websites, and social media ● Applicants of EJP RD joint transnational ● EU-funded projects’ Newsletters (Solve- calls RD, RD-Connect, Share4Rare, Orphanews, ● ERNs etc.) ● ePAGs (RD patient rep involved in ERNs ● Recommendations on use in calls for for task 14.5) projects of Pillar 1 and Pillar 4 ● ePAGs online communities ● ERN specific Newsletters ● ERN specific websites ● Communication channels of Learned Societies ● Other relevant EU and international networks (UDNI, EuroBioBank website, ESBB etc.) ● Journals listing (e.g Nature Events) Training of patients ● All potential participants ● Rare disease patients and representatives ● EJP RD website and Helpdesk 15 Every year and researches in rare interested in training course(s) ● ePAGs (RD patient rep involved in ● EJP RD and related partners newsletter, diseases research and informed in time for registration ERNs) websites and social media (twitter, processes ● Increase of knowledge and ● YPAGs (young patient advisory groups LinkedIn, facebook) awareness within the targeted representatives) ● ePAGs online communities community ● Academic researchers ● EURORDIS website (Open Academy), e- News, ePAGs Newsletter and EURORDIS working groups/Task Force mailing lists (e.g. DITA, Summer School Alumni, TAG, SWAN Europe etc.) ● TEDDY and, EPTRI and eYPAGnet mailing lists/Newsletters/website ● C4C Website/Newsletter Online academic RD ● Increase awareness of the online ● Academic clinicians and researchers ● EJP RD website and Helpdesk 16 Every year and education course course among several ● Medical & biomedical students ● EJP RD and related partners (e.g. more starting stakeholder groups ● Industry researchers/scientists universities) newsletters M12 ● RD patient representatives and advocates ● Dedicated printed materials (leaflets, ● Industry posters) to be distributed by partner ● Lecturers organizations ● University managers ● FutureLearn platform and Newsletter ● Professional organizations ● Communication channels of Learned ● Organizations of academic institutions Societies (like UEMS) ● Scientific meetings and congresses 825575 – EJP RD – Part B 27 (RE(ACT), IRDiRC Congress, Associated with ECRD, document Ref. Ares(2018)6091977 - 28/11/2018 ESHG ● Conferences and events dedicated to academic education ERN training & ● All potential participants ● Academic clinicians and researchers ● ERNs specific Newsletters 17 Every year support interested in training involved in ERNs ● ERNs specific websites programme informed in time for ● Mailing list ERN training and education registration working groups Development and ● Needs of RD research ● Ministries of Research & Health ● Policy Board meetings 18 Every year adaptation of training community as a whole and ● National Mirror Groups ● EJP RD website and Helpdesk from year 2 activities relevant groups of stakeholders ● Patient Organizations ● EJP RD and related partners newsletter and (ERN, countries) well captured ● ERNs websites ● Transparent decision-making ● Organizations of academic institutions ● Conferences and events dedicated to process for EJP RD annual academic education priorities Innovation ● Appropriate and timely ● RD research community especially ● ERNs, website and roadshows 19 Continuous Management Toolbox connections between innovators researchers with a potential product ● EJP RD website and Helpdesk and facilitators of innovation ● ERNs ● EJP RD and related partners newsletter & ● Self-help resources openly ● RD research community websites accessible to RD research ● Institutional innovation managers community Real-time mentoring ● Timely design and resource ● Researchers with a potential product ● ERNs, website and roadshows 19 Continuous and technical support identification for researchers ● E-Rare & Pillar 1 funded projects ● EJP RD website and Helpdesk for translational ● EJP RD and related partners newsletters projects Support in exploitation ● Timely match between investors ● Researchers with an evaluated product ● ERNs, website and roadshows 19 Continuous of research results and and product ● Investors (industry, venture capitals, ● EJP RD website and Helpdesk follow-up funding charities, etc.) ● EJP RD and related partners newsletter ● Dedicated meetings and congresses Roadmap for EU ● Shared agenda for research in ● Funders ● Publication of outcomes on EJP RD 19 M36 investment platform RD and clear entry points for ● Clinicians and heads of reference centers websites investors ● Researchers on rare diseases ● Targeted reports or/and publications in peer ● Technology platforms review journals ● European infrastructures ● Presentation at relevant workshops and ● Patients organizations conferences ● SMEs Activity: Support in ● Timely design and resource ● Researchers with a potential product ● ERNs, website and roadshows 20 Continuous design and planning of identification for clinical studies ● clinicians with a potential project of a ● EJP RD website and Helpdesk RD clinical studies clinical study ● EJP RD and related partners newsletter ● Demonstration studies ● Increased range of ● Funders ● Publication of outcomes on EJP RD 20 M12 – M48 to validate promising methodologies that have been ● Clinicians and heads of reference centers websites 825575 – EJP RD – Part B 28 methodologies to validated for use in RD clinical ● Researchers on rare diseases ● Targeted reports or/and publications Associated in peer with document Ref. Ares(2018)6091977 - 28/11/2018 improve RD clinical trials ● methodologists involved in RDs review journals trials ● Large pharma and SMEs ● Presentation at relevant workshops and ● Regulators conferences ● diffusion through clinical trials help desk Innovative ● Increased range of innovative ● Funders ● Publication of outcomes on EJP RD 20 M15 – M56 methodologies to methodologies and new ● Clinicians and heads of reference centers websites improve RD clinical statistical designs for use in RD ● Researchers on rare diseases ● Targeted reports or/and publications in peer trials in limited clinical studies to fill the urgent ● Methodologists involved in RDs review journals populations gaps ● Large pharma and SMEs ● Presentation at relevant workshops and ● Regulators conferences ● Webinars EJP RD project as a ● Increased use of EJP RD ● RD community at large (researchers, ● Creation of unique, recognizable identity 1 Continuous whole tools and services healthcare providers, patients) ● Annual Progress Report ● More knowledgeable RD ● Policy makers ● EJP RD website, newsletter and printable stakeholders ● Research institutions and infrastructures publicity elements ● Better connected RD ● Funders ● Presentations at national, EU and stakeholders ● Industry and SMEs international congresses ● Improved alignment of ● Patient Organisations ● Targeted videos adapted to different types national, EU and ● General public of stakeholders international strategies ● Scientific and strategic publications 825575 – EJP RD – Part B 29 Associated with document Ref. Ares(2018)6091977 - 28/11/2018 3. IMPLEMENTATION A more detailed description of the specific activities to be carried out in the first year will be included in Annex 7 Figure 6. EJP RD implementation structure (interactions being represented in the table below) 825575 – EJP RD – Part B 30 Associated with document Ref. Ares(2018)6091977 - 28/11/2018 Table 2: Description of interactions between different work packages of the EJP RD 825575 – EJP RD – Part B 31 Associated with document Ref. Ares(2018)6091977 - 28/11/2018 3.2. Management structure, milestones and procedures An initiative such as EJP RD, aiming at developing into an ambitious sustainable structure, needs to establish clear roles and responsibilities in order to meet the objectives, build trust from the wider rare diseases community and mechanisms to solve potential conflicts. The management structure aims at transparent decision-making process with well-defined responsibilities in pillars, WPs and tasks. It will provide efficient and adaptive structure, necessary to capture and deal with emerging strengths and weaknesses. It will manage the strategy planning, annual work (plans) and allocation of resources. It will be responsible for interactions with external (policy and political) stakeholders. It is developed according to the principles of subsidiarity and should stimulate co-decision of each partner and co- creation of knowledge, be it at the EU-level, the national level or at the level of the scientific community. The management structure of the EJP RD will be defined to: ● Plan, organize and monitor the effort to achieve the EJP RD’s objectives within constraints of time schedule and budget. ● Define clearly the decision-making procedures and bodies. ● Run performance control procedures leading to the expected quality of achievements and deliverables described in the work plan. ● Continually inform the partners on the project status and progress. ● Drive the project implementation in accordance with administrative, financial and legal issues defined by the European regulations and national specificities. ● Guarantee that the rights and obligations of the partners are kept compliant with the Grant Agreement signed with the European Commission and the Consortium Agreement. A Consortium Agreement will be signed between the partners to specify the project governance, the internal organization of the consortium, the management of the project and any other critical aspects such as liability and confidentiality. The proposed organizational structure of the consortium is as follows: ● The General Assembly will be the ultimate decision-making body of the EJP RD and will take major decisions with regards to its implementation. General Assembly members will liaise with Policy Board and National Mirror Groups established at national level and outside the framework of this EJP. ● The Coordinator will monitor compliance by the partners with their obligations under the Grant Agreement and will be the intermediary between the European Commission and the consortium. He/she will be responsible for the EJP overall management and coordination as well as the supervision of transversal activities. Given the important size of the EJP RD, the Coordinator will be assisted in these tasks by a Management Office composed of experienced project managers, communication and administrative support. ● Pillar leaders and Work package Leaders will be the operational arms of the EJP. They will be responsible for the EJP proper implementation and the follow up of annual work plans. Together with the chair of ERN coordinators and representative of EURORDIS they will form the Executive Committee (ExCom) that provides assistance to the Coordinator for the monitoring of the programme. 825575 – EJP RD – Part B 32 Associated with document Ref. Ares(2018)6091977 - 28/11/2018 Figure 6. EJP RD governance structure Strategy level: General Assembly: GA will be composed of ALL beneficiaries of the EJP RD. GA will be the ultimate decision making body dealing with extraordinary decision requiring vote of all members like inclusion of new ones or exclusion of a non- performing partner. For other decisions the vote will be centralized and put in hands of Governing Board. Voting procedure: The GA will strive to reach consensus and if consensus cannot be reached, the GA will vote on different options. GA Quorum and voting arrangements will be elaborated on in the Consortium Agreement. Governing Board (GB) GB composition: The Governing Board shall consist of one representative per participating country, one representative of ERNs, one representative of participating EU infrastructures, 1 patient organization representative (EURORDIS), one representative of Orphanet and one representative of other non-profit organizations. Such distribution of representation will reflect and incentivize the need for agreement between stakeholders representing specific country and/or type of beneficiaries (ex. ERNs or infrastructures) on one hand and limit the unbalance that could be provoked by over-representation or a single country or type of beneficiary. It will be up to each participating country/type of beneficiary to decide on the nomination procedure for their representative. One country = one vote will ensure equality between bigger and smaller countries or less numerous type of stakeholders 825575 – EJP RD – Part B 33 and avoid inappropriate silencing of minority opinions. In addition, the representatives Associated ofAres(2018)6091977 with document Ref. EC DG RTD and DG - 28/11/2018 Santé will be invited as “observers”. The GB will elect a chair and set down its rules for procedures (Terms of Reference) as well as Rules for Participation in advance of the official start of the EJP RD. It will be convened by the Coordinator in collaboration with the Executive Committee. The GB will validate the decisions proposed by the Executive Committee such as the annual work plan, the budget, internal calls etc. In particular, the GB will: ● Approve the initial 5-year work plan before submission of the proposal; ● Approve the annual work plans and annual summary reports; ● Monitor and approve the achievement of the most significant milestones; ● Approve ethical, legal and data management frameworks developed; ● Support the Executive Committee in developing a long-term sustainability plan for the EJP RD. Voting procedure: The GB will strive to reach consensus and if consensus cannot be reached, the GB will vote on different options. GB Quorum and voting arrangements for the GB will be elaborated on in the Consortium Agreement. Meetings: once a year. Coordination level: The Coordinator Role: The Coordinator will be in charge of the day-to-day overall scientific, administrative and financial management of the project and will be the primary contact point for the European Commission. In particular, the Coordinator will: ● Prepare the Consortium Agreement to be signed by the partners, with the support of the Executive Committee; ● Update and maintain the Consortium Agreement and submit amendment requests to Grant Agreement; ● Oversee deadlines and milestones of activities, and quality control of deliverables; ● Report on the implementation of the initiative and challenges encountered to the Executive Committee, the Consortium, General Assembly and the European Commission; ● Chair the Executive Committee and act as the scientific secretariat for their meetings; ● Ensure cooperation across WPs and Pillars; ● Ensure technical and financial reporting to the European Commission and budget management; ● Organize the General Assembly Meeting once a year; ● Ensure transversal activities of the EJP on RDs; ● Supervise the Scientific Secretariat of IRDiRC; ● Represent the EJP on RDs at the EU and international level; ● Together with the Executive Committee manage the project reserve budget. ● The Coordinator will be supported in all these tasks by the Management Office. The Coordination Office The Coordination Office will be under the responsibility of the Coordinator and will be constituted by four project managers, one Communication manager, one financial and administrative manager and one assistant. The project manager will share their time between direct support of EJP RD and of the scientific secretariat of the International Rare Diseases Research Consortium (IRDiRC). Role: The Coordination Office (CO) will be responsible for the day-to-day operational management of the EJP and the Scientific Secretariat of IRDiRC. The financial and administrative officer will provide financial advice support to all partners. Members of the CO will continuously support the Operating Group, Executive Committee and all other partners of the consortium in fulfilling their obligations according to the work plan. 825575 – EJP RD – Part B 34 Associated with document Ref. Ares(2018)6091977 - 28/11/2018 Figure 7: Structure of the EJP RD coordination office Operational level: The Executive Committee (ExCom) The ExCom will consist of the Coordinator, Pillar Leaders and all WP Leaders. It will be chaired by the Coordinator. The ExCom will set down its rules for procedures (Terms of Reference) in advance of the official start of the EJP RD. Role: The ExCom will ensure the implementation of the EJP RD according to the overall 5-year plan of the initiative and the individual annual work plans. It will monitor progress according to the milestones as set out in the 5-year plan and the annual work plan. The ExCom will be responsible for the overall quality control of deliverables and reports. The ExCom will be in charge of adopting solutions to problems encountered during the implementation and can refer to the Governing Board if no agreement can be found or if the solution will imply major deviations from the work plans agreed by the GB. In this case, the Coordinator is in charge of duly informing the European Commission about expected deviations. The ExCom will oversee how resources are spent and propose changes if needed. The ExCom will be the entity preparing the basis for the decisions to be taken in the GB based on input from the Operating Group (see below) and WP leaders. The ExCom will also inform the GB about connections established with sister initiatives at national, EU- and international level and can ask for the GB 's assistance to establish contacts if needed. Meetings: every two months, starting month 1 (physical or web conference), adapting the number of meetings to the necessary the following years. The Operating Group (OG) Since the ExCom will count about thirty persons a more restricted group is necessary for the efficient administration of day-to-day activities. The Operating Group is part of the ExCom and will be composed of members of Coordinator, projects managers and eight Pillar leaders. The representation of funders, ERNs, patients and EU infrastructures is currently ensured via the Pillar 1, 2, 3 and 4 leaders respectively. Pillar leaders are nominated for the lifetime of the project. However, in case of change attention will be taken to keep fair representation of respective groups in the Operating Group. The OG will be responsible for close communication and coordination of activities between different pillars and WPs. The OG will reflect on progress and engage in a collective brainstorming on future directions and visions for the EJP RD. Regular (twice a month) conference calls will ensure close follow up of activities, continuous alignment and adequate reactivity in case of urgent situations and risk management. The OG will participate in the preparation of the Executive Committee meetings and will be the driving force for the elaboration of the Annual Work Plans. Pillar Leaders (PL) Pillar leaders (PL) will support the coordination and interaction of Work Package Leaders (WPL) within their respective Pillars, as well as across the Pillars. The tasks of the PLs are to: ● Ensure the coordination of activities across the WPs in the pillar to deliver a coherent set of results both within the pillar, and with respect to the outputs generated under the other pillars. This will ensure that the overall outcomes of the EJP for RDs are coherent and complementary and together generate a robust and harmonized rare diseases platform and ecosystem; ● Ensure good communication with the coordinator and management office; ● Ensure coordination and collaboration across pillars and promote knowledge transfer within and across pillars (via the Operating Group activities); 825575 – EJP RD – Part B 35 ● Ensure that tasks are not duplicated and promote complementarity and Associated withsynergies. The document Ref. main forum -for Ares(2018)6091977 this 28/11/2018 process will be the ExCom meetings; ● Organization of regular management meetings (telephone conferences and/or personal meetings) with the respective WP leaders to ensure that work within the WPs is in line with the annual work plans and contributes to the development of annual work plans for upcoming years; ● Collecting training needs from the respective pillar WPs and reporting them to the Pillar 3 leaders; ● Participate in the OG and ExCom meetings and teleconferences; ● Feed into the development of the annual communication plan. Work Package Leaders (WPL) Work Package Leaders (WPL) will be in charge of implementing the tasks of the WPs as agreed in the annual work plans, cross-coordinating with other WPLs, informing the PL about any deviations to the annual work plan and developing contingency plans. The WPL will be supported by a number of Task and Subtask leaders who are responsible for the implementation of a specific task within the work package. The tasks of the WPL therefore are: ● Manage implementation of the WP and tasks, and ensure good communication within the WP in order to ensure efficient flow of information; ● Ensure that work within the WP is in line with the annual work plans; ● Identify any bottlenecks or obstacles, as well as links, synergies and overlaps across WPs, and report them to the Pillar Leaders. ● Formal reporting of progress to the Pillar Leaders and the Coordinator for discussion at the Executive Committee meetings, and contributing the sections of the annual report for their WP; ● Draft the WP descriptions for upcoming annual work plans; ● Provide input to training measures; ● Participate in the Pillar and ExCom meetings and teleconferences. Advisory Regulatory Ethics Board The Advisory Regulatory Ethics Board (AREB) will be set up in order to ensure compliance of the project and its activities with ethical and regulatory requirements. It will be composed of internal EJP RD ethics/regulatory/legal experts, including members with recognised expertise from involved European RIs and the Independent Ethics Advisor. It will ensure compliance with all international and European relevant rules and ethical norms, including but not limited to fundamental and patients’ rights, data management, protection and confidentiality, of the EJP RD as well as of the projects founded within EJP RD. The Independent Ethics Advisor will supervise the actions of AREB and will be in charge of advising on and monitoring ethical/legal/regulatory issues of the EJP RD, of the Data Management Plan as well as of the projects founded within EJP RD to ensure that the ethics management of the projects are carried out within the H2020 framework. Satellite Boards Policy Board The members of the EJP RD are aware of the importance of continuous feedback and dialogue with relevant national, European and international stakeholders. This is necessary to translate efficiently the specific needs and strategy represented by countries or European Commission as well as the outcomes of the EJP RD. The Policy Board will have a major role in ensuring this dialogue and translation through its participation is EJP RD strategy and sustainability development. The Policy Board will be constituted from: ● Representatives of national ministries of research and health; ● Representatives of European Commission Directorates: DG RTD, DG Santé, DG Connect; ● Representative of the pharmaceutical industry and public-private initiatives (e.g. European Federation of Pharmaceutical Industries and Associations, EFPIA; Innovative Medicines Initiative, IMI); ● Representative of EuropaBio; ● Representative of regulatory authorities (e.g. European Medicines Agency, EMA, esp. Committee for Orphan Medicinal Products, COMP, EuNetHTA); ● Chair of the European Strategy Forum on Research Infrastructures (ESFRI); ● Chair and vice-chair of the International Rare Diseases Research Consortium (IRDiRC). Meetings: Once a year. National mirror groups (NMG) Participating countries will be strongly advised to constitute NMG, bringing together the national representatives of the EJP RD and other relevant RD stakeholders. The role of the NMGs will be to ensure national coordination, contribute to the objectives of the EJP RD and benefit from it. The creation and composition of a NMG is at the discretion of each participating country. It is expected that NMGs will include representatives of the National plan 825575 – EJP RD – Part B 36 for RD, national nodes of the European Reference Networks, relevant national Associated authorities with document Ref. and research institutions Ares(2018)6091977 - 28/11/2018 (whether participating to the EJP RD or not), as well as the relevant national partners of the EJP RD and GB member that will report NMG views and positions during GB meetings. Although not mandatory, it is expected that the establishment of National Mirror Groups will ensure that national activities, strategies and needs are taken into account when taking decisions at the EJP RD level and when designing the annual work plans. Board of funders In order to ensure the independence of joint transnational calls management (Pillar 1), the final decisions on call topics and implementation of calls will be taken autonomously by the Board of Funders (BOF). The composition of Board of Funders will be variable depending on the configuration of funding bodies participating in the joint transnational calls. BOF will be chaired by the Pillar 1 leaders. Meetings: Ad hoc meetings before and after the launch of each joint transnational call for proposals. Ad hoc Advisory Board (AB) The ad hoc Advisory Board(s) will be constituted on demand of BOF or Pillar 2 and 4 leaders in relation to pilot projects foreseen. The AB will consist of international experts and RD stakeholders to include their knowledge and experience and use their input for the definition of the research strategy for joint transnational calls or pilot projects. 3.3: Consortium as a whole The objectives of the EJP RD, namely improvement of integration, efficacy, production and social impact of research on rare diseases and its translation into clinical applications and uptake in healthcare for the benefit of patients can only be achieved by bringing together key actors and stakeholders thus guaranteeing integrity of the pipeline. The EJP RD consortium is composed of 87 (full) partners from 23 European (AT, BE, CZ, DE, ES, EE, FI, FR, GR, HU, IE, IT, NL, LT, LV, LU, PL, PT, RO, SE, SK, SV, UK), 4 associated (AM, CH, IL, TK) and 1 non-EU country (CA) bringing together expertise necessary to fulfill set aims. The majority of EJP RD’ partners have existing collaborations established through previous projects or are united within existing (infra)structures. Funding: All Pillar 1 members are leading organizations that fund, manage and implement strategically planned focused research programmes in the field of health. They put into action and fund international collaborative research programmes, (e.g. bi-lateral, multi-lateral), and participate into numerous international and European initiatives that match their national strategic issues on research. Most of these funding bodies (20) have previously worked under the ERA-Net E-Rare. At present twenty-nine funding agencies/ministries in Life Science and Health, from twenty-two countries, are part of the EJP RD consortium. The addition of Estonia, Ireland, Luxembourg, Slovakia, Sweden and two Italian regions (Lombardy and Tuscany), enables further European expansion of the programme. Most importantly, the engagement of funders will be translated through strong commitment, that all funding bodies made during the preparation phase of this application, to participate to the two co-funded and subsequent joint calls. Providing financial support to projects is crucial for acceleration of collaborative research on rare diseases and enhancement of knowledge sharing between different national teams. Previous experience of E-Rare has demonstrated that such projects structure the community via long-lasting collaborations and bring direct and meaningful benefit for patients via discovery of new genes, establishment of diagnostic guidelines and development of new treatments. Furthermore, projects financed in Pillar 1 will take advantage of additional tools and support provided within Pillars 2, 3 and 4 creating an optimal ecosystem for accelerated diagnosis and exploitation of results for therapy development. In addition to the well-established joint transnational calls, EJP RD will profit from the know-how of new partners to build novel initiatives needed by the RD community. The proposition of support to Networking scheme stems from numerous demands expressed by the RD research community and (additonal) stakeholders including addressing the need for reinforcement of cooperation and knowledge sharing between EU13 and EU15 countries and stronger integration of patients in research. The management of the Networking scheme will be based on the past experience of ZonMw (NL) complemented by knowledge of partners representing different regions (Latvia, Israel, Sweden, Turkey, Canada) and rare disease patients (EURORDIS). EJP RD will also benefit from the extensive experience and management capacities of new partners (FFRD, AFM Telethon & EATRIS) to implement a unique support to the so-called RD Research Challenges to accelerate innovation through public-private partnerships. Moreover, the scheme will be closely connected to Pillar 4 and collaborate with other members of the consortium (EURORDIS, FTELE, IMAGINE, ERNs) to set up effective portfolio of private partners and sponsors interested in challenges. Resources: The development of the virtual platform for rare diseases information and research data, based on existing resources (samples, tools and standards), linked directly with funded research projects to support and accelerate rare diseases research can only be achieved with extensive contribution of research performing 825575 – EJP RD – Part B 37 organizations and infrastructures. This will be achieved through participation Associated withof 20 institutions document and 24 ERNs Ref. Ares(2018)6091977 and 5 - 28/11/2018 European research infrastructures (members of ESFRI). Again, EJP RD capitalizes on the previously acquired experience, know-how and, most importantly, standards, resources and tools created by projects and infrastructures including Orphanet, RD-Connect, HPO, RaDiCo, or ERDRI. This will be complemented by strong commitment of several biomedical European Research Infrastructures such as BBMRI, ELIXIR, EATRIS, Infrafrontier and ECRIN, which were developed in the past years through collaborative efforts of Member States. Although not specific for RDs, these infrastructures aim to develop services facilitating access for researchers to resources and knowledge and to enhance data sharing thus avoiding duplication of efforts. Their direct involvement will be key to achieve harmonized user access to biological and medical technologies, samples and services for rare diseases. Even if findable under single virtual platform, the resources can only be efficiently used if they are made accessible and interoperable. That is why EJP RD will be armed with know-how of top-level institutions focusing on the development and implementation of FAIR approaches in Europe. LUMC, UMCG, University of Leicester, CNAG- CRG, AIT and BBMRI will be the driving force to “FAIRification” of key RD resources and enabling FAIR ecosystem at larger scale by assisting the RD community. Furthermore, the capacities of EJP RD research institutions (UM, RUMC, ISCIII, ISS, ACU/ACURARE, INSERM (AMU)) coupled with potential of external projects (Solve-RD, UDNI) as well as European Reference Networks, will extend the platform with workflows that allow holistic research based on rare disease data and biological knowledge, closing the circle between initial data production and its reutilization in explorative studies. The participation of above-mentioned institutions will not be limited to activities foreseen in Pillar 2 but also expanded to, and strongly connected with Pillars 3 and 4. Education and empowerment: In Pillar 3, infrastructures will join leading players to anchor and expand rare diseases education and empowerment programmes. This is where national universities, charities and patient organizations bring their competences, taking advantage of the already established education/trainings and creating a new, coherent landscape for education on rare diseases. The courses on data/resources management and quality initiated by institutions including INSERM (Orph), KULeuven, ISS, FTELE, LUMC and JRC will be enriched by contributions of new partners (EKUT, IPCZD (CMHI), IMAGINE, Charité, LBG (LBI-RUD), HUGEN (HACETTEPE) and more) and also made specifically accessible to EU13 countries in order to enhance capacity and knowledge sharing across Europe. Participation of EURORDIS, TEDDY, FSJD and C4C will be central to further engage and empower rare disease patients into research and provide them with the tools required to apprehend and actively contribute to innovation and therapy development. Furthermore, EJP RD will work with universities, learned societies and ERNs to design first the European rare diseases academic course. Once more, the consortium will take advantage of already existing capacities within national institutions and transform them for the benefit of all. This innovation in education will seek the active participation of the European Reference Networks fostering crosscutting needs of healthcare professionals interested or active in research. Translation: EJP RD can only fully contribute to IRDiRC goals, namely delivery of diagnosis within one year for patients coming to medical attention and development of 1000 new therapies for rare diseases by 2027, by including the participation of the European Reference Networks. All twenty-four ERNs will be part of the consortium. The majority will participate through their coordinating institutions representing the tremendous potential of 900 units from 300 hospitals. ERNs will be the driving wheel of translation of research results into clinical diagnosis and treatment of patients. Accompanied by RPOs, they will be responsible for guidance of Pillar 2 in identification of key resources to be FAIRified and creation of new tools for efficient exploitation and interpretation of data. The know-how of ERNs will command the process of development and validation of methodologies and approaches in clinical research (endpoints, trial layout, randomisation techniques, power calculation, patient centred outcomes, etc.) leading to their dissemination and increased implementation in healthcare systems. Finally, the enhanced uptake of research results and improved innovation potential will be achieved with mentoring and solid support for translational research projects. This link (between Pillar 1 and Pillar 4) will be ensured by the group of partners (EATRIS, FTELE, FGB, CVBF, AFM, HUGEN (HACETTEPE) and UNEW) experienced in drug/diagnostic, regulatory, pre-clinical and clinical development. Research projects financed in joint transnational calls will have access to innovation management tools and accompanying of innovation manager allowing maximization of exploitation potential and opening routes to follow-on funding. EU 13 countries: The participation of EU13 countries was tailored to progressively increase their capacity and go beyond the initially available resources (budgetary, administrative and scientific). For Pillar 1 the budgets dedicated to joint transnational calls reflect not only the financial capacities of different countries but also, are adapted to the size and success rate of their scientific community. Furthermore, previous experience (E-Rare) confirmed that an increase in budget is not sufficient (and most often unnecessary) while the strategies to increase the success rate and capacity building are better adapted. That is why the focus of EJP RD is on increased capacity building, continuation and expansion of already approved strategies. This will be done and pursued for joint transnational calls but also further expanded through the Networking scheme. In addition, the EU13 play leading role in the training activities of Pillar 3 as creators, providers and strategic advisors to develop tailored capacities. 825575 – EJP RD – Part B 38 They will contribute to databasing activities in Pillar 2 as most ofAssociated them arewith constituents ofAres(2018)6091977 document Ref. the Orphanet Network. - 28/11/2018 Finally, the EU13 needs will be translated through the prioritization strategy based, among others, on the feedback received from the EU 13 mirror groups and RD stakeholders. Other (international) collaborations: Although one of the main goals of the EJP RD is to strengthen European capacity in the field of rare diseases, it does not mean that the ecosystem should be closed to international collaborations. Actually, the linkage with international partners will be ensured at different levels. First of all, through the integration of IRDiRC Scientific Secretariat in the Coordination Office of the EJP RD and joint management of research and innovation strategy (via the participation of IRDiRC Chair and Vice chairs in the EJP RD Policy Board and organization of common Task Forces). Secondly, through the already established collaboration with partners like Australia (Western Australian Department of Health) that expressed interest to participate as so-called Associated Partners contributing to and aligning with research and training activities proposed under Pillars 2, 3 and 4. The status of Associated Partner will be also granted to DECIPHER (Sanger Institute, UK) and ChemBioNet (DE) that could not join EJP RD as full beneficiaries but expressed their willingness to contribute to the EJP RD goals. Finally, EJP RD intends to pursue efforts in expanding the collaboration and integration of other countries willing to join with their knowledge and resources to achieve shared benefits for rare diseases patients. At present, the possibility of cooperation with Japan Agency for Medical Research and Development (AMED) is being discussed. AMED is a key player in rare disease research field, member of IRDiRC since 2015 and would be an invaluable partner for EJP RD bringing the unique opportunity to build the bridges for Japanese-European actions covering research, sharing of resources and acceleration of drug development. The route to exploitation of EJP RD results at policy and industrial levels: Creating an efficient and stable rare diseases research ecosystem will be efficient and productive if it can realistically be translated at the policy-makers level. Therefore, from the very start, EJP RD will be accompanied by the Policy Board composed of representatives of research and health ministries, relevant Commission directorates and other central policy stakeholders. The Board will have the responsibility to consciously contribute in prioritization strategy of the EJP RD by orienting towards the imperatives and at the same time aligning its own activities to support outcomes of the EJP RD. This will be further strengthened by the creation of national Mirror Groups guaranteeing proficient dialogue at national level. The Board will be also primary interlocutor of the EJP RD sustainability work package and recipient of the business plan and sustainability roadmap. The involvement of different types of stakeholders will be kept at different level and goes beyond the Policy Board. More specifically the potential investors and industrial partners will be implicated directly in establishment and participation of RD Challenges fostering unexploited potential of academic/SME partners. The representatives of industry and specialists in venture capitals will assist Innovation Manager (WP19) in real-time mentoring of funded projects with high translation potential. Furthermore, the contact with EFPIA or EuropaBio will be exploited to prepare and promote candidate projects at public-private partnerships events. Finally, the EJP RD will be advised by the Companies Constituent Committee of IRDiRC to maximize the development and exploitation of EJP RD “products” stemming from the activities of Pillars 2 and 4 (registries, natural history studies, FAIRified resources, clinical trials methodologies). Thus, the integrated connection with relevant stakeholders at both public (policy) and private (industry, venture capitals) levels will provide the route to proficient exploitation of EJP RD results. 3.4: Resources to be committed The EJP RD consortium members are strongly committed and will support the programme with in cash or in kind contributions. This includes: personnel, resources like data infrastructures, tools, training and education materials, meeting rooms and high level expertise. The initial, earmarked (in cash) budget of EJP RD involved funders is about 37 M€ and further commitments of at least 20 M€ are foreseen (to support non-cofunded joint transnational calls). Due to the large span of proposed activities and related capacity to generate in cash or in kind support, the consortium agreed to apply, rather than fixed 70%, different reimbursement rates and redistribute EC contribution accordingly. The table below details the settled reimbursement percentage per activity and maximum budget per pillar agreed by the consortium: Type of activity Reimbursement rate Max budget per Pillar Central coordination, management and transversal activities (WP1 – 100% 8 929 031 € WP5) 825575 – EJP RD – Part B 39 Associated with document Ref. Ares(2018)6091977 - 28/11/2018 Pillar 1 co-funded joint transnational calls (WP6) Variable depending on the 15 978 333 € result of calls (max. 33%) Pillar 1 Networking scheme and RDR Challenge (WP7 – WP8) 100% Pillar 1 all management costs (WP6 – WP9) 100% Pillar 2 all activities (WP10 – WP13) 70% 17 765 609 € Pillar 3 training activities (WP14 – WP18) 80 – 90% 5 934 160 € Pillar 3 subcontracting of e-learning platform (WP16) 100% Pillar 4 all activities (WP19 – WP20) 70% 6 477 306 € TOTAL EJP RD budget 55 084 438 € In addition, each of the WPs identified activities to be implemented at later stage for which the budget was pre- defined but the allocation to specific partners will take place in subsequent years, based on the agreed Annual Work Plans. It was agreed that the “non-assigned” budget would remain for the time being with the coordination (INSERM): WP Details Reimbursement rate (%) Non-assigned EC contribution (overhead included) WP6 Evaluation meetings 100 % 280 000 € WP8 RDR Challenge scheme 100 % 1 500 000 € WP9 Monitoring meetings 100 % 80 000 € WP10 Workshops & meetings 70 % 49 720 € WP11 FAIRification costs 70 % 100 000 € WP12 FAIRification costs 70 % 900 000 € WP13 Proof of concept projects – data provision by ERNs 70 % 150 000 € WP20 Evaluation of internal calls for demonstration and innovation in 70 % 40 000 € methodologies projects WP20 Demonstration & new methodologies pilot projects 70 % 3 600 000 € TOTAL non-assigned to be kept with coordination (INSERM) 6 699 720 € It is important to note that by reason of different reimbursement rates, the exact redistribution of budget per partner has been defined and will be different from the one presented on the ECAS platform. The real budget redistribution agreed will be part of the Consortium Agreement. Table 3.4a: Summary of staff effort (per participants and per WP) Explanation of allocation of PM: Pillar 1: the number of PM allocated for the majority of the funding bodies correspond to the “basic” participation in funding activities consisting of participation in the process of joint transnational call(s). The number of PMs was calculated based on the solid previous experience (12 years) of running the same activity in ERA-Net E-Rare. Specific case of European Reference Network: the consortium took the decision to involve ALL ERNs from the start of the project even if many of the activities in which ERNs will be fully involved (like WP13 or WP20) will take place at later stage (starting from year 2). However, it is crucial that ERNs are involved from the start via their 825575 – EJP RD – Part B 40 participation in Annual Retreats of Pillar 2, dedicated Task Forces or meetings Associated of General with document Assembly, as they Ref. Ares(2018)6091977 are - 28/11/2018 the key actors to guide the work of Pillars 2 and 4, as well as the driving force for the trainings of Pillar 3 WP17. All partners of the EJP RD agreed that any work related to the participation in the meetings will be done as in kind contribution (accountable or not) and thus no PM are allocated to this type of activities for any of the EJP RD partners. This results also in a low number of PM allocated to ERNs. In WP13 and WP20, where extensive participation of ERNs is expected, the distribution of budget will be done at later stage and thus also the distribution of respective PMs. Therefore, the low budget or number of PM of some partners are often related to the fact that these partners are expected to take more active participation from year 2 onwards and the budget related to the planned actions has not been yet distributed. In addition, a business plan with detailed share of budget was made during the proposal preparation and all partners agreed on this defined allocation of funds and confirmed their strong commitment. Table 3.4b: ‘Other direct cost’ items (travel, equipment, other goods and services, large research infrastructures) N° Cost (€) Justification WP1 Travel to 5 GA meetings ; WP1 Travels policy board (X5); WP3 travel (6 meetings 6 pax) ; WP4 travel (5 meetings 11 pax) ; WP1 travel to 5 EX Com meetings + Kick off; PL2 Travel costs 1 INSERM Travel 218 910 (Radico, Orphanet+LTP, AMU); WP10 Travel to annual retreat (ORPHANET); WP14 Task 14.1 Travel costs; WP20 Travel costs of experts WP20 PL4 ERN Pilot projects (to be allocated); WP1 General assembly meetings org (X5) ; WP1 Executive com meetings org (X5) ; WP1 ERN CHAIR costs to be assigned; WP1 Policy Board+Ethics+ExecCom joint meetings org (X5); WP1 Monitoring meetings org (X5); WP2 Irdirc Task Forces: Workshops organisation; WP3 meeting org (6 meetings 6 pax) ; WP4 meeting org (5 meetings 11 pax) ; WP5 EJP website; WP5 Printing/translation/publication/video; WP6 Evaluation Other 6 735 027 meetings (2/year x 4 calls) at average cost 35 000 € (to be allocated); WP9 Meeting costs (to be allocated); WP10 PL2 Annual retreats from year 2 (to be allocated); WP10 PL2 Workshop Orphanet; WP11 Fairification costs (to be allocated); WP12 Fairification costs (to be allocated); WP13 Data provision by ERNs (to be allocated); WP14 Task 14.1 Catering costs; WP20 Organisation of 2 evaluation meetings (to be allocated); WP20 Task Force meetings and experts TOTAL 6 953 937 WP1 Travel to 5 GA meetings ; WP6 Travel costs ; WP9 Travel 2 FWF Travel 14 850 costs; Other 4 000 CFS Cost TOTAL 18 850 WP1 Travel to 5 GA meetings ; WP6 Travel costs ; WP9 Travel 5 FNRS Travel 14 850 costs TOTAL 14 850 WP1 Travel to 5 GA meetings ; WP6 Travel costs ; WP9 Travel 6 FWO Travel 2 000 costs Other 4 000 CFS Cost TOTAL 6 000 7 KULeuven Travel 12 730 WP1 Travel to 5 GA meetings ; PL3 Task 14.2 Travel costs ; Other 4 056 PL3 Task 14.2 Catering TOTAL 16 786 WP1 Travel to 5 GA meetings ; WP6 Travel costs ; WP9 Travel 9 MOSAE Travel 14 610 costs TOTAL 14 610 825575 – EJP RD – Part B 41 WP1 Travel to 5 GAAssociated meetings ; WP6 with Travel document costs ; WP9 Travel Ref. Ares(2018)6091977 - 28/11/2018 10 AKA Travel 14 850 costs Other 4 000 CFS Cost TOTAL 18 850 WP1 Travel to 5 GA meetings ; WP6 Travel costs ; WP9 Travel 11 ANR Travel 16 850 costs Other 4 000 CFS Cost TOTAL 20 850 WP1 Travel to 5 GA meetings; WP1 travel to 5 EX Com meetings + 12 FFRD Travel 49 510 Kick off; WP6 Travel costs ; WP8 Travel costs ; WP9 Travel costs ; WP16 Task 16.2 Travel costs; WP16 Task 16.3 Travel costs WP8 1 meeting call development; WP8 2 Evaluation meetings for Other 50 006 RD challenge ; WP8 Networking event for RDR challenge; WP16 Task 16.2 Catering costs; WP16 Task 16.3 Catering costs CFS Cost TOTAL 99 516 13 AFM Travel 5 900 WP1 Travel to 5 GA meetings TOTAL 5 900 14 IMAGINE Travel 5 900 WP1 Travel to 5 GA meetings TOTAL 5 900 WP1 Travel to 5 GA meetings ; WP6 Travel costs ; WP9 Travel NKFIH Travel 14 850 19 costs Other 0 TOTAL 14 850 WP1 Travel to 5 GA meetings ; WP6 Travel costs ; WP9 Travel HRB Travel 14 610 20 costs Other 4 000 CFS Cost TOTAL 18 610 WP1 Travel to 5 GA meetings ; WP6 Travel costs ; WP9 Travel IT MoH Travel 14 850 21 costs Other 4 000 CFS Cost TOTAL 18 850 WP1 Travel to 5 GA meetings ; WP6 Travel costs ; WP9 Travel RT (TuscReg) Travel 14 610 22 costs TOTAL 14 610 WP1 Travel to 5 GA meetings ; WP6 Travel costs ; WP9 Travel FRRB Travel 14 610 23 costs Other 4 000 CFS Cost TOTAL 18 610 WP1 Travel to 5 GA meetings ; WP2 travel (1 meeting 50 pax); WP1 travel to 5 EX Com meetings + Kick off; PL2 travel costs; PL3 ISS Travel 185 880 Task 14.2 Travel costs; PL3 Task 14.3 Travel costs; PL3 Task 14.5 26 Travel costs; PL3 Task 15.3 Travel costs WP2 meeting org (1 meeting 50 pax); PL2 annual retreat year 1 (meeting costs); PL3 Task 14.2 Catering costs; PL3 Task 14.3 Other 136 893 Catering costs; PL3 Task 14.5 Catering costs; PL3 Task 15.3 Catering costs ; CFS Cost TOTAL 322 773 WP1 Travel to 5 GA meetings ; FSJD (LTP TEDDY) -Task 15.4 TEDDY Travel 30 440 28 Travel costs; TEDDY -Task 15.4 Travel costs FSJD (LTP TEDDY) -Task 15.4 Catering costs; TEDDY -Task 15.4 Other 15 404 Catering costs ; TOTAL 45 844 WP1 Travel to 5 GA meetings ; WP6 Travel costs ; WP9 Travel MIUR Travel 14 610 29 costs TOTAL 14 610 30 VIAA Travel 6 140 WP1 Travel to 5 GA meetings ; WP9 Travel costs ; 825575 – EJP RD – Part B 42 TOTAL 6 140 Associated with document Ref. Ares(2018)6091977 - 28/11/2018 WP1 Travel to 5 GA meetings ; WP6 Travel costs ; WP9 Travel LMT Travel 14 610 31 costs TOTAL 14 610 WP1 Travel to 5 GA meetings ; WP1 travel to 5 EX Com meetings + VUHSK Travel 44 480 32 Kick off; PL3 Task 14.4 travel costs; PL3 WP18 travel costs; Other 28 686 PL3 Task 14.4 catering costs; PL3 WP18 catering costs ; TOTAL 73 166 WP1 Travel to 5 GA meetings ; WP6 Travel costs ; WP9 Travel FNR Travel 14 610 33 costs TOTAL 14 610 WP1 Travel to 5 GA meetings ; WP6 Travel costs ; WP9 Travel NCBR Travel 14 850 37 costs Other 4 000 CFS Cost TOTAL 18 850 WP1 Travel to 5 GA meetings ; WP2 travel (1 meeting 50 pax); PL2 MUW Travel 34 400 38 travel costs Other 6 650 WP2 meeting org (1 meeting 50 pax) TOTAL 41 050 WP1 Travel to 5 GA meetings ; PL3 Task 14.4 Travel costs; PL3 MUG Travel 24 840 39 Task 15.3 Travel costs Other 7 263 PL3 Task 14.4 Catering costs; PL3 Task 15.3 Catering costs ; TOTAL 32 103 WP1 Travel to 5 GA meetings ; WP1 travel to 5 EX Com meetings + IPCZD Travel 15 550 40 Kick off; PL3 Task 14.2 travel costs Other 4 056 PL3 Task 14.2 catering costs TOTAL 19 606 WP1 Travel to 5 GA meetings ; WP6 Travel costs ; WP9 Travel FCT Travel 14 850 41 costs TOTAL 14 850 42 INSA Travel 10 900 WP1 Travel to 5 GA meetings ; PL2 travel costs ; TOTAL 10 900 WP1 Travel to 5 GA meetings ; WP6 Travel costs ; WP9 Travel SAS Travel 14 610 43 costs TOTAL 14 610 47 CIBER Travel 10 900 WP1 Travel to 5 GA meetings; PL2 travel costs ; TOTAL 10 900 WP1 Travel to 5 GA meetings ; WP6 Travel costs ; WP9 Travel SRC Travel 14 610 48 costs Other 4 000 CFS Cost TOTAL 18 610 WP1 Travel to 5 GA meetings ; WP6 Travel costs ; WP9 Travel Vinnova Travel 14 610 49 costs Other 4 000 CFS Cost TOTAL 18 610 ERN EYE Travel and subsistence for WP20 PL4; WP1 Travel to 5 HUS Travel 13 600 55 GA meetings ; ERN EYE PL2 Travel costs TOTAL 13 600 EURACAN Travel and subsistence for WP20 PL4; WP1 Travel to 5 CLB Travel 14 070 56 GA meetings ; EURACAN PL2 Travel costs TOTAL 14 070 ERN KNET Travel and subsistence for WP20 PL4; WP1 Travel to 5 UKL-HD Travel 25 560 GA meetings (2 teams); ERKnet WP1 travel to 5 EX Com 57 meetings + Kick off; ERKnet PL2 Travel costs ; PL3 WP17 Training delivery for 4,5 years; 4 training networks with Other 409 000 6 ERNs each; 90.000 per training network per year (15k€ per ERN) 825575 – EJP RD – Part B 43 CFS Cost Associated with document Ref. Ares(2018)6091977 - 28/11/2018 TOTAL 434 560 ERN RND Travel and subsistence WP20 PL4 ; .WP1 Travel to 5 GA meetings (X2, ERN+nonERN) EKUT Travel 63 460 .WP1 travel to 5 EX Com meetings + Kick off (Holm); ERN RND PL2 Travel costs ; PL3 Task 14.2 travel Costs; PL3 WP17 ERN RD 58 training and support programme travel PL3 Task 14.2 catering; PL3 WP17 ERN RD training and support programme catering; PL3 WP7: Training delivery for 4,5 years; 4 Other 422 632 training networks with 6 ERNs each; 90.000 per training network per year (15k€ per ERN) CFS Cost TOTAL 486 092 ERN Bond Travel and subsistence for WP20 PL4; WP1 Travel to 5 IOR Travel 15 840 61 GA meetings ; ERN Bond PL2 Travel costs TOTAL 15 840 ERN Reconnect Travel and subsistence WP20 PL4 ; WP1 Travel to AOUP Travel 14 070 62 5 GA meetings ; ERN Reconnet PL2 Travel costs TOTAL 14 070 ERN Ithaca Travel and subsistence WP20 PL4 ; WP1 Travel to 5 AOUS Travel 14 070 63 GA meetings ; Ithaca PL2 Travel costs TOTAL 14 070 ENDO Ern Travel and subsistence WP20 PL4 ; WP1 Travel to 5 GA meetings (all LUMC teams X2); WP1 travel to 5 EX Com LUMC Travel 30 490 meetings + Kick off (M Roos); Travel costs to PL2 meetings (all 64 LUMC teams X2); PL2 workshop costs (M Roos); WP17 Training delivery for 4,5 Other 429 000 years; 4 training networks with 6 ERNs each; 90.000 per training network per year (15k€ per ERN) ; CFS Cost TOTAL 459 490 ERN Genturis&Eurogen Travel and subsistence WP20 PL4 ; WP1 RUMC Travel 39 040 Travel to 5 GA meetings (X3 RUMC teams); ERN 65 Genturis&Eurogen Travel for PL2 ; Travel for PL2 (non ERN); Equipment 0 PL2 workshop costs (non ERN); PL3 WP17 Training delivery for Other 426 500 4,5 years; 4 training networks with 6 ERNs each; 90.000 per training network per year (15k€ per ERN) ; CFS Cost TOTAL 465 540 ERN Cranio & ERNICA Travel and subsistence WP20 PL4 ; WP1 Erasmus MC Travel 28 140 Travel to 5 GA meetings (X2 ERN); PL2 travel costs (Cranio & 67 ERNICA) TOTAL 28 140 ERN Transplant staff for WP20 PL4; ERN Transplant WP1 Travel SERMAS Travel 14 070 68 to 5 GA meetings ; ERN Transplant PL2 travel TOTAL 14 070 ERN Rare Liver,Rita, EuroNMD Travel and subsistence WP20 PL4 NUTH Travel 42 210 ; WP1 Travel to 5 GA meetings (X3 ERNs); ERN Rare Liver,Rita, 69 EuroNMD Travel for PL2 TOTAL 42 210 EPICARE travel and subsistence for WP20 PL4; WP1 Travel to 5 GOSH Travel 15 840 70 GA meetings ; EPICARE travel for PL2 TOTAL 15 840 71 EORTC Travel 5 900 WP1 Travel to 5 GA meetings TOTAL 5 900 Travel and subsistence for WP20 PL4; WP1 Travel to 5 GA EURORDIS Travel 180 850 meetings; 77 WP1 Travel to 5 EX Com meetings + Kick off; WP6 Travel costs ; 825575 – EJP RD – Part B 44 WP8 Travel costs; WP9 Travel Associated withcosts; WP14 document Ref. Task 14.5 Travel- costs; Ares(2018)6091977 28/11/2018 WP15 Task 15.1 Travel costs; WP15 Task 15.2 Travel costs; WP15 Task 15.3 Travel costs WP8 2 Multi-stakeholder workshops for set-up RDR challenge Other 89 547 scheme ; WP15 Task 15.1 Catering costs; WP15 Task 15.2 Catering costs; WP15 Task 15.3 Catering costs ; CFS Cost TOTAL 270 397 WP1 Travel to 5 GA meetings ; WP6 Travel costs ; WP9 Travel SNSF Travel 14 850 79 costs Other 4 000 CFS Cost TOTAL 18 850 80 BLACKSWAN Travel 5 900 WP1 Travel to 5 GA meetings Other 150 000 WP5 - REACT congress organisation costs TOTAL 155 900 WP1 Travel to 5 GA meetings ; WP6 Travel costs ; WP9 Travel TUBITAK Travel 14 850 81 costs Other 4 000 CFS Cost TOTAL 18 850 WP1 Travel to 5 GA meetings ; PL2 travel costs; PL3 Task 14.2 ACURARE Travel 34 550 82 travel costs; PL3 Task 15.3 travel costs; Other 9 243 PL3 Task 14.2 catering; PL3 Task 15.3 catering ; TOTAL 43 793 83 HUGEN Travel 8 020 WP1 Travel to 5 GA meetings ; PL3 Task 14.4 Travel costs Other 2 076 PL3 Task 14.4 Catering costs TOTAL 10 096 WP1 Travel to 5 GA meetings ; WP6 Travel costs ; WP9 Travel GSRT Travel 14 610 87 costs TOTAL 14 610 4.1. Participants (applicants) Type of partner (Programme owner N° Partner Acronym Participant organisation name Country [PO], Programme manager [PM], other [O] INSTITUT NATIONAL DE LA SANTE DE DE PM 1 INSERM FR LA RECHERCHE MEDICALE FONDS ZUR FÖRDERUNG DER PO & PM 2 FWF AT WISSENSCHAFTLICHEN FORSCHUNG AIT AUSTRIAN INSTITUTE OF O 3 AIT AT TECHNOLOGY GMBH LUDWIG BOLTZMANN GESELLSCHAFT O 4 LBG (LBI-RUD) AT GMBH FOND DE LA RECHERCHE SCIENTIFIQUE- PO & PM 5 FNRS BE FNRS FONDS VOOR WETENSCHAPPELIJK PO & PM 6 FWO BE ONDERZOEK - VLAANDEREN 7 KULeuven KU LEUVEN (UNIVERSITY OF LEUVEN) BE O MINISTRY OF EDUCATION YOUTH AND PO & PM 8 MEYS CZ SPORT MINISTRY OF SOCIAL AFFAIRS OF PO & PM 9 MoSAE EE ESTONIA 10 AKA SUOMEN AKATEMIA FI PO & PM 11 ANR AGENCE NATIONALE DE LA RECHERCHE FR PM FONDATION MALADIES RARES - FRENCH PO & PM 12 FFRD FR FOUNDATION FOR RARE DISEASES 825575 – EJP RD – Part B 45 ASSOCIATION FRANÇAISE CONTRE LES O Associated with document Ref. Ares(2018)6091977 - 28/11/2018 13 AFM FR MYOPATHIES IMAGINE - INSTITUT DES MALADIES O 14 IMAGINE FR GENETIQUES NECKER ENFANTS MALADES DEUTSCHES ZENTRUM FUER LUFT - UND PM 15 DLR DE RAUMFAHRT EV 16 UKA UNIVERSITAETSKLINIKUM AACHEN DE O 17 CHARITE CHARITE - UNIVERSITÄTSMEDIZIN BERLIN DE O 18 UKLFR (Freiburg) UNIVERSITAETSKLINIKUM FREIBURG DE O NEMZETI, KUTATASI, FEJLESZTESI ES PO & PM 19 NKFIH HU INNOVACIOS HIVATAL 20 HRB HEALTH RESEARCH BOARD IE PO & PM 21 IT MoH MINISTRY OF HEALTH IT PO & PM 22 RT (TuscReg) TUSCANY REGION - REGIONE TOSCANA IT PO & PM FONDAZIONE REGIONALE PER LA PO & PM 23 FRRB IT RICERCA BIOMEDICA FONDAZIONE PER LA RICERCA O 24 FGB IT FARMACOLOGICA GIANNI BENZI ONLUS 25 FTELE FONDAZIONE TELETHON IT O 26 ISS ISTITUTO SUPERIORE DI SANITA IT PO & PM CONSORZIO PER VALUTAZIONI O 27 CVBF IT BIOLOGICHE E FARMACOLOGICHE TEDDY- EUROPEAN NETWORK OF O 28 TEDDY EXCELLENCE FOR PAEDIATRIC CLINICAL IT RESEARCH MINISTERO DELL'ISTRUZIONE, PO & PM 29 MIUR IT DELL'UNIVERSITA E DELLA RICERCA VALSTS IZGLITIBAS ATTISTIBAS PO & PM 30 VIAA (SEDA) LV AGENTURA 31 LMT (RCL) LIETUVOS MOKSLO TARYBA LT PO & PM VILNIUS UNIVERSITY HOSPITAL O 32 VUHSK LT SANTAROS KLINIKOS 33 FNR FONDS NATIONAL DE LA RECHERCHE LU PO & PM 34 ZON (ZonMw) ZORGONDERZOEK NEDERLAND NL PO & PM 35 UMCG ACADEMISCH ZIEKENHUIS GRONINGEN NL O 36 UM UNIVERSITEIT MAASTRICHT NL O NATIONAL CENTRE FOR RESEARCH AND PM 37 NCBR DEVELOPMENT PL MEDICAL UNIVERSITY OF WARSAW O 38 MUW (POLAND) PL GDANSKI UNIWERSYTET MEDYCZNY O 39 MUG (MEDICAL UNIVERSITY GDANSK) PL INSTYTUT "POMNIK- CENTRUM ZDROWIA O 40 IPCZD (CMHI) DZIECKA" PL FUNDAÇÃO PARA A CIENCIA E A PO & PM 41 FCT TECNOLOGIA PT INSTITUTO NACIONAL DE SAUDE DOUTOR PM 42 INSA RICARDO JORGE, I.P. PT 43 SAS SLOVAK ACADEMY OF SCIENCES SK PO & PM INSTITUTO DE SALUD CARLOS III / PO & PM 44 ISCIII INSTITUTE OF HEALTH CARLOS III ES FUNDACIO CENTRE DE REGULACIO O 45 CNAG-CRG GENOMICA ES 46 UPM UNIVERSIDAD POLITECNICA DE MADRID ES O CONSORCIO CENTRO DE INVESTIGACION O 47 CIBER BIOMEDICA EN RED, M.P. ES 48 SRC SWEDISH RESEARCH COUNCIL SE PO & PM 49 Vinnova VINNOVA SE PO & PM 825575 – EJP RD – Part B 46 50 ULEIC UNIVERSITY OF LEICESTER UK O Associated with document Ref. Ares(2018)6091977 - 28/11/2018 51 ULIV UNIVERSITY OF LIVERPOOL UK O 52 UNEW UNIVERSITY OF NEWCASTLE UPON TYNE UK O 53 CCRI ST. ANNA KINDERKREBSFORSCHUNG AT O ASSISTANCE PUBLIQUE HOPITAUX DE O 54 APHP PARIS FR HOPITAUX UNIVERSITAIRES DE O 55 HUS STRASBOURG FR 56 CLB CENTRE LEON BERARD FR O 57 UKL-HD UNIVERSITAETSKLINIKUM HEIDELBERG DE O EBERHARD KARLS UNIVERSITÄT O 58 EKUT TÜBINGEN DE 59 GUF GOETHE UNIVERSITÄT FRANKFURT DE O HELIOS DR. HORST SCHMIDT KLINIK O 60 HSK GMBH DE 61 IOR ISTITUTO ORTOPEDICO RIZZOLI - IRCCS IT O AZIENDA OSPEDALIERO UNIVERSITARIA O 62 AOUP PISANA IT AZIENDA OSPEDALIERA UNIVERSITARIA O 63 AOUS SENESE IT ACADEMISCH ZIEKENHUIS LEIDEN / O 64 LUMC LEIDEN UNIVERSITY MEDICAL CENTER NL 65 RUMC STICHTING KATHOLIEKE UNIVERSITEIT NL O ACADEMISCH MEDISCH CENTRUM BIJ DE O 66 AMC UNIVERSITEIT VAN AMSTERDAM NL ERASMUS UNIVERSITAIR MEDISCH O 67 Erasmus MC CENTRUM ROTTERDAM NL 68 SERMAS SERVICIO MADRILEÑO DE SALUD ES O THE NEWCASTLE UPON TYNE HOSPITALS O 69 NUTH NHS FOUNDATION TRUST UK 70 GOSH GREAT ORMOND STREET HOSPITAL UK O EUROPEAN ORGANISATION FOR O 71 EORTC RESEARCH AND TREATMENT OF CANCER EU org EU O 72 INFRAFRONTIER INFRAFRONTIER GMBH Infra 73 BBMRI BBMRI-ERIC EU Infra O EUROPEAN CLINICAL RESEARCH O 74 ECRIN/PedCRIN INFRASTRUCTURE NETWORK EU Infra 75 EATRIS EATRIS-ERIC EU Infra O EUROPEAN MOLECULAR O 76 BIOLOGYLABORATORY (FORELIXIR ELIXIR ANDEMBL-EBI) EU Infra 77 EURORDIS EURORDIS-RARE DISEASES EUROPE EU org O CHIEF SCIENTIST OFFICE - MINISTRY OF PO & PM 78 CSO/MoH HEALTH IL 79 SNSF SWISS NATIONAL SCIENCE FOUNDATION CH PO & PM 80 BLACKSWAN BLACKSWAN CH O TÜBITAK TURKIYE BILIMSEL VE PO & PM 81 TUBITAK TEKNOLOJIK ARASTIRMA KURUMU TK 82 ACU/ACURARE ACIBADEM UNIVERSITY TK O HUGEN O 83 (HACETTEPE) HACETTEPE UNIVERSITY TK CANADIAN INSTITUTES OF HEALTH PO & PM 84 CIHR RESEARCH CA FONDS DE RECHERCHE DU QUEBEC - PO & PM 85 FRQS SANTE CA 86 IT INSERM TRANSFERT FR O 87 GSRT GENERAL SECRETARIAT OF RESEARCH GR PO & PM 825575 – EJP RD – Part B 47 AND TECHNOLOGY Associated with document Ref. Ares(2018)6091977 - 28/11/2018 DEUTSCHE PO & PM 88 DFG FORSCHUNGSGEMEINSCHAFT DE 01-INSERM (a) INSERM-ITGGB (Institut Thématique Génétique, Génomique et Bioinformatique) Full legal name (Acronym) – Country Institut National de la Santé et de la Recherche Médicale (INSERM) Principal investigator Catherine Nguyen Relevant Network INSERM is the only public research organization in France entirely dedicated to human health. Its objective is to promote the health of all by advancing knowledge about life and disease, treatment innovation, and public health research. Inserm brings together 15,000 researchers, engineers, technicians, and administrative staff around one common goal: to improve the health of all by advancing knowledge of life and disease, innovation in treatment, and public health research. Since its foundation in 1964, Inserm has played a part in many key medical advances, including the first prenatal diagnostic tests, understanding of the HLA system, the first in vitro fertilization, identification of the AIDS virus, radiotherapy for cancer, the first skin graft, deep brain stimulation, and gene therapy. Inserm is the leading European academic biomedical research institution, and with nearly 12,000 publications a year; is second in the world only to the National Institutes of Health (NIH). According to the 2016 ranking by Thomson-Reuters, Inserm is also the world’s 9th most innovative public research organization. Inserm plays a crucial role in the structure of the European Research Area and its international position is strengthened by close collaborations (teams abroad and associated international laboratories). In 2015, the Institute had 22 associated international laboratories at its disposal, 9 mixed international units set up abroad and around thirty international cooperation agreements. With involvement in more than 400 European projects financed by the European Commission within the 7th Research and Development Framework Programme, Inserm has been confirmed as one of the principal European players in the area of research into life sciences and health. Inserm has also been one of the foremost European research institutions in terms of IMI (Innovative Medicines Initiative) financing of public/private research partnerships with a strong presence in the European Research Council. Its mission is supported by the work of 9 theme-based institutes, whose role is to monitor progress and take a lead on research in their respective fields. The Institute of Genetics, Genomics and Bioinformatics (IT GGB) covers genetics and genomics in all living organisms, from viruses, micro-organisms and plants to humans. Scientific projects are focused on organization, evolution, genome variability, gene expression regulation, population genetics as well as genetic and epigenetic determinism of diseases and treatments of genetic diseases. The Institute coordinates discussions and research in the following fields: • Bioinformatics, setup of intermediate platforms to existing national centers relying on mass sequencing platforms, • Genomic diversity, rare diseases, population genomics, metagenomics, evolution, • Molecular genetics, genetic regulation: from transcriptomics to epigenetics, • Genome dynamics, transposable elements, mutations, • Quantitative genetics, multifactorial diseases, rare diseases, complex traits. This Institute liaises with thematic institutes for cross-disciplinary purposes, but particularly with the Cell biology, development and evolution, Molecular and structural bases of living organisms and Cancer. Main tasks in the project per Pillar/WP: Coordination and transversal activities: WP1: Inserm-ITGGB will be responsible for the overall coordination, management and strategy of the EJP RD. It will establish a coordination office composed of: coordinator (Daria Julkowska, PhD), four project managers, communication manager, financial officer and assistant. It will be responsible for the coordination and support within and across all pillars and transversal work packages. Inserm-ITGGB will be also in charge of the Scientific Secretariat of IRDiRC. WP2: Inserm-ITGGB will be involved in Task 2.2 and 2.4 where it contribute to the mapping of research and innovation needs and establishment of short, medium and long-term research and innovation strategy. Inserm-ITGGB will also ensure interaction and common strategy with IRDiRC by organization of joint Task Forces. 825575 – EJP RD – Part B 48 WP3: Inserm-ITGGB will participate in Task 3.1 and focus on alignment of needs, Associated with expectations document and engagement Ref. Ares(2018)6091977 - 28/11/2018 of different RD stakeholders in Europe with respect to EJP RD sustainability. WP4: Inserm-ITGGB will support the Advisory Regulatory Ethics Board in management of ethical and regulatory issues of the EJP RD. WP5: Inserm-ITGGB will be leading this work package dedicated to communication and dissemination of EJP RD. It will be in charge of the implementation of communication and dissemination strategy as set in the Annex 1. It will develop and provide various communication tools in line with the needs of EJP RD partners. It will liaise and strengthen the integration of EJP RD communication and dissemination strategy with the strategies of involved stakeholders at national and international level. Finally, Inserm-ITGGB will support IRDiRC in its communication and dissemination activities as agreed within the responsibilities of IRDiRC Scientific Secretariat. Previous experience relevant to the Tasks: Inserm-ITGGB is strongly involved in the coordination of national strategic vision and actions of different stakeholders in the field of genetics, genomics and bioinformatics. It represents INSERM in actions related to rare diseases and accompanies the 3rd National Plan for Rare Diseases. It is strongly involved in the implementation of National Plan of Genomic Medicine through the reorganization of French Institute of Bioinformatics to meet specific needs of institutions and organizations involved in biology and health research. It is responsible for animation of scientific community and organization of dedicated events like annual bioinformatics school, advance epigenetics conference or rare diseases and personalized medicine meetings. Short Profile of key Staff Members who will be undertaking the work Dr. Daria Dr. Daria Julkowska has over 15 years of experience in research and management. She is Julkowska responsible for the management of several European and international funding programmes. (Female) Among others, since 2010 she is involved in E-Rare, the ERA-Net for Research programmes on rare diseases, where for the first two years she occupied the position of the project manager to finally (April 2013) take over the coordination of the programme. As the coordinator she developed and put into action a set of collaborations facilitating rare diseases research, including the partnerships with European Research Infrastructures and Patients’ Organizations. She has an extensive knowledge and understanding of European funding schemes and programmes. Since February 2017 she serves as the chair of the Funders Constituent Committee of IRDiRC. Of Polish origin, Dr. Julkowska obtained her international PhD in molecular biology at the University of Paris XI, France and University of Gdansk, Poland in 2005. She pursued her scientific vocation by the post-doctoral experience in cellular biology, at Institut Pasteur, Paris and extensive training in communication and European Union counselling. She also holds MSc in Management of Research from the University of Paris Dauphine (FR). D.Julkowska was also responsible for coordination and preparation of the EJP RD proposal and will be the coordinator of the EJP RD. Dr. Catherine Nguyen Dr.Catherine Nguyen is the director of the INSERM Genomic, Genetic and Bioinformatic (Female) Thematic Institute. She has extensive training in genetics and functional genomics. Between 2002 and 2018 she was leading the Inserm TAGC Transcriptome laboratory in Marseille, France. Her unit dedicated to functional genomics studies (TAGC laboratory) with a transcriptome facility at the Luminy campus, which is nationally recognized as a platform for functional genomics studies within different research organizations in France, focused on bioinformatics analysis of data collected from DNA microarrays and other (bio)informatics fields. Domains of expertise or consultancy: Genomic, transcriptome, immunology and cancer research, DNA chips, splicing, molecular biology. Member (vice chairwoman) authorities of valuation of INSERM (ICSS3 then CT2), of the commission of reflection STIC-INSERM, of the committee of piloting of transcriptome of Marseilles Génopole, of jury of INSERM,-CNRS engineers recruitment. Member of the Committee of Strategic Organization AGENAE INRA. Member of the CHSHS PACA, INSERM. Expert for the authorities of evaluation for the Ministry of research and New Technologies (MRNT), employment and solidarity (PHRC), CNRS (Action DNA chips), Genopoles, the National Association of Technical Research (ANRT), National Network Technologies and Health (RNTS), of IMTSSA Tropical Institute of Medicine dependent of the army office, the French society against myopathies (AFM), the national Research fund (FNR) of Luxembourg, of the French-Indian centre for the promotion of advanced Research (CEFRIPRA), System of Research 825575 – EJP RD – Part B 49 Grants Council, (CERG) Hong Kong), of the Mission ofwith Associated expertise documentfor Ref.the Ministry for French- Ares(2018)6091977 - 28/11/2018 Korean Research, Edition in Immunology of the Medical Research Council, MRC, UK, of ANR (INCA, PNANO), FRM (bioinfo). Member of HUGO (Human Genome Organisation) since 1995, member of SFI (French Society of Immunology) since 1997, coordinator ESF network on technologies for functional genomics, member of scientific comity of the Forum 2000- 2006 (Industrial meeting organization). Patents: 1-N°US 10-007 926 (sight entry): gene expression profiling of primary breast carcinomas using arrays of candidates genes. International Extension PCT/IB01/02811. 2- European Number.EP: 02290949.9 « gene expression profiling of blood tumors using polynucleotides arrays. Grants: since 1999, 35 grants from fundations (ARC, LNCC, AFM, ANRS), from MNRT, from the industry (GALDERMA, IPSOGEN, GENSODI,) and 3 european grant (5th- 7th PCRD); Student training: >30 courses in a frame of National and InterNational university (Pasteur Institut, Paris, Faculty of Sciences St Jérôme, Marseille; ESIL GBMA Marseille, Welcome trust summer schools, UK; European School of Haematology (ESH) Dublin, Irland; University of St Joseph, Lebanon, USTH Vietnam .45 master, 24 PhD student supervision. Publications: 102 research articles in international journals, 31 reviews and 6 book chapters. 43 invited lecturer; more than 100 oral communications in national & international meeting, up to 120 communications in national and international conferences. Personnel to INSERM will recruit four project managers; communication officer, financial officer and assistant be recruited to support the coordinator in management and coordination responsibilities under EJP RD. List of the most relevant publications and/or products, services (including widely-used datasets or software), or other achievements 1. Analysis of ERA-NET Cofund actions under Horizon 2020. Final report of the expert group. Niels Gøtke (Chairperson), Effie Amanatidou (Rapporteur), Ioana Ispas, Daria Julkowska, Joaquín Serrano. Directorate- General for Research and Innovation. Publications Office of the European Union, 2016. 2. Future of Rare Diseases Research 2017-2027: An IRDiRC Perspective. Austin CP, Cutillo CM, Lau LPL, Jonker AH, Rath A, Julkowska D, Thomson D, Terry SF, de Montleau B, Ardigò D, Hivert V, Boycott KM, Baynam G, Kaufmann P, Taruscio D, Lochmüller H, Suematsu M, Incerti C, Draghia-Akli R, Norstedt I, Wang L, Dawkins HJS; International Rare Diseases Research Consortium (IRDiRC). ; Clin Transl Sci. 2018 Jan;11(1):21- 27. 3. The importance of international collaboration for rare diseases research: a European perspective. Julkowska D, Austin CP, Cutillo CM, Gancberg D, Hager C, Halftermeyer J, Jonker AH, Lau LPL, Norstedt I, Rath A, Schuster R, Simelyte E, van Weely S. ; Gene Ther. 2017 Sep;24(9):562-571. 4. Improved Diagnosis and Care for Rare Diseases through Implementation of Precision Public Health Framework. Baynam G, Bowman F, Lister K, Walker CE, Pachter N, Goldblatt J, Boycott KM, Gahl WA, Kosaki K, Adachi T, Ishii K, Mahede T, McKenzie F, Townshend S, Slee J, Kiraly-Borri C, Vasudevan A, Hawkins A, Broley S, Schofield L, Verhoef H, Groza T, Zankl A, Robinson PN, Haendel M, Brudno M, Mattick JS, Dinger ME, Roscioli T, Cowley MJ, Olry A, Hanauer M, Alkuraya FS, Taruscio D, Posada de la Paz M, Lochmüller H, Bushby K, Thompson R, Hedley V, Lasko P, Mina K, Beilby J, Tifft C, Davis M, Laing NG, Julkowska D, Le Cam Y, Terry SF, Kaufmann P, Eerola I, Norstedt I, Rath A, Suematsu M, Groft SC, Austin CP, Draghia-Akli R, Weeramanthri TS, Molster C, Dawkins HJS. ; Adv Exp Med Biol. 2017;1031:55-94. List of relevant previous projects or activities, connected to the subject of this proposal E-Rare-1 (2007 – 2011), GA036248 E-Rare-2 (2011 – 2014), GA266608 01-INSERM (b) INSERM-US14 Full legal name (Acronym) – Country Institut National de la Santé et de la Recherche Médicale (INSERM), France Principal investigator Ana Rath Relevant Network Orphanet Network Description of the legal entity/department/laboratory/group: The INSERM-US14 houses Orphanet, the knowledge base of rare diseases and orphan drugs. Its goal is to 825575 – EJP RD – Part B 50 contribute to improve the diagnosis, management and treatmentAssociated of rare with diseases. For document Ref.these purposes, the Ares(2018)6091977 unit - 28/11/2018 produces, compiles and conveys information as well as scientific and medical data with added value, complete, validated and updated for researchers, clinicians, the general public and all the actors in the field of rare diseases (researchers, patients, industrialists, decision-makers, professionals in the medico-social sector). INSERM-US14 has been acting as coordinator of the Orphanet network (41 countries in 2018) since the beginning of the European projects in 2001. The INSERM-US14 also acted as coordinator of the Joint Action on RD (RD- ACTION) 2015-2018 and of the HIPBI-RD project. He currently coordinates SUPPORT-IRDiRC (2012-2018) and has acted as the coordinator of the Rare Diseases Task Force (2004-2009) and the European Union Committee of Experts on Rare Diseases (EUCERD)(2010-2013). Main tasks in the project per Pillar/WP: Pillar 2: Dr. Ana Rath will act as Pillar 2 co-leader. WP10: Inserm-Orphanet will co-lead the WP and lead the Task 10.1 Convene yearly retreats leading to Pillar 2 annual strategic plans (in particular being co-responsible for subtask 10.1.2 Annual strategic plan for Pillar 2) WP11: Inserm-Orphanet will co-lead the WP and lead Task 11.2: FAIR-compliant virtual platform for discovery of RD resources (in particular subtasks 11.2.1 and 11.2.2). Orphanet TLP will contribute to subtasks 11.2.1 Collaboratively assemble and curate metadata into the Orphanet catalog, on an ongoing basis, to represent all key databases and resources and 11.2.2. Create a catalog of research projects and clinical trials, on an ongoing basis, to inform funders (IRDiRC Roadmap priority) WP12: Orphanet will contribute to subtasks related to the generation and maintenance of semantic standards and metadata (subtasks 12.1.1, 12.1.5., 12.2.1., 12.3.1.) Pillar 3: WP 14: Training on data management and quality. Inserm-Orphanet will lead the Task 14.1: Developement of a novel training modules for clinicians and scientists involved in various rare disease research fields. After some adaptation to country-specific needs, the Orphanet Network teams will organise trainings in their countries in their national language. Orphanet will contribute also to the Task 14.6. Training on the European RD Registry Infrastructure (ERDRI) and to the Task 14.2 Developing the online course in WP3: Online academic education course Coordination and transversal activities Inserm-Orphanet will contribute to subtasks in the WP1 Coordination and Management, as Pillar 2 co-leader and as Coordinator of the pan-European Orphanet network. Inserm-Orphanet will co-lead the Task 2.1: Mapping and prioritizing the needs in the WP2: Integrative research strategy. Inserm-Orphanet will lead and Orphanet TLP will contribute to the Task 5.2: Integrating EJP RD communiation and dissemination strategies with the strategies of involved stakeholders in the WP5: Communication & dissemination. Previous experience relevant to the Tasks: Orphanet produces the standard nomenclature, classification and ontology for rare diseases including genomic and phenomic data, is a IRDiRC recognized resource and is also recognized as a Human Variome Project recommended system. Orphanet maintains a database of RD-specific expert resources since 1997 by the collection, manual curation and quality control of expert centres (including ERNs), diagnostic tests, patient organisations, infrastructures, registries and databases and RD research projects and clinical trials and orphan drugs in 35 countries of the 41 countries in the Orphanet network. Orphanet has maintained, and contributes to maintain in the frame of RD-Action, the State of the Art of activities related on RD, based on the work of national Orphanet hubs covering all EU countries. Orphanet coordinates RD-Action, the DG Santé Joint action for RD, dealing with data and policies, including codification of RD in health information systems. Description of any significant infrastructure and/or major items of technical equipment, relevant to the proposed work : Orphanet database owned by Inserm, with its access services and formats : www.orpha.net 825575 – EJP RD – Part B 51 www.orphadata.org (XML, JSON, OWL) Associated with document Ref. Ares(2018)6091977 - 28/11/2018 www.orpha.net/sparql/ SPARQL Endpoint ORDO http://bioportal.bioontology.org/ontologies/ORDO (OWL, CSV, RDF/XML) HOOM http://www.orphadata.org/cgi-bin/inc/hoom_orphanet.inc.php Orphanet is hosted at CINES (National Computing Center for Higher Education, a French public institution). The Orphanet IT infrastructure is managed both by US14 Inserm unit and by Inserm Department of Information System and has productions, pre-production and development servers organized in several Virtual Machines. Short Profile of key Staff Members who will be undertaking the work Dr. Ana Rath, Ana Rath is a medical doctor with a background in general surgery and a Masters degree in (Female) Philosophy. She oriented her career to medical information in 1997 and joined Orphanet (www.orpha.net) in 2005. She acts as managing editor of the Topic Advisory Group on rare diseases at the World Health Organization. She chairs the Orphanet rare diseases ontology (ORDO:http://bioportal.bioontology.org/ontologies/ORDO). Ana is the current Director of Orphanet and the coordinator of RD-ACTION, the EU Joint Action for rare diseases (2015-2018) and of the HIPBI-RD project. She chairs the Orphanet Rare Disease Ontology (ORDO). Marc Marc Hanauer is an engineer at INSERM and Chief Technology Officer at Orphanet since 2007 Hanauer, and Orphanet Deputy director since 2017. He is also in charge of managing Orphanet's innovation (Male) strategy. Previous to his current position, Marc worked for different internet start-ups from 2000 on-wards. He has an academic background in information and communication sciences." Sylvie Maiella Sylvie Maiella has a PhD in Human Immunology and has been trained to Transversal (Female) management. She oriented her career to scientific project management in 2010 and since 2011 she has been acting as Orphanet international coordinator and project manager of the previous Orphanet- Inserm coordinated Joint actions (OEJA 2011-2014 and RD-ACTION 2015-2018). List of the most relevant publications and/or products, services (including widely-used datasets or software), or other achievements 1. orphadata.org 2. ORDO (http://www.orphadata.org/cgi-bin/inc/ordo_orphanet.inc.php/) 3. Harmonising phenomics information for a better interoperability in the rare disease field. Maiella S, Olry A, Hanauer M, Lanneau V, Lourghi H, Donadille B, Rodwell C, Köhler S, Seelow D, Jupp S, Parkinson H, Groza T, Brudno M, Robinson PN, Rath A. Eur J Med Genet. 2018 Feb 7. pii: S1769- 7212(17)30506-2. doi: 10.1016/j.ejmg.2018.01.013. [Epub ahead of print] Review. PMID:29425702 4. Future of Rare Diseases Research 2017-2027: An IRDiRC Perspective. Austin CP, Cutillo CM, Lau LPL, Jonker AH, Rath A, et al; International Rare Diseases Research Consortium (IRDiRC). Clin Transl Sci. 2018 Jan;11(1):21-27. doi: 10.1111/cts.12500. Epub 2017 Oct 23. Review. PMID:28796445 5. International Cooperation to Enable the Diagnosis of All Rare Genetic Diseases. Boycott KM, Rath A, et al Am J Hum Genet. 2017 May 4;100(5):695-705. doi: 10.1016/j.ajhg.2017.04.003. List of relevant previous projects or activities, connected to the subject of this proposal Harmonising phenomics information for a better interoperability in the RD field (HIPBI-RD) 2016 – 2019, project financed by ERA-Net E-Rare-3. Promoting implementation of recommendations on policy, information and data for RD Joint action (RD- ACTION); 2015-2018 SUPPORT-IRDiRC; 2012 – 2018, FP7 GA N°: 305207 01-INSERM (c) INSERM-U993/RaDiCo Full legal name (Acronym) – Country Institut National de la Santé et de la Recherche Médicale (INSERM), France Principal investigator Serge Amselem Relevant Network Description of the legal entity/department/laboratory/group: The research unit UMR_S933 from INSERM “Pathophysiology of Paediatric Genetic Diseases”, led by Prof. Serge Amselem is subdivided into two distinct 825575 – EJP RD – Part B 52 components: the Genetic research group and the RaDiCo French national platform Associated on RD with document cohorts. Ref. Ares(2018)6091977 - 28/11/2018 The genetic research group of the UMRS 933 INSERM/UPMC is devoted to the study of the pathophysiology of several human Mendelian disorders, including auto-inflammatory disorders, primary ciliary dyskinesia, growth disorders of endocrine origin, and disorders of sex development & infertility. It has access to several cohorts of patients with these disorders, which are exceptional, both in their size and their phenotypic characterization. For each pathology investigated, the group develops on the top of the genetic profile (identification of new genetic factors involved the studied diseases), a functional profile with the design of disease-specific studies aimed at: developing disease-specific cell models, characterizing the molecular networks to which the proteins involved belong, evaluating, using different model systems, the consequences of the mutations identified in patients, and opening up new therapeutic avenues. The research conducted in this team leads to clinical implications with diagnostic, prognostic and therapeutic repercussions (translational research). The RaDiCo national platform on RD cohorts: RaDiCo (for Rare Disease Cohorts, see www.radico.fr) is a French platform and programme coordinated and administratively managed by the French Institute of Health and Medical Research (Inserm / UMR S 933). Its activities started in November 2013 and are funded within the scope of the ‘Investissements d’Avenir’ (Investments for the Future) programme implemented by the MESR (French Ministry for Higher Education and Research), the Agence Nationale pour la Recherche (ANR, the French National Research Agency). The aim of RaDiCo is to bring in-kind services and large spectrum of expertise to the RD community in France and in Europe to optimizing the design and implementation of high quality multicentric RD cohorts with clearly defined scientific objectives: describing natural history of RDs, establishing genotype- phenotype correlations, assessing the impact of environmental factors, elucidating their physiopathology, identifying new therapeutic approaches and diagnostic / prognostic / theranostic biomarkers, or assessing their medical, economical and societal impacts. To date, RaDiCo is involved in sixteen RD cohort studies, all selected following a national call for proposals by independent experts. Two of them (RaDiCo-ECYSCO and RaDiCo- EURBIO Alport) are already of European. One original cohort (RaDiCo-GenIDA) proposes to the patient community an international social network for data collection on the natural history of rare monogenic forms of intellectual disabilities. Several Public-Private Partnerships with big pharma industries have already been initiated for the use of certain cohort resources through Specific Research Projects. To summarise, the major activities performed by the RaDiCo team are the following: eHealth Ø Interoperability with pre-existing local databases and information sources, FAIRification Ø Webservices and e-form building (eCRF, questionnaires) Ø Integration of data from mobile-health and connected devices Ø Secure-by-design, GDPR-compliant electronic infrastructure / IS resource orchestration and maintenance Transversal affairs Ø Training courses on regulatory, ethical and standardization issues Ø Preparation of legal documents Ø Intellectual property and data access management Ø Communication Ø Public-private partnerships agreements Ø Dissemination and exploitation plans / cohort resource access management (data and bio-collections) Ø European and international collaborations Ø Cohort infrastructure as a service: sustainability solutions Research Ø Cohort longitudinal study design and methodology Ø Design of the case report forms and patient questionnaires Ø Preparation of the regulatory dossiers Ø Real time data monitoring and management Ø Biostatistical expertise and scientific valorisation of the data/knowledge Main tasks in the project per Pillar/WP: Coordination and transversal activities: WP3: Co-leader of WP3 “Sustainability strategy and business plan”, leader of Task 3.1, joint development of a dynamic catalogue of EJP-RD sustainable resources including Service Roadmap Database and Study cases of innovative sustainability solutions for specific EJP RD outcomes 825575 – EJP RD – Part B 53 WP4: Participant in WP4 “Ethical, regulatory, legal and IPR framework Associatedof the with EJP RD” document Ref. (expertise in ethical Ares(2018)6091977 and - 28/11/2018 regulatory issues in the MS related to RD patient databases, secure by design information systems and GDPR obligations in Europe, expertise in IPR issues and collaborative contractual frameworks (eg Consortium Agreement, Public-Private contracts, involving use and exploitation of data). Pillar 2: WP10: “User-driven strategic planning and transversal activities for Pillar 2 data ecosystem”: Participant in Task 10.3: Coordination of technical GDPR implementation (expert), Task 10.4: Quality oversight (expert), Task 10.5: Sustainability and scaling up (to coordinate with WP3 activities). WP11: “Common virtual platform for discoverable data and resources for RD research”: Participant in notably Task 11.3: Data deposition and access to data infrastructures for RD research (concerning patient cohort data), Task 11.4: Provision of RD analysis and data sharing capabilities through online resources. WP12: “Enabling sustainable FAIRness and Federation at the record level for RD data, patients and samples”: Participant in notably in Task 12.1: Compare and align core interoperability standards of relevance and Task 12.3: Combining expertise for practical FAIRification: experience and PoCs based on RaDiCo cohorts’ databases. Pillar 3: WP14: “Training on data management & quality”: in Task 14.5: Training on rare disease registries and FAIRification of data at the source: trainer in data management and data quality best practices and approaches, next generation registries and database governance models, integration of IoTs, valorisation and exploitation activities. Pillar 4: Involvement in WP20 “Accelerating the validation, use and development of innovative methodologies tailored for clinical trials in RDs” due to strong expertise in clinical trial and study design and implementation at European level within transnational RD patient cohorts. Previous experience relevant to the Tasks: RaDiCo team: 16 fully dedicated employees act within 3 different sub-units: Clinical research, e-Health and Information System. They are bringing complementary expertise and tools since 2014 enabling RD cohorts’ design and implementation. 16 RD cohorts were conceived and are currently managed by the RaDiCo platform at national and European levels, covering more than 40 different rare diseases. The team composition, expertise and organisation has been continuously adapted to cope with the evolution of RaDiCo activities for the supported cohorts. Description of any significant infrastructure and/or major items of technical equipment, relevant to the proposed work : The Inserm-RaDiCo platform has selected the free, secured, web-based, and user-friendly electronic data capture (EDC) tool REDCap as its clinical research software suite for electronic data capture and management. All information systems proposed by RaDiCo run in a virtual, redundant and supervised, GDPR- compliant architecture in a certified health data hosting and facilities management centre (HADS in French) in the framework of a service contract with the Inserm. Security audits are performed each year. The equipment is dedicated and isolated. The required operating system is LINUX long term support, Apache, the MySQL database engine and the PhP application scripting language, i.e. the LAMP suite. Short Profile of key Staff Members who will be undertaking the work Prof. Serge Prof. Serge Amselem (Male) - MD (paediatrician), PhD, Professor of human genetics at Université Amselem Pierre et Marie Curie (UPMC) in Paris (France) and director of the U933 Inserm research unit (Male) (UMR_S933 INSERM/UPMC) dedicated to the study of the pathophysiology of several Mendelian disorders. He is the scientific coordinator of the RaDiCo program ~ 150 papers in peer-reviewed journals (first / corresponding author in several international journals, including Nat Genet, New Engl J Med, Am J Hum Genet, J Clin Invest, PNAS, EMBO J, PLoS Genet, Hum Mol Genet). Prof. Paul Landais (Male) - Professor of Public Health, Clinical Epidemiologist and Nephrologist Prof. Paul (MD). Director of the UPRES EA2415 Research Unit, Clinical Research Institute, Montpellier Landais University. Founded the French Renal Epidemiology and Information Network (REIN), the (Male) SCETIDE program with Pr A. Fischer, the CEMARA platform for rare diseases (RD) & past- coordinator of the French national Rare Diseases Data Bank (BNDMR). Co-Coordinator of the national RaDiCo program for RD cohorts. Founder of the Institute for clinical evaluation of medical devices (IDIL). Prof. Prof. Annick Clement (Female) – MD (paediatrician) PhD, Professor of pediatricsSorbonne Annick Université, Paris, France. Director of the pediatric pulmonary department of the Eastern university Clement hospital of Paris. Coordinator of the national reference centre for rare respiratory diseases. Coordinator of the national nework for rare lung diseases. Team leader of national and international 825575 – EJP RD – Part B 54 research programs in the field of rare lung diseases. Co-Coordinator Associated with document Ref.ofAres(2018)6091977 the national RaDiCo - 28/11/2018 program for RD cohorts. Dr. Sonia Dr. Sonia Gueguen (Female) - Science & Operations Director of the RaDiCo platform at the Gueguen French National Institute of Health and Medical Research (Inserm). PhD degree in Epidemiology (Female) and Public Health from Faculté de Pharmacie, Nancy I University. Fifteen years of experience in clinical research. Deputy Director of Clinical Research Department of the French National Institute of Health and Medical Research (Inserm) which had 146 ongoing projects with 5 % of international or European studies over the past five years (2012-2018). Dr. Laure Dr. Laure Jamot (Female) Head of RaDiCo’s Clinical Research Department. PhD degree in neuro- Jamot genetics from Paris V René Descartes University in Paris. After 5 years of basic research on rare (Female) neurodegenerative diseases (Mount Sinaï hospital, Toronto Canada), moved to the Trophos biotechnology company in 2001, in Marseille to set up the R&D programme on Huntington’s disease. In 2008, joined the Alfact Innovation company, based in Paris, as head of pre-clinical and clinical research programmes. Backed by her team of clinical research project and data-managers, biostatistician and methodologist, she now takes advantage of her 13 year experience in the private sector for dealing with all aspects of translational and clinical research for the benefit of the RaDiCo programme and its cohorts. List of the most relevant publications - Olcese C*, Patel MP*, Shoemark A*, Kiviluoto S*, Legendre M*, Hayward J, Goldenberg A, Emes RD, … Armengot M, Escudier E,Hogg C; UK10K Rare Group., Amselem S*, Sun Z*, Bartoloni L*, Blouin JL*, Mitchison HM* X-linked primary ciliary dyskinesia due to mutations in the cytoplasmic axonemal dynein assembly factor PIH1D3. Nat Commun. 2017 Feb 8;8:14279. (*co-first and co-last authors) - El Khouri E, Lucie L, Jeanson L, Bequignon E, Vallette V, Duquesnoy P, Montantin G, Copin B, Dastot-Le Moal F, Blanchon S, Papon JF, Lorès P, Yuan L, Collot N, Tissier S, Faucon C, Gacon G, Patrat C, Wolf JP, Dulioust E, Crestani B, Escudier E, Coste A, Legendre M, Touré A, Amselem S. Mutations in DNAJB13, which encodes an HSP40 family member, cause primary ciliary dyskinesia and male infertility Am J Hum Genet. 2016 Aug 4;99(2):489-500 - Jeanson L, Copin B, Papon JF, Dastot-Le Moal F, et al., Clement A, Escudier E, Amselem S (corresp author), Legendre M. RSPH3 mutations cause primary ciliary dyskinesia with a near absence of radial spokes and central complex defects. Am J Hum Genet. 2015 Jul 2;97(1):153-62. - Kott E, Legendre M, Copin B, Papon JF, Dastot-Le Moal F, et al., Clement A, Housset B, Louis B, Escudier E, Amselem S. Loss-of-function mutations in RSPH1 cause primary ciliary dyskinesia with central-complex and radial-spoke defects. Am J Hum Genet. 2013 Sep 5;93(3):561-70. - Grateau G, Hentgen V, Stojanovic KS, Jéru I, Amselem S, Steichen O. How should we approach classification of autoinflammatory diseases? Nat Rev Rheumatol. 2013 Oct;9(10):624-9. - Kott E, Duquesnoy P., Copin B, Dastot-Le Moal F, Montantin G, Jeanson L, Tamamlet A, Papon JF, Rives N, Mitchell V, de Blic J, Coste A, Clement A, Escalier D, Touré A, Escudier E, Amselem S. Loss-of-function mutations in LRRC6, a gene essential for proper axonemal assembly of inner and outer dynein arms, cause primary ciliary dyskinesia. Am J Hum Genet. 2012, 91(5):958-64. - Merveille A.C., Davis E.E., Becker-Heck A., Legendre M., et al., Georges M., Lequarré A.S., Katsanis N., Omran H., Amselem S. CCDC39 is required for assembly of inner dynein arms and the dynein regulatory complex and for normal ciliary motility in humans and dogs. Nat Genet., 2011, 43(1):72-79. - Transplantation of hematopoietic stem cells and long-term survival for primary immunodeficiencies in Europe: entering a new century, do we do better? Gennery AR, Slatter MA, Grandin L, Taupin P, Cant AJ, et al., Neven B, Blanche S, Fischer A, Cavazzana-Calvo M, Landais P. Inborn Errors Working Party of the European Group for Blood and Marrow Transplantation; European Society for Immunodeficiency. J Allergy Clin Immunol. 2010 Sep;126(3):602-10.e1-11. - Straathof KC, Rao K, Eyrich M, Hale G, Bird P, Berrie E, Brown L, Adams S, Schlegel PG, Goulden N, Gaspar HB, Gennery AR, Landais P, Davies EG, Brenner MK, Veys PA, Amrolia PJ. Haemopoietic stem-cell transplantation with antibody-based minimal-intensity conditioning: a phase 1/2 study. Lancet. 2009 Sep 12;374(9693):912-20. - Antoine C, Müller S, Cant A, Cavazzana-Calvo M, Veys P, .. , Bredius R, Schulz A, Landais P, Fischer A; European Group for Blood and Marrow Transplantation; European Society for Immunodeficiency. Long-term survival and transplantation of haemopoietic stem cells for immunodeficiencies: report of the European experience 1968-99. Lancet. 2003 Feb 15;361(9357):553-60. - Choquet R, Maaroufi M, de Carrara A, Messiaen C, Luigi E, Landais P. A methodology for a minimum data set for rare diseases to support national centers of excellence for healthcare and research. J Am Med Inform Assoc. 2015 Jan;22(1):76-85. 825575 – EJP RD – Part B 55 - Kodra Y, Posada de la Paz M, Coi A, Santoro M, Bianchi F, Ahmed F, Rubinstein Associated YR, with document Weinbach Ref. J, Taruscio Ares(2018)6091977 D. - 28/11/2018 Data Quality in Rare Diseases Registries. Adv Exp Med Biol. 2017;1031:149-164. - Kodra Y, Weinbach J, Posada-de-la-Paz M, Bros-Facer V, .., Landais P, .., Reis R, Rubinstein YR, Ambrosini A and Taruscio D. Recommendations for Improving Quality of Rare Disease Registries. Int J Environ Res Public Health. 2018 Aug 3;15(8). pii: E1644. - Taruscio D, Vittozzi L, Choquet R, Heimdal K, Iskrov G, Kodra Y, Landais P, Posada M, Stefanov R, Steinmueller C, Swinnen E, Van Oyen H. National registries of rare diseases in Europe: an overview of the current situation and experiences. Public Health Genomics. 2015;18(1):20-5. List of relevant previous projects or activities, connected to the subject of this proposal MINDDS – a pan- European network for Neurodevelopmental Disorder research - supported as a European COST Action. COST (European Cooperation in Science and Technology) – 26 countries participating. RaDiCo represents France in this project. 01-INSERM (d) INSERM-AMU (LTP) Full legal name (Acronym) – Country Institut National de la Santé et de la Recherche Médicale (INSERM), France Principal investigator Christophe Béroud Relevant Network RD-Connect, IRDiRC, ELIXIR Description of the legal entity/department/laboratory/group: The “Marseille Medical Genetics” (MMG, JRU 1251) is a JRU between INSERM and AMU, headed by Pr. Nicolas Levy, with employees from INSERM, AMU and CNRS. The main areas of research investigated by MMG teams are the genetic and cellular mechanisms involved in rare genetic disorders, and exploration of the phenotypic consequences of these mutations. Our research Center is part of the Timone campus that comprises fundamental research laboratories at the School of Medicine and the Children's Hospital in Marseille – la Timone. Research activities led by the different teams are closely connected to clinical research conducted in the Department of Medical Genetics. MMG occupies 2150 m2 of research space that was designed specifically for its mission. MMG gathers in a fully equipped space over 150 people shared out among 8 research teams. AMU manages this JRU, as confirmed by the INSERM and AMU framework agreement. AMU is thus Linked third Party of INSERM to handle this project Main tasks in the project per Pillar/WP: Pillar 2: WP11: AMU will contribute to the WP: Common virtual platform for discoverable data and resources for RD research (in particular subtasks 11.3 and 11.4). The "Genetics and Bioinformatics" Team (led by Prof. Christophe Béroud) has a strong expertise in the Rare Disease management of data and resources and is a key partner of the RD-Connect platform that will be central for the EJP platform. All team members (Dr. David Salgado, Dr. Gwenaëlle Collod-Béroud, Jean-Pierre Desvignes, Marc Garibal and Céline Guien as well as a new Research Engineer specifically hired for the EJP-RD, will be involved in this WP as well as WP12, 13, 14 and 16). WP12: AMU will contribute to the WP: Enabling sustainable FAIRness and Federation at the record level for RD data, patients and samples (in particular subtasks 12.2 and 12.3). Inserm-AMU has a strong expertise in software and tool developments for the analysis of genomics and other types of -omics data, and various groups may contribute to this WP. The team led by Prof. C. Béroud has an international recognized expertize in the development of NGS pipelines and tools, expertise in RNA-seq and CHIP-seq analyses, NGS data management and analysis, in Locus Specific Databases (GEN2PHEN, TREAT-NMD, NMD-CHIP). Overall, Inserm-AMU will participate to the demonstration that the application of the FAIR principles to various existing resources developed and hosted at AMU, as the TREAT-NMD global registries, is feasible in practice. WP13: AMU will contribute to the WP: Enabling multidisciplinary, holistic approaches for rare disease diagnostics and therapeutics. The MMG Network and Systems Biology group (NSBD, led by Dr. Anaïs Baudot (see Partner CNRS), a member of Nicolas Lévy's group, has a strong expertize in modeling, mining and integration of multi-omics data in the disease contexts. Two post-doctoral fellows from AMU of the group (Pooya Zakeri and post-doc to be recruited in January 2019) will be involved. The group collaborates closely with the MABIOS team led by Dr. Elisabeth Remy (see Partner CNRS), from the Marseille Mathematic Institute, composed of mathematicians and computer scientists, to develop algorithms to study biological networks. The MABIOS team includes two AMU associate researchers (Laurent Tichit and Brigitte Mossé) as well as an AMU post-doctoral fellow (Léo Pio-Lopez) who will be implicated in the project. 825575 – EJP RD – Part B 56 Associated with document Ref. Ares(2018)6091977 - 28/11/2018 Pillar 3: AMU, the largest worldwide French speaking University, has all requirements to become a partner in training workpackages. WP 14: Training on data management & quality. Inserm-AMU will contribute to the "Training on-omics" thanks to C. Béroud team, which has long experience in international training sessions (3Gb-test, VEP, ELIXIR, RD-Connect, TREAT-NMD, HGVS …). Inserm-AMU will also contribute to the training on undiagnosed once again thanks to "Genetics and Bioinformatics" Team's long experience on this topic. They regularly give international conferences on mutations and their effects on splicing signals. They are also leading the ELIXIR Human-CNV community that is also highly relevant for this task. Moreover, the A Baudot's group, expert in systems biology, is specifically dealing with undiagnosed and multi-omics data analysis. WP16: Online Academic education course. The MMG unit hosts various key teachers involved in general trainings on rare diseases, bioinformatics, databases and registries (DIU "rare diseases", Master 2 "Human pathologies"). Thanks to this recognized expertise, the MMG will be responsible for the "Bioinformatics" part of the "Developing the online course". Previous experience relevant to the Tasks: C. Béroud's team is leading the European RD-Connect WP dedicated to "Clinical Bioinformatics"; international "TREAT-NMD global registries"; national databases BANCCO and RDVD dedicated to the collection of NGS mutations; and various national and international patients' registries and mutations databases. In the context of NGS data analysis, the team developed multiple reference systems including (UMD-Predictor, Human Splicing Finder and VarAFT); Internationally recognized Locus Specific Database (LSDB) for various genes. The team has been involved in multiple international projects such as TREAT-NMD, GEN2PHEN, NMD-CHIP, RD-Connect. Complementarily, the NSBD group develops tools and approaches with strong theoretical bases and apply them to biological questions related to human diseases. It will bring its expertise in networks and systems biology that will address complementary aspects of the project. Description of any significant infrastructure and/or major items of technical equipment, relevant to the proposed work : C. Beroud team: Leading Elixir human CNV Community, Elixir French node/IFB (French bioinformatics institute) platform, Share memory supercomputer (SGI UV 2000, 256 cores, 1Tb RAM), its HPC cluster node (3 x 64Gb RAM, 16 cores nodes) as well as its storage capacity (∼1Pb). Short Profile of key Staff Members who will be undertaking the work Prof. C. Béroud has over 20 years of experience in research laboratories. He is a Pharmacist, geneticist, Christophe bioinformatician, and professor of Human Genetics at the AMU. He leads the Genetics and Béroud, Bioinformatics" research team at INSERM U1251, which is labeled "Platform of the French (Male) Bioinformatics Institute" and a French node of ELIXIR. His team has become an internationally recognized center for the creation and management of genetic databases and analysis systems. C. Béroud is a member of the scientific committee of the "Human Genome Variation Society" and an expert in the evaluation of research proposals for the French Ministry of Research and various international organizations. Prof. Nicolas Nicolas Lévy is Professor of Medical Genetics (MD, PhD) at the Aix-Marseille Faculty of Levy (Male) Medicine and Chief of Service Department of Medical Genetics and Director of the research unit Aix-Marseille University / INSERM UMR_S910 "Marseille Medical Genetics" Author of 189 publications, 90 invited conferences since 2010, and co-inventor of 10 patents with four operated licenses, Nicolas Levy won the Grand Research Robert Debré Award in 2013 and the Prix Rose Lamarca assigned by the FRM (Foundation for Medical Research) in 2014. Specialist of rare diseases, he established the Rare Diseases Foundation of which he has been the director until November 2015. Specialist in genetics of neuromuscular diseases and laminopathies, he identified the mutation responsible for the progeria in 2003, and since then, the pathophysiological mechanisms and genes associated withProgeria and related premature aging syndromes. Dr. Anaïs A. Baudot is a bioinformatician with more than 14 years of expertize in network biology, both in Baudot biology, cancer and mathematics research centers. She is leading the NSBD group dedicated to (Female) the development of systems and network approaches to better understand human diseases, and rare monogenic diseases in particular. She leads and participates to various national projects. Dr David D. Salgado is a computer scientist with 12 years experience in research laboratories. Since 2012 Salgado, he is a Research Engineer in C. Béroud's research team, and is responsible of the MMG 825575 – EJP RD – Part B 57 (Male) Bioinformatics platform. He has contributed to the development Associated of multiple with document Ref. bioinformatics Ares(2018)6091977 - 28/11/2018 systems including pathogenicity prediction system, rare disease patient registries and therapeutic tools, all dedicated to translational research in human rare diseases. Dr Elisabeth After initial training and a PhD in applied mathematics, E. Remy joined the CNRS in 2002. She Remy, has several years of experience in modeling and analysis of logical regulatory networks. She is (Female) now heading the MABIOS group (Mathematics and Algorithms for Systems Biology) in the Marseilles Institute of Mathematics (I2M), working in close collaboration with the NSBD group. She participated in several national/international projects and managed young researcher ANR grant. List of the most relevant publications and/or products, services (including widely-used datasets or software), or other achievements • F.-O. Desmet, D. Hamroun, M. Lalande, G. Collod-Beroud, M. Claustres, and C. Béroud, “Human Splicing Finder: an online bioinformatics tool to predict splicing signals.,” Nucleic Acids Res., vol. 37, no. 9, p. e67, May 2009. (Highly Cited paper: 902 citations Web of Science) • D. Salgado, J.-P. Desvignes, G. Raï, A. Blanchard, M. Miltgen, A. Pinard, N. Lévy, G. Collod-Beroud, and C. Béroud, “UMD-Predictor: a High Throughput Sequencing Compliant System for Pathogenicity Prediction of any Human cDNA Substitution.,” Hum. Mutat., vol. 37, no. 5, pp. 439–446, Feb. 2016. • Didier G, Brun C and Baudot A. Identifying communities from multiplex biological networks. PeerJ 2015. 2015. • Bladen CL, Salgado D,et al. The TREAT-NMD DMD Global Database: analysis of more than 7,000 Duchenne muscular dystrophy mutations. Hum Mutat. 2015 Apr;36(4):395-402. doi: 10.1002/humu.22758. • C. Béroud, G. Collod-Beroud, C. Boileau, T. Soussi, and C. Junien, “UMD (Universal mutation database): a generic software to build and analyze locus-specific databases.,” Hum. Mutat., vol. 15, no. 1, pp. 86–94, 2000. List of relevant previous projects or activities, connected to the subject of this proposal EU FP7 (01.02.2008 – 31.01.2013), GEN2PHEN (partner) EU-FP7 (01.12.2009 – 30.11.2012), BIO-NMD (WP leader) EU-FP7 (01.11.2012 – 30.10.2018), RD-CONNECT (WP leader) 02-FWF Full legal name (Acronym) – Country Fonds zur Förderung der wissenschaftlichen Forschung (FWF), Austria Principal investigator Stephanie Resch Relevant Network Description of the legal entity/department/laboratory/group: The Austrian Science Fund (FWF) is Austria's main funding organisation for basic research. The FWF supports the ongoing development of top-notch Austrian science and basic research based on international standards. In this way, the organisation makes a significant contribution to cultural development, to the advancement of our knowledge-based society, and thus to the creation of added value and prosperity in Austria. One of the FWF's key objectives is to strengthen Austria's international performance and capabilities in science and research as well as the country's attractiveness as a location for high-level research. This is achieved primarily by funding top-quality projects for individuals and teams, and by enhancing the competitiveness of Austria's innovation system and research facilities. Guided by the principle of research-driven education, the FWF also works to develop Austria's human resources for science and research in both qualitative and quantitative terms. In addition, the organisation strives to emphasize and enhance the interaction of science and research with all other areas of society, culture and the economy, and in particular to increase the acceptance of science and research through concerted public relations activities. The FWF's annual funding budget came to EUR 197.8 million in 2016. Main tasks in the project per Pillar/WP: Pillar 1: In WP6, we will join the transnational calls for collaborative research projects (task 6.1, 6.2, 6.3, 6.4) In WP9, we will contribute to the monitoring activities (task 9.1) Previous experience relevant to the Tasks: One of the key objectives guiding the FWF’s activities at the international level is to enhance Austria’s international visibility as a research location. The FWF’s international programmes include a variety of funding instruments which are essentially designed to support bilateral and multilateral research projects as well as 825575 – EJP RD – Part B 58 international networking. Associated with document Ref. Ares(2018)6091977 - 28/11/2018 Since 2003, the FWF has participated in more than 130 bilateral and multilateral international calls, including some 60 ERA-Net calls. The FWF’s funding volume for international programmes amounted to EUR 22.1 million in 2016. The FWF will use its prior experience to make an active contribution to the activities related to the joint calls. The FWF’s Department of Biology and Medical Sciences has participated actively in the following ERA-Nets: E-Rare- 1; E-Rare-2; E-RARE-3; TRANSCAN; TRANSCAN-2; EUROPOLAR; ERA-CAPS; Pathogenomics; Infect-ERA; NEURON I, II and III; BIODIVERSA 1, 2 and 3; ERASynBio; New Indigo; ERA-CVD; ERACoSysMed and ERA PerMed. As a partner in EJP RD, the FWF will be represented on the Network Steering Committee. The FWF will also participate in the COFUND calls as well as other joint calls in the coming years. The personnel involved have vast experience in running joint calls for projects, and in monitoring and strategic activities. Short Profile of key Staff Members who will be undertaking the work Dr. Stephanie Diploma and PhD in microbiology and genetics. Co-founder and R&D manager of a biotech Resch(female) company focusing on vaccine development (Germany and USA). Head of the Department of Biology and Medicine at the FWF since 2005. Participant in various ERA-Nets (e.g. E-RARE, TRANSCAN, ERA-PerMed). List of the most relevant publications and/or products, services (including widely-used datasets or software), or other achievements 1. Funding of 17 Austrian sub-projects with a total budget of 3.6M€ within the framework of E-RARE (sum of all three running periods). List of relevant previous projects or activities, connected to the subject of this proposal : . E-RARE-1; Funder; 2009-2010: promoting transnational funding activities by active participation in the JTC 2009 as well as participation in strategic research funding policy . E-RARE-2; Funder; 2010-2014: promoting transnational funding activities by active participation in the JTC 2011, JTC 2012, JTC 2013, JTC 2014 as well as participation in strategic research funding policy . E-RARE-3; Funder; 2015-2019: promoting transnational funding activities by active participation in the JTC 2015, JTC 2016, JTC 2018 as well as participation in strategic research funding policy . 03-AIT Full legal name (Acronym) – Country AIT Austrian Institute of Technology GmbH (AIT), Austria Principal investigator Günter Schreier Relevant Network Description of the legal entity/department/laboratory/group: AIT Austrian Institute of Technology is Austria’s largest non-university research institute with more than 1.300 employees, structured in 8 centres. AIT’s vision is to bridge the gap between basic research and applied science. Its Digital Health Information Systems (HIS) research team is part of the Center for Health & Bioresources and has comprehensive experience, infrastructure, tools and skills for the design, development and operation of ICT solutions for healthcare and biomedical research – from rapid prototyping through feasibility studies to proof-of- concept and clinical evaluation trials. The interdisciplinary HIS team consists of about 45 scientists and engineers and has been a key partner in numerous EC funded projects and a variety of funding schemes (SIOPEN-R-NET, CARE-MAN, RegIonCo, iStoppFalls, FoSIBLE, ENVIROFI, ENCCA, ExPO-r-Net, CARE, SymbIoTe, …). AIT is currently running various ICT infrastructures for clinical trials and research networks, e.g. in the fields of paediatric oncology, as well as eHealth infrastructures and healthcare IT systems that provide direct links to patients in telehealth settings and to collect so called patient reported outcomes (ePRO). Several large-scale telehealth systems have been developed and operated by AIT, adding up to more than 1.000.000 patient monitoring days so far. More recently, the team has been instrumental in a number of Big Healthcare Data predictive analytics activities, e.g. to predict hospital re-admission, delirium or the need for blood transfusions. The HIS team is supported by AIT’s administrative, financial, legal and marketing units, which provide the ideal project management environment for carrying out also large collaborative research projects. AIT operates the EUropean Patient IDentity management (EUPID) service and will provide this as a basis and key element for pseudonymisation and privacy preserving record linkage in the present project (see also https://eupid.eu). 825575 – EJP RD – Part B 59 Main tasks in the project per Pillar/WP: Associated with document Ref. Ares(2018)6091977 - 28/11/2018 Pillar 2: In WP11, we will be leading subtask 11.3.3, with a focus on providing EUPID based registration/pseudonymisation services for the network of EJP partners. In WP12, we will be leading the task 12.2 “Multi-team software development to enable the FAIR ecosystem” and contribute to improving existing software solutions, previously developed in the RD community. Pillar 3: In WP14, we will be contributing to the “Training on the European Rare Diseases Registry Infrastructure (ERDRI)”, in particular regarding patient registration and pseudonymisation with EUPID (task 14.6). Previous experience relevant to the Tasks: In preceding projects, AIT has been leading IT tasks similar to the ones required in the present project in general, both in funding and industrial settings. In particular, the AIT team has already managed EUPID pilot integration projects with partners from the rare disease and paediatric oncology community. AIT has been an IT partner to those communities for many years, and in charge of different kinds of tasks relevant to the present project, including development of IT solution architectures, managing interdisciplinary and cross-institutional system development efforts and providing demonstrations and trainings to end users in face 2 face and virtual sessions. Description of any significant infrastructure and/or major items of technical equipment, relevant to the proposed work : AIT operates the EUropean Patient IDentity management (EUPID) services which, in its version 1.0, implements the basic UPID concept descripted below in [4] and mainly consists of a database containing the necessary metadata and functionalities, a RESTful web service (EUPID App Service) providing the EUPID Pseudonymisation Service to clients and the utilisation of an Identity Provider Service allowing to manage users, their authentication and authorisation to use EUPID Services (see https://eupid.eu for up-to-date information). Short Profile of key Staff Members who will be undertaking the work Guenter Günter’s Role in the project will be to manage AIT’s activities in the project. He will provide his Schreier expertise in related ICT / Biomedical Informatics fields, ranging from dataset standardisation, (Male) standards-based interoperability, identity management and data linkage, to security and privacy aspects as well as mHealth and Big Healthcare Data. Günter serves as an advisor to the Austrian Ministry of Health and as a member of the IT advisory board for EC’s European Reference Networks. He is the founder and president of the annual scientific conference on “Medical Informatics and eHealth” in Vienna (www.eHealth20xx.at). Michael Michael will contribute to the IT system architecture and will be leading AIT’s implementation Nitzlnader, activities. He will coordinate related software developments and operational activities, i.e. (Male) adapting, extending, setting-up and operating the core components of the EUropean Patient Identity management (EUPID) system. He will also be involved in linking the existing sources systems and responsible for the overall security and privacy concept. Michael holds a number of IT certificates highly relevant to the present project and related to IT security, requirements engineering and data protection. List of the most relevant publications and/or products, services (including widely-used datasets or software), or other achievements 1: Hayn D, Falgenhauer M, Kropf M, Nitzlnader M, Welte S, Ebner H, Ladenstein R, Schleiermacher G, Hero B, Schreier G. IT Infrastructure for Merging Data from Different Clinical Trials and Across Independent Research Networks. Stud Health Technol Inform. 2016;228:287-91. PubMed PMID: 27577389. 2: Hochedlinger N, Nitzlnader M, Falgenhauer M, Welte S, Hayn D, Koumakis L, Potamias G, Tsiknakis M, Saraceno D, Rinaldi E, Ladenstein R, Schreier G. Standardized data sharing in a paediatric oncology research network—a proof-of-concept study. Stud Health Technol Inform. 2015;212:27-34. PubMed PMID: 26063254. 3: Nitzlnader M, Falgenhauer M, Gossy C, Schreier G. Architecture for an advanced biomedical collaboration domain for the European paediatric cancer research community (ABCD-4-E). Stud Health Technol Inform. 2015;212:167-74. PubMed PMID: 26063273. 4: Nitzlnader M, Schreier G. Patient identity management for secondary use of biomedical research data in a distributed computing environment. Stud Health Technol Inform. 2014;198:211-8. PubMed PMID: 24825705. 5: Schreier G, Messmer J, Rauchegger G, Modre-Osprian R, Ladenstein R. A Web-based platform for interdisciplinary biomedical research. Front Biosci (Landmark Ed). 2009 Jan 1;14:2738-46. PubMed PMID: 19273232. List of relevant previous projects or activities, connected to the subject of this proposal (max 5): 1. ENCCA (www.encca.eu) – European Network for Cancer Research in Children and Adolescents – FP7 (2011 – 2015) Network of excellence project to establish a Virtual Institute for cancer research in Europe. AIT served as the IT work package leader and guided the development of the information portal of the Virtual Institute. 825575 – EJP RD – Part B 60 Some elements developed in ENCCA were the starting point forAssociated developments of important with document ICT infrastructure Ref. Ares(2018)6091977 - 28/11/2018 for data sharing, in particular EUPID. 2. ExPO-r-Net (www.expornet.eu) - European Expert Paediatric Oncology Reference Network for Diagnostics and Treatment - ExPO-r-Net (EC, Health Programme, 2014 – 2017) was the pilot project for the European Reference Network (ERN) for Paediatric Oncology, now established as Paediatric Cancer ERN (PaedCan). AIT was responsibility for the overall IT architecture and the interoperability strategyy and lead the development of a Virtual Tumour Board application. 3. RegIonCo (http://www.regionco.eu) – ERDF project (2008-2012) to foster collaboration between Austria and Hungary regarding the new Ion Therapy facility MedAustron which is currently being established in Austria. AIT’s role has been to design and build a prototype of an interoperable IT infrastructure for cross-border transfer of medical images in order to facilitate continuity of care in accordance with European and international interoperability concepts. 4. SIOPEN-R-NET (www.siopen-r-net.org) –SIOP Europe Neuroblastoma Research Network – FP5 (2002-2006) Thematic Network project to link European Neuroblastoma research – AIT was the IT partner and responsible for design, development and operation of this tailored ICT platform to support research activities on the basic science as well as the clinical level. The resulting SIOPEN-R-NET system is still up and running until today with almost 5000 patients being registered in the system in the course of five different clinical trials. 04-LBG Full legal name (Acronym) – Country Ludwig Boltzmann Gesellschaft (LBG) GmbH, Austria Principal investigators Kaan Boztug, Christoph Bock Relevant Network Orphanet, UDNI (Undiagnosed Diseases Network International), International Human Epigenome Consortium, Human Cell Atlas Description of the legal entity/department/laboratory/group: The Ludwig Boltzmann Society is a research institution, with a strong focus on medicine, hosting 18 research institutes of various disciplines in Austria. The Ludwig Boltzmann Institute for Rare and Undiagnosed Diseases (LBI-RUD) is Austria’s first and leading research institute dedicated to a broad spectrum of rare and undiagnosed diseases research. LBI-RUD consist of 4 groups focusing on the identification and characterization of inborn errors of the immune and nervous system, the development and improvement of bioinformatics tools for next generation sequencing and safe data exchange, and the ethical and societal implications of rare diseases and rare diseases research. Main tasks in the project per Pillar/WP: Pillar 2: we will make some contributions (limited by budget allocation) to the following specific tasks: - Collaborative integrated analysis of multi-omics data from selected use cases - Provide capabilities for custom analyses through cloud-based solutions - User-driven implementation of new analysis functionalities and tools Pillar 3: we will contribute to training (limited by budget allocation) for clinicians and scientists about the Orphanet database, the Orphanet nomenclature, genetic data prioritization using bioinformatics tools developed in LBI-RUD. We will participate in training activities sharing our expertise in functional dissection of molecular patomechanisms of rare disease patients using a through specific case-studies. Previous experience relevant to the Tasks: LBI-RUD is well-connected in Austria and several Eastern European countries and together with its clinical partners established well-studied patient cohorts of rare and ultra-rare diseases. LBI-RUD has built an effective bioinformatics infrastructure for processing, interpreting, and securely sharing genome/exome/panel sequencing data (e.g. Müller et al. 2017 Nucleic Acids Res). LBI-RUD scientists have a strong track record in the functional dissection of rare disease mechanisms especially in the area of hematopoietic, immune, and neurological disorders (e.g. Dobbs et al. NEJM 2015, Salzer et al. Nat Immunol 2016; Ozen et al. NEJM 2017). LBI-RUD developed and applied advanced multi-omics technology including epigenome mapping (e.g. Farlik et al. Cell Stem Cell 2016, Sheffield et al. Nat Med 2017), proteomics, metabolomics, and single-cell sequencing (e.g. Bock et al. Trends Biotechnol 2016, Mass et al. Science 2016). Description of any significant infrastructure and/or major items of technical equipment, relevant to the proposed work : Computational infrastructure. LBI-RUD and CeMM maintain a powerful scientific computing cluster that is upgraded annually to keep pace with steeply increasing data generation (current status: >100 CPUs, >1,000 cores, >10 TB memory, >1,000 TB storage). For even more computation-intensive tasks, CeMM researchers have 825575 – EJP RD – Part B 61 institutional access to the Vienna Scientific Cluster, a global TOP500 supercomputer Associated with documentoperated by a consortium Ref. Ares(2018)6091977 of - 28/11/2018 universities and research institutes in Vienna. Biomedical Sequencing Facility (BSF). The BSF is a large technology platform dedicated to next generation sequencing in biomedicine. It is jointly operated by CeMM and the Medical University of Vienna under the scientific leadership of Christoph Bock. It is equipped with the following machines: (i) three large-scale sequencing machines (1x NovaSeq 6000, 1x HiSeq 4000, 1x HiSeq 3000) for production sequencing; (ii) two medium-scale sequencing machines (1x NextSeq, 1x MiSeq) for technology development; (iii) a PerkinElmer Sciclone NGS (pre- PCR) and Zephyr (post-PCR) supporting 96-well automated library preparation for RNA-seq (PolyA+, RiboZero, and 3’mRNA fingerprinting), RRBS, and ChIP-seq; (iv) a 10x Genomics Single Cell Controller, a Silicon Biosystems DEPArray and a Fluidigm C1 for single-cell sequencing. Short Profile of key Staff Members who will be undertaking the work Dr. Kaan Boztug Kaan Boztug studied Medicine in Düsseldorf, Freiburg and London, followed by his graduate (male) training with Iain Campbell at the Scripps Research Institute (La Jolla, USA), and clinical training and postgraduate research with Christoph Klein at Hannover Medical School (Germany). He joined CeMM in 2011 and holds a dual appointment as Associate Professor at the Department of Paediatrics and Adolescent Medicine at the Medical University of Vienna. Since 2016, Kaan Boztug is director of the LBI-RUD and the CeRUD Vienna Center for Rare and Undiagnosed Diseases and joint director of the Jeffrey Modell Foundation Center for Immunodeficiencies at the Medical University of Vienna and St. Anna Children’s Hospital. Dr. Christoph Christoph Bock is a principal investigator at LBI-RUD and the CeMM Research Center for Bock / male Molecular Medicine of the Austrian Academy of Sciences. His research focuses on disease genomics/epigenomics and on high-throughput technologies for precision medicine. He is also a guest professor at the Medical University of Vienna, scientific coordinator of the Biomedical Sequencing Facility at CeMM, and adjunct group leader for bioinformatics at the Max Planck Institute for Informatics. He has received several research awards, including the Max Planck Society’s Otto Hahn Medal (2009), an ERC Starting Grant (2016-2021), and the Overton Prize of the International Society of Computational Biology (2017). Dr. David David Medgyesi studied molecular biology and received his PhD in immunology at the Medgyesi / male Eötvös Loránd University Budapest, Hungary. He was a postdoctoral fellow and project leader at Max Planck Institute of Immunobiology and Epigenetics, Freiburg, Germany. He joined LBI-RUD as a senior research associate in 2017. Dr. Matthias Matthias Haimel studied bioinformatic engineering at Upper Austria University of Applied Haimel / male Sciences at Hagenberg and completed his PhD studies in 2017 at the Department of Medicine, University of Cambridge, UK. He joined LBI-RUD as a bioinformatician in 2018. List of the most relevant publications and/or products, services (including widely-used datasets or software), or other achievements 1. Ozen A et al. CD55 Deficiency, Early-Onset Protein-Losing Enteropathy, and Thrombosis. (2017) N Eng J Med, 377(1): 52-61. 2. Sheffield NC et al. DNA methylation heterogeneity defines a disease spectrum in Ewing sarcoma. (2017) Nat Med, 23(3):386-395. 3. Müller H et al. VCF.Filter: Interactive prioritization of disease-linked genetic variants from sequencing data. (2017) Nucleic Acids Res, 45, W567–W572. 4. Salzer E et al. RASGRP1 deficiency causes immunodeficiency with impaired cytoskeletal dynamics. (2016), Nat Immunol, 17 (12), 1352-60. 5. Dobbs K et al. Inherited DOCK2 deficiency in patients with early-onset invasive infections. (2015) N Eng J Med, 372(25): 2409-22. List of relevant previous projects or activities, connected to the subject of this proposal: . Precise PID; Vienna Science and Technology Fund (WWTF); 2017-2020, leader; using PIDs as model diseases to rationalize patient-specific workflows from gene discovery and pathomechanisms to targeted treatments. . Immuno Core; European Research Council (ERC); 2013-2018, leader; using systems genomics tools to uncover primary deficiencies with a focus on phagocyte deficiencies such as congenital neutropenia syndromes. . Epigenome Programming; European Research Council (ERC); 2013-2018, leader; development methods for targeted (and potentially therapeutic) editing of epigenetic alterations 825575 – EJP RD – Part B 62 05-FNRS Associated with document Ref. Ares(2018)6091977 - 28/11/2018 Full legal name (Acronym) – Country Fond de la Recherche Scientifique-FNRS (F.R.S.-FNRS) – Belgium Principal investigator Florence Quist Relevant Network E-RARE, NEURON, JPIAMR, Description of the legal entity/department/laboratory/group: The Fund for Scientific Research - FNRS (F.R.S.-FNRS) is a research funding agency that promotes and supports basic scientific research in the French-speaking Community of Belgium. Founded in 1928, it mainly receives public subsidies, currently from the French-speaking Community of Belgium, the Walloon Region and the Federal Government of Belgium. The Fund supports individual researchers on the basis of the criterion of excellence by offering temporary or permanent positions; funding to research teams; grants and credits for international collaboration and scientific prizes. F.R.S.-FNRS fosters research in all scientific fields, following a bottom-up approach of investigator-driven research. Further, the Fund supports researchers in an ever growing context of internationalisation through facilitating their mobility, allowing for collaborative transnational projects and supporting a high level international working environment. Since October 2008, Dr. Ir. Véronique Halloin is the Secretary-General of F.R.S.-FNRS. Main tasks in the project per Pillar/WP: Pillar 1: In WP6, we will participate in the Joint Transnational Calls for collaborative research projects (tasks 6.1, 6.2, 6.3 and 6.4) In WP9, we will participate in the Monitoring of funded projects (tasks 9.1, 9.2 and 9.3) Previous experience relevant to the Tasks: The Fund for Scientific Research - FNRS runs a programme supporting mainly basic research through project- based funding for the French speaking community of Belgium. Research projects are funded through a bottom-up principle following an open competition in a yearly call for research proposals and grants. The F.R.S.-FNRS is currently involved in various European initiatives and bilateral agreements at the international level. The Fund is and has been full partner in several FP7 ERA-Nets (CHIST-ERA, ERA-CAPS, FLAG-ERA, GENDER-NET, PASTEUROA, HERA, E-RARE 2) and has participated in numerous ERANET calls (JPND, Neuron, JPI-AMR, ERANET-LAC, Inno Indigo, SEA-EU NET, among others). The F.R.S.-FNRS participated in the E-RARE Joint Transnational Calls in 2011, 2013, 2015 and 2017. Moreover, the F.R.S.-FNRS is also part of practically all the ERANET COFUND initiatives that permit to perform basic science in H2020 (EURONANOMED III, ERA-CVD, M-ERANET 2, NEURON, TRANSCAN, among others) not in the least those that support the Joint Programming Initiatives such as WaterWorks 2014; WaterWorks 2015; WaterWorks 2017; JPCofund; Urban Europe (Smart Cities and Urban Futures); and FACCE Surplus and SusCrop. The F.R.S.-FNRS has been involved in the monitoring of funded projects for E-RARE 2 and is in charge of the whole monitoring work package for E-RARE 3. Description of any significant infrastructure and/or major items of technical equipment, relevant to the proposed work : Due to its responsibilities in E-RARE 2 and E-RARE 3, the F.R.S.-FNRS has developed an online monitoring tool, which will be adapted to perform the monitoring of the EJP-RD projects. Short Profile of key Staff Members who will be undertaking the work Dr. Florence Dr. Florence Quist, PhD in Chemistry, is a scientific officer at the Unit of International and Quist / Female European Affairs in charge of European cooperation, evaluation and monitoring processes. She has extensive experience in material science through several post-docs and as head of R&D Development in an SME specialized in recycling photovoltaic material. In this capacity, she was also responsible for several projects financed by the Walloon region and the European Commission. Florence complements these experiences with a solid background in management through a complementary Certificate at Solvay Business School. Florence participates in many different ERANETs, including E-RARE III, in which the F.R.S.-FNRS is responsible for project monitoring activities. Mr. Joël Joël Groeneveld, M.A. in Political Science, is a policy officer at the Unit of International and Groeneveld / European Affairs in charge of international cooperation and bilateral agreements. He acquired a Male thorough understanding of project management, monitoring and reporting while working as Finance and Program Officer for the Institute for Historical Justice and Reconciliation. Prior to this experience, he successfully pursued a degree in journalism in The Netherlands and performed extensive editing work as media analyst for Report International in Paris for several years while studying history. Joël has a wide ranged experience in participating in ERANETs, in particular the 825575 – EJP RD – Part B 63 geographically based FP7 ERANETS, and GENDERNET PLUS Associated with and E-RARE document III, where FNRS Ref. Ares(2018)6091977 is - 28/11/2018 responsible for monitoring activities. Dr. Arnaud Dr. Arnaud Goolaerts, PhD in Respiratory physiology/Biophysics and MSc in Geochemistry, is a Goolaerts / scientific officer at the Unit of International and European Affairs in charge of European Male cooperation and evaluation and monitoring processes. Prior to coming to the F.R.S.-FNRS, he was a doctoral fellow at the University of California San Francisco and a Marie Curie Fellow at the European Respiratory Society in Paris. Arnaud co- leads the monitoring of projects in E- RARE III and is involved in all biomedical ERANETs. His background in Geochemistry also allows him to work in more climate related topics. He also leads 2 Scientific Commissions in Life Sciences and Natural Sciences in the programmes executed by the F.R.S.-FNRS. List of relevant previous projects or activities, connected to the subject of this proposal . E-RARE III; ERANET; 2014-2019 – WP Leader for Monitoring of funded projects . E-RARE II; ERANET; 2010-2014 – Task Leader for Monitoring of funded projects . Gendernetplus; 2017-2021 – Participant in Monitoring of funded projects 06-FWO Full legal name (Acronym) – Country Fonds Wetenschappelijk Onderzoek - Vlaanderen (FWO) – Belgium (Flanders) Principal investigator Dr. Alain Deleener Relevant Network N/A Description of the legal entity/department/laboratory/group: The Research Foundation - Flanders (FWO) is the agency that supports ground-breaking fundamental and strategic research at the universities and research centres of the Flemish Community. The FWO also stimulates cooperation between the Flemish universities and other research institutes. Main tasks in the project per Pillar/WP: The FWO will limit its active participation to Pillar 1, as project funding – similar to the ERA-NET scheme - is the main goal of our participation. The FWO will not take up specific tasks within the consortium. Previous experience relevant to the Tasks: The FWO participated in several ERA-NETs up to now, on a so-called ‘remote’ basis. This implies that we don’t take up any ‘Work Packages’. Our participation is mostly limited to the actual funding of our national/regional research community, besides the administrative basic modalities for participation, e.g.: verifying call docs, eligibility check, acting as national contact point, providing input for deliverables, etc. Additionally, the FWO has the required experience with project funding due to its management of application rounds for projects, fellowships and mobility grants on a yearly basis, and as already mentioned, also the participation in past joint ERA-calls. Short Profile of key Staff Members who will be undertaking the work Dr. Alain Science Policy Advisor Strategic Research Programmes at FWO and responsible - among other Deleener/ things - for the European SBO-projects (Strategic Basic Research) policy and cooperation within male FWO. Dr. Olivier Coordinator Strategy and Policy Cell at FWO and responsible - among other things - for European Boehme/ male joint programming and cooperation within FWO. Toon Advisor Research Affairs at FWO and responsible for the general, daily follow-up of joint Monbaliu/ programming, especially ERA-NET and JPI. male 07-KU Leuven Full legal name (Acronym) – Country Katholieke Universiteit Leuven (KU Leuven) – Belgium Principal investigator Gert Matthijs Relevant Network EuroGentest-ESHG, MetabERN, EURO-CDG(2), IRDiRC, Description of the legal entity/department/laboratory/group: 825575 – EJP RD – Part B 64 KU Leuven boasts a rich tradition of education and research thatAssociated dates back with six centuries. document The university’s Ref. Ares(2018)6091977 basic - 28/11/2018 research orientation has always been and will remain fundamental research From a basis of social responsibility and scientific expertise, KU Leuven provides high-quality, comprehensive health care, including specialised tertiary care, in its University Hospitals. In doing so it strives toward optimum accessibility and respect for all patients. KU Leuven is currently by far the largest university in Belgium in terms of research funding and expenditure (EUR 466.55 million in 2016), and is a charter member of LERU. KU Leuven conducts fundamental and applied research in all academic disciplines with a clear international orientation. In the Times Higher Education ranking KU Leuven is ranked as the 14th European university, while in the Reuters Top 100 of the World’s most innovative institutions, KU Leuven is listed as the first European university. Leuven participates in over 540 highly competitive European research projects (FP7, 2007-2013), ranking sixth in the league of HES institutions participating in FP7. In Horizon 2020, KU Leuven currently has been approved more than 260 projects and is ranked sixth HES institution with regard to number of signed grants. To date, the 107 ERC Grantees (including affiliates with VIB and IMEC) in our midst confirm that KU Leuven is a breeding ground (55 Starting Grants) and attractive destination for the world’s best researchers. In our 229 Actions, of which 111 Initial/European Training Networks, hundreds of young researchers have been trained through research and have acquired the necessary skills to transfer their knowledge into the world outside academia. In Horizon 2020, KU Leuven is ranked first institution of higher education with regard to number of MSCA-ITNs ‘(54) and second for all entities. KU Leuven employs 8,084 researchers on its academic staff (2015). To strengthen international collaboration, KU Leuven has its own international research fellowship programme and supports international scholars in international funding applications. KU Leuven Research & Development (LRD) is the technology transfer office (TTO) of the KU Leuven. Since 1972 a multidisciplinary team of experts guides researchers in their interaction with industry and society, and the valorisation of their research results (110 spin offs, …) . The Center for Human Genetics is the largest genetics department in Belgium. The staff includes clinical geneticists, genetic counsellors, psychologists, laboratory geneticists, principal investigators in research, post-docs, PhD students, masters, bio-informaticians and technicians (over 200 co-workers in total). The diagnostic activities focus on rare diseases, with specific interests in intellectual disabilities, multiple congenital anomalies, neurological and neuro-muscular diseases, nephropathies,cardiopathies, immune deficiencies, genodermatoses, metabolic diseases and familial cancer syndromes. The laboratories also offer testing for (rare) cancers. The translation research focusses on the introduction of genomics into medicine. Main tasks in the project per Pillar/WP: Pillar 3 WP14 – task 14.2 Standards and quality of genetics/genomics data in laboratory and clinical research practice ; Leader KU Leuven, Contributor University of Tubingen, ACU RARE, ISS, CMHI, CNAG, INSERM-AMU, UMCG; ‘Next generation sequencing’ (NGS) generates overwhelming amounts of data. Clinical and basic researchers are increasingly confronted with the complexity of genomic data. It is of importance to provide training on the interpretation of genetic variants and quality standards. We will therefore organize residential courses for scientists, bio-informaticians and clinicians with an interest in genomic technologies and applications. The aim is to teach participants about the evaluation of the pathogenic nature and clinical significance of genetic variants, on the criteria that have to be set to the NGS analysis pipelines and on the use of international databases. The course will build on expertise gained by EuroGentest and help in the translation of research tools to diagnostic applications (in line with the IRDiRC objectives). The impact is on the quality and reliability of NGS results, obtained through rare disease research. Over the years, the course content will shift to total genome interpretation, which will entail novel molecular mechanisms for disease and further increase the complexity. Training courses typically host 20-30 participants and last 3-days. It is envisaged to provide the course every year. The courses will travel across Europe: Rome, Warsaw, Istanbul, Tübingen and Leuven. Previous experience relevant to the Tasks: KU Leuven and the Center for Human Genetics have been the coordinator of EuroGentest, a project to harmonize the process of genetic testing, from sampling to counselling, across Europe. It was funded as a Network of Excellence (from 2005 to 2010) and as a Coordination action (2011-2013). The ultimate goal was to ensure that all aspects of genetic testing are of high quality thereby providing accurate and reliable results for the benefit of the patients. A major part of the activities concerned training and the generation of guidelines for good practice. Hence, the courses will build on expertise gained by EuroGentest (www.eurogentest.org. In 2014, EuroGentest has been integrated with the European Society for Human Genetics (ESHG). Description of any significant infrastructure and/or major items of technical equipment, relevant to the proposed work : The Center for Human Genetics has a genetic clinic, and different diagnostic and research facilities, including a 825575 – EJP RD – Part B 65 Next Generation Sequencing facility (the ‘Genomics Core’ or GC) and bio-informatics Associated support. with document Ref. Researchers Ares(2018)6091977 have - 28/11/2018 easy access to the animal breeding facilities, microscopy services etc. The laboratories are located on the Health Sciences Campus in Leuven. Short Profile of key Staff Members who will be undertaking the work Gert Pharmacist, PhD in Pharmaceutical Sciences , Laboratory Geneticist. Head of laboratory at the Matthijs Laboratory for Molecular Diagnosis, Center for Human Genetics .Professor at the Faculty of (male) Medicine and Faculty of Pharmacy, University of Leuven;Molecular geneticist, involved in the diagnostics of inherited diseases since 1994. The laboratory offers diagnostic for a large range on rare diseases. His (translational) research activities deal with the development and validation of novel technologies for diagnostic use. Currently, the focus is on the implementation of the newest massive parallel sequencing platforms including whole-genome sequencing for mutation scanning and on the interpretation of genetic variants. His (fundamental) research interest is in Congenital Disorders of Glycosylation, a group of rare inborn errors of metabolism. His group has been focusing on the systematic search for novel types of CDG since 1995. The success is partly due to the fact that the group has committed itself, since 1999, to the coordination of EUROGLYCANET, a network that has been funded by the Commission (FP5, FP6). He was the coordinator of EuroGentest, a network for development, harmonization, validation and standardization of genetic testing in Europe, that was funded by the European Commission from 2005 until 2013. He is a member of the Diagnostic Scientific Committee of IRDiRC (International Rare Disease Research Consortium). He was an alternate member of the Commission Expert Group on Rare Diseases (formally EUCERD). He has been a scientific committee member for INSERM, AERES, INCa, FNRS, ANR and other granting agencies. He was active on the steering committee of the Global Genomic Medicine Collaborative (G2MC), created in 2014. At the national level, he has been a thriving force for a revision of the reimbursement system for genetic tests for rare diseases. At the University of Leuven, he has co-coordinated a workgroup on legal, ethical and societal aspects of total genome analysis. In 2013 and 2014, he has published 2 books about genetics and genomics for the public. He is involved in MetabERN, the European Reference Network for Hereditary Metabolic Disorders, wherein the Congenital Disorders of Glycosylation are recognized as one of the disease groups. List of the most relevant publications and/or products, services (including widely-used datasets or software), or other achievements 1. Community activity towards the improvement of quality in genetic testing: The EuroGentest ‘Guidelines for Diagnostic NGS’ have been prepared by a multidisciplinary group of experts and stakeholders. Guidelines for diagnostic next-generation sequencing, Gert Matthijs et al.,European Journal of Human Genetics (2016) 24, 2–5 and supplement. 2. Coordination of EuroGentest, a European network for quality in genetic testing, described in EuroGentest NoE, the ESHG, and genetic services, Jean-Jacques Cassiman, European Journal of Human Genetics (2017) 25, S47-S49) 3. Evaluation of the use and treats of patents in genetic testing The European BRCA patent oppositions and appeals: coloring inside the lines, Matthijs G et al., Nature Biotechnology, 31(8):704-10, 2013. 4. Books on genetics, genomics and rare diseases for a specialized and general readerships ‘Mes Gènes, Mon Identité’ (ISBN:9782804702144, Ed. Mardaga 2014). This book was translated from the Flemish boek ‘Wat met genetica’ (ISBN 9789401411462, Ed. Lannoo Campus 2013) was written for medical doctors and other professionals working in the medical field, for interested lay people and for policy makers. The content was compiled from the work of a multidisciplinary ‘think thank’ about ‘Total genome analysis’ at the University of Leuven in 2011-2012. The Human Recipe’ (ISBN 9789462700727, Ed. University Press Leuven), translated from ‘Iedereen GENiaal’ (ISBN 978-94-62101-98-2, Ed. Ballon Media 2014 ), a book really directed towards the public and illustrated by 9 cartoonists, known in Flanders by their cartoons in the newspapers. 825575 – EJP RD – Part B 66 List of relevant previous projects or activities, connected to theAssociated subject with of this proposal): document Ref. Ares(2018)6091977 - 28/11/2018 Acronyme; Funder; starting year-ending year; role in the project; description • EuroGentest; Eur.Comm.-FP6-7; Coordinator; 2005-2013 Community activity towards the improvement of quality in genetic testing , EuroGentest started in 2005 as an network of excellence (NoE) for development, harmonization, validation and standardization of genetic testing in Europe (www.eurogentest.org). From 2011 to 2013, it was funded as a coordination action (CA). • TECHGENE; Eur.Comm.-FP7; Partner; 2009-2011 High throughput molecular diagnostics in individual patients for genetic diseases with heterogeneous clinical presentation.TECHGENE was a European integrated project (IP) for the introduction of next generation sequencing tools in diagnostics. • EURO-CDG, E-RARE, Coordinator, 2012-2014 A European research network for a systematic approach to CDG and related diseases. • 3Gb-TEST; Eur.Comm.-FP7; WP Leader; 2013-2015 Introducing diagnostic applications of ‘3Gb-testing’ in human genetics • EURO-CDG-2, E-RARE, Coordinator, 2016-2018 A European research network directed towards improving diagnosis and treatment of inborn errors of glycosylation. 08-MEYS Full legal name (Acronym) – Country Ministry of Education, Youth and Sports (MEYS), Czech Republic Principal investigator PhDr. Pavel Doleček, Acting Deputy Minister for Higher Education, Science and Research Relevant Network Description of the legal entity/department/laboratory/group: Ministry of Education, Youth and Sports (MEYS) According to the Act No. 130/2002 Coll. on the Support of Research, Experimental Development and Innovation from Public Funds and on the Amendment to Some Related Acts, MEYS is the central administration authority responsible for R&D, particularly institutional funding for higher education sector, research infrastructures policy and funding and international R&D collaboration. Main tasks in the project per Pillar/WP: MEYS as a member of EJP and a Beneficiary will contribute to the Pillar 1 in WP 6 as a funding agency participating in a Joint Transnational Call. Its role and tasks are clearly defined by the description of tasks 6.1. Joint Transnational Call 2019 – Call co-funded by the EC for three years and 6.2. Joint Transnational Call 2020 – Call co-funded by the EC for two years. The MEYS will actively cooperate as a participants on following subtasks analogous for both calls mentioned above: • Topic selection • Preparation of the call and establishment of the joint call secretariat • Evaluation of the joint call and funding decision • Quality management of call procedures Previous experience relevant to the Tasks: MEYS – Department of Research and Development participates in different initiatives supporting international cooperation in R&D including participation in programme Horizon 2020, ERANets and JPIs (e.g. E-Rare, ERA- Net QuantERA, HERA, JPND, JPICH, JPI AMR, JPI HDHL, JPI Facce). Short Profile of key Staff Members who will be undertaking the work Dr Lukáš Director of the Department of Research and Development in the MEYS. Lukáš Levák was Levák (male) appointed Director of Department for Research and Development in 2014. His current duties and responsibilities comprise particularly formulation and implementation of the strategy for cross- border and international cooperation of the Czech Republic in R&D, mainly within the European Research Area, and defying the research infrastructures policy of the Czech Republic. Renata Hrubá Ing. Renata Hrubá works in the Department of Research and Development in the Unit of the (female) European Research Area in the MEYES. 825575 – EJP RD – Part B 67 List of the most relevant publications and/or products, servicesAssociated (including widely-used with document datasets or software), Ref. Ares(2018)6091977 - 28/11/2018 or other achievements : In 2015, Lukáš Levák was the main co-author of “Roadmap of the Czech Republic of Large Infrastructures for Research, Experimental Development and Innovation for the years 2016-2022”. In 2016 he was the main coordinator of preparation of the “ERA Roadmap of the Czech Republic for the years 2016-2020”. Since 2014 he is the leading delegate of the Czech Republic to the ERAC (European Research Area and Innovation Committee). His major current tasks consist mainly in further alignment of the Czech research infrastructures policy with the ESFRI (European Strategy Forum on Research Infrastructures) good practice examples and in updating the Czech national large research infrastructures roadmap (to be accomplished in 2018). Regarding the further integration of the Czech research and innovation system into the European Research Area, the major challenges of Department for Research and Development comprise strengthening the participation of the Czech Republic in Joint Programming process. As for the Czech national R&D policy, the Department of Research and Development will focus on preparation of an overarching national strategy of the Czech Republic for development of human resources and gender equality in R&D. List of relevant previous projects or activities, connected to the subject of this proposal : Department of Research and Development supports and funds the Czech research community in different international initiatives, the most relevant to the EJP are ERANets and JPIs (e.g. E-Rare, JPND, JPI AMR,JPI HDHL,). 09-MoSAE Full legal name (Acronym) – Country Ministry of Social Affairs of Estonia (MOSAE), Estonia Principal investigator Heli Paluste Relevant Network Description of the legal entity/department/laboratory/group: The Ministry of Social Affairs (MOSAE) is a government agency. The MOSAE area of government includes the preparation and implementation of national strategies in the field of public health and health care, social security and welfare, employment, the labor market, the working environment, the promotion of equal treatment and the promotion of equality between women and men and the coordination of children's rights and families promotion of quality of life, promotion and support of sporting activities of people with disabilities and drafting of relevant legislation. Main tasks in the project per Pillar/WP: Pillar 1: In WP6, we will provide in cash contribution to Pillar 1 co-funded calls: earmarked funds for co-funded call 1: 25 000 euros for 2019, 25 000 euros for 2020, 25 000 euros for 2021 (task 6.1) Previous experience relevant to the Tasks: The tasks of the Ministry of Social Affairs of Estonia in the area of research and development are: a) the organization of the research and development activities necessary for its area of government and its financing, taking into account the results of the evaluations and the related assessments and recommendations; b) justification and appointment of funds necessary for the financing of R & D activities within its area of government in the preparation of the budget draft of the government area and approval of budgets of these research and development institutions in the amount of the state budget allocated to the amount allocated to research and development within the area of government. Short Profile of key Staff Members who will be undertaking the work Dr/ Heli Head of Health Care Unit, MD Paluste/F Department of Health System Development MOSAE Ms/ Angela Research Adviser for Health Policy, 825575 – EJP RD – Part B 68 Ivask/F Analysis and Statistics Department Associated with document Ref. Ares(2018)6091977 - 28/11/2018 MOSAE List of the most relevant publications and/or products, services (including widely-used datasets or software), or other achievements 1. National Health Plan 2009–2020 2. Estonian health system research and development and innovation strategy 2015-2020 3. Estonian eHealth Strategic Development Plan 2020 4. Estonian Rare Disease Development Plan 5. Estonian Health Care System Roadmap 2020 List of relevant previous projects or activities, connected to the subject of this proposal 2 hospitals from Estonia are the members of ERN-s. Tartu University Hospital is a member of ERN-ENDO and ERN-BOND. East Tallinn Hospital is a member of ERN-EYE. 10-AKA Full legal name (Acronym) – Country Suomen Akatemia (AKA) - Finland Principal investigator Heikki Vilen Relevant Network Description of the legal entity/department/laboratory/group: The Academy of Finland’s mission is to fund high-quality scientific research, provide expertise in science and science policy, and strengthen the position of science and research. We are an agency within the administrative branch of the Finnish Ministry of Education, Science and Culture. We work to contribute to the renewal, diversification and increasing internationalisation of Finnish research. Our activities cover the full spectrum of scientific disciplines. We support and facilitate researcher training and research careers, internationalisation and the utilisation of research results. We are also keen to emphasise the importance of research impact and breakthrough research. We therefore encourage researchers to submit boundary-crossing applications that involve risks but also offer promise and potential for scientifically significant breakthroughs. Each year, our funding contributes to some 2 700 people’s work (FTEs) at universities and research institutes. Main tasks in the project per Pillar/WP: Pillar 1: In WP6, we will take part in the transnational research funding calls (task 6.1) Previous experience relevant to the Tasks: The Academy of Finland has participated in several ERA-NETs and joint calls. For example, in recent years the Academy of Finland has participated in the calls of JPco-fuND, ERA-NEURON, E-RARE and JPI-AMR. Short Profile of key Staff Members who will be undertaking the work Dr. Heikki Vilen Science Adviser in Health Research Unit of the Academy of Finland, highly experienced in (male) organizing peer-reviewed research panels. Currently, he is the AKA representative in the Call Steering Committee of E-RARE3. List of relevant previous projects or activities, connected to the subject of this proposal : The Academy of Finland has participated / is currently participating in the JTC2017 and JTC2018 calls of the rare diseases research Era-NET E-RARE3 11-ANR Full legal name (Acronym) – Country French National Research Agency (ANR) Principal investigator Dominique Dunon-Bluteau Relevant Network E-Rare Description of the legal entity/department/laboratory/group: The French National Research Agency (ANR) was established by the French government in 2005 to fund research projects, based on competitive schemes giving researchers the best opportunities to carry out their projects and paving the way for ground-breaking new knowledge. The main mission of ANR is to fund the best basic research, but also targeted and applied research in particular through partnerships between companies and public sector laboratories. Its action is thus intended to support French research excellence at both academic and technological 825575 – EJP RD – Part B 69 levels by means of a rigorous selection process based on evaluation by peer Associated withreview. documentFinally, it is also the- ANR's Ref. Ares(2018)6091977 28/11/2018 mission to strengthen international cooperation by contributing in particular to the funding of international consortia in partnership with other funding agencies in Europe and beyond. ANR funds are available in all scientific fields, for both fundamental and industrial research. Since 2010, ANR has also been the principal operator of the Investments for the Future programme in the field of higher education and research. In this role it ensures the selection, funding and monitoring of projects relating to the centres of excellence, health, biotechnologies, and the transfer of technology and the creation of value from research. Since its inception in 2005, the ANR agency awarded approximately 15,600 grants investing 6,5 billion €. In 2016 for example, 1,257 projects were awarded for an amount of 595,5 M€. Developing European and international collaborations is one of the priorities of the ANR. The ANR has participated/is participating in multiple ERA-NETs, CSAs and JPIs. Currently the Health & Biology Department is contributing to 13 ERA-Nets (JPI-EC-AMR, SEA-EU-NET, ERA-HDHL, HDHL INTIMIC, JPI-JPcofuND, NEURON, FLAG-ERA II, ERA-CVD, ERACoSysMed, ERA PerMed, EuroNanoMedIII and E-Rare-3) and coordinates two of them (E-Rare and ERA-HDHL). ANR also participates in 3 JPIs (JPND, JPAMR, JPI HDHL), as well as other type of collaborative initiatives like IC PerMed or CRCNS (computational neurosciences). In the context of rare diseases, the ANR has funded research projects through the generic programme and thematic programmes not focused on rare diseases, but also thanks to a dedicated yearly thematic call (MRARE, in 2005, 2006 and 2007). Between 2005 and 2017 a total of 496 research projects related to rare diseases have been funded with a budget of 177.6 M€. At the transnational level, the ANR participates in E-Rare since 2007 and coordinates the programme since 2014. In this context, 89 E-Rare projects with French researchers were financed (17,74 M€ of ANR budget + 2,24 M€ other resources [EC and DGOS]). In addition, the ANR is a member of the IRDiRC Executive Committee since its inception. Through its involvement in the EJP RD, ANR will continue its strong involvement and support for rare diseases research. Main tasks in the project per Pillar/WP: Pillar 1: WP6: ANR intends to participate in the two EC co-funded joint transnational calls (2019, 2020) with the budget of 6 M€ (3 M€ per call) and two non-cofunded calls (2021, 2022; budget to be defined). In addition, ANR will act as joint transnational call 2020 secretariat, which involves the preparation of the call, the establishment of the joint call secretariat and the implementation of the call. WP9: ANR will support WP and Task leaders in the monitoring activities by providing necessary information on the financed projects with FR components. Coordination and transversal activities WP1 (Coordination): As future member of the EJP RD Consortium, ANR will participate in the prioritization strategy, preparation of the Annual Work Plans and Summary Reports. ANR will be also involved in the activities related to the translation of the EJP RD outcomes and alignment at national level (for example through its participation in National Mirror Group). WP5 (Communication and dissemination): ANR will contribute to the dissemination and communication activities of the EJP RD in order to strengthen the capacity of outreach at national level. Previous experience relevant to the Tasks: As mentioned above ANR (Department of Health & Biology) is currently coordinating E-Rare-3. ANR was also responsible for two JTC secretariats (2011, 2016) and in addition was actively involved in the preparation of all previous E-Rare calls (calls documents’ preparation, selection, monitoring and evaluation of projects). Thus, the experience necessary to overtake the responsibilities foreseen in Pillar 1 is already acquired and available at ANR. In addition, ANR is an active actor in the field of rare diseases at national level by participating in the 2nd Rare Diseases National Plan and as member of the Rare Diseases Mirror Group specifically created by the French Ministry of Research to reflect the needs and align the activities of French stakeholders with EJP RD plans. Short Profile of key Staff Members who will be undertaking the work Prof. Dominique PhD, director of the Biology and Health Department at the ANR, worked for 20 years at the Dunon-Bluteau University Pierre and Marie Curie (UPMC) and CNRS as a group leader in developmental cell (male) biology. In parallel of his scientific activities, he was dean of the Faculty of Biology at UPMC and member of the HCERES (French Agency for evaluation). He became scientific adviser at the French Embassy in Switzerland and then member the Cabinet of Minister of French Higher Education and Research as scientific adviser for Biology and Health. Recently, he was scientific deputy director at Institute of Biology (CNRS) in charge of interdisciplinary research programme implementation. As the head of department, he supervises the involvement of ANR in 3 joint programs (JPI), 10 ERA-NETs and multilateral projects. ANR scientific ANR scientific project manager (yet to be defined). 825575 – EJP RD – Part B 70 project manager Associated with document Ref. Ares(2018)6091977 - 28/11/2018 Ms Blandine Ms Castrillo joined the ANR in 2016 as administrative & financial officer for ERA-NETs. She Castrillo graduated in European Project Management from the University of Cergy-Pontoise (UCP) and (female) has been working since then at ANR. She currently assists the ANR’s scientific project managers and coordinators on the administrative and financial management of European projects of the Biology and Health Department and the Digital Technology and Mathematics Department of ANR. She will be the administrative and financial officer for EJP RD at ANR. List of relevant previous projects or activities, connected to the subject of this proposal: E-Rare-1 (2007 – 2011), GA036248 E-Rare-2 (2011 – 2014), GA266608 E-Rare-3 (2014 – 2019), GA643578 Member of IRDiRC, International Rare Diseases Research Consortium. 12-FFRD Full legal name (Acronym) – Country French Foundation for rare diseases (FFRD) Principal investigator Roseline Favresse Relevant Network N.A. Description of the legal entity/department/laboratory/group: FFRD is a unique cooperative framework coordinating research resources and expertise in the RD field. Flagship of the 2nd French National Rare Diseases Plan, with a growing team of 15 people, FFRD acts as a federative hub to fund research and accelerate scientific, clinical and social innovation by stimulating cross-sector cooperation towards effective healthcare to the benefit of RD patients. Its active financial support spans from biomedical sciences to Social Sciences and Humanities. Since its creation in 2012, FFRD has funded 325 projects (out of 994 submitted) for a cumulated amount of 9,4M€ (30 calls for proposals). With headquarters located in Paris, FFRD also relies on a team of seven regional field coordinators in direct contact with academic and clinical teams all over the national territory to ensure that priorities are driven by grounded needs. FFRD main objectives include: accelerating the translation of research into clinical development; detecting business development opportunities; enhancing access to innovative technologies; facilitating cross-sector partnerships. With its close contacts with academic researchers and clinicians in the field, FFRD is contributing to early identification of proofs of therapeutic concept and making links with other partners in the research value chain, namely SMEs, Pharmas, and TTOs. Main tasks in the project per Pillar/WP: Pillar 1: - In WP6 (Joint Transnational Calls for collaborative research projects) FFRD will be task leader for Task 6.3 Joint Transnational Call 2021 (JTC 2021): call not co-funded by the EC. - In WP8 (Rare Disease Research Challenges), FFRD will coordinate the WP and be involved in task 8.1: Development of the scheme as participant and as task leader for task 8.2: Set-up of challenges; task 8.3: Call for proposals, evaluation and selection of proposed projects for solutions in first phase; task 8.4: Call for proposals, evaluation and selection of proposed projects for solutions in second phase and task 8.5: Management of the funding resources, establishment of contracts and distribution of funding to selected projects. - In WP9 (Monitoring of funded projects), FFRD will participate to task 9.1: Monitoring of Joint Transnational Calls for collaborative research projects and will co-lead task 9.3: Monitoring of Rare Disease Research Challenge Pillar 3: - In WP16 (Online academic education course), FFRD will coordinate the WP (task leader on task 16.1: Assess the needs, target audience, main topics of the academic education course and task 16.2: Developing the online course and task participant in task 16.3: Follow-up, assessment and monitoring of the course). - In WP18 (Development and adaptation of training activities), FFRD will co-lead task 18.1: Evaluation of developing needs according to progress of work in Pillars 2 and 4 and relevant adaptation of training activities and be task participant in task 18.2: Evaluation of strategic priorities and development of existing training activities according to specific needs of EU-13 countries. Pillar 4: In WP19 (Facilitating partnerships and accelerating translation for higher patient impact), FFRD will be involved as task participant in task 19.2: Development and exploitation plan and task 19.3: Follow-on funding. Previous experience relevant to the Tasks: FFRD has developed a French inter-University diploma on RD translational research in 2014-2015 together with 5 825575 – EJP RD – Part B 71 French Universities (hence its coordination of WP16/Pillar 3 and participation Associated within WP18/Pillar document 3). Ref. Ares(2018)6091977 - 28/11/2018 FFRD coordinates a group of pharmaceutical and biotech companies that have an interest in the early identification and promotion of development projects for candidate medicines, (the “Promotion of Proof of Therapeutic Concepts” Club) (hence its coordination of WP8/Pillar 1 and participation in WP19/Pillar 4). FFRD has successfully handled multiple calls for proposals both in Biomedical Sciences and Social Sciences and Humanities (hence its involvement in Pillar 1 in the management and monitoring of Calls for proposals) Description of any significant infrastructure and/or major items of technical equipment, relevant to the proposed work: FFRD has a significant background in launching, managing and monitoring calls for proposals (from start to closure). More than 325 grants have been awarded at the French national level for above 9,4M€ in approved funding since the launch of FFRD in February 2012. More than 1000 external experts have been involved in reviewing applications, more than 2500 evaluations have been performed and 50 expert committees organised. FFRD is working with a renowned service provider (eVision) for electronical submission of projects. Short Profile of key Staff Members who will be undertaking the work Ms.Roseline Favresse Roseline Favresse has an academic background in Social Sciences and Humanities in (female) France and Canada (MA in Geopolitics from Sorbonne University and Ecole Normale Supérieure (Paris). She is specialized in the set-up, development and management of international research projects & capacity-building programs in Europe and worldwide. While working for international organizations, NGOs and consulting companies, she has developed a strong knowledge of EU public policies and funding schemes/instruments. For 9 years now, she has been working in the RD field, first as a consultant by setting-up and managing FP6/FP7/H2020 projects (incl. TREAT-NMD) in answer to EC Calls for proposals; then, at FFRD since 2012 where she is coordinating international involvement of FFRD and also acting as a Regional Coordinator helping clinicians and researchers speeding up their RD development projects for new medicines. Dr. Christine Fetro Dr Christine Fetro is a Pharm. D. specialized in Clinical Pharmacy, Regulatory Affairs (female) (MSc) and Public Health. She started working at Canadian and French hospitals with involvement in effective medication management and clinical trials. She then worked for 20 years in the pharmaceutical industry holding various positions in the area of public and medical affairs at an international level. As a medical affairs manager (OPI/Eusa) she had the opportunity to focus on RD and orphan drugs challenges and develop a medical and regulatory strategy to register a drug in the Lambert Eaton syndrome. At FFRD, she coordinates the group of pharmal companies with a common interest in RD and early identification of PoC from academic researchers. The main objective is to build successful partnerships between academia and industry. Dr. Ingrid Zwaenepoel Dr Ingrid Zwaenepoel has obtained a PhD in Human Genetics with a Cell and Molecular (female) Biology specialty. She managed research projects at the Pasteur Institute (Paris), the Faculty of Medicine (Geneva) and Curie Institute (Paris). Since 2012, as the FFRD Scientific policy officer, she animates and implements the Scientific Policy, by coordinating in close interaction with the Scientific Advisory Board, calls for proposals in Biomedical Sciences as well as Social Sciences and Humanities and by managing partnerships with technological platforms and providers. Prof. Daniel Scherman Prof Daniel Scherman is a Member of EURASC (European Academy of Sciences) and (male) Head of its Division Medicine and Life Sciences. As FFRD Director, he is in close relationship with the main EU pharmaceutical companies involved in RD, with which common actions are undertaken, such as: co-development of PoC projects, research funding and linking academics with pharma/biotech companies. His academic production is of 490 publications, h index: 62, 16 000 quotations without self-citations. Most of his recent works concern the field of RD, such as Mucopolysaccharidoses of types III-A (Sanfilippo) and VII (Sly), Duchene Muscular Dystrophy, and Leber congenital amaurosis. Prof Scherman has coordinated the FP6 MOLEDA Project (Molecular optimization of laser/electrotransfer DNA administration into muscle and skin for gene therapy) (2005-2008) and the TRANSPOSMART E-Rare2 Project (An innovating platform using transposon and S/MAR for von Willebrand disease gene therapy) (2012- 2015). List of the most relevant publications and/or products, services (including widely-used datasets or software), or other achievements : 825575 – EJP RD – Part B 72 1. French inter-University diploma on RD translational research setAssociated up in 2014 with with 5 French document Universities. - 28/11/2018 Ref. Ares(2018)6091977 2. FFRD group of pharmaceutical and biotech companies that have an interest in the early identification and promotion of development projects for candidate medicines, (the “Promotion of Proof of Therapeutic Concepts” Club). Launched in April 2017, the club has led to a series of meetings and first partnerships are being concluded between researchers and companies. 3. Five to seven annual calls for proposals for boosting RD research in the fields of NGS, animal model, translational research, HTS and Social Siences and Humanities. List of relevant previous projects or activities, connected to the subject of this proposal: . RD-Connect; H2020, European Commission; 2012-2018; at FFRD, R. Favresse is responsible for inventorying tools developed by RD-Connect in the "–omics" field within the Impact WP. . IRDiRC: FFRD is a member of the IRDiRC Consortium Assembly as a Funding organisation. 13-AFM Full legal name (Acronym) – Country AFM Téléthon (Association Française contre les Myopathies), France Principal investigator Alexandre MEJAT Relevant Network ERN-EuroNMD, Orphanet Description of the legal entity/department/laboratory/group: AFM-Téléthon is a French neuromuscular disease patient association funding research on rare genetic diseases and supporting development of innovative biotherapies such as cell and gene therapies. It also supports and manages three Institutes of research: Genethon (Evry, France) dedicated to gene therapy development; I-Stem (Evry, France) dedicated to stem cell therapy and drug screening; and the Institute of Myology (Paris, France) dedicated to clinical research, medical follow-up and clinical trial management for neuromuscular diseases. Main tasks in the project per Pillar/WP: Pillar 1: In WP8 (Rare Disease Research Challenges), we will participate to the workshops implicating industries and stakeholders to identify the specific challenges related to research on rare diseases (Task 8.1) and to the committee approving the Challenges (Task 8.2). Pillar 4: In WP19 (Facilitating Partnerships and accelerating translation for higher patient impact), we will provide our expertise to advise and support projects approaching the end of EC funding (Task 19.2) and participate in the definition of a funding platform dedicated to rare diseases in collaboration with FTELE and EATRIS (Task 19.4). In WP20 (Accelerating the validation, use and development of innovative methodologies tailored for clinical trials), AFM Telethon Medical Affairs department and Institute of Myology (Third party) will provide experts reinforcing the “Task force group on clinical trials” (Task 20.1) and help more particularly in Subtask 20.1.3 “Mapping existing methodologies and prioritize the needs for demonstration or innovative methodologies for clinical studies in rare diseases”. Previous experience relevant to the Tasks: AFM-Téléthon has been creating and developing its own research and development platforms (Genethon and I- Stem) dedicated to research on rare diseases to address unsolved issues in terms of innovative biotherapies development (Pillar 1 – WP 8). It also initiated, in collaboration with the French Bank for Investment (BPI France), its own investment fund investing 50M euros to support 6 start-ups companies dedicated to early stage of research in rare diseases. Moreover, AFM Telethon established research partnerships with several pharmaceutical companies in the field of rare diseases (Pillar 4 – WP 19). AFM-Téléthon and its associated Institute of Myology have developed innovative devices (MyoTools) generating new outcome measures dedicated to the validation of therapeutics approaches implicating mobility limitations (Pillar 4 – WP20). 825575 – EJP RD – Part B 73 Associated with document Ref. Ares(2018)6091977 - 28/11/2018 Description of any significant infrastructure and/or major items of technical equipment, relevant to the proposed work : AFM-Téléthon manages and financially supports three Institutes dedicated to the development of innovative biotherapies (Gene therapy in Genethon and Stem cells in I Stem) and to the clinical trials (Institute of Myology) for rare genetic diseases. Short Profile of key Staff Members who will be undertaking the work Dr Alexandre Alexandre MEJAT is a patient and a PhD in molecular and cellular biology by training. He is in MEJAT (Man) charge of the International Scientific Affairs at the scientific department of AFM Telethon. He was a member of the Board of AFM Telethon (2010-2017) and of the I Stem Institute (2004- 2017). Dr Sandrine Sandrine SEGOVIA-KUENY is Director of the Medical Affairs department at AFM-Telethon. SEGOVIA- Medical doctor and PhD in legal affairs by training, Dr Segovia-Kueny has been previously vice- KUENY director of a French Regional Health Agency (ARS). (Woman) List of the most relevant publications and/or products, services (including widely-used datasets or software), or other achievements (max 5) 1. MyoTools description and use: Upper limb strength and function changes during a one-year follow-up in non- ambulant patients with Duchenne Muscular Dystrophy: an observational multicenter trial. Seferian AM, Moraux A, Annoussamy M, Canal A, Decostre V, Diebate O, Le Moing AG, Gidaro T, Deconinck N, Van Parys F, Vereecke W, Wittevrongel S, Mayer M, Maincent K, Desguerre I, Thémar-Noël C, Cuisset JM, Tiffreau V, Denis S, Jousten V, Quijano-Roy S, Voit T, Hogrel JY, Servais L. PLoS One. 2015 (Fév).10(2) : e0113999. 2. Motor Function Measure : http://www.motor-function-measure.org/home.aspx 3. 4. 5. List of relevant previous projects or activities, connected to the subject of this proposal (max 5): - AFM Téléthon has been at the initiative, in collaboration with INSERM, of the Orphanet portal. - AFM Téléthon has been at the initiative of Eurordis creation. 14-IMAGINE Full legal name (Acronym) – Country Institut des Maladies Génétiques Necker Enfants Malades (IMAGINE), France Principal investigator Stanislas Lyonnet Relevant Network EURORDIS Description of the legal entity/department/laboratory/group: Imagine is a research institute dedicated to the study of genetic diseases. Its main objective is to integrate research into clinical practice in order to better understand genetic diseases with unmet medical needs, and to propose and validate diagnostic and therapeutic approaches. The study of genetic diseases is fed by knowledge of fundamental biological mechanisms, and in reverse may uncover novel biological concepts. This vision can be considered according to four core missions: patient-focused research; innovative care; education and training; and technology transfer. The Innovation and Technology Transfer Department of Imagine supports the development of public-private partnership and the valorization of the academic research performed in the institute. Main tasks in the project per Pillar/WP: Pillar 3: In WP14, we will provide a number of cases to ISS for the 3-day training course. We will also be involved in the follow-up phase (task 14.3) In WP15, we will provide in-kind facilities plus on-site visits to genetic labs, bioinformatics, animal facilities and interactive discussions with research teams during the training for patient advocates on scientific innovation and 825575 – EJP RD – Part B 74 translational research aspects in rare diseases (task 15.2) Associated with document Ref. Ares(2018)6091977 - 28/11/2018 Previous experience relevant to the Tasks: The institute is focused on genetic diseases and is involved in the organization of several courses dedicated to rare genetic diseases, with academic and private partners. Imagine institute already hosts the Eurordis Winter School. Indeed, Imagine institute for Genetic Disease is perfectly relevant to the topic of this Winter School. The institute provides speakers and in-kind facilities. Description of any significant infrastructure and/or major items of technical equipment, relevant to the proposed work: Imagine institute is located in the middle of Paris and is fully accessible to people with disabilities. The laboratories and facilities are located in the same place and can be visited by all the participants of the training. Short Profile of key Staff Members who will be undertaking the work Pr.Lyonnet Stanislas Director of Imagine Institute (male) Marlange Romain Head of Innovation and Technology Transfer Department (male) List of the most relevant publications and/or products, services (including widely-used datasets or software), or other achievements: - Hosting of the Eurordis Winter School - Organization of a Master Class program on rare diseases with a large pharma company - Participation to the training program EUR-GENE with Descartes University - Organization of the Master “Bioentrepreneurs” with Ecole Polytechnique, HEC Paris and Descartes University List of relevant previous projects or activities, connected to the subject of this proposal: - Several research projects focused on rare diseases are coordinated by Imagine, some funded by institutional partners (RHU C’IL-LICO funded by ANR on ciliopathies, others by foundations such as MSD-Avenir on developmental disorders. - Imagine institute is coordinator of a DIM project, funded by the “Ile-de-France” region, which supports a major interest area, the gene therapy, capitalizing on the expertise acquired by academic, hospital, industrial, associative and socio-economic actors of the “Île-de-France” region. - Imagine is partner of the SeqOIA (Sequencing, Omics, Information Analysis) pilot project for very high- throughput health sequencing platforms, of the Plan France Médecine Génomique 2025 which promotes the implementation and prospective over 10 years of the conditions of access to genetic diagnosis in France. 15-DLR Full legal name (Acronym) – Country Deutsches Zentrum für Luft- und Raumfahrt e.V. (DLR), Germany Principal investigator Dr. Ralph Schuster Relevant Network ERA-Net E-Rare Description of the legal entity/department/laboratory/group: DLR is a non-governmental, non-profit German research organisation. Its Project Management Agency DLR-PT is mandated by the Federal Ministry of Education and Research (BMBF) and other ministries with regard to implementation and management of governmental programmes for research funding. Being a trustee for the funding budget, PT-DLR administrates, with a staff of over 1000, more than one billion € of research funding p.a. Fields covered – amongst others – are information technology, education, environment, and life sciences. Within the life sciences, the “health research” department of DLR-PT manages the areas of clinical research and biomedical research for BMBF, administrating a total of more than 200 million € annually in several governmental programmes aiming at fostering all areas of health research, health related research infrastructure as well as internationally competitive research. Main tasks in the project per Pillar/WP: Pillar 1: we will be responsible for co-leading Pillar 1 activities In WP6, we will be responsible for leading the WP and for leading and performing the first Joint Transnational Call (task 6.1) In WP8, we will contribute to planning and implementing the Rare Disease Challenge (tasks 8.1-8.3) In WP9, we will contribute to the monitoring of the Joint Transnational Calls (task 9.1) and the Rare Disease Research Challenge (task 9.3) 825575 – EJP RD – Part B 75 Pillar 0: Coordination and transversal activities: Associated with document Ref. Ares(2018)6091977 - 28/11/2018 In WP1, we will contribute to the management as part of the operating group and the executive committee (task 1.2, 1.3, 1.4). In WP2, we will we will contribute to the strategy development as part of the operating group and the executive committee (task 2.2, 2.4)as well as one of the responsible task leaders for one of the Joint Transnational Calls (task 2.3). In WP3, we will contribute to the sustainability development as part of the operating group (task 3.1). In WP4, we will contribute to the ethical, regulatory, legal and IPR framework as part of the operating group and (task 4.2). In WP5, we will contribute to the communication and dissemination as part of the operating group (task 5.1). Previous experience relevant to the Tasks: On behalf of BMBF, the “health research” department of DLR-PT has already participated in E-Rare1-3 and managed 3 of the 10 joint call secretariats for the transnational calls implemented within these three ERA-Nets. Additionally, it is currently acting as coordinator of the ERA-Nets NEURON and ERA-CVD, and has participated / is participating in a number of other health research related ERA-NETs (e.g. TRANSCAN, HIVERA, ERA PerMed) and Joint Programming Initiatives (JPND, HDHL). Other departments of DLR-PT are coordinating or participating in many other ERA-Nets, and there are regular meetings dedicated to discuss the experience with the various ERA-Nets. DLR-PT is also involved as a partner in ERA-LEARN. Also, DLR-PT manages a large and growing number of transnational calls both within and outside of ERA-Nets and JPIs for BMBF, and is serving as call secretariat for many of them. Relevant know-how is pooled, and very experienced personnel available. Description of any significant infrastructure and/or major items of technical equipment, relevant to the proposed work : DLR-PT has developed the online proposal submission and evaluation tool PT-Outline which has been and will be used for managing the joint transnational calls. This tool is also available for the management of other research funding schemes in the EJP RD. Short Profile of key Staff Members who will be undertaking the work Dr. Ralph Dr. Ralph Schuster obtained his PhD in biology at the University of Gießen in 2000 with studies Schuster on the molecular biology of the hepatitis B virus. In 2001 he joined the DLR-PT as a scientific (male) officer. Since then, he has been involved in several funding programmes including rehabilitation, genomics and rare disease research. Since 2004, he is the coordinating scientific officer for the national rare disease research funding programme. He participated from the start in setting up the ERA-Net E-Rare and coordinates the German efforts in this network. He has been co-chair of the E-Rare network steering committee since 2013. In addition, he is involved in the national action league for people with rare diseases (NAMSE) which drafted the national plan for people with rare diseases in Germany. He is also member of the IRDiRC consortium on behalf of the BMBF. Dr. Michaela Dr. Michaela Fersch obtained her PhD in biomedicine at the University of Bonn in 2009 working Fersch on immunoregulation in the liver. After a 2-year post-doc she joined the DLR Project (female) Management Agency (DLR-PT) in 2011. Since then she has been involved in several funding programmes including clinical studies, health services research on aging, integrated research and treatment centers as well as rare disease research. Within the programmes of rare disease research she worked on the national funding initiative as well as in the ERA-Net E-Rare. In addition, she is involved in the national action league for people with rare diseases (NAMSE). Dr. Katarzyna Dr. Katarzyna Saedler obtained her PhD in genetics at the University of Cologne in 2015 working Saedler on the genetic mechanism of adipositas and cancer. Completing her PhD work during a short (female) post-doc she joined the DLR Project Management Agency (DLR-PT) in 2017. Since then she has been involved in several funding programmes including clinical studies, child and youth health, integrated research and treatment centers as well as rare disease research. Within the programmes of rare disease research she worked on the national funding initiative as well as in the ERA-Net E- Rare. List of the most relevant publications and/or products, services (including widely-used datasets or software), or other achievements: 1. Joint call secretariats for E-Rare calls in 2009, 2013, 2015 2. Participation in E-Rare 1-3 3. Participation in IRDiRC consortium 4. Involvement in drafting the national action plan for rare diseases 5. Julkowska D, Austin CP, Cutillo CM, Gancberg D, Hager C, Halftermeyer J, Jonker AH, Lau LPL, Norstedt I, Rath A, Schuster R, Simelyte E, van Weely S. Gene Ther. 2017 Sep;24(9):562-571. The importance of international collaboration for rare diseases research: a European perspective. 825575 – EJP RD – Part B 76 List of relevant previous projects or activities, connected to theAssociated subject with of this proposal document : Ref. Ares(2018)6091977 - 28/11/2018 . E-Rare; European Commission; 2006-2010, participating in all activities and the 2 joint transnational calls, management of the 2009 Joint Transnational Call . E-Rare-2; European Commission; 2010-2014 participating in all activities and the 4 joint transnational calls, management of the 2013 Joint Transnational Call, co-chair of the Network steering committee since 2013 . E-Rare-3 co-fund; European Commission; 2014-2019- participating in all activities and the 4 joint transnational calls, management of the 2015 Joint Transnational Call, co-chair of the Network steering committee 16-UKA Full legal name (Acronym) – Country Universitätsklinikum Aachen (UKA), Germany Principal investigator Prof. Dr. rer. Nat. Ralf-Dieter Hilgers Relevant Network IDeAl The University Hospital Aachen combines consistent patient care, efficient teaching and innovative research. The building of UKA combines the hospital, the Medical Faculty and dentistry and is a place for collaboration of physicians, scientists and engineers. Currently around 2.700 students in medicine and dentistry are studying at the Medical Faculty of RWTH Aachen University. At the moment 59 professors, 824 scientific assistants and 4.347 non-scientific employees work together in 34 clinical departments and 23 institutes and administration facilities. The Department of Medical Statistics (IMSA) being part of the Medical Faculty of the RWTH Aachen University was founded in 2001. Nowadays the team consists of 1 professor, 1 assistant professor, 3 scientist, 3 non scientific employees, secretary and 10 student workers. Since 2013 the department coordinated the FP7 funded IDeAl project (No. 602552). Main tasks in the project per Pillar/WP: Professor Ralf Dieter Hilgers is co-lead of WP20 in Pillar 4 and recognizes the corresponding responsibilities resulting from the work and results of this work package. He contributes as member of the TFG to task 20..1, and perhaps provides research in projects of task 20.3 and20. 4. He also interacts with ECRIN in task 20.2. Previous experience relevant to the Tasks: Professor Ralf-Dieter Hilgers coordinated the FP7 funded IDeAl project (No. 602552) developing new statistical methodologies in the design and analysis of small population clinical trials. Among other dissemination activities IDeAl results in around 70 peer reviewed publications (www.ideal.rwth- aachen.de). Description of any significant infrastructure and/or major items of technical equipment, relevant to the proposed work : Professor Ralf-Dieter Hilgers coordinated the FP7 funded IDeAl project (No. 602552) developing new statistical methodologies in the design and analysis of small population clinical trials. He has IPP rights of the developments. Within his department of medical statistics at UKA, computer resources are available to conduct the proposed activities within the EJP. He will be assisted by Professor Dr. rer. medic Nicole Heussen the co-lead and senior statistican of the IDeAl project. Short Profile of key Staff Members who will be undertaking the work Dr. Ralf Dieter Hilgers Professor who studied mathematics at RWTH Aachen University. He finished his (male) doctoral thesis at the statistical faculty of the University of Dortmund in 1991. In 2000 he received the Venia Legendi for Medical Statistics at the University of Cologne. Since 2001 he is head of the Department of Medical Statistics (IMSA) at the Medical Faculty, RWTH Aachen University. His research interest is in optimal design of experiments, randomizations procedure and clinical trials. Since 1987 he gives biostatistical advice to clinical and experimental trials in all clinical and preclinical areas. Professor Hilgers teaches 300 students in different bio-scientific areas per year and is responsible for the education of investigators in clinical trials. He also acts as reviewer for methodological and clinical journals with main focus on surgical trials. He was coordinator of the IDeAl project funded by the European Community (www.ideal.rwth- aachen.de) form 2013-2017, which established new methodologies for small population group trials. Pr. Nicole Heussen Professor Dr, Nicole Heussen (female) is a biostatistician. She graduated in Statistics at 825575 – EJP RD – Part B 77 (female) the University of Dortmund and received her PhD Associated in theoretical with document medicine (2004) Ref. Ares(2018)6091977 and - 28/11/2018 the habilitation with venia legendi for Medical Biometry and Clinical Epidemiology (2012) from the Medical Faculty at RWTH Aachen University. In April 2016, she was appointed to a professorship for Evidence Based Medicine at the Medical School of the Sigmund Freud University in Vienna. Her research interest centres around the design of pre-clinical studies and randomization based inference. She provides statistical input into clinical development plan, project objectivities, experimental design, and data analysis since 1998. Currently she is working as a researcher and teacher for biostatistics and related areas in Aachen and Vienna. List of the most relevant publications and/or products, services (including widely-used datasets or software), or other achievements : 1. Hilgers RD., Bogdan M., Burman CF., Dette H., Karlsson M., König F., Male Ch., Mentré, F., Molenberghs, G., Senn, SJ.: Lessons learned from IDeAl — 33 recommendations from the IDeAl‐Net about design and analysis of small population clinical trials. Orphanet Journal of Rare Diseases (under review) 2. Hilgers, R.-D., Uschner, D., Rosenberger, W. F., Heussen, N.: ERDO – a framework to select an appropriate randomization procedure for clinical trials. BMC Medical Research Methodology, 4. December 2017. 3. Hilgers, R.-D., König, F., Molenberghs, G., Senn, S.: Design and analysis of clinical trials for small rare disease populations. Journal of Rare Diseases Research & Treatment. Volume 1. Issue 3. pages 53-60. November 2016. 4. Reetz, K., Dogan, I., Hilgers, R.-D., Giunti, P., Mariotti, C., Durr, A., Boesch, S., Klopstock, T., Rodriguez de Rivera, F., Schöls, S., Klockgether, T., Bürk, K., Rai, M., Pandolfo, M., Schulz, J.: Progression characteristics of the European Friedreich’s Ataxia Consortium for Translational Studies (EFACTS): a 2 year cohort study,The Lancet Neurology. Volume 15. pages 1346-1354. December 2016. 5. Hilgers, R. D., Roes, K., and Stallard, N.: Directions for new developments on statistical design and analysis of small population group trials. Orphanet Journal of Rare Diseases. Volume 11. Issue 1. pages 78. June 2016. List of relevant previous projects or activities, connected to the subject of this proposal : . Coordinator and WP1 an 2 lead of the IDeAl, FP7 funded IDeAl project (No. 602552) . Persist a Innovative Training Networks (ITN) within MARIE SKŁODOWSKA‐CURIE ACTIONS (Call: H2020‐ MSCA‐ITN‐2018) proposal submit to EC 17th January 2018 17-CHARITE Full legal name (Acronym) – Country Charité Universitätsmedizin Berlin (Charité), Germany Principal investigator Andreas Kurtz, Sebastian Köhler Relevant Network hPSCreg Description of the legal entity/department/laboratory/group: Charité (www.charite.de) is the joint medical faculty of the Humboldt University - and the Free University Berlin. The Charité is one of Europe’s largest university hospitals with over 100 clinical departments and specialized research institutions with 160.000 in-patients and a turnover of about 1 billion EUR per year. Innovative capacity and responsible governance are the central tenets behind Charité research endeavors; with approximately 3,700 researchers developing innovations in the field of medicine. Committed to highest standards of quality and sustainability, they work across 1,000 projects, working groups and collaborative projects. There is a particular focus on the interface between basic and patient-oriented research, which seeks to foster interdisciplinary collaborations with both national and international partners. High priority is given to research areas that offer an interdisciplinary approach and close integration of basic and clinical research. While to ensure that new research findings are quickly translated into clinical practice, training of the next generation of physicians and researchers is equally important. The Berlin-Brandenburg Center for Regenerative Therapies (BCRT – www.b-crt.de) and its associated graduate school is located at one of Charité's 4 campuses and associates more than 15 institutional partners. The BCRT is was established by the German Federal Ministry of Education and Research as a translational center, and is a joint initiative between the Charité and Germany’s largest research organization the Helmholtz-Association. The Laboratory for Stem Cell Research and Knowledge Management at the BCRT coordinates the European human pluripotent stem cell registry (https://hPSCreg.eu), a platform to collect, comprehend and make available data for human stem cells. 825575 – EJP RD – Part B 78 Main tasks in the project per Pillar/WP: Associated with document Ref. Ares(2018)6091977 - 28/11/2018 Pillar 2 In WP11, we will be working on the organization and integration into the consortium data framework of cell related data and implement FAIR principles. Task 11.1 : (HPO/Köhler group) Metadata and ontological model definition for cataloging resources for RD research 11.1.2. Define an ontological model compatible with existing key databases and resources Task 11.2 : (hPSCreg/Kurtz group) FAIR-compliant platform for discovery of RD resources 11.2.1. Collaboratively assemble and curate metadata based on the Orphanet catalog, on an ongoing basis, to represent all key databases and resources Task 11.3 : (hPSCreg/Kurtz group) Data deposition and access to data infrastructures for RD research 11.3.3. Adopt a Privacy-Preserving Record Linkage solution to enable data from the same individual to be connected across resources 11.3.4. Provide data deposition guidelines and documentation In WP12, we will Enabling sustainable FAIRness and Federation at the data record, patient and sample level for RD Task 12.1 : (hPSCreg/Kurtz group) Compare and align core interoperability standards of relevance management 12.1.5. Ontologies & semantics for record-level clinical and preclinical information 12.2.1. Semantic and syntactic harmonisation of data records Task 12.3 : (hPSCreg/Kurtz group) Combining expertise for practical FAIRification support. Subtask 12.3.3 (“FAIR data stewardship service”) entails practical FAIRification activities. Pillar 3: In WP14, we will provide Training on data management & quality Task 14.4: (hPSCreg/Kurtz group) Training for biobanks and researchers/clinicians on sample data Previous experience relevant to the Tasks: The Kurtz group (hPScreg) established and manages several cell focused databases (hPSCreg.eu, CellFinder.org) on the international level and within consortia, and developed relevant tools for their exploitation, association, standardization and improved accessibility (e.g. standard naming tool, ontologie tools, sample classifier). The work involved the management of data of diverse formats, from different sources and multiple levels of standardization, which are highly relevant for the proposed work. The Köhler group has led the development of the Human Phenotype Ontology (HPO) and disease annotations, developed several algorithms for matching of phenotypic profiles (i.e. sets of HPO terms) and provided knowledge integration for phenotype-driven genomics. He personally has 9+ years experience as leader, major developer, and maintainer of the HPO and HPO infrastructure, including maintaining and developing HPO-based tools for clinical diagnostics and variant prioritisation. Description of any significant infrastructure and/or major items of technical equipment, relevant to the proposed work : All necessary infrastructure for the proposed tasks, including IT hard and software as well as maintenance, data safety and security implementations and governance structures are available. Also available are relevant training data sets and infrastructure for training as part of the graduate school and the Einstein Center, both associated with BCRT. Short Profile of key Staff Members who will be undertaking the work Prof. Andreas Dr. Kurtz, is managing the EU-hESCreg project (https://hescreg.eu). He is head of the Laboratory Kurtz of Stem Cell Research and Knowledge Management at the BCRT. He established several national Male and international communications-, information technology-, and infrastructure projects in the field of stem cell research and regenerative medicine, including the European Bank of iPSC (EBiSC), Regenerative Medicine Initiative Berlin (RMIB), the Regenerative Medicine Initiative Germany (RMIG), the internet platforms CellFinder.de. He co-established the stem cell core at the BCRT and conducts research in organ modelling for preclinical cell therapy assessment based on iPSC. Prof. Kurtz became in 2006 founding PI of the BCRT and has previously worked as Professor at Georgetown (1995-2000), Harvard (2000-2003) and Seoul National (2009-2016) Universities. Prof. Dr.Köhler recently been appointed as Junior Professor at Charité and before worked at a post-doc Sebastian at NeuroCure in the group of Dr. Dominik Seelow. He is also a PI in the EU-funded project Köhler Solve-RD (http://solve-rd.eu/). He participated in the EU-project HIPBI-RD lead by Orphanet. Male The major focus of Dr. Köhler and his group is the phenotype-driven analysis of patients, 825575 – EJP RD – Part B 79 genomes, and cohorts using ontologies. He is one of thewith Associated co-founders ofAres(2018)6091977 document Ref. the Human Phenotype - 28/11/2018 Ontology (HPO) and has developed several algorithms and applications of HPO to data from different areas, such as genomics and clinics. Dr. Nancy Dr. Mah is a research scientist at the Berlin-Brandenburg Center for Regenerative Therapies at Mah Charité University Medicine Berlin. As an experienced data wrangler and analyst of transcriptome Female data, she has contributed to a number of publications in the development and stem cell fields, including pluripotent stem cells (PSC) and their PSC-derived cell types. Concurrently, she is developing bioinformatic methods to evaluate the cell identity of PSC-derived cell types compared to their native counterparts. A member of the International Society for Stem Cell Research (ISSCR) and German Stem Cell Network (GSCN), she is also involved in implementing interchangeable data formats for the European Stem Cell Registry (hPSCreg.eu) and actively represents hPSCreg at national and international stem cell conferences. Dr. Stefanie Dr. Seltmann is a bioinformatician and has been implementing stem cell related ontologies and Seltmann databases related to hPSCreg as well as the platform CellFinder. Her main activities are the concept Female and implementation of the database management system (DBMS) behind the public hPSCreg platform and development of long-term storage solutions. She will be responsible for implementing, monitoring, updating the technical concept, database, interface and dissemination. List of the most relevant publications and/or products, services (including widely-used datasets or software), or other achievements 1. Kurtz A, Bairoch A, Bittner MS, Bruce K, Capes-Davis A, Clarke L, Crook JM, Daheron L, Dewender J, Faulconbridge A, Fujibuchi W, Gutteridge A, Hei D, Kim YO, Kim JH, Kolb- Kokocinski A, Lekschas F, Lomax G, Loring JF, Ludwig T, Mah N, Matsui T, Müller R, Parkinson H, Seltmann S (*), Sheldon M, Smith K, Stachelscheid H, Stacey G, Streeter I, Veiga A, Xu RH. A standard nomenclature for referencing and authentication of pluripotent stem cells. Stem Cell Reports Stem Cell Reports. 2018 Jan 9;10(1):1-6. 2. Amrani KE, Stachelscheid H, Lekschas F, Kurtz A*, Andrade-Navarro MA. MGFM: a novel tool for detection of tissue and cell specific marker genes from microarray gene expression data. BMC Genomics. 2015 Aug 28;16:645. 3. Seltmann S, Lekschas F, Müller R, Stachelscheid H, Bittner MS, Zhang W, Kidane L, Seriola A, Veiga A, Stacey G, Kurtz A. hPSCreg--the human pluripotent stem cell registry. Nucleic Acids Res. 2016 Jan 4;44(D1):D757-63. 4. Zemojtel*, Köhler*, Mackenroth*, Jager, Hecht, Krawitz, Graul-Neumann, Doelken, Ehmke, Spielmann, Oien, Schweiger, Kruger, Frommer, Fischer, Kornak, Flottmann, Ardeshirdavani, Moreau, Lewis, Haendel, Smedley, Horn, Mundlos and Robinson (2014). "Effective diagnosis of genetic disease by computational phenotype analysis of the disease-associated genome." Sci Transl Med 6: 252ra123.10.1126/scitranslmed.3009262 5. Köhler, Vasilevsky, Engelstad, Foster, McMurry, et al. (2017). "The Human Phenotype Ontology in 2017." Journal/Nucleic Acids Res 45: D865- D876.10.1093/nar/gkw1039 List of relevant previous projects or activities, connected to the subject of this proposal . A. Kurtz is coordinator of hPSCreg, EU-funded since 2007: iPSC registry and data platform . A. Kurtz is responsible for the Information Management System of the EU-Bank of iSC-lines (IMI- EBiSC), since 2015 . A. Kurtz implemented the CellFinder database, a human cell atlas funded by German Research Foundation 2010-2013 . Dr Köhler is a PI within the Solve-RD project, responsible for phenotype-similarity calculation between solved and unsolved cases. . Dr Köhler was a postdoctoral researcher in the HIPBI-RD project, which aims at harmonising phenomics information for a better interoperability in the rare disease field. 18-UKLFR Full legal name (Acronym) – Country UNIVERSITAETSKLINIKUM FREIBURG (UKLFR) Principal investigator Prof. Janbernd Kirschner Relevant Network TREAT-NMD, EURO-NMD, ECRIN Description of the legal entity/department/laboratory/group: The Medical Faculty is one of the most prestigious research-driven medical schools in Germany and renowned for experimental as well as clinical research. The Medical Center – University of Freiburg is an independent public institution of the University of Freiburg. It is amongst the largest university hospitals in Germany. It collaborates 825575 – EJP RD – Part B 80 closely with the Medical Faculty, University of Freiburg according to Baden Associated withWuerttemberg state law and engages document Ref. Ares(2018)6091977 - 28/11/2018 in research, training and patient care as its core responsibilities, with the goal of offering its patients treatment informed by latest scientific findings. In 2009 UKLFR has established the Freiburg Center for Rare Disease and members of the center are involved in 10 different European Reference Networks for Rare Diseases including the EURO-NMD network for neuromuscular diseases. The Department of Neuropediatrics and Muscle Disorders has a long tradition in clinical research with special focus on rare diseases. UKLFR was founding member of the German muscular dystrophy network MD-NET and the TREAT-NMD network for translational research in neuromuscular disorders. The Department of Neuropediatrics and Muscle Disorders delivers its activities in close close cooperation with the Clinical Trial Unit (CTU) of UKLFR. The CTU is a central facility of UKLFR founded in 1997 which ensures compliance with international quality standards and participates in a number of international joint research projects. The CTU is an ECRIN certified center for data management. Main tasks in the project per Pillar/WP: Pillar 2: In WP11, the data of the CTSR will be linked to the EJP platform. In addition, the CTSR will be expanded further or replicated, to include all rare diseases organised along the lines for the ERN Thematic Groupings, extending beyond the original remit in TREAT-NMD. Participation in tasks 11.3.1, 11.3.3, 11.3.4, 11.4.4). Previous experience relevant to the Tasks: The Care and Trial Site registry (CTSR, PubMed 24148153) at Freiburg University – Medical Center is an IRDiRC recognized resource contributing to the European data infrastructure for rare neuromuscular and neurodegenerative disease and exposes highly phenotyped patient cohorts and specialist centres for clinical research (linked to ERNs EURO-NMD and RND). The CTSR currently contains information on the personnel, facilities and patient population of 320 centres in 48 countries, and site-reported data indicates that 60,000 patients are seen in these centres. Description of any significant infrastructure and/or major items of technical equipment, relevant to the proposed work: The Care and Trial Site registry (CTSR, PubMed 24148153) at UKLFR is part of the TREAT-NMD activities and contains information of more than 320 centres for neuromuscular and/or neurodegenerative disease in a single database. The CTSR is also used to collect relevant information for the ERN EURO-NMD from pariticipating centres. The information on patient numbers, investigators, infrastructure has been used in numerous feasibility requests from academic partners and industry to plan and conduct clinical and health care research projects. The Clinical Trial Unit (CTU) of UKLFR has more than 50 employees and provides all services to plan, conduct and evaluate clinical research projects. Together with the Department of Neuropediatrics and Muscle Disorders the CTU has developed specific expertise in the area of rare diseases. CTU has been certified by ECRIN as a European data management centre. Short Profile of key Staff Members who will be undertaking the work Pr.Janbernd Kirschner Acting Medical Director of the Department of Neuropediatrics and Muscle Disorders. As (male) paediatric neurologist his main interest is clinical research in neuromuscular diseases and other rare diseases. Under his leadership UKLFR has developed to one of the leading institutions for clinical research in neuromuscular diseases in Germany. He has been principal investigator for numerous clinical trials for spinal muscular atrophy and Duchenne muscular dystrophy. These include IIT-trials as well as industry sponsored trials. Kirschner was coordinator of the EU-funded project CARE-NMD which explored the care situation of Duchenne patients in 7 EU countries. Kirschner has recently established the SMArtCARE database to collect long-term observational data for patients with spinal muscular atrophy. Kirschner is designated chair of the TREAT-NMD alliance executive committee and member of the ERN EURO-NMD executive committee. Kirschner has authored more than 100 peer-reviewed publications und is section editor of the Orphanet Journal of Rare Diseases. Dr. Hanns Lochmüller Hanns Lochmüller has joined the Department of Neuropediatrics and Muscle Disorders (male ) at the UKLFR in February 2018. Previously, he held the Chair of Experimental Myology at the Institute of Genetic Medicine, Newcastle University, where he is co-led the MRC Centre for Neuromuscular Diseases. Recently, he set up and coordinated the EU funded RD-Connect project, and chaired the Interdisciplinary Scientific Committee of the International Rare Diseases Research Consortium (involving most major Rare 825575 – EJP RD – Part B 81 Disease funders such as the EuropeanAssociated Commission and theRef. with document NIH), which advises Ares(2018)6091977 this - 28/11/2018 global consortium on issues around data sharing, bioinformatics, registries and biobanks. These roles place him at the heart of efforts to bring together data, analysis methods and clinical bioinformatics tools applicable to rare disease. His research group has successfully established zebrafish as a tool for investigating hereditary muscle disorders and continues to publish basic and translational research in leading journals. Lochmüller has been principal investigator for several natural history and clinical trials for spinal muscular atrophy, Duchenne muscular dystrophy, myotonic dystrophy, and GNE myopathy. He has authored more than 450 peer-reviewed publications and is the editor- in-chief of the J of Neuromuscular Disease. Kirsten König Kirsten König works as an IT specialist at the Clinical Trials Unit of the University of (female) Freiburg – Medical Center. She has programmed registries such as the CTSR, of which she is also curator, as well as other web-based investigational tools. Adrian Tassoni Adrian Tassoni works as IT specialist and is responsible for the IT team at the Clinical (male) Trials Unit of the University Freiburg – Medical Center. He works in collaboration with the Department of Neuropediatrics since 2007 and is responsible the technical aspects of the CTSR, the TREAT-NMD Regulatory Affairs Database and the TREAT-NMD TACT Application Form. Within the Clinical Trials Unit he is responsible for a working IT infrastructure including the GCP-compliant development, validation and maintenance of computerized systems like data entry systems, electronic CRFs, and the IT for data-managers, bio-statisticians and pharmaco- vigilance. List of the most relevant publications and/or products, services (including widely-used datasets or software), or other achievements : 1. Finkel RS, Mercuri E, Darras BT, Connolly AM, Kuntz NL, Kirschner J, et al.; ENDEAR Study Group. Nusinersen versus Sham Control in Infantile-Onset Spinal Muscular Atrophy. N Engl J Med. 2017 Nov 2;377(18):1723-1732. 2. Rodger S, Lochmüller H, Tassoni A, Gramsch K, König K, Bushby K, Straub V, Korinthenberg R, Kirschner J. The TREAT-NMD care and trial site registry: an online registry to facilitate clinical research for neuromuscular diseases. Orphanet J Rare Dis. 2013 Oct 23;8:171. 3. Boycott KM, Rath A, Chong JX, Hartley T, …, Lochmüller H. International Cooperation to Enable the Diagnosis of All Rare Genetic Diseases. Am J Hum Genet. 2017 May 4;100(5):695-705. 4. Austin CP, Cutillo CM, Lau LPL, Jonker AH, Rath A, Julkowska D, … Lochmüller H, et al.; International Rare Diseases Research Consortium (IRDiRC). Future of Rare Diseases Research 2017-2027: An IRDiRC Perspective. Clin Transl Sci. 2018 Jan;11(1):21-27 5. Lochmüller H, et al.; RD-Connect consortium; NeurOmics consortium; EURenOmics consortium. RD-Connect, NeurOmics and EURenOmics: collaborative European initiative for rare diseases. Eur J Hum Genet. 2018 Feb 27. List of relevant previous projects or activities, connected to the subject of this proposal : . TREAT-NMD: EU-funded period 2007-2013; continuing as TREAT-NMD alliance . MD-NET: German Ministry of Research and Education, 2004-2011, co-lead, coordination of clinical trials . CARE-NMD: EU-funded, DG SANCO, 2010-2013, project lead, Evaluation of Care and Quality of Life of patients with Duchenne muscular dystrophy . CoordinateRare: German Ministry of Research and Education, 2011-2013, project lead, methodological centre for clinical research in rare diseases. . NEUROMICS: EU-funded; 2012-2017, sub investigator, Integrated European Project on Omics Research of Rare Neuromuscular and Neurodegenerative Diseases . ERN EURO-NMD: EU-funded reference network for neuromuscular diseases; since 2017, clinical site and member of the executive committee 19-NKFIH Full legal name (Acronym) – Country Nemzeti Kutatási, Fejlesztési és Innovációs Hivatal (NKFIH) – Hungary Principal investigator Gábor Tóth Relevant Network Description of the legal entity/department/laboratory/group: 825575 – EJP RD – Part B 82 The National Research, Development and Innovation Office (NKFIH, or NRDI Associated Office)Ref. with document was founded on 1 January Ares(2018)6091977 - 28/11/2018 2015 by the Act on scientific research, development and innovation (Act 2014/LXXVI) of the Hungarian Parliament (RDI Act) with the aim to create a stable institutional framework for the governmental coordination of the national research, development and innovation ecosystem, provide predictable funding and implement efficient and transparent use of available resources. It is a national strategic and funding agency for scientific research, development and innovation, the primary source of advice on RDI policy for the Hungarian government, and the primary RDI funding agency. It manages the National Research, Development and Innovation Fund to provide state support for research, development and innovation. Its mission is to develop RDI policy and ensure that Hungary adequately invests in RDI by funding excellent research and supporting innovation to increase competitiveness. Its mandate is to prepare the RDI strategy of the Hungarian government, to handle the National Research, Development and Innovation Fund, and represent the Hungarian government and the Hungarian RDI community in international organisations. Is vision is to be a world-class RDI funding agency, create an internationally attractive RDI environment in Hungary, and a stronger link of RDI to the economy and society to increase growth and prosperity. Main tasks in the project per Pillar/WP: Pillar 1 (Funding Collaborative Research on Rare Diseases): In WP6 NKFIH as a funding agency will participate in both co-funded Joint Translational Calls for collaborative research projects. We will be involved in topic selection, call preparation, call secretariat tasks, evaluation and funding decision. Previous experience relevant to the Tasks: With regard to supporting basic research, NKFIH administers open calls for proposals with a bottom-up approach towards research proposals, postdoctoral research proposals, and proposals for international cooperation (often based on bilateral agreements between NKFIH and foreign research funding agencies with the view of Europe and Hungary investing in a knowledge-based society) – without thematic priorities and with a special emphasis on the careers of talented young researchers and on the reintegration of Hungarian researchers returning from postdoctoral trainings or research projects carried out abroad. Competition is intense: in recent years, the average support ratio has been approximately thirty percent of the total number of proposals received. Their evaluation is based on a peer review system where individual expert reviews are collected through an online electronic proposal review system and proposals are further evaluated and ranked by a two-level system of review panels and scientific councils. Previous experience also includes active participation in the call secretariats of the ERA-Chemistry and the M- ERA.NET ERA-NET projects. In the annual program strategy, a specific budget line is dedicated to the support of Hungarian participation in the Horizon 2020 Programme, as well as in related ERA-NET projects such as FLAG-ERA, M-ERA.NET, Quantera, Infect-ERA, E-Rare and ERA PerMed. Furthermore, NKFIH participates in the AAL Joint Programme, in the Joint Programme – Neurodegenerative Disease Research (JPND) as well as in the ECSEL joint technology initiative, in the EUREKA and in the EUROSTARS programmes, and has numerous bilateral international agreements for joint programmes. As a member of the E-Rare-3 ERA-NET consortium NKFIH participated in all joint transnational calls launched by E-Rare-3. Short Profile of key Staff Members who will be undertaking the work Dr. Gábor Tóth Scientific background: bioengineering (MSc degree), molecular genetics (teaching and (male) research experience), bioinformatics (teaching and research experience, PhD degree). PhD in Biology (2001). Recent positions: Head of Department of Life Sciences at the Hungarian Scientific Research Fund, OTKA (2012–2014); Head of Unit of Medical and Biological Sciences at NKFIH (2015); Head of Department of Research and Development at NKFIH (2016–). In the above positions, he has been responsible for the administrative management of national funding programmes in the field of discovery (basic) research, coordinating evaluation of research proposals and monitoring of funded projects. He represents NKFIH in the ERA-NET consortium E-Rare-3. He is the national administrative delegate in the ELIXIR Board. Dr. Előd Nemerkényi PhD in Medieval Latin (2004). (male) Positions: Assistant of International Affairs at the Hungarian Scientific Research Fund, OTKA (2007–2014); Assistant of International Affairs in the Department of Research 825575 – EJP RD – Part B 83 and Development at NKFIH (2015–). Associated with document Ref. Ares(2018)6091977 - 28/11/2018 He represents NKFIH in the Working Group of the M-ERA.NET programme. He is also involved in the administrative management of proposal evaluation and project monitoring in national funding programmes. Dr. Klára Horváth She studied Physics and has a PhD degree in Experimental Molecular Biophysics. She (female) has been working with national and EU research programmes at NKFIH (and its legal predecessors) since 2009. Between 2009 and 2012, she took part in the management and monitoring tasks of major Hungarian programmes at the Department of Programme Planning, at present she is working with H2020-related projects and programmes in the field of Health at the Department of International Affairs. She is the national delegate in the Health Programme Committee, in the Innovative Medicines Initiative (IMI) States Representative Group, in the Joint Programme – Neurodegenerative Disease Research (JPND) Management Board and takes part in the ERA PerMed ERA-NET project. List of relevant previous projects or activities, connected to the subject of this proposal : E-Rare-3; Funder: European Commission; 2014-2019 participant; participation in the launching of joint transnational calls, funding and monitoring of projects. 20-HRB Full legal name (Acronym) – Country Health Research Board (HRB)- Ireland Principal investigator Dr Annalisa Montesanti Relevant Network Description of the legal entity/department/laboratory/group: The Health Research Board (HRB) is a state agency that supports research and provides evidence to prevent illness, improve health and transform patient care. Main tasks in the project per Pillar/WP: Pillar 1: WP6 Funding collaborative research on rare diseases -earmarked funds for co-funded call 1: 370,000 three hundred and seventy thousands euros -earmarked funds for co-funded call 2: 370,000 three hundred and seventy thousands euros Previous experience relevant to the Tasks: We have previous experience with the funding of JPI HDHL DEDIPAC which I managed from start to finish. Also there is plenty of additional expertise in the organisation as we are involved in several JPIs activities. Short Profile of key Staff Members who will be undertaking the work Dr. Annalisa Montesanti Programme Manager managing the Health Research Careers portfolio at the Health (Female) Research Board (HRB). She is responsible for developing and managing a portfolio of training and career development initiatives through a number of mechanisms and at many different levels – ranging from PhD students and mid-career researchers to leaders in health research and other training courses or training initiatives - and generally develop a coordinated approach to building capacity in health research in Ireland. She has previous experience in managing a variety of initiatives, including investigator-led projects, programmatic awards and several career development schemes, including securing funding from European Commission under FP7 MSCA COFUND. At international level she has represented the HRB in the steering committee of funders of the EC Joint Programme Initiative (JPI) Healthy Diet for Healthy Life (HDHL) and in the European Science Foundation (ESF) and Science Europe Research Careers working group. Before joining the HRB in 2005, Annalisa had 13 years’ experience in scientific research in institutions and Universities in Italy, England and Ireland. She has a Bachelor of Science (Molecular Biology) from Palermo University in Italy and a PhD in cancer biology from the Institute of Molecular Medicine in Oxford, UK. She was also awarded a fellowship from the Italian Association for Cancer Research while working in Italy and a Marie Curie Training and Mobility for Researchers fellowship while in Oxford 825575 – EJP RD – Part B 84 21-IT MoH Associated with document Ref. Ares(2018)6091977 - 28/11/2018 Full legal name (Acronym) – Country Ministry of Health – (IT- Moh) - Directorate of Research and Innovation in Healthcare, Italy Principal investigator Giselda Scalera Relevant Network Description of the legal entity/department/laboratory/group: The Ministry of Health represents the central level of the Italian National Health Service and is responsible for overall planning and control and to establish the Italian NHS targets and most important measures to be implemented. The Ministry is the leading body of the national information system on health, which includes data on hospital admission and health interventions; the Ministry is also responsible for the overall coordination of Prevention Programmes, including those for elderly and disabled people, in particular correct life-style promotion, surveillance of chronic diseases and c.d. risk factors, promotion and surveillance of secondary prevention. The Ministry is entitled of the resource management of operational Health research, and it is also the Governing body for the legislation on Medical Devices and Health Professionals. The participating Department/Director General has as general task the coordination of Health prevention, Health Research, International and EU Relations and External Communication activities. It also promotes actions and grants in several fields of public health. Main tasks in the project per Pillar/WP: Pillar 1: Task 2.3: Scientific programming of joint transnational calls (M1 – M36) Task 2.5: Translation/impact of prioritization on national and EU strategies (M13 – M60) Previous experience relevant to the Tasks: The Ministry of Health is the main public body funding biomedical research and biomedical innovation in Italy. As a strategic health policy instrument, the Italian the Ministry of Health runs two types of funding programmes in the fields of biomedicine: one on current research and another on targeted research. Current research funding is available to Scientific Institutes of Research, Hospitalisation and Healthcare (IRCCS), the yearly amount is around 170 Mio € and in the evaluation criteria used to allocate this type of research is included the results of the capacity of these Institutions to enter in EU Research Consortium funding in Joint Activities as ERANET and JPIs. Whereas the targeted research funding is open to all researchers of the National HealthSystem. Both programmes constitute priority initiatives for the improvement of the population’s health through the rapid translation of research results into new or improved preventive, diagnostic, and treatment products and processes, and incorporation into health policies and practice.In the period 2011-2012, in line with what was implemented in previous years, efforts were made to ensure transparency and competitive research with a call for proposals for "Targeted Research and Young Researchers 2011-2012". Within the framework of such programme, the Italian Ministry of Health allocated a total funding of about 135 Mio. €. By means of the Ministry of Health research funding vital synergies between public research and private research, including national research and research within and outside Europe are strengthened. At present, the MoH-IT is involved in the following European health research programmes: • E-Rare-3 • ERA PerMed • ERA-CVD • EuroNanoMed III • GENDER NET Plus • HBM4EU • ICPerMed Secretariat • JPco-fuND • JPI-EC-AMR • NEURON Cofund • TO-REACH • TRANSCAN-2 • ERA-NET for Latin American and Caribbean States II (ERA-NET-LAC II) • Active and Assisted Living - 2 (AAL- 2) The MoH-IT is also committed to support the ESFRI Research Infrastructures in the biomedical science sector, ECRIN, EATRIS and BBMR. Short Profile of key Staff Members who will be undertaking the work Dr.Gaetano Guglielmi Dr. Gaetano Guglielmi (is the Head of the Office of Health Research, DG for Research 825575 – EJP RD – Part B 85 (male) and Innovation in Healthcare. He represents thewithItalian Associated Ministry document of Health in - all Ref. Ares(2018)6091977 EU 28/11/2018 initiatives in which the DG for Research and Innovation in Healthcare is involved. Dr. Giselda Scalera Head of the Office of Health Research, DG for Research and Innovation in Healthcare; (female) she is involved for the Italian Ministry of Health in following EU initiatives: E-Rare-3; EuroNanoMed III ;GENDER NET Plus ; JPI-EC-AMR ; Active and Assisted Living - 2 (AAL- 2) List of relevant previous projects or activities, connected to the subject of this proposal: ERA-Net for Research Programmes on Rare Diseases E-Rare: Funder. . 22-TuscReg Full legal name (Acronym) Regione Toscana (TuscReg) - Italy – Country Principal investigator Katia Belvedere, Head of Sector for legal advice, research and support for clinical governance bodies, Directorate for Citizenship Rights and Social Cohesion, Tuscany Region Relevant Network These are the ERN where the Centre of Tuscany Region participates: BOND - European Reference Network on Rare Bone Disorders Endo-ERN - European Reference Network on Rare Endocrine Conditions EpiCARE - European Reference Network on Rare and Complex Epilepsies ERKNet - European Rare Kidney Diseases Reference Network ERN-RND - European Reference Network on Rare Neurological Diseases ERNICA - European Reference Network on Rare inherited and congenital anomalies ERN-LUNG - European Reference Network on Rare Respiratory Diseases ERN-Skin - European Reference Network on Rare and Undiagnosed Skin Disorders EURACAN - European Reference Network on Rare Adult Cancers (solid tumors) EuroBloodNet - European Reference Network on Rare Hematological Diseases EURO-NMD - European Reference Network for Rare Neuromuscular Diseases ERN-EYE - European Reference Network on Rare Eye Diseases ITHACA - European Reference Network on Rare Congenital Malformations and Rare Intellectual Disability MetabERN - European Reference Network for Rare Hereditary Metabolic Disorders PaedCan-ERN - European Reference Network for Paediatric Cancer (haemato- oncology) ReCONNET - Rare Connective Tissue and Musculoskeletal Diseases Network VASCern - European Reference Network on Rare Multisystemic Vascular These are the Health care Providers involved in ERN's: University Hospital Careggi University Hospital of Siena University Hospital of Pisa University Hospital Meyer Central Tuscany Local Health Authorities Gabriele Monasterio Tuscany Foundation Description of the legal entity/department/laboratory/group: Tuscany is a region in central Italy with an area of about 23,000 square kilometres and a population of about 3.8 million inhabitants. Regione Toscana (Tuscany Region) is the regional authority and administrative body of the region; it has legislative, administrative, and financial autonomy and is responsible, on a regional level, for issues including education, social issues, healthcare, international cooperation, and the environment. The Tuscan health system includes three Local Health Authorities and four university hospitals: • Central Tuscany: Local Health Authorities (Florence, Prato, Pistoia, Empoli) • Northwest Tuscany: Local Health Authorities (Lucca, Massa e Carrara, Versilia, Pisa and Livorno) • Southeast Tuscany: Local Health Authorities (Siena, Arezzo and Grosseto) • University hospital Careggi (Florence) 825575 – EJP RD – Part B 86 • University hospital Meyer (Florence) Associated with document Ref. Ares(2018)6091977 - 28/11/2018 • University hospital of Pisa • University hospital of Siena. The health system is the sector to which the region commits the largest share of its budget and organizational structure, and constitutes an infrastructure of services and activities that can generate positive effects throughout the region. It is, in spite of and even more so in a period of economic crisis, a driving force of development for the entire regional economy, in which economic development is seen not as an end in itself but also includes, in a context of sustainability, measures tied to the social sector and the environment. Regione Toscana is also actively involved in the promotion of the Tuscan Life Sciences Cluster for large and small companies operating in the sector. Regione Toscana has a long-standing tradition of activities to promote wellness, including healthy diets and physical activity. The latest version of Regione Toscana’s multi-year health plan includes a major focus on “health in all policies”, i.e. the promotion of healthy lifestyles across all sectors (urban planning, environment, welfare, transportation, commerce, schools, culture, sport, etc.). The project team will include colleagues in other relevant sectors of the regional government as well as the region’s associated health agencies for specific expertise on obesity; expertise in the management of European projects will also be present. Tuscany Region promotes health research and innovation policies to structure an integrated and synergistic research and innovation system in a coordinated context among Tuscan university hospitals and other institutions of the Regional Health Service. Main activities in this field: • calls for funding (using regional, national e structural funds); • creation of UVaR - office for exploitation of research results – that is engaged in assessing, monitoring and exploiting the results of research in terms of applicability and transferability. An activity to support the Tuscan university hospitals and other institutions of the Regional Health Service, universities and public research organizations in order to develop and leverage innovative capacity and technology transfer, also through the creation of collaborative channels with companies and other stakeholders in the Life Sciences sector; • Support to Tuscany Life Sciences Cluster, founded in 2011 by an initiative of the Tuscany Region aimed at creating an integrated Life Sciences system. Its mission is to act as the “glue” between the specialist industrial dimension and the institutional and systemic one, promoting dialogue among companies and the network of excellence present in the field of research and technology transfer in the region. The Rare Diseases Regional Network in Tuscany is the result of a process started in Italy with DM 279/2001 almost 17 years ago when the Regional Coordination group for rare diseases was established to represent highly specialized units, patients no-profit organizations, healthcare institutions. Tuscany region is implementing the National Plan on Rare Diseases with the aim of better organising both the healthcare paths for patients affected by rare diseases, and the regional network activity of the Centres of Expertise. The Centres for rare diseases must ensure continuity with the recommendations through specialized units within the regional network. 6 Health Care Providers in Tuscany are the seat of Centers of expertise on Rare diseases according the Recommendations of the EUCERD committee (2011) on the quality criteria for the selection and the evaluation of the "Centres of expertise" (CEs) for the rare diseases European Reference Networks (ERNs). This HCP partecipates with 28 specialised units in 17 ERN’s and one of them (Reumatology Unit - AOU Pisana) coordinates the ERN ReConnect. Main tasks in the project per Pillar/WP: Pillar 1: In WP6, we will participate in joint transnational calls of Pillar 1 task 6.1 with support of TLS (Linked Third Party) Previous experience relevant to the Tasks: Competence in the issue of calls for research using regional, national (MoH) e structural funds (ERDF) Short Profile of key Staff Members who will be undertaking the work Mrs Donatella Tanini Dontella Tanini has worked for Tuscany Region - Health Direction since 1990 in the (female) dealing mainly health research and health system. She is responsible of the posizione organizzativa "Health research and cooperation international health". Skills: Organization and coordination of activities related to health research, for the development and funding of research-innovation projects financed by regional, state and community funds. Relations with health research subjects and with regional directorates interested in the research and innovation system. Relations with regional technical structures of the European Union for the promotion and development of the Tuscan health research system. Coordination of administrative activities related to international health cooperation. 825575 – EJP RD – Part B 87 Mrs Ceclia Berni Middle manager in Tuscany Region, with a Master Associated DiplomaRef. with document in Ares(2018)6091977 Healthcare Management - 28/11/2018 (female) with honours (Sant’Anna School of Advanced Studies – Pisa) after been graduated with honours in Political Science. She supports the set up of regional policies and procedures for the development of the regional network on rare diseases and on pregnancy and child care. She is involved in the implementation of standards of diagnosis and care and of mechanism for evaluation. She coordinates the work of the Regional group for rare diseases and she is the regional representative in the Nationl working group for rare diseases. She is also involved in the Regional Committee on pregnancy and birth and in the National Committee on monitoring induced abortion. Ms Teresa Vieri Master’s Degree in Art, Music and Performing Arts Disciplines, University of Bologna, (female) graduated with honours; First Level Master in “Local human development and International Cooperation: theories, methods and best practices”. She has been Deputy Coordinator of the ART Secretariat for Decentralized Cooperation UNOPS/PNUD in Florence; Area Manager in the Nusa Tengara Timur Province, Indonesia for the ART Programme (Articulating Territorial and Thematic Networks for Human Development) of UNDP (United Nations Development Programme), Public Officer for International Relations and Cooperation in staff of the Mayor of Florence, Municipality of Florence. She is currently Assistant for the Management of National and European Funds, Directorate for Citizenship Rights and Social Cohesion, Tuscany Region. List of the most relevant publications and/or products, services (including widely-used datasets or software), or other achievements : 1. The Rare Disease Regional Network 2.http://toscanaopenresearch.it/ 3.http://www.meetthelifesciences.it/it/ List of relevant previous projects or activities, connected to the subject of this proposal : Projects financed by RT in the field of rare diseases currently in progress: . UNAVIR “Rare Viral Diseases: an innovative strategy to combat them with a single antiviral agent” UNIV. Siena, UNIV. Florence, UNIV. Pisa . GLIOMICS “Proteomic/genomic/metabolomics for biomarker detection and development of an ultra-sensitive detection platform in peripheral body fluids: application to multiform glioblastoma” Scuola Normale Superiore Pisa, Istituto Italiano di Tecnologia IIT, National Research Council CNR . DIAMANTE “Innovative molecular diagnostics for the individual therapeutic choice of pancreatic ductal adenocarcinoma” UNIV Pisa, National Research Council CNR, Scuola Normale Superiore Pisa, IIT NEST. 23-FRRB Full legal name (Acronym) – Country Fondazione Regionale per la ricerca Biomedica (FRRB)- Italy Principal investigator Gianni D’Errico Relevant Network IC-PERMED, ERA-PERMED, TRANSCAN2 Description of the legal entity/department/laboratory/group: The Lombardy Foundation for Biomedical Research (Fondazione Regionale per la Ricerca Biomedica - FRRB) is an entity governed by public law, a non-for-profit organization, established in October 2011 by Regione Lombardia, with the aim of promoting and supporting scientific research in Life Sciences in Lombardy (100 Million € from 2011 have been committed in innovative R&D projects so far). The Foundation represents the main strategic platform for boosting progress, research, development and innovation within the health sector among the regional academic and industrial life science players. Its raison d'être is to serve as support to and for implementing the regional health care research policy, in order to place the Lombardy regional system in a leading position in Europe within this field. In addition, the Foundation aims to distribute local and European resources to innovative basic and translational research projects which enable a positive impact on the local health care eco-system and citizens. Main Activities: • Promote research and innovation in Lombardy by assigning regional funds to basic and translational research projects through public tenders and calls for proposals as to create a financially sustainable and suitable environment for adding value to biomedical projects focused on different pathological conditions including rare diseases. 825575 – EJP RD – Part B 88 • Through R&D infrastructures, support and coordinate theAssociated with document Ref. Ares(2018)6091977 - 28/11/2018 implementation of scientific research on disease prevention, personalized medicine, medical devices and drug manufacturing and distribution. • Support and promote local and national technological clusters in life sciences, thus enabling a better coordination of research agendas in the biomedical field, as well as a more productive use of the available funds. • Attract European and International research funds to Lombardy by participating to European projects, as those in the EU HORIZON 2020 research and innovation funding program, and international partnerships. • Add value to funded projects derived research results through technology transfer activities in order to support and promote the development of new treatments, therapies and devices for the diseases of interest. • Promote the dissemination of scientific knowledge and culture including Responsible Research and Innovation (RRI) principles and promoting a gender balance among Research Funding Organisation (RFOs )and Research Performing Organisations (RPOs). Main tasks in the project per Pillar/WP: Pillar 1: In WP6 - We will participate on all the tasks listed in WP6 (Tasks 6.1 -6.2 -6.3 -6.4) Previous experience relevant to the Tasks: We are building a strong experience in the participation, coordination and management of Transnational Caals for Proposal. Particularly we are already part of the following networks: Main National and International Projects: 1. IC PERMED: FRRB is part of the Executive Committee of IC Permed and participates to the implementation of the roadmap in liaison with the Italian ministry of Health; 2. ERA-NET Transcan 2: FRRB is part of the call steering committee for the Joint Transnational call 2016 and has committed 1 Million € for the call. The support is continuing in the JTC 2017 with 1,25 M€. 3. ERA-PERMED: FRRB is partner and Work package Leader of Era-PerMed Projects and has committed 4 Million € for the joint Transnational Call 2018 Description of any significant infrastructure and/or major items of technical equipment, relevant to the proposed work : As a funding Agency we do not own Research/Innovation Infrastructure, nor technical equipment. We do use all the IT tools for the correct execution of regional and transnational Calls for Proposals Short Profile of key Staff Members who will be undertaking the work Mrs Marina Gerini General Director at FFRB.She obtained her degree cum laude in classic literature in 1981 at (Female) University of Florence. Since 1983 she became a civil servant and started her carrier in the Public Administration. In 1997 she became manager in the Lombardy Government serving at DG Family with responsibility of financial and human resources and between 2004 and 2005 she covered the interim position as responsible of public health interventions. In 2005 she was responsible of the Central DG for external and International Relations till 2009.Between 2009 and 2011 she became General Manager of Directorate General for Social Associations and Volunteering Organisation Associations at the National Ministry of Labour and Social Policy. Between 2011 and 2013 she covered the position of General Secretary of the Lombardy Assembly and was responsible of coordinating the work between the regional activities, the regional and national Government, as well as of realisation of the activities and programmes of the national presidency of the council of ministries. From 2013 to 2014 she was director at Regional agency for transparency and anti-corruption. From 2014 to 2015 she was appointed as Special Manager at Melegnano General hospital.In 2015 she was appointed as Social Director of the at Primary Care Trust (the Italian Azienda Sanitaria Locale) Milano 1 and in 2016 she was appointed as socio medical Director and PCT West Milano. Since February, 2nd 2017 she is General Manager at Lombardy Foundation for Biomedical Research Gianni D’Errico After graduated cum laude at University Federico II in Napoli and obtained my post (Male) graduate master’s degree in project management at SIOI in Rome, I started working in Brussels and then in Maribor, where I got acquainted with R&D programmes and innovative projects in Life Sciences. In Slovenia I cooperated with the University of Maribor, providing lectures to PhD students on IP issues within R&D international projects (competences certificated at University of Bonn). Since September 2015 I have been working at the Regional Foundation for Biomedical Research (a strategic agency specialized in financing highly scientific projects in Life Sciences), where I am in charge of the European strategy, programmes and projects with the aim to create synergies between Lombardy and other 825575 – EJP RD – Part B 89 European regions’ R&D&I projects/programmes/policy. I am member Associated with document of the IC-PERMED Ref. Ares(2018)6091977 - 28/11/2018 (International consortium on Personalised Medicine)Executive Committee, main facilitator of the ESTHER (Emerging and Strategic Technologies for Healthcare) Interregional cooperation group, and I have been implementing the participation of the Lombardy Region to TRANSCAN 2, ERA-PerMed (WP4 Leader – Monitoring of Cofunded projects) Dr. Paola Larghi Scopus Author ID: 24740841600 (Female) ORCID: http://orcid.org/0000-0001-7074-1590 Paola, Since 2017 is Scientific Officer at Fondazione Regionale per la Ricerca Biomedica. She got her degree in Biologic Sciences a University of Milan in 2005 followed by a PhD in experimental Pathology and Neuropathology. She worked as immunologist at European Institute of Oncology (2003-2005), Humanitas Clinical institute (2006-2010 e 2013-2014), and l’Institut Curie in Paris (2010-2013), University of Padova (2015) and at National Institute of Molecular Genetics (INGM) – University of Milan (2015-2017). As researcher she has published different papers on peerrewied international magazines, included Nature Immunology, and a book. (24 Scientific papers – h index 11). List of relevant previous projects or activities, connected to the subject of this proposal : . IC PERMED: FRRB is part of the Executive Committee of IC Permed and participates to the implementation of the roadmap in liaison with the Italian ministry of Health; . ERA-PerMed: we are WP leader of the ERA-PerMed, and we have committed for the JTC 2018 4 Million € . ERA-NET Transcan 2: FRRB is part of the call steering committee for the Joint Transnational call 2016 and has committed 1 Million € for the call. The support will continue in the JTC 2017. . TITTAN (Interreg Europe): Fostering the design, uptake and use of innovative technology based products and solutions for a healthy and active ageing. . TARGET: TAking a Reflexive approach to Gender Equality for institutional Transformation. We are partner of the project whose aim is to contribute to the advancement of gender equality in research and innovation (R&I) by supporting a reflexive gender equality policy in seven Gender Equality Innovating Institutions (GEIIs) in the Mediterranean basin. 24-FGB Full legal name (Acronym) – Country Fondazione per la Ricerca Farmacologica Gianni Benzi onlus (FGB)- Italy Principal investigator Viviana Giannuzzi Relevant Network ENERCA, TEDDY Description of the legal entity/department/laboratory/group: Fondazione per la Ricerca Farmacologica Gianni Benzi Onlus (FGB) is a registered not-for-profit scientific research organisation promoting research in biological, medical and pharmaceutical areas, with particular reference to patients affected by rare diseases and other populations with specific therapeutic needs. FGB aims are inspired to the work of Professor Gianmartino Benzi, a scientist who dedicated a large part of his life to promoting the translation of the emerging biological and pharmacological discoveries into new products for humans, as expert and member of the EMA Management Board and COMP. FGB main effort in the rare diseases field is EuOrphan, a database collecting regulatory and scientific information on drugs having orphan designation and/or approval for rare diseases in the EU and US. Analyses of developmental status, research results, marketing success and availability for patients are regularly produced. Originated by an eTen grant (510774 2003/C 118/19), it is voluntarily managed by FGB since 2008. FGB activities are mainly focused on the regulatory, ethical and methodological support to research. In the context of national and international collaborative projects, FGB contributes to the plan and conduct of clinical studies and project management. Besides research, FGB activities are addressed to training activities consolidating the existing knowledge in regulatory sciences, including the annual ‘Foresight Training Courses’. More recently, FGB has hosted an IT & Research laboratory applied to clinical and pharmaceutical research formally acknowledged as Research Organisation/Laboratory in the list of Living Labs organisations (Apulia Region). The laboratory is also working on the design and implementation of patient registries. Main tasks in the project per Pillar/WP: FGB will co-lead WP4 of transversal activities and will lead Tasks 4.1 and 4.2, coordinating regulatory and ethical activities. 825575 – EJP RD – Part B 90 Pillar 3: In WP16, we will co-coordinate the e-learning module Associated on social with sciences andRef. document humanities applied- 28/11/2018 Ares(2018)6091977 to RD (task 16.2). Pillar 4: In WP19, we will support the identification of suitable funding opportunities (task 19.2). Previous experience relevant to the Tasks: With regards to regulatory and ethics, FGB 1) has acted as a partner of the following projects to deal with the compliance with the relevant requirements in interventional and non-interventional clinical studies, consent and assent process, data collection and analysis, secondary use: ARPEC (2009 11 01, Health Programme), CloSed, DEEP, EPIICAL (Viiv Healthcare grant), GAPP (FP7-HEALTH-2013-INNOVATION-1-602962), GRiP (FP7- HEALTH–2010-261060), InNerMeD, SMART (H2020-TWINN-2015-692327), High-Technology District “Health and Biotechnology” (H-BIO Puglia); 2) has organised training activities at national and international level: ten annual ‘Foresight Training Courses’ devoted to create a critical mass of experts in the field of the regulatory sciences and two international e-learning courses on registrative procedures and regulatory novelties; 3) has participated in public consultations on European policies and regulations. FGB will support and guide the identification of funding for projects as foreseen in Pillar 4 (WP1), thanks to the consolidated experience in not-for-profit research networking, funds scouting and applications. Finally, FGB participates in the c4c project, as responsible of WP5 dealing with research performance and quality, utility, reusability, and uniformity of data gathered from the studies performed by c4c. Overall, the robust expertise in the regulatory and ethical field as well as in the standardised collection of data on rare diseases represents a key element to provide EJP with a well-addressed coordination of these activities spanning from the conduction of clinical and non-clinical studies and regulatory validation procedures to the collection of health data, guidance for researchers and protection of patient rights. Description of any significant infrastructure and/or major items of technical equipment, relevant to the proposed work : FGB hosts an IT & Research laboratory that develops platforms, databases and other tools (e.g., surveys and e- learning environment) to support research activities. FGB manages two databases in the rare diseases field: 1) EuOrphan, developed on Windows Server 2008 operating system and using SQL Express 2008 for data storage. Queries are designed for the advanced research by active substance, therapeutic area, sponsor, trade name, type of disease; 2) HTA-THAL, a patients’ registry based on electronic case report forms, one for adults and one for minors, written in HTML language using scripts in PHP and JAVA language. Data are stored on MySQL database. It is hosted on servers with RAID 5 disks with HDSL connection and daily backup. A user authentication system controls the access for data entry and standard security measures have been adopted. According to the relevant rules, patient data are anonymised and securely stored in each centre. Forms to obtain the patient's consent have been developed. In the framework of InNerMeD project, FGB issued the IT platform containing regulatory, genetic, clinical and therapeutic information, as collected through advanced crowling and data mining services from pre-selected public databases after a validation process carried out by the network. Short Profile of key Staff Members who will be undertaking the work Dr Viviana Giannuzzi PharmD, PhD, post-graduate Degree Master in Clinical Research of Medicines, (female) PDCO alternate member representing patients affected by rare haemoglobinopathies. Researcher, ethical and regulatory expert, project manager of EuOrphan, scientific director of Foresight Training Courses at FGB. She was the Scientific Secretary of the Ethics Committee in Lecce (IT). Eng Fedele Bonifazi Biomedical Engineer, post-graduate Master in HTA and Management, member (male) of HTA working group in the Apulia Region Health Agency, expert for the Health Dept of Basilicata Region. FGB Vice President. Project Manager of many projects (GRiP, TEDDY, InNerMeD, HTA-Thal). Mrs Annalisa Landi PharmD and student of the second level postgraduate Master in Regulatory (female) Sciences “G.Benzi”. Research Assistant at FGB, where she is involved in scientific and regulatory activities related to data protection and confidentiality, patient registries and medicine databases management. List of the most relevant publications and/or products, services (including widely-used datasets or software), or other achievements : 1. Giannuzzi V, Landi A, Bosone E, et al. Failures to further developing orphan medicinal products after designation granted in Europe: an analysis of marketing authorisation failures and abandoned drugs. BMJ Open. 2017;7(9):e017358. 2. Giannuzzi V, Conte R, Landi A, et al. Orphan medicinal products in Europe and United States to cover needs of patients with rare diseases: an increased common effort is to be foreseen. Orphanet J Rare Dis. 2017;12(1):64. 825575 – EJP RD – Part B 91 3. Giannuzzi V, Devlieger H, Margari L, et al. The ethical framework for with Associated performing research document Ref. with rare inherited Ares(2018)6091977 - 28/11/2018 neurometabolic disease patients. Eur J Pediatr. 2017;176(3):395-405. 4. Ruggieri L, Giannuzzi V, Baiardi P, et al. Successful private-public funding of paediatric medicines research: lessons from the EU programme to fund research into off-patent medicines. Eur J Pediatr. 2015;174(4):481-91. 5. Bonifazi F, Conte R, Baiardi P, et al. on behalf of HTA-THAL Multiregional Registry. Pattern of complications and burden of disease in patients affected by beta thalassemia major. Curr Med Res Opin. 2017; 33(8):1525-33. List of relevant previous projects or activities, connected to the subject of this proposal: 1. InNerMeD-I-network; 2nd Health Programme 2008-2013 – G.A. n. 2012 12 12; 01/04/2013 - 31/05/2016. It was aimed to create a network of information on diagnosis and treatment of inherited neurometabolic diseases, based on the collection and exchange of information. FGB was in charge of developing the IT platform, preparing ethical and methodological recommendations and supported the project management. 2. DEEP; FP7-HEALTH-2010 G.A. n. 261483; 01/01/2011 - 31/08/2016. Is aimed to study the efficacy and safety of deferiprone in children affected by rare transfusion-dependent haemoglobinopathies. FGB was involved in regulatory and ethical issues and pharmacoeconomic analyses. 3. c4c; H2020-JTI-IMI2-2016-10-04; proposal number 777389-2; 01/05/2018 (foreseen start date). It aims to generate a sustainable infrastructure on paediatric trials. FGB co-leads WP5 “Data coordinating centre and data quality standards” to contribute to implementing performance metrics, quality improvement plan of expert groups, training materials, and awareness and dissemination campaign. 4. PEPPER; DETERMINAZIONE 22-12-2017, n. 162 “POR Puglia FESR-FSE 2014-2020 - “Innolabs”; 01/04/2018 - 01/09/2019 (foreseen). It is aimed to set up and validate methodologies and tools to evaluate research performance and quality in all the different phases (trials, prototyping, basic research). The system will suggest corrective/improvement measures for performance optimization. 5. CloSed; FP7-HEALTH-2013-INNOVATION-1 G.A. n. 602453; 01/12/2013 – ongoing. It is aimed to perform a multinational paediatric trial on clonidine for sedation in the intensive care. FGB is involved in regulatory, ethical and dissemination activities, and supports the project management. 25-FTELE Full legal name (Acronym) – Country Fondazione Telethon (FTELE) - Italy Principal investigator Lucia Faccio Relevant Network UDNI, EuroBioBank, IRDiRC, NORD, Rete delle Associazioni Amiche di Fondazione Telethon, ENMC, Alliance Regenerative Medicine Description of the legal entity/department/laboratory/group: Fondazione Telethon is an Italian charity founded in 1990 at the behest of a group of patients to support research on rare genetic diseases. Research is the central activity that FTELE pursues to fulfil its mission. This is done through both intramural research in three Telethon institutes (all focusing on rare genetic diseases) directly managed by FTELE and research performed in extramural laboratories funded through competitive calls. FTELE invests in the whole pipeline of research, from basic laboratory research up to clinical studies, as well as in the support of infrastructures for research, such as the Telethon Network of Genetic Biobanks. As a charity, FTELE has also built a strong expertise in drug development, including patenting, negotiation and management of industrial alliances and regulatory affairs. Moreover, FTELE, being a reference for RD patients, works in partnership with almost 200 Italian patient organizations. Main tasks in the project per Pillar/WP: Pillar 0: In WP2 FTELE co-leads Task 2.1: Prioritization scheme for EJP-RD actions. FTELE is involved in Task 2.5: Translation/impact of prioritization on national and EU strategies. FTELE also co-leads WP4 and is responsible of Task 4.3: Managing legal and IPR issues Pillar 2: FTELE participates in a number of tasks related with the development, monitoring and management of RD Biobanks data and related networking activities (WP10, WP11, WP12). Below listed 3rd parties will contribute use cases. Pillar 3: In WP14, FTELE contributes to Task 14.3 and leads Task 14.4: Training for biobanks and researchers/clinicians on sample data management. FTELE participates in activities of WP18 on Development and adaptation of training activities. Pillar 4: FTELE co-leads WP19, participates in Task 19.1 and is responsible of Task 19.2: Support in exploitation and 825575 – EJP RD – Part B 92 follow-on funding Associated with document Ref. Ares(2018)6091977 - 28/11/2018 and co-responsible of Task 19.4: Roadmap for a European investment platform for RD. Previous experience relevant to the Tasks: IP and Research Exploitation: FTELE currently has a portfolio of 36 active patent families and is involved in 5 alliances with industrial partners for the development of therapies for 14 rare/genetic disorders. Moreover in 2017 FTELE in partnership with Sofinnova designed a technology transfer fund dedicated to RD in Italy that was approved by the European Investment Fund Board of Directors in November of the same year. Biobanking: FTELE has been supporting EuroBioBank since 2012, in the role of administrative coordinator and more recently as general coordinator. EuroBioBank has become the biobank network of RD-Connect, whose biobanking work-package is led by FTELE. Within RD-Connect, FTELE has continued to work towards alignment of data models and FAIR principles, interoperability and quality protocols of EuroBioBank biobanks with new- generation tools. Patients’ empowerment: FTELE has set an informal network of 200 Patient Organizations called Telethon Friends with the aim of sharing information on research. Since 2009 FTELE trained more than 1.000 patients through annual meetings focusing on the mechanism of research and its tools (Clinical Trials, biobanks, registries, etc.). Short Profile of key Staff Members who will be undertaking the work Lucia Faccio, Lucia is the Director of Research & Development at FTELE. She directs a team of 18 PhD, Female professionals in charge of the peer reviewed research evaluation process, monitoring of research results, strategic analyses of performance and translational potential of the funded research, technology transfer, intellectual property protection, regulatory affairs, negotiation and management of alliances with partnering organizations. Lucia has more than 17 years of technology transfer and business development experience in the life science field. Lucia obtained a PhD in Biotechnology in association with the Harvard Medical School. Simona Simona is the IP Manager at FTELE and has over 12 years of experience as a patent professional Varani, in the life science field. Previously Simona was a partner of Zebra Ventures, a consultancy firm Female dedicated to providing business development, licensing and IP support to life-science companies and academic institutions. She also served as head of IP for Allozyne Inc, a US Biotech company based in Seattle, and BioXell SpA, an Italian biopharmaceutical Company. Simona has a degree in pharmaceutical chemistry obtained from the University of Milan. Chiuhui Mary Mary has been working in the field of RD biobanking since 2014 and is managing the biobank Wang, PhD, activities in RD-Connect and EuroBioBank. Mary is experienced in organising international Female biobank training workshops and webinars. At Telethon she also oversees the program support for the Telethon Network of Genetic Biobanks. Mary received her PhD in Cell Biology from University College London, UK. After the completion of her PhD she worked as postdoctoral researcher in the UK and Italy. Lucia Lucia is the Head of Research Impact and Strategic Analysis of FTELE and was Telethon’s Chief Monaco, PhD, Scientific Officer between 2008 and 2017. She is leading the biobanking WP of RD-Connect and Female is the EuroBioBank coordinator. She represents FTELE in IRDiRC and is a member of the Horizon 2020 Advisory Group for Societal Challenge 1 – Health, demographic change and well- being. Alessia Alessia is the manager of relations with Patient Organizations and coordinator of the Telethon Daturi, helpline for RD. She has been working at FTELE since 2006 taking care of patients’ advocacy Female and empowerment. She graduated in Philosophy at the Università Cattolica del Sacro Cuore of Milan and specialized in Business and Social Communication for non profit organizations. List of the most relevant publications and/or products, services (including widely-used datasets or software), or other achievements : 1. L. Monaco, L. Faccio, Patient-driven search for rare disease therapies: the Fondazione Telethon success story and the strategy leading to Strimvelis, EMBO Molecular Medicine, 2017 2. S. Gainotti, et.al., The RD-Connect Registry & Biobank Finder: a tool for sharing aggregated data and metadata among rare disease researchers. Eur J Hum Genet. 2018 3. C. Baldo et.al., The alliance between genetic biobanks and patient organisations: the experience of the telethon network of genetic biobanks. Orphanet J Rare Dis. 2016 4. M. Mora et.al., EuroBioBank Network: 10 years of hands-on experience of collaborative, transnational biobanking for rare diseases. Eur J Hum Genet. 2015 5. Willmann R., et. Al., 227th ENMC International Workshop:: Finalizing a plan to guarantee quality in translational research for neuromuscular diseases Heemskerk, Netherlands, 10-11 February 2017, Neuromuscul Disord. 2018 825575 – EJP RD – Part B 93 List of relevant previous projects or activities, connected to theAssociated subject with of this proposal: document Ref. Ares(2018)6091977 - 28/11/2018 1. RD-Connect; European Commission – FP7; 2012-2018, leader of the WP on biobanks. 2. Determinazione Rara; Ministero del Lavoro e delle Politiche Sociali; 2013-2014, FTELE has provided contents and speakers for the experience-based training for Patient Organisations on clinical trials, registries and biobabanks. 3. T2B – Translation to Business; Regione Lombardia, 2017-2018, coordinator of the feasibility study for a PoC- like call at Regional level in the biomedical sector. 4. Sofinnova Telethon SCA; European Investment Fund, 2018-2030, Technology transfer fund focused on early stage life sciences investments, primarily supporting the development of therapies and drugs for rare genetic diseases, in Italy. 26-ISS Full legal name (Acronym) – Country Istituto Superiore di Sanità (ISS), Italy Principal investigator Domenica Taruscio Relevant Network ECRIN, EATRIS, UDNI Description of the legal entity/department/laboratory/group: The Istituto Superiore di Sanità (ISS), Rome, Italy, is the scientific advisory body of the National Health System in Italy, namely of the Ministry of Health, the Regions and the Local Health Unit. The National Health Fund allocates to the ISS resources for research and action according to the objectives of the National Health Plan. The ISS undertakes research funding, management and training functions in relation to public health in Italy. The ISS: a) collaborates with the Minister of Health in preparing and implementing scientific and health planning; b) promotes programmes in line with the objectives of the National Health Plan, and c) promotes programmes of research on the relationship between environment and health, as well as programmes and clinical trials of national interest. With regard to rare diseases, the ISS, through the National Centre for Rare Diseases, acts as a coordinator of rare disease research, surveillance and public health actions at the national and international levels. Actually, the ISS is one of the key bodies targeting health-related aspects of rare diseases in Italy; in particular, the ISS coordinates the Italian Network on Rare Diseases; it is responsible for the organization and implementation of the National Registry of Rare Diseases. Main tasks in the project per Pillar/WP: Pillar 0: COORDINATION & TRANSVERSAL ACTIVITIES ISS will be co-leader in - WP2 Integrative research and innovation strategy - Task 2.2 Mapping the research and innovation needs - Task 2.5: Translation/impact of prioritization on national and EU strategies of WP2 ISS will be Partner in - Task 2.1: Prioritization scheme for EJP RD actions - Task 2.4: Management of the medium, longer-term research strategy questions and dedicated linkage with Task Forces of IRDiRC Pillar 2: INNOVATIVE COORDINATED ACCESS TO DATA AND SERVICES FOR A TRANSFORMATIVE RARE DISEASE RESEARCH ISS will be leader of - Subtask 13.1.8. Environmental toxicology of Task 13.1: Fill a number of pre identified gaps to allow integrative systems biology approaches for rare diseases ISS will be co-leader in - Subtask 10.1.1 (“Whole-RD-community annual retreat”) of the Task 10.1 (“Convene yearly retreats leading to Pillar 2 annual strategic plans”) ISS will be partner - Task 10.5: Sustainability and scaling up - Task 11.3: Data deposition and access to data infrastructures for RD research - Task 11.4: Provision of RD analysis and data sharing capabilities through online resources ISS will participate in kind in the activities of WP12: Enabling sustainable FAIRness and Federation at the record level for RD data, patients and samples Pillar 3 CAPACITY BUILDING & EMPOWERMENT ISS will be leader of 825575 – EJP RD – Part B 94 - WP 14: Training on data management & quality Associated with document Ref. Ares(2018)6091977 - 28/11/2018 - Task 14.3: Training on strategies to foster solutions of undiagnosed rare disease cases - Task 14.5: Training on rare disease registries and FAIRification of data at the source ISS will be partner of: - Task 14.2: Standards and quality of genetics/genomics data in laboratory and clinical research practice - Task 15.3: Training for patient representatives and advocates on leadership and communication skills - Task 18.1: Evaluation of developing needs according to progress of work in Pillars 2 and 4 and relevant adaptation of training activities - Task 18.2: Evaluation of strategic priorities and development of existing training activities according to specific needs of EU-13 countries Previous experience relevant to the Tasks: National Centre for Rare Diseases (CNMR) employs a wide range of scientific and technical expertise from various fields (medicine, genetics, molecular biology, epidemiology, public health, psychology, sociology etc.) and holds a network of national and international collaborations, which allow the development of a sound and integrated approach to RDs. The history of the CNMR dates back to the institution of the National Registry for Rare Diseases in 2001, which was the first nucleus of the Centre and now there are also specific rare disease registries maintained by the CNMR. A number of national, European and international projects on RDs are undertaken yearly by the Centre. The CNMR holds a portal on RDs which provides topics of interest to RD patients, to the scientific community and to anyone interested in RDs . Every year, the CNMR organises a number of education and training activities on RD directed to various stakeholders (patients and their families, patient organisations, physicians, nurse practitioners, paediatricians, residents of professional schools, etc.) Since 2013 the Center has organised and held a specific course on Rare Disease and Orphan drug registries for health professionals, researchers, clinicians and representatives of patient associations engaged in rare disease patient registries. The Center is actively involved in undiagnosed rare diseases research at National and International level. Since 2016, at National level the Center, is coordinator of a project (namely "Undiagnosed Rare Diseases: a joint Italy - USA project" funded by Ministry of Foreign Affairs and International Cooperation) aimed at developing a national strategy to foster undiagnosed rare diseases. At International level the Center is co-founder of the "undiagnosed diseases network international" network established in 2014 across several countries to improve the rate of definite diagnosis for persons living with undiagnosed conditions. Short Profile of key Staff Members who will be undertaking the work Dr. Domenica Degree in Medicine and Surgery. Post graduate Specialist in Histopathology. Post-doctoral fellow Taruscio/F in Human Genetics (Yale University, USA) and Ethics. Director of the Italian National Centre for Rare Diseases (Istituto Superiore di Sanità). Responsible of the Italian National Registry for Rare diseases. Coordinator of the following EU projects: NEPHIRD, EUROPLAN, EPIRARE, RARE- BestPractices. WP Leader: ADVANCE HTA, EUROCAT JA, E-RARE, RD-Connect. WP co- Leader: Endo-ERN, EuRRECa. Member of: EU Task Force on Rare Diseases, Expert EU Commission Group on Rare Diseases, EMQN Management Board. Coordinator of the Italy-USA bilateral project “Undiagnosed Rare Diseases”. Advisory Member of SOLVE-RD. Co-Founder of Undiagnosed Diseases Network International (UDNI, www.udni.org). Past President and Board Member of ICORD (www.icord.se). Vice Chair of ISC IRDiRC (www.irdirc.org). Coauthor of more the 150 peer reviewed publications (https://www.ncbi.nlm.nih.gov/pubmed/?term=taruscio+d) Prof. Degree in Medicine and Surgery-Postgraduate Specialist in Hygiene and Preventive Medicine Gualtiero President of Istituto Superiore di Sanità (ISS) from September 2015 . Expert Panel Member on the (Walter) Effective Ways of Investing in Health (EXPH) European Commission,DG SANTE. Coordinator Ricciardi/M of TO-REACH consortium (producing research evidence supporting health care services and systems to become more resilient, effective, equitable, accessible, sustainable and comprehensive (in Europe, and abroad). Dr Claudio Claudio has a PhD in Biomedical and Cytomorphological Sciences. His previous research was Carta/M focused on the molecular basis of RASopathies caused by mutations affecting genes involved in the RAS-MAPK pathway. Since October 2012, he has been working as a researcher at the National Center for Rare Diseases, Istituto Superiore di Sanità. His current work focuses on data management for rare disease registries and particularly on how to make registries Findable Accessible Interoperable and Reusable (FAIR) for humans and computers with other registries, biobanks and bioinformatics data 825575 – EJP RD – Part B 95 Dr Marco Researcher in Molecular Genetics at the National Center Associated withRare Diseases, document Istituto Superiore Ref. Ares(2018)6091977 di - 28/11/2018 Salvatore/M Sanità. His research is focused on rare diseases and on undiagnosed rare diseases; in particular he studied i) the role of specific microRNAs in the biology of rare diseases (i.e. Hepatolastoma, Hailey-Hailey disease; osteocondromas); ii) the role of specific genetic markers for diagnosis and prognosis of rare tumours. He is member of the coordination Team of National program for External Quality Assessment of genetic test and for Sweat choloride test for cystic fibrosis. He attended at the Management Board of the European Molecular Quality Network (EMQN) (2008-14, on behalf of Italian member). He is member of Undiagnosed Diseases Network International (UDNI) and is member of the coordination team of the Italian Project for Undiagnosed Rare Diseases (Italy-USA bilateral framework). From 2016 he is member of the Scientific Committee of the Italian Cystic Fibrosis (CF) Patient Registry. Dr Alberto AM (DVM, MSc) is a senior scientist with a long-standing expertise in toxicology and Mantovani/M toxicological risk assessment, mainly on endocrine disruptors,but encompassing also trace elements, nanomaterials and pesticides . AM is a toxicology expert in EFSA Panels since 2003; in particular he has been member of the PPR Panel (pesticides, 2012-5) where he has contributed to the opinion on the use of AOP to elucidate the potential links between pesticide exposure and human diseases (Parkinson's disease, childhood leukemia) (2017). He is principal investigator for ISS in the H2020 project Eu-ToxRisk (wwww.eu-toxrisk.eu) pivoting on AOP development Dr. Paola Graduated in Chemistry and Pharmaceutical Technologies, Researcher at the National Center for Torreri /F Rare Diseases, Management of E-rare project: ERA-Net for Research Programmes on Rare Diseases; collaboration on RD-Connect project especially for the activities of WP2 on rare disease registries. Management of the Italian National Rare Disease Registry Dr. MD, specialised in Epidemiology and Public Health and PhD in Public Health. She is a researcher Yllka Kodra/F at the National Centre for Rare Diseases. Her key qualifications are: expertise in epidemiology and public health, design/implementation of rare disease and congenital malformations registry, biostatistical analysis, disease classification system, Patient-reported outcomes (PROs) studies, design/implementation of neonatal screening programme De Santis She’s researcher at the National Centre for Rare Diseases, where she’s the coordinator of the Marta/F National Helpline for Rare Diseases and of the network of institutional helpline “R.I.C.A.Ma.Re”. She's responsible for liaising with the Patient Associations; she participates as a speaker/teacher in conferences and courses and promotes training&information initiatives for the general public and specifically to the patients (e.g. Educational programs for patients on several issues on RD as orphan drugs and expanded newborn Screening; Open Days on Rare Diseases, Parent training courses to family members of people with rare disease, ecc). She's deputy representative of Dr. Taruscio on the Italian Scientific Board of the EUPATI project ("European Patients' Academy on Therapeutic Innovation"). Currently a member of the Coordinating Team of Task 2.5 "Sustainable Health Systems for Rare Diseases" in Work package 2 - Joint Action "RD-ACTION. Data and policies for rare diseases "(2015-2018). Angela She’s a psychologist and works at the National Centre for Rare Diseases-Istituto Superiore di Ruocco/F Sanità. She’s a counselor of the National Helpline for Rare Diseases and is a member of the coordinating team of the network of institutional helpline “R.I.C.A.Ma.Re”. She collaborates in open days on rare diseases and several training/informative initiatives aimed at patient associations. She’s member of the organizational staff of “Volo di Pegaso”, artistic, literary and musical contest on rare diseases. She's in the staff of an association that deals with the rights of the weakest part of the population end leads self-help groups. She participates as speaker in conferences and courses on social inclusion. Federica Researcher at National Centre of Rare Diseases; Degree in Biology; specialist medical training in Censi/F medical genetics. I have a broad background in human genetic, with specific expertise in Genetic testing. She carried out the Organization of the Italian External Quality Assessment for nine schemes of genetic testing included Oncology genetic, Cytogenetics and Molecular Genetics Fabrizio Tosto Researcher at National Centre of Rare Diseases; Degree in Biology. He has a broad background in /M genetic testing, with long experience in External Quality Assessment in Genetic Testing Organization. He carried out the Organization of the Italian External Quality Assessment for nine schemes of genetic testing included in the area of Oncology genetic, Cytogenetics and Molecular Genetics. List of the most relevant publications and/or products, services (including widely-used datasets or software), or other achievements : 825575 – EJP RD – Part B 96 Associated with document Ref. Ares(2018)6091977 - 28/11/2018 1.The RD-Connect Registry & Biobank Finder: a tool for sharing aggregated data and metadata among rare disease researchers. Eur J Hum Genet. 2018 Feb 2. 2. Data Quality in Rare Diseases Registries. Adv Exp Med Biol. 2017; Adv Exp Med Biol. 2017;1031:149-164. 3. Undiagnosed Diseases: Italy-US Collaboration and International Efforts to Tackle Rare and Common Diseases Lacking a Diagnosis. Adv Exp Med Biol. 2017;1031:25-38. doi: 10.1007/978-3-319-67144-4_2. 4. Adverse outcome pathways: opportunities, limitations and open questions. Arch Toxicol. 2017 Nov;91(11):3477-3505 5. Linked Registries: Connecting Rare Diseases Patient Registries through a Semantic Web Layer. Biomed Res Int. 2017;2017:8327980. List of relevant previous projects or activities, connected to the subject of this proposal : . EPIRARE (European Platform for Rare Disease Registries); 2011-2013; is a three-year project co-funded by the European Commission within the EU Program of Community Action in the field of Public Health. ISS was the coordinator. The general objective of the EPIRARE project is to build consensus and synergies to address legal, ethical and technical issues associated with the registration of RD patients and to elaborate a proposal for a EU web-based multi-disease platform which, by sharing information and resources, can increase the sustainability of registries, promotes the use of standards and of registry quality procedures and provides an effective way of dissemination of the results. . RD‐Connect; FP7; 2012-2018, ISS is WP leader " Databases/patient registries" in the European RD-Connect project, and developed the online searchable catalogue that is meant to offer detailed information on the content of the databases included . E-rare3: "ERA-NET rare disease research implementing IRDiRC objectives", Horizon 2020, 2015-2020-ISS is WP leader “Strengthening research collaboration and enhancing knowledge translation” . RD-Action; EU Health Programme-2015-2018, promoting implementation of recommendations on policy, information and data for RD; the ISS is co-leader, with EURORDIS, of Workpackage 2, focused on "Communication and dissemination", and Leader of Task 2.5 (WP2) “Sustainable Health Systems for Rare Diseases”. This Task aims to support national authorities to quantify the burden of RDs and available resources for sustainable and resilient health systems, taking into account principles of equity, quality and efficiency, and involving stakeholders, policy makers, and civil servants in charge of national strategies on RDs. . TO-REACH is a coordination and support action (CSA) to prepare a joint European research programme aimed at producing research evidence supporting health care services and systems to become more resilient, effective, equitable, accessible, sustainable and comprehensive (in Europe, and abroad). ISS is the coordinator. 27-CVBF Full legal name (Acronym) – Country Consorzio per Valutazioni Biologiche e Farmacologiche (CVBF) - Italy Principal investigator Giovanni Migliaccio Relevant Network EPTRI, TEDDY, C4C, INCiPiT, Enpr-EMA, EUCROF, AICRO Description of the legal entity/department/laboratory/group: Consorzio per Valutazioni Biologiche e Farmacologiche (CVBF) is a non-profit organization whose mission is to perform research and education in the pharmaceutical field integrating regulatory, methodological, ethical, clinical, epidemiological, economical and statistical expertise. CVBF has a longlasting experience in performing paediatric clinical trials where CVBF a) acts as sponsor and project coordinator of independent trials; b) provides specific services related to clinical trial management, data collection and storage, clinical operations, drug management, monitoring and quality assurance, clinical study reports and statistics, c) is registered in EudraVigilance to perform pharmacovigilance activities. CVBF has also developed a European Paediatric Medicines Database (EPMD) including information on medicines approved for children by EMA (indication, dosages, by age populations, studies and trials, etc). CVBF has significant expertise in the project coordination, conducting research activities mainly in the context of national and EU funded projects and being Coordinator of two FP7 projects (DEEP, GAPP) and Partner in many other projects funded by the European Commission (DG-Research and DG-SANCO). CVBF will participate to the 825575 – EJP RD – Part B 97 conect4children (C4C) pan-European Paediatric Clinical Trial Network funded Associated under theRef. with document IMI2 call 10. Ares(2018)6091977 - 28/11/2018 CVBF is the Coordinator of EPTRI (European Paediatric Translational Research Infrastructure), funded as a Horizon 2020 project, a new complementary Research Infrastructure (RI) in the context of the existing RIs intended to putting together and networking all the available competences and technologies useful to enhance paediatric research in paediatric medicines from drug discovery and early development phases to be translated into clinical phases and medicines uses. To harness efficiency in delivery of paediatric research activities and services, EPTRI will act as a ‘Paediatric Common Service’ in the ESFRI (European Strategy Forum on Research Infrastructures) scenario and will cover all the different scientific domains grouped in the following five thematic platforms: 1. Pediatric Medicines Discovery and Preclinical Studies; 2. Biomarkers; 3. Paediatric Pharmacology, 4. Formulation Science, 5. Underpinning Paediatric Studies. EPTRI involves 26 partners from 19 EU and non-EU countries including consolidated research infrastructures, top- level universities, research centers of excellence in Europe. Main tasks in the project per Pillar/WP: Pillar 0 WP1 Coordination and Management CVBF will lead task 1.3 (Monitoring of the EJP RD activities and achievements), aimed to evaluate the quality of the EJP RD activities and the achievement of the expected project goals. The task is further divided into: • subtask 1.3.1 (Identification of key performance indicators), leaded by ULIV • subtask 1.3.2 (Implementation of the monitoring process), leaded by CVBF. WP2 Integrative research and innovation strategy CVBF will co-lead task 2.1 (Prioritization scheme for EJP RD actions). Pillar 4 WP19 Facilitating partnerships and accelerating translation for higher patient impact CVBF will co-lead task 19.1 (Accelerating translation). In particular, will lead subtask 19.1.1 (Innovation Management Toolbox) contributing to structure and empower translational research in EU by providing key paediatric competences into operational Platforms for enhancing and optimizing the use of key technologies to be included in the rare diseases medicines developmental process, and will participate in the following subtasks: • subtask 19.1.2 Assessment of translational research projects • subtask 19.1.3 Real-time mentoring and technical support for translational research projects CVBF will also participate in task 19.2 (Support in exploitation and follow-on funding). Previous experience relevant to the Tasks: CVBF is the Coordinator of EPTRI that is aimed to overcome fragmentation, leading to efficacious use of data and resources and a faster scientific progress. Through EPTRI many dispersed and disaggregated paediatric research expertise will be linked and integrated, increasing collaboration and sharing of facilities, resources and related services. EPTRI will act as a “one-stop-shop” for advice in order to bridge the existing gaps in paediatric medicines research and development and contribute to EJP RD by providing data from its operational Platforms, including information on target drugs, new molecules, biomarkers, clinical and non-clinical innovative study results, databases and repositories of research data. In this way, CVBF and EPTRI will contribute in accelerating discovery by rapidly validating hypothesis that can give rise to further research and in producing interoperable re-usable data for researchers. CVBF has developed many surveys to increase the knowledge about different paediatric issues and currently is developing within EPTRI a large inventory of existing paediatric research resources allowing to bridge dispersed resources in a common interoperable infrastructure, including: 1) centers involved in new discovery and target identification for paediatric untreated diseases (mainly Rare diseases); 2) available resources (including data and samples repositories/databases) related to paediatric disease and pharmacological characteristics including neonates and placental research (paediatric PKPD population data and/or modelling/simulation/extrapolation application, biobanks and databases collecting data and sample from children affected by many rare pathologies including RPME data): the goal of this collection is to identify clinical, demographic and genetic biomarkers possibly linked to clinical diagnostic and therapeutic data; 3) all available good methodological guidelines usable in each sector for new therapies identification, diagnosis and treatment monitoring. Description of any significant infrastructure and/or major items of technical equipment, relevant to the proposed work : CVBF manages several databases and registries such as the Inventory of the Ethical and Regulatory procedures for paediatric clinical trial (CT) approval and conduction in EU and non-EU countries and the EPMD database related 825575 – EJP RD – Part B 98 to drugs for children authorised by the EMA under the centralised Associated procedure. with document Ref. Ares(2018)6091977 - 28/11/2018 CVBF has managed the certification process and the interoperability of a network of human biobanks in the project RIMedRI (Integrated clinical and biological Network for Rigenerative Medicine). CVBF has also created an e-learning platform to provide courses on medicines, regulatory issues and clinical research. In particular, it is recognised provider of ICH-Good Clinical Practice (GCP) Training by TransCelerate BioPharma with the e-learning “ICH-Good Clinical Practice (GCP) Training Course”. The course is based on the international E6 ICH Good Clinical Practice (R2), revised in 2016, and is aimed at providing a guide for all individuals that are involved in clinical research and clinical. It meets the Minimum Criteria for ICH GCP Investigator Site Personnel Training identified by TransCelerate BioPharma, as necessary to enable mutual recognition of GCP training among trial sponsors. Short Profile of key Staff Members who will be undertaking the work Donato Bonifazi/Mecon CVBF Chief Executive Officer, economist. Project manager and trial manager in FP7 (male) projects/clinical trials (DEEP – DEferiprone Evaluation in Paediatrics, GA n. 261483; GAPP – GAbapentin in Paediatric Pain, GA n. 602962). PedCRIN (Paediatric Clinical Research Infrastructure Network, GA n. 731046) work package leader. ID-EPTRI (European Paediatric Translational Research Infrastructure, GA n. 777544) Coordinator. Pr.Ornella Pastoris President of CVBF, Master Degree in Biological Sciences, Associate Professor of (female) Pharmacology at the University of Pavia, Department of Molecular Physiological Pharmacology. Pr.Lucia Margari Member of the Boards of Director at CVBF. Degree in Medicine and Surgery. (female) Specialist in Neurology. Full Professor and Director of Specialization School in Child and Adolescent Neuropsychiatry at University of Bari. PhD Mariagrazia Felisi Coordinator of the Clinical Research Unit, responsible for the Quality Management (female) System at CVBF. Master Degree in Pharmacovigilance, she is Qualified Person (certified as QPPV in EudraVigilance). Giovanni Migliaccio Senior Advisor at CVBF. He has been EATRIS Scientific Director from 2011 to end of (male) 2017. He was the Italian National Delegate to the Committee for Advanced Therapies at EMA from 2009 to 2011. He is currently the sitting member for Advanced Therapies Medicinal Products in the committees delegated to the authorisation of clinical trials in Italy. Pr. Oscar della Pasqua Senior Advisor at CVBF. He holds the Chair of Clinical Pharmacology & Therapeutics (male) at University College of London and is also affiliated with GlaxoSmithKline. He has authored over 100 scientific peer-reviewed articles, an H-index of 17 and has a key interest in drug development and personalised medicine. List of the most relevant publications and/or products, services (including widely-used datasets or software), or other achievements: 1. Capone, F., Lombardini, L., Pupella, S., Grazzini, G., Costa, A. N., and Migliaccio, G. (2011) Cord blood stem cell banking: a snapshot of the Italian situation. Transfusion 51, 1985-1994 2. Rubinstein, P., Dobrila, L., Rosenfield, R.E., Adamson, J.W., Migliaccio, G., Migliaccio, A.R., Taylor, P.E. and Stevens, C.E. (1995) Processing and cryopreservation of placental/umbilical cord blood for unrelated bone marrow reconstitution. Proceedings of the National Academy of Sciences of the United States of America, 92, 10119-10122 3. Cella M, Danhof M, Della Pasqua O. Bridging strategies for drug combinations in pediatric indications. Clin Pharmacol Ther. 2012; 91(4):726-33. 4. Ruggieri L, Giannuzzi V, Baiardi P, Bonifazi F, Davies EH, Giaquinto C, Bonifazi D, Felisi M, Chiron C, Pressler R, Rabe H, Whitaker MJ, Neubert A, Jacqz-Aigrain E, Eichler I, Turner MA, Ceci A; on behalf of the GRiP Consortium. Successful private-public funding of paediatric medicines research: lessons from the EU programme to fund research into off-patent medicines. Eur J Pediatr. 2015 174(4):481-91. 5. Bellanti F, Del Vecchio GC, Putti MC, Maggio A, Filosa A, Cosmi C, Mangiarini L, Spino M, Connelly J, Ceci A, Della Pasqua O; Consortium DEferiprone Evaluation in Paediatrics (DEEP). Population pharmacokinetics and dosing recommendations for the use of deferiprone in children younger than 6 years. Br J Clin Pharmacol. 2017 Mar;83(3):593-602. doi: 10.1111/bcp.13134. Epub 2016 Nov 6. List of relevant previous projects or activities, connected to the subject of this proposal : . DEEP (DEferiprone Evaluation in Paediatrics); European Commission, Grant Agreement n°261483 - FP7- HEALTH-F4-2010; 2011-2016; CVBF is the project Coordinator and provides the overall scientific strategy and coordination of the project. It is responsible for the project management activities, the planning, designing, implementation and analysis of the Efficacy/Safety Clinical Trial as well as the dissemination activities. DEEP is 825575 – EJP RD – Part B 99 a project involving EU and non-EU countries to study deferiprone, in children Associated affected with document by congenital anaemias Ref. Ares(2018)6091977 - 28/11/2018 requiring chronic transfusion therapy and iron chelation, such as the β-thalassaemia major and the Sickle Cell Disease (SCD) and develop a new formulation suitable for children. To this aim, the project has conducted three multi-national paediatric studies. Results from paediatric clinical studies will be used for a PUMA (Paediatric Use Marketing Authorisation) application. In the context of DEEP, for the first time the cardiac MRI T2* is evaluated as primary endpoint and will be validated as biomarker. . GAPP (GAbapentin in Paediatric Pain); European Commission, Grant Agreement n° 602962 - FP7‐HEALTH‐ 2013‐INNOVATION‐1; 2013-2017, CVBF is the project Coordinator, responsible of the Project Management activities, guaranteeing that the project plan is completed in due time with the contribution of all the participating Beneficiaries and with the highest quality standards) and of the regulatory activities. GAPP is aimed to develop, test and made available a new formulation of gabapentin for the treatment of neuropathic chronic pain in the paediatric population. Results from paediatric clinical studies will be used for a PUMA application. Genomic biomarkers are evaluated in the context of GAPP clinical trials. . GRiP (Global Research in Paediatrics), European Commission, Grant Agreement n°261060 - FP7-HEALTH-F5- 2010; 2011-2017. CVBF was partner in the project and was responsible for the development of innovative methodologies to facilitate the implementation of paediatric clinical trials and for developing contents of two of the ten modules of the International Master of Science in “Paediatric Medicines Development and Evaluation”. GRiP is a 5-year EU-funded Network of Excellence aimed at stimulating and facilitating the development and safe use of medicines in children. An International Master in Paediatric Clinical Pharmacology has been realised and proposed at global level (Europe, USA, Canada, Japan, China, etc.). . ID-EPTRI (Infradev –European Paediatric Translational Research Infrastructure); European Commission, Grant Agreement n° 777554 – H2020 - INFRADEV-2017-1; 2018-2019; CVBF is coordinator of the project; ID- EPTRI is aimed to create the framework for a new Research Infrastructure (RI) intended to enhance technology- driven paediatric research in discovery and early development phases to be translated into clinical research and paediatric use of medicines . PedCRIN (Paediatric Clinical Research Infrastructure Network); European Commission, Grant Agreement n°731046 - H2020-INFRADEV-2016-1; 2017-2020; CVBF is partner in the project and is responsible for the development of tools and databases specific for paediatric and neonatal clinical trials. PedCRIN is a four-year project funded by the European Union’s Horizon 2020 programme, aimed to bring together the European Clinical Research Infrastructure Network (ECRIN) and the founding partners of the European Paediatric Clinical Trial Research Infrastructure (EPCT-RI) to develop capacity for the management of multinational paediatric clinical trials. PedCRIN will effectively bridge paediatricians and other partners across Europe (and internationally) to combine resources and expertise to conduct and manage robust studies, while minimising risk and protecting the child participants . SMART (Small Medicines Advanced Research Training), European Commission, Grant Agreement n°692327 - H2020-TWINN-2015, 2016-2018. CVBF is partner in the project and acts as internationally-leading research institutions providing specific expertise in paediatric clinical trial government and developing, M&S and Extrapolation applications, new formulation generation. SMART is aimed at raising the Instytut Pomnik Centrum Zdrowia Dziecka (IPCZD – Poland) staff’s research profile and increase capacity in providing innovative paediatric research methods. A specific training programme is foreseen. 28-TEDDY Full legal name (Acronym) – Country European Network of Excellence for Paediatric Clinical Research (TEDDY) - Italy Principal investigator Annagrazia Altavilla Relevant Network Enpr-EMA, ENCePP, EPTRI, C4C, INCiPiT, RECLIP Description of the legal entity/department/laboratory/group: TEDDY European Network of Excellence for Paediatric Clinical Research is a scientific organisation arisen from the Task-force in Europe for Drug Development for the Young, a consortium funded in 2005 as TEDDY project (LSHB-CT-2005-005216) within the Sixth Framework Programme of the European Commission with the aim to favour the integration of the paediatric pharmacological research activities, the implementation of adequate health policies and a social awareness on the importance of the paediatric medicines across Europe covering different specialty areas (haematology, oncology, infectious diseases, respiratory diseases, intensive care, pain, endocrinology, rare diseases, neonatology). At the end of the 5-years funding period, the consortium was further renewed and now TEDDY is operating as an 825575 – EJP RD – Part B 100 independent multidisciplinary, multinational network including 50 members Associated with documentin Ref.20 EU and non- Ares(2018)6091977 EU - 28/11/2018 countries. In June 2017 TEDDY has acquired an autonomous legal status allowing the Network to be fully represented and consolidated in the paediatric research community framework. The main objective of TEDDY network is to promote research on medicinal products in children providing methodological expertise and implementing good practices, Standard Operating Procedures (SOPs) and tools to plan, design and perform clinical studies at national and international level. TEDDY is a category 1 network member of Enpr-EMA, the European Network of Paediatric Research at the European Medicines Agency and registered at ENCePP (the European Network of Centres for Pharmacoepidemiology and Pharmacovigilance), an initiative coordinated by the EMA with the aim of strengthening post-authorisation research, pharmacoepidemiological research and risk-benefit monitoring of medicines. TEDDY can count on the expertise and collaboration of researchers, scientists, health experts and paediatric clinical research centers working together to identify the most appropriate research tools and procedures that reflect the specificity of the paediatric patient population and collaborates with existing paediatric networks and research organisations with the goal to promote and foster scientific and technological excellence in paediatric research. Thanks to the international recognition and the wide geographical representativeness, TEDDY is able to provide the paediatric community of: easy dissemination of relevant information; consultation on paediatric drug development issues; involvement in paediatric studies; documents and recommendations in the sector of paediatric study methodology. Moreover, TEDDY has developed many surveys to increase the knowledge about different paediatric issues (Expert Groups and research priorities in 2007-8, Ethic and Regulatory in 2009 and 2011, Off-label use in 2010) and currently is managing a Survey on the assessment of paediatric sites’ services and capacities. TEDDY is particularly committed to setting up and implementing appropriate methodologies to conduct clinical research, with reference to innovative and traditional studies including population PK study, Modeling & Simulation, extrapolation. To this aim, TEDDY is both involved in the scientific discussion to prepare and disseminate recommendations and publication on this issue and in the practical development and conduction of paediatric national or multinational clinical trials using innovative methodologies. TEDDY is also particularly engaged in favouring awareness on the topics of paediatric research, to spread information on the rational use of paediatric medicines and to identify unmet medical needs in paediatrics. Moreover, by developing ad hoc informative and educational tools, TEDDY aims to increase awareness on the topics of paediatric research and to encourage the participation of children in all the relevant experimental procedures. Regarding the patients empowerment and the involvement in the paediatric clinical research, TEDDY has promoted the creation the first Italian (in Bari) and Albanian (in Tirana) Young Persons Advisory Group (YPAG). Main tasks in the project per Pillar/WP: Pillar 3: In WP15, we will lead the task related to “Educational materials and activities for paediatric patients” (task 15.4) dedicated to the development and organization of educational materials and activities for paediatric patients. Several tools such as videos, cartoon and serious game for children and adolescents will be developed and disseminated and a yearly face to face “paediatric patients experts training course’ will be organized. Pillar 0: Transversal WP5 “Communication & Dissemination”: We will be involved in Task 5.2: Integrating EJP-RD communication and dissemination strategies with the strategies of involved stakeholders. We will be in charge of communication, dissemination and networking activities, establishing a live mechanism of interactions and providing a link between the parties involved in the project and the European scientific community. Previous experience relevant to the Tasks: Experience of the team relevant to the tasks in the proposal: - Patients Advocacy on research: TEDDY provides support, education and information to patients and families regarding their participation in clinical trials. Currently, we have designed different educational resources with different format, e.g. serious games, comics, videos on the development of clinical trials. - KIDS Bari and Albania: Regarding the patients empowerment and the involvement in the paediatric clinical research, TEDDY has promoted the creation the first Italian (in Bari) and Albanian (in Tirana) Young Persons Advisory Group (YPAG) named respectively KIDS Bari (in collaboration with Consorzio per Valutazioni Biologiche e Farmacologiche and the paediatric University Hospital Azienda Ospedaliero-Universitaria Consorziale Policlinico di Bari – Ospedale Pediatrico “Giovanni XXIII”) and KIDS Albania (in collaboration with the Albanian Branch Office of CVBF and the University Hospital Center Tirana “Mother Teresa”, Service of Paediatrics) in order to provide the youths to be able to help researchers in trials design, prioritizing future researches, improving communication with the target population and increase awareness on clinical research 825575 – EJP RD – Part B 101 through the different means of communication. Associated with document Ref. Ares(2018)6091977 - 28/11/2018 - Communication and dissemination on clinical research: TEDDY is leading different projects on this field developing different kind of activities: webinars, social media education, specific website about clinical trials for patients and families, conferences, etc. TEDDY has developed age-appropriate informative materials (age-tailored information booklets, assent forms and videos) to duly inform children and families involved in clinical study, prepared in the framework of the DEEP and GAPP projects, two EC-FP7 funded project. All the materials have been developed with a language and a wording appropriate to age, psychological and intellectual maturity, taking into account the cultural and linguistic differences, in a collaborative effort among pharmacologists, paediatricians, child psychologists and illustrators. - Training: TEDDY has created an e-learning platform to provide courses on medicines, regulatory issues and clinical research, realised in the context of the TEDDY FP6 project (http://www.teddylearning.org/). Description of any significant infrastructure and/or major items of technical equipment, relevant to the proposed work : To conduct the networking and dissemination activities, TEDDY is able to provide communication and dissemination activities such as websites and newsletter, in order to deliver relevant publications or guidelines which were believed to be of interest for the Network and useful to stimulate scientific debate. TEDDY Network pays particular attention to the theme of the empowerment of paediatric patients in the healthcare field and is involved in several activities such as: - Videos (a spoonful of info helps the medicine go down) and training material, specifically addressed to children explaining some main concepts on drugs and their use. - Development of age-appropriate informative material to duly inform children and families involved in clinical studies (e.g. DEEP project informative material) - Quality evaluation of informative materials addressed to paediatric patients involved in clinical trials - Advisory group setup in the international paediatric project GAPP - Analysis of existing Young Person Advisory Groups and improvement of strategies to involve paediatric patients in the healthcare decisions (GRiP project activity) - Participation to public consultations and roundtables on this topic. Finally, TEDDY is always proactive to ensure a collaborative and continuous action involving paediatricians and healthcare professionals, psychologists, families, children. An e-learning Platform has been created by TEDDY aimed to distribute to different stakeholders updated Information on Medicines for children with particular reference to their better use, valuable effects and possible risks. Short Profile of key Staff Members who will be undertaking the work Mariangela Lupo/ M. Lupo has a Master’s Degree in Political Science, International Relations. Bachelor’s Communication and Degree in Foreign Languages - Linguistic Mediation in the European Union. She is Patient Advocacy responsible for Communication and Development at TEDDY and involved in the Manager/ female communication and dissemination activities in several European projects (e.g. GAPP and DEEP). She is responsible for the activities dedicated to patient’s advocacy and coordinates the KIDS Bari and KIDS Albania, the first Young Persons Advisory Group in Italy and in Albania. Annagrazia Altavilla/ A. Altavilla Professor (PAST) at Aix-Marseille University – EEM (Bioethics Research Lawyer and Ethicist/ Centre) and lawyer specialised in Health Law and Bioethics (LL.M. in Health Law and female PhD Sciences –Ethics). Former member of the European Medicine Agency (EMA) Paediatric Committee (2008/2011) and of the “Third countries clinical trials” EMA Working Group; rapporteur on ethical and legal aspects of the “Reflection paper on ethical and GCP aspects of clinical trials of medicinal products for human use conducted in third countries and submitted to marketing Authorisation to EMA” (2009/2012). Author of a book and about 40 publications in national and international journals. Joana Claverol/ CTO Paediatric Clinical trials Unit Manager at FSJD, where she manages and oversees Coordinator of more than 100 clinical trials in all paediatric specialities. She is paediatric clinical research Clinical Trial Office consultant for pharmaceutical companies and lecturer of different masters of the University at HSJD/female of Barcelona, ESAME business school and Moebio. She has over 13 years of medical and clinical research experience in the pharmaceutical and biotechnology industry, particularly in Drug Development, Clinical Operations, Commercial, Marketing, Regulatory, and Medical Affairs functions. Together with Ms Begoña Nafria, she coordinates the Young Patient’s Advisory Group KIDS Barcelona and the European network of YPAG (eYPAGnet). 825575 – EJP RD – Part B 102 Begonya Nafría/ Experience in coordinating and managingAssociated projectswith in document clinical Ref. research on rare diseases. Ares(2018)6091977 - 28/11/2018 Patient Advocacy Coordinator of YPAG-KIDS Barcelona and RareCommons platform. Fellow of the Manager on Research EUPATI IMI2 project (first cohort), member of the Course Committee and member of the at FSJD/ female Spanish National Platform and Course Committee of Eupati. Chair of the Educational Committee of ICan. Before her professional relationship with FSJD, she worked during two years as a research technician of CIBERER (Biomedical Center for the Research on Rare Diseases Networks) and during three years in a research project about the involvement on clinical research and health education for patients’ associations in agreement with the Open University of Catalonia (APTIC Project) and the Hospital Sant Joan de Déu. Antonella Minervini/ She is responsible for the organization of meetings and training activities within TEDDY Administrative and organizational Manager/ female List of the most relevant publications and/or products, services (including widely-used datasets or software), or other achievements: 1. Veal GJ, Malik S, Lupo M, MacFarlane S, Lepola P, Costello M, Ceci A, Boué C, Lecour C, Otto A, Rastegari M, Berry P. Investigating the roles and training of paediatric research nurses working across Europe: a questionnaire-based survey. BMJ Paediatrics Open. 2017 August 11 2. Giannuzzi V, Altavilla A, Ruggieri L, Ceci A. Clinical Trial Application in Europe: What will change with the new Regulation? Sci Eng Ethics. 2016 Apr;22(2):451-66. doi: 10.1007/s11948-015-9662-0. Epub 2015 Jun 3. 3. Baiardi P, Giaquinto C, Girotto S, Manfredi C, Ceci A; TEDDY Network of Excellence. Innovative study design for paediatric clinical trials. Eur J Clin Pharmacol. 2011 May; 67 Suppl 1:109-15. 4. Altavilla A, Manfredi C, Baiardi P, Dehlinger-Kremer M, Galletti P, Pozuelo AA, Chaplin J, Ceci A. Impact of the new European paediatric regulatory framework on ethics committees: overview and perspectives. Acta Paediatr. 2012 Jan;101(1):27-32. 5. Armayones, M., Camino-León, R., Cantarín, V., De la Fuente, J., Families Lowe Syndrome, S., Gómez, B., Maldonado, E., Nafría, B., Ojea, T., Pascual, S., Pérez, B., Pousada, M., Serrano & M., Vidal- Valls, J. (2013). Results of a families-researchers collaborative project in Lowe Syndrome: ten patients with a wide neurological phenotype. Journal of Inherited Metabolic Disease, (2), 330. doi: 10.1007/s10545-013- 9635-x. List of relevant previous projects or activities, connected to the subject of this proposal : . ID-EPTRI (Infradev –European Paediatric Translational Research Infrastructure); European Commission, Grant Agreement n° 777554 – H2020 - INFRADEV-2017-1; 2018-2019; TEDDY is Third party of CVBF in the project and is involved in the communication , networking and patients engagement; ID-EPTRI is aimed to create the framework for a new Research Infrastructure (RI) intended to enhance technology- driven paediatric research in discovery and early development phases to be translated into clinical research and paediatric use of medicines . GAPP (GAbapentin in Paediatric Pain); European Commission, Grant Agreement n° 602962 - FP7‐ HEALTH‐2013‐INNOVATION‐1; 2013-2017, TEDDY was involved in the preparation of age-appropriate informative materials aimed to duly inform children and families involved in the clinical studies conducted within the project: GAPP was aimed at designing paediatric studies with gabapentin for the treatment of chronic pain of neuropathic origin in children. . PedCRIN (Paediatric Clinical Research Infrastructure Network); European Commission, Grant Agreement n°731046 - H2020-INFRADEV-2016-1; 2017-2020; TEDDY is involved in the project in developing or adapting tools to be used for multinational paediatric and neonatal clinical trials. PedCRIN is aimed to enrich the current ECRIN (European Clinical Research Infrastructure Network) tools and actions with paediatric components in order to better address the real needs and the gaps of the paediatric research community. . GRiP (Global Research in Paediatrics), European Commission, Grant Agreement n°261060 - FP7- HEALTH-F5-2010; 2011-2017. TEDDY was involved in the project for the development of innovative methodologies to facilitate the implementation of paediatric clinical trials and for developing contents of two of the ten modules of the International Master of Science in “Paediatric Medicines Development and Evaluation”. GRiP is a 5-year EU-funded Network of Excellence aimed at stimulating and facilitating the development and safe use of medicines in children. An International Master in Paediatric Clinical Pharmacology has been realised and proposed at global level (Europe, USA, Canada, Japan, China, etc.). . RESPECT (Relating Expectations and Needs to the Participation and Empowerment of Children in Clinical 825575 – EJP RD – Part B 103 Trials - 201938 - FP7- HEALTH-2007-4.1-4), a project aimed toAssociated identify with thedocument needs and Ref.motivations of children Ares(2018)6091977 - 28/11/2018 and their families participating in clinical trials in Europe. The project makes available recommendations for researchers about how to empower children, respect their interests and motivate their participation in future clinical trials. CVBF has provided an extensive knowledge on the ethical procedures with the current European and national provision (guidance and control), on-line questionnaires (elaboration and validation), statistical support. 29-MIUR Full legal name (Acronym) – Country Ministero dell’Istruzione, dell’Università e della Ricerca (MIUR) - Italy Main contact / Principal investigator Gianluigi Consoli Relevant Network NA Description of the legal entity/department/laboratory/group: The Italian Ministry for Education, University and Research (MIUR) is the key RTD policy actor and funding agency in Italy at state level. MIUR is in charge to prepare and to submit the National Research Programme (PNR – Piano Nazionale della Ricerca) proposal to the Government and to directly manage it. Besides, the Ministry, in charge of definition of strategic priorities in Research and higher education, has the following responsibilities: • coordination, assessment and evaluation of the national university system and advanced training schools; • supporting and fostering basic research in university and research institutions, programming intervention in public research institutions; • coordination, regulation and funding of national research institutions; • coordination of the research activities promoted by other Ministries; • monitoring and supporting the integration between the research system and industries; • integration between public research and applied research; • promoting and supporting research in the industry system; • funding research programmes for southern regions; • promoting initiatives such as the Funds for the diffusion of scientific culture; • enforcement of EU and international rules on university education and research. The Ministry also has key responsibilities for international co-operation. It concludes bi- and multilateral agreements on research and technology collaboration and is in charge of co-ordinating Italy’s participation in the European Union’s Framework Programme. Main tasks in the project per Pillar/WP: Pillar 1: WP 6: Joint Transnational Calls for collaborative research projects. Previous experience relevant to the Tasks: MIUR has a large experience in joining Calls for proposals. MIUR has participated in 7 FP6 ERANETs, 11 FP7 ERANET and 3 FP7 ERANET PLUS. MIUR is participating also in more than 20 ERANET Cofund of which: CoBioTech, CORE Organic, EMEurope, ENSUF, ERA4CS, ERA-HDHL, ERA-MIN 2, EURONANOMED III, FACCE Surplus, FLAG-ERA II, GEOTHERMICA, HDHL INTIMIC, JPco-fuND, M-ERA.NET2, MANUNET III, MarTERA, QuantERA, SUSFOOD2, TRANSCAN2, WaterWorks 2014, WaterWorks2015, WaterWorks2017. Description of any significant infrastructure and/or major items of technical equipment, relevant to the proposed work : NA Short Profile of key Staff Members who will be undertaking the work Dr Gianluigi Consoli Dr Gianluigi Consoli is in charge as a Head of Planning and promotion of international (male) scientific research and coordination of aerospace research Office within MIUR. He is also the Italian representative in several EU initiatives and he is the person in charge of the administrative, legal and financial aspects in all the ERANET and ERANET+ projects in which MIUR participates. Dr Aldo Covello Dr Aldo Covello is a senior scientific advisor for MIUR and represents the ministry in (male) several European initiatives and committees: JTI ECSEL, JPIs, ERANETs and ERANET+. Dr Valeria Cardia Dr Valeria Cardia is a Project Officer at MIUR. She is involved in the administrative and (female) financial management of several European initiatives: JPIs, CSAs, ERANETs, ERANET+ and ERANET Cofund. 825575 – EJP RD – Part B 104 Associated with document Ref. Ares(2018)6091977 - 28/11/2018 30-VIAA Full legal name (Acronym) – Country VALSTS IZGLITIBAS ATTISTIBAS AGENTURA (VIAA), LATVIA Principal investigator Dr. Janis Ancans Relevant Network E-Rare-3, other subject related ERA NET/ EJP partnership Description of the legal entity/department/laboratory/group: VIAA ensures evaluation, administration and supervision of international cooperation programme projects in the field of science and technology development in the Republic of Latvia. Main tasks in the project per Pillar/WP: Pillar 1: In WP7 «Networking to share knowledge on rare diseases», Task 7.2. Evaluation of applications. VIAA will participate in the Evaluation Committee that will evaluate the applications for network meetings, workshops or conferences to share knowledge on rare diseases based on specific criteria and on a competitive basis. This will be performed according to confidentiality and conflict of interest issues rules. In WP9 Task «Monitoring of granted projects», Task 9.2. Monitoring of networking to share knowledge on rare diseases (WP2).VIAA will participate in the follow-up, monitoring and assessment of results of the networking grants funded by the Evaluation Committee under WP7, as the result of Task 7.2 activity. Previous experience relevant to the Tasks: VIAA responsibilities include Erasmus+ programme; joint programmes and joint technology initiatives stipulated in Article 185 and 187 of the Treaty on the Functioning of the European Union as well as EU COST, EJP, JPI, ERA-NET un ERA-NET+ projects; Euroguidance and Eurydice networks in accordance with the aims and tasks set out in EU guidelines; administration of the European Economic Area financial instruments, Norway and Swiss financial instrument programmes and projects; and other international and bilateral programmes. VIAA is involved in nationwide management of the EU Structural Funds in education and science sector. The Agency ensures implementation of EU policy initiatives in Latvia in the field of education and science policy. Description of any significant infrastructure and/or major items of technical equipment, relevant to the proposed work : Human resources with professional expertise relevant to abovementioned Pillar 1 tasks. Short Profile of key Staff Members who will be undertaking the work Dr. Janis Ancans Senior expert at VIAA Horizon 2020 National Contact point, responsible for Health, (male) Demographic Change and Wellbeing since 2017. Previously served as Head of Laboratory at University of Latvia, 2005-2017. Delegate from Latvia to the Committee for Advanced Therapies at European Medicines Agency (EMA) 2009 - 2014; European expert at EMA WPs. External expert at the national medicines agency for medical biotechnology and biopharmaceutical products. Expert for medical biotechnology and pharmaceutical project evaluation at Lithuanian Business Support Agency (LBSA) 2013 - 2016. Personal expertise includes consulting for experimental medicinal, bioanalytical, biotech R&D services biotechnology service and product development. TBC (involvement VIAA personal or experts will be involved as required by specific Pillar 1 tasks, including as required by networking project evaluation stage, and provide expertise on project management, financial tasks) issues, monitoring and assessment, and related competencies. List of the most relevant publications and/or products, services (including widely-used datasets or software), or other achievements: In Horizon 2020, VIAA has participated in 22 projects as ERA-NET/EJP/JU partner and funding agency. List of relevant previous projects or activities, connected to the subject of this proposal : VIAA is partner in the following projects: E-Rare/ E-Rare-3. ERA-NET for research programmes on rare diseases which has been extended under Horizon 2020 to the third phase, implementing IRDiRC objectives 01.12.2014. - 30.11.2019. TRANSCAN-2. ERA-NET aligning national/regional translational cancer research programmes and activities. 01.01.2015. - 31.12.2019. NEURON. ERA NET in the area of brain-related diseases and disorders of the nervous system. 01.01.2016. - 31.12.2020. HBM4EU. COFUND-EJP European Human Biomonitoring Initiative. 01.01.2017. - 31.12.2021. ERA PerMed. ERA NET in Personalised Medicine. 01.12.2017. - 31.11.2022. 825575 – EJP RD – Part B 105 31-LMT Associated with document Ref. Ares(2018)6091977 - 28/11/2018 Full legal name (Acronym) – Country Lietuvos mokslo taryba (LMT), Lithuania Principal investigator Dr. Aistė Vilkanauskytė, Head of International Programmes Unit (head of Department which is responsible for the implementation of international programmes at LMT (Research Council of Lithuania)) Relevant Network Description of the legal entity/department/laboratory/group: The Council is a counsellor of the Lithuanian Parliament and the Government on research and researchers training issues, implements programme based competitive funding of research, administers most important Lithuanian science development programmes, evaluates research performance and represents Lithuanian science in various European institutions and other international organisations. The Council is the principal national institution providing competitive R&D funding in Lithuania, focusing on financing high-level research projects. The Council regularly holds competitions for R&D in every area, taking responsibilities of conducting (administrative) verification, evaluation by experts, selection of winning projects and administrative management during implementation. Main tasks in the project per Pillar/WP: Pillar 1: WP6: participation in joint transnational calls for collaborative research projects. Previous experience relevant to the Tasks: Every year the Council publishes more than 30 calls for research proposals. The funding portfolio includes top- down schemes with pre-define research topics, such as National Research Programmes, national Lithuanian studies, as well as bottom-up schemes. The list of the programmes comprises in average 40 national and international programmes and the EU funds' schemes designed to provide funding for different research, career, mobility and dissemination activities. The Council, as an institution implementing the national research programmes, is engaged in the international initiatives of coordination of the national research programmes: the European research area networks developed under the FP7 (such as ERA-NET), and the networks for cofunding European research (ERA-NET COFUND), joint programming and the initiatives under Article 185 of the Treaty establishing the European Community. The Council participates in seven ERA-NET/ERA-NET COFUND projects, engaged in the activities of Joint Programming Initiatives (JPI) also organises the participation of Lithuanian researchers in the activities of the COST programme. Short Profile of key Staff Members who will be undertaking the work Dr. Saulius Marcinkonis Chief officer at the international programmes unit of the Council in charge of (male) international cooperation and bilateral agreements. He is programme manager for the Lithuanian–Ukrainian Cooperation Programme in the Fields of Research and Technologies, M-ERA.NET programme (ERA-NET COFUND project) and national support scheme for preparation of Horizon 2020 proposals, also acting as national contact point (NCP) for Health, demographic change and well-being (SC1) and ERC under Horizon 2020. Dr. Marcinkonis has extensive former researcher experience (over 20-years) also worked as a strategist in leading institution of Lithuanian UAS sector. List of relevant previous projects or activities, connected to the subject of this proposal: . Research Council of Lithuania is the participant of 11 ongoing H2020 projects (JHEP2, FLAG-ERA II, CHIST-ERA III, EuroNanoMed III, HERA JRP UP, BiodivScen, HERA-JRP-PS, DIAL, BiodivERsA3, ENSUF and M-ERA.NET 2. . 32-VUHSK Full legal name (Acronym) – Country Vilnius University Hospital Santaros Klinikos (VUH SK) – Lithuania Principal investigator Birute Tumiene 825575 – EJP RD – Part B 106 Relevant Network ITHACA ERN Associated with document Ref. Ares(2018)6091977 - 28/11/2018 Description of the legal entity/department/laboratory/group: Vilnius University Hospital Santaros Klinikos (VUH SK) is one of the largest University hospitals in Lithuania and Eastern Europe encompassing all main medical specialties. VUH SK is founded by Vilnius University and Lithuanian Ministry of Health with three key assignments of highly specialized healthcare, research and education/training. Considerable part of VUHSK human resources is active in research and education including > 320 PhD and 43 professors. All rare disease activities in VUH SK are coordinated by Joint Center for Competences and Biomedical Research (JCCBR) that serves as a clinical and biomedical research hub providing IT infrastructures, managerial, administrative and coordination services for 36 Competence centres for rare and complex diseases. The volumes of JCCBR include approx. 7,000 rare disease patients/year and at least 90-100 clinical research studies for investigational medical products and devices at a time. VUH SK is a designated national coordinator of Orphanet Lithuania, a hub of Human Biological Resource Center – a national biobanking system integrated with BBMRI-ERIC, a true Member of 8 European Reference Networks (ERN; ITHACA ERN, EuroBloodNet, MetabERN, ERN RND, ERKNet, eUROGEN, TransplantChild, PaedCanERN). Main tasks in the project per Pillar/WP: Pillar 0: Coordination and transversal activities: In WP1, we will carry out the overall management of EJP RD including HelpDesk activities as one of Pillar 3 leaders (Task 1.1; Task 1.2; Task 1.3) In WP5, we will develop and implement EJP RD communication and dissemination strategy as one of Pillar 3 leaders (Task 5.1) Pillar 2: In WP11 VUSHK will represent ERN-ITHACA participate in Task 11.2 FAIR-compliant virtual platform for discovery of RD resources Pillar 3: In WP14, we will perform national training on Orphanet nomenclature and RD ontologies as a LTP of Orphanet (Task 14.1); training for biobanks and researchers/clinicians on sample data management as a LTP of FTELE (Task 14.4). In WP16, we will participate in the development of on-line academic education course modules (Task 16.2) In WP18, we will adapt Pillar 3 training activities according to the developing EJP RD needs (Task 18.1; Task 18.2; Task 18.3) Previous experience relevant to the Tasks: In collaboration with Vilnius University, Faculty of Medicine, VUH SK is the main provider of rare disease education/training and research activities in Lithuania. From 2004, it is a national coordinator of Orphanet Lithuania. Besides, it participates in multiple other international RD-related activities including RD-Action, JARC, EORTC, BBMRI and ERNs, among others. Short Profile of key Staff Members who will be undertaking the work Pr. Birute Tumiene Clinical geneticist and Coordinator for Competence Centers at VUH SK, lecturer and (female) researcher at Vilnius University, Faculty of Medicine, with special interests in clinical genetics/rare diseases, epilepsy genetics and inborn errors of metabolism; Orphanet Lithuania National Coordinator and a member of Orphanet Operating Committee responsible for Northern Eastern European countries (LT, LV, EE, SK, SI, PL); RD- Action WP6 (Policy Development for Rare Diseases and Integration), WP5 (Steering, maintaining and promoting the adoption of Orphacodes across MS), WP4 (Orphanet, the European database for Rare Diseases) partner; ERN Board of Member States Lithuanian representative. Pr. Algirdas Utkus Clinical geneticist, the Head of Medical Genetics Centre at VUH SK, the Dean of Faculty (male) of Medicine, Vilnius University, the Chair of Lithuanian Society of Human Genetics. Association of Medical Schools in Europe Board Member. Special interests: clinical genetics, syndromology, dysmorphology. List of the most relevant publications and/or products, services (including widely-used datasets or software), or other achievements: 1. Tumienė B, Maver A, Writzl K, et al. Diagnostic exome sequencing of syndromic epilepsy patients in clinical practice. Clin Genet. 2017 Dec 29. doi: 10.1111/cge.13203. [Epub ahead of print] 2. http://kimg.eu/en/tools/epigene-database 3. Savickienė J, Matuzevičius D, Baronaitė S, et al. Histone Modifications Pattern Associated With a State of Mesenchymal Stem Cell Cultures Derived From Amniotic Fluid of Normal and Fetus-Affected Gestations. J Cell Biochem. 2017;118(11):3744-3755. 825575 – EJP RD – Part B 107 4. Inashkina I, Jankevics E, Stavusis J, et al. Robust genotyping Associated tool for autosomal with documentrecessive type of limb-girdle Ref. Ares(2018)6091977 - 28/11/2018 muscular dystrophies. BMC Musculoskelet Disord. 2016;17:200. 5. Stavusis J, Inashkina I, Jankevics E, et al. CAV3 gene sequence variations: National Genome Database and clinics. Acta Neurol Scand. 2015;132(3):185-90. List of relevant previous projects or activities, connected to the subject of this proposal: . Joint Action RD-Action; European Union’s Health Programme (2014-2020), 677024; 2015-2018; WP5 (Steering, maintaining and promoting the adoption of Orphacodes across MS), WP4 (Orphanet, the European database for Rare Diseases) partner . Orphanet; supported by grants from EC; 2004-current; National Coordinator, Orphanet Lithuania . COST EUCID Action; FP7/2007–2013, BM12082013-2017, partner . UNIGENE; Lithuanian –Swiss cooperation programme; 2014-2016, partner. 33-FNR Full legal name (Acronym) – Country Fonds National de la Recherche (FNR) - Luxembourg Principal investigator Sean Sapcariu Relevant Network Description of the legal entity/department/laboratory/group: The National Research Fund (FNR) was set up by the Law of 31 May 1999. Through the FNR, an additional impetus was given to Luxembourg research, with the aim to create and strengthen competences and knowledge and to develop national and international synergies in order to increase the attractiveness of Luxembourg as a scientific and economic site of excellence.Since 2000, several multi-annual research programmes have been launched in specific fields of interest to Luxembourg. Calls are addressed to public institutions, Luxembourg administrations and public establishments authorised to undertake R&D activities or technology transfer in their respective fields of activity.As an outcome of the 2007 Foresight Exercise and the subsequent choice of national research priorities by the Government, the new thematic research programme CORE was launched in 2008 with the prime objective fostering scientific quality in selected areas of Luxembourg public research. The FNR also regularly launches calls in the three structural programmes: ATTRACT (Attract Researchers to Luxembourg), the PEARL (Excellence Award for Research in Luxembourg) and the INTER (Promoting International collaboration. The FNR is also in charge of the Luxembourg research grants for PhDs and post-docs. Furthermore, the FNR subsidises accompanying measures, addressed to a larger public and aiming to strengthen the general framework of scientific research in Luxembourg. The FNR also wishes to strengthen the links between science and society and the general public to feel concerned with science. Activities for promoting scientific culture are mostly targeted to young people.FNR funds running research projects within the biomedical field through its CORE programme, which has an annual budget of approximately 4 Mio € and covers the following areas: Regenerative Medicine in Age-related, Translational Biomedical Research and Public Health research. Main tasks in the project per Pillar/WP: Pillar 1: In WP 6, we intend to participate in two co-funded and two non-cofunded joint transnational calls. In WP 9, we will FNR will support the WP leaders in the monitoring of funded research projects. FNR will participate in the co-funded call. It will contribute to the overall implementation of the co-funded call by commenting on the proposed call text and other call documents, publication and promotion of the call, eligibility check of candidates applying for FNR support and participation in funding decision. In addition, FNR will participate in additional funding activities by contribution to the workshops in which the topics of the additional activities will be determined Previous experience relevant to the Tasks: At an international level, the FNR currently participates to the following initiatives: - ERA-Nets: TRANSCAN, NEURON I and II, ERA-SysAp, MATERA, MNT, ERA-SysBio, ERA-Age, HERA, CHIST-ERA, CORE Organic. - Coordinated Actions: CoA-SysMed, CoA-PerMed; - JPND: Joint programming in neurodegenerative diseases; - Agreements with 11 funding agencies in Europe to fund bilateral research projects. By participating to these initiatives, the main objective of the FNR is foster cooperation and coordination of research activities carried out across Europe, and to increase visibility of Luxembourg research in selected domains. Short Profile of key Staff Members who will be undertaking the work 825575 – EJP RD – Part B 108 Sean Sapcariu Sean Sapcariu, Ph. D. is a Programme ManagerAssociated of the biomedical sciences with document research programme Ref. Ares(2018)6091977 - 28/11/2018 (male) (CORE BM) at the FNR. He has over 6 years of experience in the Luxembourgish research ecosystem, involved in biomedical research, university administration and strategy, and facilitation of funding agency programs. 34-ZonMw Full legal name (Acronym) – Country ZORGONDERZOEK NEDERLAND ZON (ZonMw), The Netherlands Principal investigator Sonja van Weely Relevant Network E-Rare, IRDiRC Description of the legal entity/department/laboratory/group: ZonMw, The Netherlands Organisation for Health Research and Development, funds health research and stimulates use of the knowledge developed to help improve health and health care. Research on rare diseases is funded in several clusters within ZonMw. Main tasks in the project per Pillar/WP: Pillar 1: - Coleader of Pillar 1 “Funding Collaborative Research on Rare Diseases” P1WP6 - Participant in WP6: “Joint Transnational Calls for collaborative research projects” P1WP7 - Leader of WP7: “Networking to share knowledge on rare diseases” - Co-taskleader WP7 task 7.1: “Development of the networking scheme” - Taskleader WP7, task 7.2: “Implementation of networking scheme” - Taskleader WP7, task 7.3: “Evaluation of applications” P1WP8 - Participant in WP8, task 8.1: “Development of the scheme” - Participant in WP8, task 8.2: “Set-up of challenges” - Participant in WP8, task 8.3: “Call for proposals, evaluation and selection of proposed projects for solutions in first phase” - Participant in WP8, task 8.4: “Call for proposals, evaluation and selection of proposed projects for solutions in second phase” P1WP9 - Co-taskleader WP9, task 9.2: “Monitoring of networking to share knowledge on rare diseases” Pillar 0: Coordination and Transversal activities As Coleader of Pillar 1 involved in - WP1 “Coordination and management” - WP2 “Integrative research strategy” - WP3 “Sustainability strategy and business plan” - WP4 “Legal, ethical and regulatory framework of the EJP RD” - WP5 “Communication and Dissemination” Previous experience relevant to the Tasks: ZonMw is a co-creating party in European research programming and is involved in four Joint Programming Initiatives and many ERA-Nets related to health, and in four Research Infrastructures (BBMRI, BBMRI, EATRIS, ELIXIR and EuroBioImaging). From 2006 ZonMw is involved in the ERA-Net E-Rare and was leader of several work packages and/or tasks. In the current programme E-Rare 3, ZonMw is co-chair of the Network Steering Committee, leader of the work package “Strategy” and Call Secretariat for E-Rare Joint Transnational Call JTC 2018. ZonMw has executed several national network subsidy programmes, including a specific network subsidy programme for rare diseases research. ZonMw is member of the Consortium Assembly of the International Rare Disease Research Consortium (IRDiRC) from 2011. Description of any significant infrastructure and/or major items of technical equipment, relevant to the proposed work : ZonMw has its own online project portal (ProjectNet), which could be used for the submission of applications for the networking scheme, for which ZonMw will be WP leader. 825575 – EJP RD – Part B 109 Short Profile of key Staff Members who will be undertaking the work with document Ref. Ares(2018)6091977 - 28/11/2018 Associated Dr. Sonja Van Weely The professional career of Sonja van Weely is dedicated to rare diseases. After working for (female) more than 10 years as scientist in the field of biochemistry of rare diseases, she became scientific officer of the multidisciplinary Dutch Steering Committee on Orphan Drugs that was installed by the Minister of Health (2001-2011). Subsequently, she was appointed as senior programme officer dedicated to research and network programmes on rare diseases and orphan drugs at ZonMw (2011-now). As representative of ZonMw she is involved in E-Rare from 2006. In the current programme E-Rare 3 she is co-chair of the Network Steering Committee, leader of the work package Strategy and takes part in the Call Secretariat JTC 2018. She is also representative of ZonMw in the Consortium Assembly of the International Rare Disease Research Consortium (IRDiRC) from 2011. Sonja is involved in the preparation of the EJP RD from the beginning and will act as one of the two coleaders on funding of rare disease research. Dr. Harald Moonen Dr. Moonen was originally trained as a chemical engineer at the Eindhoven University of (male) Technology. He then shifted his focus of interest towards biomedical research and obtained his PhD at the University of Maastricht, after investigating the relationship between dietary habits, the formation of endogenous formation of carcinogenic compounds and colorectal cancer risk. Subsequently he worked for almost 4 years as a postdoctoral researcher on the relationship between dietary factors and modulation of chronic oxidative stress. In 2007 he continued his career in research management and –policy. Since 2009 he has been working as senior programme officer at ZonMw on several programmes including research and network programmes on rare diseases, both in a national and international context (E-Rare). List of the most relevant publications and/or products, services (including widely-used datasets or software), or other achievements: 1. Julkowska D, Austin CP, Cutillo CM, Gancberg D, Hager C, Halftermeyer J, Jonker AH, Lau LPL, Norstedt I, Rath A, Schuster R, Simelyte E, van Weely S. Gene Ther. 2017 Sep;24(9):562-571. The importance of international collaboration for rare diseases research: a European perspective. 2. Results of Networking Subsidy scheme in ZonMw programme Priority Medicines Rare Diseases and Orphan Drugs, page 131-132; https://www.zonmw.nl/fileadmin/documenten/Corporate/ZonMw_jaarverslag_2015.pdf 3. Report on E-Rare Strategic Workshop “Strategic Research Agenda of E-Rare in relation to other initiatives on rare diseases”, organised by ZonMw on March 7, 2016 in Barcelona (Spain), http://www.erare.eu/sites/default/ files/Report%20E-Rare%20Strategic%20Workshop%20March%207%202016%20VFF.pdf 35-UMCG Full legal name (Acronym) – Country Academisch Ziekenhuis Groningen (UMCG) - The Netherlands Principal investigator Prof.Dr. Morris Swertz Relevant Network BBMRI, ELIXIR Description of the legal entity/department/laboratory/group: The UMCG (Academisch Ziekenhuis Groningen) is the second largest academic hospital in the Netherlands with a staff of 10,000 people in patient care, education & training and research, with a focus on ‘Healthy Ageing’. The work is planned at the Genomics Coordination Center (GCC) a multi-discipliniary 25fte streong bioinformatics core facility and big data stewardship hotel of the UMCG and University of Groningen on a mission to unlock big data for personalized genomics using smart informatics software, methods and tools. GCC is part of the Department of Genetics, having Prof. dr. Richard Sinke (male) - head of diagnostics and power user from diagnostic perspective, Prof. dr. Nine Knoers (female) – head of department, Prof. dr. Cisca Wijmenga (female) – head of BBMRI-NL 2.0, immune/complex disease, Mw Prof. dr. Irene van Langen MD (female) – head of clinic, ELSI, power user from clinical perspective, Prof. dr. Lude Franke – head of research and leading in multi-omics data integration, Prof. dr. Rolf Sijmons MD (male) – daily power user, national ontology expert, consultant to the project. Main tasks in the project per Pillar/WP: In Pillar 2: WP11 UMCG will participate in tasks on Metadata and ontological model definition for cataloging resources for RD research (Task 11.1), FAIR-compliant virtual platform for discovery of RD resources (Task 11.2), Data deposition and access to data infrastructures for RD research (Task 11.3), and Provision of analysis and data sharing capabilities to the RD community through online resources (Task 11.4). 825575 – EJP RD – Part B 110 /WP12 UMCG will participate in tasks to Compare and align core interoperability Associated standards with document of relevance- 28/11/2018 Ref. Ares(2018)6091977 (Task 12.1), Multi-team software development to enable the FAIR ecosystem (Task 12.2), and Combining expertise for practical FAIRification support (Task 12.3). WP12 UMCG will participate in tasks to Fill a number of pre identified gaps to allow integrative systems biology approaches for rare diseases (Task 13.1) In Pillar 3: WP14 UMCG will participate in tasks on Standards and quality of genetics/genomics data in laboratory and clinical research practice (Task 14.2), Training on strategies to foster solutions of undiagnosed rare disease cases (Task 14.3), Training for biobanks and researchers/clinicians on sample data management (Task 14.4) and Training on rare disease registries and FAIRification of data at the source (Task 14.5) Previous experience relevant to the Tasks: The GCC is and has been part of several national and EU Rare Disease and Infrastructure grants in which we have developed tools to make biobank and registries data and samples findable and accessible and link it with sample/data request workflows. We developed the MOLGENIS software that we used to build the BBMRI-ERIC (Biobank) Directory and the RD-Connect Sample Catalogue. MOLGENIS is also used for Rare Disease patient registries, e.g. CHARGE database (chd7.org) DEB central (www.deb-central.org) AIP (aip.fipapatients.org), MVID (mvid-central.org). In particularly relevant the GCC develops and operates the UMCG facilities for large scale DNA and RNA data processing for research and genome diagnostic health care. In addition, GCC is lead of the BBMRI-NL Dutch national IT infrastructure for biobanking, the BBMRI-ERIC Directory (catalogue), BBMRI-NL Dutch data and sample catalogue, LifeCycle large scale harmonization and federated analysis of EU child cohort data; RD-connect sample catalogue, Solve-RD bioinformatics team, and task lead in EU CORBEL access to sensitive project and RD-connect linked data project. All software is available as open source as part of the MOLGENIS software platform for scientific data at http://www.molgenis.org. UMCG is ISO 9001 and ISO 27001 certified. Description of any significant infrastructure and/or major items of technical equipment, relevant to the proposed work : GCC has a multi-discplinary team of 25 biologists, statisticians and computer scientist providing research, support, large scale analysis and data management. Next to open source software MOLGENIS, GCC hosts a database cloud consisting of 4 servers, 100 database servers and a computer cluster consisting of 20+ servers hosting >1500 Terabyte of NGS data, >1000 CPU cores and >5Terabyte of RAM. GCC is also host of the UMCG research IT infrastructure, in particular big data. In addition, UMCG is partner in University of Groningen Center for Information Technology, the second largest academic compute center in the Netherlands and part of SURF and Excelerate, with ample of capacity to host big data compute projects. Short Profile of key Staff Members who will be undertaking the work Pr. Morris Swertz Adj. Prof. dr. Swertz coordinates large scale bioinformatics research and support to the Dept. (male) of Genetics, other UMCG departments, and several (inter)national consortia. His research lines focus on: (1) methods for DNA, RNA and phenotype data analysis, and (2) user-friendly systems for large scale data management, analysis, interpretation and sharing. Swertz developed a novel data framework (Bioinformatics 2012) and computational framework (Molgenis/Compute) to enable large genome analyses, e.g. used in Genome of the Netherlands (EJHG 2013, Nature Genetics 2014), discovery of novel human gene-disease associations based on eQTL studies (NAR 2014), inconsistencies in the metabolic pathway knowledge (BMC Systems Biology 2013), and to inform genetic variant interpretation in various diseases (Human Mutation 2011-2015). Swertz also developed analysis methods to call genotypes from RNA-sequencing that enables identification of (rare) variants affecting gene- expression levels (Genome Med 2015) and a framework to estimate RD variant pathogenicity classification for clinical application (Human Mutation 2015, Genome Biology 2017). Finally, Swertz is Co-Lead of BBMRI-NL 2.0 'IT', genetics datasharing in VKGL & VKGN, Co-lead of UMCG Personalized Genomics Medicine programme Lead of UMCG Research IT program, focus on big data. David Van Before making the switch to bioinformatics in 2010 David van Enckevort has worked in Enckevort different roles at commercial ICT providers in the Netherlands. From 2010 - 2013 he was a (male) Senior Software Integration Engineer and Technical project lead (TPL) for the biobanking task force at the Netherlands Bioinformatics Center (NBIC). As TPL he was responsible for the day-to-day management of the development of BBMRI-NL catalogue and the day to day management of the GoNL Imputation Working Group. In 2013 he joined the department of Genetics at the UMCG as a project manager and he is responsible for the day to day management of the BBMRI-ERIC CS-IT WP1 (development of the BBMRI-ERIC Directory), 825575 – EJP RD – Part B 111 BBMRI-NL catalogue, RD-Connect SampleAssociatedCatalogue and the Ref. with document RD-Connect Data Linkage Ares(2018)6091977 - 28/11/2018 plan (co-Lead by Marco Roos, LUMC) and the harmonisation effort as Dutch representative in the MIABIS working group. He is a member of GA4GH and was a key participant in the GA4GH/IRDiRC joint Privacy Preserving Record linkage working group and he is co-Chair of the ISBER Resource Locator Working Group. Dr. K. Joeri van K. Joeri van der Velde graduated as BSc Bioinformatics on pathway visualizations of kinase der Velde activity at the Groningen Bioinformatics Centre in collaboration with the UMCG dept. of Cell (male) Biology and then continued to work on MOLGENIS software infrastructure for multi-omics research in Arabidopsis, mice and C. elegans at the Groningen Bioinformatics Centre. In 2018 he obtained his PhD at the UMCG dept. of Genetics, working on new methods for downstream clinical analysis of next-generation sequencing data in the group of Prof. Swertz. Now, as a postdoc amongst a unique crowd of clinicians, software developers, geneticists, parallel computing experts, wet-lab technicians and statisticians, he aims to discover new ways to revolutionarize the speed, yield and applications of genome interpretation for medical genetics, powered by NL and EU collaborations (e.g. Solve-RD) and a wealth of untapped resources available in the public domain. Dr. Salome Salome Scholtens (PhD) is a programme manager and epidemiologist at the University Scholtens (female) Medical Center Groningen in the Netherlands. She is expert on data management training and the set-up of research data infrastructure. Patrick Deelen Patrick Deelen completed his BASc bioinformatics at the Hanze University Groningen in (male) 2010 and his MSc of bioinformatics at the VU University Amsterdam in 2012 with honors. He is currently working on his PhD thesis at the genetics department of the UMCG. He mostly works on DNA and RNA data of population’s cohorts. He worked on the Genome of The Netherlands, Lifelines, and the BIOS cohort. List of the most relevant publications and/or products, services (including widely-used datasets or software), or other achievements: 1. Holub, Swertz, Reihs, van Enckevort, Muller and Litton (2016). "BBMRI-ERIC Directory: 515 Biobanks with Over 60 Million Biological Samples." Journal/Biopreserv Biobank 14: 559-562. DOI: https://doi.org/10.1089/bio.2016.0088 2. Pang, Hendriksen, Dijkstra, van der Velde, Kuiper, Hillege and Swertz (2015). "BiobankConnect: software to rapidly connect data elements for pooled analysis across biobanks using ontological and lexical indexing." Journal/J Am Med Inform Assoc 22: 65-75. DOI: https://doi.org/10.1136/amiajnl-2013-002577 3. Van Diemen, et al, van der Velde, et al, Swertz, Sinke, van Langen, Wijmenga (2017) Rapid Targeted Genomics in Critically Ill Newborns. Peadiatrics 140(4). DOI: https://doi.org/10.1542/peds.2016-2854 4. K. Joeri van der Velde, et al, Morris A. Swertz. “GAVIN: Gene-Aware Variant INterpretation for medical sequencing.” Genome Biology, 201718:6. DOI: https://doi.org/10.1186/s13059-016-1141-7 5. Patrick Deelen, et al, Morris A Swertz and Lude Franke "Calling genotypes from public RNA-sequencing data enables identification of genetic variants that affect gene-expression levels" Genome Medicine2015 7:30, DOI: https://doi.org/10.1186/s13073-015-0152-4 List of relevant previous projects or activities, connected to the subject of this proposal : 1. RD-Connect; European Union; 2012-2018; lead development of the RD-Connect Sample catalogue and integrated it with the Registry and Biobanks finder; co-Lead of the RD-Connect data linkage plan to link data from different sources; Data harmonisation and improving findability according to the FAIR principles. 2. Solve-RD; European Union; 2018-2022; Development of the Solve-RD Sandbox environment for development and piloting of innovative diagnostic tools; Data harmonisation and improving findability according to the FAIR principles. 3. ADOPT; European Union; 2015-2018; As part of ADOPT and the BBMRI-ERIC Common Services for IT we developed the BBMRI-ERIC biobank Directory and integrated the Directory with the BBMRI-ERIC Negotiator tool. 4. SAID, E-RARE; European Union/ZonMW; 2016-2020; lead large scale data sharing, annotation and integration for DNA variants, *omics and phenotypes from patients suffering from systemic autoinflammatory diseases 5. CORBEL; European Union; 2016-2020; We focussed in particular on interoperability (e.g. BiobankConnect) and systems to access sensitive human data. 825575 – EJP RD – Part B 112 36-UM Associated with document Ref. Ares(2018)6091977 - 28/11/2018 Full legal name (Acronym) – Country Maastricht University (UM), The Netherlands Principal investigator Prof. Chris Evelo Relevant Network ELIXIR Description of the legal entity/department: Maastricht University (UM), the most international university in the Netherlands, stands out for its innovative approach to learning and international outlook. With almost 16,000 students and 4,000 staff, UM offers a wide choice of academic programs, all of which are designed to bring out the best in its students. The Department of Bioinformatics – BiGCaT uses bioinformatics and integrative systems biology approaches to answer questions in biology. Technologies and algorithms are continuously explored to make biological knowledge and data more Findable, Accessible, Interoperable, and Reuseable (FAIR) and then actually reuse them for multi- omics data integration to answer new questions. Pathway and network biology form the heart of the in silico approaches used to explain health and disease issues with including the role of nutrients, the interaction of (nano)materials with biological matter, and the role of metabolism and other small compounds in human health. The unit comprises 6 FTE senior researchers and 8 PhD candidates, all doing research around biological data integration and analysis. Main tasks in the project per Pillar/WP: Contribution in Pillar 2: In WP10, we will contribute to the annual strategic plans for WP2&3 and to the bi-monthly progress reports and strategy discussions with WP11 and 12 leaders . In WP11 we will contribute to define ontological and metadata models for new relevant sources, to adapt the ELIXIR’s bio.tools for the RD community, to enhance the catalogue platform for query capabilities and collaboratively analysis multi-omics data from the selected use cases. In WP 12, we will contribute to develop and improve metadata (and other data) models, and the federation architecture, networks and registries In WP13, we will act as WP leader; we will co-lead the gap filling task to help facilitate holistic approaches using omics and genetics data in rare diseases ; we will participate in the proof principle studies to show and improve the usability of the work flows from task 13.1; we will make a connection with pillar 3 to provide training in the usage of the workflows developed in the WP. Previous experience relevant to the Tasks: Our work focuses on integrative (FAIR) data approaches in systems biology. This WP tries to make that approach work for rare diseases and is thus exactly in line with our expertise and available skills and resources. Description of any significant infrastructure and/or major items of technical equipment, relevant to the proposed work : Servers to run WikiPathways and related tool and data collections Short Profile of key Staff Members who will be undertaking the work Pr. Chris Evelo Prof. Evelo is the founder and head of the department of Bioinformatics - BiGCaT and is a PI in (male) the Maastricht Center for Systems Biology (MaCSBio). His research focus is on bioinformatics for integrative systems biology; aiming at a better interpretation of experimental data through integration in data models that build on structuring existing knowledge. Integrative approaches are multi-faceted, and as a generalist he is involved in many projects related to capturing and processing, integrating and understanding experimental data. This includes the interoperability approaches underlying such efforts: standards, ontologies, mapping tools and documentation of the origin of the data and methods used (the provenance). He is a co- lead of the interoperability platform of ELIXIR which he represents in the rare disease use case. WikiPathways and the accompanying mapping, analysis and network biology tools form his core project. WikiPathways is a resource for community curation of biological pathways and originates from collaboration with Alex Pico’s group at UCSF. He is a board member of the Open PHACTS foundation for large-scale semantic web based knowledge structuring of relations between chemicals, gene-products and diseases. Chris is scientific advisor for the IMI project for translational quantitative systems biology (TransQST) and for two SME’s (Edgeleap and Micelio). He is a.o. governing council member of the nutrigenomics organization NuGO, a member of the micronutrient genomics organization for which he lead the IRSES project Microgennet, involved in H2020 projects OpenRiskNet and EUToxRisk and a workpackage leader in the COST CHARME for harmonization of standards in biology and a member of the JPI ENPADASI that works on the development of a phenotype database that he helped conceptualize and develop. Dr. Friederike Dr. Friederike Ehrhart is currently post-doc researcher at the Department of Bioinformatics (head 825575 – EJP RD – Part B 113 Ehrhart of department: Prof. Dr. Chris Evelo) and the Dutch Rettwith Associated Expertise documentCentre-GKC (director: Ref. Ares(2018)6091977 Prof. - 28/11/2018 (female) Dr. Leopold Curfs). Educated and trained as cell and molecular biologist, working on tissue engineering of neurological, pancreatic and liver tissue, and high throughput and omics data approaches. Joining the Department of Bioinformatics at Maastricht University in 2015 she works on systems biology and bioinformatics methods to analyze (single or multi) omics data, especially within pathway and network analysis. Together with the Dutch Rett Expertise Centre in Maastricht she is working since 2016 on the systems biology of Rett syndrome, a rare neurological disorder with a genetic cause. Friederike has coordinated and co-coordinated 7 public and 3 industry funded projects and published 23 papers. Within ELIXIR (EU bioinformatics infrastructure project) she coordinated an implementation study which analyses and improves molecular data interoperability of rare diseases. She is a member of the SSBP (Society for the Study of Behavioral Phenotypes) to investigate (rare) genetic syndromes and their phenotypic outcome including fetal alcohol syndrome, Prader-Willi and Angelman syndrome. List of the most relevant publications and/or products, services (including widely-used datasets or software), or other achievements: 1. WikiPathways and PathVisio biological pathway collections and related analytical tools including network biology connections including BridgeDb database identifier mapping services and mappings for gene products and gene variants. 2. WikiPathways: capturing the full diversity of pathway knowledge. 2015. M Kutmon et al. NAR 44 (D1), D488. 3. The FAIR Guiding Principles for scientific data management and stewardship. 2016. MD Wilkinson et al., Scientific data 3 4. Open PHACTS: semantic interoperability for drug discovery. 2012. AJ Williams et al., Drug discovery today 17 (21-22), 1188. 5. Rett syndrome–biological pathways leading from MECP2 to disorder phenotypes. 2016. F Ehrhart et al. Orphanet journal of rare diseases 11 (1), 158. List of relevant previous projects or activities, connected to the subject of this proposal: . ELIXIR EXCELERATE; H2020; 2015-19; helps ELIXIR coordinate and extend national and international data resources to ensure the delivery of world-leading life-science data services: co-leading the interoperability platform and linking this to the rare disease use case. . Open PHACTS; IMI; 2011-16; Open Pharmacological Concepts Triple Store for drug discovery: central tech team, providing RDF formatted pathways, identifier mapping services & mappings, driver question resolution. . OpenRiskNet; H2020; 2016-19; Open e-Infrastructure to support risk assessment: API & ontology development. . EUToxRisk; H2020; 2016-21; ‘Flagship’ program driving mechanism-based toxicity testing and risk assessment: Adverse Outcome Pathway development and use in analysis, link to Open PHACTS . MICROGENNET; FP7/H2020; 2012-15; collaborations for a community-driven knowledge base for micronutrient genomics, coordinator. 37-NCBR Full legal name (Acronym) – Country The National Centre for Research and Development (NCBR), Poland Principal investigator Marcin Chmielewski Relevant Network E-Rare-3 / EJP RD Description of the legal entity/department/laboratory/group: The National Centre for Research and Development is the implementing agency of the Minister of Science and Higher Education. It was appointed in the summer 2007 as an entity in charge of the performance of the tasks within the area of national science, science and technology and innovation policies. When if was founded, it was the first entity of this type, created as the platform of an effective dialogue between the scientific and business communities. The main task of the National Centre for Research and Development is management and execution of strategic research and development programs, which lead directly to the development of innovativeness. Among the tasks of the National Centre for Research and Development, are the support of commercialization and other forms of transfer of scientific research results, the management of applied research programs and the performance of national security and defense projects. The Centre also attempts to provide young scientists with training and 825575 – EJP RD – Part B 114 development opportunities i.a. by implementing international scientific mobility Associated programs. with document Special attention- is Ref. Ares(2018)6091977 paid 28/11/2018 to the participation of young scientists in research programs. The Centre enables young researchers to expand their business and intellectual property management skills and to learn how to commercialize research results. At the same time, via implemented initiatives, it draws attention to the necessity of rasing the R&D staff’s awareness of the importance of industrial property protection to the commercialization of modern solutions and international patent protection opportunities for research units. Main tasks in the project per Pillar/WP: Pillar 1: In WP6, we will participate in JTCs for proposals as a programme partner (WP6.1, 6.2, 6.3 and 6.4). Previous experience relevant to the Tasks: NCBR is the most important research funding agency in Poland. Currently, it operates under the Act on National Centre for Research and Development dated 30 April 2010 (Journal of Laws from 2010, No. 96 item 616). The science reform adopted in the autumn 2010 gave the Centre more freedom to manage its financial assets, within the scope of a strategic research programme. In addition, the National Centre for Research and Development extended its activity with new initiatives and possibilities on 1 September 2011. Assigned by the Ministry of Science and Higher Education the function of the Mediation Institution in three operational programmes: Human Capital, Innovative Economy and Infrastructure and Environment, the Centre became one of the greatest innovation centres in Poland. The activity of the Centre is funded by the national treasury and the European Union. NCBR participates in more than 30 different international initiatives (ERA-NETs, JPIs, bilateral cooperation programmes). Short Profile of key Staff Members who will be undertaking the work Dr Marcin Marcin Chmielewski, Chief expert in Programmes Management Department, studied Chmielewski Biology at the University of Warsaw, specialisation - Parasitology. He got his PhD from the /Male Warsaw Medical University on the thesis “Apoptosis during the course of infection with hepatitis C virus (HCV) and human immunodeficiency virus (HIV).” Former lecturer at Warsaw Medical University. Since summer 2011 employed in National Centre for Research and Development (NCBR) as a Scientific officer. Currently responsible for coordination of international programs in the field of medicine. Main task is to take care of the projects during the whole funding period. It includes administrative and formal issues, but also scientific reviews. Matylda Matylda Marczak, Senior Expert in Financial Department of NCBR. Main responsibilities Marczak/Female are: financial control of the projects financed from national and international programs. 38-MUW Full legal name (Acronym) – Country Medical University of Warsaw (MUW) Poland Principal investigator Associate Professor Maciej Kosieradzki Relevant Network Description of the legal entity/department/laboratory/group: Department of General and Transplantation Surgery, Medical University of Warsaw is a clinical department that has a great experience with organ’s transplantation and it is an active member of European Transplantation Society. Our experience is based on transplantation liver, kidney and pancreas/ islet cells including patients with rare disease. The Department has clinical facilities and laboratory space dedicated just for departments’’ needs, diagnostic facilities are also included and High-class specialists with international experience. Main tasks in the project per Pillar/WP: Pillar 0: WP2 Task 2.5: Translation/impact of prioritization on national and EU strategies-co-leader Task 2.2 Mapping the research and innovation needs - Verification of integrated and coordinated set of commitments and actions designed to exploit core competencies on national level. 825575 – EJP RD – Part B 115 - Sharing the good practice. Associated with document Ref. Ares(2018)6091977 - 28/11/2018 - Grouping, verifying of specific therapeutic needs. - Identification of tasks during ongoing program, which were not included in the program. - Monitoring and controlling of the ongoing activities. - Analysis of risks and problems and adjusting the tools to solve them. Pillar 2: Task 12.1: Compare and align core interoperability standards of relevance Task 12.2 : Multi-team software development to enable the FAIR ecosystem We will 1) Identify diagnosis and standardization of procedures for international and interdisciplinary system which will classify diseases based on geno-diagnosis. 2) Improve the diagnostic and therapeutical standards. 3) Verification of caring out the preclinical and clinical research within Rare Disease 4) Monitor of oncological patients with RD 5) Develop infrastructure of R&D based on research of ATMPs indicated to RD, Oncology and Personalized Medicine. 6) Assessment of pharmacotherapy including safety and efficacy of medicinal products and analysis of benefit-risk ratio We will try to develop IT program together with centres, which have already existing data to harmonize diagnosis, symptoms, clinical treatment and monitoring follow-up in patients with RD. Development of clinical protocol to introduce as international standards for clinical study phase 1,2 and 3 including primary and secondary points to evaluate the benefit/risk ratio. Pillar 3: Task 14.1: Training on the Orphanet nomenclature and RD ontologies for RD research We will take a part in scientific committee for training on the Orphanet nomenclature and RD ontologies for RD research. Previous experience relevant to the Tasks: 1) develop diagnosis and standardization of procedures for international and interdisciplinary system 2) set the diagnostic and therapeutical standards. 3) Monitor of oncological patients with RD We have profound experience in transplantations of patients with RD proceeded from 2000: PSC – 48, Wilson – 24, HEHE – 2, Frantz tumor – 2, FAP – 2 Description of any significant infrastructure and/or major items of technical equipment, relevant to the proposed work (if applicable): We have full equipment and laboratory with specialization of ATMP research adequate to European standards for developing research and clinical trails for advanced therapy medicinal products in patients with rare disease and/or personalized medicine in oncology. Short Profile of key Staff Members who will be undertaking the work Associate Professor Maciej Head of the Department of General and Transplantation Surgery, Medical Kosieradzki, University of Warsaw. High class specialist with international experiance, from Male 2011 has been certified a European Board of Surgery Qualification in Transplantation Surgery. Research intern in the Division of Transplantation, Department of Surgery of the University of Wisconsin, Madison. President of an NGO, Polish Union for Transplantation Medicine. He was involved in EC project “Coordinationg a European Initiative among National Organizations for Organ Transplantation”. He manages a department that treats 24 patients with Wilson disease, nearly 50 patients with primary sclerotising cholangitis and some rare liver tumors. He authored 51 articles indexed in Medline. Professor Piotr Fiedor Prof. Piotr Fiedor, since 2010 up to 2017 held position of polish member of Male Committee for Medicinal Products for Human Use (CHMP) in European Medicine Agency (EMA). Prof. Fiedor is an clinicial professor hired by Medical University of Warsaw and was Chief of Executive Officer at National Medicines Institute in Warsaw, Poland. 2010-2013 – alternate member of Biological Working Party, European Medicines Agency. Additionally, he is an active expert in Scientific Advisory Group EMA. Professor Fiedor is clinical professor with long-term clinical experience (surgery, oncology, transplantology, immunology). He was a member of Orphan Diseases Group by the Ministry of Health and member of Medicinal 825575 – EJP RD – Part B 116 Product Commission by the President of The Associated withOffice forRef. document Registration of Medicinal Ares(2018)6091977 - 28/11/2018 Products, Medical Devices and Biocides. Prof. Fiedor is a international Expert in assessment and review of research programs and scientific collaboration by The Ministry of Science and Higher Education. He published over 140 scientific papers. Associate Professor Marek High class specialist, transplantologist with international experiance, involved in Pacholczyk The European Society of Organ Transplantation, The Polish Hepatology Society, Male Male The Polish Surgery Society. Currently he is working in the Department of General and Transplantation Surgery, Medical University of Warsaw. Asc. Profesor with long-term clinical experience. He authored 62 articles indexed in Medline. PhD Karolina Maria PhD, currently MBA student at ESG University of Quebec at Montreal (ESG Nowak UQAM) and Warsaw School of Economics, Internship in Stanford Biomaterials and Female Advanced Drug Delivery Laboratory, School of Medicine, she finished with honors Postgraduate Management Studies, Leadership 2.0 at the Warsaw School of Economics. Participation in Science Management and Commercialization Program, Stanford Centre for Professional Development, Stanford University. Previous experience as a acting head of R&D office in National Medicine Institute. Eight years of experience in research and development in Pharmaceutics. List of the most relevant publications and/or products, services (including widely-used datasets or software), or other achievements: 1. Immune biomarkers and long-term graft survival: a prospective follow-up of 457 kidney transplant recipients. Ciszek M, Mucha K, Foroncewicz B, Żochowska D, Kosieradzki M, Grochowiecki T, Durlik M, Górski A, Pączek L. Pol Arch Intern Med. 2017 Feb 15;127(3):178-183. doi: 10.20452/pamw.3937. 2. Fibrosing Cholestatic Hepatitis C After Liver Transplantation: Therapeutic Options Before and After Introduction of Direct-Acting Antivirals: Our Experience and Literature Review Tronina. O, Ślubowska K, Mikołajczyk-Korniak N, Komuda-Leszek E, Wieczorek-Godlewska R, Łągiewska B, Pacholczyk M Lisik W, Kosieradzki M, Durlik M. Transplant Proc. 2017 Jul - Aug;49(6):1409-1418. doi:10.1016/j.transproceed.2017.01.077. 3. The effects of in vitro hemodilution and fibrinogen concentrate substitution on thromboelastometry analysis in patients qualified for liver transplantation - Preliminary results. Nicińska B, Pluta J, Kosieradzki M, Lągiewska B, Wasiak D, Lazowski T, Chmura A, Trzebicki J. Transplant Proc. 2014 Oct;46(8):2758-61. doi: 10.1016/j.transproceed.2014.09.048. 4. Regulatory evaluation of Glybera in Europe - two committees, one mission. Melchiorri D, Pani L, Gasparini P, Cossu G, Ancans J, Borg JJ, Drai C, Fiedor P, Flory E, Hudson I, Leufkens HG, Müller-Berghaus J, Narayanan G, Neugebauer B, Pokrotnieks J, Robert JL, Salmonson T, Schneider CK.Nat Rev Drug Discov. 2013 Sep;12(9):719. doi: 10.1038/nrd3835-c1. 5. Liver transplantation for nonresectable metastatic solid pseudopapillary pancreatic cancer. Annals of Transplantation 2013; 18: 651-3. List of relevant previous projects or activities, connected to the subject of this proposal : • BIOOPA (Epidermolisis bullosa), NCBR; 2016- is pending – Coordinator of project, This project is the world's first research project based on the use of allogeneic human skin matrix ADM seeded with allogeneic stem cells and on a dressing of autologous cells taken from the areas of revertant mosaicism in the epidermolysis bullosa treatment. • International cooperation to develop new research for medicinal product in RD (preclinical study) • Isolation/immunomodyfication of hepatocytes and pancreatic islets National transplantation program-Polgraft, steam cells. 39-MUG Full legal name (Acronym) – Country Medical University Gdansk (MUG),Gdanski Uniwersytet Medyczny (GUMed), Poland Principal investigator Aleksandra Zurowska Relevant Network MUG members of ERKNet, PaedCan,eUROGEN, BBMRI.pl Description of the legal entity/department/laboratory/group: Medical University Gdansk teaches nearly 3000 students( including >800 international students) at its teaching hospital which is the largest in Northern Poland (1300 beds) with all specialities represented and full diagnostic and 825575 – EJP RD – Part B 117 research facilities on site. Its Centre for Rare Diseases incorporates research, Associated withteaching document activities of the departments Ref. Ares(2018)6091977 - 28/11/2018 which are members of several European Reference Networks. Department of Pediatrics, Nephrology & Hypertension and Department of Nephrology, Transplantation & Internal Medicine are members of ERKNet involved in the care of rare kidney diseases. Department Surgery & Urology for Children and Adolescents , a member of PaedCan ERN, eUROGEN ERN Department Pediatrics, Oncology & Hematology includes Infant Ward dedicated to rare diseases, member of PaedCan ERN Department Clinical Analytics- Central Bank Frozen Tissues and Genetic Specimens – member of BBMRI.pl Main tasks in the project per Pillar/WP: Pillar 3: WP 14. Capacity Building and Empowerment. We will be one of task leaders for Training for biobanks and researchers/clinicians on sample data management hosting 1 of annual workshops in Gdansk, Poland (Task 14.4) WP 15. Capacity building and training of patients and researchers in Rare Disease research and processes. We will be one of task leaders for Training for patient representatives and advocates on leadership and communication skills supporting the development of the annual face-to-face 2 days training programme for 30 participants and organising 1 of the rotating location courses in Gdansk, Poland (Task 15.3) Previous experience relevant to the Tasks: We have helped in the establishment of several patients organisations for rare diseases e.g Tuberous Sclerosis Complex (TSC), Hemolytic Uremic Syndrome (aHUS), Alport Syndrome. We have been long term cooperation with non-governmental organizations from all over Poland, including: Cornelia de Lange Association, Parent Project ( DMD) , Williams Syndrome Association , Fra X Family, Prader Willi Association, TSC, aHUS etc. We have organized a series of nationwide conferences on rare diseases with the participation of representatives of patient organizations and two international conferences for Duchenne Disease Families (Sobieszewo 2013 and 2015) as well as three conferences for Down Syndrome patients and families from Pomeranian district for Phenyloketonuria and LCHADD. We participate in annual conferences for Cornelia de Lange and William Syndrome Families and TSC Association. The CBTFT&GS functions as an IT node biobank for the Polish biobanking network as well as for the Biobanking and Biomolecular Resources Research Instructure (BBMRI) - European Research Instructure (ERIC). The CBTFT&GS is a gating biobank of BBMRI.PL for retrieving data from health- and public-related country databases (National Health Fund, Central Statistical Office, National Cancer Registry) as well as with the biobanks databases of BBMRI.EU. Description of any significant infrastructure and/or major items of technical equipment, relevant to the proposed work : we have well equipped lecture halls with multimedia support and simultaneous translation capabilities and modern Biobank facilities (Fully automated and robotized repository, Omics labs, Cell biology unit , histochemical unit with fully automated system for tissue staining procedures, IT scanning and telemetric transfer system of images, TMA equipment, Unit for preclinical studies with modalities for in vivo imaging). Short Profile of key Staff Members who will be undertaking the work Prof Aleksandra Zurowska, professor in pediatric nephrology, head Department Paediatrics, Aleksandra Nephrology & Hypertension, the President of The Polish Pediatric Nephrology Association, Zurowska former council member of ESPN and IPNA. Organiser of Polish Registry for Renal femle Replacement Therapy in Children closely collaborating with International Registries – ESPN ERA/EDTA Registry and IPDN involving other ERKNet Centres . Poland’s national representative in the ESPN/ERA-EDTA Registry, member of the European Pediatric Dialysis Working Group which issues guidelines on the management of children with Chronic Kidney Disease. Endorses multicentre activities like PolTube, Polish HUS Registry. Disseminates knowledge and guidelines organising working groups for National Guidelines for both specialists and the general practitioner. Organiser of national multicentre projects in rare diseases initiating the Polish PODONET, Nephrosis Online, paediatric ADPKD Registry and Alport Registry. International collaboration > 15years in the ESCAPE Clinical Research Network IPDN, PodoNet and ESPN Registries. Author of > 200 publications ( 40 joint international publications). Prof Ass Professor Jolanta Wierzba Pediatrician, Clinical Genetist, specialist of pediatric metabolism Jolanta , Head of Department of Infant Pathology, Consultant of the Outpatients Genetic Department. Wierzba Member of the World Scientific Advisory Council Cornelia de Lange syndrome. Member of female board of Polish Society of Human Genetics .Author of > 200 publications mostly related to genetically determined diseases. Prof Alicja Slizien Debska, professor of nephrology. Head of the Department of Nephrology, Alicja Debska Transplantology and Internal Medicine. Coordinator of Transplantation programme for Northern Slizien Poland, organiser of Reference centre for Tuberous Sclerosis Complex, involved in setting 825575 – EJP RD – Part B 118 female national guidelines for ADPKD and kidney Associated management in TSC. with document Ref. Author of nearly Ares(2018)6091977 500 - 28/11/2018 publications. Prof Piotr Czauderna, professor paediatric surgery. Head Department Surgery and Urology for Piotr Children and Adolescents and President of European Pediatric Surgeon's Office of European Czauderna Union of Medical Specialists (UEMS).Former member of Scientific Committee of the male International Society for Pediatric Oncology (SIOP), chairman of International Liver Tumors Strategy Group in Children – SIOPEL, former president of the Polish Society of Pediatric Surgeons. Involved in several European projects on rare paediatric cancers (ENCA,EXPORNET). Author of >180 publications. Prof Head of Department of Clinical Analytics at Faculty of Pharmacy and co-organiser of Central Leszek Bank of Frozen Tissues and Genetic Specimens in MUG. Co-organiser and vice-national Kalinowski coordinator of BBMRI.pl a partner of BBMRI-ERIC and a member of BBMRI.EU clinical male biobank working group. Author of > 100 scientific publications in clinical analytics. List of the most relevant publications and/or products, services (including widely-used datasets or software), or other achievements 1.Members of 3 ERN’s: ERKNet, eUrogenERN, PedCanERN since 1st March 2017 2.Datasets : National Registries for: Renal Replacement Therapy in Children , Alport Syndrome, ADPKD, PolishPODONET (steroidresistant nephrotic syndrome- modern diagnostic genetic programme ), Hemolytic-Uremic Syndrome. Close collaboration with International Registries – ESPN ERA/EDTA Registry and IPDN which includes 16 other ERKNet centres 3.International research activities and clinical trials ( ESCAPE, PREDICT, PODONET, Levamisol Trial in SDNS) and national multicentre activities;. 10 year record of organising national workshops for promoting national multicentre studies and dissemination of specialized guidelines in nephrology. National Reference Centre for Tuberous Sclerosis Complex, Cornelia di Lange Syndrome and Williams Syndrome, National node for Pediatric Liver Tumours affiliated with the SIOPEL [International Childhood Liver Tumors Strategy Group], internartional projects on rare tumours ENCA,EXPORNET. 4. Publications : Kidney Versus Combined Kidney and Liver Transplantation in Young People With ARPKD: Data From the ESPN/ERA/EDTARegistry. Mekahli D, van Stralen KJ, ..Zurowska A, et al Am J Kidney Dis. 2016 Nov;68(5):782-788. European Reference Networks: Share, Care, and Cure-Future or Dream? Wijnen R, Anzelewicz SM, Petersen C, Czauderna P. Eur J Pediatr Surg. 2017 Oct;27(5):388-394. Organization of BBMRI.pl: The Polish Biobanking Network. Witoń M, Strapagiel D, .., Kalinowski L, et al. Biopreserv Biobank. 2017 Jun;15(3):264-269. List of relevant previous projects or activities, connected to the subject of this proposal : 1.ERKNet Registry for Rare Kidney Diseases [ERK-REG] grant [PARTNER} and ERN-PAEDCAN: Paediatric Rare Tumours Network - European Registry grant [PARTNER]: CHAFEA Health programme grants 1/1/2018-30/12/2020 2. Introduction of reimbursed Eculizumab drug programme for atypical Hemolytic Uremic in Poland in cooperation with aHUS patient organisation on 1st Jan 2018 3. International 2 day conferences for Duchenne Disease Families ( Poland, Sobieszewo 2013 and 2015) 3. National 2 day Conference “ Rare disorders”,Dec.2016,Gdansk,Poland:participation 15 patient organisations 5. co-organizer of BBMRI.pl partner with BBMRI-ERIC 40-IPCZD Full legal name (Acronym) – Country “Instytut Pomnik- Centrum Zdrowia Dziecka” (IPCZD), Poland Principal investigator Prof. Krystyna Chrzanowska Relevant Network Orphanet 825575 – EJP RD – Part B 119 Description of the legal entity/department/laboratory/group: Associated with document Ref. Ares(2018)6091977 - 28/11/2018 The Children's Memorial Health Institute is a research institute, and also one of the largest specialized pediatric hospitals in Poland acting for the benefit of modern pediatrics. The aim of the Institute is to conduct research and development activities and to provide medical services focused on the health needs of children, adolescents and young adults. The Institute also undertakes teaching responsibilities aimed at adapting the results of research and development into practice. The CMHI has been awarded category A+ by the Polish Ministry of Science and Higher Education, a category granted only to research institutes with the highest quality R&D. The CMHI’s scientific and clinical achievements are the result of nearly 40 years of work of its medical staff. The CMHI is one of the main Polish reference centers for rare diseases- it leads two ERNs (transplantation and epilepsy). The Department of Medical Genetics of the CMHI is focused on both diagnostics of a wide spectrum of rare genetic diseases/syndromes to provide complete genetic counseling for families at risk, and on translational research aimed at unravelling physiologic and disordered molecular mechanisms leading to a disease, with the ultimate aim of improving patient care. Dysmorphic syndromes, inherited errors of metabolism (including mitochondrial disorders), imprinting disorders, and chromosomal instability syndromes are of particular interest. Various genetic techniques are used: cytogenetic, molecular (including NGS, i.e. targeted diagnostic panels, WES, WGS), methylation analysis). In the period 1980-2017, over 110 research projects were realized, and over 215 peer-reviewed papers were published (IF=985.517). Main tasks in the project per Pillar/WP: Pillar 2: Orphanet LTP and Network will contribute to subtask 2.2.2. Create a catalog of research projects and clinical trials, on an ongoing basis, to inform funders (IRDiRC Roadmap priority). Pillar 3: In WP14(Training on data management & quality): • Task 14.1: Developement of a novel training modules for clinicians and scientists involved in various rare disease research fields: After some adaptation to country-specific needs, the Orphanet Network teams will organise trainings in their countries in their national language. • CMHI (KCH) is a contributor of the Task 14.2: Standards and quality of genetics and genomics data in laboratory and clinical research practice. One of the courses will be organised by CMHI in Poland. • CMHI (KCH/PS) is a contributor of the Task 14.3: Training on strategies to foster solutions of undiagnosed rare disease cases. CMHI will contribute in presenting one or two selected cases. In WP18 (Development and adaptation of training activities): • CMHI (KCH) is a Co-Leader of the Task 18.2 together with VUHSK: Evaluation of strategic priorities and development of existing training activities according to specific needs of EU-13 countries. Short Profile of key Staff Members who will be undertaking the work Prof. Krystyna Chrzanowska Krystyna Chrzanowska MD, PhD: Paediatrician and Consultant in Clinical (female) Genetics, Full Professor and Head of the Department of Medical Genetics and Genetic Counseling Unit, CMHI, Warsaw, Poland. Special interest in clinical and molecular aspects of dysmorphic syndromes, chromosomal instability syndromes and imprinting disorders. Principal investigator (10) and investigator (16) in national projects sponsored by government institutions, contributed in 7 EU projects (PERFECT, EURO-PID-NAS, DYSCERNE, ORPHANET EUROPE, RD ACTION, EUCID, EuroCID). Over 155 peer reviewed publications (125 indexed in PubMed, IF >540, h-index 29, citations >3200); also review articles and book contributions. Member of the Orphanet Poland since 2011. 825575 – EJP RD – Part B 120 Prof. Piotr Socha Professor of Pediatrics & Associated Gastroenterology in Ares(2018)6091977 with document Ref. the Department of - 28/11/2018 (male) Gastroenterology, Hepatology, Nutritional Disorders and Pediatrics in CMHI and the Director Deputy for Research. His research and clinical work were mainly devoted to cholestatic liver disease, non-alcoholic fatty liver disease,rare metabolic liver diseases (eg. Wilson disease, newly described PGM-1), nutrition in hepatology and gastroenterology (eg. LCPUFA deficiency), obesity prevention and therapy, feeding disorders, protracted diarrhoea of infancy and early childhood. Piotr Socha was the chair of the Hepatology Committee of ESPGHAN (2010-2013) and he was appointed Scientific Secretary of ESPGHAN in 2015. Piotr Socha contributs/contributed to 7 EU projects (CHOP, EUROWILSON, EARNEST, PERFECT, NUTRIMENTHE, TOYBOX, EARLY NUTRITION). He was the president of the Polish Society for Pediatric Gastroenterology, Hepatology and Nutrition. He published over 400 peer reviewed papers (160 indexed in pubmed) and contributed to 40 book chapters. List of the most relevant publications and/or products, services (including widely-used datasets or software), or other achievements: 1. Krystyna Chrzanowska actively participated in EUCID (COST Action project BM 1280), and in writing recommendations by 36 international Silver-Russell syndrome specialists: Diagnosis and management of Silver-Russell syndrome: first international consensus statement. Wakeling EL, Brioude F, Lokulo-Sodipe O, O'Connell SM, Salem J, Bliek J, Canton AP, Chrzanowska KH, et al. Nat Rev Endocrinol. 2017;13(2):105- 124. Krystyna Chrzanowska initiated Nijmegen breakage syndrome registry in Poland (a world largest group of patients with NBS), and continued international collaboration contributing in EURO-PIDNAS and EuroCID grants, which resulted many publications, e.g.: Nijmegen Breakage Syndrome: clinical and immunological features, long- term outcome and treatment options - a retrospective analysis. Wolska-Kusnierz B., Gregorek H., Chrzanowska K., et al. on behalf of the Inborn Errors Working Party of the Society, for European Blood and Marrow Transplantation, the European Society for Immune Deficiencies. J Clin Immunol. 2015;35(6);538-549 Piotr Socha- led the Polish group of experts in the EU EUROWILSON project, which was devoted to construction of a European database for Wilson disease 3. Wilson's Disease in Children: A Position Paper by the Hepatology Committee of the European Society for Paediatric Gastroenterology, Hepatology and Nutrition. Socha P, Janczyk W, Dhawan A, Baumann U, D'Antiga L, Tanner S, Iorio R, Vajro P, Houwen R, Fischler B, Dezsofi A, Hadzic N, Hierro L, Jahnel J, McLin V, Nobili V, Smets F, Verkade HJ, Debray D. J Pediatr Gastroenterol Nutr. 2018 Feb;66(2):334-344. 5. A heterozygous mutation in GOT1 is associated with familial macro-aspartate aminotransferase. Kulecka M, Wierzbicka A, Paziewska A, Mikula M, Habior A, Janczyk W, Dabrowska M, Karczmarski J, Lazniewski M, Ginalski K, Czlonkowska A, Socha P (corresponding author), Ostrowski J (corresponding author). J Hepatol. 2017 Nov;67(5):1026-1030. List of relevant previous projects or activities, connected to the subject of this proposal : Prof. Krystyna Chrzanowska: . PERFECT; EC FP5; 2002-2005, leader WP4 . EURO-PID-NAS; 2003-2004; investigator . DYSCERNE, 2007-2010; investigator . ORPHANET EUROPE; EC 2nd Health Programme; 2011-2014; partner, Co-Coordinator in Poland . RD ACTION; EC 3rd Health Programme EU; 2015-2018; partner, member of the Polish team . EUCID; COST ACTION BM 1208; 2013-2016, member of the management board . EuroCID, ERA-NET e-Rare; 2016-2019; investigator Prof. Piotr Socha: . CHOP; EC FP5, 2002-2006, investigator . EUROWILSON; EC FP6, 2004-2008, principal investigator . PERFECT; EC FP5, 2003-2005, investigator . EARNEST; EC FP6, 2005-2010, investigator . NUTRIMENTHE; EC FP7, 2008-2013, investigator . Toybox; EC FP7, 2010-2014, principal investigator 825575 – EJP RD – Part B 121 Associated with document Ref. Ares(2018)6091977 - 28/11/2018 . 41-FCT Full legal name (Acronym) – Country Fundação para a Ciência e a Tecnologia (FCT), Portugal Principal investigator Anabela Isidro Relevant Network E-Rare-2, NEURON II, Infect-ERA, FLAG-ERA, BESTF Plus Description of the legal entity/department/laboratory/group: Fundação para a Ciência e a Tecnologia is the national funding agency that supports science, technology and innovation, in all scientific domains, under responsibility of the Ministry for Science, Technology and Higher Education, in Portugal. FCT started its activity in August 1997, succeeding the Junta Nacional de Investigação Científica e Tecnológica (JNICT). Since March 2012 FCT has coordinated public policies for the Information and Knowledge Society in Portugal, after the integration of the Knowledge Society Agency-UMIC. In October 2013, FCT took over the attributions and responsibilities of the Fundação para a Computação Científica Nacional (FCCN), [Foundation for National Scientific Computation]. FCT’s mission is to continuously promote the advancement of knowledge in science and technology in Portugal, attain the highest international standards in quality and competitiveness, in all scientific and technological domains, and encourage its dissemination and active role in society and in economic growth. FCT pursues its mission by funding fellowships, studentships and research contracts for scientists, research projects, internationally competitive research centres and state-of-the-art infrastructures, via competitive calls with international peer-review. FCT ensures Portugal’s participation in international scientific organisations, fosters the participation of the scientific community in international projects and promotes knowledge transfer between R&D centres and industry. Working closely with international organisations, FCT coordinates public policy for the Information and Knowledge Society in Portugal and ensures the development of national scientific computing resources. The results of FCT accomplishments are, in essence, the outcome of the work carried out by the individual scientists, research groups and institutions that are funded by FCT. Main tasks in the project per Pillar/WP: Pillar 1: In WP9, we will participate, as contributors, in the monitoring exercise of the Joint Transnational Calls for collaborative research projects (task 9.1), led by CSO-MOH (Israel) and co-led by DLR (Germany). Previous experience relevant to the Tasks: Over the last years, FCT team has been involved in the monitoring processes of the Joint Transnational Calls in several ERA instruments and initiatives, from all scientific domains (Social Sciences and Humanities, Exact Sciences and Engineering, Natural and Environmental Sciences, and Life and Health Sciences). During the last years, FCT was involved in the monitoring of the funded projects of the E-Rare ERA-NET. Short Profile of key Staff Members who will be undertaking the work Dr. Anabela Isidro PhD in Molecular Biology in 2002 at the Institute for Chemical and Biological (female) Technology, New University of Lisbon (PT). From 2002 to 2004 she got Postdoctoral training period at the Centre National de la Recherche Scientifique (CNRS). From 2005 to 2009 she was a Post-doc at the Institute for Biological Chemistry, New University of Lisbon (PT) and later got a principal investigator position at the Faculty for Veterinary Medicine till 2010. Her current scientific officer position at the Department of International Relations, FCT, involves the management of ERA-NETs in the field of Medical and Life Sciences, and Engineering (e.g., E-Rare-2, NEURON II, Infect-ERA, FLAG-ERA and BESTF Plus). Dr Carlos Almeida PhD in Bioethics / Philosophy of Science, with a Master’s degree in Management of Pereira Science, Technology & Innovation, a Specialization Course in Anthropology and Health, (male) and a Post-Graduation Course in Neurosciences. Science Officer at the Department for International Relations, FCT, since February 2013, taking various tasks and roles in transnational funding programmes: JPIs (JPND; JPI CH); ERA-NETs (HERA; Neuron; NORFACE, EuroNanoMed III; E-Rare); CSAs (JHEP2, ProSafe). Co-coordinator of the Programme for Responsible Research of FCT. FCT’s representative in the European Network of Research Integrity Offices (ENRIO). FCT’s representative in the National Commission for the Protection of Animals Used for Scientific Purposes. Head of the 825575 – EJP RD – Part B 122 Thematic Group «Social Sciences and Humanities» (fordocument Associated with the transnational cooperation). Ref. Ares(2018)6091977 - 28/11/2018 List of relevant previous projects or activities, connected to the subject of this proposal: . Neuron; funder: EC/national and regional partners; 2003-…; role in the project: partner . E-Rare; funder: EC/national and regional partners; 2006-2019; role in the project: partner . EuroNanoMed; funder: EC/national and regional partners; 2008-…; role in the project: partner . Infect-ERA; funder: EC/national and regional partners; 2013-2016; role in the project: partner . JPND; funder: EC/national and regional partners; 2011-…; role in the project: partner 42-INSA Full legal name (Acronym) – Country Instituto Nacional de Saúde Dr. Ricardo Jorge (INSA)- Portugal Principal investigator Sandra Alves Relevant Network Description of the legal entity/department/laboratory/group: INSA develops its activity as the Portuguese State Laboratory, National Reference Laboratory and National Observatory of the health sector. INSA’s Human Genetics Department has contributed for more than three decades now to the diagnosis and research of a large set of rare diseases (RD), such as thalassemias, cystic fibrosis, hemophilias, mitochondrial and lysosomal storage disorders among others, being the major Portuguese centre in the diagnosis of RD (including the Portuguese Newborn Screening Program). A great effort has also been put in fostering the research activities involving all aspects of these pathologies: molecular and biochemical characterization of the patients, establishment of genotype-phenotype correlations, study of the patophysiological mechanisms, cell biology studies, development of novel therapies and monitoring of the efficacy of the already available ones. As a consequence INSA’s team includes experts that have accumulated a large and very significant experience on RD. Main tasks in the project per Pillar/WP: Pillar 2: In WP10, we will participate as contributors in the task 10.2. 2 (Survey and structured interview approaches on technical and scientific matters, to monitor progress and inform strategic decisions) led by FTELE (Italy). Previous experience relevant to the Tasks: Relevant experience for Pillar 2: INSA Human Genetics Department research groups have widely contributed to the identification of the molecular basis of many rare genetic diseases leading to an improvement in the functional annotation of the human genome and in diagnosis precision and personalized medicine approaches. Participation in the Joint Action N° 20112201 under EU Health Programme 2008-2013, EUCERD Joint Action: working for rare diseases; INSA was responsible for the Evaluation Work package. Participation in international networks and COST actions related to Rare Diseases. (e.g. E-HOD European Network and Register and Cost action BM1207-Networking towards application of antisense-mediated exon skipping). Relevant experience for Pillar 3: Partner of the Portuguese Rare disease integrated strategy: interministerial, intersectorial and interinstitutional cooperation towards the complementary usage of medical, social, educational and scientific resources for the benefit of rare disease affected people and their caregivers. Contribution to increased public awareness in health science through the regular reception of visitor groups from schools and high schools, participation in public events such as the European Researchers' Night and summer hands-on lab training initiatives. Furthermore a 10-minute educational video was produced for students at age 10 to 15 to explain basic genetics concepts. Special attention was given to the interaction with patient organizations for rare or chronic diseases as well as the distribution of informative health guide leaflets on to promote health literacy of patients, families and communities . Related Outreach activities also included: training and networking initiatives such as “One day with the Newborn Screening Programme”. Description of any significant infrastructure and/or major items of technical equipment, relevant to the proposed work: Next Generation Core facility Short Profile of key Staff Members who will be undertaking the work PhD. Sandra Alves PhD in Molecular Biology in 2002 at Faculty of Sciences of the University of Porto (PT). (female) From 2002 to 2004 she had a PostDoctoral training period in the Institute of Molecular Pathology and Immunology of the University of Porto. In 2004 she became Auxiliary 825575 – EJP RD – Part B 123 Researcher in the Department of HumanAssociated Geneticswith in document the Instituto Nacional de Saúde Ref. Ares(2018)6091977 Dr. - 28/11/2018 Ricardo Jorge (INSA), Porto and Head of the Lysosomal Storage Diseases Research Group in 2009. Since 2013, she is the INSA’s representative in the Portuguese Commission for the Treatment of Lysosomal Storage Diseases.. As principal investigator she conducted 8 R&D projects and has the authorship in more than 30 peer reviewed scientific publications. Focused on biochemical and molecular aspects of inherited metabolic diseases she has the domain of specialization in lysosomal storage diseases. Dr. Glória Isidro Expert in Molecular Biology and Genetics. Coordinator of the Human Genetics (female) Department (Instituto Nacional de Saúde Doutor Ricardo Jorge – INSA). She was responsible for the Evaluation WP of the EUCERD Joint Action: Working for Rare Diseases. PhD.Laura Vilarinho PhD in Biomedical Sciences in 2000. She has over 130 articles published in peer (female) reviewed journals and more than 150 lectures in scientific meetings. Responsible for the Unit of Newborn Screening and Diagnosis of Inherited Metabolic Diseases (Department of Human Genetics, Instituto Nacional de Saúde Dr. Ricardo Jorge - INSA). Coordinator of the Executive Committee of the Portuguese Newborn Screening Program. PhD. Olg Amaral PhD in Biomedical Sciences (Faculty of Sciences, University of Porto-UP) in 2001. (female) Specialization domain: Human Molecular Genetics and Lysosomal Storage Disorders (LSD). She has worked in research and diagnosis in the field of rare metabolic disorders, having participated in several research projects, as well as being responsible for the set up, coordination and supervision of molecular diagnosis of sphingolipidoses and mucopolysaccharidoses at U.Enzimologia of IGMJM and Unilipe at IBMC-UP (1989- 2005). At INSA she´s a member of the Unit of Research & Development in the LSDs Group (DGH). She’s been principal investigator of projects with competitive financing, with 30 peer reviewed papers and over 80 peer reviewed presentations List of the most relevant publications and/or products, services (including widely-used datasets or software), or other achievements (: 1.Vilarinho L1, Rocha H, Sousa C, Marcão A, Fonseca H, Bogas M, Osório RV. Four years of expanded newborn screening in Portugal with tandem mass spectrometry J Inherit Metab Dis. 2010;33 Suppl 3:S133-8. 2. Matos L, Canals I, Dridi L, Choi Y, Prata MJ, Jordan P, Desviat LR, Pérez B, Pshezhetsky AV, Grinberg D, Alves S, Vilageliu L. Therapeutic strategies based on modified U1 snRNAs and chaperones for Sanfilippo C splicing mutations. Orphanet J Rare Dis. 2014; 9:180. 3. Matos L, Gonçalves V, Pinto E, Laranjeira F, Prata MJ, Jordan P, Desviat LR, Pérez B, Alves S. Functional analysis of splicing mutations in the IDS gene and the use of antisense oligonucleotides to exploit an alternative therapy for MPS II. Biochim Biophys Acta. 2015;1852:2712-21. 4. Cruz S, Taipa R, Nogueira C, Pereira C, Almeida LS, Neiva R, Geraldes T, Guimarães A, Melo-Pires M, Vilarinho L. Clinical, biochemical, molecular, and histological features of 65 Portuguese patients with mitochondrial disorders. Muscle Nerve. 2017;56(5):868-872. 5. Huemer M, Diodato D, Schwahn B, Schiff M, Bandeira A, Benoist JF, Burlina A, Cerone R, Couce ML, Garcia- Cazorla A, la Marca G, Pasquini E, Vilarinho L, Weisfeld-Adams JD, Kožich V, Blom H, Baumgartner MR, Dionisi-Vici C. Guidelines for diagnosis and management of the cobalamin-related remethylation disorders cblC, cblD, cblE, cblF, cblG, cblJ and MTHFR deficiency. J Inherit Metab Dis. 2017;40(1):21-48. List of relevant previous projects or activities, connected to the subject of this proposal :Desvendar. NORTE- 2020. (2016-2018). Proponent. This project focuses the application of innovative methods of molecular biology for the study of rare diseases. The main objective is the implementation of a Next Generation Core facility in INSA Human Genetics Department in Porto. . Joint Action N° 20112201 under EU Health Programme EUCERD Joint Action: working for rare diseases. (2008-2013). General objectives: The EUCERD was mandated to assist the EC in formulating & implementing the Community's activities in the RD field, to foster exchanges of relevant experience, policies & practices between the MS & stakeholders. Specifically, the JA addressed the following: a) Enhanced visibility and recognition of RD; b) Contributed to the development and dissemination of knowledge on RD; c) Contributed to improvements in access to quality services and care, from diagnosis, through to care and social support and innovative therapies. INSA was responsible for the Evaluation WP. . Splicether. FCT (Fundação para a Ciência e a Tecnologia). (2016-2019). Proponent. This research project is in the rare diseases disease field and makes the bridge between patient diagnosis and characterization of the mutations found and the development of alternative therapeutic approaches (mutation-specific). 825575 – EJP RD – Part B 124 Associated with document Ref. Ares(2018)6091977 - 28/11/2018 . CeMoLy. FCT (Fundação para a Ciência e a Tecnologia). (2016-2019). Proponent. This research project aims at establishing cellular models for the investigation of rare diseases, through the use of iPSCs, in order to provide alternative means for pathophysiology and therapeutic studies. . Genetic Defects of Mitochondrial Diseases: a Next Generation Sequencing Approach. FCT (Fundação para a Ciência e a Tecnologia). (2016-2018). Proponent. The overall aim of this project is the development of a Next Generation Sequencing strategy to identify genetic defects in patients with a presumptive diagnosis of Mitochondrial Disease. 43-SAS Full legal name (Acronym) – Country Slovak Academy of Sciences (SAS) - Slovakia Principal investigator Ján Barančik, PhD. Relevant Network www.sav.sk Description of the legal entity/department/laboratory/group: The Slovak Academy of Sciences (SAS) a governmental research organization, is the recognized leading research and scientific institution aimed at excellent basic, strategic and applied research in Slovakia. The SAS as a funding body supports those scientific disciplines which have attained international level and which are deemed necessary for the advancement of Slovakia. It consists of 70 organizations and publishes 54 scientific and professional journals and 8 yearbooks. There are 49 scientific and scholarly associations, societies and unions affiliated with the SAS. The Assembly, the Scientific Council, and the Presidium are the Academy’s self-governing bodies. The SAS governs the total budget of more than 60 Mio. Euro. Significant part of this amount is distributed on the competitive principle via annual project calls. The scientific policy of SAS supports interdisciplinary research and collaboration with research teams at Universities and with the industry.The SAS together with the Slovak universities operates the Scientific Grant Agency (VEGA – Vedecka grantova agentura) to which the project proposals in different research fields including the Rare Diseases research can be submitted in the frame of the “ Research in the field of biological, medical and farmaceutical sciences”. A part of the budget is reserved for international research cooperation within the schemes such as FP EU, ERA-Net, Horizon 2020 COST, ESA etc. The funding supports multidisciplinarity and synergy effects stemming from international cooperation with the emphasis on incorporation of post docs and young researchers. The duration of funding is based on the individual project needs (as a rule, several years). SAS has an expertise concerning ERA.NET (Cofund) scheme in the various fields of science. The participation of SAS in the ERA-Nets projects have been based on the official mandate of the Ministry of Education of the Slovak Republic for the SAS to act as R&D programme owner and manager. Selection procedures for the applications have been established and approved by the SAS Presidium. Main tasks in the project per Pillar/WP: Pillar 1: In WP6, we will participate in task 1.1 – Joint Transnational Call 2019 In WP6, we will participate in task 1.2 – Joint Transnational Call 2020 SAS will actively participate in the project as committed partner in several tasks. Previous experience relevant to the Tasks: Participation of SAS in the “EJP Rare Diseases” project as committed partner will result from participation and experience in many ERA.NETs (cofund) including the field of medicine e. i. TRANSCAN, NEURON, ERACoSysMed, ERA-CVD, EuroNanoMed, etc. Description of any significant infrastructure and/or major items of technical equipment, relevant to the proposed work (if applicable): Short Profile of key Staff Members who will be undertaking the work 825575 – EJP RD – Part B 125 Jan Barancik, PhD. Coordinating person responsible for the Associated overall timely management with document of the “EJP Ref. Ares(2018)6091977 Rare - 28/11/2018 Diseases project, comprising the content of the work plan, the finances and the administration. He is the head of International Cooperation Dpt. at SAS. He has a teorethical and working experience as a coordinator and project manager of many European networks (ERA.NETs) and international projects not only in the field of medicine e.g. TRANSCAN, NEURON II, EuroNanoMed II, ERACoSysMed,, ERA-CVD but also in other scientific fields e.g. , M-ERA.NET, INCOMERA, ANIHWA,CONCERT Japan, ERA.NET RUS Plus QuantERA, FLAG-ERA, ICT-CHIST ERA III etc. Katarina Bibova Project Manager responsible for the day-to-day operational management of administrative and organizational aspects in this project. He is engaged in several european and international projects at SAS i.e NEURON, ERACoSysMed, EuroNanoMed and in the SAS bilateral JRP Programmes related to the field of medicine and environment (Japan, Korea, Russia) Tbc Senior scientist. He/She will act as Scientific Manager responsible for scientific aspects in this project. List of relevant previous projects or activities, connected to the subject of this proposal (max 5): SAS as a financing member of several consortia in the scheme of ERA-NETs (cofund) in the field of biological, medical and farmaceutical sciences, as mentioned above. . 44-ISCIII Full legal name (Acronym) – Country Instituto de Salud Carlos III (ISCIII) − Spain Principal investigator Eva Bermejo-Sánchez, PhD Relevant Network Description of the legal entity: The Instituto de Salud Carlos III (National Institute of Health Carlos III, ISCIII) is the main Public Research Entity funding, managing and carrying out biomedical research in Spain. The Institute has been conducting research and providing key services in the life and health sciences for over 25 years. Its mission focuses on basic, translational and applied research as well as health technologies. ISCIII performs intramural activities and has a regulatory role as far as accreditation of research centres is concerned. It is also the body responsible for managing Spain's Health Research and Development Strategy within the framework of the National R+D+I Plan. Reports directly to the Ministry of Economy, Industry and Competitiveness (Royal Decree 345/2012) and in operational terms to both this Ministry and to the Ministry of Health, Social Services and Equality (Royal Decree 200/2012), has as its main mission to support the development of scientific knowledge in the health sciences and to contribute to innovation in treatment, healthcare and the prevention of disease. Putting patients and the public at the heart of all its activities and objectives, the Institute promotes and coordinates biomedical research and provides scientific and technical services of the highest quality in partnership with all the organizations forming part of the Spanish System of Science, Technology and Innovation. In terms of budget, the Institute is publicly funded (more than 270 M€ year 2016) and allocates funds to extramural research, including competitive annual calls. Since its inception, through a rigorous selection process based on peer review evaluation, ISCIII has awarded grants for research projects, networks, equipment, fellowships, technical manpower and research contracts. Moreover, under the Horizon 2020 umbrella, the Institute has been actively involved in the promotion of Spanish research excellence via its participation in key European transnational initiatives such as: ERA-Net cofund, ERA-Nets, ERICs, ESFRI project preparatory phases, Art. 185 TFEU initiatives, and Joint Programming Initiatives. The Institute also participates in other international research consortia (e.g. IRDiRC, ICGC and the Personalized Medicine Coalition). Departments involved in this EJP: The principal investigator from ISCIII for this EJP is Eva Bermejo-Sánchez, Head of department of the IIER (Institute of Rare Diseases Research), under the Sub-Directorate General for Applied Services, Training And Research (SGSAFI). Manuel Posada, Director of the IIER and member of the Executive Committee of the IRDiRC will be also deeply involved. Both are included in “Team b” below. There will be 2 main departments of ISCIII involved in this EJP: - Team a: from the Sub-Directorate General for International Research Programmes and Institutional 825575 – EJP RD – Part B 126 Relations (SGPIIRI). Associated with document Ref. Ares(2018)6091977 - 28/11/2018 - Team b: from the Sub-Directorate General for Applied Services, Training and Research (SGSAFI). There will be mainly researchers from IIER, but also from other two units, as it will be detailed in a separate table, as indicated in the instructions. Team a: The specific team of the SGPIIRI involved in this EJP leads the follow-up of the international research activities and programs, mainly the European ones. It has also leaded other like the Spanish participation in multilateral and international organizations like IARC (International Agency for Research on Cancer), TDR (Special Programme for Research and Training in Tropical Disease), IANPHI (International Association of National Public Health Institutes), EuSANH (European Science Advisory Network for Health) and RIMAIS (Red Interministerial de Aprendizaje e Investigación en Salud). Moreover,it has collaborated with European research infrastructures in the development of the ESFRI roadmap (e.g. ECRIN, EATRIS, ELIXIR and ERINHA) and it has also been involved in the reinforcement of cross-border cooperation of research programmes through Joint Programme Initiatives: JPND, JP HDHL, JPAMR, JP MYBL; Article 185 TFEU (AAL and EDCTP); ERA-Net cofund (ERACoSysMed, E-RARE-3, TRANSCAN 2, JPco-fuND); ERA-Nets (E-RARE, NEURON, TRANSCAN, EuroNanoMed, Infect-ERA), JPIs to Co-Work and EULAC Health. Within the context of these initiatives, the Institute has adopted a number of roles: Coordinator, National Contract Point and Joint Call Secretariat. [Details on “Team b” can be found in a separate table, as indicated in the instructions] Main tasks in the project per Pillar/WP: TEAM A will participate in: Coordination & Transversal Activities: In WP3: Co-leader, together with INSERM and EATRIS. - Task Co-leader for tasks 3.1, 3.3 and 3.4 - Task 3.2: Participant. Pillar 1: In WP6: Participant, and - Task 6.4: Leader, for the 4th Joint Transnational Call (JTC 2022) not co-funded by the EC In WP9: Participant in Task 9.1 (Subtasks 9.1.1, 9.1.3 and 9.1.4), and Task 9.2. Previous experience relevant to the Tasks: ERA-Net Infect-ERA is an initiative in which ISCIII contributed to the development of Work Package 7. The latter dealt with the design of a long-term collaboration framework, the set-up of the external scientific committee and the generation of a network with similar initiatives. ERA-Net Cofund ERACoSysMed aimed to enhance the implementation of Systems Medicine approaches in both clinical research and medical practice throughout Europe and beyond. ISCIII was WP leader of the WP devoted to the evaluation of the cofounded call and will be in charge on an additional call as Joint Call Secretariat. ERA-Net Neuron II seeked to coordinate national and regional research programmes in neuroscience. ISCIII was responsible for Neuron II’s Work Package 7, which dealt with the development of a long-term collaboration framework. Additionally, ISCIII participated in the execution of Work Package 2, which dealt with the creation of the strategic agenda; Work Package 5, intended to provide support to young researchers; and the monitorization of the consortia’s communication activities. ERA-Net EuroNanoMed III seeked to foster the competitiveness of European research centres engaged in Nanomedicine. ISCIII was responsible of the Work Package that dealt with the development of the Research Strategic Agenda, the drafting of joint call documents and the design of the long-term collaboration framework. ERA-NET Cofund E-Rare-3, ISCIII was responsible of the management of the call secretariat of the third JTC. In two occasions (2012 and 2014) ISCIII has been in charge of running the Joint Call Secretariat (ERA-Net E-Rare- 2). The tasks executed during both Calls included: drafting of call documents, design and coordination of the assessment process, management of the IT platform, selection of reviewers and the organization of the evaluation panels −among other things. Joint Call 2012 was focused on Young Investigators. EU Joint Programme – Neurodegenerative Disease Research (JPND) ISCIII participated in kind in the JUMPAHEAD project that supported the implementation of JPI to combat neurodegenerative diseases. It is a three year project funded by an FP7 2 million euro grant GA no. 260774, in which ISCIII actively contributed with the execution of organizational tasks. In ERA-Net cofund JPco-fuND ISCIII mainly participated in the WP for additional activities and is co-leader in 825575 – EJP RD – Part B 127 the alignment of national research plans task. Associated with document Ref. Ares(2018)6091977 - 28/11/2018 J-AGE is a Coordination Action for the implementation of the JPI "More Years, Better Lives - the Challenges and Opportunities of Demographic Change". ISCIII was responsible of the management of the call secretariat of the second and third JTC. ISCIII participated in the drafting of a non-comprehensive list of possible instruments that could be used for the implementation of the Strategic Research Agenda (SRA) and the compilation of results of a Workshop held in Madrid on 22/03/2013. Short Profile of key Staff Members who will be undertaking the work Mr./ Ignacio Project Officer managing and coordinating European transnational research collaborations at the Baanante- EU and Internationalization Dept of SGPIIRI at ISCIII. In 2010 and 2012 he worked at the Balastegui/ European Office of the Spanish Ministry of Science and Innovation, based in Brussels, where he Male participated in the evaluation and monitoring of scientific policies at National, European and International level, and contributed to drafting analytical documents (i.e. Impact Assessment). In 2008 he was involved and provided support in other initiatives [PRIOMEDCHILD, Art. 185 TFEU (AAL), ERA-Nets (TRANSCAN, INFECT-ERA), and JPI More Years Better Life and its CSA (J-AGE), as well as in training activities in the biomedical field. Undertook several Joint Call Secretariats (ERA-Net E-Rare, EuroNanoMed). He will be in charge of call-4 secretariat and Pillar 1 activities of ISCIII, and will provide support for the ones in transversal WP3, in this EJP. Mrs./ María Project Officer at the Deputy Director’s Office for International Research Programmes and Druet- Institutional Relations (SGPIIRI) at the National Institute of Health Carlos III. Ms Druet is Ampuero/ actively involved in the coordination, management and follow-up of European transnational Female collaborations European network of transnational collaborative RTD such as: EURONAOMED, TRANSCAN, NEURON, and E-RARE. Ms Druet plays an instrumental role in the management and coordination of E-RARE, TRANSCAN, NEURON and EURONANOMED Joint Call Secretariat’s administrative and financial activities. A total of 21 funding agencies cooperate within the novel EURONAOMED III where the Institute of Health Carlos III is the coordinator.Previously, during 2011-2013, she worked in the European project office like the Project Manager of the CSA Joint Programming Initiatives a process of mutual learning Toward a Common adoption of framework Conditions, (VIIPM). She will support the call-4 secretariat and Pillar 1 activities of ISCIII, as well as of the ones in transversal WP3 in this EJP. Dr./ Carlos Carlos Segovia-Pérez has been involved in several European and international health research Segovia- initiatives since 2007. He has been structural trainee at DG Research (EC) and National Focal Pérez/ Male Point for the EC Health programme. He is the current chair of the Joint Programming Initiative on Antimicrobial Resistance. He was Deputy Director of International Research Programmes (2009- 13) at ISCIII, and as such, Spain’s representative at IARC, TDR, IVI, RIMAIS, IANPHI, Coordinator of FP7 ‘EU-LAC Health’ and ‘JPIs to Co-Work’, and President of EuSANH. Technical Advisor of International Research Programmes (2006-2009) at ISCIII and National Focal Point for EC-SANCO Health Programme. Technical Advisor at the Social and Health Care Coordination Unit, at the Regional Department of Health Castilla y Leon. Carlos Segovia is primary care physician and master of public health from Harvard University. Before joining ISCIII, Carlos has been coordinator of a primary care centre for two years, deputy director for primary care quality and research of a province for ten years, and expert for social and health care coordination at a Regional Department of Health for two years. He will be in charge of WP3, which is co-leaded by ISCIII. List of the most relevant publications and/or products, services (including widely-used datasets or software), or other achievements See above the cell on Previous Experience, that includes some achievements from a set of relevant activities of similar nature to the one of this proposal. List of relevant previous projects or activities, connected to the subject of this proposal See above the cell on Previous Experience, that includes a set of relevant activities of similar nature to the one of this proposal. Full legal name (Acronym) – Country Instituto de Salud Carlos III (ISCIII) − Spain Principal investigator Eva Bermejo-Sánchez, PhD Relevant Network 825575 – EJP RD – Part B 128 Description of the legal entity: Associated with document Ref. Ares(2018)6091977 - 28/11/2018 The description of the Instituto de Salud Carlos III (National Institute of Health Carlos III, ISCIII) is included in a separate table, where the description of ISCIII’s “Team a”, also involved in this EJP, is described. Departments involved in this EJP: The principal investigator from ISCIII for this EJP is Eva Bermejo-Sánchez, Head of department of the IIER (Institute of Rare Diseases Research), under the Sub-Directorate General for Applied Services, Training And Research (SGSAFI). Manuel Posada, Director of the IIER and member of the Executive Committee of the IRDiRC will be also deeply involved. Both are included in “Team b” below. There will be 2 main departments of ISCIII involved in this EJP: - Team a: from the Sub-Directorate General for International Research Programmes and Institutional Relations (SGPIIRI). [Details on “Team b” can be found in a separate table, as indicated in the instructions] - Team b: from the Sub-Directorate General for Applied Services, Training and Research (SGSAFI). There will be mainly researchers from IIER, but also from UITeS (Telemedicine and eHealth Unit) and BU-ISCIII (Bioinformatics Unit). These are the details on them: The Institute of Rare Diseases Research (IIER) is a national center belonging to the ISCIII. It has two different areas of work: Rare Diseases Epidemiology, and Human Genetics. The IIER was officially designed as a WHO Collaborating Center for the epidemiology of diseases of unknown origin, between 1996 and 2011. It was also responsible for the coordination of the Spanish Network for Epidemiological Research on Rare Diseases (REpiER) and the Spanish National Rare Diseases Registry (SpainRDR). Currently, IIER is leading the National Rare Diseases Biobank, being a founder of EuroBioBank network. On behalf of ISCIII, it assists the Ministry of Health, Social Services and Equity in the development of its Strategy regarding Rare Diseases. Some members of the IIER form part also as a research group of the Centre for Biomedical Research on Rare Diseases as a Network (CIBERER). The IIER has also contributed to projects as RD-Connect, RIBERMOV, RareBestPractices, EUROPLAN and EPIRARE, among others. It also takes part in the International Conference on Orphan Drugs and Rare Diseases (ICORD) and the Undiagnosed RD Cases Network International (UDNI). Since 1981, IIER has been responsible for the old Spanish cohort with more than 20,000 people involved and followed by more than 37 years due to their affection by a rare disease, and at the same time IIER has contributed to the creation of some patient RD registries or cohorts of patients. UITeS (Telemedicine and eHealth Unit): Its mission is to promote and develop research, development and innovation work in the field of ICT applied to health. Its work follows the priorities of the National R&D&I Programme, the EU Framework Programme in ICT for health, public health and environmental health. Its main areas of interest are: telemedicine; e-health; mobile systems, network service platforms, biomedical instrumentation; wireless networks, electromagnetic security and compatibility, plus applications to support assistance for people with chronic conditions and help to prevent dependence. Its work covers scientific and technological research and the promotion of innovation in the National Health System by carrying out pilot projects, demonstrations and clinical trials jointly with other research groups, healthcare institutions and relevant industrial concerns. BU-ISCIII (Bioinformatics Unit): It is a transversal unit at ISCIII that gives support to other of its units. Therefore, BU-ISCIII will act supporting “Team b” of ISCIII for this EJP in what refers to the general analysis of data, genomic data and big data of any nature, linked to research on rare diseases, as it has been doing since its inception at ISCIII. Main tasks in the project per Pillar/WP: (See details on ISCIII’s “Team a” in a separate table, according to the instructions) TEAM B will participate in: Coordination & Transversal Activities: In WP2: Co-leader, together with ISS. - Task Co-leader for tasks 2.2 and 2.3 - Participant for Tasks 2.1, 2.4 and 2.5. Pillar 2: (Costs of the in-kind contribution of ISCIII to Pillar 2 will be of at least 39,000.00 €, including indirect costs) - WP11: Participant for Tasks 11.1, 11.3, and 11.4 - WP12: Participant for Task 12.1 - WP13: Participant for Task 13.1 Pillar 3: (Costs of the in-kind contribution of ISCIII to Pillar 3 will be of at least 18,000.00 €, including indirect costs) - WP14: Participant for Tasks 14.3, 14.4 and 14.5 825575 – EJP RD – Part B 129 - WP16: Participant for Task 16.2 (Subtask 16.2.2) Associated with document Ref. Ares(2018)6091977 - 28/11/2018 Previous experience relevant to the Tasks: More than 30 years working in the field of Rare Diseases (RD), in their research, development and coordination of networks, creation of: the platform of the Spanish National Registry of RDs and the work for its FAIRification, the Spanish National biobank for RD, a program for undiagnosed cases of RD, worldwide contribution to the match-maker exchange approach to RD patients, leading and participation in numerous research projects (either in Spain and at the international level –Europe and worldwide). Working on biospecimen and patient registries, diagnosis, genomic studies, therapies development, orphan drugs, clinical studies, and e-health. Hundreds of scientific papers. Contributing to the Spanish National Policy on RD. Very close contact to the Spanish Federation of patients with Rare Diseases and their families (FEDER), and specific patients’ associations. Member of the Steering Committee for the MOOC Course at Coursera “Preparing for an Ageing Population” (Univ. of Melbourne). Chair of the Intl. Medical Informatics Association´s WG on Exposome Informatics. Description of any significant infrastructure and/or major items of technical equipment, relevant to the proposed work : - Platform: Spanish Rare Diseases Research Registries Network (SpainRDR) - Platform: Spanish National Biobank for Rare Diseases (BioNER) - On-line course on rare diseases for health professionals, developed by IIER at ISCIII. - Computational infrastructure, High Performance Computing and Data storage, required for achieving the aims of this project. Short Profile of key Staff Members who will be undertaking the work Dr. (MD, Director of IIER, member of the Executive Committee of the IRDiRC, President of the PhD)/ Manuel International Conference on Orphan Drugs and Rare Diseases (ICORD), and Member of the past Posada-de-la- European Commission’s Experts Group of RD (CEGRD) by designation. Director of BioNER Paz/ Male (National Biobank on Rare Diseases). Chief of Research Group U-758 at CIBERER (Centre for Biomedical Research as a Network). Director of the WHO Collaborating Centre in the Epidemiology of Environment-Related Illnesses (1996-2011), Director of the Research Center CISATER, International General Coordinator of the Research Programme on the Spanish Toxic Oil Syndrome (WHO-Health Research Fund). Principal investigator for the Spanish Network for Epidemiological Research on Rare Diseases (REpiER) and the Spanish Rare Diseases Research Registries Network (SpainRDR). Leading one IRDIRC project and numerous projects funded by the EU and main Spanish agencies, with hundreds of papers published. Dr.(MSc, Tenured Scientist, Chief of Area of the Institute of Rare Diseases Research (IIER), ISCIII. Past PhD)/ Eva President of the Executive Committee of ICBDSR, Chief of Research Group U-724 at CIBERER. Bermejo- Scientific Coordinator of the Spanish Collaborative Study of Congenital Malformations Sánchez/ (ECEMC), its registry, and its clinical network. Scientific Director of the National Biobank of the Female Institute of Health Carlos III. Accredited in Human Genetics. Working in the field of epidemiology, clinical genetics and clinical teratology, for congenital anomalies, and in the Spanish Undiagnosed Rare Diseases Program of IIER (SpainUDP). 130 peer-reviewed papers published (h-index: 24) and Principal Investigator of several research projects on congenital anomalies and other rare diseases. Long participation in EUROCAT and JRC. Dr. (PhD, Research Professor in Biomedical Informatics and Digital Health at ISCIII. Full Professor at the FACHI, Division of Health Informatics at Weill Cornell Medicine and participated in the US Precision FACMI, Medicine Initiative (2015-17). Former Chair of Health Informatics at the Melbourne Medical CHIA, School and foundational Director of the Health and Biomedical Informatics Centre (HaBIC) at the MIAHSI)/ University of Melbourne. PhDs in Informatics and Medicine; MSc in Knowledge Engineering Fernando and BSc in Biochemistry and Molecular Biology. Served as Vice-President of the International Martín- Medical Informatics Association and Chair of the Scientific Program Committee for the XV Sánchez/ Male World Conference in Health and Biomedical Informatics, MEDINFO 2015. More than 180 peer- reviewed publications (h-index: 25). 40 grants from the EC and main agencies from Spain, Australia and the USA. Dr.(MSc, Tenured Scientist at the Institute of Rare Diseases Research (IIER), of ISCIII. She is also part of PhD)/ the Centre for Biomedical Network Research on Rare Diseases. Involved in different European Verónica and national projects in Spain, her research is focused on Rare Diseases: morbidity and mortality Alonso- studies, geographical analysis, population-base and patient registries, biobanking and Ferreira/ interoperability, among other topics. Female Dr. (PhD)/ Researcher. PhD in Pharmacy. Skills in Pharmacy, Biochemistry, Microbiology, Environmental 825575 – EJP RD – Part B 130 Estrella Health and Rare Diseases research. Current postdoctoral Associated position in IIER with document of ISCIII, participating Ref. Ares(2018)6091977 - 28/11/2018 López-Martín/ in several tasks related to the Spanish Undiagnosed Rare Diseases Program SpainUDP. Also Female involved in activities derived from the European projects RD-Connect and Solve-RD, focused on infrastructures and research on RD. Expertise within the rare diseases field: interoperability strategies at international level, undiagnosed diseases programs, phenotype ontologies and research projects. Dr.(PhD)/ Leader of the Computational Biology Unit of the UFIEC in the Institute of Health Carlos III. She Victoria has a Master of Biotechnology from the University of Madison Wisconsin (USA) and a PhD in López- Biochemistry and Molecular Biology from the University of Valencia. Wide experience in Alonso/ bioinformatics and system biology data analysis. She has participated in several research projects Female related to new technologies at the intersection of biology and computer science. Mrs.(PhD)/ Scientist and Bioinformatics Unit leader at ISCIII (BU-ISCIII). Master degree in Bioinformatics Isabel Cuesta- and Computational Biology. Taught by Complutense University in partnership with National Plaza/ Female Center of Biotechnology and ISCIII. Additional training visiting leading groups in Principe Felipe Research Center Bioinformatic service (CIPF), European Bioinformatic Institute (EMBL-EBI). She directs final master degree projects, organises and participates in courses on data mining and high throughput sequencing data analysis at ISCIII. BUISCIII is involved in national and EU- funded projects, among others, and is partner of Spanish Undiagnosed Rare Diseases Program (SpainUDP), project leaded by IIER and integrated in RD-Connect European project, focusing on the diagnosis of RD based on WES data analysis and sharing. List of the most relevant publications and/or products, services (including widely-used datasets or software), or other achievements 1. Spanish National Registry of Rare Diseases (SpainRDR): https://registroraras.isciii.es/ 2. Spanish National Biobank for Rare Diseases (BioNER): http://bioner.isciii.es/ 3. Spanish Program for Undiagnosed Rare Diseases (SpainUDP): http://portal-spainudp.isciii.es 4. Book: “Rare disease Epidemiology Book: Update and Overview” [2017] http://www.springer.com/la/book/9783319671420 5. Martin-Sanchez FJ, Lopez-Campos GH. The New Role of Biomedical Informatics in the Age of Digital Medicine. Methods Inf Med. 2016 Oct 17;55(5):392-402. List of relevant previous projects or activities, connected to the subject of this proposal REpIER (Spanish Network for Epi Research on RDs); Funder: ISCIII-Call for Networks of Thematic Cooperative Research; 2002-05. Project Leader (MPP). Development of a program for epidemiological research on RDs in Spain, for better orientation of social and health policies. . SpainRDR; Funder: IRDiRC; 2012-14; Project Leader (MPP). Creation of the National Rare Diseases Registry in Spain based on the input of two different strategies: patient registries addressed to patient outcome research and population-based registries aimed at epidemiologic research and health-social planning. . BioNER (Natl. Biobank on Rare Diseases); Funder: ISCIII; 2013-present. Creation and Manager (MPP). Spanish National Biobank for RDS. . NYC-PMI (New York City Precision Medicine Initiative); Funder: NIH. 2015-17. Co-investigator (FMS); . BiomarkerCard; Funder: NICTA (National Information and Communications Technology Australia); 2013-14. Principal investigator (FMS); Knowledge representation systems to assess the clinical relevance of biomarkers. 45-CNAG-CRG Full legal name (Acronym) – Country Fundació Centre de Regulació Genòmica (CNAG-CRG), Spain Principal investigator Ivo Gut Relevant Network ELIXIR Description of the legal entity/department/laboratory/group: The CRG is as a multidisciplinary research centre focusing on biomedicine. It is a first-class multidisciplinary research center that hosts a total of 30 group leaders, of which ~half hold an ERC grant. The «Centro Nacional de Análisis Genómico» (CNAG-CRG) is a non-profit organization founded in 2009 and integrated with the CRG. CNAG-CRG is funded by the Spanish Ministry of Economy and Competitiveness and the Catalan Government. CNAG-CRG’s mission is to carry out projects in DNA sequence analysis for the improvement of quality of life in collaboration with the European and International Research Community. It has a staff of 79. CNAG-CRG’s director, Dr. Ivo Gut, leads the Biomedical Genomics group. Its main line of research is mining, 825575 – EJP RD – Part B 131 analysis and re-analysis of genomic data from biomedical studies focussing Associated on projects with document in rare disease- 28/11/2018 Ref. Ares(2018)6091977 (RD), common diseases and cancer. Dr. Sergi Beltran leads the Bioinformatics Unit at CNAG-CRG, composed by 21 people and devoted to the development and operation of tools and pipelines for the analysis and interpretation of sequencing data. In 2017, the group analysed more than 250 projects in genomics, including germline variant identification, somatic variant identification and differential gene expression analysis. Dr. Beltran leads the development of the RD-Connect Genome-Phenome Analysis Platform (GPAP). Since 2013, the CRG is co- managing the European Genome-phenome Archive (EGA) in partnership with the EBI. The CRG EGA group is led by Jordi Rambla, and has expertise in different areas, especially software development and database design. The EGA is hosting many studies and datasets from RD. Main tasks in the project per Pillar/WP: Pillar 2: In WP10, we will participate in Coordinating Pillar 2 Work Packages and aligning to RD community needs (Task 10.1), Convene yearly retreats leading to Pillar 2 annual strategic plans (Task 10.2), Coordination of technical GDPR implementation (Task 10.3), Quality oversight (Task 10.4) and Developing sustainable models (Task 10.5). In WP11, we will co-lead WP11 and lead Provision of analysis and data sharing capabilities to the RD community through online resources (Task 11.4). We will also participate in tasks, FAIR-compliant platform for discovery of RD resources (Task 11.2) and Data deposition and access to data infrastructures for RD research (Task 11.3). In WP12, we will participate in Multi-site teams for software and tool development with respect to WP12 (Task 12.2) and Practical FAIRification support (Task 12.3). In WP13 we will participate in Fill pre-identified gaps (Task 4.1). Pillar 3: In WP14, we will participate in Standards and quality of genetics/genomics data in laboratory and clinical research practice (Task 14.2) and Training on strategies to foster solutions of undiagnosed RD cases (Task 14.3) Previous experience relevant to the Tasks: PILLAR 2: The CNAG-CRG has been collaborating in sequencing and analysing RD patients since its foundation. In 2014 the CNAG-CRG opened a call to sequence 300 exomes for RD research within Spain. In 2016, the CNAG- CRG launched a call to sequence 900 exomes for RD research within the framework of the EU-FP7 project BBMRI-LPC. Currently, the center is leading the sequencing and analysis of 1,000 RD whole genomes within the NAGEN-1000 project (http://www.navarrabiomed.es). Dr Sergi Beltran team has led the development of the RD-Connect platform (platform.rd-connect.eu) which, among other, enables the standardised analysis and interpretation of genomic data linked to the corresponding clinical information collected with controlled vocabularies and the Human Phenotype Ontology (HPO). PILLAR 3: The CNAG-CRG provides training at several levels to researchers, clinicians, patients and students, through dedicated hands-on workshops and courses on genome analysis and bioinformatics. Specifically for RD- Connect, the CNAG-CRG has already led 14 hands-on workshops since 2015 in nine EU countries The CNAG- CRG also generates online training materials and collaborates closely with the ELIXIR training platform through Task 8.3 from ELIXIR-EXCELERATE and RD-Connect. Description of any significant infrastructure and/or major items of technical equipment, relevant to the proposed work : To analyse the data the CNAG-CRG operates a 3,500 core supercomputer, with nodes carrying from 48 GB to 2 TB of RAM. CNAG-CRG uses CPUs, GPUs and FPGAs and has compute capacity in excess of 200 Tflops. The computer has 7.6 PB of disk and tape storage. An internal 10 Gb/s network and multiple 10 Gb/s physical connections to the Barcelona Supercomputing Center (BSC, www.bsc.es) which has over 50,000 compute cores and provides backup.The RD-Connect cluster is hosted at the CNAG-CRG's Data Processing Center (DPC). The cluster includes 19 nodes with a total of 304 cores, 4.8 TB of RAM, 336TB HDD and 19TB SDD. The operation of CNAG-CRG is certified ISO9001 and accredited ISO17025. Short Profile of key Staff Members who will be undertaking the work PhD. Ivo Gut Ivo Gut is Director of the CNAG-CRG. He has more than 20 years’ experience in high- (male) throughput nucleic analysis (genotyping and sequencing DNA, RNA and DNA methylation), technology development in nucleic acid and protein analysis. He was Head of Technology Development and Associate Director at the Centre National de Génotypage (CNG) – CEA (1999-2009), where he established the highest throughput genotyping platform in Europe, executed many genome-wide association studies, initiated and was the coordinator of the EU-funded Project READNA. He is currently participating as principal investigator in five FP7/ H2020 projects: BCAST, RD-CONNECT, ELIXIR- EXCELERATE, SINGEK and SPIDIAP4P. He is author of more than 350 research papers, 11 reviews and 12 book chapters, cited over 34,000 times (H-Index = 82, Google Scholar), inventor of 25 patents or patent applications, founder of 4 biotech start-ups, and serves on numerous international advisory boards. 825575 – EJP RD – Part B 132 PhD.Sergi Beltran Sergi Beltran has over 15 years of experience withwith Associated genomics and Ares(2018)6091977 document Ref. bioinformatics and has - 28/11/2018 (male) participated in over 45 international publications. He leads the development of the RD- Connect platform (platform.rd-connect.eu). His group participates in the IRDiRC/GA4GH MatchMaker Exchange (MME) and GA4GH Beacon projects through RD-Connect and is co-leading the development of the new MME API, which will enable more complex queries while maintaining the same privacy standards. Within ELIXIR-EXCELERATE, Dr. Beltran participates in the RD use case co-led from the CNAG-CRG and in benchmarking activities. Jordi Rambla(male) Jordi Rambla is project manager for the EGA since 2013. He has 30 years of experience in developing complex IT projects involving data integration, data cleansing, database architecture and data warehousing exploitation. List of the most relevant publications and/or products, services (including widely-used datasets or software), or other achievements : 1. RD-Connect, NeurOmics and EURenOmics: collaborative European initiative for rare diseases. Lochmuller, H, et al. including Gut, I and the RD-Connect consortium. Eur J Hum Genet. 2018 Feb 27. 2. From Wet-lab to Variations: Concordance and Speed of Bioinformatics Pipelines for Whole Genome and Whole Exome Sequencing. Laurie S, et al. including Gut I and Beltran S. (last author). Hum Mutat. 2016 Sep 8. 3. A comprehensive assessment of somatic mutation detection in cancer using whole-genome sequencing. Alioto TS et al. including Beltran S and Gut I (last author). Nat Commun. 2015 Dec 9;6:10001. 4. The Matchmaker Exchange: A Platform for Rare Disease Gene Discovery. Philippakis AA, Azzariti DR, Beltran S et al. Hum Mutat. 2015 Oct;36(10):915-21. doi: 10.1002/humu.22858. 5. Genomic characterization of mutant laboratory mouse strains by exome sequencing and annotation lift-over. Derdak S et al., including Beltran S. (last author). BMC Genomics. 2015 May 6;16:351. List of relevant previous projects or activities, connected to the subject of this proposal: 1. RD-CONNECT: An integrated platform connecting registries, biobanks and clinical bioinformatics for rare disease research (Coordinator: Hanns Lochmüller). CNAG-CRG PI: Ivo Gut; CNAG-CRG budget: 1,997,994 €; timeline: nov12-oct18; Call: FP7-HEALTH.2012.2.1.1-1-C 2. SOLVE-RD: Solving the unsolved rare diseases (Coordinator: Olaf Riess). CNAG-CRG PI: Sergi Beltran; CNAG-CRG budget: 1,505,132 €; timeline: jan18-dec22; Call H2020-SC1-2016-2017 3. ELIXIR-EXCELERATE: Fast-track ELIXIR implementation and drive early user exploitation across the life- sciences. (Coordinator: Niklas Blomberg). CNAG-CRG PI: Ivo Gut; CNAG-CRG budget: 200,000 €; timeline: sep15-ago19; Call: H2020-INFRADEV-1-2015-1. 4. BBMRI-LPC: BBMRI – Large Prospective Cohorts (Coordinator: Markus Perola). CNAG-CRG PI: Ivo Gut; CNAG-CRG budget: 535,660 €; timeline: feb13-ene17; Call: FP7-INFRA-2012-1.1.9. More than 900 exomes from RD patients and their relatives sequenced and analysed through a transnational access call.. 5. MatchMaker Exchange (www.matchmakerexchange.org, MME, IRDiRC and GA4GH) and Beacon project (http://ga4gh.org/#/beacon, GA4GH) participants. Co-leaders of new MME API. 46-UPM Full legal name (Acronym) – Country Universidad Politecnica de Madrid (UPM), Spain Principal investigator Mark Wilkinson Relevant Network none Description of the legal entity/department/laboratory/group: The Technical University of Madrid is the largest Spanish technological university as well as a renowned European institution being twice recognized as a Campus of International Excellence. It boasts 114 Departments, more than 36,600 undergraduate students, more than 1,600 Masters’ Degree students and over 2,700 PhD Degree and Postgraduate students, all under the supervision of nearly 3,300 teachers. UPM’s annual budget is 370 million Euros. UPM heads the Spanish participation in the 7th Framework Program of the European Union for research and technological development. More than 2,400 researchers carry out their activity at the UPM, which is committed to technology transfer and startups, with a dedicated “incubator” facility, and staff dedicated to commercialization of intellectual property. CBGP has four primary objectives (i) generation of knowledge on the genomics and biotechnology of plants and plant-interacting organisms; (ii) development of new technologies and tools for functional analyses (iii) development of new products and processes relevant to the productive sectors; and (iv) transmission of information and implementation of educational programmes for scientists and technicians. In the last few years, knowledge on plant biology has progressed at an unprecedented pace. A major cause for this progress is the development of innovative technologies that allow efficient and global analyses of genome structure, information and expression. 825575 – EJP RD – Part B 133 The new technologies are rooted in advances in the sequencing ofAssociated DNA and withproteins, in the document Ref. use of microchips, Ares(2018)6091977 in - 28/11/2018 the automation of many laboratory procedures, and in the possibility of handling large amounts of information through bioinformatic tools. UPM is a leading center in Spain for pursuing both pure research and product development, using these cutting-edge technologies. Main tasks in the project per Pillar/WP: Pillar 2 • We will contribute our expertise in FAIR data modelling in the BBMRI/ELIXIR RD Connect project to guide the selection, design, and extension of data and metadata models. (Task 11.1.1, 11.1.3) • We will apply our expertise in the domain of ontology building and use to define ontological models for the project (Task 11.1.2) • We will create FAIR Accessors and smartAPI meta-descriptors to help with accessing the ELIXIR BioTools database (Task 11.2.3) • We will use our expertise, as the inventors of the FAIR Discovery model (FAIR Accessors/Projectors) to better enable dynamic discovery of appropriate catalogues to query, and facilitate metadata extraction from these Accessor metadata documents (Task 11.2.4). • We will align our data and metadata models with other biomedical initiatives globally (Task 12.1.1). • We will implement our existing federation architecture (the FAIR Data Point) into the project infrastructure to enable federated query and discovery (Task 12.1.2). • We will implement the prototype of our semantic consent/privacy negotiation infrastructure, and evaluate its utility; we will assist in the task of anonymising data outputs Task (12.1.3). • We will ensure that all components are compliant with existing data and representation standards v.v. federated query and data exchange, including the use of static and dynamic FAIR data sources. (Task 12.1.4) • We will apply our expertise in clinical ontologies to the representation of clinical and pre-clinical information • We will oversee the harmonization between participating sites by harmonizing data models (Task 12.2.1) • We will utilize our FAIR Accessor platform to enable metadata and sample-level discovery (Task 12.2.3) • We will apply our FAIR Projector technology as a self-directed FAIRification service. (Task 12.3.3) Previous experience relevant to the Tasks: Our laboratory were lead authors on the FAIR Principles, and inventors and lead-authors on the first fully FAIR platform that spanned from metadata to individual cells in an underlying spreadsheet. The laboratory head, Mark Wilkinson, has spent more than a decade in clinical ontology creation, dynamic and automated discovery, integration, and analysis clinical data, and the design of biomedical data systems that can support automated workflow construction. Our flagship technologies – SADI and SHARE – were the first to use the global standard SPARQL to drive the discovery, synthesis, and execution of analytical workflows that represented the solutions to conceptual questions asked by biomedical researchers, and won the prize for best demonstration of semantic technologies for their ability to support multi-lingual queries. Short Profile of key Staff Members who will be undertaking the work Dr. Mark For the past 15 years, my laboratory has focused on designing biomedical data/tool Wilkinson, representation, discovery, and automated reuse infrastructures - what would now be called FBBVA Chair in "FAIR". I am the EU technical lead of the FAIR "Skunkworks" initiative, charged with rapidly Biotechnology prototyping cutting-edge FAIR infrastructures. I participate in the emergent GO FAIR initiative, and Isaac Peral including being founding members of the FAIR Metrics working group, tasked with defining Distinguished the precise, measurable behaviors that FAIR resources should exhibit. Beyond data Researcher. integration, we have extensive machine-learning experience over a diverse range of data types including longitudinal microbiome data, and were the first to identify shifting “states” in microbiomes that could be attributed to specific interventions, opening-up approaches to microbiome engineering. Senior TBA Technician List of the most relevant publications and/or products, services (including widely-used datasets or software), or other achievements 1. Wilkinson MD; Dumontier M; Aalbersberg IjJ; et al. "The FAIR Guiding Principles for scientific data 825575 – EJP RD – Part B 134 management and stewardship". Sci. Data 3:160018. 2016. Associated with document Ref. Ares(2018)6091977 - 28/11/2018 2. Wilkinson MD; Verborgh R; Bonino da Silva Santos LO; et al. "Interoperability and FAIRness through a novel combination of Web technologies". PeerJ Comput. Sci. 3:e110. 2017. 3. Egaña Aranguren M; Wilkinson MD. “Enhanced reproducibility of SADI web service workflows with Galaxy and Docker”, GigaScience 4(1), p59, 2015. 4. Wilkinson M, Vandervalk B, McCarthy L. “The Semantic Automated Discovery and Integration (SADI) Web service Design-Pattern, API and Reference Implementation”. Journal of Biomedical Semantics, 2:8, 2011. 5. Samadian S; McManus B; Wilkinson MD. Extending and encoding existing biological terminologies and datasets for use in the reasoned semantic web. Journal of Biomedical Semantics, 3:6, 2012. List of relevant previous projects or activities, connected to the subject of this proposal 1. Founding Member. FAIR Metrics Group. 2017-date. A group of 6 stakeholders representing researchers, technologists, public databases, and journal editors, assembled to create quantifiable metrics to evaluate the FAIRness of a resource. 2. Co-Chair, Common Repository Interfaces, Force11 Data Citation Implementation Group, 2012-2014. 3. European Lead, Data FAIRport Working Group 3 - “Skunkworks”, 2015-date. 4. Invited Expert – Semantics in Health Care and Life Sciences (HCLS) Working Group, World Wide Web Consortium: May 2009 – 2015. 5. Board of Trustees, Identifiers.org Project: 2012 – date. 47-CIBER Full legal name (Acronym) – Country Consorcio Centro de Investigación Biomédica en Red, M.P. (CIBER) - Spain Principal investigator Pablo Lapunzina Relevant Network Description of the legal entity/department/laboratory/group: CIBER is a Public Research Consortium created in 2006 under the leadership of the Carlos III Health Institute (ISCIII, the main Public Research Entity responsible of funding, managing and carrying out biomedical research in Spain), to promote research excellence and build a critical mass of researchers in the field of Biomedicine and Health Sciences. Organized in 11 research areas including Cardiovascular Diseases (CIBERCV), Bioengineering, Biomaterials and Nanomedicine (CIBERBBN), Mental Health (CIBERSAM), Hepatic Diseases (CIBEREHD), Diabetes and Metabolic Diseases (CIBERDEM), Rare Diseases (CIBERER), Respiratory Diseases (CIBERES), Public Health and Epidemiology (CIBERESP), Obesity and Metabolic Diseases (CIBEROBN), Cancer (CIBERONC), Fragility and Healthy Ageing (CIBERFES), CIBER is the largest Research Network in Spain. CIBER counts with more than 800 dedicated employees and 6,000 associated researchers integrated in more than 400 leading-edge research groups. Thanks to its network structure, CIBER is capable of bringing together more than 100 different associated institutions including Hospitals, Research Centers, Technology Centers, Private Institutions and Universities selected to join CIBER consortium on the basis of their excellence.Within this consortia CIBERER is the area of CIBER designed for the development and implementation of cooperative research in the field of rare diseases (RD), to the study of Rare Diseases, integrating 61 research groups and 20 associated clinical groups, furthering scientific and technical research, stressing the aspects of genetic molecular, biochemical and cellular research, with the aim of improving the understanding of causes and pathogenic mechanisms of these disorders as a fundamental item for developing and implementing new diagnostic techniques and therapeutic strategies. The following are specific aims of CIBERER: Contributing to research in the field of RDs; Helping to solve healthcare problems connected with RD; Reinforcing the participation of research groups in scientific-technical activities on an international scale; Promoting the transfer of research results to society and in particular to the National Health System and to the pharmaceutical and biotechnological production sector; and Supporting dissemination and participation in educational activities connected with RD. Main tasks in the project per Pillar/WP: In Pillar 2 we will contribute to: - WP11: Common platform for discoverable data and resources for RD research Task 11.1: Metadata and ontological model definition for cataloging resources for RD research Task 11.2: FAIR-compliant platform for discovery of RD resources Task 11.3: Data deposition and access to data infrastructures for RD research Task 11.4: Provision of analysis and data sharing capabilities to the RD community through online resources 825575 – EJP RD – Part B 135 - WP12. Enabling sustainable FAIRness and Federation at the data record, Associated patientRef. with document andAres(2018)6091977 sample level for- 28/11/2018 RD Task 12.1: Compare and align core interoperability standards with respect to WP3 - WP13. Enabling multidisciplinary, holistic approaches for rare disease diagnostics and therapeutics Previous experience relevant to the Tasks: CIBERER research groups expertise range from basic genetic research to its clinical application in a day to day context, so the whole chain from basic knowledge to bedside is tackled by our diverse groups. Such diversity encompasses expertise in NGS data generation and interpretation, together with complementary physiological and biochemical data, all applied in a clinical context to provide high quality diagnostic on rare diseases. As a result, we act as catalysts between basic research and clinical practice (Both highly represented in our network), and cooperate with industry to transforming the latest -omics technologies into useful tools for the clinical routine. In their daily exercise many CIBERER groups face the challenges arising for the NGS and omics application to the diagnosis of rare diseases, many of them as responsible of genetic testing services in the main hospitals of Spain. Also involved in the definition of Good Clinical Practice guidelines form the technical, procedural and ethical points of view. CIBERER groups have diagnostic activity on a wide range of rare diseases, most of them genetic through genetic testing. Up to 48 CIBERER research groups have activity on this field, as part of their research and/or in a clinical context, with more than 20 providing genetic clinical diagnostics and some being responsible of Genetic Diagnostic Services of the main Spanish hospitals. CIBERER is seriously involved in the new challenges associated with cross-border genetic testing for RD. With a wide range of our staff (physicians, researchers, technicians, bioinformatics…) working to carry out large scale projects in DNA sequencing and analysis in collaboration with researchers around the world, in order to ensure the best implementation of this new technology in our hospitals genetics services. Description of any significant infrastructure and/or major items of technical equipment, relevant to the proposed work : 1. - CIBERER BIOBANK (CBK) is a public and non-profit-making biological sample repository which centralices the reception of samples connected with rare diseases. It is a CIBERER initiative and it is located at the Centro Superior de Investigación en Salud Pública (CSISP) in Valencia, Spain. 2- Bioinformatics Platform for Rare Diseases (BIER) (http://www.ciberer.es/BIER/?q=node/1), is a transversal work group whose main task is to cooperate with the experimental groups working with genomic data, by giving them I.T. and scientific support for the analysis and interpretation of this information. 3- CIBERER Exome Server (http://bioinfo.cipf.es/apps-beta/exome-server/beta/), a public, free online tool, launched in 2014, designed to improve the filtering of potentially pathogenic genetic variants found in Spanish individuals. As local variations could be significant, this server contributes to other international available exome servers. Any researcher using CIBERER Exome Server will be able to obtain information about all variants detected in the Spanish population. CIBERER aims to set up a repository of variant data contributed by all investigators (academic, clinical or industrial) having sequenced exomes from Spanish individuals. Short Profile of key Staff Members who will be undertaking the work PhD. Pablo Lapunzina Specialist in pediatrics and medical genetics. Head of Department and Director of the (male) Instituto de Genética Médica y Molecular (INGEMM), Hospital La Paz (Madrid, Spain). Scientific director of CIBER on Rare Diseases (CIBERER). Beatriz Gómez BSc in Nursing and BA in Journalism. CIBERER’s, WP7 EJA and RD-ACTION (female) Manager. Ingrid Mendes BSc in Biology. CIBERER’s Scientific Manager. Asst. to CIBERER´s Scientific (female) Director. Dr. Juan Luque PhD in Biology. CIBERER´s Scientific and Transfer Manager. (male) Dr. Andrés Medrano PhD in Biology. CIBERER´s Scientific and Training Manager. (male) Dr. Beatriz Morte PhD in Pharmacist CIBERER´s Scientific Manager of the Undiagnosed RD Programme. (female) List of the most relevant publications and/or products, services (including widely-used datasets or software), or other achievements: 1. Technical and Institutional Committees. Rare Diseases Strategy of the National Health System. Spanish Ministry of Health and Social Services. Madrid, 2009. NIPO: 840-09-0752-X. 2. “Report on the State of the Art of Rare Disease Activities in Europe”, 2011-2016. 3. Villanueva A, Woolley R, Corrochano V, Gómez B, Molas J, Barberá JD, Palau F. EUCERD Joint Action - WP7: “Quality of Care and Centres of Expertise”. ECRD. Berlin, Germany, 8-10th May 2014. 825575 – EJP RD – Part B 136 4. EUCERD Joint Action Workshop. From Centers of ExpertiseAssociatedto European Reference with document Networks. Ministry Ref. Ares(2018)6091977 of - 28/11/2018 Health, Social Services and Equality. Madrid, Spain 28-29 October, 2015. 5. RD Registries Workshop, Organized by CIBERER and financed by CHAFEA. Madrid, Spain, 21-22 March 2017. List of relevant previous projects or activities, connected to the subject of this proposal: - Programme for “Genes in non-diagnosed Rare Diseases”. Through this project, CIBERER has promoted and enabled the application of the exome sequencing technique to discover new genes and variants involved in pathologies such as metabolism disorders, neuromuscular pathologies, mitochondrial diseases, polymalformation syndromes, birth defects or primary immunodeficiencies. - Partner of EUCERD Joint Action: Working on Rare Diseases.2012-2015. - Partner of RD-ACTION: Promoting Implementation of Recommendations on Policy, Information and Data for RD. 2016-2018. - Others describe in Orphanet-Spain description partner template. 48-SRC Full legal name (Acronym) – Country Swedish Research Council (SRC), Stockholm, Sweden Principal investigator Malin Eklund Relevant Network Funder Description of the legal entity/department/laboratory/group: In 2001, the Swedish parliament enacted legislation to set up the Research Council “in order to support basic research of the highest academic quality within all areas of knowledge", hence merging five councils into one. The Swedish Research Council (SRC) has a leading role in developing Swedish research of the highest scientific quality, thereby contributing to the development of society. The SRC is also responsible for coordinating participation and funding of national and international research infrastructures. The SRC is working to stimulate Swedish participation in European and international research cooperation. The aim is a greater exchange of experience and collaboration. The SRC has a specific responsibility for research cooperation within the EU, as well as a large commitment in Science Europe. The Swedish Research Council tasks include also research policy analysis and research policy advice, as well as communication about research and public understanding of science. The annual budget was around SEK 6 billion for 2017. Main tasks in the project per Pillar/WP: Pillar 1: In WP6, we will participate as funder in task 6.1 WP7 Previous experience relevant to the Tasks: SRC, together with the Ministry of Education, has responsibility for programme committee work in seven areas of the EU's current framework programme mainly within the excellence pillar but also within the Societal Challenge pillar. SRC is also hosting the National Contact Point within these areas. SRC is taking part in three joint programming initiatives JPI Climate, JPND and JPIAMR and is the coordinator of the latter. SRC participates in a number of ERA-Net cofund such as ERA-PerMed, Gender-net Plus, Quant-ERA, Flag-ERA. Short Profile of key Staff Members who will be undertaking the work Dr Malin Eklund Senior Research Officer within the field of medicine and health. PhD in Biotechnology from KTH, Stockholm. 10 years of experience as a researcher and project manager in the pharmaceutical industry before joining SRC in 2014. SRC representative in IC PerMed and ERA PerMed. Previously Policy Officer based in Brussels between 2015-2017. 49-VINNOVA Full legal name (Acronym) – Country Vinnova - Sweden Principal investigator Frida Lundmark Relevant Network Description of the legal entity/department/laboratory/group: Vinnova is Sweden's government agency for innovation. Our mission is to contribute to sustainable growth by 825575 – EJP RD – Part B 137 improving the conditions for innovation. We do this mainly by funding innovation Associated projects with document and the research -needed Ref. Ares(2018)6091977 28/11/2018 to develop new solutions. We also invest long term in strong research and innovation environments. We stimulate collaborations between companies, universities and other higher education institutions, public services, civil society and other actors. Our activities also focus on strengthening international cooperation. Each year, Vinnova invests around SEK 3 billion in fostering innovation. Most of these funds are allocated via calls for proposals in which companies, public sector actors and other organisations apply for funding. All investments are continuously monitored and evaluated and we regularly analyse the impacts of our investments. Main tasks in the project per Pillar/WP: Pillar 1: In WP6, we will participate as a funder (task 6.1) Previous experience relevant to the Tasks: Vinnova participate in several international initiatives and consortia such as “International consortia for personalised medicine” (ICPerMed), “JPI More years better lives”, “Nordic call on personalised medicine” (NordicPerMed), “Innovative medicines initiative” (IMI). Description of any significant infrastructure and/or major items of technical equipment, relevant to the proposed work : Not relevant Short Profile of key Staff Members who will be undertaking the work Frida Lundmark Doctoral degree in neurogenetics from Karolinska institute, Sweden. More than 12 years (female) of experience from pharma industry focusing on translational science and precision medicine. Before joining Vinnova several years of experience from public health sector focusing on strategies for clinical research for Karolinska university hospital as well as national strategies for biobanking in Sweden. 50-ULEIC Full legal name (Acronym) – Country University of Leicester (ULEIC) Principal investigator Anthony J Brookes Relevant Network Solve-RD Description of the legal entity/department/laboratory/group: The University of Leicester (ULEIC) is a publicly funded university based in Leicester, UK. It is a research- intensive university and was ranked in the top quartile of universities in the 2014 REF assessment of UK university research. ULEIC contributions in this project will be led by the Department of Genetics and Genome Biology, within the College of Medicine, Biological Sciences and Psychology - which is the largest and best-funded of the University’s four Colleges, attracting substantial funding from the European Community. Notable discoveries made in the Department of Genetics include the discovery and development of DNA fingerprinting (profiling) and, more recently, the DNA-based identification of the remains of King Richard III. This Department also leads various University wide initiatives, under the Directorship of lead applicant Anthony Brookes, namely: a) the 'NUCLEUS' service group which provides a full spectrum of advanced genomics technology services to university researchers; and b) the regional 'BINERI' network of health data science researchers and professionals, which brings together and facilitates multi-disciplinary projects between mathematicians/statisticians, data analysts, bioinformaticians, ethics/governance experts, healthcare providers, IT services, computer scientists and physicists. Main tasks in the project per Pillar/WP: ULEIC will contribute to many tasks in EJPRD, but has specific responsibility for leading or coleading the following: Pillar 2: In WP10, we will co-lead the whole WP. Additionally we will coordinate all parties involved in drafting the Annual Strategic Plan (SubTask 10.1.1) based on input from surveys, the user community, the VP developers, and the outcomes of the Pillar 2 Annual Retreat. This will be enabled by our role as lead of Task 10.2, which will drive and summarise regular TC discussions between Pillar 2 WP leaders, and in parallel undertake survey and structured interview approaches on technical and scientific matters. In WP11, we will make supportive contributions in Tasks 11.1, 11.2 and (mainly) 11.3. In WP12, we will co-lead the whole WP. We will also lead Task 12.1 to compare and align core interoperability standards relevant to the Pillar 2 mission. This will entail coordinating 5 subtask teams, of which we will lead two concerning machine-readable access (Subtask 12.1.3) and query languages plus data exchange formats (Subtask 12.1.4). This will require us to find and engage relevant experts within and beyond EJPRD, and facilitate them to work together to identify and align relevant standards needed by the VP and support their adoption by the project's 825575 – EJP RD – Part B 138 software developers. We will also lead Subtask 12.2.3, which is building Associated withsoftware document tools and modules for Ref. Ares(2018)6091977 data - 28/11/2018 discovery. This must be done as a multi-team effort, ensuring different technologies can interoperate. So as well as developing our own contributions to this area we will be responsible for getting all the different development teams to collaborate effectively. Additionally, within Task 12.3 we will lead Subtask 12.3.2. Thereby we and others will enable people to make their data and samples and subjects safely and appropriately discoverable if they cannot do that within their own data systems, and we will achieve this by providing a brokered hosting service with concomitant data harmonisation support. Previous experience relevant to the Tasks: ULEIC researchers contributing to this project have wide-ranging expertise in areas including Human/Medical Genetics and Informatics, relevant to the proposal, including: (1) Leading a multi-disciplinary ‘Bio-Informatics Network for Education, Research and Industry (BINERI)’ across the UK Midlands to ensure data synergies, discoverability, and appropriate sharing across the regional biomedical research and healthcare sectors by activities that entail interacting, not least, with Genomics England Ltd for which we head up the national data analysis clinical interpretations partnership. (2) Playing a central role in several major international initiatives for data standards development, not least the GA4GH/IRDiRC Beacon, MatchMaker Exchange, and ADA-M Task Teams. The latter is a metadata standard for the digitisation of conditions of use and consent, essential for future: (i) unambiguous communication of conditions of use; (ii) inclusion of conditions of use considerations in resource discovery settings; and (iii) automation of controlled access decision making. (3) Creating Café Variome, a flexible data discovery platform with the ability to handle large, diverse and complex datasets. It is agnostic regarding the types of entity it enables to be discovered, and it can be deployed as a central through to a highly federated architecture. A core Oath2-based authorisation and authentication server, compatible with the AAI from ELIXIR, enables fine-grained control of user permissions. (4) Running large-scale databasing and data management projects, not least providing the world's largest public domain GWAS database (GWAS Central), leading IT aspects of biomedical EU projects (GEN2PHEN, BioShare, GCOF, Solve-RD), contributing 'discovery science' aspects of IMI projects (EMIF, eTOX, EPAD), and direct translational medicine data management in large consortia (COPD-MAP (UK MRC), REQUITE (EU)). Short Profile of key Staff Members who will be undertaking the work Professor Director BINERI, Director HDR-UK Leicester, Research Group leader. Anthony J Qualifications in preclinical Medicine (Honors) and Medical Biochemistry (1st Class), creator of Brookes / various technology patents, Founder of two biodata related companies, 30 year's experience as Male academic researcher in leading institutions. Published >180 peer reviewed articles and reviews, served two 3-year terms on the HUGO Council, co-founded the Human Variome Project and the Human Genome Variation Society (now Vice-President) Dr Colin Veal Senior bioinformatician and Brookes Research Group co-lead. / Male Biology degree plus 20 years experience as academic researcher conducting biomedical informatics, human genomic technology innovation, and genetic disease studies. Additional degree qualifications in mathematics and statistics Dr Tim Beck / Current position: Independent 'Future Leaders' Research Fellow, associated with HDR-UK Male Profile description: Biology degree plus 15 years experience as academic researcher in biomedical informatics, spanning human and animal model investigations, operational lead on GWAS Central, and with special expertise in semantics and ontologies. Professor Professor in genetics Raymond Support and guidance role as independent PI running several LSDBs, plus contribution and Dalgleish / further development of the 'Variant Validator' platform for management of mutation nomenclature Male List of the most relevant publications and/or products, services (including widely-used datasets or software), or other achievements 1. World’s largest public-domain GWAS database (http://www.gwascentral.org/) 2. Café Variome platform for federated data discovery (www.cafevariome.org) 3. Nature Reviews Genetics (2015) 16, 702-715. Human Genotype-Phenotype Databases: Aims, Challenges And Opportunities. A.J.Brookes and P.N.Robinson. 4. Human Mutation (2012) 33, 867-873. Observ-OM and Observ-TAB: Universal Syntax Solutions for the Integration, Search and Exchange of Phenotype And Genotype Information. . T.Adamusiak, H.Parkinson, J.Muilu, E.Roos, 5. Nature Reviews Genetics (2009) 10, 9-18. Genotype-Phenotype Databases: Challenges and Solutions For The Post-Genomic Era. G.A.Thorisson, J.Muilu and A.J.Brookes 825575 – EJP RD – Part B 139 List of relevant previous projects or activities, connected to theAssociated subject with of this proposal document : Ref. Ares(2018)6091977 - 28/11/2018 1. GEN2PHEN (RTD): Genotype-To-Phenotype Databases: A Holistic Solution (HEALTH-F4-2007-20075): To June 2013. 2. BioShaRE (RTD): Biobank Standardisation and Harmonisation for Research Excellence in the European Union (261433): To November 2015. 3. GCOF: Stepping stone approach towards the Genetics Clinic of the Future (H2020-HCO-2014-643439): To June 2017. 4. EMIF: A European Medical Information Framework of patient-level data to support a wide range of medical research (115372-2): Ends June 2018. 5. Solve-RD: Solving the unsolved Rare Diseases (779257). To December 2022 51-ULIV Full legal name (Acronym) – Country University of Liverpool (ULIV), United Kingdom Principal investigator Mark Turner Relevant Network EPTRI, PedCRIN (after 01 May conect4children) Description of the legal entity/department/laboratory/group: The University of Liverpool (ULIV) is one of the great centres of research, knowledge and innovation and one of the UK’s leading research institutions with an annual turnover of £400 million, including £140 million for research. The university’s pioneering reputation attracts students, experts and partners from around the world. Through research, teaching and collaborations ULIV seeks to be life changing and world shaping. The University is globally recognised for its research in health and life sciences, science and engineering, and humanities and social sciences. ULIV is 75th in Europe according to the Times Higher Education rankings, is 61 – 100 in medicine according to the global QS rankings and is the 78th most international university in the world. The Department of Women’s and Children’s Health is internationally renowned for its research and has specialist groups covering obstetrics, gynaecology, neonatology and medical and surgical paediatrics. The department’s main research facilities are integrated with two of the largest specialist Women’s and Children’ hospitals in Europe – Centre for Women’s Health research within the Liverpool Women’s Hospital and Institute in the Park within the Alder Hey Hospital. Main tasks in the project per Pillar/WP: Pillar 0 WP1: Coordination SubTask 1.1.2: Central Helpdesk; Task 1.3: Monitoring of the EJP RD activities and achievements; Leader of Subtask 1.3.1: Identification of key performance indicators SubTask 1.3.2: Implementation of the monitoring process Task 3.1: Service roadmap: alignement of needs, expectations and engagement of the different RD research stakeholders in Europe with repsect to EJP RD sustainability; Task 3.2: Preparation of sustainable EJP RD service calalogue; Task 3.3: Preparation of the EJP RD sustainability plan with business plan; Task 3.4: Sustaainability roadmap; Task 5.2: Integrating EJP RD communication and dissemination strategies with the strategies of involved stakeholders; WP20: Task 20.1: Task Force Group (100% in kind contribution) Previous experience relevant to the Tasks: Mark Turner’s expertise is about developing new and improved medicines for children. This includes leadership of clinical studies in neonates: Phase 0 microdosing; Phase 1 first-in-human; Phase 2 PK and PD, particularly for antibiotics; excipient kinetics; Phase 3 studies. Other work includes mixed methods assessment of: adverse drug reactions in children by professionals and parents; manipulations of drugs used by children; management of stillbirth; induction of labour. Turner has extensive experience bridging between research communities. He has chaired the UK NIHR AMR Neonatal Clinical Studies Group (2007 – present); chaired the European Network for Paediatric Research at the European Medicines Agency (2013 – present); been European Co-Director of the International Neonatal Consortium (2014 – present). This includes developing relationships between all stakeholders in drug development (families, regulators, industry, investigators) and at all stages of drug development (basic science, formulations, clinical studies etc.). 825575 – EJP RD – Part B 140 He developed the European Paediatric Clinical Trials Research Infrastructure Associated which with document was recognised Ref. Ares(2018)6091977 as a - 28/11/2018 complementary research infrastructure in the 2016 ESFRI Roadmap. He is the Scientific Coordinator of the Conect4Children consortium that has applied to IMI2 Call 10 Topic 4 “European Paediatric Clinical Trials Network”. Description of any significant infrastructure and/or major items of technical equipment, relevant to the proposed work : Mark Turner developed the European Paediatric Clinical Trials Research Infrastructure which was recognised as a complementary research infrastructure in the 2016 ESFRI Roadmap. He is the Scientific Coordinator of the Conect4Children consortium that will receive the award for the IMI2 Call 10 Topic 4 “European Paediatric Clinical Trials Network”. Collaborative Network for European Clinical Trials for Children (conect4children) will begin 01 May 2018. Short Profile of key Staff Members who will be undertaking the work Dr. Mark Turner Mark Turner BSc, MBChB, PhD, DRCOG, MRCP, MRCPCH, FFPM(Hon) is a (male) Neonatologist at Liverpool Women’s Hospital and the University of Liverpool. He aims to improve the access of newborn babies and children to high quality medicines. He has studied the dosing, safety and efficacy of 12 medicines in neonates with rare conditions in the past 5 years. In older children his group is currently working on manipulations of medicines, the avoidability of adverse drug reactions and the pharmacoeconomics of age-appropriate formulations. List of the most relevant publications and/or products, services (including widely-used datasets or software), or other achievements 1. A systematic review of the use of dosage form manipulation to obtain required doses to inform use of manipulation in paediatric practice. Richey RH, Hughes C, Nunn AJ, Turner MA Int J Pharm. 2017 25:155-166 2. The International Neonatal Consortium: collaborating to advance regulatory science for neonates. Turner MA, Davis JM, McCune S, Bax R, Portman RJ, Hudson LD. Pediatr Res. 2016 80:462-4 3. Essential medicines containing ethanol elevate blood acetaldehyde concentrations in neonates. Pandya HC, Mulla H, Nunn AJ, Turner MA. Eur J Pediatr. 2016 175:841-7 4. Observational infant exploratory [(14) C]-paracetamol pharmacokinetic microdose/therapeutic dose study with accelerator mass spectrometry bioanalysis. Garner CR, Park KB, Maruszak W, Turner MA. Br J Clin Pharmacol. 2015 80:157-67 5. Potentially harmful excipients in neonatal medicines: a pan-European observational study. Nellis G, Metsvaht T,Turner MA, Lutsar I. Arch Dis Child. 2015 100:694-9. List of relevant previous projects or activities, connected to the subject of this proposal 1. EPRTI WP 9 Lead funded by the European Commission H2020 INFRADEV programme from Jan 2018 – Dec 2019 2. PedCRIN WP 2 Lead funded by European Commission H2020 from Jan 2017 – Dec 2019 3. Global Research in Paediatrics (GRIP): Scientific Coordinator of this FP7 Network of Excellence; funded European Commission FP7 from Jan 2015-Jun 2017 4. European Study of Neonatal Excipient Exposure (ESNEE): Chief Investigator of this project, funded by ERA-NET PRIOMEDCHILD from Jan 2011 – Mar 2014 5. Treat Infection in Neonates (TINN): Work Package Lead and Clinical Chief Investigator; European Commission FP7 funded from Nov 2008 – Oct 2015 6. NeoVanc: Work Package 2 and 5 European Commission FP7Lead European Commission FP7 funded from Feb 2014 – Jan 2019 52-UNEW Full legal name (Acronym) – Country University of Newcastle upon Tyne (UNEW) -– UK Principal investigator Volker Straub Relevant Network TREAT-NMD Description of the legal entity/department/laboratory/group: The team at UNEW performing this work is based in the John Walton Muscular Dystrophy Research Centre (JWMDRC), Institute of Genetic Medicine, Newcastle University. Newcastle University is one of the top research- intensive universities in the UK: in the recent Research Excellence Framework (REF) evaluation, Newcastle University was ranked 16th (out of 154) in the UK for research power. The university also ranks in the top 5 for both hospital and laboratory based clinical subjects. Within the University, the JWMDRC is a clinical and research 825575 – EJP RD – Part B 141 reference centre led by Prof. Volker Straub, providing a depthAssociated of clinical expertiseRef.inAres(2018)6091977 with document Muscular Dystrophies - 28/11/2018 unparalleled elsewhere in the UK. Clinical management and drug development for Neuromuscular diseases (NMDs) are core activities of the Centre, with national and international clinical trials funded via Wyeth, Sarepta, GSK, Prosensa, BioMarin, Trophos, Roche, Ultragenyx, NIH, BHF, EU, NIHR and MRC. In addition, Newcastle houses the MRC Translational Research Centre for Neuromuscular Diseases and Biobank, jointly established with UCL (London). Over the least decade, the team in the JWMDRC has increasingly built a reputation for rare disease expertise per se, from a disease-agnostic policy and infrastructure perspective (consolidated through leadership positions in the EUCERD Joint Action for Rare Diseases, RD-Connect, and RD-ACTION (the Policy stream of which is led from the JWMDRC)). Main tasks in the project per Pillar/WP: Pillar 4: UNEW is a partner in P4 WP19 Facilitating partnerships and accelerating translation for higher patient impact. Task19.1. The team will participate to the creation of an Innovation Management Tool Kit, by elaborating and tailoring a ‘handbook’ for disease areas wishing to develop an ‘ACT’ (Advisory Committee on Therapeutics), based upon the successful TACT model in the neuromuscular field. Most of the PM activity will be spent on liaising with ERN communities (in greater detail where that ERN is able to dedicate person time, in-kind or funded externally) to set-up an ACT in disease areas outside of the NMD field, based upon ERN thematic groupings/subdomains. A workshop will be organised to support this broad ERN engagement. Previous experience relevant to the Tasks: TREAT-NMD has now been successfully operating for 10 years and has generated a number of tools and strategies to support the development of therapies for rare neuromuscular diseases. Amongst these – and led from UNEW, at present by V. Straub and C. Turner)- is the TREAT-NMD Advisory Committee for Therapeutics (TACT) model. TACT is a model to convene a unique multidisciplinary international group of well recognized academic and industry drug development experts, patient representatives and institutional governmental scientific research centres, who meet twice a year to review development plans from academic groups and industry and provide guidance on the translation and development path of therapeutics programs in rare neuromuscular diseases with large unmet need. By suggesting improvements or changes to pre-clinical research or trial design TACT can help academics and industry to avoid potential pitfalls in the therapeutic development pipeline and facilitate the faster development of therapies. ● Since its launch, TACT has formally reviewed 46 programme applications from both Industry (29) and Academics (17) 21 of these reviews have been for novel compounds, 25 for repurposed drugs. ● The added-value is the approach is clear – in fact, some funders now request that a TACT review has been completed before (co)-funding clinical trials ● The strength of the model lies in the assembly of bespoke panels for each application. Thus, the UNEW team is ideally-placed to explore the expansion of this model to other disease areas, through elaboration and deployment of a ‘Tool-Kit’ or handbook to support communities in embedding a model along these lines. The ERNs are a logical ‘target’ for such discussions (and, as far as resources allow, more practical action) and in this respect too, the UNEW team possesses the relevant experience and expertise to forge such synergies. UNEW led a EU Joint Action dedicated to Rare Diseases (the EUCERD JA), and continues to lead the Policy Strand of the current Joint Action, RD-ACTION – these initiatives have played a key role in supporting the conceptualisation and implementation of ERNs, and as such the team currently led by V.Hedley developed robust working relationships with many of the ERN coordinators and their teams, and understands the opportunities and challenges for expansion of an ACT model into these communities. Description of any significant infrastructure and/or major items of technical equipment, relevant to the proposed work : N/A Short Profile of key Staff Members who will be undertaking the work Pr. Volker Straub Current Director of the John Walton Centre, founding joint co-ordinator of TREAT-NMD (male) (www.treat-nmd.eu), executive board member of the World Muscle Society and R&D Director of the North Tees and Hartlepool NHS Foundation Trust. Trained as a paediatric neurologist, Volker has a longstanding interest in the pathogenesis of muscular dystrophies and is engaged in research using zebrafish and mouse models. He has a special interest in the use of MRI in muscular dystrophies. Catherine Turner Duchenne Liaison and TACT Coordinator. She oversees the running of TACT, solicits (female) applications, works with expert panel members to facilitate the review process and ensures funding and sustainability. She also provides the link between TACT and multiple stakeholders including the patient community, industry and regulators. 825575 – EJP RD – Part B 142 Victoria Hedley Policy Manager (previously Thematic Coordinator) forwith Associated RD-ACTION, the EU Joint Action document Ref. Ares(2018)6091977 for - 28/11/2018 (female) rare diseases. She leads on the RD-ACTION provision of policy support to ERNs, and is in charge of generating the Resource on the State of the Art of Rare Disease Activities in Europe. List of the most relevant publications and/or products, services (including widely-used datasets or software), or other achievements 1. Leary R, Oyewole AO, Bushby K, Aartsma-Rus A. ‘Translational Research in Europe for the Assessment and Treatment for Neuromuscular Disorders (TREAT-NMD)’. Neuropediatrics 2017 Aug;48(4):211-220. doi: 10.1055/s-0037-1604110. Epub 2017 Jul 6. 2. Heslop E. et. al. ‘The TREAT-NMD advisory committee for therapeutics (TACT): an innovative de-risking model to foster orphan drug development’, Orphanet J Rare Dis. 2015 Apr 23;10:49. doi: 10.1186/s13023-015- 0258-1. 3. Evangelista T, Hedley V, Atalaia A, Johnson M, Lynn S, Le Cam Y, Bushby K, ‘The context for the thematic grouping of rare diseases to facilitate the establishment of European Reference Networks’, Orphanet J Rare Dis 2016 (11) 10.1186/s13023-016-0398-y 4. Numerous outputs related to Policy support for ERNs (http://www.rd-action.eu/european-reference-networks- erns/) Including Hedley et.al. Recommended Practices for Standardising Data in the Framework of the Operation of ERNs (2017) 5. TGDOC – TREAT-NMD has established a global network of patient registries, with an agreed core data set. This allows academia and industry to conduct feasibility and recruitment enquiries through the registries to accelerate clinical trials. List of relevant previous projects or activities, connected to the subject of this proposal : TREAT-NMD: FP6, 2007-2011, Acted as coordinator. EU funded ‘network of excellence’ with the remit of ‘reshaping the research environment’ in the neuromuscular field. RD-ACTION : 3rd Public Health Programme, EC, 2015-2018, WP lead (WP6,Policy and Integration). Leading on support for the implementation and (policy-oriented) development of ERNs, and on the generation of the State of the Art resource. EURO-NMD: 3rd Public Health Programme, EC, 2017-2021, Current coordinator. EURO-NMD is the ERN for neuromuscular diseases. EUCERD-JA: 2nd Public Health Programme, 2012-2015, Coordinator. Led the Joint Action to support EC and the MS in formulating and implementing policies pertaining to rare diseases 53-CCRI Full legal name (Acronym) – Country St. Anna Kinderkrebsforschung (CCRI) - Austria Principal investigator Ruth Ladenstein Relevant Network ERN-PaedCan Description of the legal entity/department/laboratory/group: The CCRI is owned by the private charity-based association St. Anna Kinderkrebsforschung, with the overall aim to improve treatment options for children suffering from cancer through basic, translational and clinical research. The CCRI is closely affiliated with the St. Anna Children’s Hospital, the largest clinical haemato-oncological centre for the treatment of childhood cancer in Austria. The CCRI and the St. Anna Children´s Hospital have formed a comprehensive cancer centre in order to address patient-relevant scientific questions to better understand the disease and effective therapies through bidirectional knowledge exchange from research to clinical applications and diagnostics. The CCRI hosts 12 research groups in the areas of molecular and cellular biology, molecular genetics, genomics and epigenomics, immunology, cellular therapies and clinical research with a focus on bone and soft tissue sarcomas, neuroblastoma and acute leukaemias. The CCRI is devoted to bench to bedside research translational activities. The Unit for Clinical Trails and Statistics of the CCRI (S2IR: Studies and Statistics for integrated Research Projects) under the leadership of Prof Dr Ruth Ladenstein serves as the national trial centre for almost all childhood cancer trials and registries in Austria, but also is a recognised international trial unit running several world-wide international phase 3 trials in the area of neuroblastoma, Langerhans Cell Histiocytosis and Stem Cell transplantation as international academic sponsor. The unit has major experience in setting up and running academic trials and has initiated and then supported a drug development in partnership with industry achieving EMA approval in 2017 which made a new immunotherapy for neuroblastoma accessible across Europe. Main tasks in the project per Pillar/WP: Pillar 2 - Coordinated access to data and services: 825575 – EJP RD – Part B 143 WP 11 Common virtual platform for discoverable data and resources for RD Associated withresearch document Ref. Ares(2018)6091977 - 28/11/2018 Pillar 3 - Capacity building and empowerment: WP 14 Training on data management & quality WP 16 Online Academic education course WP 18 Development and adaptation of training activities Pillar 4 - Accelerating research translation & therapy development: Accelerating the validation, use and development of innovative methodologies tailored for clinical: .participation to Task force .demonstration calls organization and FU (methodologists/Erns) .new methodologies development calls (methodologists/ERNs/regulatory) Previous experience relevant to the Tasks: With Prof Dr Ruth Ladenstein acting as coordinator, the CCRI has acquired extensive experience in the management of strategic EU-funded projects, namely large pan-European paediatric cancer networks such as: SIOPEN-R-NET (QLRI-CT-2002-01768) - the SIOP European Neuroblastoma Research Network; ENCCA (261474) - the European network for cancer research in children and adolescents; ExPO-r-Net (20131207) - the pilot network European Expert Paediatric Oncology Reference Network for Diagnostics and Treatment; and of particular relevance for this project, ERN-PAEDCAN - the European Reference Network for Paediatric Oncology . The CCRI has also played a leading role and coordinated other EU-funded projects such as MODICELL (285875) - a Marie Curie Industry-Academia Partnerships and Pathways network aiming to improve the understanding of the complexity of immune cell responses by studying cells designed for therapies in the settings of cancer or transplantation; and FUNGITECT (602125) - an innovation project aiming at optimising diagnostics for improved treatment stratification in invasive fungal diseases. In addition, the CCRI has also been the initiator and key partner of other EU-funded projects, including AutoFLOW (610872) - a Marie Curie Industry-Academia Partnerships and Pathways network aiming at developing innovative IT-based automation tools for flow cytometric assessment of pediatric leukaemia; ASSET (259348) - an HEALTH project aimed at tackling human diseases through systems biology approaches; and currently, the CCRI is also a partner in the strategic IMI-2 consortium ITCC-P4 (116064), which will develop a large-scale platform comprising 400 novel research tools based on cells and tissues from patients covering 10 common childhood cancers, including neuroblastoma, high grade glioma, and osteosarcoma. Description of any significant infrastructure and/or major items of technical equipment, relevant to the proposed work : The Research Support Office of the CCRI (RSO) provides active assistance and expertise in the implementation of national and international actions. A team of project managers, which also integrates the ERN-PAEDCAN network manager, is involved in the day-to-day management of projects, monitoring the status of milestones and deliverables, timely technical and financial reporting, and with the dissemination of results. Short Profile of key Staff Members who will be undertaking the work Professor/Ruth Head of the Studies and Statistics Department at the CCRI and a senior consultant in the St. Ladenstein Anna Children’s Hospital. Chief investigator of the high risk neuroblastoma trial (HR-NBL- (MD, MBA, 1/SIOPEN) with over 3000 patients enrolled. Past president of SIOPEN (SIOP Europe cPM)/Female Neuroblastoma Group; 2007- 2011) and past president of SIOPE (2009- 2012) and Head of the Austrian Paediatric Oncology Group (AGPHO) and Chair of OKIDS (Austrian medicines for children network). She has 144 full publications in peer-reviewed journals and 20 published book chapters. She coordinated the ERN Pilot project ExPO-r-Net (European Expert Paediatric Oncology Reference Network for Diagnostics and Treatment, 2014 – 2017) and is now the Coordinator of the ERN PaedCan (European Reference Network for Paediatric Cancer). Nuno Andrade, Head of the Research Support Office at the CCRI. Manages and supervises the management of (PhD, numerous international grants, including of the ERN PaedCan. He is experienced in the MBA)/Male establishment of project management and procedures and has contributed in numerous initiatives to acquire projects funded at the national and international levels. Karoline ERN PaedCan Project Manager. She is responsible for the management and implementation of Noworyta ERN´s non-clinical activities. She has experience with EU funded projects, coordination of (B.Sc., communication and dissemination activities for European projects as well as advocacy and event MPH)/Female organization. List of the most relevant publications and/or products, services (including widely-used datasets or software), or other achievements: 1. Ladenstein R, et al. Validation of the mIBG skeletal SIOPEN scoring method in two independent high-risk neuroblastoma populations: the SIOPEN/HR-NBL1 and COG-A3973 trials. Eur J Nucl Med Mol Imaging. 825575 – EJP RD – Part B 144 2018 Feb;45(2):292-305 Associated with document Ref. Ares(2018)6091977 - 28/11/2018 2. Ladenstein R, et al. Busulfan and melphalan versus carboplatin, etoposide, and melphalan as high-dose chemotherapy for high-risk neuroblastoma (HR-NBL1/SIOPEN): an international, randomised, multi-arm, open-label, phase 3 trial. Lancet Oncol. 2017 Apr;18(4):500-514 3. Park JR, et al. Revisions to the International Neuroblastoma Response Criteria: A Consensus Statement From the National Cancer Institute Clinical Trials Planning Meeting. J Clin Oncol. 2017 Aug 1;35(22):2580-2587 4. Ranft A, et al. Quality of Survivorship in a Rare Disease: Clinicofunctional Outcome and Physical Activity in an Observational Cohort Study of 618 Long-Term Survivors of Ewing Sarcoma. J Clin Oncol. 2017 May 20;35(15):1704-1712 5. Abbasi MR, et al. Impact of Disseminated Neuroblastoma Cells on the Identification of the Relapse-Seeding Clone. Clin Cancer Res. 2017 Aug 1;23(15):4224-4232 List of relevant previous projects or activities, connected to the subject of this proposal : SIOPEN-R-NET (QLRI-CT-2002-01768) – funded under FP5, from 2002-11-01 to 2006-04-30 – Project Coordinator of the SIOP European Neuroblastoma Research Network. ENCCA (261474) – funded under FP7, from 2011-01-01 to 2015-12-31 – Project Coordinator of the European network for cancer research in children and adolescents. ExPO-r-Net (20131207) – funded under 2HP, from 2014-03-01 to 2017-08-31 – Project Coordinator of the pilot network European Expert Paediatric Oncology Reference Network for Diagnostics and Treatment. 54-APHP (a) Full legal name (Acronym) – Country Assistance Publique-Hôpitaux de Paris (AP-HP) - France Principal investigator Rima Nabbout (Hôpital Necker) Relevant Network Reference centre for rare epilepsies (as ERN EPICARE member) Description of the legal entity/department/laboratory/group: The group is composed by the team of the reference centre for rare epilepsies leaded by Pr Rima Nabbout. Necker enfants Malades, AP-HP, Imagine Institute, Paris Descartes, Paris, France Main tasks in the project per Pillar/WP: Rima nabbout is a member of the steering group and leader of the Pillar 4 (WP19-20) together with A Ussi (Eatris) Pillar 0: Rima Nabbout will participate to all transversal activities as part of the operating group Pillar 4: Rima Nabbout is the leader of Pillar 4. She is leading also the task force group (WP20, task 1 and will participate to task 20.1.1, task 20.1.2, 20.1.3 as well as tasks 20.3 and 20.4). Her role will be to coordinate the work of the pillar, to chair the task force for mapping, dissemination, validation and innovation in clinical studies dedicated to rare diseases. Previous experience relevant to the Tasks: PI in many orphan drugs development in rare epilepsies. Rima Nabbout is the coordinator of the French centre for rare epilepsies and member of the steering committee of EPICARE (European network of rare and complex epilepsies) where she is in charge for laboratory diagnosis and clinical trials. She is involved in clinical trials since over 10 years and is PI in CT in rare epilepsies with new orphan drugs designation and proposed recently a work on composite end points for a better evaluation in CTs. She is a member of the regulatory task force for drugs in epilepsy in the International league against epilepsy. Her expertise in genetics and phenotyping adds to the actual search for mechanisms for drugs and her close work with patient groups help in a better understanding of patients centered outcome. Description of any significant infrastructure and/or major items of technical equipment, relevant to the proposed work : Short Profile of key Staff Members who will be undertaking the work MD, PhD Pr. Rima Nabbout as supervision of the work Pr. Rima Nabbout Pr. Rima Nabbout is Professor of Paediatric Neurology at Paris Descartes University as Female well as Director of the Centre for Rare Epilepsies at Necker Enfants Malades Hospital, Imagine Institute, Paris, France. She is a member of the steering committee of EPICARE (European reference network on rare epilepsies) and of scientific committees of patients associations on rare epilepsies. Pr. Nabbout areas of research include electro clinical delineation of rare childhood 825575 – EJP RD – Part B 145 epilepsies, genetics of epileptic encephalopathies, clinical Associated with documenttrials in rare epilepsies Ref. Ares(2018)6091977 and - 28/11/2018 transition from childhood into adulthood. She has authored or co-authored more than 150 peer-reviewed papers, and is presently leading a research group at Imagine in the group of Dr. Kabashi Translational Research for Neurological Diseases, Institut des Maladies Génétiques Imagine, Research Unit UMR1163 Inserm / Université Paris Descartes. To be recruited Post doc to be assigned for the work under the supervision of Pr. Nabbout with an expertise in trials and in research and bibliography. Mrs Wenzel Coordination part time to help in the coordination of Pillar 4 and to organise the Task force Female and the different groups meeting (face to face or webex…) and to do the secretary of the group. A person fluent in English, French and German is already previewed. List of the most relevant publications and/or products, services (including widely-used datasets or software), or other achievements 1) Gaspard N, Hirsch LJ, Sculier C, Loddenkemper T, van Baalen A, Lancrenon J, Emmery M, Specchio N, Farias-Moeller R, Wong N, Nabbout R. New-onset refractory status epilepticus (NORSE) and febrile infection-related epilepsy syndrome (FIRES): State of the art and perspectives. Epilepsia. 2018 Apr;59(4):745-752. doi: 10.1111/epi.14022. Epub 2018 Feb 24. Review. PubMed PMID: 29476535. 2) Nabbout R, Auvin S, Chiron C, Irwin J, Mistry A, Bonner N, Williamson N, Bennett B. Development and content validation of a preliminary core set of patient- and caregiver-relevant outcomes for inclusion in a potential composite endpoint for Dravet Syndrome. Epilepsy Behav. 2018 Jan;78:232-242. doi: 10.1016/j.yebeh.2017.08.029. Epub 2017 Nov 4. PubMed PMID: 29108913. 3) Devinsky O, Cross JH, Laux L, Marsh E, Miller I, Nabbout R, Scheffer IE, Thiele EA, Wright S; Cannabidiol in Dravet Syndrome Study Group. Trial of Cannabidiol for Drug-Resistant Seizures in the Dravet Syndrome. N Engl J Med. 2017 May 25;376(21):2011-2020. doi: 10.1056/NEJMoa1611618. PubMed PMID: 28538134. 4) French JA, Lawson JA, Yapici Z, Ikeda H, Polster T, Nabbout R, Curatolo P, de Vries PJ, Dlugos DJ, Berkowitz N, Voi M, Peyrard S, Pelov D, Franz DN. Adjunctive everolimus therapy for treatment-resistant focal-onset seizures associated with tuberous sclerosis (EXIST-3): a phase 3, randomised, double-blind, placebo-controlled study. Lancet. 2016 Oct 29;388(10056):2153-2163. doi: 10.1016/S0140-6736(16)31419-2. Epub 2016 Sep 6. PubMed PMID: 27613521 List of relevant previous projects or activities, connected to the subject of this proposal . EPISTP FP7 Health project: 2013-2018 . DESIRE FP7 project 2013-2018 . Coordinator of the reference centre for rare epilepsies 2010-2022 . WP leader at EPICARE 2017-2022 54-APHP (b) Full legal name (Acronym) – Country Assistance Publique-Hôpitaux de Paris (AP-HP) - France Principal investigator Guillaume Jondeau (Hôpital Bichat) Relevant Network VASCERN (as ERN coordinator) Description of the legal entity/department/laboratory/group: The National Center de Reference located in the Bichat Hospital, 75018 Paris is the place where the patients are seen. The hospital includes 1000 beds, and all the medical specialists are presents, including reanimation, heart and lung transplantation. The radiological department possesses MRI, CT scanner, and all last imaging techniques. In the same hospital, the research center, which is composed of more than 100 researchers, includes 5 teams. Team 2 is leaded by Guillaume Jondeau, and is dedicated to genetics in rare diseases (INSERM U1148 / Team 2). Lastly, this HCP is coordinating VASCERN, the European Rare Disease Network devoted to vascular diseases, which is present in 11 countries and includes 30 other HCPs. [Other VASCERN team is involved in the project under the coordination of AP-HP: Radboudumc, Prof Leo 825575 – EJP RD – Part B 146 Schultze Kool - see Beneficiary Radboudumc description.] Associated with document Ref. Ares(2018)6091977 - 28/11/2018 Main tasks in the project per Pillar/WP: Pilar 3 In WP17 ERN RD training and support programme AP-HP/VASCERN, as contributor of “systemic” training Previous experience relevant to the Tasks: A long history of research in both the fundamental and clinical areas, with strong interaction between the 2: from bedside to bench and back from bench to bedside, allowing discovery of new diseases, proposition of new therapies. Interaction with numerous HCPs and research teams within Europe through VASCERN. Description of any significant infrastructure and/or major items of technical equipment, relevant to the proposed work : Structuration of the clinical and research entities with strong interactions between the 2: Centre de Référence pour le Syndrome de Marfan et appârentés (www.marfan.fr) and LVTS INSERM U 1148 (https://lvts.fr/). Short Profile of key Staff Members who will be undertaking the work Pr Guillaume Professor Jondeau has been a Professor of Cardiology since 1999, in Université Paris V, and has Jondeau moved to Université Paris VII - Denis Diderot, since 2007. He is also leading a research team (team 2 LVTS, INSERM U1148) focusing on aortic aneurysm, and has authored more than 200 publications in peer-reviewed international journals. Professor Jondeau’s research interests are in the field of aortic aneurysms and heart failure. He is leading the centre de reference for the Marfan syndrome (www.marfan.fr) and related disorders, which is seeing more than 1000 patients every year, following >1200 patients with FBN1 mutations, and is responsible for the organization of the care of these patients throughout the country. Research units on genetics (co-leaded by Catherine Boileau) and pathophysiology (leaded by JB Michel) in INSERM U1148 are closely linked to this centre de reference. He is a funding member of the nucleus of the new ESC working group on Aorta and peripheral vascular diseases. He is leading the “Filière de Santé maladies rares” on rares vascular diseases, which is taking care of patients with thoracic aortic aneurysms, aneurysms of systemic arteries, and HHT and lymphatic pathologies throughout France, networking 3 reference centers, more than 30 competence centers, 5 diagnostic laboratories, 3 research units (www.favamulti.fr). He is leading the European Rare Disease Network VASCERN (www.vascern.eu), gathering 31 centers from 11 European countries. He is involved in studies in acute heart failure and chronic heart failure. He is a former president of the Heart Failure Working Group of the French Society of Cardiology and has been a member of the board of the Heart Failure Association of the European Society of Cardiology. He is a fellow of the European Society of Cardiology, American College of Cardiology, and American College of Chest Physicians and is a member of the board of the French Society of Cardiology. Professor Jondeau participated in the steering or executive committees of international trials, and was the principal investigator of investigator-driven and industry-sponsored clinical trials. He was end-point committee’s member. Dr Jondeau has authored more than 200 articles in peer-reviewed international journals. List of the most relevant publications and/or products, services (including widely-used datasets or software), or other achievements 1) Jondeau G, Boileau C, Milleron O. Marfan Syndrome: Always Evolving. Circ Cardiovasc Genet. 2017 Jun;10(3). pii: e001785. doi: 10.1161/CIRCGENETICS.117.001785. PubMed PMID: 28600389. 2) Milleron O, Arnoult F, Ropers J, Aegerter P, Detaint D, Delorme G, Attias D, Tubach F, Dupuis-Girod S, Plauchu H, Barthelet M, Sassolas F, Pangaud N, Naudion S, Thomas-Chabaneix J, Dulac Y, Edouard T, Wolf JE, Faivre L, Odent S, Basquin A, Habib G, Collignon P, Boileau C, Jondeau G. Marfan Sartan: a randomized, double- blind, placebo-controlled trial. Eur Heart J. 2015 Aug 21;36(32):2160-6. doi: 10.1093/eurheartj/ehv151. Epub 2015 May 2. PubMed PMID: 25935877. 3) Aubart M, Gross MS, Hanna N, Zabot MT, Sznajder M, Detaint D, Gouya L, Jondeau G, Boileau C, Stheneur C. he clinical presentation of Marfan syndrome is modulated by expression of wild-type FBN1 allele. Hum Mol Genet. 2015 May 15;24(10):2764-70. doi: 10.1093/hmg/ddv037. Epub 2015 Feb 4. PubMed PMID: 25652400. 4) Barbier M, Gross MS, Aubart M, Hanna N, Kessler K, Guo DC, Tosolini L, Ho-Tin-Noe B, Regalado E, Varret M, Abifadel M, Milleron O, Odent S, Dupuis-Girod S, Faivre L, Edouard T, Dulac Y, Busa T, Gouya L, Milewicz DM, Jondeau G, Boileau C. MFAP5 loss-of-function mutations underscore the involvement of matrix alteration in the pathogenesis of familial thoracic aortic aneurysms and dissections. Am J Hum Genet. 2014 Dec 4;95(6):736-43. 825575 – EJP RD – Part B 147 doi: 10.1016/j.ajhg.2014.10.018. Epub 2014 Nov 26. PubMedAssociated PMID: with 25434006; PubMed document Ref. Central PMCID: Ares(2018)6091977 - 28/11/2018 PMC4259978. 5) Boileau C, Guo DC, Hanna N, Regalado ES, Detaint D, Gong L, Varret M, Prakash SK, Li AH, d'Indy H, Braverman AC, Grandchamp B, Kwartler CS, Gouya L, Santos-Cortez RL, Abifadel M, Leal SM, Muti C, Shendure J, Gross MS, Rieder MJ, Vahanian A, Nickerson DA, Michel JB; National Heart, Lung, and Blood Institute (NHLBI) Go Exome Sequencing Project, Jondeau G, Milewicz DM. TGFB2 mutations cause familial thoracic aortic aneurysms and dissections associated with mild systemic features of Marfan syndrome. Nat Genet. 2012 Jul 8;44(8):916-21. doi: 10.1038/ng.2348. PubMed PMID: 22772371; PubMed Central PMCID: PMC4033668. List of relevant previous projects or activities, connected to the subject of this proposal 1) ANR-05-PCOD-014 : « diversité génétique et monotonie phénotypique des anévrysmes artériels non athéromateux » avec l’U 698 (Bichat), l’U 383 (Necker), l’U 36 (HEGP) 2) ANR-14-CE15-0012 (porteur de projet) : 420243 € 3) CRC 10 043 : Apport de la PET pour le suivi des patients présentant une dissection de l’aorte descendante (porteur de projet) : 100 000 € 54-APHP (c) Full legal name (Acronym) – Country Assistance Publique-Hôpitaux de Paris (AP-HP) - France Principal investigator Pierre Fenaux (Hôpital Saint Louis) Relevant Network ERN EuroBloodNet (as ERN coordinator) Description of the legal entity/department/laboratory/group: Prof Pierre Fenaux moved in 2013 to Hôpital St Louis/Paris 7 university to create a new clinical hematology section for myeloid disorders in the elderly which he is currently chairing. He is involved in clinical and laboratory research in the field of myelodysplastic syndromes (MDS) and acute myeloid leukemia (especially promyelocytic leukemia). He is a founding member and chairman of the French speaking MDS group (Groupe Francophone des Myélodysplasies) and of the French APL group (GT-LAP), and currently part of INSERM unit 1131 in Paris for his research [Other EuroBlooNet teams are involved in the project under the coordination of AP-HP: AOUFIIN with Prof. Achille Iolascon, CING with Prof. Marina Kleanthous, CHUM with Prof. Patricia Aguilar Martinez and IRCCSCG with Dr. Paola Bianchi] AP-HP remains coordinator but Pr. Achille Iolascon from AOUFIIN will be more involved in this EJP. Since 1983 Prof. Iolascon Research group is currently an international reference group for genetics of rare hemolytic anemias, either due to hyporegenerative defects and RBCs membrane defects. Achille Iolascon is a full Professor of Medical Genetics at University of Naples “Federico II” and PI of a group composed by: 2 researchers, 2 post-doctoral fellows, 4 PhD students, 9 post graduate students in residency school of medical genetics at Ceinge - Biotecnologie Avanzate, Naples, Italy. Main tasks in the project per Pillar/WP: Pillar 2 Contribution to WP10 annual retreats to guide the priorities for Virtual Pltaform development and FAIRification of resources. Previous experience relevant to the Tasks: The ERN EuroBloodNet coordinator Pierre Fenaux, AP-HP has contributed in RESEARCH ACTIVITIES mainly concern acute myeloid leukemias (AML) and myelodysplastic syndromes (MDS). 1° clinical research - Coordinator of European clinical trials in Acute Promyelocytic Leukemia since 1990 - Founding member of the French MDS group (groupe francophone des myélodysplasies –GFM-in 1992), Président (1992-1995, and since 1999) Vice- Président (1996-1998). The GFM is sponsor of about 10 clinical trials in the field of myelodysplastic syndromes 2° biological research P Fenaux part of INSERM Unit 1131, Hôpital St Louis, Paris, where the main subject of our research is: 825575 – EJP RD – Part B 148 translational research in MDS and APL Associated with document Ref. Ares(2018)6091977 - 28/11/2018 For what concerns ERN-EuroBloodNet LTPs, some relevant experience: LTP CING - PKDeep 2017-2018. Funded by the FUNDACIÓ INSTITUT RECERCA CONTRA LA LEUCÈMIA JOSEP CARRERAS - H2020-INFRADEV-01-2017 – ID-EPTRI project European Paediatric Translation Research Infrastructure (777554-ID-EPTRI) 2018-2020. LTP AOUFIIN - 2014-2017: PRIN research grant “Study of the molecular mechanisms of erythropoiesis for the identification of therapeutic targets” LTP CHUM The principal investigator of CHUM has acted as a workpackage leader in the field of education and training in 3 European projects. We have developed several e-learning platforms and many of us are university professors/teachers having participated to numerous educational programmes The principal investigator of CHUM and her team are specialists in molecular biology applied to rare diseases, including sequencing and next generation sequencing tools. LTP IRCCSCG -2016-present BBMRI-LPC Whole Exome Sequencing Call: “Sequencing the exome of 500 rare disease samples in collaboration with EuroBioBank” (PI) - 2013-2016 e-Health workplan for the European reference network on rare anaemias (e-ENERCA), EU Executive Agency for Health and Consumers. (Italian Partner) Description of any significant infrastructure and/or major items of technical equipment, relevant to the proposed work : - The Cyprus Institute of Neurology and Genetics (CING) is a non-profit research organization, with the vision of operating as a Regional Centre of Excellence, in the areas of Neurology, Genetics and Biomedical Sciences. With a particular focus on rare diseases, the activities of the CING include delivery of state-of-the-art diagnostic and clinical services, execution of innovative research programmes and participation in postgraduate education. - The CHU of Montpellier is fully equipped with a platform of next generation sequencing (NGS) and all genetics and genomics facilities which are shared by the different laboratories. Short Profile of key Staff Members who will be undertaking the work Prof. Pierre Pierre Fenaux, after training at the University Hospital of Lille, France, where he became Fenaux Professor in Hematology in 1993, created and was head of the clinical hematology section at Hôpital Avicenne/Paris 13 university (belonging to Assistance Publique- Hôpitaux de Paris) from 2002 to 2013. He moved in 2013 to Hôpital St Louis/Paris 7 university to create a new clinical hematology section for myeloid disorders in the elderly which he is currently chairing. He is involved in clinical and laboratory research in the field of myelodysplastic syndromes (MDS) and acute myeloid leukemia (especially promyelocytic leukemia ). He is a founding member and chairman of the French speaking MDS group (Groupe Francophone des Myélodysplasies) and of the French APL group (GT-LAP), and currently part of INSERM unit 1131 in Paris for his research. Prof. Since 1983 Prof. Iolascon works in the field of rare anemias and he gradually gained international Achille recognition in this field. Using continuously renewed methods in molecular biology and in Iolascon medical genetics, he characterized a large number of previously unknown genes and mutations: SPTA1, ANK1, AE1, SEC23B, ABCB6, KCNN4 and PIEZO1. Prof. Iolascon Research group is currently an international reference group for genetics of rare hemolytic anemias, either due to hyporegenerative defects and RBCs membrane defects. Achille Iolascon is a full Professor of Medical Genetics at University of Naples “Federico II” and PI of a group composed by: 2 researchers, 2 post-doctoral fellows, 4 PhD students, 9 post graduate students in residency school of medical genetics at Ceinge - Biotecnologie Avanzate, Naples, Italy. Dr. Paola Since 1993 she is involved in diagnosis and translational research on hemolytic anemias, both Bianchi congenital (red cell membrane defects, erythroenzymopathies, congenital dyserythopoietic anemias) and acquired (paroxysmal nocturnal hemoglobinuria), contributing to the identification and characterization of more than 200 erythroenzymopathies, 50 CDAII and 30 PNH and some 825575 – EJP RD – Part B 149 peculiar cases of red cell membrane defects (HS,Associated HE and with HSt). As Head document Biologist responsible Ref. Ares(2018)6091977 of - 28/11/2018 the molecular biology of “Pathophysiology of Anemia UOS”, she shared National and International projects on moleculear characterization and genotype-phenotype correlation (by mutagenesis and in vitro expression of recombinant mutants), and studied the epigenetic factors that might influence clinical phenotype in these disorders. By NGS (whole exome sequencing, targeted NGS platforms and genomic–proteomic approach she identified new genes responsible for rare forms of hemolytic anemia (SEC23B, KCNN4, PARP4). She is involved in molecular diagnonsis of mieloprolopherative disorders (qualitative /quantitatative evaluation of JAK2V617 allele burden, JAK2, MPL sequencing) and rare forms of congenital erythrocytosis, participating to the JakNet Italian Network. List of the most relevant publications and/or products, services (including widely-used datasets or software), or other achievements 1) Russo R, Andolfo I, Manna F, Gambale A, Marra R, Rosato BE, Caforio P, Pinto V, Pignataro P, Radhakrishnan K, Unal S, Tomaiuolo G, Forni GL, Iolascon A. Multi-gene panel testing improves diagnosis and management of patients with hereditary anemias. Am J Hematol. 2018 Feb 3. (LTP AOUFIIN) 2) De Franceschi L, Iolascon A, Taher A, Cappellini MD. Clinical management of iron deficiency anemia in adults: Systemic review on advances in diagnosis and treatment. Eur J Intern Med. 2017 Jul;42:16-23. (LTP AOUFIIN) 3) Charitou G, Petousis V, Tsertos C, Parpottas Y, Kleanthous M, Phylactides M, Christou S. First study on iron complexes in blood and organ samples from thalassaemic and normal laboratory mice using Mössbauer spectroscopy. Eur Biophys J. 2017 Jul 10. doi: 10.1007/s00249-017-1234-6 (LTP CING) 4) Reorganisation of the WHO Human Genetics programme (HGN) website, during a mission at WHO headquarter, Geneva (LTP CHUM) 5) *Grace RF, Bianchi P, van Beers E, Eber EW, Glader B, Ya ish HM, et al. The clinical spectrum of pyruvate kinase deficiency: data from the Pyruvate kinase deficiency Natural History Study March 2018 Blood, DOI10.1182/blood-2017-10-810796 (LTP IRCCSCG) List of relevant previous projects or activities, connected to the subject of this proposal : 1) Non Invasive Prenatal Diagnosis of β-thalassaemia based on the detection of paternally inherited alleles using Targeted Next Generation Sequencing2015-2018. Funded by Telethon grant. (LTP CING) 2) eENERCA; DG SANCO; 2009-2013-WP leader, WP: “Education and training”: organisation of European Courses,(LTP CHUM) 3) 2011-2013: AIRC research grant “Targeting neuroblastoma tumours through the hypoxia-induced dedifferentiation in cellular systems” (LTP AOUFIIN) 4) 2009-2012: European Network for Rare and Congenital Anaemias (LTP IRCCSCG) 5) 2009-2012: Telethon research grant “Congenital Dyserythropoietic Anemia Type II: genotype-phenotype correlation, molecular mechanisms, animal model New insights in erythropoiesis and iron overload”(LTP AOUFIIN) 54-APHP (d) Full legal name (Acronym) Country Assistance Publique-Hôpitaux de Paris (AP-HP) - France Principal investigator Christine Bodemer (Hôpital Necker) Relevant Network ERN-Skin (as ERN coordinator) Description of the legal entity/department/laboratory/group: Necker-Enfants Malades Hospital activity concerns more particularly patients with rare and chronic diseases and its excellence is certified in the field of health care and research. The Dermatology department is a referral dermatology department and prioritizes seeing patients with rare skin diseases. We are recognized as National Referral Centre (MAGEC centre) for many rare and complex skin diseases. The expansion of the research activities in the department has led to close partnership with in house, national and international research laboratory HCPs and benefits of the environment of 36 other national referral centres in its institution, covering other specialities, with strong interaction. Prof C Bodemer, MD, PhD is in charge of the Dermatology Department and lastly is coordinating ERN-Skin, the European Rare Disease Network devoted to dermatological rare diseases, which is present in 18 countries and includes 56 HCPs. She is also the coordinator of the French network for rare skin diseases [Other ERN-Skin teams are involved in the project as LTP under the coordination of AP-HP: EBHS, Pr. Johann 825575 – EJP RD – Part B 150 Bauer and IRCCS, Pr. Maya El Hachem] Associated with document Ref. Ares(2018)6091977 - 28/11/2018 AP-HP remains coordinator but Pr. Johann Bauer from EBHS will be more involved in this EJP. The EB House Austria which opened in November, 2005 is located as part of the hospital complex of the General Hospital Salzburg and is closely aligned to the Paracelsus Medical University (PMU), Department of Dermatology. It is the single point of contact for people who are suffering from Epidermolysis bullosa (EB). It consists of 3 units: EB Outpatient Unit, EB Research Unit and the EB Academy. Main tasks in the project per Pillar/WP: ERN-Skin's (AP-HP/Christine Bodemer/Necker Hospital-Paris) main tasks in the project per Pillar/WP are : Pillar 2: In WP1, Johann Bauer from EBHS (LTP : EBHS / ERN-Skin) will take part to the management of the next- generation data ecosystem strategic plan, by : - optimizing and aligning WP1 and WP2 activities with real-world community needs, and taking part to 3-day strategy meetings (annual retreat) (task 1.1.1). - working on continuous monitoring and coordination of the usefulness of WP1 and WP2 activities, moreover on survey and structured interview approaches on technical and scientific matters, to monitor progress and inform strategic decisions (incl. Definition of indicators) (task 1.2.2). - and by working on quality management system, on the design and deployment of the QMS processes, documentation, internal tools and procedures, continuous improvement system, dysfunction tracing (task 1.3.1). Christine Bodemer (Necker Hospital / ERN-Skin) and Johann Bauer will participate to the ERN task force in Pillar2, Pillar 3: Maya El-Hachem from IRCCS (LTP : IRCCS / ERN-Skin) and Christine Bodemer will participate to the ERN task force. Pillar4 : in WP 20, Christine Bodemer will take part to Task 20.2: for “support in design and planning of RD clinical trials” (M3 – M60)”. Previous experience relevant to the Tasks: Prof. C. Bodemer has participated to numerous Congress in the domain of rare diseases in Dermatology, and to many selection committees, advisory boards, scientific committee for Grants in the same field, such as ESPD congress, WCD congress, scientific board meeting of the Fondation René Touraine. Dr J. Bauer was studying medicine from 1981-1988 at the Leopold Franzens University of Innsbruck, Austria. After several post-doc years in Innsbruck, Atlanta and Philadelphia he joined faculty of the Department of Dermatology, Paracelsus Medical University Salzburg. In 2014 he was appointed Chairman of the Department of Dermatology of the SALK, the University Hospital of the Paracelsus Medical University Salzburg. Concurrently he is medical director of the EB House Austria, the accredited national center for patients with Genodermatoses. Description of any significant infrastructure and/or major items of technical equipment, relevant to the proposed work : Short Profile of key Staff Members who will be undertaking the work Professor Professor Christine Bodemer (MD, PhD) is the head of the Department of Dermatology at the Christine Necker Enfants- Malades Hospital, Paris, France. Bodemer, She received her PhD on Cutaneous Biology in 1997, a qualification to direct Research in 2000, MD,PhD and she is Professor in Dermatology at the Paris Descartes-Sorbonne Paris Cité University since 2001. She is regularly invited to give lecture in international congresses and is more particularly specialized in Pediatric dermatology. Pr Bodemer has published more than 300 articles in international Journals, and taken part in the main textbook of Pediatric dermatology as author. She received regular grants to lead research programs. One of this main field of interest concerns rare skin disorders in children and she coordinates a national certified centre for rare pediatric skin diseases (mostly Genodermatoses) (MAGEC) the French national network (FIMARAD) and European network (ERN-SKIN) for rare skin diseases. She is a member of many scientific societies, associated editor of different journal, as the British Journal of Dermatology, and she is actually the president of the French Society of Pediatric Dermatology and in the board of the European Society of Pediatric Dermatology. She took part in the organization of the World Congress of Pediatric Dermatology in Paris and organized recently the 13th congress of Pediatric 825575 – EJP RD – Part B 151 Dermatology (Paris, 2016). She developed regular international Associated training with document supported by European Ref. Ares(2018)6091977 - 28/11/2018 Grants. Professor Prof. Bauer was studying medicine from 1981-1988 at the Leopold Franzens University of Johann Innsbruck, Austria. After several post-doc years in Innsbruck, Atlanta and Philadelphia he joined Bauer, faculty of the Department of Dermatology, Paracelsus Medical University Salzburg. In 2014 he MD was appointed Chairman of the Department of Dermatology of the SALK, the University Hospital of the Paracelsus Medical University Salzburg. Concurrently he is medical director of the EB House Austria, the accredited national center for patients with Genodermatoses and Co- coordinator of ERN-Skin. List of the most relevant publications and/or products, services (including widely-used datasets or software), or other achievements Christine Bodemer : 1) Eosinophilic esophagitis and colonic mucosal eosinophilia in Netherton syndrome. Paluel-Marmont C, Bellon N, Barbet P, Leclerc-Mercier S, Hadj-Rabia S, Dupont C, Bodemer C. J Allergy Clin Immunol. 2017 Jun;139(6):2003-2005.e1. 2) Multicentre consensus recommendations for skin care in inherited epidermolysis bullosa.El Hachem M, Zambruno G, Bourdon-Lanoy E, Ciasulli A, Buisson C, Hadj-Rabia S, Diociaiuti A, Gouveia CF, Hernández- Martín A, de Lucas Laguna R, Dolenc-Volj M, Tadini G, Salvatori G, De Ranieri C, Leclerc-Mercier S, Bodemer C. Orphanet J Rare Dis. 2014 May 20;9(1):76 3) Live rubella virus vaccine long-term persistence as an antigenic trigger of cutaneous granulomas in patients with primary immunodeficiency. Bodemer C, Sauvage V, Mahlaoui N, Cheval J, Couderc T, Leclerc-Mercier S, Debré M, Pellier I, Gagnieur L, Fraitag S, Fischer A, Blanche S, Lecuit M, Eloit M. Clin Microbiol Infect. 2014; 20):O656-63 4) Autosomal dominant STAT3 deficiency and hyper-IgE syndrome: molecular, cellular, and clinical features from a French national survey. Chandesris MO, Melki I, Natividad A, Puel A, Fieschi C, Yun L, Thumerelle C, Oksenhendler E, Boutboul D, Thomas C, Hoarau C, Lebranchu Y, Stephan JL, Cazorla C, Aladjidi N, Micheau M, Tron F, Baruchel A, Barlogis V, Palenzuela G, Mathey C, Dominique S, Body G, Munzer M, Fouyssac F, Jaussaud R, Bader- Meunier B, Mahlaoui N, Blanche S, Debré M, Le Bourgeois M, Gandemer V, Lambert N, Grandin V, Ndaga S, Jacques C, Harre C, Forveille M, Alyanakian MA, Durandy A, Bodemer C, Suarez F, Hermine O, Lortholary O, Casanova JL, Fischer A, Picard C. Medicine (Baltimore). 2012 91:e1-19. 5) Pediatric mastocytosis is a clonal disease associated with D816V and other activating c-KIT mutations. Bodemer C, Hermine O, Palmérini F, Yang Y, Grandpeix-Guyodo C, Leventhal PS, Hadj-Rabia S, Nasca L, Georgin-Lavialle S, Cohen-Akenine A, Launay JM, Barete S, Feger F, Arock M, Catteau B, Sans B, Stalder JF, Skowron F, Thomas L, Lorette G, Plantin P, Bordigoni P, Lortholary O, de Prost Y, Moussy A, Sobol H, Dubreuil P. J Invest Dermatol. 2010;130: 804-15. Johann Bauer : 1) Wally V, Lettner T, Peckl-Schmid D, Klausegger A, Murauer EM, Hintner H and Bauer JW. The pathogenetic role of interleukin-1 beta in severe epidermolysis bullosa simplex. J Invest Dermatol 2013. 133(7):1901-3 2) Gruber C, Koller U, Murauer EM, Hainzl S, Hüttner C, Kocher T, South AP, Hintner H, Bauer JW. The design and optimization of RNA trans-splicing molecules for skin cancer therapy. Mol Oncol 2013 Dec;7(6):1056-68 3) Bauer JW, Brandl C, Haubenreisser O, Wimmer B, Karl T, Klausegger A, Breitenbach M, Hintner H, von der Haar T, Tuite M, Breitenbach-Koller H. Personalized ribosomes: a customized tool for selective mRNA translation. PLOS one 2013 10.1371/journal.pone.0067609 4) Bauer JW, Koller J, Murauer EM, De Rosa L, Enzo E, Carulli S, Bondanza ,S, Recchia A, Muss W, Diem A, Mayr E, Schlager P, Gratz IK, Pellegrini G and De Luca M. Closure of a large chronic wound through transplantation of gene-corrected epidermal stem cells. J Invest Dermatol 2016 Nov 10. pii: S0022- 202X(16)32636-7. doi: 10.1016/j.jid.2016.10.038 5) Hirsch T*, Rothoeft T*, Teig N*, Bauer JW*, Pellegrini G*, De Rosa L*, Scaglione D, Reichelt J, Klausegger A, Kneisz D, Romano O, Secone Seconetti A, Contin R, Enzo E, Jurman I, Carulli S, Jacobsen F, Luecke T, Lehnhardt M, Fischer M, Kueckelhaus M, Quaglino D, Morgante M, Bicciato S, Bondanza S, De Luca M. Regeneration of the entire human epidermis using transgenic stem cells. Nature 2017 Nov 16;551(7680):327- 332. doi: 10.1038/nature24487. Epub 2017 Nov 8. PMID: 29144448 *shared first authors 825575 – EJP RD – Part B 152 List of relevant previous projects or activities, connected to theAssociated subject with of this proposal document Ref. Ares(2018)6091977 - 28/11/2018 Christine Bodemer : Examples of recent research programs supported b grants 1) Phase II clinical trial using Humira in Nztherton syndrome (anti TNF-SN) 2) A replacement protein administrated to male infants with X-Linked hypohydrotic Ectodermal Dysplaisa (Phase II) 3) A Multi-Centre, Open Label, Single Arm, Phase IB/IIA, Trial of Taselisib (GDC0032) in PIK3CA-Related Overgrowth 4) Treatment of superficial voluminous complicated slow-flow vascular malformations with sirolimus: a phase 2 trial in children observational-phase designed Johann Bauer : 1) GENESKIN Website; European Commission (contract LSHM-CT-2005-512117) between 2005 and 2008. In 2011 the EDF (European Dermatology Foundation) has taken over responsibility to manage the website. Co- ordinator 2) EB House Austria; DEBRA Austria; 2006-ongoing; Medical director 54-APHP (e) Full legal name (Acronym) – Country Assistance Publique-Hôpitaux de Paris (AP-HP) - France Principal investigator Dr. Belmatoug (Hôpital Beaujon) Relevant Network ERN MetabERN (participation as ERN member) Description of the legal entity/department/laboratory/group: Assistance Publique-Hôpitaux de Paris (AP-HP) is the legal entity where all research projects including clinical trials are administered. The Referral Centre for Lysosomal Diseases (RCLD) certified by the health ministry since 2004, is located at AP-HP, University Hospital, Paris-Nord Val de Seine, Department of internal medicine, Beaujon Hospital. The characteristics of the centre are: multidisciplinarity, collaborative approach, coordination, symptomatic and specific care for disabled patients, epidemiology and registries, reactivity to give expertise, transition programme from childhood to adulthood, enzyme replacement therapy for outpatients, home therapy, clinical trials, research. Various platforms are present. High-level specialized performances with multidisciplinary meetings locally and with external consultants in structured national organizations that exist since 2000 : CETL (Treatment Evaluation multidisciplinary Committee for Lysosomal Diseases). Our HCP contributes to the continuous training for lysosomal diseases for nurses, dietitians, residents, interns, fellows and medical students etc. Teaching courses in LD are organized by HCP locally and in many university hospitals. Beaujon hospital has a 3 research departments called DHU organizing teaching courses for trainees (medical and research : http://hupnvs.aphp.fr/dhu/. Clinical research department in Beaujon Hospital give methodological assistance for clinical trials, monitoring and coordinating data management (http://hupnvs.aphp.fr/liste-des- specialites/epidemiologie-recherche-clinique-beaujon/). The centre is included in the French Inherited Metabolic Diseases (IMDs) network “G2M” that integrates 19 rare diseases centres and was certified in 2013. 9 HCP of “G2M” are members of MetabERN. MetabERN is being coordinated by Prof Maurizio Scarpa. MetabERN represents 69 nationally certified healthcare providers from 18 European countries, 44 patients organisations and is endorsed by the Society for the Inborn Errors of Metabolism (SSIEM). The centre has numerous academic national registries: The French Gaucher registry, RaDiCo (MPS), Niemann Pick. Bio-banks are affiliated to registries Main tasks in the project per Pillar/WP: Pillar 3 In WP16 : Online academic education course Task 16.1 : Access the needs, target audience, main topics of the academic education course Task 16.2 : Developing the online courses Our main contribution will be based on our experience and model and find new concepts to give courses in the field of rare diseases. Education of health care professionals outside the field of rare diseases is also crucial. Previous experience relevant to the Tasks: - Leader of work package : Education, Training and Capacity Building for MetabERN - Organisation and participation of courses for rare diseases : inter-universitary diploma on lysosomal diseases and metabolic diseases with Pascal de Lonlay (AP-HP Necker Hospital) - Organisation and participation of education programmes for the patients and families in patient 825575 – EJP RD – Part B 153 associations. Associated with document Ref. Ares(2018)6091977 - 28/11/2018 - Lessons for medical students at University Paris Diderot - Responsible of rare diseases websites : For Lysosomal Diseases : www.cetl.net For the European working group on Gaucher: www.ewggd.com For MetabERN website : the section on education and training : metabern-edu.eu Since 2004, our HCP is interested in developing new tools to create original programmes and curriculum for education and training in the field of rare diseases. The creation of a pilot programmes that integrates a multidisciplinary approach with physicians, researchers, scientists, biologists, nurses, etc.), “around “patients and families stories with the participation of patient associations is already set up and need evaluation. Different perspectives on rare diseases must be offered and developed for the students. Description of any significant infrastructure and/or major items of technical equipment, relevant to the proposed work : Two members of the referral centre for lysosomal diseases and of MetabERN with an expertise in the field will be dedicated to the tasks. Short Profile of key Staff Members who will be undertaking the work MD, MD, Rheumatologist-Internist, master of infectiology, 123 publications. Knight of the Order of Belmatoug the Legion d’Honneur in 2010 given by the health ministry. Head of the outpatient unit in the Nadia Female department of internal medicine. Involved in rare diseases since 1992. Coordinator of the Referral Centre for Lysosomal Diseases since 2004. Coordinator of the French National Gaucher disease Registry (600 patients) certified by Inserm. Head of the multidisciplinary committee CETL : Comité d’Evaluation du Traitement des maladies Lysosomales, for the french filère « G2M”. Investigator for clinical trials on enzyme replacement therapy and Substrate Reduction Treatment. Clinical research on lysosomal diseases, collaboration with research units : laboratory of excellence GR-Ex : Inserm U1149, Inserm U1134; university of Orsay (LETIAM) for basic research on pathophysiology of Gaucher. Member of the scientific committee of the patient association : Vaincre les Maladies Lysosomales. Member of the European Gaucher Alliance. Member of Maladies Rares Info-services. Coordinator of TENALYS programme (Transition from childhood to adulthood for Lysosomal Diseases). Expert at the social security for reimbursement of care and approval of treatment for metabolic diseases since 1996. Expert and copilote at the French Health Ministry for the second and third rare disease plans. PhD Beaujon University Hospital Khemiri Head of mission for the French « filière G2M » in charge of research and clinical trials Azza Female Education and training in MetabERN List of the most relevant publications and/or products, services (including widely-used datasets or software), or other achievements 1. Regenboog M, van Dussen L, Verheij J, Weinreb NJ, Santosa D, Vom Dahl S, Häussinger D, Müller MN, Canbay A, Rigoldi M, Piperno A, Dinur T, Zimran A, Mistry PK, Salah KY, Belmatoug N, Kuter DJ, Hollak CEM. Hepatocellular carcinoma in Gaucher disease: an international case series. J Inherit Metab Dis. 2018 Feb 8. 2. Bremova-Ertl T, Schiffmann R, Patterson MC, Belmatoug N, Billette de Villemeur T, Bardins S, Frenzel C Malinová V, Naumann S, Arndt J, Mengel E, Reinke J, Strobl R, Strupp M. Oculomotor and Vestibular Findings in Gaucher Disease Type 3 and Their Correlation with Neurological Findings.Front Neurol. 2018 Jan 15;8:711. 3. Lefebvre T, Reihani N, Daher R, de Villemeur TB, Belmatoug N, Rose C, Colin-Aronovicz Y, Puy H, Le Van Kim C, Franco M, Karim Z. Involvement of hepcidin in iron metabolism dysregulation in Gaucher disease. Haematologica. 2018 Apr;103(4):587-596. 4. Mehta A, Belmatoug N, Bembi B, Deegan P, Elstein D, Göker-Alpan Ö, Lukina E, Mengel E, Nakamura K, Pastores GM, Pérez-López J, Schwartz I, Serratrice C, Szer J, Zimran A, Di Rocco M, Panahloo Z, Kuter DJ, Hughes D. Exploring the patient journey to diagnosis of Gaucher disease from the perspective of 212 patients with Gaucher disease and 16 Gaucher expert physicians. Mol Genet Metab. 2017 Nov;122(3):122-129. 5. Belmatoug N, Di Rocco M, Fraga C, Giraldo P, Hughes D, Lukina E, Maison-Blanche P, Merkel M, Niederau C, Plӧckinger U, Richter J, Stulnig TM, Vom Dahl S, Cox TM. Management and monitoring recommendations for the use of eliglustat in adults with type 1 Gaucher disease in Europe. Eur J Intern Med. 2017 Jan;37:25-32. List of relevant previous projects or activities, connected to the subject of this proposal : EUROPLAN National conferences 2010 825575 – EJP RD – Part B 154 EUCERD Joint Action April 2014 : Workshop on Centres of Expertise for Rare Associated Diseases with document Ref. Ares(2018)6091977 - 28/11/2018 RaDiCo MPS 2017 MetabERN : Leader of WP 7 : Education, training, Capacity building, 2017-2022. French Health Ministry : Leader of the workpackage “Research and Treatment” for the construction of the 3 rd French rare disease plan, 2017-2018 54-APHP (f) Full legal name (Acronym) – Country Assistance Publique-Hôpitaux de Paris (AP-HP) - France Principal investigator Jérôme Bertherat (Hôpital Cochin) Relevant Network ERN Endo (participation as ERN member) Description of the legal entity/department/laboratory/group: Assistance Publique - Hôpitaux de Paris (AP-HP) is the Legal entity where all research projects including clinical trials are administered in the field of endocrine diseases within the ERN Endo. AP-HP hosts the French Reference Centre for Rare Adrenal Disease and the French Network for Rare Endocrine Diseases, Service d’Endocrinologie, Hôpital Cochin, HUPC. [ERN Endo is under the coordination of LUMC: PI Prof Alberto Pereira – See Beneficiary LUMC description] Main tasks in the project per Pillar/WP: Pillar 3: We will contribute to assess the needs, target audience and main topics of the academic education course. (task 16.1) We will co-coordinate the development of on-line course module: choice of the lecturers/speakers, the harmonization and general design of the module's content (task 16.2) We will participate in the follow-up, evaluation and monitoring of the course. Previous experience relevant to the Tasks: Professor of endocrinology, responsible for various post-graduate course dedicated to are endocrine diseases at Paris 5 University, coordinator of the French reference center for rare adrenal disease and the French national network for rare endocrine disease, Description of any significant infrastructure and/or major items of technical equipment, relevant to the proposed work : Short Profile of key Staff Members who will be undertaking the work Pr Jérôme MD, PhD, Head of the Endocrinology dept of Cochin hospital Bertherat, M Pr Lionel MD, PhD, Professor of endocrinology, Paris Descartes University, coordinator of the national Groussin diploma on endocrine tumors List of the most relevant publications and/or products, services (including widely-used datasets or software), or other achievements 1. On line course on endocrine tumors (Paris Descartes University) 2. Web site of the French network for rare endocrine diseases (www.firendo.fr) 3. Assié G, Libé R, Espiard S, … Groussin L, Bertagna X, Stratakis CA, Ragazzon B, Bertherat J. ARMC5 mutations in macronodular adrenal hyperplasia with Cushing's syndrome. N Engl J Med. 2013 Nov 28;369(22):2105-14. List of relevant previous projects or activities, connected to the subject of this proposal : 1) Coordinator Work Package geneomics of adrenal tumors ENSAT-CANCER (FP7) : FP7-HEALTH-2010; 259735 (2011-2016) 2) Coordinator E-RARE Genomics and signalisation of cAMP in adrenal Cushing, (RARE 0008-01) (2014-2017) 3) Coordinator Work-Package 2, H2020 633983, ENSAT-HT (2015-2020) 54-APHP (g) Full legal name (Acronym) – Country Assistance Publique-Hôpitaux de Paris (AP-HP) - France Principal investigator Marc Humbert (Hôpital Bicêtre) Relevant Network ERN-LUNG (participation as ERN member) 825575 – EJP RD – Part B 155 Description of the legal entity/department/laboratory/group: Associated with document Ref. Ares(2018)6091977 - 28/11/2018 Assistance Publique - Hôpitaux de Paris (AP-HP) is the Legal entity where all research projects including clinical trials are administered in the field of pulmonary hypertension within the ERN LUNG. AP-HP hosts the French Reference Centre for Pulmonary Hypertension, Service de Pneumologie, Hôpital Bicêtre, France. ERN-LUNG is being coordinated by Prof. Dr. TOF Wagner, head of the FRZSE, the clinical Rare Disease Unit of Universitätsklinikum Frankfurt (UKF). ERN-LUNG is a project of building a clinical care network for all rare diseases of the respiratory system. ERN-LUNG has been evaluated by the European Commission and on 15 December 2016 the European Reference Network Board of Member States approved ERN-LUNG. ERN-LUNG is a network of European healthcare providers dedicated to ensuring and promoting excellence in care and research for the benefit of patients affected by rare respiratory diseases. [ERN-LUNG is under the coordination of GUF : PI Prof TOF Wagner – See Beneficiary UKF description] Main tasks in the project per Pillar/WP: Pillar 2: WP11 Task 11.1.1. Define metadata model compatible with existing key databases and resources – contributing experience with metadata registries and minimum data sets (e.g. ERDRI) WP11 Task 11.2.4. Enhance the catalogue platform to optimise and federate query capabilities, and to automate metadata collection/curation– contributing experience and work done on federate search and inter-operability WP12 Task 12.2.1. Semantic and syntactic harmonisation of data records – contributing experience and work done on federate search data and inter-operability Pillar 4: WP19 Task 19.1. Survey to understand the ERN community needs and evaluation of services provided– perform a survey to understand the ERN community needs in terms of educational resources for translational research (to inform the population of our virtual library), and then later to perform an evaluation of the translational and partnering services provided in the WP. WP 19 Task 19.3. Evaluation of Innovation Management and exploitation support tasks Other activities: Several contributions to other Tasks in its role as one of the ERNs, and in close collaboration with JRC, Ispra, Italy (ERDRI). Previous experience relevant to the Tasks: AP-HP, represented by M. Humbert, and O. Sitbon has many years of experience in registry work by running registries and registry infrastructure. The group has developed the national French Pulmonary Hypertension Registry. Description of any significant infrastructure and/or major items of technical equipment, relevant to the proposed work : Short Profile of key Staff Members who will be undertaking the work Pr. Marc Marc Humbert, MD, PhD, is Professor of Respiratory Medicine at the South Paris University Humbert (Université Paris-Saclay) in Le Kremlin-Bicêtre, France. In addition to his academic responsibilities, he is the Director of the French Reference Centre for Pulmonary Hypertension, Department of Respiratory and Intensive Care Medicine, Hôpital Bicêtre, Assistance Publique Hôpitaux de Paris, France. Along with membership to several scientific councils and institutes, Marc Humbert is the current Director of the INSERM Unit "Pulmonary Hypertension: Pathophysiology and Innovative Therapies" and of the “Thorax Innovation” University Hospital Department. He has been the Chief Editor of the European Respiratory Journal from 2013 to 2017. Pr. Olivier Sitbon, MD, PhD, is Professor of Respiratory Medicine at the South Paris University Olivier (Université Paris-Saclay) in Le Kremlin-Bicêtre, France. In addition to his academic responsibilities, Sitbon he is in charge of the French Pulmonary Registry, Hôpital Bicêtre, Assistance Publique Hôpitaux de Paris, France. 825575 – EJP RD – Part B 156 List of the most relevant publications and/or products, servicesAssociated (including widely-used with document datasets or software), Ref. Ares(2018)6091977 - 28/11/2018 or other achievements 1) Galiè N, Humbert M, Vachiery JL, Gibbs S, Lang I, Torbicki A, Simonneau G, Peacock A, Vonk Noordegraaf A, Beghetti M, Ghofrani A, Gomez Sanchez MA, Hansmann G, Klepetko W, Lancellotti P, Matucci M, McDonagh T, Pierard LA, Trindade PT, Zompatori M, Hoeper M. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J 2015; 46: 903-75. 2) Montani D, Girerd B, Jaïs X, Levy M, Amar D, Savale L, Dorfmüller P, Seferian A, Lau EM, Eyries M, Le Pavec J, Parent F, Bonnet D, Soubrier F, Fadel E, Sitbon O, Simonneau G, Humbert M. Clinical phenotypes and outcomes of heritable and sporadic pulmonary veno-occlusive disease: a population-based study. Lancet Respir Med 2017; 5:125-34. 3) Ghofrani HA, Grimminger F, Grünig E, Huang Y, Jansa P, Jing ZC, Kilpatrick D, Langleben D, Rosenkranz S, Menezes F, Fritsch A, Nikkho S, Humbert M. Predictors of long-term outcomes in patients treated with riociguat for pulmonary arterial hypertension: data from the PATENT-2 open-label, randomised, long-term extension trial. Lancet Respir Med 2016; 4:361–71. 4) Humbert M, Lau EM, Montani D, Jaïs X, Sitbon O, Simonneau G. Advances in therapeutic interventions for patients with pulmonary arterial hypertension. Circulation 2014; 130 :2189-208. 5) Eyries M, Montani D, Girerd B, Perret C, Leroy A, Lonjou C, Chelghoum N, Coulet F, Bonnet D, Dorfmüller P, Fadel E, Sitbon O, Simonneau G, Tregouet DA, Humbert M, Soubrier F. EIF2AK4 mutations cause pulmonary veno-occlusive disease, a recessive form of pulmonary hypertension. Nat Genet 2014; 46:65-9. List of relevant previous projects or activities, connected to the subject of this proposal 1)EFORT; Funder; PHRC (French MoH); 2011-2017: Biomarkers of outcomes in PAH 2)VIGIAPATH; ANSM (French EMA); 2013-2018: Pharmacovigilance of drugs inducing PAH 3)SNOOPY-2; (Inserm, Univ. Paris-Sud, Technion, AP-HP) 2015-2018: Associated International Laboratory Technion – Univ. Paris-Sud - Inserm on the development on an electronic nose to detect pulmonary hypertension 4)ERN-LUNG; EC DG SANTE; 2017-2022-TOF Wagner Coordinator, ERN for rare diseases of the respiratory system 5)RD REGWAREHOUSE; EC DG SANTE; 2018-2021-TOF Wagner Ccoordinator, three level registry infrastructure for ERN-LUNG 55-HUS Full legal name (Acronym) – Country Hôpitaux Universitaires de Strasbourg (HUS) - France Principal investigator Hélène Dollfus Relevant Network ERN-EYE Description of the legal entity/department/laboratory/group: Ranked among the top French university hospitals, the University Hospital of Strasbourg (HUS) is renowned for the quality of the care provided, the excellence of its level of clinical research, innovation expertise, and its leadership in the primary or life-time training of the healthcare professionals in the Alsace region and beyond. The HUS as a university hospital (CHU) providing primary, secondary, tertiary care, teaching and research works in close in connection with the University of Strasbourg (IDEX label) . For the last 20 years, the HUS has developed expertise for diagnosis, care, clinical research and scientific research in the field of Rare Eye Diseases (RED) and since 2004 is a national centre for rare diseases (CARGO). Since then >6000 files have been opened and >1750 consultations for secondary and tertiary referral of pediatric and adult RED are done yearly. CARGO has established a highly specialized multidisciplinary network for care of syndromic eye diseases (with pediatrics, neurology, nephrology, dermatology…). CARGO has low vision aid expertise for poorly sighted or blind patients of all ages with a regional and national network for specialized careers. CARGO is one of the 3 French centres authorized to perform patient selection and rehabilitation for artificial retinal implantation. CARGO is highly specialized in genetic counselling for RED in close collaboration with the HUS Medical genetics department. CARGO deals with preimplanatory diagnosis (PID) as well as prenatal diagnosis (PND) for various RED in close contact with the HUS pluridisciplinary centre for prenatal diagnosis. The Molecular Genetics Unit of is constantly developing various NGS panels for retinitis pigmentosa and for ciliopathies. CARGO is embedded in the stimulating environment of the IGMA (Institut de Génétique Médicale d’Alsace) that brings together biologists, clinicians, ophthalmologists and bio informaticians. CARGO leads or participates in clinical research protocols (R= regional or N=national; PHRC) as principal investigator: Bardet-Bield syndrome I and II, Alström syndrome, NGS panel for retinitis pigmentosa (R); or as associated investigator: Leber’s congenital amaurosis (N), retinitis pigmentosa autosomal recessive and dominant (N). CARGO is tightly linked to fundamental research laboratories especially the INSERM UMRS_S1112 and other human genetics laboratories in Strasbourg and many others 825575 – EJP RD – Part B 157 worldwide. Since 2014, CARGO is the chair of the nationalAssociated networkwith fordocument rare sensory diseases in - France Ref. Ares(2018)6091977 28/11/2018 (SENSGENE) providing medical coordination of RED care for France including: mapping social care, child to adult transition, education, national molecular network. The HUS coordinates the European Reference Network dedicated to RED, ERN-EYE constituted by 29 Healthcare providers through 13 European Member States. Main tasks in the project per Pillar/WP: ERN-EYE members carry research with highly heterogeneous (phenotype and genotype) non-syndromic rare eye diseases (ie: eye developmental anomalies, retinal degenerations, corneal dystrophies, optic neuropathies, ...) as well as syndromic conditions (i.e.: ciliopathies, ultra rare syndromes, mitochondrial disorders etc. …) overlapping with other ERN’s fields prompting for ERNs close interactions. 43 research entities are collaborating with ERN-EYE members of which 25 are working in the close vicinity of the ERN HCPs; a premise to an excellent setting for holistic approaches to be developed. Genomics research for rare eye diseases is tackled by ERN-EYE members with a continuous effort for solving the unsolved leading to multiple novel gene identifications and with regular novel pathway & biomarker discovery . ERN-EYE will share this holistic systemic biology approach strategy in this project and will solicit our network members & their research partners for this purpose. Most importantly, therapies are being elaborated in preclinical terms by many groups of ERN-EYE (often based on system biology approaches) and tackles the very high degree of phenotypic variability and as well as the high number of genes involved to date putting multi-omics and holistic research at the forefront of our priorities in the next years. We will fulfil the here under described tasks in PILLAR 2: WP 10. User-driven strategic planning and transversal activities for Pillar 2 data ecosystem Task 10.1: Pillar 2 annual strategic plans (M1-M60) including participation to prioritization, elaboration of WP11 and 12 of the proof of concept demonstrators, active participation to the annual retreat (we will propose use case, use testers , …) Task 10.2: Coordinating Pillar 2 Work Packages outputs and aligning to RD community needs (M1-M60) where will be involved in advising, designing and responding to the activities. Task 10.4: Quality oversight (M1-M60). We will offer regular participation to the process. WP 13. Enabling multidisciplinary, holistic approaches for rare disease diagnostics and therapeutics Task 13.1: Fill a number of pre identified gaps to allow integrative systems biology approaches for rare diseases (M1-M60). We can contribute to most subtasks due to the ERN-EYE ongoing collaboration with platforms and institutes focusing on a holistic approach to diagnosis, biomarker identification and design of novel therapies. Task 13.2: Organize proof of principle studies to identify efficacy of the work done and identify remaining (including new) gaps (M1-M60) Previous experience relevant to the Tasks: We are highly interested in next generation data infrastructure and can contribute with our expertise in the field of RED. WP10 is of concern for members of ERN-EYE involved in genomics research in RED , especially in solving the unsolved and having access to common validated datasets would be a tremendous resource. Many collaborators (i.e: Germany, France, UK, the Netherlands) are leading world experts in the field of gene identification and genotype-phenotype studies in the field of retinal dystrophies. Therapies are also at the fore front of RED (i.e: gene therapy getting into market, retinal implants also on the market and pharmacological therapies on the way) with many preclinical studies as well as ongoing clinical trials. Description of any significant infrastructure and/or major items of technical equipment, relevant to the proposed work : These are the one from each institute member of ERN-EYE, for the coordinating HCP we lean on INSERM and the university of Strasbourg facilities (i.e.: for bioinformatics for instance). Short Profile of key Staff Members who will be undertaking the work Pr. Hélène Dollfus Hélène Dollfus, MD, PhD is specialized in Medical Genetics and Ophthalmology. She is (female) the head of the Medical Genetics Department of the Strasbourg University Hospitals (HUS) since 2003, Coordinator of the Rare Diseases in Ophthalmic Genetics Reference Center (CARGO) since 2004, as well as the national rare diseases network SENSGENE since 2014, Director of the Medical Genetics Laboratory Inserm UMRS_S 1112 since 2002, Instigator of the future Institute of Medical Genetics of Alsace (IGMA), President of the scientific council of Retina France and Coordinator of the European Reference Network ERN-EYE since 2017. Dr. Jean Muller Jean Muller, PhD is specialized in Human Genetics testing and Bioinformatics. Member of (male) the diagnostic laboratory of the HUS since 2009, he is responsible of the post and prenatal diagnosis of rare sensory diseases. He is coordinator of the French network “NGS- 825575 – EJP RD – Part B 158 Diagnostic” since 2014. Member of the Medical AssociatedGenetics Laboratory with document INSERM UMRS_S Ref. Ares(2018)6091977 - 28/11/2018 1112 since 2015 is coordinating research around bioinformatics and rare ophthalmologic diseases including ciliopathies as well as development of WES and WEGS in novel gene identification and novel path way discoveries. Dr. Dorothée Leroux Dorothée Leroux (PharmD, PhD) is the project Manager of ERN-EYE since its creation. (female) She manages ERN-EYE operatatiosn with important interactions with patients and patient groups. She is particularly involved in the ontology work organized last year and in the development of a training program for ERN-EYE. List of the most relevant publications and/or products, services (including widely-used datasets or software), or other achievements 1. A mutation in VPS15 (PIK3R4) causes a ciliopathy and affects IFT20 release from the cis-Golgi.Stoetzel C, Bär S, De Craene JO, Scheidecker S, Etard C, Chicher J, Reck JR, Perrault I, Geoffroy V, Chennen K, Strähle U, Hammann P, Friant S, Dollfus H.Nat Commun. 2016 Nov 24;7:13586 2. Mutations in TUBGCP4 alter microtubule organization via the γ-tubulin ring complex in autosomal- recessive microcephaly with chorioretinopathy.Scheidecker S, Etard C, Haren L, Stoetzel C, Hull S, Arno G, Plagnol V, Drunat S, Passemard S, Toutain A, Obringer C, Koob M, Geoffroy V, Marion V, Strähle U, Ostergaard P, Verloes A, Merdes A, Moore AT, Dollfus H.Am J Hum Genet. 2015 Apr 2;96(4):666-74. 3. [Bardet-Biedl syndrome: cilia and obesity - from genes to integrative approaches].Chennen K, Scerbo MJ, Dollfus H, Poch O, Marion V.Med Sci (Paris). 2014 Nov;30(11):1034-9 4. Insights into Ciliary Genes and Evolution from Multi-Level Phylogenetic Profiling.Nevers Y, Prasad MK, Poidevin L, Chennen K, Allot A, Kress A, Ripp R, Thompson JD, Dollfus H, Poch O, Lecompte O.Mol Biol Evol. 2017 Aug 1;34(8):2016-2034. 5. Comparing the Bbs10 complete knockout phenotype with a specific renal epithelial knockout one highlights the link between renal defects and systemic inactivation in mice.Cognard N, Scerbo MJ, Obringer C, Yu X, Costa F, Haser E, Le D, Stoetzel C, Roux MJ, Moulin B, Dollfus H, Marion V.Cilia. 2015 Aug 13;4:10. List of relevant previous projects or activities, connected to the subject of this proposal - RADICO Cohort COBBALT (Cohort for Bardet-Biedl and Alström syndrome); start 2016 first inclusion 2018 for next 7 years - OCUTher project, Call H2020 –MSCA-ITN-2016 Maria SKLODOWSKA-CURIE Action ITN innovative training Educational network in ocular drug delivery and therapeutics (PI: Pr Arto URTi University of Eastern Finland (UEF).Ongoing, until 2020 - Identification of novel genes in ultra rare sensorial diseases, PI, various sources of funding, Hospital calls, Fondation Maladies Rares, Retina France, on going since 2004 - ALSM1, PHRC national, for the study of Alström syndrome patients, PI, ends 2018 - PHRI retinopathies pigmentaires, PI, Panel sequencing for retinal dystrophies, 2016 ends 2018 56-CLB Full legal name (Acronym) – Country Centre Leon Berard (CLB),FRANCE Principal investigator Jean-Yves BLAY Relevant Network ERN EURACAN Description of the legal entity/department/laboratory/group: The legal entity is the Centre Leon Berard, the comprehensive cancer center in Lyon France The Participating department is the Department of Medicine within the Centre Leon Berard Main tasks in the project per Pillar/WP: Pillar 2: In WP10, we will contribute to the definition of the needs of the rare cancer community to the RD analysis and sharing capabilities Pillar 4: EURACAN will participate in Task 19.2: Support in exploitation and follow-up funding 825575 – EJP RD – Part B 159 Previous experience relevant to the Tasks: Associated with document Ref. Ares(2018)6091977 - 28/11/2018 Development of shared facilities in the SIRIC program of the French NCI (INCA). Contribution to the creation of training courses in rare cancers with ESO and ESMO Description of any significant infrastructure and/or major items of technical equipment, relevant to the proposed work : Molecular platformes and bioinformatics, participation to rare cancer networks, national and international level, in house department for education and training courses, links with the University of Lyon. Short Profile of key Staff Members who will be undertaking the work Prof Isabelle Professor of medical oncology, head of the subdomain rare ovarian cancer in the EURACAN Ray-Coquard ERN female Prof Sylvie Professor of pathology, head of the translational pathology department in the CLBN Lantuejoul female Dr Pierre MD, PhD, Head of the platform for molecular characterization of Cancer in the CLB Saintigny Male List of the most relevant publications and/or products, services (including widely-used datasets or software), or other achievements: 11: Casali PG, Le Cesne A, Poveda Velasco A, Kotasek D, Rutkowski P, Hohenberger P, Fumagalli E, Judson IR, Italiano A, Gelderblom H, Adenis A, Hartmann JT, Duffaud F, Goldstein D, Broto JM, Gronchi A, Dei Tos AP, Marréaud S, van der Graaf WT, Zalcberg JR, Litière S, Blay JY. Time to Definitive Failure to the First Tyrosine Kinase Inhibitor in Localized GI Stromal Tumors Treated With Imatinib As an Adjuvant: A European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Intergroup Randomized Trial in Collaboration With the Australasian Gastro-Intestinal Trials Group, UNICANCER, French Sarcoma Group, Italian Sarcoma Group, and Spanish Group for Research on Sarcomas. J Clin Oncol. 2015 Dec 20;33(36):4276-83. doi: 10.1200/JCO.2015.62.4304. Epub 2015 Nov 16. PubMed PMID: 26573069. 2: Gelderblom H, Cropet C, Chevreau C, Boyle R, Tattersall M, Stacchiotti S, Italiano A, Piperno-Neumann S, Le Cesne A, Ferraresi V, Penel N, Duffaud F, Cassier P, Toulmonde M, Casali P, Taieb S, Guillemaut S, Metzger S, Pérol D, Blay JY. Nilotinib in locally advanced pigmented villonodular synovitis: a multicentre, open-label, single-arm, phase 2 trial. Lancet Oncol. 2018 Mar 20. pii: S1470-2045(18)30143-8. doi: 10.1016/S1470-2045(18)30143-8. [Epub ahead of print] PubMed PMID: 29571946. 3: Blay JY, Soibinet P, Penel N, Bompas E, Duffaud F, Stoeckle E, Mir O, Adam J, Chevreau C, Bonvalot S, Rios M, Kerbrat P, Cupissol D, Anract P, Gouin F, Kurtz JE, Lebbe C, Isambert N, Bertucci F, Toumonde M, Thyss A, Piperno-Neumann S, Dubray-Longeras P, Meeus P, Ducimetière F, Giraud A, Coindre JM, Ray-Coquard I, Italiano A, Le Cesne A; NETSARC/RREPS and French Sarcoma Group–Groupe d’Etude des Tumeurs Osseuses (GSF-GETO) networks. Improved survival using specialized multidisciplinary board in sarcoma patients. Ann Oncol. 2017 Nov 1;28(11):2852-2859. doi: 10.1093/annonc/mdx484. PubMed PMID: 29117335; PubMed Central PMCID: PMC5834019. 4: Blay JY, Coindre JM, Ducimetière F, Ray-Coquard I. The value of research collaborations and consortia in rare cancers. Lancet Oncol. 2016 Feb;17(2):e62-e69. doi: 10.1016/S1470-2045(15)00388-5. Review. PubMed PMID: 26868355. 5: Blay JY, Brahmi M, Ray-Coquard I. European Journal of Cancer's Biennial report on soft tissue and visceral sarcomas or the rapid evolution of treatment concepts in sarcomas. Eur J Cancer. 2017 Jan;70:83-86. doi: 10.1016/j.ejca.2016.07.028. 825575 – EJP RD – Part B 160 Epub 2016 Nov 24. Review. PubMed PMID: 27889671. Associated with document Ref. Ares(2018)6091977 - 28/11/2018 List of relevant previous projects or activities, connected to the subject of this proposal: . NETSARC ; INCA; 2009-ongoing, head/PI, national network for sarcoma management in France . LYRIC/LYRICAN ; INCA; 20011-ongoing, head/PI, site of excellencenetwork for translational research development . EUROSARC : FP7; 2011-17, head/PI, Acadelic clinical trials in sarcoma EURACAN ERN ; FEur Commission; 2017-22r-Director, ERN of rare adult cancers AURAGEN: DGOS/INSERM, France Medecine Genomic 2025 platform in Lyon, scientific director 57-UKL-HD Full legal name (Acronym) – Country Universitätsklinikum Heidelberg (UKL-HD) - Germany Principal investigator Prof. Dr. Franz Schaefer Relevant Network ERN ERKNet Heidelberg University is ranked #42 globally, #13 in Europe and #1 in Germany in the field of life science and medicine (World University Rankings 2017). Heidelberg University Center for Paediatrics and Adolescent Medicine has a strong focus on clinical and translational research in rare diseases, in particular hereditary kidney and metabolic disorders. The Pediatric Nephrology division, headed by Prof. Franz Schaefer, has an international reputation in clinical, genetic and experimental research in pediatric kidney diseases. The unit has recently been awarded the status of a European Reference Center for Rare Kidney Diseases. Main tasks in the project per Pillar/WP: Pillar 0: In WP1, we will serve in the Operationg Group. In this function, we will be part of the Operating Group and Central Helpdesk (Subtask 1.1.2), provide coordination and support within and across the pillars (Task 1.2), participate in the writing of the Annual Progress Reports and Annual Work Plans (Subtask 1.2.1), contribute to the development of key performance indicators (Subtask 1.3.1), and help updating the Data Management Plan (Task 1.4). In WP2, we will participate in the mapping of the research and innovation needs of the RD community from the ERN perspective (Task 2.2). Pillar 2: In WP10, we will participate in the annual retreats (task 10.1). In WP11, we will participate in data FAIRification and in PPRL development (task 11.2). In WP12, we will participate in the development of Federation architectures subserving the interoperabilty of ERN patient registries Task 12.1). In WP13, we will help organizing proof of concept studies by identifying and making available suitable data sets from ERN partners (Task 13.2). Pillar 3: In WP16, we will be instrumental in assessing the needs of the ERNs and developing the contents of the academic education course (Tasks 16.1, 16.2). In WP17, we will lead the sub-network “Organs” within the ERN Training Network and will lead Task 17.2 “Development of training programs for the ERN training networks”. Pillar 4: In WP20, we will participate in the Task Force directing the topic selection for demonstrator projects regarding rare disease clinical research methodologies and trial designs (task 20.1) Previous experience relevant to the Tasks: Prof. Schaefer’s unit has ample experience in organizing clinical and translational collaborative research projects. Also we have created several international registries and cohort studies and have performed clinical trials in children with rare diseases and cohort studies, and have carried out multi-level omics studies in rare kidney diseases. Description of any significant infrastructure and/or major items of technical equipment, relevant to the proposed work : The unit is home to the Central Office of the European Rare Kidney Disease Network (ERKNet) and hosts several large rare kidney disease registries (see below) with a team of project managers, IT experts, data managers and 825575 – EJP RD – Part B 161 biostatisticians. The unit runs a fully equipped laboratory for translational, Associated withgenetic documentand Ref. clinical research- with Ares(2018)6091977 a 28/11/2018 central biorepository containing more than 180,000 serum, plasma, urine and DNA aliquots from patients with rare kidney diseases. Short Profile of key Staff Members who will be undertaking the work Dr. Franz Schaefer Professor of Pediatrics and Chief of the Pediatric Nephrology Division at Heidelberg (male) University Hospital. His research interests include the genetic basis of hereditary kidney diseases, the physiopathology and prevention of kidney disease progression, the cardiovascular, metabolic and endocrine consequences of kidney disease in children, and the mangement of end-stage kidney disease by renal replacement therapy. Prof. Schaefer has a special interest in rare disease research. He established the PodoNet Project for Research in Steroid Resistant Nephrotic Syndrome and coordinates the EURenOmics Consortium for High-Throughput Research in Rare Kidney Diseases. He is a member the Scientific Advisory Board of the Global aHUS Registry. Recently he founded and currently coordinates the European Rare Kidney Disease Reference Network (ERKNet). Furthermore, he conducted numerous collaborative clinical trials and established several international research consortia including the European Study Group for Progressive Chronic Kidney Disease in Children (ESCAPE), the International Pediatric Dialysis Network (IPDN), coordinated the European registry for pediatric dialysis and transplantation for six years and is the current chair of the Global IPNA Registry for pediatric renal replacement therapy. Dr. Schaefer has published more than 500 scientific articles and book chapters, is co-editor of the standard textbooks ‘Pediatric Kidney Disease’ and ‘Pediatric Dialysis’ and is Associate Editor of two leading nephrology journals. List of the most relevant publications and/or products, services (including widely-used datasets or software), or other achievements • Chesnaye NC, Schaefer F, Bonthuis M, et al. Mortality risk disparities in children receiving chronic renal replacement therapy for the treatment of end-stage renal disease across Europe. Lancet 2017; 389:2128-2137 • Devuyst O, Knoers NVA, Remuzzi G, Schaefer F. Rare inherited kidney diseases: Challenges, opportunities and perspectives. Lancet 2014; 383:1844-59 • Lemaire M, Frémeaux-Bacchi V, Schaefer F, .... Recessive mutations in DGKE cause atypical hemolytic- uremic syndrome. Nat Genet 2013; 45:531-6. • Lapeyraque AL, Malina M, Fremeaux-Bacchi V, ..., Schaefer F. Eculizumab in severe Shiga-toxin-associated HUS. New Engl J Med 2011; 364: 2561-3. • Wühl E, Trivelli A, Matteucci MC, ..., Schaefer F. Strict blood pressure control and progression of renal failure in children. N Engl J Med 2009; 361: 1639-50. List of relevant previous projects or activities, connected to the subject of this proposal . EURenOmics; EU FP7; 2012-2017; Coordinator . ERK-REG; EU/Chafea; Coordinator; 2018-2020 . RenalTract; Marie-Curie-ETN; 2016-2018; project leader . NeoCyst; BMBF (German Reseach Ministry); 2016-2018; WP leader . PodoNet; eRare; 2009-2011; Coordinator 58-EKUT Full legal name (Acronym) – Country Eberhard Karls Universität Tübingen (EKUT), Germany Principal investigator Holm Graessner Relevant Network ERN-RND, Solve-RD Description of the legal entity/department/laboratory/group: EKUT is the coordinator and leading center of the ERN-RND (European Reference Network on Rare Neurological Diseases). This ERN establishes a large patient-centred network to address the needs of patients with RND of all age groups, with or without a definite diagnosis, by implementing an infrastructure for diagnosis, evidence-based management, treatment and collection of patient data. It represents a large-scale network of expert centres dedicated to rare neurological diseases (RND) and exploits all well-established international rare disease infrastructures such as Orphanet, EURORDIS and RD-Connect. This ERN will provide a rich expertise network and infrastructure resource for EJP-RD. 825575 – EJP RD – Part B 162 Additionally, EKUT is a world-leading cluster of expert institutions focussing Associated on next-generation with document genomics- of Ref. Ares(2018)6091977 rare 28/11/2018 neurological diseases, bringing together the expertise and methodologies from the Centre for Rare Diseases, Clinical Department of Neurodegeneration, the Hertie-Institute for Clinical Brain Research (HIH), the German Center for Neurodegenerative Diseases (DZNE), and the Institute of Medical Genetics and Applied Genomics. This renowned infrastructure provides the resources that allows EKUT to coordinate Solve-RD a H2020 diagnostic RD research project that will interconnect and interlink with EJP-RD. Furthermore, EKUT has been leading many prominent European consortia on rare diseases such as Solve-RD, NeurOmics, MultiSyn, EUROSCA. Main tasks in the project per Pillar/WP: Pillar 2: In WP10, we will provide important contribution to the management of the next-generation data ecosystem strategic plan. In WP13, we will provide important contribution to • Task 13.1: Identification of areas in which a holistic, systemic biology approach is needed to overcome the diagnostic and therapeutic challenges of RD Pillar 3: In WP17, we will lead the WP and provide important contribution throughout. In WP14, we will provide important contribution • Task 14.2: Standards and quality of genetics/genomics data in laboratory and clinical research practice • Task 14.3: Training on strategies to foster solutions of undiagnosed rare disease cases In WP18, we will provide important contribution to the assessment and adaptation of the Pillar 3. Furthermore, ERN-RND will be participating (as applicants) in the calls as issued by Pillars 1,2 and 4. Previous experience relevant to the Tasks: EKUT is coordinator of ERN-RND and Solve-RD, two main networks that will contribute to EJP-RD. Furthermore with regards to training activities and besides the activities being pursued in ERN-RND and Solve- RD as well as the seven EU Initial Training Networks that we have been coordinating in our group over the last years, we have set up the German Academy for Rare Neurological Diseases (www.dasne.de) and the Academy for Further Medical Education for rare diseases (www.fakse.info) Description of any significant infrastructure and/or major items of technical equipment, relevant to the proposed work : 1. Centre for Rare Diseases Tübingen (www.zse-tuebingen.de) 2. Recognised German NGS centre 3. Neurobiobank with biomaterials from >22.000 patients with neurodegenerative diseases, in particular FTD, ataxias, HSP, rare movement disorders 4. Coordinator of the international EOA registry (>350 patients included) and HSP registry (> 1400 patients included) Short Profile of key Staff Members who will be undertaking the work Dr. Holm Graessner PhD, MBA, is coordinator of ERN-RND, managing director of the Rare Disease Centre (male) Tübingen and head of the research management unit of the Institute of Medical Genetics and Applied Genomics at the University Hospital Tübingen. He has profound experience in rare disease research and care. He has been coordinating/been responsible for the project management of collaborative projects such as the FP6, FP7 and H2020 EU projects EUROSCA, MEFOPA, RATstream, SENSE-PARK, TreatPolyQ, MultISyn, NeurOmics and Solve-RD. Dr. Carola Reinhard PhD, is project manager of ERN-RND. She has previously been managing EU FP7 and (female) H2020 projects like Moving-beyond, Keep-Control and TreatPolyQ. List of the most relevant publications and/or products, services (including widely-used datasets or software), or other achievements 1. RD-Connect, NeurOmics and EURenOmics: collaborative European initiative for rare diseases. Lochmüller H, Badowska DM, Thompson R, Knoers NV, Aartsma-Rus A, Gut I, Wood L, Harmuth T, Durudas A, Graessner H, Schaefer F, Riess O; RD-Connect consortium; NeurOmics consortium; EURenOmics consortium. Eur J Hum Genet. 2018 Feb 27. doi: 10.1038/s41431-018-0115-5. [Epub ahead of print] PMID: 29487416 2. European Reference Networks : Consequences for healthcare in Germany. Graessner H, Schäfer F, Scarpa M, Wagner TOF. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2017 May;60(5):537- 541. doi: 10.1007/s00103-017-2533-x. German. 3. Participatory design in Parkinson's research with focus on the symptomatic domains to be measured. Serrano JA, Larsen F, Isaacs T, Matthews H, Duffen J, Riggare S, Capitanio F, Ferreira JJ, Domingos J, Maetzler W, Graessner H; SENSE-PARK Consortium. J Parkinsons Dis. 2015;5(1):187-96. doi: 825575 – EJP RD – Part B 163 10.3233/JPD-140472. PMID: 25588357 Associated with document Ref. Ares(2018)6091977 - 28/11/2018 4. German Academy for Rare Neurological Diseases (www.dasne.de) 5. Academy for Further Medical Education for Rare Diseases (www.fakse.info) List of relevant previous projects or activities, connected to the subject of this proposal . ERN-RND; EU; 2017-2022; coordinator; the European Network of rare neurological diseases is a network of care providers set up to share and enhance the knowledge and resources used for treating rare neurological diseases. . Solve-RD; EU-H2020; 2018-2022; coordinator; Solve-RD will work directly with four ERNs to improve the diagnosis of RD. The main ambitions are to solve large numbers of RD for which a molecular cause is not known yet by combined omics approaches, and to improve diagnostics of RD patients through a “genetic knowledge web”. . NeurOmics; EU-FP7; 2012-2017; coordinator; NeurOmics is a European –omics research project for diagnosis and therapy in rare neuromuscular and neurodegenerative diseases. . EUROSCA; EU-FP6; 2004-2009; coordinator; EUROSCA is a European project on spinocerebellar ataxias. 59-GUF Full legal name (Acronym) – Country Johann Wolfgang Goethe-Universität Frankfurt am Main (GUF) Principal investigator Thomas WAGNER Relevant Network ERN-LUNG Description of the legal entity/department/laboratory/group: Universitätsklinikum Frankfurt (UKF) is the legal entity coordinating ERN-LUNG. Goethe University Frankfurt (GUF) is the Legal entity where all research projects including clinical trials run at UKF are administered. There is a clear legal link between both legal entities. All activities within EJP will be organized by GUF with UKF being a linked third party, coordinated by TOF Wagner. ERN-LUNG is being coordinated by Prof. Dr. TOF Wagner, head of the FRZSE, the clinical Rare Disease Unit of UKF. Professors holding lead positions at the UKF are Professors of GUF. ERN-LUNG is a project of building a clinical care network for all rare diseases of the respiratory system. ERN-LUNG has been evaluated by the European Commission and on 15 December 2016 the European Referece Network Board of Member States approved ERN-LUNG as one of the 23 ERNs for rare diseases. ERN-LUNG is a network of European healthcare providers dedicated to ensuring and promoting excellence in care and research for the benefit of patients affected by rare respiratory diseases. [Other ERN-LUNG teams involved in the project under the coordination of GUF: APHP, PI Prof Humbert – See Beneficiary APHP description] Main tasks in the project per Pillar/WP: Pillar 2: WP11 Task 11.1.1. Define metadata model compatible with existing key databases and resources (Co-Task Leader) – contributing experience with metadata registries and minimum data sets (e.g. ERDRI) WP11 Task 11.2.4. Enhance the catalogue platform to optimise and federate query capabilities, and to automate metadata collection/curation (Task Leader) – contributing experience and work done on federate search and inter- operability WP12 Task 12.2.1. Semantic and syntactic harmonisation of data records (Co-Task Leader) – contributing experience and work done on federate search data and inter-operability Pillar 4: WP19 Task 19.1. Survey to understand the ERN community needs and evaluation of services provided (Sub-Task leader) – In WP 19 we will perform a survey to understand the ERN community needs in terms of educational resources for translational research (to inform the population of our virtual library), and then later to perform an evaluation of the translational and partnering services provided in the WP. Other activities: Several contributions to other Tasks in its role as one of the ERNs, and in close collaboration with JRC, Ispra, Italy (ERDRI). Previous experience relevant to the Tasks: The Frankfurt group, represented by TOF Wagner, Holger Storf, and Gernot Rohde has many years of experience in registry work by running registries and establishing registry software and registry infrastructure. The group has developed the national RD registry platform (OSSE) containing cutting edge open source modules for registry development, registry of registry, meta data repository and pseudonymization. These modules have been used to build the European Rare Disease Registry Infrastructure (ERDRI) which is being built at JRC, Ispra, Italy. All 825575 – EJP RD – Part B 164 structures developed and run respect the highest possible standards of with Associated datadocument safety Ref. andAres(2018)6091977 data ownership- 28/11/2018 and sovereignty. Another module built is the ‘bridgehead’ which allows interoperability of existing registries with the European registry platform. Description of any significant infrastructure and/or major items of technical equipment, relevant to the proposed work : https://www.osse-register.de/de/ Short Profile of key Staff Members who will be undertaking the work Pr. TOF Wagner Head of the Dept. for Rare Diseases of the Universitätsklinikum Frankfurt (UKF), pulmonary (male) medicine, Cystic Fibrosis and Lung transplantation. Coordinator of ERN-LUNG; PI of the ERN-LUNG RD registry data warehouse project Dr. H. Storf Head of the Medical Informatics Group of the Universitätsklinikum Frankfurt (UKF) and (male) project coordinator of OSSE and ERDRI and partner in ERN-LUNG RD registry data warehouse project Pr. G. Rohde Head of the Dept. of Pulmonary Medicine of the Universitätsklinikum Frankfurt. Leads the (male) section on Rare Respiratory diseases of the Universitätsklinikum Frankfurt as well as the Christiane Herzog Zentrum for Cystic Fibrosis in Children, Adolescents and Adults. List of the most relevant publications and/or products, services (including widely-used datasets or software), or other achievements 1: Storf H, Schaaf J, Kadioglu D, Göbel J, Wagner TOF, Ückert F. [Registries for rare diseases : OSSE - An open- source framework for technical implementation]. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2017 May;60(5):523-531. 2: Pauer F, Göbel J, Storf H, Litzkendorf S, Babac A, Frank M, Lührs V, SchauerF, Schmidtke J, Biehl L, Wagner TO, Ückert F, Graf von der Schulenburg JM, Hartz T. Adopting Quality Criteria for Websites Providing Medical Information AboutRare Diseases. Interact J Med Res. 2016 Aug 25;5(3):e24. doi: 10.2196/ijmr.5822. 3: Storf H, Hartz T, Tegtbauer N, Pfeiffer W, Schmidtke J, Graessner H, Wagner T, Uckert F. Vision and challenges of a cartographic representation of expert medical centres for rare diseases. Stud Health Technol Inform. 2014;205:677-81. 4: Hirche TO, Knoop C, Hebestreit H, Shimmin D, Solé A, Elborn JS, Ellemunter H, Aurora P, Hogardt M, Wagner TO; ECORN-CF Study Group. Practical guidelines: lung transplantation in patients with cystic fibrosis. Pulm Med. 2014;2014:621342. 5: Hirche TO, Bradley J, d'Alquen D, De Boeck K, Dembski B, Elborn JS, Gleiber W,Lais C, Malfroot A, Wagner TO; European Centres of Reference Network for Cystic Fibrosis (ECORN-CF) Study Group. Travelling with cystic fibrosis: recommendations for patients and care team members. J Cyst Fibros. 2010 Dec;9(6):385-99. List of relevant previous projects or activities, connected to the subject of this proposal : . ECORN-CF; EC DR SANTE; 2012-2016-TOF Wagner Coordinator, Cross border online Expert advice for RD . ENCE-CF-LAM-LTX; EC DG Research; starting year-ending year-TOF Wagner Coordinator, blueprint for ERNs . ERN-LUNG; EC DG SANTE; 2017-2022-TOF Wagner Coordinator, ERN for rare diseases of the respiratory system . RD REGWAREHOUSE; EC DG SANTE; 2018-2021-TOF Wagner Ccoordinator, three level registry infrastructure for ERN-LUNG 60-HSK Full legal name (Acronym) – Country Helios Dr. Horst Schmidt Kliniken (HSK), Wiesbaden DE Principal investigator MetabERN Relevant Network MetabERN Description of the legal entity/department/laboratory/group: The HELIOS Dr. Horst Schmidt Kliniken in Wiesbaden is a highly qualified multidisciplinary center aimed at the treatment of patients with rare diseases as a maximum care facility involving 22 specialized departments and 4 institutes. The team at the Center for Rare Diseases coordinates a multidisciplinary care aimed to satisfy patients´ need. As Health Care Provider HSK is coordinating the MetabERN, the first European Reference Network for Hereditary Metabolic Diseases connecting 69 Center of excellence in rare diseases, in 18 EU countries and following 43000 RD Patients. The MetabERN is running the U-IMD, project, the first EU funded project to create registry for all metabolic diseasesin Europe Main tasks in the project per Pillar/WP: 825575 – EJP RD – Part B 165 WP 11, task 11.3 to serve the needs for depositing, integrating and storingwith Associated quality controlled document (meta)data produced Ref. Ares(2018)6091977 - 28/11/2018 by the EJP and the overall RD community building on existing resources including registries, in particular HSK will be involved in evaluating strategies to integrate registries from patients in charge of the MetabERN. In WP14 task 14.5, we will participate in course for the FAIRification of rare diseasae registries In WP19, task 19.2 we will participate together with other ERNs to support and guidance to projects approaching the end of EC funding, in particular for the definition and implementation of a development and exploitation plan. In WP 20, task 20.1 we will participate actively to the Task Force on clinical trial to joint discussion to identify the areas of action to improve RD research on clinical trials, design and methodology on evaluation for safety and efficacy of new treatments Previous experience relevant to the Tasks: The team is involved in the management of registries for rare disease since over 15 years, following at clinical level 400 patients affected by rare disease. Furthermore the Team is coordinating the European Reference Network for Metabolic Diseases at European level. Maurizio Scarpa and Christina Lampe are experienced with the running of phase I-III clinical trials for lysosomal diseases. Short Profile of key Staff Members who will be undertaking the work Dr. Maurizio Prof. Dr. Maurizio Scarpa is the Director of the Institute for Rare Diseases at the Scarpa Department of Pediatrics of the Helios Dr. Horst Schmidt Klinik. He is the Coordinator of MetabERN. He will collaborate in the Coordination and the dissemination of the project inside MetabERN. He will participate in all the tasks. Dr. Christina Dr. Christina Lampe, MD is the ViceDirector of the Institute for Rare Diseases at the Lampe Department of Pediatrics of the Helios Dr. Horst Schmidt Klinik. She is actively participating in registries for lysosomal disease, she will participate to task 11.3 and 14.5 Dr. Cinzia Dr. Cinzia Bellettato PhD is the MetabERN Project Manager will coordinate the Bellettato involvement of the MetabERN in the project List of the most relevant publications and/or products, services (including widely-used datasets or software), or other achievements: 1. Inborn Errors of Metabolism Involving Complex Molecules: Lysosomal and Peroxisomal Storage Diseases. Bellettato CM, Hubert L, Scarpa M, Wangler MF. Pediatr Clin North Am. 2018 Apr;65(2):353-373 2. Treatment of brain disease in the mucopolysaccharidoses. Scarpa M, Orchard PJ, Schulz A, Dickson PI, Haskins ME, Escolar ML, Giugliani R. Mol Genet Metab. 2017 Dec;122S:25-34. 3. A Phase 3 Trial of Sebelipase Alfa in Lysosomal Acid Lipase Deficiency. Burton BK, Balwani M, Feillet F, Barić I, Burrow TA, Camarena Grande C, Coker M, Consuelo-Sánchez A, Deegan P, Di Rocco M, Enns GM, Erbe R, Ezgu F, Ficicioglu C, Furuya KN, Kane J, Laukaitis C, Mengel E, Neilan EG, Nightingale S, Peters H, Scarpa M, Schwab KO, Smolka V, Valayannopoulos V, Wood M, Goodman Z, Yang Y, Eckert S, Rojas-Caro S, Quinn AG. N Engl J Med. 2015 Sep 10;373(11):1010-20. 4. Long-term experience with enzyme replacement therapy (ERT) in MPS II patients with a severe phenotype: an international case series. Lampe C, Bosserhoff AK, Burton BK, Giugliani R, de Souza CF, Bittar C, Muschol N, Olson R, Mendelsohn NJ.J Inherit Metab Dis. 2014 Sep;37(5):823-9 5. Enzyme Replacement Therapy in Mucopolysaccharidosis II Patients Under 1 Year of Age. Lampe C, Atherton A, Burton BK, Descartes M, Giugliani R, Horovitz DD, Kyosen SO, Magalhães TS, Martins AM, Mendelsohn NJ, Muenzer J, Smith LD. JIMD Rep. 2014;14:99-113. List of relevant previous projects or activities, connected to the subject of this proposal: MetabERN: DGSANTE contract 769046 starting 2017-running U-IMD: DGSANTE contract 777259 starting 2018-running InnerMEd: DGSANTE contract 20121212, starting 2012- ending 2015 61-IOR Full legal name (Acronym) – Country ISTITUTO ORTOPEDICO RIZZOLI – IRCCS (IOR), Italy Principal investigator Dr. Luca Sangiorgi Relevant Network ERN BOND Description of the legal entity/department/laboratory/group: The Rizzoli Orthopaedic Institute (Bologna) is the main Italian institute for orthopedics and traumatology. Since 1981, the Italian Ministry of Health recognized to Rizzoli Institute the status of a “Scientific Research Hospital” 825575 – EJP RD – Part B 166 due to its close integration between healthcare (about 150,000Associated patients with examined and document Ref.over 20,000 orthopaedic Ares(2018)6091977 - 28/11/2018 operations every year) and scientific research, which is carried out in nine different laboratories employing physicians, biologists, engineers, physicists, statisticians and technicians. High expertise, organization aimed at integration between research and treatment, high quality healthcare and innovative technologies in continuous evolution – are the ingredients for Rizzoli’s success in Italy and worldwide. With reference to its specializations, the following shall be mentioned: treatment of degenerative pathologies of the hip, knee and ankle joints; spine pathologies; pathologies of the foot and upper limbs; sports related pathologies; tumours of the musculoskeletal system; paediatric orthopaedic pathologies; diagnosis and treatment of rare skeletal diseases. Rizzoli also houses the specialization school of Orthopedics and Traumatology and the specialization school of Physical Therapy and Rehabilitation of University of Bologna; indeed, there is a special cooperation agreement between Rizzoli Orthopedic Institute and the University. Furthermore, the Institute participates in the Emilia-Romagna Regional High Technology Network (Tecnopolo) with additional six research laboratories oriented toward translational research; their activities is characterized by strong relations with industrial partners of the area operating in the following fields: regenerative medicine, biomedicine, biomedical device, pharmaceutics, biomechanics and clinical IT. The Department of Medical Genetics and Rare Orthopaedic Diseases directed by Dr. Luca Sangiorgi, is accredited from the Emilia-Romagna region as centre of coordination for the Regional Hub and Spoke Network of Rare Skeletal Diseases. The Department is composed of a) the Molecular Laboratory that performs diagnosis and research on RDs, b) the Medical Genetics Outpatient Clinic, welcoming patients with suspected familiar syndromes and offering counselling and c) the Biobank of Genetic Samples (BIOGEN) created in order to collect high quality biological materials of patients affected by skeletal dysplasias and other rare diseases. The samples collected, more than 6500 different biospecimens, cover many fields of genetic and genomic research applications; in fact, the biobank includes human blood, blood components and derivates, DNA, RNA, urine, serum, tissues. Most of the samples are collected for diagnostic purpose, but patients are asked to use the blood/buccal scraping for research scopes, after reading and signing informed consent agreement. Other samples are collected only for research finality, like tissues, urine and serum. The Department works also in concert with the Clinical Bioinformatics Lab - CLIBI - (always under the direction of Dr. Sangiorgi) and performs activities of research, development and consultancy in the field of Clinical Bioinformatics. Being part of the Regional Network of RareSkeletal Diseases, mentioned above, means that the Dept. and BIOGEN are in a net which involves 11 hospitals/institutions in Emilia- Romagna region. Furthermore, the Rizzoli Institute is the Coordinator of European Reference Network on BONe rare Diseases (ERN BOND) that involves 38 health care providers, from 10 EU countries. The main ambition of the ERN BOND is to implement measures that facilitate multidisciplinary, holistic, continuous, patient-centred and participative care provision to people living with rare bone diseases (RBD), supporting them in the full realisation of their fundamental human rights. In particular, BOND ERN aims to ensure that people living with a RBD are afforded the same standards of care and support as the ones available to other citizens with similar requirements. To meet this goal, BOND ERN gathers European professionals highly specialized in the field of RBD for both scientific research and multidisciplinary care to increase knowledge on RDs, to improve healthcare quality and patient safety, to increase access to ultra specialized medical expertise and accessible information beyond national borders, in accordance with Directive 2011/24/EU. Main tasks in the project per Pillar/WP: Comtribution to the following pillars Pillar 2: Development of ontologies to facilitate implementation of clinical trials and research activity. Pillar 3: Improvement of timely diagnosis and care. Pillar 4: Implementation of a help desk to support implementation of clinical trials. PILLAR 2. In WP10 we will participate in annual retreats and in definition of priorities for Virtual Pltaform and FAIRification. ERN BOND Research Working Group (WG2) is promoting good quality and safe care for those with rare bone diseases, and clinical research in this field. The WG is mapping the ongoing clinical and research activity, to understand where this research activity is complimentary and where there are areas of weakness, in order to facilitate the development of new research programs and collaboration between different partners. PILLAR 3. In WP 14 we will contribute to Task 14.2 Standards and quality of genetics/genomics data in laboratory and clinical research practice. ERN BOND Training and Education Working Group (WG8) is increasing awareness and knowledge about Rare Bone Diseases in order to prevent unacceptable diagnostic delays and their associated burden of potentially disabling complications, and allow timely use of the best available therapeutic options. 825575 – EJP RD – Part B 167 PILLAR 4. Associated with document Ref. Ares(2018)6091977 - 28/11/2018 In WP 20 we will contribute to Task 20.1 Task Force Group and lead the Task 20.3 Demonstration projects on existing statistical methodologies to improve RD clinical trials ERN BOND Clinical Trials Working Group (WG4) is engaging relevant ERN members and relevant professional groups (eg ESPE, ECTS, ICCBH) and regulators (EMA) in order to ensure patient benefit, inclusion and collaboration in clinical trials to liaise with patient groups to identify and prioritise the clinical trials needed in relation to unmet need, To developing a robust process for interaction with industry. Previous experience relevant to the Tasks: The scientific area of interest covers the diagnosis and the genetic and genomic research on hereditary skeletal diseases furthermore we collect also clinical and genetic data of our patients (disease registries), we integrate clinical data and molecular results in a genotype‐phenotype correlation. To date 4 disease registries are active at MGD (Osteogenesis Imperfecta, Multiple Exostoses, Ehlers-Danlos Syndrome & Ollier Maffucci). Description of any significant infrastructure and/or major items of technical equipment, relevant to the proposed work : Facilities: Biobank of Genetic Samples (BIOGEN): The samples collected are more than 6500 different biospecimens, cover many fields of genetic and genomic research applications; in fact, the biobank includes human blood, blood components and derivates, DNA, RNA, urine, serum, tissues. Most of the samples are collected for diagnostic purpose, but patients are asked to use the blood/buccal scraping for research scopes, after reading and signing informed consent agreement. Other samples are collected only for research finality, like tissues, urine and serum. Networks: EATRIS (European infrastructure for translational medicine), BBMRI-ERIC (Biobanking and BioMolecular Resources Research Infrastructure – ERIC), TNGB (Telethon Network of Genetic Biobank). Short Profile of key Staff Members who will be undertaking the work Phd. Luca Sangiorgi Head of the Department of Medical Genetics, Rizzoli Orthopaedic Institute, Bologna, (male) Italy and Head of the Clinical Bioinformatics Lab and Rare Disease. He is also the coordinator of the Rizzoli Rare Disease Centre and responsible of 4 National Registers of Rare Diseases (REM: Multiple Hereditary Exostoses, ROI: Osteogenesis Imperfecta and RED: Ehlers-Danlos Syndrome, ROM: Ollier-Maffucci diseases). He was nominated in December 2014 as Italian representatives to the expert group on the "Committee for Advanced Therapies" of EMA (European Medicines Agency) by the Italian Minister of Health. He is also a Member of the National Coordination Team for Clinical Genetics Department and manages the National and Regional Hub and Spoke Network on Skeletal Dysplasia. Luca Sangiorgi is a Member of HL7 interest group for bioinformatics. Contributor of more than 50 articles published in peer-reviewed journals such as American Journal of Human Genetics, Journal of Clinical Oncology, Human Mutation and International Journal of Cancer, he is an active Member of several international medical associations, serving on the Executive Committee of the CTOS as President. Since 2013 he has been appointed as Italian government representative for the Assembly of the Member States for BBMRI Italy in Europe and he is Member of the National Node Coordination Office and coordinator of the Rare Disease Interest Group. He is also Member of the BBMRI-ERIC Steering Committee and Vice‐Chair of the Financial Committee. Expert Reviewer for the European Union Commission for the Framework Projects 6 (FP6) and Framework Projects 7 (FP7) grants and Horizon 2020, he is the coordinator of a European Project within the ERA‐NET on Translational Cancer Research (TRANSCAN) on the Identification of molecular therapeutic targets and diagnostic/prognostic biomarkers for malignant transformation of osteochondromas. He has been an invited speaker in several national and international conferences and workshops. Dr. Sangiorgi research interests are on clinical and molecular genetics and correlation between genotype and phenotype in musculoskeletal genetic disorders and bone sarcomas. He is also interested in bioinformatics applications that correlate genomic alteration and occurrence of diseases. Phd. Marina Mordenti Senior Research Scientist at MGD & CLIBI Lab (IOR) and she is, at present, Registry (female) Manager of four disease registries of rare skeletal disorder (REM, ROI, RED and ROM) and curator of data management and protection of BIOGEN, the Biobank of Genetic Sample (at MGD, IOR). Her main domains of interest include the design of biomedical platforms for disease registries, for genotype-phenotype correlation, for sample management, imaging as well as software for quality and risk management procedures. She acquired good knowledge of international standards in the biomedical field and 825575 – EJP RD – Part B 168 databases on-line related to the world Associated of scientific researchRef. with document and a good command Ares(2018)6091977 of - 28/11/2018 quality control processes and risk management and good preparation on the protection of privacy and security. She has been involving in several European projects, such as ADOPT-BBMRI and CORBEL and she is author of peer-reviewed articles. List of the most relevant publications and/or products, services (including widely-used datasets or software), or other achievements - Bonafe L, Cormier-Daire V, Hall C, Lachman R, Mortier G, Mundlos S, Nishimura G, Sangiorgi L, Savarirayan R, Sillence D, Spranger J, Superti-Furga A, Warman M, Unger S Nosology and classification of genetic skeletal disorders: 2015 revision American Journal of Medical Genetics, Part A (167), 2869- 2892 (2015) 10.1002/ajmg.a.37365 - Baldo C, Casareto L, Renieri A, Merla G, Garavaglia B, Goldwurm S, Pegoraro E, Moggio M, Mora M, Politano L, Sangiorgi L, Mazzotti R, Viotti V, Meloni I, Pellico MT, Barzaghi C, Wang C, Monaco L, Filocamo M. The alliance between genetic biobanks and patient organisations: the experience of the telethon network of genetic biobanks. Orphanet J Rare Dis (11(1)), 142 (2016) - Mordenti M, Ferrari E, Pedrini E, Fabbri N, Campanacci L, Muselli M, Sangiorgi L. Validation of a new multiple osteochondromas classification through Switching Neural Networks Am J Med Genet A. (161A(3)), 556-60 (2013) - Gentile FV, Zuntini M, Parra A, Battistelli L, Pandolfi M, Pals G, Sangiorgi L. Validation of a quantitative PCR-high-resolution melting protocol for simultaneous screening of COL1A1 and COL1A2 point mutations and large rearrangements: application for diagnosis of osteogenesis imperfecta. Hum Mutat. (33(12)), 1697-707 (2012) - D'Eufemia P, Palombaro M, Lodato V, Zambrano A, Celli M, Persiani P, De Bari MP, Sangiorgi L. Child abuse and osteogenesis imperfecta: how can they be still misdiagnosed? A case report. Clin Cases Miner Bone Metab. (9(3)), 195-7 (2012) List of relevant previous projects or activities, connected to the subject of this proposal : 1. “Ma.Tr.OC - Identification of molecular therapeutic targets and diagnostic/prognostic biormarkers for malignant transformation of osteochondromas” - ERA-Net Transcan-2 JCT 2012 – Italian Ministry of Health – Coordinator – 2014-2018 2. “ADOPT BBMRI-ERIC: implementAtion anD OPeration of the gateway for healTh into BBMRI-ERIC" - Grant agreement n. 676550 - Horizon 2020- European Commission - beneficiary, WP Leader – 2015-2018; 3. "CORBEL: Coordinated Research Infrastructures Building Enduring Life-science services”– Grant Agreement n.654248 – Horizon 2020 – European Commission - Linked third party – 2015-2019; 4. ERN BOND: European Reference Network on BONe rare Diseases – Framework Partnership Agreement n. 739539 - 3rd Health Programme – European Commission – Coordinator – 2017-2022; 5. “MCDS-Therapy - Repurposing of carbamazepine for treatment of skeletal dysplasia” - Grant Agreement n.754825 – Horizon 2020 – European Commission – beneficiary – 2018-2022. 62-AOUP Full legal name (Acronym) – Country Azienda Ospedaliero Universitaria Pisana (AOUP), Italy Principal investigator Prof. Marta Mosca Relevant Network ERN ReCONNET Description of the legal entity/department/laboratory/group: The Rheumatology Unit is part of the University Department of Clinical and Experimental Medicine of University of Pisa (Italy); patients care, clinical research and education are the three main objectives of the Unit. The Unit is the coordinating Clinical Centre of the ERN-RECONNET, the European Reference Network on Rare Connective Tissue and Musculoskeletal Diseases approved by the European Commission in 15th December 2016. The clinical activity of the Unit is focused on inflammatory rheumatic diseases and it is the Tuscany referral center for systemic autoimmune diseases including SLE, undifferentiated connective tissue disease, antiphospholipid syndrome, Systemic Vasculitides, Inflammatory myopathies and Systemic Sclerosis. The clinical activity of the Unit is structured in three levels of patient care: outpatients visits, day-hospital for daily drug infusions and inpatients ward. The outpatients clinic provides 16 daily visits for first rheumatologic assessment and disease-specific second-level clinics for SLE (Lupus clinic), Systemic sclerosis (Scleroderma clinic), Sjogren’s Syndrome (Sjogren Clinic), rheumatoid arthritis, Inflammatory myopathies, systemic vasculitis and fibromyalgia. All these dedicated clinics share common characteristics including the multidisciplinary approach to the patients as several health professionals other than rheumatologists are involved in the clinics: nurses, physical therapists, obstetrics and gynaecologists, nephrologists, ophthalmologists, psychiatrist, cardiologists and orthopaedics. Moreover, all these clinics are characterized by a strong effort toward quality of 825575 – EJP RD – Part B 169 care and a patient-centered approach. Overall, 400 SLE, 350 UCTD, 350 SSc, Associated 600 SS,Ref. with document 200 SAPL, 2000 RA, Ares(2018)6091977 250 - 28/11/2018 vasculitis and 650 fibromyalgia patients are regularly followed at the dedicated clinics of the Rheumatology Unit. The research activity of the Unit is focused on epidemiological studies and prognostic factors of systemic autoimmune diseases; quality of care, imaging studies, outcomes measures are other topics of the research activity of the Rheumatology Unit. The research activity is documented in more than 500 published scientific articles over 40 years of activity, several participations to national and international congresses and a worldwide esteem of the research activity. The Rheumatology Unit takes part and leads of several collaborative research studies with Italian and European centers. The educational mission of the Rheumatology Unit is achieved by several initiatives addresses to medical students, internal and external rheumatologists in training, rheumatologists, nurses, general practitioners. Among these initiatives, a particular mention goes to the bi-annual EULAR scientifically endorsed course on SLE successfully arrived at its VIII edition and entirely organized by Prof. Marta Mosca and her staff. The Course is aimed at 70 young rheumatologists (aged less than 40 years of age) coming from all over the world; the course is aimed at providing a comprehensive and intensive training on various aspects of systemic lupus erythematosus (SLE). Main tasks in the project per Pillar/WP: Pillar 2: In WP10, we will contribute in 5x pan-RD-community, 3-day strategy meetings (annual retreat)(task 10.1.1), and in carrying out survey and structured interview approaches on technical and scientific matters, to monitor progress and inform strategic decisions - incl. Definition of indicators (task 10.2.2) Pillar 3: In WP17, we will contribute in the assessment of the needs and development of training activities for ERNs as members of Group 2 Neoplasm and Malformation”. Previous experience relevant to the Tasks: Recently Prof. Marta Mosca has coordinated the development of “EULAR Recommendations for monitoring SLE patients in clinical practice and observational studies”, of quality measures in SLE and of a core set of measures to be used in clinical practice to standardize patients care. In addition, she is part of the Steering Committee for the development of the "Treat to Target Recommendations in SLE" and for the definition of Remission in SLE. She is also participating to a SLICC/ACR project aiming at defining flares in SLE. She is coordinating and has coordinated entire projects and/or Research Units on SLE and other Musculoskeletal Disorders at a national and international level. Since 2011, she is part of the medical panel of the European Lupus Patients Association LUPUS EUROPE. Since 2013, she is member of the Ethical Committee of the district area of Western Tuscany (including the Pisa University Hospital and other 15 hospitals). Description of any significant infrastructure and/or major items of technical equipment, relevant to the proposed work : The Rheumatology Unit (the day hospital section) includes 12 seats and 2 beds for daily intravenous drug-infusion; two rheumatologists and three nurses are assigned to this section of the Unit. The inpatients ward consists of 18 beds addressed to severely ill patients with rheumatology conditions; two experienced rheumatologists and four rheumatologists in training are assigned to the inpatients care with two daily nurses and a team of 12 shift worker nurses. Short Profile of key Staff Members who will be undertaking the work Pr. Marta Mosca Associate Professor of Rheumatology at the Department of Clinical and Experimental (female) Medicine of the University of Pisa, Italy and chief of the Rheumatology Unit of the Azienda Ospedaliero Universitaria Pisana. She graduated from the Medical School of the University of Pisa in 1992 and in the same year she has started her fellowship in Rheumatology. In 1999 she has obtained a PhD in Immunology of Organ Transplantation. Her research interests are represented by connective tissue diseases, with special interest in systemic lupus erythematosus (SLE) and undifferentiated connective tissue diseases (UCTD), with particular interest to clinimetrics. She is the Network Coordinator of ERN-RECONNET, the European Reference Network on Rare Connective Tissue and Musculoskeletal Diseases approved by the European Commission in 15th December 2016. Her clinical activity includes the follow up of patients with connective tissue diseases followed at the Rheumatology Unit, where she runs the Lupus Clinic and the Pregnancy Clinic.Prof. Marta Mosca has co-authored 176 papers published in peer reviewed journals (at March 16th, 2018), with an H index of 40 (SCOPUS, March 16th, 2018), and 6684 citations. Dr. Rosaria Talarico Rosaria Talarico, MD, PhD. Rheumatologist at the Rheumatology Unit of AOUP (Since (female) March 2017). Employed under independent contract in the INFORMaR project, University 825575 – EJP RD – Part B 170 of Pisa, Italy. (from October 2013 to March2017) Associatedand from September with document 2011 to September Ref. Ares(2018)6091977 - 28/11/2018 2013 she was employed under independent contract in the Rheumatology Division, University of Pisa, Italy, within the Rare Diseases Regional Project. Member of the Coordinating Centre for Rare Diseases at the “Azienda Ospedaliera Universitaria Pisana (AOUP)”, University of Pisa, Italy, as epidemiological expert. Experience in research. 2007-2009: Participation as Fellow for the research of the literature for the EULAR project “Development of recommendations for monitoring systemic lupus erythematosus (SLE) patients in clinical practice and in observational studies”. 2012: Participation as Fellow for the research of the literature for the project “Systematic review of 2008-2012 literature and update of recommendations for the use of methotrexate in rheumatic diseases, with a focus on rheumatoid arthritis”; 2012-ongoing: Participation as Methodological coordinator for the research of the literature for the FIRMA project “Development of recommendations for the clinical application of autoantibodies determination in systemic autoimmune diseases”. Rosaria Talarico has co-authored 150 papers published in peer reviewed journals (at March 21th, 2018), with an H index of 18 (SCOPUS, March 21th, 2018), and 943 citations. Dr. Chiara Baldini MD, PhD. Associated Professor in Rheumatology (MED/16), Rheumatology Unit, (female) University of Pisa, Italy. Her clinical research activity and interests are in the field of clinical Research on connective tissue diseases and vasculitis. Lab Research identification and validation of novel non-invasive diagnostic, prognostic and therapeutic proteomic biomarkers for primary Sjogren’s syndrome and other systemic autoimmune disorders which might eventually improve the diagnostic processes and the assessment of patients affected by systemic autoimmune disorders. Principal investigator and co-investigator in several phase III and IV clinical trials carried out in systemic autoimmune disorders; has co- authored 150 papers published in peer reviewed journals (at March 21th, 2018), with an H index of 26 (SCOPUS, March 21th, 2018), and 1541 citations. List of the most relevant publications and/or products, services (including widely-used datasets or software), or other achievements 1. Tani C, Vagelli R, Stagnaro C, Carli L, Mosca M. Remission and low disease activity in systemic lupus erythematosus: an achievable goal even with fewer steroids? Real-life data from a monocentric cohort. Lupus Sci Med. 2018 Feb 27;5(1):e000234. 2. van Vollenhoven R, Voskuyl A, Bertsias G, Aranow C, Aringer M, Arnaud L, Askanase A, Balážová P, Bonfa E, Bootsma H, Boumpas D, Bruce I, Cervera R, Clarke A, Coney C, Costedoat-Chalumeau N, Czirják L, Derksen R, Doria A, Dörner T, Fischer-Betz R, Fritsch-Stork R, Gordon C, Graninger W, Györi N, Houssiau F, Isenberg D, Jacobsen S, Jayne D, Kuhn A, Le Guern V, Lerstrøm K, Levy R, Machado-Ribeiro F, Mariette X, Missaykeh J, Morand E, Mosca M, Inanc M, Navarra S, Neumann I, Olesinska M, Petri M, Rahman A, Rekvig OP, Rovensky J, Shoenfeld Y, Smolen J, Tincani A, Urowitz M, van Leeuw B, Vasconcelos C, Voss A, Werth VP, Zakharova H, Zoma A, Schneider M, Ward M. A framework for remission in SLE: consensus findings from a large international task force on definitions of remission in SLE (DORIS). Ann Rheum Dis. 2017 Mar;76(3):554-561. 3. Barsotti S, Zampa V, Talarico R, Minichilli F, Ortori S, Iacopetti V, D'ascanio A, Tavoni AG, Bombardieri S, Mosca M, Neri R. Thigh magnetic resonance imaging for the evaluation of disease activity in patients with idiopathic inflammatory myopathies followed in a single center. Muscle Nerve. 2016 Oct;54(4):666-72. 4. Luciano N, Baldini C, Tarantini G, Ferro F, Sernissi F, Varanini V, Donati V, Martini D, Mosca M, Caramella D, Bombardieri S. Ultrasonography of major salivary glands: a highly specific tool for distinguishing primary Sjögren's syndrome from undifferentiated connective tissue diseases. Rheumatology (Oxford). 2015 Dec;54(12):2198-204. 5. Ruffatti A, Salvan E, Del Ross T, Gerosa M, Andreoli L, Maina A, Alijotas-Reig J, De Carolis S, Mekinian A, Bertero MT, Canti V, Brucato A, Bremme K, Ramoni V, Mosca M, Di Poi E, Caramaschi P, Galeazzi M, Tincani A, Trespidi L. Treatment strategies and pregnancy outcomes in antiphospholipid syndrome patients with thrombosis and triple antiphospholipid positivity. A European multicentre retrospective study. Thromb Haemost. 2014 Oct;112(4):727-35. doi: 10.1160/TH14-03-0191. Epub 2014 Jul 10. List of relevant previous projects or activities, connected to the subject of this proposal : ERN RECONNET; Funder: European Commission (CHAFEA); 2017-2021; PI-Network Coordinator. 825575 – EJP RD – Part B 171 63-AOUS Associated with document Ref. Ares(2018)6091977 - 28/11/2018 Full legal name (Acronym) – Country Azienda Ospedaliera Universitaria Senene (AOUS), Siena, Italy Principal investigator Alessandra Renieri Relevant Network ITHACA Description of the legal entity/department/laboratory/group: The mission of AOUS is to provide clinical care, training and research. AOUS delivers inpatients and outpatient specialist services, emergency and urgency services and pursues the development of high medical specialization. The Hospital operates within the Regional Health Service that guarantees to all users treatment and rehabilitation in accordance with the principles of equality, fairness and compassionate care, free of charge or with a contribution according to the National Health Service regulations. The main objective of AOUS is to achieve a high level of response to the health demand, meant as recovery and preservation of physical, mental and social health. Medical Genetics Unit provides genetic counselling, genetic tests, information and support to people who have, or may be at risk for, genetic disorders and, in particular, for pediatric and adult patients with intellectual disability and their families. During a consultation, a medical geneticist meets with an individual or family to discuss genetic risks or to diagnose, confirm, or rule out a genetic condition and to evaluate the possibility to perform a prenatal diagnosis. The AOUS offers molecular tests for a large number of genetic conditions characterized by intellectual disability: Rett, Coffin Siris, Nicolaides Baraitser, Cohen, Angelman, Prader Willi, and Lesch Nyhan Syndromes and others. Furthermore, it provides array-CGH analysis for Rare Chromosomal Disorders. All patients with other rare intellectual disability syndromes and rare undiagnosed malformation syndromes hospitalized are evaluated by several healthcare professionals, namely Geneticists, Child Neuropsychiatrists, Neuroradiologists, Neurophysiopatologist, Cardiologists, Odontologists, Gastroenterologists, Physical Therapists and Pediatricians in order to obtain a complete examination, to ameliorate health conditions and to obtain a defined diagnosis. Weekly multidisciplinary discussions regarding specific cases are in place. The majority of these diseases do not have a specific cure. However, providing specific diagnosis may help in patient daily care and rehabilitation therapy including physiotherapy and speech therapy. Whenever the syndrome includes epileptic involvement, treatment with specific antiepileptic drugs (even multidrug teraphy) in both pediatric and adult patients is administered. The clinical service is complemented by a wide range of research activities, which include genetic and experimental research in a dedicated laboratory as well as the coordination of national and international clinical research consortia. Medical Genetics Unit is certified through a National Assessment Program concerning specifically the ISO 9001:2008 certification released by ACCREDIA. Site visits are annually planned. It certifies that the Management System of the Unit has been audited and found to be in accordance with the requirements of the management system standard. Supplies services are Clinical Genetics, Genetics Biobank, Scientific research in Medical Genetics and Laboratory of Medical Genetics including Molecular Genetics, Cytogenetics, Forensic Genetics and Preimplantation Genetic Diagnosis. Furthermore, every year the Italian Society of Human Genetics (SIGU) certifies that the above organisation has been audited and found to be in accordance with SIGU. Main tasks in the project per Pillar/WP: Pillar 2: In WP11, we will contribute to facilitate data generated from RD research to be deposited in existing repositories by improving their capacity, interoperability, privacy protection and security compliance through the development of a specific informatic tool, named “IVANA/FastPG”. The searching algorithm, based on a machine-learning approach, will combine data from several sources (i.e. bibliometric databases, and specialized biological databanks) using data-mining techniques. Pillar 3: In WP16, we will contribute in Online Academic education course. A streamlined education programme could be made available to all stakeholders via an established e-learning service provider. The e-learning modules will be created or adapted with the help of interested universities. Since Education is also part of the future activities to be developed by the European Rare Disease Networks (ERNs), the EJP on RD will provide support, complimentary access to the e-learning platform, and visibility to the research training activities and educational material developed by the ERNs. The EJP will also develop its own educational material which should be complementary to the ERN resources rather than overlapping. Specifically, we will contribute to assess the needs, target audience, main topics of the academic education course (task 3.1 - VUH SK). This task will be performed through a thorough benchmark of existing RD academic courses at EU level and through survey and audits of potential target audiences and experts involved in those courses (not restricted to students) and the main topics to address, the most relevant lecturers. The e-learning programme will be based on already existing initiatives such as the French inter- university diploma. The contribution will be also related to task 3.2 (CHU DIJON) in developing the online course. E-learning approaches could combine different components: e-learning content, e-tutoring, collaborative learning, virtual classroom. Activities can be synchronous or asynchronous. One key component to be addressed in this task will be 825575 – EJP RD – Part B 172 the status of this academic course (free-access or based on tuition Associated fees fromwith each partnered document organisation; European Ref. Ares(2018)6091977 - 28/11/2018 Credit Transfer System eligibility (ECTS); the most relevant length of the course; etc.). The identification of an established e-learning service platform will be also performed (on going discussions with FutureLearn). The platform will develop and implement the e-learning scholar content received from lecturers. Pillar 4: In WP20, we intend to contribute to Task 20.2 Support in design and planning of RD clinical studies . We will also contribute to Task 20.4 Projects on innovative methodologies to improve RD clinical trials in limited populations Previous experience relevant to the Tasks: Universities of beneficiary and LTP have developed specific academic courses for RD. There is a great need to share this knowledge and make it available to the broader public including students, medical doctors, healthcare providers or patients at the European level. The beneficiary directs the Genetic Biobank of Siena (GBS, http://www.biobank.unisi.it), one of the few in Italy certified SIGU-CERT and ISO9001, and funded by Telethon since 2002. GBS is the Italian Partner of BBMRI (Biobanking and Biomolecular Resources Research Infrastructure), member of EuroBioBank and RD-Connect. Since 2009, she coordinates the international Rett database network (http://www.rettdatabasenetwork.org). The Medical Genetics of AOUS also coordinates the Italian Registry of Alport disease, an Italian network for Alport disease. The beneficiary is leading for ERN ITHACA the Registry Work Package. The beneficiary already experienced preclinical trials on gene therapy within four different genetic diseases. Thus, we can contribute to develop a system devoted to assess if a disease can be treated more or less effectively with gene therapy. Description of any significant infrastructure and/or major items of technical equipment, relevant to the proposed work : Beneficiary and LTP are equipped with the all major equipment relevant to the proposed work. Short Profile of key Staff Members who will be undertaking the work Pr.Francesca Mari Prof. Mari F. is currently Associate Professor of Medical Genetics at University of Siena (female) and Medical Geneticist of AOUS. She contributed to the development of the genetic counselling activity in the Medical Genetics Unit in Siena performing and supervising thousands of genetic counselling clinics. Her main research interests are focused on understanding the genetic bases of rare disorders mainly Intellectual disability, including Rett syndrome, Alport syndrome, and rare cancers. Dr.Simone Furini Dr. Furini S. is currently a Researcher / Assistant Professor at the Department of Medical (male) Biotechnologies of the University of Siena. His main area of expertise is Systems Biology, with a particular interest on how deterministic and stochastic models can be used to predict the outcome of gene networks. Dr.Elisa Frullanti Dr. Frullanti E. is currently a Researcher / Assistant Professor of Medical Genetics at (female) University of Siena. Her main research interests were aimed to dissect the molecular and genetic bases of lung cancer in never smoker young patients as well as genetic bases of rare disorders following an innovative “omics” approach that will integrate genomic (Whole- Exome/Genome Sequencing) and transcriptomic (RNA sequencing) data. List of the most relevant publications and/or products, services (including widely-used datasets or software), or other achievements 1. Ivanovski I, Djuric O, Caraffi SG, Santodirocco D, Pollazzon M, Rosato S, Cordelli DM, Abdalla E, Accorsi P, Adam MP, Ajmone PF, Badura-Stronka M, Baldo C, Baldi M, Bayat A, Bigoni S, Bonvicini F, Breckpot J, Callewaert B, Cocchi G, Cuturilo G, De Brasi D, Devriendt K, Dinulos MB, Hjortshøj TD, Epifanio R, Faravelli F, Fiumara A, Formisano D, Giordano L, Grasso M, Grønborg S, Iodice A, Iughetti L, Kuburovic V, Kutkowska- Kazmierczak A, Lacombe D, Lo Rizzo C, Luchetti A, Malbora B, Mammi I, Mari F, Montorsi G, Moutton S, Møller RS, Muschke P, Nielsen JEK, Obersztyn E, Pantaleoni C, Pellicciari A, Pisanti MA, Prpic I, Poch-Olive ML, Raviglione F, Renieri A, Ricci E, Rivieri F, Santen GW, Savasta S, Scarano G, Schanze I, Selicorni A, Silengo M, Smigiel R, Spaccini L, Sorge G, Szczaluba K, Tarani L, Tone LG, Toutain A, Trimouille A, Valera ET, Vergano SS, Zanotta N, Zenker M, Conidi A, Zollino M, Rauch A, Zweier C, Garavelli L. Phenotype and genotype of 87 patients with Mowat-Wilson syndrome and recommendations for care. Genet Med. 2018 Jan 4. doi: 10.1038/gim.2017.221. 2. Mari F, Marozza A, Mencarelli MA, Lo Rizzo C, Fallerini C, Dosa L, Di Marco C, Carignani G, Baldassarri M, Cianci P, Vivarelli R, Vascotto M, Grosso S, Rubegni P, Caffarelli C, Pretegiani E, Fimiani M, Garavelli L, Cristofoli F, Vermeesch JR, Nuti R, Dotti MT, Balestri P, Hayek J, Selicorni A, Renieri A. Coffin-Siris and Nicolaides-Baraitser syndromes are a common well recognizable cause of intellectual disability. Brain Dev. 2014 Sep 20. pii: S0387-7604(14)00212-5. 825575 – EJP RD – Part B 173 3. Grillo E, Villard L, Clarke A, Ben Zeev B, Pineda M, Bahi-Buisson N, Hryniewiecka-Jaworska Associated A, Bienvenu with document Ref. Ares(2018)6091977 T, - 28/11/2018 Armstrong J, Martinez AR, Mari F, Veneselli E, Russo S, Vignoli A, Pini G, Djuric M, Bisgaard AM, Mejaški Bošnjak V, PolgárN, Cogliati F, Ravn K, Pintaudi M, Melegh B, Craiu D, Djukic A, Renieri A. Rett networked database: an integrated clinical and genetic network of Rett syndromedatabases. Hum Mutat. 2012 Jul;33(7):1031- 6. 4. Ariani F, Hayek G, Rondinella D, Artuso R, Mencarelli MA, Spanhol-Rosseto A, Pollazzon M, Buoni S, Spiga O, Ricciardi S, Meloni I, Longo I, Mari F, Broccoli V, Zappella M, Renieri A. FOXG1 is responsible for the congenital variant of Rett syndrome. Am J Hum Genet. 2008 Jul;83(1):89-93. 5. Renieri A, Mari F, Mencarelli MA, Scala E, Ariani F, Longo I, Meloni I, Cevenini G, Pini G, Hayek G, Zappella M. Diagnostic criteria for the Zappella variant of Rett syndrome (the preserved speech variant). Brain Dev. 2009 Mar;31(3):208-16. List of relevant previous projects or activities, connected to the subject of this proposal . “FoxG1 gene therapy using CRISPR/Cas9 technology and AAV9 iPSCs-derived neurons”; Blackswan Foundation; 2017-2018 - PI: Renieri A. Building on the possibility of obtained and characterized iPSCs from skin biopsy of Rett patients, we propose a combination of CRiSPR/Cas9 technology with AAV9 system to delete the FOXG1 mutated gene and replace it with the “healthy”/wild type gene in FOXG1 mutated iPSCs. We plan to apply this strategy on an ex-vivo model, to prove efficacy and safety of the method. . “Development of an innovative strategy of personalized medicine for the diagnosis and therapy of kidney diseases in children”; Tuscany Region; 2016-2018 - PI: Renieri A. We propose an innovative diagnostic strategy, potentially extending to all pediatric nephropathies, for the diagnosis and therapy of kidney diseases in children. . “Telethon Network of Genetic Biobanks”; Telethon; 2013-2017 – Unit PI: Renieri A. The goal is to realize the first national, standardized biospecimen/genetic data Resource, creating a nationally coordinated network of pathological biospecimens and related data collection as well as normal controls, and developing a centralized bioinformatics system of rare diseases for improving links between the existing Telethon biobanks as well as for facilitating Network presentation world−wide and external access to the collections. 64-LUMC Full legal name (Acronym) – Country Academisch Ziekenhuis Leiden, also acting under the name Leiden University Medical Centre (LUMC), The Netherlands, (Team A): Human Genetics department / Biosemantics group Principal investigator Dr. Marco Roos, team A Relevant Network Description of the legal entity/department/laboratory/group: The LUMC is a university medical centre for research, education and patient care with a high-quality profile and a strong scientific orientation and ranks as the 6th best medical research institute in Europe (Shanghai 2015/2014). It has a unique research practice, ranging from pure fundamental medical research to applied clinical research. This enables LUMC to offer patient care and education that is in line with the latest international insights and standards – and helps it to improve medicine and healthcare both internally and externally. The LUMC participates in the League of European Research Universities (LERU), a strong international network of 21 renowned research universities based in 10 European countries (www.leru.org). LUMC’s well-structured and productive research and training environment annually produces ~115 PhD theses and ~1750 scientific publications. Each year, LUMC welcomes many visiting scientists and foreign MSc/PhD students, who will also be enrolled in the LUMC Graduate School (now > 900 PhD-students). Currently, LUMC is active in 54 granted Horizon2020 projects (17 as coordinator). Thus, LUMC has ample experience with the legal and financial implementation of these projects. Website: https://www.lumc.nl/research/. The department of Human Genetics (team A) is a broadly oriented research department with focus on the (epi)genomic contribution to inherited and acquired diseases. HG has research focus on genome technology, functional genomics, novel diagnostics, model systems and bioinformatics of human diseases. The department provided leadership for the human genome project, BBMRI, and Orphanet-NL (professor emeritus dr. GJB van Ommen, Dr. Petra van Overveld) to which it contributed information for the Netherlands. The BioSemantics group (PIs Dr. M. Roos, Prof. Dr. B. Mons) focuses on the development and application of the FAIR data principles for translational research, particularly in the domain of rare diseases, and the automated discovery of new biological knowledge from FAIR data. Main tasks in the project per Pillar/WP: Team A 825575 – EJP RD – Part B 174 Pillar 0: Associated with document Ref. Ares(2018)6091977 - 28/11/2018 In WP1, we will contribute to data management planning of the EJP RD (task 1.4) as per our responsibility as co- lead of WP12 in Pillar 2. For WP3, we will contribute to the communication between WP10 Task 1.5 (sustainability and scaling up of the VP) and WP3. Pillar 2 In WP10, we will contribute to: - Coordination of Pillar 2 Work Packages and aligning to RD community needs (task 10.1) - Convening yearly retreats leading to Pillar 2 annual strategic plans (task 10.2) - Coordination of technical GDPR implementation (task 10.3) - Quality oversight (task 10.4) - Developing sustainable models (task 10.5) In WP11, we will contribute to the following tasks: - Metadata and ontological model definition for cataloguing resources for RD research (task 11.1) - FAIR-compliant platform for discovery of RD resources (task 11.2) - Provision of analysis and data sharing capabilities to the RD community through online resources (task 11.4) In WP12, we will contribute to: - Comparing and aligning core interoperability standards with respect to WP12 [in conjunction with other standards bodies, & spanning RD patient data, biobanks, registries] (task 12.1) - Multi-site teams for software and tool development with respect to WP3 (task 12.2) - leading practical FAIRification support (task 12.3) LUMC, team A, co-leads WP3. In WP13 we will contribute to: - Filling a number of pre-identified gaps to allow integrative systems biology approaches for rare diseases (task 13.1) - Organising proof of principle studies (task 13.2) Pillar 3 In WP14, we will contribute to training on rare disease registries and FAIRification of data at the source (task 14.5) In WP15, we will contribute to the ExPRESS Expert Patients and Researchers EURORDIS Summer School (task 2.1) Previous experience relevant to the Tasks: LUMC team A will contribute significantly to the implementation and exploitation of FAIR data principles as core elements of the Virtual Platform for the RD community via protocols, tools, training, and practical FAIRification support. LUMC team A is one of the founders of the FAIR data principles and has extensive experience with developing and applying technologies related to FAIR. It organised the meeting where the principles were first conceived (Lorentz workshop, Leiden, 2014). It has a track record in activating communities towards better data and knowledge management (PMID:18507872; PMID:21445068). It previously developed the nanopublication model as a means to share research findings in a machine-readable format (PMID:26464783; nanopub.org), and contributed to the development of the research object model to improve reproducibility of analysis (PMID: 25276335; researchobject.org). In recent years LUMC team A software engineers formed the core of the DTL-P led FAIR engineering team that developed FAIRification protocols and a suite of FAIR data tools to create, publish, index and annotate FAIR data sources (https://github.com/DTL-FAIRData). LUMC team A was one of the initiators of OpenPHACTS, an IMI project that served as a milestone project on enabling queries over distributed linkable data. Over the past 2 years, the Biosemantics group has (co)organized 10+ Bring Your Own Data workshops: a combination of hackathon and training event to introduce techniques for making data linkable and FAIR at the source. BYODs and hackathons in the rare disease domain, co-organised between DTL-P, ISS and LUMC, have contributed significantly to the FAIR guiding principles (PMID:26978244). LUMC team A successfully submitted the application for these guidelines as an IRDiRC recognized resource with several RD community representatives also involved with this EJP proposal. Together with UMCG, LUMC team A is leading the so-called ‘Rare Disease Data Linkage Plan’ that provides a starting point for WP3 in Pillar 2, and some tasks in WP2 and WP4. The plan helps stakeholders make a rare disease registry or biobank FAIR ‘at the source’ by temporarily providing FAIR data stewardship expertise to a group that manages RD data and would like to make those more FAIR. The plan has been supported by RD-Connect, ELIXIR, ELIXIR-EXCELERATE, BBMRI-NL, and stakeholders (currently it is running pilots with VASCERN, BOND-ERN, and DMD resources). LUMC team A has a leading role in European-wide efforts to harmonize data and establish FAIR-compliant infrastructure, particularly for rare diseases. PI Mons was co-lead of the interoperability platform in ELIXIR, was chair of the high-level expert group for developing the European Open Science Cloud, and is leading the organisation that 825575 – EJP RD – Part B 175 supports starting Global Open FAIR implementation networks. Associated PI Rooswith is document co-leading Ref. the Rare Disease- 28/11/2018 Ares(2018)6091977 Work package within ELIXIR-EXCELERATE. Together with leaders from the RD-Connect community, such as V. Bros-Facer from EURORDIS, A. Rath from Orphanet, Y. Rubinstein from NIH, PI Roos initiated the creation of a rare disease GO FAIR implementation network to foster FAIR in the rare disease community. In addition, LUMC team A has extensive experience in extracting and structuring knowledge from literature, and developed algorithms that use structured knowledge for the purpose of finding novel genotype - phenotype relationships, drug targets and drug repurposing, and multi-omics analysis, for rare and genetic diseases (PMID:26919047, PMID:27524956, PMID:23356878, PMID:29441734, PMID:27476530). Finally, LUMC team A is also responsible for the Leiden Open Variation Database software (IRDiRC recognized resources) and Mutalyzer. Description of any significant infrastructure and/or major items of technical equipment, relevant to the proposed work : • Resource of gene-disease associations predicted from the literature: https://datadryad.org//resource/doi:10.5061/dryad.gn219 • FAIR service suite: https://github.com/DTL-FAIRData • Leiden Open Variation Database: http://www.lovd.nl/ • Mutalyzer sequence variant nomenclature checker: https://mutalyzer.nl/, https://github.com/mutalyzer/mutalyzer Short Profile of key Staff Members who will be undertaking the work Dr. Marc Roos Dr. Marco Roos is group leader of the Biosemantics group of Prof. dr. Barend Mons. His (male) background is in molecular biological research and computer science. He has expertise in enhancing biomedical research by interdisciplinary collaboration and methods emerging from computer science (e-Science), particularly Semantic Web, ontologies, and computational workflows. He is currently interested in FAIR data stewardship and FAIR data analytics to enhance translational research in the domain of rare diseases. He co-leads the rare disease use case in ELIXIR-EXCELERATE, and (together with UMCG) he co- leads the rare disease data linkage plan to make rare disease registries and biobanks interoperable, and he chairs the Rare Disease Linked Data and Ontology task force that originated from RD-Connect. He has initiated a Rare Disease GO FAIR implementation network towards the implementation of FAIR principles in the rare disease community Dr.Kristina Hettne Kristina is a senior research scientist in the Biosemantics group at the Human Genetics (female) department of LUMC. She obtained her PhD in bioinformatics of toxicogenomics from the University of Maastricht in 2012. She has developed resources and methods for in-silico knowledge discovery in the biomedical domain and integrated prior knowledge from literature with statistical pathway analysis methods to analyze and integrate -omics data. She has contributed to setting standards for providing resources and methods to the research community in a Findable, Accessible, Interoperable and Re-useable (FAIR) way through the development and application of Research Objects (standard format for describing an in- silico experiment), Nanopublications (standard format for stating an assertion), and scientific research pipelines (workflows), within the EU FP7 project Workflow forever. Since 2017, she leads the working group on integrating transcriptomics data with proteomics and metabolomics data in the RD-Connect project. Dr.Mark Thompson Mark Thompson is a senior research scientist in the Biosemantics group at the Human (male) Genetics department of LUMC. He obtained a PhD in Computer Science from the University of Amsterdam in 2012. He has expertise in hardware and software architecture (co-)design, data management, data modeling, FAIR data infrastructure and computational aspects of knowledge discovery. He serves as a Linked Data expert and trainer at Bring Your Own Data (BYOD) events and FAIR Data hackathons. Currently he is developing a FAIR data stewardship program for the LUMC. He leads local and international pilots towards the adoption of FAIR principles in a translational research environment. MSc.Annika Annika Jacobsen studied systems biology engineering at the Technical University of Jacobsen Denmark. She did her PhD research computational modeling of biological networks at the (female) Vrije Universiteit Amsterdam in an interdisciplinary setting (planned graduation in 2018). Apart from technical skills, she has developed her organisational and communicative skills as active member of the Dutch and international ISCB student council. She is currently the FAIR data steward for the Rare Disease Data Linkage plan, where she has the central role in the FAIRification process between registry managers and FAIR data software engineers and ontology experts. 825575 – EJP RD – Part B 176 MSc.Rajaram Rajaram Kaliyaperumal studied biomedicalAssociated engineering in IndiaRef. with document and Linköping University Ares(2018)6091977 - 28/11/2018 Kaliyaperumal in Sweden. Over the last four years he has worked as scientific software engineer at the (male) LUMC as part of the FAIR software engineering team, contributing to prototyping and stabilizing FAIR software services, and recently also as software project lead. Prof.Barend Mons Barend Mons is Professor in Biosemantics at the Human Genetics department of Leiden (male) University Medical Center, and leads the international GO FAIR office in the Netherlands. He is a molecular biologist by training (PhD Leiden University 1986) and spent over 15 years in malaria research. After that he gained experience in computer-assisted knowledge discovery. Barend has worked as head-of-node of ELIXIR-NL, Integrator Life Sciences at the Netherlands eScience Center, board member of the Leiden Centre of Data Science, and director of DTL Projects. In 2014, Barend initiated the FAIR data initiative and in 2015, Barend Mons was appointed Chair of the European Commission's High Level Expert Group for the “European Open Science Cloud”, DG Research and Innovation. List of the most relevant publications and/or products, services (including widely-used datasets or software), or other achievements 1. Wilkinson MD., Dumontier M., Aalbersberg IjJ., Appleton G., Axton M., Baak A., Blomberg N., Boiten J- W., Da Silva Santos LB., Bourne PE., Bouwman J., Brookes AJ., Clark T., Crosas M., Dillo I., Dumon O., Edmunds S.,Evelo CT., Finkers R., Gonzalez-Beltran A., Gray AJG., Groth P., Goble C., Grethe JS., Heringa J., ’t Hoen PA.,Hooft R., Kuhn T., Kok R., Kok J., Lusher SJ., Martone ME., Mons A., Packer AL., Persson B., Rocca-Serra P.,Roos M., van Schaik R., Sansone S-A., Schultes E., Sengstag T., Slater T., Strawn G., Swertz MA., Thompson M.,Van der Lei J., van Mulligen E., Velterop J., Waagmeester A., Wittenburg P., Wolstencroft K., Zhao J., Mons B. 2016. The FAIR Guiding Principles for scientific data management and stewardship. Scientific Data 3:160018. DOI: 10.1038/sdata.2016.18. (IRDiRC recognized resource) 2. Mark Thompson, Luiz Bonino, Mark D Wilkinson, Rajaram Kaliyaperumal, Kees Burger, Shamanou van Leeuwen, Annika Jacobsen, Claudio Carta, Erik Schultes, David van Enckevort, Richard Finkers, Mascha Jansen, Barend Mons, and Marco Roos Overview of a suite of middle-ware services for implementing FAIR data principles, Proceedings of the 2017 edition of SWAT4HCLS, Rome, December 4-7, 2017 (http://CEUR-WS.org/Vol-2042) http://www.swat4ls.org/wp-content/uploads/2017/12/paper_23.pdf 3. B. Mons, H. Van Haagen, C. Chichester, P.-B. ’t Hoen, J. T. Den Dunnen, G. Van Ommen, E. M. Van Mulligen, B. Singh, R. Hooft, M. Roos, J. Hammond, B. Kiesel, B. Giardine, J. Velterop, P. Groth, E. Schultes, and J. T. Den Dunnen, The value of data., Nat. Genet., vol. 43, no. 4, pp. 281–283, 2011. 4. Hettne KM, Thompson M, van Haagen HH, van der Horst E, Kaliyaperumal R, Mina E, Tatum Z, Laros JF, van Mulligen EM, Schuemie M, Aten E, Li TS, Bruskiewich R, Good BM, Su AI, Kors JA, den Dunnen J, van Ommen GJ, Roos M, 't Hoen PA, Mons B, Schultes EA. The Implicitome: A Resource for Rationalizing Gene-Disease Associations. PLoS One. 2016 Feb 26;11(2):e0149621. PMID: 26919047 5. Mastrokolias A, Pool R, Mina E, Hettne KM, van Duijn E, van der Mast RC, van Ommen G, 't Hoen PA, Prehn C, Adamski J, van Roon-Mom W. Integration of targeted metabolomics and transcriptomics identifies deregulation of phosphatidylcholinemetabolism in Huntington's disease peripheral blood samples. Metabolomics.2016;12:137. PMID: 27524956 List of relevant previous projects or activities, connected to the subject of this proposal ELIXIR-EXCELERATE, H2020-INFRADEV-1-2015-12, 2015-2019, co-lead work package rare disease use case, contributor to work package interoperability, contributor to ELIXIR Bring Your Own Data workshops, EXCELERATE helps ELIXIR coordinate and extend national and international data resources to ensure the delivery of world-leading life-science data services. It supports a pan-European training programme, anchored in national infrastructures, to increase bioinformatics capacity and competency. It provides efficiencies in management and operation throughout the infrastructure, which is distributed amongst 17 countries. Open Data Exchange for all, Data Science program NWO/e-Science Center. Project coordinator and contributor to core FAIR service software development. The ODEX4all project focuses on the challenges associated with the ever-growing amount of research data in the life sciences. In Next Generation Sequencing alone the data doubles every 6-8 months and high-throughput datasets contain up to millions of new associations. Traditional ways of publishing, retrieving and using these massive data sources are inadequate to provide researchers and computers access to information in a manner needed for the scientific reasoning process. ODEX4all sets out to generate the infrastructure for the comprehensive exploitation of available data sets in a continuous machine-mind interaction. RD-Connect, FP7-HEALTH-2012-INNOVATION-1: contributor to bioinformatics services, registry interoperability, and rare disease data linkage plan. RD-Connect develops an integrated platform connecting registries, biobanks and clinical bioinformatics for rare disease research. The Open Pharmacological Concepts Triple Store, Open PHACTS, grant agreement n° 115191, FP7/2007-2013 825575 – EJP RD – Part B 177 and EFPIA, contributor to nanopublication model and interoperability services. Associated The Open with document PHACTS Discovery Ref. Ares(2018)6091977 - 28/11/2018 Platform has been developed to reduce barriers to drug discovery in industry, academia and for small businesses. The integrated pharmacological data can be accessed via the Open PHACTS API, the Open PHACTS Explorer and explorer apps. BBMRI-NL2.0, Netherlands Organisation for Scientific Research (NWO) National Roadmap Large Research Facilities program, contribution to development of FAIR and interoperability for biobanks and catalogues. BBMRI-NL2.0 produces a collaborative hub between biobanks in the Netherlands. Full legal name (Acronym) – Country Academisch Ziekenhuis Leiden, also acting under the name Leiden University Medical Centre (LUMC), The Netherlands, (team b): Coordinating Endo-ERN Principal investigator Prof.dr. Alberto Pereira Arias Relevant Network Endo-ERN Description of the legal entity/department/laboratory/group: See description in the Partner Description Form of team a. Main tasks in the project per Pillar/WP: Pillar 2 In WP10, we will contribute in optimising and aligning WP10 and WP11 activities with real-world community needs (task 10.1), in utilisation of the EuRRECa platform to monitor the utility of these activities amongst the Endo-ERN members (task 10.2), and in designing and deployment of the QMS (task 10.3). In WP2, we will provide details to be used to serve the registry needs and to ensure that compatibility of ontological models can be compared between ERN based registries and this project (task 11.1). We will utilise the EuRRECa platform to provide metadata and create a catalogue of research projects (task 11.2) and ensure the EuRRECa platform acts as an effective data deposition facility for core endocrine data including exploration of linkages to other datasets (task 11.3). We will contribute to the improvement of RD phenomics-genomics and multi-omics analysis capabilities (task 11.4). In WP12, we will be instrumental in providing the EuRRECa platform as a model of a RD registry which can be operated within a harmonised environment for registries to ensure maximum interoperability (task 12.1) and will ensure that our platform will achieve semantic and syntactic harmonisation of other parallel activities (task 12.2). We will contribute to the practical FAIRification support process (task 12.3). Pillar 3 In WP 14 we will participate and teach a course on International Registry Summer School (task 14.5) and provide training on the European Rare Disease Registry Infrastructure (ERDRI) (task 14.6) through the experience of the EuRRECa platform and the I-DSD and I-CAH Registries. In WP17, we will lead task 17.1 (development of online survey) and contribute (task 17.2, 17.3 and 17.4) to the develop and deliver research training programs including accreditation for the European Reference Networks (ERNs). Pillar 4 In WP19, Endo-ERN will be surveyed enabling the development of an openly accessible Library of self-help resources and materials for good RD translational research practice. In WP20, Endo-ERN is ready to be included by providing specific additional scientific, clinical and methodological experts for the Task Force Group (TFG) of experts . In Tasks 20.3 and 20.4, Endo-ERN will participate in the preparation of innovative methodology projects calls. Previous experience relevant to the Tasks: Endo-ERN is the largest European Reference Network for Rare Diseases, encompassing the broadest range of rare endocrine conditions from birth to senescence. Endocrine RDs are highly heterogeneous conditions of variable origin, but with severe impact on development, well-being and life expectancy, and specific age-related phenotypic and biochemical profiles. Several endocrine rare conditions have an unknown origin and/or lack therapeutic options. Endo-ERN is founded on several EU networks and projects that have already in the past contributed to data infrastructure, -omics strategies, model systems, and innovative therapies. In specific, we will contribute to all proposed tasks, such as FAIRification processes, the operational management of the NGS-platform (linked to the overarching registry. Endo-ERN is one of the few ERNs which was successful in securing a CHAFEA grant for the development of a core registry for rare endocrine conditions (EuRRECa). Furthermore, Endo-ERN is officially supported by ESE and ESPE, the main pan-European professional and scientific societies which, between them, 825575 – EJP RD – Part B 178 cover people of all ages for all the conditions covered withinAssociated Endo-ERN. Finally,Ref. with document Endo-ERN prioritizes Ares(2018)6091977 the - 28/11/2018 inclusion of ePAGs, training and capacity building of professionals, patients and support groups. Description of any significant infrastructure and/or major items of technical equipment, relevant to the proposed work : Short Profile of key Staff Members who will be undertaking the work: Pr.Alberto Pereira Alberto M. Pereira is professor of medicine, and head of the division of Endocrinology at the Arias (male) Leiden University Medical Center, the Netherlands. In addition, he is coordinator of the European Reference Network on Rare Endocrine Conditions (2017-2022), and president of the European Neuroendocrine Association (2016-2018). His research focusses on the long- term effects of pituitary tumours and of its treatment, and in specific on the effects of stress hormones on the central nervous system. He (co)authored more than 250 papers and book chapters, and supervised 15 PhD students. Pr. O. Hiort Professor Hiort specialised in Paediatrics and the subspecialities Neonatology, Paediatric (male) Endocrinology and Diabetes, as well as in Laboratory Medicine. He was appointed as Professor of Paediatrics in 2001 at the University of Lübeck. He is heading the Division of Paediatric Endocrinology and Diabetes at the University Hospital of Schleswig-Holstein in Lübeck. His scientific interest is with the natural history and pathophysiology of complex rare conditions, namely with disorders of sex development and calcium and phosphate metabolism. Pr.F.Ahmed Professor Faisal Ahmed was appointed in 2000 as a consultant at the Royal Hospital for Sick (male) Children, Yorkhill, Glasgow. In 2012 he was appointed to the Samson Gemmell Chair of Child Health at the University of Glasgow where he leads the Developmental Endocrinology Research Group and has published over 230 scientific communications, with a focus on rare conditions. In addition, he coordinates the long-standing International DSD (I-DSD) Registry and a new EU CHAFEA project, the European Registries for Rare Endocrine Conditions (EuRRECa). Professor Ahmed currently serves as the Chair of the Science Committee of the European Society for Paediatric Endocrinology (ESPE) and leads the e-Health & ICT Working Group within the European Reference Network for Rare Endocrine Conditions (Endo-ERN). List of the most relevant publications and/or products, services (including widely-used datasets or software), or other achievements 1. Cox K, Bryce J, Jiang J, RodieM, Sinnott R, Alkhawari M, Arlt W, Audi L, Balsamo A, Bertelloni S, Cools M, Darendeliler F, Drop S, Ellaithi M, Guran T, Hiort O, Holterhus P-M, Hughes I, Krone N, Lisa L, Morel Y, Soder O, Wieacker P, Ahmed SF. Novel associations in disorders of sex development: findings from the I-DSD Registry. J Clin Endocrinol Metab. 2014;99:e348-355. 2. Lucas-Herald A, Bertelloni S, Juul A, Bryce J, Jiang J, Rodie M1, Sinnott R, Boroujerdi M, Lindhardt-Johansen M, Hiort O, Holterhus PM, Cools M, Guaragna-Filho G, Guerra-Junior G, Weintrob N, Hannema S, Drop S, Guran T, Darendeliler F, Nordenstrom A, Hughes IA, Acerini C, Tadokoro-Cuccaro R, Ahmed SF. The long term outcome of boys with partial androgen insensitivity syndrome and androgen receptor gene mutations. J Clin Endocrinol Metab. 2016 Nov;101(11):3959-3967. 3. Doehnert U, Bertelloni S, Werner R, Dati E, Hiort O. Characteristic features of reproductive hormone profiles in late adolescent and adult females with complete androgen insensitivity syndrome. Sex Dev. 2015;9(2):69-74. doi: 10.1159/000371464. Epub 2015 Jan 20. 4. Bas-Hoogendam JM, Andela CD, van der Werff SJA, Pannekoek JN, van Steenbergen H, Meijer OC, van Buchem MA, Rombouts SA, van Mast RC, Biermasz NR, van der Wee NJ, Pereira AM. Altered neural processing of emotional faces in remitted Cushing's disease. Psychoneuroendocrinology 2015;59:134-46 5. Andela CD, Repping-Wuts H, Stikkelbroeck NMML, Pronk MC, Tiemensma J, Hermus AR, Kaptein AA, Pereira AM, Kamminga NGA, Biermasz NR. Enhanced self-efficacy after a self-management programme in pituitary disease: a randomized controlled trial. Eur J Endocrinol. 2017 Jul;177(1):59-72. doi: 10.1530/EJE-16- 1015. List of relevant previous projects or activities, connected to the subject of this proposal . Endo-ERN; EU/CHAFEA, 2017-2022, Coordinator (LUMC), European Reference Network on Rare Endocrine Conditions, grant agreement nr. 739527 / 769031 . CEF Telecom: EU/INEA, 2018-2019, Coordinator (LUMC), Operational Helpdesk for Endo-ERN to ensure structured and tailored Use of Collaborative Platform and CPMS . EuRRECa: EU/CHAFEA, 2018-2021, Coordinator (UoG), European Registries For Rare Endocrine Conditions, grant agreement nr. 777215 825575 – EJP RD – Part B 179 Associated with document Ref. Ares(2018)6091977 - 28/11/2018 . DSDnet: EU-H2020, COST Action, Coordinator (UzL/USKH), Systematic elucidation of Differences of Sex Development 65-Raboudumc Full legal name (Acronym) – Country Stichting Katholieke Universiteit (Radboudumc), The Netherlands Principal investigator Nicoline Hoogerbrugge Relevant Network ERN GENTURIS Description of the legal entity/department/laboratory/group: Radboud University Medical Center (Radboudumc) is a leading academic center with expertise in medical science and healthcare. Expertise plays an essential part in our organization and connects research, education and patient care. Our more than 8,500 staff and 3,000 students are committed and ambitious, helping to shape the future of healthcare and medical science. Team (a): The department of Human Genetics is one of its largest departments, employing 300+ staff (including clinicians, diagnosticians, and scientific researchers), treating over 5,000 patients annually. The department of Human Genetics is nationally and internationally acknowledged for the implementation of genomic medicine, at the levels of patient care, genetic diagnostics and research, using expert knowledge and innovation to reach this goal. With this mission, the department of Human Genetics is recognized as one of the centers of expertise for rare Diseases in the Netherlands and Europe. Main tasks in the project per Pillar/WP: Pillar 2: In WP10 we will participate in Task 10.1: regular retreats with ERNs Pillar 3: In WP16 (Online Education Course), we will participate in: Task 16.1.: Assess the needs, target audience, main topics of the academic education course (Inst. Curie) Task 16.2.2.: Developing the online course Diagnostic of rare diseases (Inst. Curie). In WP17, we will contribute to: Task 17.1.: Mapping to collect information on preferences, needs and resources from the ERNs ecosystem Task 17.2.: Development of training programs for the ERN training networks based on the results of survey Task 17.3.: Deliver training programs through the ERN training networks Task 17.4.: Accreditation by universities (Radboudumc, KI, CMFT) Previous experience relevant to the Tasks: N. Hoogerbrugge is coordinator of ERN GENTURIS and initiator and chair of national and international teaching programs, such as the Dutch Up-to-date in hereditary cancer thematic days (http://www.vkgn.org/files/190/2017Up-to-date%20LYnch%20syndroom.pdf) and the Spring Course in Hereditary Cancer Genetics in Bertinoro, Italy (http://www.ceub.it/default.asp?id_c=772&id=436#.WqlNY6- ouHs). Description of any significant infrastructure and/or major items of technical equipment, relevant to the proposed work : The Radboud Health Academy is specifically equipped to develop and organise training programs. Short Profile of key Staff Members who will be undertaking the work Prof.dr. Nicoline Hoogerbrugge (female) is currently full professor hereditary cancer and head of the multidisciplinary expert center in hereditary cancer RadboudUMC. She has initiated and conducted many research projects on innovation of care and on genetic predisposition of cancer. She has published more than 250 peer- reviewed manuscripts. She is coordinator of the European Reference Network on Genetic Tumour Risk Syndromes (ERN GENTURIS). 825575 – EJP RD – Part B 180 Associated with document Ref. Ares(2018)6091977 - 28/11/2018 Full legal name (Acronym) – Country Stichting Katholieke Universiteit (Radboudumc), The Netherlands Principal investigator Wout Feitz Relevant Network ERN eUROGEN Description of the legal entity/department/laboratory/group: Team (b) Department of Urology Main tasks in the project per Pillar/WP: Pillar 2: In WP10 we will participate inTask 10.1: regular retreats with ERNs Previous experience relevant to the Tasks: Prof. Wout Feiz is the coordinator of ERN eUROGEN for rare and complex urogenital diseases and conditions. eUROGEN aims to improve diagnosis, create more equitable access to high-quality treatment and care for patients with rare urogenital diseases and complex conditions needing highly specialised surgery. Short Profile of key Staff Members who will be undertaking the work Prof.dr. Wout Feitz (male) works as a pediatric urologist at Radboudumc (including Amalia children’s Hospital) which is one of the 8 University Hospitals in The Netherlands and has been involved in more than 200 scientific publication and mentored students, PHD’s, post docs and Fellows for paediatric urology. Radboudumc Pediatric urology care and research has been recognized by the ministry of Health as an expertise center for congenital urogenital anomalies. He participates in the Radboudumc Urology Research Laboratory (Heads Prof. J. Schalken and Dr. E. Oosterwijk) which is one of the leading urological research laboratories in Europe and is the coordinator for the Radboudumc Research Theme Reconstructive and Regenerative Medicine (13 departments). He has coordinated FP6 Integrated project EuroSTEC with 15 European partners including 5 SME’s, a Marie Curie program and EU funded regional urology directed research collaborations (7 partners including 5 SME). He is a member of the EUMS/JCPU Board for the fellowship programs in paediatric urology and a member of the EAU Scientific Congress Office for Paediatric Urology. He is the director of the EUMS/JCPU fellowship program for Pediatric Urology, coordinator for the EBU-EAU Host Center for Pediatric Urology, Radboudumc health care representative in the Strategic Board of the ERN eUROGEN (11 EU countries with 29 HCP partners), Member of the operational board of eUROGEN, Workstream 1 coordinator for the disease areas for rare congenital uro-recto- genital anomalies (23 HCP partners). Full legal name (Acronym) – Country Stichting Katholieke Universiteit (Radboudumc), The Netherlands Principal investigator Leo Schultze Kool Relevant Network ERN VASCERN Description of the legal entity/department/laboratory/group: Team (c) Department of Radiology and Nuclear Medicine: The group of Schultze Kool at the Radboudumc is a mutlidisciplinairy team composed of 12 different disciplines focussed on the treatment of vasculair malformations in adults and children. On a yearly basis approx 5000 patients are seen and treated. The HCP is part of the ERN vascern which covers mulitsystemic vasculair diseases like rendu osler weber, lymfatic diseases HTAD and MSA. The group has a close collaboration with the patient organizations for the development of patient centered and patient controlled health systems. In collaboration with the biosemantic group in Leiden a FAIR based patient signal bank has recently been developed. A pilot for a FAIR based registry among the vasculair malformations centers in europe is in progress. The group is closely related to the DTL and the bioinformatics group of the Radboudumc with focus on interoperability and federated data management Main tasks in the project per Pillar/WP: Pillar 2: In WP10, we will participate in: Task 10.1.1: 5 x pan-RD community, 3 days strategy meetings Task 10.1: regular retreats with ERNs 825575 – EJP RD – Part B 181 Task 10.2.2: Survey and structured interview approaches on technical and scientific Associated matters with document Ref. Ares(2018)6091977 - 28/11/2018 In WP11, we will participate in: Task 11.1.1: Defíne metadata model compatible with existing key databases and resources Task 11.2.1: Collaboratively assemble and curate metadata based on the Orphanet catalog, on an ongoing basis, to represent all key databases and resources In WP12, we will participate in: Task 12.3.3: FAlRification service for data from Pillar 1 studies, from Pillar 2-WP10 activities, and prioritized EU data sources Radboud umc will actively participate in the above mentioned WP with our partners in the Radboudumc (‘t Hoen) and the biosementics (Roos) group in Leiden. The work will be building on already existing partnerships. Joint datastewards will ensure that an optimal collaboration effort is obtained. Previous experience relevant to the Tasks: Schultze Kool is part of the FAIR group of the Radboud umc, chair of the registry WG of VASCERN and co chair of the vasculair malformations WG. He developed several new innovative treatments (2 patents), was co director of the digital research group of the university of leiden (1986-1993) and is the chair of the Biodatabank congenital anomalies. He has recently been proposed as a boardmember of the steering committee Research data management of the Radboud University. Short Profile of key Staff Members who will be undertaking the work Prof.dr. Leo J Schultze Kool (male) is a full professor of Interventional Radiology of the Radboud University Medical Center. Before he was head of the radiology department of the Dutch Cancer Institute in Amsterdam. His main topic is the further development of main innovative treatments for patients with vasculair malformations and further development of personalized care for these groups. Interests are the development of FAIR based registries, linking with FAIR based biodatabanks and EHR to allow datamining. List of the most relevant publications and/or products, services (including widely-used datasets or software), or other achievements A FAIR compliant registry for the vascular malformation centres within the European Reference Networks. How it was done. Author(s): Leo Schultze Kool, Alan IRVINE, Päivi Salminen, Nader Ghaffarpour, Andrea Diociaiuti, Jochen Rössler, C.T. van den Bosch, Eulalia Baselga, Anne Dompmartin, Laurence Boon, Miikka Vikkula, Luiz Bonino, Mark Thompson, Annika Jacobsen, David van Enckevort and Marco Roos. ISSVA meeting 2018 Enrichment of rare disease patient registries by FAIRification. Authors: Annika Jacobsen, Mark Thompson, Erik A. Schultes, Ronald Cornet, Mark Wilkinson, Rachel Thompson, Marina Mordenti, Luca Sangiorgi, Claudio Carta, Karlijn Groenen, Martijn Kersloot, Leo Schultze Kool, David van Enckevort, Marco Roos. ECRD meeting 2018 Full legal name (Acronym) – Country Stichting Katholieke Universiteit (Radboudumc), The Netherlands Principal investigator Peter-Bram ‘t Hoen Relevant Network DTL / ELIXIR / Solve-RD / RD-Connect / EATRIS / EURO- NMD Description of the legal entity/department/laboratory/group: Team (d) Centre for Molecular and Biomolecular Informatics: The group of ‘t Hoen focuses on the identification of diagnostic, prognostic and therapeutic biomarkers from multi-omics profiles through innovative data integration methods. They are implementing and further developing FAIR data stewardship approaches to increase reusability of data and tools. Radboudumc is a member of the Dutch Techcentre for the Life Sciences (DTL, the Dutch ELIXIR node) and actively contributes to DTL services on FAIR data infrastructures, stewardship and training. Main tasks in the project per Pillar/WP: 825575 – EJP RD – Part B 182 Associated with document Ref. Ares(2018)6091977 - 28/11/2018 Pillar 2: In WP10, we will participate in: Task 1.1.: regular retreats with ERNs In WP11 we will participate in: Task 11.4.1.: Provide RD phenotype-genotype analysis and data sharing capabilities through the RD-Connect platform for molecular diagnostics and gene discovery Task 11.4.4.: User-driven implementation of new analysis functionalities and tools We will be collecting and modeling experimental metadata for RD studies and contribute to method development for knowledge discovery through integration of FAIR data resources relevant to the RD field. In WP12, we will participate in: Task 12.2.4.: Consent and data use management, plus automated access control Task 12.3.3.: FAIRification service for data from Pillar 1 studies, from Pillar 2-WP1 activities, and prioritized EU data sources. We will co-develop federated architectures and systems recording patient consent and enabling the use of patient- related data in a privacy-protective manner. In WP13, we will contribute to the development of integrative systems biology approaches for rare diseases, we fill a number of pre-identified gaps, allowing linkage of external FAIR data sources, and discovering environmental factors influencing disease (task 13.1), and lead task 13.2 to organize proof-of-concept studies around these gaps. Previous experience relevant to the Tasks: Developing new methods for interpreting -omics information in the context of health and disease is the core activity of the group. In the context of RD-Connect, we have developed workflows for mapping and integration of multi-level -omics data and applied these to the study of rare neuromuscular, neurodevelopmental disorders and thalassemias. I emphasise data interoperability to facilitate data integration and professional software engineering, as to make my research and data optimally useful for the community, and are actively contributing to the principles and metrics for FAIR data management. I am actively contributing to the Personal Health Train, an infrastructure that facilitates health data exchange, is fully based on FAIR data architecture and empowers patients / citizens to be in control of their data. In the context of the Personal Health Train and a BBMRI-funded project, we developed a prototype for a machine readable consent systems that is based on FAIR data architecture and is a way for patients to provide dynamic consent to the use of their data by researchers and/or health care providers. Description of any significant infrastructure and/or major items of technical equipment, relevant to the proposed work : Digital Research Environment, FAIR data infrastructure, Personal Health Train Short Profile of key Staff Members who will be undertaking the work Prof.dr. Peter-Bram ’t Hoen (male) started in February 2018 as full professor in bioinformatics at Radboudumc (Centre for Molecular and Biomolecular Informatics). Before that, he was postdoc, assistant and associate professor in the Human Genetics department at Leiden University Medical Center. His group studied the aetiology of rare muscular dystrophies using state-of-the-art molecular technologies. He was among the first researchers in the Netherlands to implement microarray and (novel) RNA-sequencing technologies, and organized many (inter)national courses on these topics. With these new technologies, he identified major players and mechanisms in the transcriptional and post-transcriptional regulation of gene expression in health and disease. His main drive is to optimally analyze and interpret large -omics data sets to facilitate diagnosis, patient stratification and personalized medicine approaches.. In their interpretation, he typically goes beyond standard (pathway) analysis methods and develops and employs automated knowledge discovery approaches and new statistical routines. This resulted in the prediction and validation of novel biomarkers, novel protein:protein interactions, and new candidate drugs. ‘t Hoen is member of the International Rare Diseases Research Consortium (IRDiRC ) taskforce on data mining and drug repurposing, board member of the research working group European Reference Network on neuromuscular diseases (EURO-NMD) and management team member of the Personal Health Train consortium, developing a data infrastructure to advance healthcare and biomedical science through interoperable and federated data management. List of the most relevant publications and/or products, services (including widely-used datasets or software), or other achievements 825575 – EJP RD – Part B 183 1. Daria V. Zhernakova, Patrick Deelen, Martijn Vermaat, Maarten vanwith Associated Iterson, Michiel document van Galen, Wibowo Ref. Ares(2018)6091977 - 28/11/2018 Arindrarto, Peter van 't Hof, Hailiang Mei, Freerk van Dijk, Harm-Jan Westra, Marc Jan Bonder, Jeroen van Rooij, Marijn Verkerk, P. Mila Jhamai, Matthijs Moed, Szymon M. Kielbasa, Jan Bot, Irene Nooren, René Pool, Jenny van Dongen, Jouke J. Hottenga, Coen D.A. Stehouwer, Carla J.H. van der Kallen, Casper G. Schalkwijk, Alexandra Zhernakova, Yang Li, Ettje F. Tigchelaar, Niek de Klein, Marian Beekman, Joris Deelen, Diana van Heemst, Leonard H. van den Berg, Albert Hofman, André G. Uitterlinden, Marleen M.J. van Greevenbroek, Jan H. Veldink, Dorret I. Boomsma, Cornelia M. van Duijn, Cisca Wijmenga, P. Eline Slagboom, Morris A. Swertz, Aaron Isaacs, Joyce B.J. van Meurs, Rick Jansen, Bastiaan T. Heijmans*, Peter A.C. ’t Hoen*, Lude Franke*. * shared last author. Identification of context-dependent expression quantitative trait loci in whole blood. Nature Genetics 49:139-145 (2017) IF:31.6 2. Kristina M. Hettne, Mark Thompson , Herman H. H. B. M. van Haagen,Eelke van der Horst,Rajaram Kaliyaperumal, Eleni Mina, Zuotian Tatum, Jeroen F. J. Laros, Erik M. van Mulligen, Martijn Schuemie, Emmelien Aten, Tong Shu Li, Richard Bruskiewich,Benjamin M. Good, Andrew I. Su, Jan A. Kors, Johan den Dunnen, Gert-Jan B. van Ommen, Marco Roos, Peter A.C. ‘t Hoen, Barend Mons, Erik A. Schultes The Implicitome: A Resource for Rationalizing Gene-Disease Associations PLoS One 11:e0149621 (2016) IF: 3.057 3. F. Cynthia Martin, Monika Hiller, Pietro Spitali, Stijn Oonk, Hans Dalebout, Magnus Palmblad, Amina Chaouch, Michela Guglieri, Volker Straub, Hanns Lochmüller, Erik H. Niks, Jan J.G.M.Verschuuren, Annemieke Aartsma-Rus, André M. Deelder, Yuri E.M. van der Burgt, Peter A.C. ’t Hoen Fibronectin is a serum biomarker for Duchenne muscular dystrophy Proteomics 8:269-78 (2013) IF: 4.079 4. Harish Dharuri, Peter Henneman, Ayse Demirkan, Jan Bert van Klinken, Dennis Owen Mook-Kanamori, Rui Wang-Sattler, Christian Gieger, Jerzy Adamski, Kristina Hettne, Marco Roos, Karsten Suhre, Cornelia M. Van Duijn, EUROSPAN consortia, Ko Willems van Dijk, Peter A.C. ’t Hoen Automated workflow-based exploitation of pathway databases provides new insights into genetic associations of metabolite profiles. BMC Genomics 14:865 (2013) IF: 3.867 5. Peter A.C. ’t Hoen, Marc R. Friedländer, Jonas Almlöf, Michael Sammeth, Irina Pulyakhina, Seyed Yahya Anvar, Jeroen F.J. Laros, Henk P.J. Buermans, Olof Karlberg, Mathias Brännvall, The GEUVADIS Consortium, Johan T. den Dunnen, Gert-Jan B. van Ommen, Ivo G. Gut, Roderic Guigó, Xavier Estivill, Ann-Christine Syvänen, Emmanouil T. Dermitzakis, Tuuli Lappalainen. Reproducible mRNA and small RNA sequencing across laboratories. Nature Biotechnol 31:1015-22 (2013) IF 32.4 List of relevant previous projects or activities, connected to the subject of this proposal : . RD-Connect, EU-FP7, 2012-2018, . BIO-NMD, EU-FP7, 2013-2015, identification of biomarkers for neuromuscular disorders, workpackage leader 66-AMC Full legal name (Acronym) – Country Academic Medical Center (AMC) – The Netherlands (Team a) Principal investigator Arthur A.M. Wilde Relevant Network ERN GUARD-Heart Description of the legal entity/department/laboratory/group: In 1996, the Cardiogenetics team of the AMC was one of the first worldwide to start a specialized cardiogenetic outpatient clinic where cardiologists, clinical genetic counsellors, and molecular geneticists act synergistically. Our Cardiogenetics team aims to identify the diagnosis and to provide timely often presymptomatic treatment to the carriers of pathogenic mutations. These carriers are, for the greater part, followed, supported, and treated in our outpatient clinic, according to state-of-the-art methods. At the same time, specific molecular-genetic expertise has been deployed to determine whether gene variants thus found can be regarded as the disease-causing gene defects. This knowledge and expertise is extremely important in the light of the great technological advances in DNA testing in recent years. With the advent of NGS techniques (e.g., whole-exome sequencing), the number of DNA variants to be found, both disease-causing mutations and rare variants of unknown significance in known and 825575 – EJP RD – Part B 184 unknown genes, increased drastically. We anticipate, that with the enormous Associated amountRef. with document of Ares(2018)6091977 molecular-genetic data, - 28/11/2018 intensive collaboration between cardiologists, genetic counsellors, and (molecular) geneticists who combine research and patient care in specialized cardiogenetics centres and share their knowledge in international databases will become even more important. In addition, the Cardiogenetics team of the AMC has a strong national and international position in clinical research. A biobank has been implemented. Since 2004, patients with a familial heart disease are included in a national (GENCOR) database. Main tasks in the project per Pillar/WP: Pillar 2: In WP11, we will participate in the process of optimising and align the activities of EJP with real-world community needs by taking active part in annual strategy meetings with other stakeholders in the rare disease community and discuss the management of the next-generation data ecosystem strategic plan) and the setup of a common platform for discoverable data and resources for rare diseases research (Pillar 2 WP11)). In WP10, we will also provide experts to assist in monitoring and coordination of the progress and the usefulness of the activities of Pillar 2 WP10. Previous experience relevant to the Tasks: The Cardiogenetics team of the AMC consists of a dedicated group of cardiologists, clinical geneticists, counsellors, a psycho-social worker and molecular geneticists with expertise in the management of patients with rare and low prevalence diseases of the heart. Since 1996, members of our Cardiogenetics team work together to diagnose and treat patients with familial electrical diseases and familial cardiomyopathies. This design has allowed us to adopt a candidate-gene approach to find the familial-disease gene variant, often driven by specific knowledge about familial electrical diseases and familial cardiomyopathies. The yearly number of counselees increased to reach ~1100 in the last few years. In addition, our team has established a strong position in basic, clinical and translational research and has participated in many national and international research projects, databases and patient registries. In addition, since March 2017, AMC coordinates the activities of the European Reference Network for rare diseases of the heart (ERN GUARD-Heart). It is for these reasons that our Cardiogenetics team is an ideal partner for the EJP to optimise and align Pillar WP 1 and WP2 activities with real-world community needs (which are very well identified by our team members), and to assist in monitoring and the usefulness of WP1 and WP2 activities, according to the needs and the requirements of the rare disease community. Description of any significant infrastructure and/or major items of technical equipment, relevant to the proposed work : The Cardiogenetics team of the AMC consists of 7 (paediatric) cardiologists, 6 clinical geneticists / genetic counsellors, a psycho-social worker and 3 molecular geneticists, all of them being specialized in the management of patients with rare and genetic heart diseases. The team members work together in multidisciplinary teams according to a strategic work plan, in which the tasks and responsibilities of each team member are well described. The care is provided according to national and international guidelines and patient pathways with the use of specialised and state-of-the-art equipment, infrastructure, and information technology. The team discusses patients who suffer from high complex rare conditions within the ERN GUARD-Heart using the Clinical Patient Management System (CPMS). Short Profile of key Staff Members who will be undertaking the work Prof. Dr. Arthur A.M. Wilde is a cardiologist-electrophysiologist and head of the Department of Clinical Arthur A.M. and Experimental Cardiology at the AMC, Amsterdam, the Netherlands. He is the Coordinator of Wilde, MD, the European Reference Network for rare and complex diseases of the heart (ERN GUARD- PhD, Male Heart). He is a member of the Dutch Academy of Science. His research interest includes the genetic basis of cardiac arrhythmias, ranging from the monogenetic diseases to more broader healthcare problems as sudden cardiac death in the setting of ischemic heart disease. Recent studies centre on genotype-phenotype relationships in these disorders and the role of clinical and genetic modifiers in establishing the phenotype. Dr. Ahmad S. Ahmad Amin is a cardiologist at AMC, Amsterdam, the Netherlands. He is project manager of the Amin, MD, ERN GUARD-Heart. His research interest includes the genetic basis of familial electrical diseases PhD, Male and familial cardiomyopathies. In his recent studies, he investigates the role of genetic and clinical modifies on the phenotype in order to explain phenotypic variability in patients with these orders (even in families affected with the same pathogenic ‘familial’ mutation). List of the most relevant publications and/or products, services (including widely-used datasets or software), or other achievements 1. Priori SG,* Wilde AA,* et al. Heart Rhythm. 2013;10:1932-63. 2. Ackerman MJ, …, Wilde AA, et al. Heart Rhythm. 2011;8:1308-1339. 3. Postema PG, Wolpert C, Amin AS, …, Wilde AA. Heart Rhythm. 2009;61335-1341. 4. Hofman N, …, Wilde AA. Circulation. 2013;128:1513-1521. 5. Amin AS, …, Wilde AA, et al. European Heart Journal. 2012;33:714-723. 825575 – EJP RD – Part B 185 List of relevant previous projects or activities, connected to theAssociated subject with of this proposal document Ref. Ares(2018)6091977 - 28/11/2018 . ERN GUARD-Heart; European Union; 2017-2022 - Network coordinator (Wilde), European Reference Network for rare and complex diseases of the heart. . Improve CPVT; European Union (ERA-Net E-Rare); 2016-2020 - Project Coordinator (Wilde), improving diagnosis and treatment of catecholaminergic polymorphic ventricular tachycardia: integrating clinical and basic science. . PREDICT; Dutch Heart Foundation; 2013-2018 - Principal Investigator (Wilde), predicting sudden cardiac death. . Netherlands Organisation for health Research and Development; 2012-2016 - Principal Investigator (Wilde), preventing arrhythmias & sudden cardiac death in LQTS3 through pharmacological late sodium current inhibition. . Dutch Heart Foundation; 2014-2017- Principal Investigator (Amin), variants in the 3'UTR modify disease severity in inherited cardiac diseases by altering microRNA binding. Full legal name (Acronym) – Country Academic Medical Center (AMC) – The Netherlands (Team b) Principal investigator Ronald Cornet Relevant Network Description of the legal entity/department/laboratory/group: The Department of Medical Informatics at the Academic Medical Centre (AMC) in Amsterdam is one of the leading Medical Informatics departments in the Netherlands and Europe. It is one of the few groups that provides Medical Informatics training and research at BSc, MSc and PhD level, as well as MSc-level Health Informatics training for healthcare professionals. These training programs deliver a continuous stream of young academics and provide a fertile ground for collaboration with clinical partners. The department has a strong track record in research on standardization of healthcare information, combining a demand-driven perspective with strong theoretical foundation. Research encompasses application of description logic, semantic modelling using information models and ontologies, structured data capture, and use of structured data. The department is based in the AMC, one of the major health and care research institutions in the Netherlands, and one of its largest hospitals. Over 7,000 people work here to provide integrated patient care, fundamental and clinical scientific research, and teaching. Main tasks in the project per Pillar/WP: Pillar 2: In WP11, we will contribute to the metadata and ontological model definition for cataloguing resources for RD research. Our focus in this will be on the clinical resources. In WP12, we will lead subtasks on FAIRification of data. These tasks consist of a) development and application of methods for semantic and syntactic harmonisation of data records, and b) a coordinated effort to define strategies to move towards generating data that is FAIR from the start, rather than post-hoc FAIRification. These tasks will be led using the experience gained in the subtasks in which interoperability standards are compared and aligned. Pillar 3: In WP14, we will contribute to the training on rare disease registries and FAIRification of data at the source. In the last years, we have successfully contributed to this course, which has consisted of a summer school and a hands-on tutorial. Previous experience relevant to the Tasks: The department of Medical Informatics of the AMC has previously been involved in standardization and harmonization efforts in various domains, including intensive care, nephrology, anaesthesiology, oncology, and HIV/AIDS-care. The department has been involved in various national efforts towards standardized and structured data capture, predominantly the introduction of SNOMED CT in the Netherlands, and raising awareness of the importance of point-of-care clinical data capture. Description of any significant infrastructure and/or major items of technical equipment, relevant to the proposed work : The department has a variety of semantic resources in place, as well as knowledge, skills and permission to access even more resources. Furthermore, the department has a broad network, via active or past involvement in national, international and global data harmonisation efforts. Short Profile of key Staff Members who will be undertaking the work Dr. Ronald Ronald Cornet holds a position as associate professor at the department of Medical Informatics in Cornet, PhD, the Amsterdam Public Health research institute, Academic Medical Center - University of Male Amsterdam. His research focuses on semantic interoperability, both from a technical perspective and from a users' point of view, including natural language processing. This research has resulted in over 40 journal publications and over 70 peer-reviewed conference proceedings. Ronald is involved in the Modelling Advisory Group of SNOMED International, the organisation that is responsible for maintenance and further development of SNOMED CT. He chairs the IMIA 825575 – EJP RD – Part B 186 working group on Language and Meaning in Biomedicine. Associated with document Ref. Ares(2018)6091977 - 28/11/2018 List of the most relevant publications and/or products, services (including widely-used datasets or software), or other achievements 1. Zini EM, Lanzola G, Quaglini S, Cornet R. Standardization of immunotherapy adverse events in patient information leaflets and development of an interface terminology for outpatients' monitoring. J BIOMED INFORM 2018;77:133-144 2. Burger G, Abu-Hanna A, de Keizer N, Cornet R. Natural language processing in pathology: a scoping review. J CLIN PATHOL 2016;69 (11):949-955 3. Dentler K, Cornet R. Intra-axiom redundancies in SNOMED CT. ARTIF INTELL MED 2015;65 (1):29-34 4. Lee D, de Keizer N, Lau F, Cornet R. Literature review of SNOMED CT use. J AM MED INFORM ASSN 2014;21 (E1):E11-E19 5. Geller J, Perl Y, Halper M, Cornet R. Special issue on auditing of terminologies. J BIOMED INFORM 2009;42 (3):407-411 List of relevant previous projects or activities, connected to the subject of this proposal • International Summer School on Rare Disease and Orphan Drug Registries, organized by the Italian National Centre for Rare Diseases (CNMR) in collaboration with Services and Centre for International Affairs (ISS), RD-Connect, Elixir, RD-Action, EURORDIS and endorsed by ICORD; 2016-2017 - faculty • ASSESS-CT - Assessing SNOMED CT for Large Scale eHealth Deployments in the EU; European Union; 2015-2016; participant. • SemanticHealthNet; European Union; 2013-2014; Advisory board member. • NephroQUEST Initiative; European Union; 2007-2010; Workpackage leader 67-Erasmus MC Full legal name (Acronym) – Country Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC), The Netherlands (Team a) Principal investigator Prof. dr. I.M.J. Mathijssen Relevant Network ERN CRANIO Description of the legal entity/department/laboratory/group: Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC) Department of Plastic and Reconstructive Surgery Main tasks in the project per Pillar/WP: Pillar 2: In WP10, we will work on 5x pan-RD-community, 3-day strategy meetings (annual retreat) (task 10.1.1) In WP10, we will work on Survey and structured interview approaches on technical and scientific matters, to monitor progress and inform strategic decisions (incl. Definition of indicators) (task 10.2.2) Previous experience relevant to the Tasks: I am leading the craniofacial team of the Erasmus MC and involved in care, research and training regarding craniofacial anomalies. As secretary-treasurer of the International Society of Craniofacial Surgery I have a large network within the field. Description of any significant infrastructure and/or major items of technical equipment, relevant to the proposed work : We have all the medical specialties and all relevant equipment for this project, ranging from a electronic patient file, data bases for research, multidisciplinary teams for providing care, educational programs for all care providers, close interaction with the patient society, training programs for fellows from all over the world. Short Profile of key Staff Members who will be undertaking the work Pr. Irene M.J. MBA-Health,Head of department of Plastic and Reconstructive Surgery, and Hand Surgery Mathijssen Erasmus MC, Rotterdam (female) List of the most relevant publications and/or products, services (including widely-used datasets or software), or other achievements 1. Cornelissen MJ, Softeland M, Apon I, Ladfors L, Mathijssen IMJ, Cohen-Overbeek TE, Bonsel GJ, Kolby L Perinatal complications in patients with unisutural craniosynostosis: An international multicentre retrospective cohort study. J Craniomaxilofac Surg 45: 1809-14, 2017 2. . Van Veelen MLC, Kamst N, Touw C, Mauff K, Versnel S, Dammers R, De Jong THR, Prasad V, Mathijssen IM. Minimally invasive, spring-assisted correction of sagittal suture synostosis. Technique, outcome and 825575 – EJP RD – Part B 187 complications in 83 cases. Plast Reconstr Surg 141: 423-33, 2018 Associated with document Ref. Ares(2018)6091977 - 28/11/2018 3. Miller KA, Twigg SR, McGowan SJ, Phipps JM, Fenwick AL, Johnson D, Wall SA, Noons P, Rees KE, Tidey EA, Craft J, Taylor J, Taylor JC, Goos JA, Swagemakers SM, Mathijssen IM, van der Spek PJ, Lord H, Lester T, Abid N, Cilliers D, Hurst JA, Morton JE, Sweeney E, Weber A, Wilson LC, Wilkie AO. Diagnostic value of exome and whole genome sequencing in craniosynostosis. J Med Genet. 54: 260-8, 2017. 4. Spruijt B, Mathijssen IM, Bredeo-Boelhouwer HH, Cherian PJ, Corel LJ, Van Veelen ML, Hayward RD, Tasker RC, Joosten KF. Sleep architecture linked to airway obstruction and intracranial hypertension in children with syndromic craniosynostosis. Plast Reconstr Surg 138: 1019e-1029e, 2016. 5. Mathijssen IM. Guideline for care of patients with the diagnoses of craniosynostosis: Working group on craniosynostosis. J Craniofac Surg 26: 1735-1807, 2015. List of relevant previous projects or activities, connected to the subject of this proposal: OCT; Stichting Lijf en Leven; 2017-2020, the use of OCT for detection of raised intracranial pressure in craniosynostosis CRISPR-CAS; Dalijn Stichting; 2014-2017, repair of craniosynostosis genetic defects BRAIN; JANIVO stichting; 2016-2019, study into brain anomalies in congenital craniofacial defects Ultra; Nuts Ohra Foundation; 2013-2017, prenatal and perinatal findings in craniosynostosis 68-SERMAS Full legal name (Acronym) – Country SERVICIO MADRILEÑO DE SALUD-HOSPITAL UNIVERSITARIO LA PAZ (SERMAS) - Spain Principal investigator Eduardo López Granados Relevant Network ERN TransplantChild Description of the legal entity/department/laboratory/group: TransplantChild is the only ERN focused on a highly complex procedure: Pediatric Transplantation, both solid organ (SOT) and hematopoietic stem cell transplantation (HSCT). Transplantation is yet the only curative option for many paediatric rare diseases that compromise organ anatomy and function, or hematopoietic and immunological capacity and control. Transplanted patients overcome their severe primary disease, but acquire a life-long medical condition, that yet fulfills many characteristics of RD as low prevalence, and favors the appearance of transplant-related rare diseases (e.g. graft versus host disease) and complications (e.g. rejection, opportunistic infections). Many of these complications share a common pathogenic root, the immunosuppressed status of the transplanted individual, appear in all type of transplants, or even aggravate when several organs or SOT and HSCT are accomplished. Immune-mediated conditions present challenges because of their complexity and variety; however, they also provide research opportunities as biomarker discovery and novel therapeutics. Current transplantation outcomes in children, in terms of quality of life, morbidity and mortality can be improved. This requires better clinical management of associated complications by implementation of prognostic and diagnostic tools, for a precise and patient-centered monitoring of the transplantation process based on novel -omics and the development of innovative preventive and therapeutic procedures at all stages of transplant. The identification of patients likely to respond to novel procedures, as operational tolerance induction, would be important both in terms of health, and in terms of cost‐effectiveness. Innovative efforts are particularly challenging in paediatric transplantation, and requires dedicated coordinated efforts across pediatric-experienced institutions to overcome major challenges that are shared with others areas of research in RD: 1) existing fragmentation of efforts, data and resources in single organ-oriented efforts; 2) difficulties to re-use results of funded research; 3) the need for optimization of tools and resources that already exists and that can be adapted from their original design for primary disease diagnosis to the transplantation-related complications. Main tasks in the project per Pillar/WP: Pillar 0: WP1: Coordination and management Support of the ERN TransplantChild in the tasks. Pillar 2: WP 10: User-driven strategic planning and transversal activities Attending, participating and making decisions on the strategy at the annual retreats. Also depending on the strategic decisions, TransplantChild may be connected to the virtual platform and also may conduct POCs in WP13 depending on the POCs prioritised. Pillar 3: 825575 – EJP RD – Part B 188 WP 16: On line education course: Associated with document Ref. Ares(2018)6091977 - 28/11/2018 Task 16.1 "Assess the needs, target audience, main topics of the academic education course”. This task will be performed through a thorough benchmark of existing RD academic courses at EU level and through survey and audits of potential target audiences and experts involved in those courses (not restricted to students) and the main topics to address, the most relevant lecturers. Task 16.2 Developing the online course as Co-coordinators of development of training. E-learning approaches could combine different components: e-learning content, e-tutoring, collaborative learning, virtual classroom. The platform will develop and implement the e-learning scholar content received from lecturers. Pillar 4: WP20: Accelerating the validation, use and development of new methodologies tailored for clinical studies in RDs. As coordinators of the ERN TransplantChild and representing it, will participate in all the tasks related to the objectives of the WG. Previous experience relevant to the Tasks: TransplantChild would provide coordinated access to a comprehensive, accessible and interoperable suite of tools. We collaborate with FAIR clinical and standardized routine analytical data (collected in a pan-trasplant dedicated registry following recommendations of the DG Joint Research Centre (JRC), with identified relevant cohorts). With the aim to create a critical mass of collected biological samples, based on recommended and harmonized quality based banking procedures in each ERN HCP to increase and accelerate research opportunities. Stimulating a collaborative bridging of existing advanced data analytics services for generation and exploitation of –omics data, seeking the integration with existing European platforms, for the precise monitoring of the transplant procedure for children with rare diseases. TransplantChild provides effective interaction between patients, healthcare professionals, academics and researchers to support training activities to bridge the gap between patient needs, clinical practice and new treatment strategies at European, national and regional levels. We´ve created a best expertise knowledge platform (online) and Training Programs, based on e-learning modules, specific sessions in online courses. Collaboration with other ERNs focused on disease groups that require transplantation will be favored. Description of any significant infrastructure and/or major items of technical equipment, relevant to the proposed work : Biobank facility at Hospital premises, dedicated registry for all types of pediatric transplant procedure), integrative platform for collection and exploitation of clinical, routine lab and research data. Clinical simulation platform oriented to learn and train in the approach of the patient in critical clinical situations with the highest standards and equipment. Clinical Research Unit of Clinical Trials (UCICEC) with staff specialized in the management and development of clinical investigation and clinical trials including Phase I unit accredited. Short Profile of key Staff Members who will be undertaking the work Eduardo López Consultant Clinical Immunologist and PhD with 20 years’ experience in the diagnosis, genetic Granados and immunological characterization of Primary Immunodeficiencies (PIDs), a large group of (male) RD. Previous clinical and Research positions at NIAID/NIH and Human Immunology Unit at MRC Weatherall Institute of Molecular Medicine, Univ. of Oxford. Head of La Paz University Clinical Immunology Department. From the experience of PIDs, we are introducing cellular and molecular biomarkers for better definition of the secondary immunodeficiency and immune dysregulation generated by transplant procedures, for better clinical management of complications. TRANSPLANTChild Research Working Group Coordinator Antonio Pérez Paediatric Hemato-Oncologist with experience in hematopoietic stem cell Transplantation and Martínez Associated Professor of Paediatric at La Paz University Hospital (HULP), and Faculty of (male) Medicine of the Autonoma University, respectively, in Madrid, Spain. ERN TRANSPLANTChild Education and training Working Group Coordinator. Juan M.Torres MD, specialist in Clinical Immunology. Medical Supervisor of ERN-TRANSPLANTChild, Canizales participating in the organizational management and orientation of Research and Education and (male) Training, together with the rest of the network working groups. List of the most relevant publications and/or products, services or other achievements 1.Scientific communications about the ERN vision and orientation at: Third IRDiRC Conference on February 8-9, 2017 in Paris 2.Communication at European Conference on Rare Diseases & Orphan Products 2018 3. Oral presentation at the 5th National Congress of the Spanish Society of Transplantation 30 June 1 July 2018. 4. Continuous training course in paediatric transplantation focused on physicians, emphasizing a transversal and 825575 – EJP RD – Part B 189 holistic approach. The model used is a mixed platform: through Associated face-to-face training Ref. with document combined with multimedia Ares(2018)6091977 - 28/11/2018 and audio-visual materials available on the e-learning platform. 5. We promoted the short-term secondees program for medical specialists and specialist trainee who are currently dedicated to paediatric transplantation in any of any of the members for best practices sharing. List of relevant previous projects or activities, connected to the subject of this proposal - TRANSMIT: European TRAining Network on perSonalised Medicine for Tolerance in PaedIatric Transplantation; Innovative Training Networks (ITN) Call: H2020-MSCA-ITN-2018 (Submitted, on evaluation); Through multidisciplinary and multicentric approach strengthened by European-level cooperation and coordination, TRANSMIT will exploit immunological signatures in tolerance, alloreactivity and immunosuppression related biomarkers, allowing to centres of expertise and professionals in different countries to share knowledge of personalised medicine in PT recipient patients. - PRICISION: European Network on Paediatric transplantation Risk stratification by Immunological biomarkers-driven Clinical ImmunoSuppressIon decisiONs; COST Action OC-2017-1 (Submitted, on evaluation); The Aim of this Action is to establish a European-led multidisciplinary network of researchers collaborating in the validation and standardization of immune biomarkers for personalized immunosuppressive therapy in paediatric transplantation. - PETER: PaEdiatric Transplantation European Registry; HP-PJ-06-2016; The overall objective of the project is to create a new rational, efficient, interoperable, open, accessible and predictive paediatric transplant registry; the first that includes jointly solid organ transplantation (SOT) and hematopoietic stem cell transplantation (HSCT). 69-NUTH Full legal name (Acronym) – Country Newcastle-Upon-Tyne Hospitals NHS Foundation Trust (NUTH) Principal investigator Kate Bushby (as coordinator EURO-NMD) and Teresinha Evangelista David Jones (as coordinator RARE-LIVER) Andrew Cant (as Coordinator ERN RITA) Relevant Network ERN-EURO-NMD , ERN-Rare-Liver ,ERN-RITA Description of the legal entity/department/laboratory/group: NUTH has been providing patient-centred healthcare to communities in the North East of England and beyond for over 250 years. NUTH is one of the largest NHS trusts in the UK, offering a wider range of specialist services than any other. NUTH has a great deal of expertise in rare disease research and is the coordinator of three European Reference Networks (ERN): • ERN-EURO-NMD, the ERN for rare and complex neuromuscular diseases; • ERN-Rare-Liver for rare and complex hepatological diseases • ERN-RITA for Rare Immunodeficiency, auto inflammatory and autoimmune diseases. ERN-EURO-NMD is part of the Institute of Genetic Medicine (IGM). It is coordinated by Katie Bushby who is an honorary consultant at the world leading John Walton Muscular Dystrophy Research Centre. Her team based at the Institute of Genetic Medicine, Newcastle University and its associated hospitals work together towards the development and application of genomic and translational medicine to improve the health outcomes of people living with neuromuscular diseases. ERN-Rare-Liver (coordinated by Prof. Andrew Cant) and ERN-RITA (coordinated by Prof. David Jones) are part of the Institute of Cellular Medicine (ICM). Main tasks in the project per Pillar/WP: IGM PILLAR 2: WP10-Strategy. EURO-NMD and RITA will put themselves forward to join the monthly stakeholder board and annual meetings. The decision on exactly which ERNs will be represented on the board will be made at the up- coming ERN coordinators meeting. PILLAR 3 WP16 – Online Education course EURO-NMD has been approached by the WP lead (FFRD) and agreed to be involved in the development of an academic course this will include contributing to task 16.1-Assess the needs, target audience and main topics of 825575 – EJP RD – Part B 190 the academic training course. We will also contribute to task 16.2.2with Associated – document IdentifyRef. and work with relevant Ares(2018)6091977 - 28/11/2018 European Universities, learned societies and other institutions to develop the content of the academic course. WP17 – ERN RD Training and support Programme. Under this WP the ERN’s have been organized into four thematic diseases groupings. EURO-NMD will participate in Group 1 “Neuro”. ERN-RITA will participate in Group 2 ‘Neoplasm and Malformation”. ERN-Rare-Liver will participate in Group 3 “Organs”. Previous experience relevant to the Tasks: Within the IGM the team coordinates a number of relevant rare disease projects. Katie Bushby was a co- coordinator for TREAT-NMD and the coordinator of the EUCERD joint action on Rare diseases. The centre has the expertise and over 12 years of experience in the management and participation in EU funded initiatives. From 2006 to 2009, Andrew Cant was President of the European Society for Paediatric Infectious Diseases (ESPID). He is also a member of the Medical Advisory Board of the International Patient Organisation for Primary Immunodeficiencies (IPOPI). He has thus contributed strongly to the success of the ESID registry. He also has access (through ERN-RITA) to specific expertise in database interoperability. Short Profile of key Staff Members who will be undertaking the work - across all three departments Prof. David ICM, Coordinator of ERN-RARE-LIVER Jones David Jones is a NIHR Dean for Faculty Trainees and an active researcher in the area of Professor of Autoimmune Liver Disease, with a particular focus on the impact of the diseases on patients and Liver how we can improve outcomes through the development and evaluation of new treatment Immunology approaches. He co-wrote the European treatment guidelines for autoimmune liver disease upon which all current therapy is based. I lead the UK PBC Consortium which brings together all Male centres in the UK with the goal of improving therapy for everybody with autoimmune liver disease. David Jones is the coordinator of ERN-Rare Liver Prof. Andrew ICM, Coordinator of ERN-RITA Cant As Consultant in Newcastle for 24 years, he set up one of two national referral centres for the Hon Clin Prof treatment of children with severe immunological disorders and I am a world leader in the field of Paediatric childhood infection, immune disorders, and bone marrow transplantation, also holding clinics in Immunology Leeds, Scotland and Ireland he is a past President of the European Society for Paediatric Infectious Diseases and President Elect of the European Society for Immunodeficiencies. Male Professor Cant is a leading researcher and teacher of international repute, and in the last 28 years he has been awarded grants of over £7 million to support research into childhood tuberculosis, meningococcal disease, the epidemiology and pathology of primary immune deficiencies, defining the role of bone marrow transplantation as a treatment for primary immune deficiencies, viral infection in the immunocompromised host, polysaccharide antibody responses following solid organ transplantation and vaccine responses in preterm infants; leading to over 200 peer reviewed papers, his most recent leading work on the delineation of Activated Protein Kinase Delta syndrome. Dr. Teresinha IGM, Acting Coordinator of ERN-EURO-NMD Evangelista. Dr Teresinha Evangelista has over 20 years’ experience working as a Neurologist. Dr Teresinha Acting Evangelista played an important role in the development of a diagnostic network for EURO-NMD Neuromuscular Diseases during the years working in Portugal and was appointed as President of coordinator the Portuguese Society for The Study of Neuromuscular Diseases in 2009 in recognition of status as a leading reference for Neuromuscular Diseases in Portugal. Female Her work currently focuses on clinical and research work on hereditary muscle diseases, FSHD and Congenital Myasthenic Syndromes. Simultaneously as a member of the Joint Actions for rare diseases (EUCERD Joint Action and RD-Action), developed a particular interest on Rare Diseases policies. As a result of the policy work become responsible for the concept and setting up of the neuromuscular ERN (EURO-NMD) that integrates 61 healthcare providers from across Europe. 825575 – EJP RD – Part B 191 Associated with document Ref. Ares(2018)6091977 - 28/11/2018 Thus far, she has published over 70 peer-reviewed papers and 5 book chapters. She has given many invited lectures at meetings, symposiums and workshops as well as patient/parent organizations meetings. List of the most relevant publications and/or products, services (including widely-used datasets or software), or other achievements 1.Translational Summer School and wider NMD training programme 2. Neuropediatrics. 2017 Aug;48(4):211-220. doi: 10.1055/s-0037-1604110. Epub 2017 Jul 6. Translational Research in Europe for the Assessment and Treatment for Neuromuscular Disorders (TREAT-NMD). Leary R, Oyewole AO, Bushby K, Aartsma-Rus A. 3. Muscle Nerve. 2018 Mar;57(3):380-387. doi: 10.1002/mus.25991. Epub 2017 Nov 7. Chronic pain has a strong impact on quality of life in facioscapulohumeral muscular dystrophy. Morís G, Wood L, FernáNdez-Torrón R González Coraspe JA, Turner C, Hilton-Jones D, Norwood F, Willis T, Parton M, Rogers M, Hammans S, Roberts M, Househam E, Williams M Lochmüller H, Evangelista T. 4. Non-PTLD Malignancy post HSCT in patients with Primary Immunodeficiency: UK experience. Unni MNM, Elfeky R, Rao K, Nademi Z, Chiesa R, Amrolia P, Skinner R, Slater O, Worth A, Flood T, Abinun M, Hambleton S, Qasim W, Gaspar HB, Cant AJ, Gennery AR, Veys P, Slatter MA. J Allergy Clin Immunol. 2018 Mar 7. pii: S0091-6749(18)30391-9. doi: 10.1016/j.jaci.2018.02.038. 5. Clinical spectrum and features of activated phosphoinositide 3-kinase δ syndrome: A large patient cohort study. Coulter TI, Chandra A, Bacon CM, Babar J, Curtis J, Screaton N, Goodlad JR, Farmer G, Steele CL, Leahy TR, Doffinger R, Baxendale H, Bernatoniene J, Edgar JD, Longhurst HJ, Ehl S, Speckmann C, Grimbacher B, Sediva A, Milota T, Faust SN, Williams AP, Hayman G, Kucuk ZY, Hague R, French P, Brooker R, Forsyth P, Herriot R, Cancrini C, Palma P, Ariganello P, Conlon N, Feighery C, Gavin PJ, Jones A, Imai K, Ibrahim MA, Markelj G, Abinun M, Rieux-Laucat F, Latour S, Pellier I, Fischer A, Touzot F, Casanova JL, Durandy A, Burns SO, Savic S, Kumararatne DS, Moshous D, Kracker S, Vanhaesebroeck B, Okkenhaug K, Picard C, Nejentsev S, Condliffe AM, Cant AJ. J Allergy Clin Immunol. 2017 Feb;139(2):597-606.e4. doi: 10.1016/j.jaci.2016.06.021. Epub 2016 Jul 16. List of relevant previous projects or activities, connected to the subject of this proposal : TREAT-NMD: FP6, European commission, 2007-2011, Acted as coordinator. EU funded ‘network of excellence’ with the remit of ‘reshaping the research environment’ in the neuromuscular field. EURO-NMD: Third Health Programme, EC, 2017-2021, Current coordinator of the Network. EURO-NMD is one of the 24 European Reference Networks (ERNs) approved by the ERN Board of Member States. EURO-NMD facilitates discussion on complex or rare neuromuscular diseases and conditions that require highly specialised treatment, and concentrated knowledge and resources. ERN-Rare Liver and ERN-RITA: Third Health Programme, EC, 2017-2021, Current coordinators of the Network. EURO-NMD and ERN RITA are two of the 24 European Reference Networks (ERNs) approved by the ERN Board of Member States. 70-GOSH Full legal name (Acronym) – Country Great Ormond Street Hospital for Children NHS Trust (GOSH) Principal investigator Professor J Helen Cross Relevant Network EpiCARE Description of the legal entity/department/laboratory/group: Great Ormond Street Hospital (GOSH) is a large children’s hospital providing tertiary and quaternary services to children from across the UK and overseas. We provide the widest range of specialist paediatric health services on one site found in the UK. Together with our research partner, UCL Great Ormond Street Institute of Child Health we form the UKs only academic Biomedical Research Centre specialising in paediatrics Main tasks in the project per Pillar/WP: Pillar 2: In WP 10.2 & 10.4 (MEYER) Professor Renzo Guerrini, will to the annual retreats and guidance on priorities for Virtual Platform and FAIRification In WP11 (MEYER) we will contribute through Professor Renzo Guerrini with his knowledge and development of existing genetic epilepsy expertise, specifically his involvement in existing genetic epilepsy platform) 825575 – EJP RD – Part B 192 Pillar 3 Associated with document Ref. Ares(2018)6091977 - 28/11/2018 WP16.1 (GHE-HCL) Through Professor Alexis Arzimanoglou, assess the needs, target audience, main topics of the academic education course" as well as task 16.2.2. "Identify and work with relevant European Universities, learned societies and other institutions to develop the content of the academic course" Professor Arzimanoglou will also contribute, together with EATRIS, to Module 8 on Regulatory affairs. In the domain of the epilepsies there has been a regular collaboration between International League Against Epilepsy representatives and the EMA/FDA. Pillar 4 Task 20.1: Task Force Group WP 20 (GOSH) as a participant and contributor, and contributory to C4C, with regard to the set up and methodologies for clinical studies Previous experience relevant to the Tasks: Great Ormond Street Hospital (GOSH) is a major referral centre for rare and complex epilepsies in the UK, and coordinates the European Reference Network EpiCARE. With its partner organisation UCL-GOSH Institute of Child Health, it is part of the clinical trial network C4C and has participated in several European Funded research projects. Professor Renzo Guerrini has extensive experience in coordination of global epilepsy genetics projects including Epi4K, EuroEPINOMICS, Epi25 and as leader of the FP7 funded project DESIRE (Development and Epilepsy: Strategies for Innovative Research to improve diagnosis, prevention and treatment in children with difficult to treat Epilepsy) Professor Alexis Arzimanoglou leads the educational workpackage of EPiCARE. He is editor of the International League Against Epilepsy Educational journal Epileptic Disorders and leads on several course initiatives in rare and complex epilepsies. Description of any significant infrastructure and/or major items of technical equipment, relevant to the proposed work : All participants are centres within the European Reference Network for Rare and Complex Epilepsies EPiCARE. Short Profile of key Staff Members who will be undertaking the work Pr.Helen Cross Professor Helen Cross is The Prince of Wales’s Chair of Childhood Epilepsy and Head of the (female) Developmental Neuroscience Programme at UCL-Great Ormond Street Institute of Child Health, Honorary Consultant in Paediatric Neurology Great Ormond Street Hospital for Children NHS Foundation Trust, London and Young Epilepsy, Lingfield, UK. Her research has been targeted at improving outcomes in early onset epilepsy, specifically in assessing the role of surgery and ketogenic diet She leads the European Reference Network for Rare and Complex Epilepsies, EpiCARE Pr.Renzo Guerrini Renzo Guerrini is Medical Doctor; Neurologist; Child Neurologist and Psychiatrist; Clinical (male) Neurophysiologist. Current position: Professor of Child Neurology and Psychiatry, Director of Pediatric Neurology Unit and Laboratories, Children's Hospital A. Meyer-University of Florence. He was previously appointed Clinical Professor at Department of Neurology, GKT Medical, London, King’s College Hospital (1999-2001): Professor Pediatric Neurology, Institute of Child Health, University College London and Great Ormond Street Hospital (2001-2003). Pr.Alexis Alexis Arzimanoglou is currently consultant and Coordinator of the Epilepsy Program of the Arzimanoglou Epilepsy Unit at SJD Barcelona Children's Hospital and Director of the Epilepsy, Sleep and (male) Pediatric Neurophysiology Department at the University Hospitals of Lyon, France. He is also member of the DYCOG research team at the Centre de Recherche en Neurosciences de Lyon (France). His clinical and research activities are focused on: the pharmacological and surgical management of childhood epilepsies, the cognitive development and emotional regulation disorders in children with focal epilepsies List of the most relevant publications and/or products, services (including widely-used datasets or software), or other achievements 1. https://epi-care.eu/ 2. Blumcke I, Spreafico R, Haaker G, Coras R, Kobow K, Bien CG, Pfäfflin M, Elger C, Widman G, Schramm J, Becker A, Braun KP, Leijten F, Baayen JC, Aronica E, Chassoux F, Hamer H, Stefan H, Rössler K, Thom M, Walker MC, Sisodiya SM, Duncan JS, McEvoy AW, Pieper T, Holthausen H, Kudernatsch M, Meencke HJ, Kahane P, Schulze-Bonhage A, Zentner J, Heiland DH, Urbach H, Steinhoff BJ, Bast T, Tassi L, Lo Russo G, Özkara C, Oz B, Krsek P, Vogelgesang S, Runge U, Lerche H, Weber Y, Honavar M, Pimentel J, Arzimanoglou A, 825575 – EJP RD – Part B 193 Ulate-Campos A, Noachtar S, Hartl E, Schijns O, Guerrini R,Associated Barba with C, document Jacques Ref. TS,Ares(2018)6091977 Cross JH, Feucht M, - 28/11/2018 Mühlebner A, Grunwald T, Trinka E, Winkler PA, Gil-Nagel A, Toledano Delgado R, Mayer T, Lutz M, Zountsas B, Garganis K, Rosenow F, Hermsen A, von Oertzen TJ, Diepgen TL, Avanzini G; EEBB Consortium.Histopathological Findings in Brain Tissue Obtained during Epilepsy Surgery. N Engl J Med. 2017 Oct 26;377(17):1648-1656. 3. Whelan CD, Altmann A, Botía JA, Jahanshad N, Hibar DP, Absil J, Alhusaini S, Alvim MKM, Auvinen P, Bartolini E, Bergo FPG, Bernardes T, Blackmon K, Braga B, Caligiuri ME, Calvo A, Carr SJ, Chen J, Chen S, Cherubini A, David P, Domin M, Foley S, França W, Haaker G, Isaev D, Keller SS, Kotikalapudi R, Kowalczyk MA, Kuzniecky R, Langner S, Lenge M, Leyden KM, Liu M, Loi RQ, Martin P, Mascalchi M, Morita ME, Pariente JC, Rodríguez-Cruces R, Rummel C, Saavalainen T, Semmelroch MK, Severino M, Thomas RH, Tondelli M, Tortora D, Vaudano AE, Vivash L, von Podewils F, Wagner J, Weber B, Yao Y, Yasuda CL, Zhang G, Bargalló N, Bender B, Bernasconi N, Bernasconi A, Bernhardt BC, Blümcke I, Carlson C, Cavalleri GL, Cendes F, Concha L, Delanty N, Depondt C, Devinsky O, Doherty CP, Focke NK, Gambardella A, Guerrini R, Hamandi K, Jackson GD, Kälviäinen R, Kochunov P, Kwan P, Labate A, McDonald CR, Meletti S, O'Brien TJ, Ourselin S, Richardson MP, Striano P, Thesen T, Wiest R, Zhang J, Vezzani A, Ryten M, Thompson PM, Sisodiya SM. Structural brain abnormalities in the common epilepsies assessed in a worldwide ENIGMA study. Brain. 2018 Feb 1;141(2):391-408. 4. http://epilepsydesireproject.eu/ 5. http://www.jle.com/en/revues/epd/revue.phtml List of relevant previous projects or activities, connected to the subject of this proposal ERN EpiCARE; coordination funded through Chafea grant 769051 — EpiCARE 71-EORTC Full legal name (Acronym) – Country European Organisation for Research and Treatment of Cancer (EORTC)- BE Principal investigator Sandrine Marreaud, Saskia litière, Stéphane Lejeune Relevant Network EORTC, ERN EURACAN, IRCI, IRDIRC Description of the legal entity/department/laboratory/group: The EORTC is a non-profit international research organization created under Belgian law in 1962. Since its creation, the EORTC has contributed to improve the survival rates for several types of cancer through translational and clinical research. Over 50 EORTC sponsored clinical trials are open to patient recruitment at any given time. Both multinational and multidisciplinary, the EORTC Network comprises more than 4,000 collaborators from all disciplines involved in cancer treatment and research in more than 700 university hospitals in over 30 countries. The EORTC provides the know-how and the capacities to develop, perform, analysis and publish clinical research projects including clinical trial protocol development, trial design, trial coordination, medical review, translational research, pharmacovigilance, regulatory affairs management, contracts and insurances, Quality of Life/ PRO investigation, imaging platform, radiotherapy QA, CDISC compliant database development and data management, biostatistics, monitoring, QA/QC, etc.. The scientific activities of EORTC are strictly peer-reviewed and subject to quality assurance/quality control programs. The EORTC operates on an independent basis, and in this capacity is able to work in partnership with the pharmaceutical industry in evaluating innovative molecules. EORTC has contributed to several success stories in terms of new anti-cancer drug development including registrations by the FDA and the EMA. The EORTC has a proven track record in establishing new clinical standards, e.g. Response Evaluation Criteria In Solid Tumours (RECIST), quality of life of cancer patients, etc. The EORTC is running the SPECTA program to enable efficient access to molecular screening platforms for efficient biomarkers-driven clinical trials access in lung, colorectal, melanoma, brain, and rare cancers. EORTC works in partnership with various clinical research groups from Europe, America, Asia and Australia. Main tasks in the project per Pillar/WP: Pillar 2 – WP11 Multi-omics pipelines and reference maps for rare diseases research: pilot project in rare cancers if funded. Pillar 4 – WP20 Support office for clinical study: EORTC will provide advice and guidance to EURACAN selected clinical studies in rare cancers. Previous experience relevant to the Tasks: The EORTC holds a strong track record in the field of rare diseases. The EORTC has performed 62 international clinical trials over the past 15 years accruing a total of more than 20,123 patients in various rare disease entities such lymphomas, melanoma, leukemia, sarcoma, brain, lung, urogenital, head and neck, male breast, cutaneous T 825575 – EJP RD – Part B 194 cell lymphoma, mesothelioma, thymoma, and anal cancers. TheseAssociatedclinical with trials are multidisciplinary document and -involve Ref. Ares(2018)6091977 28/11/2018 various treatment modalities (chemotherapy, radiotherapy, surgery, hormonotherapy, targeted agent) alone or in combination. Recognizing the challenge of the complex diagnosis of rare cancers, mandatory central pathology review is enforced by EORTC and supported by international network of pathologists. Thanks to database centralization, consistent data collection, and strict quality control procedure, the EORTC has accumulated unique repositories of fully documented patient data and biological samples accessible for future research. Since 2011, the US National Cancer Institute, the UK National Clinical Research Network, Cancer Research UK and the EORTC decided to join force within the International Rare Cancers Initiative to perform new international clinical trials in rare cancers otherwise lacking infrastructural support. EORTC is member of IRDIRC. Description of any significant infrastructure and/or major items of technical equipment, relevant to the proposed work : Located in Brussels, the EORTC Headquarters with its 220 professionals is a unique facility in Europe. It provides scientific, legal, logistic, and administrative support to EORTC clinical and translational research activities with strong track record in the field of rare diseases. SPECTA is a standardized, quality-assured pan-European infrastructure collecting clinically annotated human biological material (HBM) and characterizing tumors for the purpose of biomarker discovery and ultimately integrating these newly discovered biomarkers into clinical trials. SPECTA is built on existing EORTC resources and expertise in clinical research. Amongst common cancer types, SPECTA is targeting rare cancers i.e., cancers with an incidence of less than 6/100,000 in the adult and teenager/young adult populations. Rare anal, biliary tract, neuroendocrine, endometrium, cervical, vulvar, lung, mesothelioma, thyroid, brain and sarcoma cancers will be considered in priority. The range of targeted cancer types is adapted according to the medical needs, the progress of science and the requirements from downstream research projects using SPECTA. Longitudinal patient follow-up with both clinical/pathological data and HBM collection take place for all consented SPECTA patients until death or loss to follow-up, irrespective of the patients' treatment as part of routine clinical care or participation in clinical trials within or outside the SPECTA structure (downstream clinical trial or any other clinical trial). Long-term patient follow-up (annually) enables continued acquisition of clinical data after all lines of treatment as part of routine clinical care or participation in a clinical trial. A systematic histopathological central assessment of the patient tissue sample is performed to confirm the rare cancer diagnosis and also to confirm that the quality of the material is adequate for further molecular testing(s). All analyses are centrally performed by high-quality laboratories selected according to the needs. Short Profile of key Staff Members who will be undertaking the work Msc Sandrine Head of the EORTC Medical Dept. She is a medical doctor specialized in pharmaceutical medicine Marreaud research with extensive experience in various types of cancers. She is supervising the Clinical (female) Research Physicians who coordinate and provide clinical and methodological support to EORTC clinical trials. PhD Saskia Biostatistician and associated head of the EORTC statistics Dept. Saskia has in depth expertise in Litière the design and analysis of clinical trials in various types of rare cancers. She is also a member of (female) the Response Criteria In Solid Tumors (RECIST) Working Group and is involved in the ongoing update of RECIST. MSc Head of European Program. Stephane is responsible for coordinating EORTC participation in EU Stephane funded projects. He will be the liaison person. He is experienced in various aspects of clinical Lejeune research operations. Stephane contributes to contract preparation with research group, and (male) laboratory. List of the most relevant publications and/or products, services (including widely-used datasets or software), or other achievements 1. Van den Bent M et al. Interim results from the CATNON trial (EORTC study 26053-22054) of treatment with concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma: a phase 3, randomised, open- label intergroup study. Lancet. 2017 Oct 7;390(10103):1645-1653. 2 Schöffski P et al. Activity and safety of crizotinib in patients with advanced clear-cell sarcoma with MET alterations: EORTC phase II trial 90101 ‘CREATE’. Annals of Oncology, Volume 28, Issue 12, 1 December 2017, Pages 3000–3008, 3. Perry J, et al. Short-Course Radiation plus Temozolomide in Elderly Patients with Glioblastoma. N Engl J Med 2017 Mar 16;376(11):1027-1037. 4. Baumert BG et al. Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study. Lancet Oncol. 2016 Nov;17(11):1521-1532 5. BOGAERTS J et al. Clinical trial designs for rare diseases: Studies developed and discussed by the International Rare Cancers Initiative. Eur J Cancer 2014; 51 (3):271-281. List of relevant previous projects or activities, connected to the subject of this proposal 825575 – EJP RD – Part B 195 - FP7 EUROSARC (European Clinical trials in Rare SarcomasAssociated within anwith integrated translational document Ref. trial network). Ares(2018)6091977 - 28/11/2018 EORTC is performing clinical trial. - FP7 EEC (EURO EWING Consortium – International Clinical Trials to Improve Survival from Ewing Sarcoma). EORTC is performing clinical trials. - H2020 MOTRICOLOR (Molecularly guided trials with specific treatment strategies in patients with advanced newly molecular defined subtypes of colorectal cancer). EORTC is performing clinical trials. - Associated partner to the ERN EURACAN in rare adult solid cancers, EORTC is the research infrastructure. - Collaborating partner to the Joint Action in rare cancers. EORTC is providing its expertise. 72-INFRAFRONTIER Full legal name (Acronym) – Country INFRAFRONTIER GmbH, Germany Principal investigator Martin Hrabe de Angelis Relevant Network INFRAFRONTIER Description of the legal entity/department/laboratory/group: INFRAFRONTIER is the European research infrastructure for the development, phenotyping, archiving and distribution of mammalian models. It is a distributed research infrastructure with partners in 15 European countries. The core services of INFRAFRONTIER comprise the development and systemic phenotyping of mammalian disease models, and the archiving and distribution of mouse mutant lines by the European Mouse Mutant Archive (EMMA). All INFRAFRONTIER resources and services can be accessed at www.infrafrontier.eu. The INFRAFRONTIER GmbH was established in April 2013 as management and coordination unit of the INFRAFRONTIER Research Infrastructure. It is based in Germany at the Helmholtz Zentrum München. The INFRAFRONTIER GmbH is responsible for developing the INFRAFRONTIER GmbH resources and services, for providing transnational access and for operating the INFRAFRONTIER IT infrastructure. It is also the contact point for all stakeholders of the INFRAFRONTIER Research Infrastructure and coordinates the networking and outreach activities. Main tasks in the project per Pillar/WP: Pillar 2: WP11: Common platform for discoverable data and resources for RD research; contribution of metadata and ontological models related to INFRAFRONTIER mouse mutant resources (task 2.1) to a FAIR compliant platform for discovery of RD resources (tasks 2.2 and 2.3) Previous experience relevant to the Tasks: INFRAFRONTIER operates the EMMA database and actively compiles Rare Disease relevant mouse mutant resources, which will be contributed to the common EJP RD platform for discoverable data and resources for RD research. Furthermore, INFRAFRONTIER has considerable expertise in running EU funded Trans-national Access service calls, which will inform the set-up of the EJP RD brokerage system e.g. regarding service contributors, proposal evaluation and service call administration. Description of any significant infrastructure and/or major items of technical equipment, relevant to the proposed work : INFRAFRONTIER GmbH operates the EMMA database and hosts the INFRAFRONTIER web portal at www.infrafrontier.eu. Short Profile of key Staff Members who will be undertaking the work Pr. Martin Hrabé Full professor and chair at the Technical University in Munich and holds the chair of De Angelis Experimental Genetics. At the same time he serves as director of the European Mouse (male) Mutant Archive (EMMA). His research focus is on large-scale mutagenesis, functional genomics, stem cell biology and metabolic research. He founded the German Mouse Clinic (GMC) for systemic analysis of human diseases. He is member of the Project Committee of the German National Genome Network (NGFN) for which he served as spokesman from 2006 to 2009. Prof. Dr. Hrabé de Angelis coordinated the INFRAFRONTIER preparatory phase project and other national and international research consortia funded by the German government and the European Commission (FP6/7). He is member of the Executive Steering Committee of the International Mouse Phenotyping Consortium (IMPC) and founding member and member of the Board of the German Center for Diabetes Research (DZD). Since April 2014 he serves as Scientific Director of the INFRAFRONTIER GmbH. Prof. Dr. Dr. h.c. Martin Hrabè de Angelis received numerous awards and honours. Dr. Michael Räß, Trained biologist and research manager. He did his PhD thesis in behavioral physiology in 825575 – EJP RD – Part B 196 (male) 2006. After working for two years as a postdoc Associatedinwith this field, Ref. document he changed in 2008- 28/11/2018 Ares(2018)6091977 to the Helmholtz Zentrum München as lead project manager for the INFRAFRONTIER Preparatory Phase and head of the INFRAFRONTIER Project Office. In 2010 he received a MSc degree in „Science Communications and Marketing“. Since 2014 he is Head of General Management of the INFRAFRONTIER GmbH. Michael Raess is the Leader of the CORBEL Work Package 5 (Common Solutions for User Access). Dr Sabine Fessele Dr. Sabine Fessele studied Technical Biology at the University of Stuttgart. After doing her (female) PhD in cellular and molecular immunology at LMU Munich, she worked as project manager for NascaCell GmbH in the department of Functional Biology. In another biotech start-up company, EPIDAUROS Biotechnologie AG, she held the position of Data Manager. She started to work as project manager for the Helmholtz Zentrum München in 2006 and coordinated several areas of the European Mouse Mutant Archive (EMMA). Since 2013 Sabine Fessele is a PMI-certified Project Management Professional (PMP®) and since 2015 she is the Head of Unit - Operations and IT of the INFRAFRONTIER GmbH. Philipp Gormanns Philipp Gormanns studied bioinformatics at the universities LMU and TUM in Munich. He (male) worked as a bioinformatics scientist in the Max-Planck Institute of Psychiatry in the field of biomarker discovery for depression and anxiety from 2007 to 2011. From 2012 to 2015 he was working at the Helmholtz Zentrum München as an IT scientist for the German Mouse Clinic and technical project lead for BioMedBridges. Since 2016 he is Senior Developer at the INFRAFRONTIER GmbH. List of the most relevant publications and/or products, services (including widely-used datasets or software), or other achievements 1. Meehan TF, et al. 2017. Disease model discovery from 3,328 gene knockouts by The International Mouse Phenotyping Consortium. Nature genetics, 2017-06-26 2. Meehan TF, et al. 2015. INFRAFRONTIER – providing mutant mouse resources as research tools for the international scientific community. Nucleic Acids Research 43, D1171-1175 3. Hrabě de Angelis M, et al. 2015. Analysis of mammalian gene function through broad-based phenotypic screens across a consortium of mouse clinics. Nature Genet 47(9), 969-978 4. INFRAFRONTIER portal providing access to EMMA mouse mutant resources www.infrafrontier.eu 5. IMPC portal providing access to IMPC phenotyping data www.mousephenotype.org List of relevant previous projects or activities, connected to the subject of this proposal . INFRAFRONTIER2020, Horizon2020, 2017-2020 - Towards enduring mouse resources and services advancing research into human health and disease . CORBEL, Horizon2020, 2015-2019 - Coordinated Research Infrastructures Building Enduring Life-science Services . IPAD-MD, Horizon2020, 2015-2019 - Research Infrastructures for Phenotyping, Archiving, and Distribution of Mouse Disease Models - Promoting International Cooperation and User Engagement to Enhance Biomedical Innovation . RItrain, Horizon2020, 2015-2019 - Research Infrastructures Training Program . INFRAFRONTIER-I3, FP7, 2013-2016 - Development of mouse mutant resources for functional analyses of human diseases - Enhancing the translation of research into innovation 73-BBMRI Full legal name (Acronym) – Country Biobanking and BioMolecular resources Research Infrastructure - European Research Infrastructure Consortium (BBMRI-ERIC), AT Principal investigator Erik Steinfelder Relevant Network BBMRI-ERIC Description of the legal entity/department/laboratory/group: The pan-European Biobanking and BioMolecular resources Research Infrastructure - European Research Infrastructure Consortium (BBMRI-ERIC) improves the accessibility and interoperability of the existing comprehensive collections, either population-based or clinical-oriented, of biological samples from different (sub)populations of Europe. These collections include the attached data on factors such as health status, nutrition, lifestyle, and environmental exposure of the study subjects. Combined with the expertise of the clinicians, 825575 – EJP RD – Part B 197 pathologists, bio-informaticians, and molecular biologists involved, a globally Associated unmatched, with document Europe-wide platform Ref. Ares(2018)6091977 - 28/11/2018 for translational medical research is envisaged with the aim to develop personalized medicine and disease prevention for the benefit of European citizens. To reach this goal, also biotech and pharmaceutical industry must have a possibility to collaborate with academic researchers in order to fully realize the enormous potential of European biobanking. In addition to clinical, ethical and legal experts, patient communities are involved to achieve standards and guidelines that properly balance individual values, such as protection of privacy and informed consent, with shared values of facilitated access to progress in health care and disease prevention. On 3 December 2013, BBMRI was officially awarded the Community legal framework for a European Research Infrastructure Consortium (ERIC). This specific legal form is designed to facilitate the joint establishment and operation of research infrastructures of European interest. The ERIC status allows pulling together biobanks and biomolecular resources into a pan-European facility and providing access to collections of partner biobanks and biomolecular resources, their expertise and services on a non-economic basis. BBMRI-ERIC shall establish, operate and develop a pan-European distributed research infrastructure of biobanks and biomolecular resources in order to facilitate the access to resources as well as facilities and to support high quality biomolecular and medical research. BBMRI-ERIC operates on a non-economic basis. BBMRI-ERIC is set up as a distributed research infrastructure in most, if not all European Member States. BBMRI-ERIC consists of 19 Member States and one International Organisation, making it one of the largest research infrastructures for health research in Europe. Members: Austria, Belgium, Czech Republic, Estonia, Finland, France, Germany, Greece, Italy, Latvia, Malta, the Netherlands, Norway, Poland, Sweden, and the United Kingdom. Observer Countries: Cyprus, Switzerland, Turkey, IARC/WHO Main tasks in the project per Pillar/WP: Pillar 2 Petr Holub BBMRI-ERIC will lead tasks on technical GDPR implementation (Task 10.3) and Quality oversigth (Task 10.4), and it will contribute to federated searches architectures (Tasks 11.2 and 12.1), machine readable access (Task 12.1), integration of existing services into Orphanet catalog (Task 11.1), and brokering hosting services for FAIR data provisioning (Task 12.3). Pillar 3 Michaela Th. Mayrhofer Within Pillar 3, BBMRI-ERIC will contribute with its expertise in ethical, legal and societal matters related to rare diseases. In particular, it will share its experience in operating the custom based ELSI Helpdesk and self-service Knowledge Base. Additionally, BBMRI-ERIC commits to host a 3-day training workshop in Graz ensuring awareness raising and appropriate knowledge transfer (Task 14.4). Previous experience relevant to the Tasks: BBMRI-ERIC designs, implements and operates its IT services via its Common Service IT (CS IT), with particular attention to biobanks dealing with human biological material and data. It delivers both centralized and distributed findability (Directory and Locator services), accessibility (Negotiator), interoperability (MIABIS data model), and reusability (common inteoperable provenance model developed within ISO TC276 WG5). Together with BBMRI- ERIC Rare Diseases Working Group it delivers services specific to RD community, such as RD section of BBMRI- ERIC Directory and Helpdesk for Rare Diseases. BBMRI-ERIC has also commitment to sustainably operate selected outcomes of RD-Connect, namely Registry & Biobank Finder (aka ID-cards) and Sample Catalogue. BBMRI-ERIC Negotiator is also being extended by the RD-Connect to implement the access pipeline for rare disease resources within RD-Connect. Description of any significant infrastructure and/or major items of technical equipment, relevant to the proposed work : BBMRI-ERIC Common Services form a key element for the research infrastructure as they provide the biobanking community and biobank users with expertise, services and tools specific to biobanking. The Common Services are established under BBMRI-ERIC and under the responsibility of its Director General. The ELSI Helpdesk is a personalised support service assisting researchers who have ethical, legal and societal questions in the context of a research project. We offer assistance on topics that are crucial in biobanking, such as informed consent and data protection amongst others, in order to promote compliance with regulatory requirements and best practice principles Short Profile of key Staff Members who will be undertaking the work Dr Petr Holub Associate Professor of computer science at Masaryk University, the second largest (male) university in the Czech Republic. He has background both in sciences (MSc with specialization on computational quantum chemistry in 2001) and computer science (PhD in 2005, specializing on computer networks, self-organizing systems and multimedia processing). He was head of the Division of Communication Technologies at Institute of 825575 – EJP RD – Part B 198 Computers Science, Masaryk University, as well aswith Associated architect documentof advanced Ref. multimedia Ares(2018)6091977 and - 28/11/2018 collaborative systems of the Czech national e-infrastructure developed and operated by CESNET. His research in computer networks and multimedia processing has lead to more than 40 research papers in established computer science journals and ranked conferences, as well as to practical software systems and patents. Since 2011, he has been responsible for design and development of IT infrastructure of the Czech BBMRI, as well as its subsequent operation using national research cloud e-infrastructure CERIT-SC. He is also responsible for the IT and data management infrastructure of the ongoing EU THALAMOSS project, focusing on data collection and processing for stratification of patients suffering from thalassaemia. He has been a contributor to a number of international and national projects linking computer science and biomedicine. He joined BBMRI-ERIC as its IT/Data Protection Manager in January 2015. Dr. Michaela Political scientist and historian by training. She was educated in Vienna, Louvain-la-Neuve, Mayhofer Essex and Paris. In 2010, she has earned her PhD from both the Ecole des Hautes Etudes en (male) Sciences Sociales and the University of Vienna, which was shortlisted by the Austrian Society for Political Science for 'best thesis 2010'. Prior to her involvement in BBMRI- ERIC, she was investigator in several national and international research projects focusing on the politics of biotechnology and the life sciences, especially the governance of biobanks. Her academic career led to various positions at the Centre de Recherche Médecine, Sciences, Santé et Société, the University of Vienna, the Institute of Science, Technology and Society Studies at Alpen-Adria-Universität Klagenfurt/ Vienna/Graz, the Technical University of Vienna and the Medical University of Graz. Today, she serves as the Chief Policy and Coordination Officer of BBMRI-ERIC and leads the Code of Conduct for Health Research Initiative. List of the most relevant publications and/or products, services (including widely-used datasets or software), or other achievements 1. Michaela Th. Mayrhofer (2013): About the New Significance and the Contingent Meaning of Biological Material and Data in Biobanks. IN: Hist. Phil. Life Sci 35, 449‐467. 2. Michaela Mayrhofer (2008): Patient Organisations as the (Un)Usual Suspects in Biomedical Research, IN H. Gottweis & A. Petersen (Ed.): Biobanks: Governance in Comparative Perspective, Routledge, p. 71‐87. 3. Mayrhofer MT, Holub P, Wutte A, Litton JE (2016): BBMRI-ERIC: the novel gateway to biobanks. From humans to humans. IN: Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2016 Mar;59(3):379-84. doi: 10.1007/s00103-015-2301-8. 4. Holub, P., Mayrhofer MT, Wutte, A et.al. (2018): Enhancing Reuse of Data and Biological Material in Medical Research: From FAIR to FAIR-Health. IN: Biopreservation and Biobanking, see https://doi.org/10.1089/bio.2017.0110 List of relevant previous projects or activities, connected to the subject of this proposal . 1. BioSHaRE: https://www.bioshare.eu/ . 2. BBMRI-LPC: http://www.bbmri-lpc.org/ . 3. SPIDIA4P: http://www.bbmri-eric.eu/scientific-collaboration/spidia4p/ . 4. BioMedBridges: http://www.biomedbridges.eu/ . 5. CORBEL: http://www.corbel-project.eu/home.html 74-ECRIN/PedCRIN Full legal name (Acronym) – Country European Clinical Research Infrastructure Network (ECRIN)- France Principal investigator Jacques Demotes Relevant Network ECRIN, PEDCRIN project Description of the legal entity/department/laboratory/group: The European Clinical Research Infrastructure Network (ECRIN, www.ecrin.org) is a sustainable, not-for-profit, distributed infrastructure with the legal status of a European Research Infrastructure Consortium (ERIC). ECRIN provides support for the planning and implementation of multinational clinical research projects in Europe. ECRIN currently has eight Member Countries (France, Germany, Spain, Italy, Portugal, Hungary, Czech Republic and Norway) and one Observer Country (Switzerland). Additional countries are about to join. ECRIN provides services for the management of multinational -investigators initiated and SME sponsored- trials; 825575 – EJP RD – Part B 199 central services (data management through ECRIN certified data centres, central Associated vigilance) with document and distributed services Ref. Ares(2018)6091977 - 28/11/2018 provided by the ECRIN partner in each country involved (regulatory and ethical submissions and follow-up, monitoring, local vigilance, project management etc.). As part of its trial support activities, ECRIN develops and maintains freely accessible tools such as databases on regulatory and ethical issues, outcome measures, and risk-based monitoring. ECRIN contributes to capacity building projects aiming to establish shared services in biomedical areas, and to foster international cooperation in non-commercial trials. ECRIN organisation: ECRIN’s ‘distributed infrastructure’ includes a Core Team based in Paris, France (headquarters) and European Correspondents (EuCos) working in each Member and Observer Country and hosted by the national scientific partners (networks of academic clinical trial units (CTUs) and/or clinical research centres (CRCs)). ECRIN scientific partners (a total of 80 CTUs and CRCs) are the final service providers for ECRIN-supported clinical trials; they provide services and expertise under the coordination of ECRIN. ECRIN has also partners in other countries in Europe and internationally with which it collaborates. Main tasks in the project per Pillar/WP: In WP 20, ECRIN will be in charge of the clinical trial helpdesk (tasks 20.1 and 20.2). ECRIN will also provide its regulatory and ethical expertise in the WP4 task 4.2. Previous experience relevant to the Tasks: -Development of tools and operational services for multinational clinical trials in Europe and in particular for rare diseases through the ECRIN-IA project -Leader of the Medical Infrastructure work package in the CORBEL cluster project -Co-secretariat (with US NIH) of the CRIGH (clinical research initiative for global health) promoting international cooperation in clinical trials. Short Profile of key Staff Members who will be undertaking the work Jacques Director General of ECRIN. Professor of cell biology, clinical neurologist. Dr Demotes was Demotes, MD, the coordinator of ECRIN’s four FP6- and FP7-funded projects, which supported the PhD, MBA (male) sustainable development of ECRIN as a pan-European infrastructure with “ERIC” status (awarded in 2013). He has participated in more than 50 FP6, FP7, H2020 and IMI-funded projects. Christine Operations Director of ECRIN. She holds a PhD from University Paris XI in pharmaceutical Kubiak, PharmD, sciences. She has more than 20 years’ experience in the planning, setup, and management of PhD (female) multinational clinical trials and in the coordination of clinical programmes in the pharmaceutical industry. At ECRIN since 2006, she played a key role in ECRIN’s FP6 and FP7 funded projects. She currently oversees projects development and implementation, and contributes to strategy and business development. Sabine Kläger, ECRIN Clinical Operations Manager since October 2017. She has over 30 years of experience PhD, MSc (Biol.), in biomedical research, initially in the field of tropical diseases, including drug development MSC programmes from P1 to P3, and the use of new medicines in mass treatment programmes (Epidemiology), across endemic areas (Africa, South America), and later in the planning, setup, and DLSHTM management of multi-national clinical trials in various therapeutic areas in the UK and (female) Europe. Since 2003 she was working for academic Sponsors, ensuring the implementation of necessary regulatory requirements to comply with the EU Directives on Clinical Trials, including the set-up and operational and strategic management of a CTU for Cambridge University-Hospital partnership. Currently, she is also chairing the DMECs for 3 drug trials, running across several Sub-Saharan countries Salma Malik, PEDCRIN project manager. Holds a PhD in paediatric clinical endocrinology and has PhD (female) experience in the development and conduct of paediatric clinical trials and paediatric research projects. List of the most relevant publications and/or products, services (including widely-used datasets or software), or other achievements 1.European Clinical Research Infrastructures Network: promoting harmonisation and quality in European clinical 825575 – EJP RD – Part B 200 research. Demotes-Mainard J, Ohmann C. Lancet. 2005 Jan 8-14;365(9454):107-8 Associated with document Ref. Ares(2018)6091977 - 28/11/2018 2.Cloud computing' and clinical trials: report from an ECRIN workshop. Ohmann C et al. Trials. 2015 Jul 29;16:318. doi: 10.1186/s13063-015-0835-6. 3 A systematic literature review of evidence-based clinical practice for rare diseases: what are the perceived and real barriers for improving the evidence and how can they be overcome? Ana Rath et al. Trials. 2017 Nov 22;18(1):556. doi: 10.1186/s13063-017-2287-7. 4.Global health: Boost multinational clinical research. Demotes-Mainard J et al. Nature 545:289 (2017) doi:10.1038/545289b 5.Sharing and reuse of individual participant data from clinical trials: principles and recommendations. Christian Ohmann et al. BMJ Open. 2017 Dec 14;7(12):e018647. doi: 10.1136/bmjopen-2017-018647 List of relevant previous projects or activities, connected to the subject of this proposal : -ECRIN-IA: European Clinical Research Infrastructures Network - Integrating Activity, including a competitive call to support multinational trials (FP7 Infrastructure 2011; grant number 284395) (ECRIN coordinator) -PedCRIN: Paediatric Clinical Research Infrastructure Network (H2020-INFRADEV-2016-2017; grant number 731046) (ECRIN coordinator) -CORBEL: Coordinated Research Infrastructures Building Enduring Life-science Services (H2020 INFRADEV-4- 2014/2015; grant number 654248) -CRIGH: Clinical Research Initiative for Global Health (Collaboration Agreement between international partners in order to promote and develop international collaboration) -TRANSVAC: European Vaccines Research and Development Infrastructure (H2020 INFRAIA-2016-1- grant number 730964) 75-EATRIS Full legal name (Acronym) – Country EATRIS-ERIC (EATRIS)- The Netherlands Principal investigator Toni Andreu (MD, PhD) Relevant Network EPTRI, CORBEL Description of the legal entity: EATRIS, the European Infrastructure for Translational Research offers a new collaboration model for fostering innovation. The infrastructure plays a fundamental role in the advancement of knowledge and technology in translational research and drug development. With over 90 leading institutes, across 12 EU Member States, EATRIS provides access to the entire pipeline of academic translational infrastructure and expertise, and optimises the route from discovery to proof-of-concept in medicines development. It provides a new development pathway, open to academic researchers and companies in need of support for advancing biomedical innovations. The EATRIS ‘Coordination & Support’ office employs 14 people, with expertise ranging from project management, marketing, and technology transfer to translational product development. EATRIS is a European Research Infrastructure Consortium (ERIC) since 2013, a legal entity established by the European Commission to facilitate the operation of international research infrastructures. Main tasks in the project per Pillar/WP: Pillar 0 - Coordination and Transversal activities In WP1, we will support the coordinator with the overall management of the project by being part of the operating group (tasks 1.1; 1.2; 1.3) In WP2, we will be involved in the development of EJP RD research and innovation strategy by contributing to the mapping exercise (tasks 2.2; 2.4) In WP3, we will co-lead WP activities, contribute to the design of a service roadmap and catalogue and lead the task aiming at preparing the EJP-RD sustainability plan with business plan (tasks 3.1; 3.2; 3.3) In WP4, we will provide advice on regulatory procedures (task 4.2) In WP5, we will contribute to the implementation of the communication and dissemination strategy of the project (task 5.1) Pillar 1 In WP8, we will co-develop the rare disease research challenges (tasks 8.1; 8.2; 8.3; 8.4) Pillar 3 In WP16, we will contribute to the development of online courses (task 16.2) Pillar 4 In WP19, we will act as co-WP leader and will be involved in all tasks to provide researchers with the right support 825575 – EJP RD – Part B 201 to conduct translational research (tasks 19.1; 19.2; 19.3; 19.4) Associated with document Ref. Ares(2018)6091977 - 28/11/2018 Previous experience relevant to the Tasks: Examples of services provided by the Coordination Office of EATRIS since 2013: EATRIS Matchmaking: EATRIS matches clients’ needs to the specific capabilities and expertise of the institutions, relying on a sophisticated and detailed database outlining EATRIS institutional capabilities. The EATRIS operational model in which a large consortium operates under harmonized conditions and a framework agreement, offers user the same reach of a consortium, but with the safety and effectiveness of a bilateral relationship. This service lies at the heart of EATRIS operations, has been offered to an increasing number of users since 2013, ranging from biotech companies to academia and pharmaceutical industry. EATRIS Inside: EATRIS has worked together with funders and charities to bring the European-wide EATRIS expertise and infrastructure ‘inside’ their funding procedure. Principal Investigators, shortlisted by the funder, are invited by the funding agency or the charity to contact EATRIS for translational optimisation of their proposal. EATRIS then performs a preliminary assessment of the translational feasibility of the project based on the elements available: unmet medical need and clear end-product definition; preliminary analysis of the intellectual property status; technical feasibility and regulatory pathway. Based on this potential assessment, the PI completes their full proposal for subsequent review by the funder. EATRIS has already piloted successful collaboration with several funders and charities (for instance, ZonmW - The Netherlands Organisation for Health Research and Development- and Rheumafonds). Innovation Management: EATRIS has been responsible for the facilitation of multiple public-private collaboration, involving SME’s and also large pharma. Additionally, since 2015, it has been leading the WP dedicated to Accelerating Innovation of CORBEL (see below), and set up an Innovation Helpdesk, providing partnering, legal, IP support to other biological and medical research infrastructures. Business planning: EATRIS has been in charge of drafting the sustainability plan of TRANSVAC-2 (see below), as well as the business plan of EPTRI (see below). Description of any significant infrastructure and/or major items of technical equipment, relevant to the proposed work : N/A Short Profile of key Staff Members who will be undertaking the work Anton Ussi Operations & Finance Director for EATRIS C&S. Anton Ussi has a background in engineering (male) and SME administration. He is a specialist in the establishment and execution of strategic public- private and public- public collaborations based on the deployment of high value translational research infrastructure for medicine. Anton has been co-responsible for the development of several ongoing public private partnerships and spin-out companies, among which the €130 million VU University Medical Imaging Center Amsterdam, and the Dutch Imaging Hub, a public-private translational initiative with Roche-Genentech and three Dutch university medical centers. Tim Moser EATRIS industry partnering specialist, educated in biology, later combining an MBA in Supply (male) Chain Management. His work experience includes scientific research, evolving into operational and site management in life sciences companies. Since 2010 he works in technology transfer and specializes in industry partnering. As former business developer for Industry Alliance Office of Neuroscience Campus Amsterdam, Tim has developed and negotiated collaboration agreements with many different companies ranging from biotech to international big pharma. He specializes in identifying the frontier areas in academic translational medicine that spark interest for industry and pursuing ideal routes toward partnership. Rosan Vegter After graduating and working as an emergency vet for several years, she has worked in (female) pharmaceutical industry where she completed a PhD on the Challenges in the Clinical Development of Orphan drugs. At EATRIS, she is in charge of the coordination and implementation of training activities. One of her main activities has been developing curricula for PhDs and Postdocs involved in translational medicine for the Erasmus+ funded C-COMEND project. Furthermore, she is part of the communication team as content writer. List of the most relevant publications and/or products, services (including widely-used datasets or software), or other achievements 1. G.A.M.S. van Dongen, et al. EATRIS, a European initiative to boost translational biomedical research. Am J Nucl Med Mol Imaging. 3, 166-174 (2013). 2. CT. Gilliland, et al. Putting translational science on to a global stage. Nat. Rev. Drug Discov. 15, 217–8 (2016). 3. A.E. Ussi, et al. In Search of System-Wide Productivity Gains - The Role of Global Collaborations in 825575 – EJP RD – Part B 202 Preclinical Translation. Clin. Transl. Sci. 10, 423–425 (2017). Associated with document Ref. Ares(2018)6091977 - 28/11/2018 4. A.J. Van Gool, et al. Bridging the translational innovation gap through good biomarker practice. Nat Rev Drug Discov, (2017). List of relevant previous projects or activities, connected to the subject of this proposal 1. CORBEL (H2020, 654248) (2015-2019): Coordinated Research Infrastructures Building Enduring Life- science Services project of thirteen biological and medical research infrastructures (BMS RIs), creating a platform for harmonised user access to biological and medical technologies, biological samples and data services required by cutting-edge biomedical research. EATRIS is leading the Innovation WP, which provides support for RI on public-private collaboration and industry partnering. 2. C-COMEND (Erasmus Plus, 2015-1-NL01-KA203-008986) (2015-2017): Project coordinated by EATRIS along with academic and SME partners to develop a competency profile, e-learning and face-to- face courses on medicines development for PhD students and PostDocs. 3. ID-EPTRI (H2020, 777554) (2018-2020): the project aims at designing the business and governance model for an infrastructure for pediatrics translational research. EATRIS leads the WP dedicated to Governance and is responsible for delivering the business and governance models. 76-ELIXIR Full legal name (Acronym) – Country European Molecular Biology Laboratory (EMBL) (ELIXIR, EMBL-EBI) Principal investigator Niklas Blomberg Relevant Network ELIXIR Description of the legal entity/department/laboratory/group: The European Molecular Biology Laboratory (EMBL; http://www.embl.org/ ) was established in 1974 and is supported by over twenty countries. EMBL is a centre of excellence for research in molecular biology. EMBL is a centre of excellence for research in molecular biology. It is a distributed international research organization (24 member states) with its main laboratory in Heidelberg. Research at EMBL emphasizes experimental analysis at multiple levels of biological organisation, from the molecule to the organism. One of EMBL’s five core missions is to develop and make available new technologies for the Life Sciences. Accordingly, EMBL has an extensive success record in developing new biology-driven technologies and providing service- oriented user infrastructures including the Advanced Light Microscopy Facility (ALMF) offering external user access, a high-throughput light microscopy screening facility, the Centre for Bioimage Analysis, the Electron Microscopy Core Facility (EMCF) and the EMBL-EBI data resources. Another core mission of EMBL is to provide advanced training to researchers, which is organized by the EMBL International Centre for Advanced Training (EICAT) and encompasses the EMBL International PhD Programme (EIPP), the EMBL Postdoctoral Programme and the Visitors Programme as well as a large number of workshops, courses and conferences. EMBL maintains strong interactive relationships to the major life science research institutions in Europe and has more than 40 years of experience in integrating European research. In addition to EMBL in Heidelberg, the European Bioinformatics Institute (EMBL-EBI) in Hinxton is involved in Euro-BioImaging and will host the general data services of EuBI ERIC. Established in 1996, EMBL-EBI (http://www.ebi.ac.uk/ ) is an outstation of the EMBL and has a long-standing mission to collect, organise and make available databases for biomolecular science. EMBL-EBI makes available a collection of databases along with tools to search, download and analyse their content. These databases include nucleotide sequences (European Nucleotide Archive), protein sequences (UniProt), structures (PDBe), genome annotation (Ensembl), gene expression information (ArrayExpress), molecular interactions (Intact) and pathways (Reactome). Connected to these are linking and descriptive data resources such as protein motifs (InterPro), ontologies and many others. In many of these efforts the EMBL-EBI is a European node in global data-sharing agreements. ELIXIR (https://www.elixir-europe.org/) is an inter-governmental organisation, which builds on existing life sciences data resources and services within Europe to orchestrate the collection, quality control and archiving of large amounts of biological data. It follows a hub-and-nodes model, with a single Hub located at EMBL-EBI in Hinxton, Cambridge, UK (with EMBL providing the legal entity) and a growing number of Nodes located at centres of excellence throughout Europe. ELIXIR is an ESFRI Research Infrastructure in permanent operations phase since 2013. The ELIXIR Consortium Agreement established ELIXIR as an independently governed entity within the legal framework of EMBL. To date, 21 countries plus EMBL have signed the consortium agreement: Belgium, Czech Republic, Denmark, Estonia, Finland, France, Germany, Hungary, Ireland, Italy, Israel, Luxembourg, the Netherlands, Norway, Portugal, Slovenia, Spain, Sweden, Switzerland, UK and Greece. In May 825575 – EJP RD – Part B 203 2014 ELIXIR was one of only three priority projects identified by ESFRI Associated as mature with document enough to support Ref. Ares(2018)6091977 for - 28/11/2018 implementation in 2015-2016. Governments and ministries of ELIXIR Member States are responsible for contributing funding for the ELIXIR Hub and coordinating the scientific community in their country into a national Node that provides services to the ELIXIR community, including data resources, tools, Compute provision, Standards development, Training and support to Industry. Main tasks in the project per Pillar/WP, Description of Beneficiaries and Third Parties involvement. Pillar 0 Transversal activities: In WP1: Coordination and management ● ELIXIR Hub will be co-leading Task 1.3 Monitoring of the EJP RD activities and achievements KPI definition and Subtask 1.3.1 Identification of key performance indicators In WP2: Integrative research and innovation strategy ● DTL-Projects(ELIXIR-NL) will contribute to Task 2.1 Prioritization scheme for EJP RD actions and Task 2.2 Mapping the research and innovation needs In WP4: Ethical, regulatory, legal and IPR framework of the EJP RD ● ELIXIR Hub will be contribute to Task 4.2 Managing ethical and regulatory issues Pillar 2: In WP10: User-driven strategic planning and transversal activities for Pillar 2 data ecosystem ● ELIXIR Hub will be co-leading Task 10.3 Coordination of technical implementation of General Data Protection Regulations (GDPR) task. ● ELIXIR Hub will be co-leading Task 10.4 Quality oversight task ● DTL-Projects (ELIXIR-NL) will be leading Task 10.5 Developing sustainable models. ELIXIR Hub will be contributing to this task also. In WP 11: Common virtual platform for discoverable data and resources for RD research ● EMBL-EBI will be leading Task 11.1 Metadata and ontological model definition for cataloging resources for RD research task. SIB(ELIXIR-CH) will also be contributing in this task, to define an ontological model compatible with existing key databases and resources. ● DTU(ELIXIR-DK) and BSC(ELIXIR-ES) will be contributing to the Subtask 11.2.3 To make relevant RD analysis tools and methods discoverable, the ELIXIR's bio.tools catalogue will continue its adaptation for the RD community initiated in EXCELERATE ● EMBL-EBI will be leading Task 11.3 Data deposition and access to data infrastructures for RD research. CSC(ELIXIR-FI) and MU-CERIT-SC (ELIXIR-CZ) will be contributing to Subtask 11.3.2 Implement a unified authentication and authorisation mechanism, based on ELIXIR’s AAI. EMBL-EBI, ELIXIR Hub, CSC(ELIXIR-FI), BSC(ELIXIR-ES) and UU(ELIXIR-SE) will be contributing to Subtask 11.3.4 develop data deposition guidelines and documentation. ● BSC(ELIXIR-ES) and SIB(ELIXIR-CH) will be contributing to Task 11.4 Provision of analysis and data sharing capabilities to the RD community through online resources to Provide RD phenotype- genotype analysis and data sharing capabilities through the RD-Connect platform for molecular diagnostics and gene discovery. EMBL-EBI, CSC(ELIXIR-FI), BSC(ELIXIR-ES), UU(ELIXIR-SE) and SIB(ELIXIR-CH) will contribute to Subtask 11.4.2 collaborative integrated analysis of multi-omics data from selected use cases. BSC(ELIXIR-ES) will contribute to Subtask 11.4.3 provide capabilities for custom analyses through cloud-based solutions. EMBL-EBI, BSC(ELIXIR-ES) and UU(ELIXIR-SE) will contribute to Subtask 11.4.4 user-driven implementation of new analysis functionalities and tools task. In WP12: Enabling sustainable FAIRness and Federation at the record level for RD data, patients and samples ● EMBL-EBI will contribute to Subtask 12.1.2 federation architectures, and networks registers. CSC(ELIXIR-FI) will also contribute to Subtask 12.1.3 implement machine readable access (e.g., consent & use conditions, governance, identifiers, security, anonymization). EMBL-EBI will contribute to Subtask 12.1.4 Query languages and Subtask 12.1.5 data exchange formats and ontologies & semantics for record- level clinical and preclinical information. ● EMBL-EBI will contribute to Subtask 12.3.2 Brokered hosting service for FAIR data provision, discovery and matchmaking. SIB(ELIXIR-CH) will contribute to Subtask 12.3.3 FAIRification service for data from Pillar 1 studies, from Pillar 2-WP1 activities, and prioritized EU data sources. In WP13: Enabling multidisciplinary, holistic approaches for rare disease diagnostics and therapeutics EMBL-EBI and SIB(ELIXIR-CH) will contribute to Subtask 13.1.3 the Mapping (combinations) of variants to protein function task. 825575 – EJP RD – Part B 204 Pillar 3: Associated with document Ref. Ares(2018)6091977 - 28/11/2018 In WP14: Training on data management & quality ● CNR (ELIXIR-IT) and DTL-Projects(ELIXIR-NL) will contribute to Task 14.5 training on rare disease registries and FAIRification of data at the source. In WP16: Online Academic education course ● UL(ELIXIR-SI) will be co-leading the Biotechnologies & bioinformatics: databases, NGS and -omics interpretation tools module of the online academic course. ● UCAM(ELIXIR-UK) will be leading Task 16.3 Follow-up, evaluation and monitoring, UNIMAN(ELIXIR-UK) will be also contributing to this task Previous experience relevant to the Tasks: The utility of the EMBL-EBI to the scientific community today is evidenced by massive use of its services. EMBL- EBI’s web portals receive over 27 million requests per day from 5 million unique IP addresses, 12 million compute jobs per month are executed on EMBL’s cores.The community served ranges from basic academic researchers through to applied research in diverse areas including pharmaceuticals, agriculture and nutrition. Alongside the core service activities, the EMBL-EBI is a basic research institute, with bioinformaticians regularly publishing the biological findings of computational investigations of biomolecular information. The constituency of the EMBL- EBI most emphatically includes the commercial sector as well as academic research. It has a flourishing Industry Programme and SME engagement activities for European companies involved in bioinformatics. EMBL-EBI also provides a substantial proportion of EMBL's external training. ELIXIR is an inter-governmental organisation, which builds on existing life sciences data resources and services within Europe. It currently works across 21 member states and the EMBL-EBI, collectively reaching nearly 200 institutes involved in Bioinformatics research or service provision. ELIXIR’s core role is to orchestrate the collection, quality control and archiving of large amounts of biological data, with a strong focus on ensuring that these data are made as FAIR (Findable, Accessible, Interoperable and Reusable) as possible. During the past 4 years, ELIXIR has sought to be guided by the scientific community through the establishment of Use Cases, which have included Human Data, Rare Diseases, Plant Sciences and Marine Metagenomics. Through these efforts ELIXIR has ensured that the key Bioinformatic services and resources are increasingly accessible to and embedded across LIfe Science Research in the EU. Description of any significant infrastructure and/or major items of technical equipment, relevant to the proposed work: EMBL-EBI manages large-scale biological databases, which are available to clients via web services 24/7/365. The demand for rapid access to all publicly available biological databases is constantly growing, as is the volume of biological information held within the databases. To support these needs, EMBL-EBI manages an infrastructure of extensive, high-performance compute infrastructure along with large data-storage farms. EMBL-EBI's state-of- the-art technical architecture is secure and robust, and is distributed in four discrete, Tier 3+ security data centres in different geographical locations to assure long-term security. This gives our data very high protection through redundancy, and provides sufficient capacity and reserve to ensure our management of the rising influx of data and compute requests. In August 2013 our main compute farm has ~17,000 cores and the installed disk based storage capacity is above 30 Petabytes. Part of EMBL-EBI’s core mission is to maintain large life science archives hosting critical reference data for research. This includes ENSEMBL and genome archives; the EGA for human genomes and UniProt. The ELIXIR Hub is charged with coordination activities, whilst the Nodes provide the service delivery of the key bioinformatics resources. The largest ELIXIR Node is EMBL-EBI and delivers some of Europe’s key bioinformatics services, which are described above. Further information can be found at: www.ebi.ac.uk Short Profile of key Staff Members who will be undertaking the work Dr. Niklas ELIXIR Director, Project Coordinator. Dr. Blomberg joined ELIXIR as Director in 2013 Blomberg following 14 years in the pharmaceutical industry with AstraZeneca. He led the global (M) cheminformatic function from 2006-2011 with responsibility for global delivery of novel computational approaches and external partnerships in screening, and in 2011-2013 led the build of new computational biology / computational chemistry unit for the AZ inflammatory research area. He has also previously been the Chairman of the board for Bioinformatics for Life Science in Sweden (BILS), Chair of the advisory board for the Swedish e-Science for Cancer prevention and cure project, Advisory board member for the Swedish eScience center and the IMI eTRIKS project. He was co-chair for IMI OpenPHACTS, a project with 24 industrial and academic 825575 – EJP RD – Part B 205 partners to develop standards and infrastructure for with Associated effective document data-interoperability across Ref. Ares(2018)6091977 - 28/11/2018 chemistry and biology for drug-discovery research Dr. Helen EMBL-EBI, Team Leader: Head of Molecular Archives comprising three teams and 85 people Parkinson (F) delivering core databases, data coordination activities, semantic data integration tools. Her team deliver the BioSamples database, the Ontology Lookup Service, the Knockout Mouse Project 2 informatics, PDX resources and the Human Cell Atlas Data Coordination. She is a also partner in Infrafrontier. Dr Johanna EMBL-EBI, Team Leader: Literature services. Dr. McEntyre has been Team Leader for McEntyre (F) Literature Services at EMBL-EBI since 2009. She is the PI for Europe PMC - the database of abstracts and full-text articles for the life sciences. Prior to joining EMBL-EBI, Jo was a staff scientist at the NCBI, National Library of Medicine, NIH, USA, and was the Editor at Trends in Biochemical Sciences (TiBS), Elsevier. Jo is active in the Force 11 Data Citation Implementation Group, and is interested in text mining as a means to improve the integration of literature with public data resources. Dr Steven EMBL-EBI, Head of Technical Services. Dr Newhouse leads 5 teams comprising over 85 people Newhouse supporting EMBL-EBI’s various IT functions. This includes the teams delivering the 200+PB of (M) storage and over 30,000 cores of cloud, HTC and HPC analysis platforms, the database, desktop and cloud support functions, hosting of public web services and tools, development of web sites and more general open-source software development and operations which include the EBI Cloud Portal and GA4GH compatible task-based analysis platforms. Dr Thomas EMBL-EBI, Team Leader: European Genome Phenome Archive (EGA), the European Variation Keane (M) Archive (EVA), as well as the Archival Infrastructure for the European Nucleotide Archive (ENA) at EMBL-EBI. He is responsible for strategic planning for EGA, ENA (AI) and EVA, is a member of the Global Alliance for Genomics and Health (GA4GH) steering committee and leads the Large Scale Genomics workstream. He is the scientific lead for the Mouse Genomes Project, a collaboration with the Wellcome Sanger Institute. Sandra EMBL-EBI, Team Leader: Protein Function Content team. Responsible for the curation of Orchard (F) UniProt at EMBL-EBI, and annotation of the Gene Ontology, carrying out manual annotation and producing the rules for automated annotation. The team also create and maintain value-added interfaces for exploring protein data, for example the Enzyme Portal and Complex Portal. Sandra additionally works on standards development in protein data capture and annotation and is Co- Chair of the HUPO Proteomics Standards Initiative Claire EMBL-EBI, Head of Metabolomics. Provides the biomedical community with information on O'Donovan metabolism: small molecules and their interplay with biological systems. Responsible for (F) MetaboLights, a resource for data from metabolomics experiments and derived information. The database is cross-species, cross-technique and covers metabolite structures and their reference spectra as well as their biological roles, locations and concentrations, and experimental data from metabolic experiments. Also responsible for PhenoMeNal, a comprehensive and standardised e- infrastructure that supports the data processing and analysis pipelines for molecular phenotype data generated by metabolomics applications. Dr Fiona EMBL-EBI, Team Leader: Variation Annotation team. Fiona is part of the senior management for Cunningham Ensembl (www.ensembl.org), a genome information system. Her team developed Ensembl's (F) Variant Effect predictor (VEP), the software tool for annotating variation data, and led the creation of the variation and phenotype data in Ensembl. Fiona works very closely with the GENCODE project to improve transcript annotation for clinically relevant genes. Her team deliver robust and reliable reference resources for consistent variant annotation in any species. She is also a co-PI on the NHGRI-EBI GWAS Catalog project. List of the most relevant publications and/or products, services (including widely-used datasets or software), or other achievements: 1. Postmitotic nuclear pore assembly proceeds by radial dilation of small ER membrane openings. Otsuka S, Steyer AM, Schorb M, Heriche JK, Hossain MJ, Sethi S, Schwab Y, Beck M, Ellenberg J. Nat Struct Mol. Biol. 2018 Jan; 25(1):21-8. Epub 2017 Nov 27. 2. Sister chromatid resolution is an intrinsic part of chromosome organization in prophase. Nagasaka K, Hossain MJ, Roberti MJ, Ellenberg J, Hirota T. Nat Cell Biol. 2016 Jun;18(6):692-9. doi: 10.1038/ncb3353. Epub 2016 May 2. 3. Inverted light-sheet microscope for imaging mouse pre-implantation development. Strnad P, Gunther S, Reichmann J, Krzic U, Balazs B, de Medeiros G, Norlin N, Hiiragi T, Hufnagel L, Ellenberg J. Nature 825575 – EJP RD – Part B 206 Methods. 2016 Feb;13(2):139-42. Epub 2015 Dec 14. Associated with document Ref. Ares(2018)6091977 - 28/11/2018 4. High-throughput fluorescence correlation spectroscopy enables analysis of proteome dynamics in living cells. Wachsmuth M, Conrad C, Bulkescher J, Koch B, Mahen R, Isokane M, Pepperkok R, Ellenberg J. Nat Biotechnol. 2015 Apr;33(4):384-9. Epub 2015 Mar 16. 5. Nuclear Pore Scaffold Structure Analyzed by Super-Resolution Microscopy and Particle Averaging Szymborska A, de Marco A, Daigle N, Cordes VC, Briggs JAG, Ellenberg J. Science. 2013 Aug 9;341(6146):655-8. Epub 2013 Jul 11. 6. van Gool, A. J., Bietrix, F., Caldenhoven, E., Zatloukal, K., Scherer, A., Litton, J.-E., et al. (2017). Bridging the translational innovation gap through good biomarker practice. Nature Reviews Drug Discovery, 16(9), 587–588. http://doi.org/10.1038/nrd.2017.72 7. Durinx, C., McEntyre, J., Appel, R., Apweiler, R., Barlow, M., Blomberg, N., et al. (2016). Identifying ELIXIR Core Data Resources. F1000Research, 5, 2422. http://doi.org/10.12688/f1000research.9656.1 8. Auffray, C., Balling, R., Barroso, I., Bencze, L., Benson, M., Bergeron, J., et al. (2016). Making sense of big data in health research: Towards an EU action plan. Genome Medicine, 8(1), 860. http://doi.org/10.1186/s13073-016-0323-y 9. Wilkinson, M. D., Dumontier, M., Aalbersberg, I. J., Appleton, G., Axton, M., Baak, A., et al. (2016). The FAIR Guiding Principles for scientific data management and stewardship. Scientific Data, 3, 160018. http://doi.org/10.1038/sdata.2016.18 10. Budd, A., Corpas, M., Brazas, M. D., Fuller, J. C., Goecks, J., Mulder, N. J., et al. (2015). A quick guide for building a successful bioinformatics community. PLoS Computational Biology, 11(2), e1003972. http://doi.org/10.1371/journal.pcbi.1003972 11. CE Cook, MT Bergman, G Cochrane, R Apweiler, E Birney. 2018. The European Bioinformatics Institute in 2017: data coordination and integration. Nucleic acids research 46 (D1), D21-D29 DOI: 10.1093/nar/gkx1154 List of relevant previous projects or activities, connected to the subject of this proposal: . Project coordinator of ELIXIR-EXCELERATE (2015-2019): an H2020 project (H2020-INFRADEV- 1-2015-1) Fast-track ELIXIR implementation and drive early user exploitation across the life sciences, Grant number: 676559, 2015-2019 . Project Coordinator of CORBEL (2015-2019): an H2020-funded cluster project of the thirteen ESFRI biological and medical research infrastructures (BMS RIs), which together have created a platform for harmonised user access to biological and medical technologies, biological samples and data services required by cutting-edge biomedical research. EMBL is co-leading the WP4 on the open call for users to common service pipelines commonly offered by the ESFRI BMS RIs. . Project Coordinator of BioMedBridges (2011-2015): a joint effort of twelve biomedical sciences research infrastructures on the ESFRI roadmap to develop the shared e-infrastructure—the technical bridges—to allow data integration in the biological, medical, translational and clinical domains. . Project Coordinator of Euro-BioImaging Preparatory Phase I: an ESFRI infrastructure project that will provide open user access to state-of-the-art imaging technologies in biological, molecular and medical imaging for life scientists in Europe and beyond, including advanced light microscopy and electron microscopy technologies. EMBL-HD (ALMF) participated in Euro-BioImaging Proof-of-Concept studies in 2012 during which it hosted external Euro-BioImaging users. . Partner in iNEXT consortium (infrastructure for NMR, EM and X-rays for Translational research), providing access to Advanced light microscopy and Electron microscopy techniques. . Project Coordinator of Euro-BioImaging Preparatory Phase II: EuBI PPII project aims not only at submitting the ERIC application to the European Commission but also at enabling the rapid finalization of the legal, financial, managerial and technical documents, tools and procedures to start the operation of the EuBI ERIC on the day of the signature of the ERIC statutes by all its member states. . Project Coordinator of Global BioImaging: Funded by the European Commission’s Horizon 2020 Programme it has received 1.78M €, to achieve multi-lateral international cooperation between Euro- BioImaging and its infrastructure counterparts in six countries (Argentina, Australia, India, Japan, South Africa, the USA) in the field of life sciences - including biological sciences, marine biology, biodiversity, medical sciences and agricultural sciences. GBI enables Euro-BioImaging to exchange best practice with its international infrastructure partners on open user access to their various services, and in the long term to pursue international agreements on the reciprocal use of these services Third parties involvement: 1. BSC (ELIXIR-ES) 2. CSC (ELIXIR-FI) 825575 – EJP RD – Part B 207 3. CNR (ELIXIR-IT) Associated with document Ref. Ares(2018)6091977 - 28/11/2018 4. DTU (ELIXIR-DK) 5. MU-CERIT-SC (ELIXIR-CZ) 6. SIB (ELIXIR-CH) 7. UCAM (ELIXIR-UK) 8. UU (ELIXIR-SE) 9. UNIMAN (ELIXIR-UK) 10. DTL-Projects (ELIXIR-NL) 11. UL (ELIXIR-SI) 77-EURORDIS Full legal name (Acronym) – Country EURORDIS-Rare Diseases Europe (EURORDIS) Principal investigator Virginie Bros-Facer Relevant Network EURORDIS Description of the legal entity/department/laboratory/group: EURORDIS-Rare Diseases Europe is a non-governmental patient-driven alliance of patient organisations representing 792 rare disease patient organisations in 69 countries and is the voice of the estimated 30 million patients affected by rare diseases throughout Europe. EURORDIS’ vision is to enable better lives and cures for people living with a rare disease and its mission is to work across borders and diseases to improve the lives of people living with a rare disease. Since its creation in 1997, EURORDIS has gained significant and well-recognised experience in networking and capacity building for patient organisations, in information sharing as well as in policy development, regulatory affairs, medicines development and patient engagement in RD research and research infrastructure projects. EURORDIS promotes, supports and coordinates the patient engagement with most of the stakeholders involved during the lifetime of a medicinal product. Main tasks in the project per Pillar/WP: Pillar 1: In WP8 (RD Research challenges), EURORDIS will be the co-leader (leader FFRD) of this WP, responsible for the development of the scheme (leader of task 8.1) and participant in task 8.2 and 8.3 to set up the challenges and support the evaluation of funded projects. Pillar 3: EURORDIS is co-leader of Pillar 3 with VUHSK In WP15, we will lead task 15.1 “ExPRESS Expert Patients and Researchers EURORDIS Summer School” In WP15, we will lead task 15.2 “Training for patient advocates on scientific innovation and translational research” In WP15, we will lead task 15.3 “training for patient advocates and representatives on leadership and communication skills”. In WP15, we are also participant in task 15.4 co-lead by TEDDY and FSJD to develop education materials and activities for paediatric patients. In WP18, we are co-leader with CHMI, supporting VUH as leader of this WP and we lead task 18.1 with FFRD on “Evaluation of developing needs according to progress of work in Pillars 2 and 4 and relevant adaptation of training activities”. Coordination & Transversal activities: As Pillar 3 leader, EURORDIS is a member of the Operating Group and is involved as a participant in Pillar 0 WP1, WP2, WP3, WP4 and WP5. Previous experience relevant to the Tasks: Virginie Bros-Facer (VBF) previously worked for the NC3Rs in the UK, the organisation who pioneered the CRACK IT challenges which is the funding model to be used to develop the RD Research challenge in Pillar 1 WP3 and therefore has a deep and detailed understanding of the mechanisms used in this innovative funding scheme. Furthermore, as Scientific Director, VBF represent EURORDIS is RD research and research infrastructure projects (see below) as well as other relevant European and international initiatives (IRDiRC, UDNI, SWAN Europe, Go FAIR RD Network, BBMRI-ERIC Stakeholders forum), bringing the RD patient voice & perspectives and developing specific capacity building programmes to engage and support RD patient representatives in these projects and initiatives. Description of any significant infrastructure and/or major items of technical equipment, relevant to the proposed work : N/A 825575 – EJP RD – Part B 208 Short Profile of key Staff Members who will be undertaking the work with document Ref. Ares(2018)6091977 - 28/11/2018 Associated Dr. Virginie Bros- Virginie Bros-Facer is Scientific Director at EURORDIS-Rare Diseases Europe. Her Facer responsibilities include monitoring the European landscape on rare disease research from a (female) strategy, policy and action perspectives, overseeing and managing all activities related to rare disease research, diagnostics, infrastructures and technologies as well as related ethical issues. Prior to joining EURORDIS, she worked for several research funding organisations in the UK, including as Director of Medical Research for Sparks, a children's medical research charity based in London and as Research Funding Programme Manager for the NIHR and the National Centre for Replacement, Reduction and Refinement of Animals in Research (NC3Rs under the MRC umbrella). Virginie holds an MSc and a PhD in Neuroscience from King's College London and also worked for 7 years at the UCL Institute of Neurology in London on several research projects aiming to develop new therapeutic strategies for motor neuron disease and other neuromuscular disorders. Nancy Hamilton Nancy Hamilton is part of the EURORDIS Operations team, her work is centred around (female) empowering patients’ advocates. She coordinates the organisation of the capacity-building EURORDIS Summer School, Winter School and the EURORDIS e-learning tools. She is the contact person at EURORDIS for the EUPATI and ECRIN projects respectively to develop a European Patients Academy and to set up a European Clinical Research Infrastructure Network. Her previous experience includes working as Education Resource Coordinator at the European Haematology Association in Rotterdam where she played a key role in the development of the European Haematology CME system. Nancy has a passion for human rights and volunteers at Amnesty International France and is currently completing a legal diploma (Capacité en Droit) at the Faculté de Droit of the University of Paris Sorbonne Panthéon. Nancy has a B.A. in medical sociology and an M.A in French literature. List of the most relevant publications and/or products, services (including widely-used datasets or software), or other achievements 1.The voice of 12.000 patientshttp://www.eurordis.org/IMG/pdf/voice_12000_patients/EURORDISCARE_FULLBOOKr.pdf 2. Position paper of EURORDIS on Rare Diseases Research (2012) http://www.eurordis.org/sites/default/files/EURORDIS_Rapport_Research_2012.pdf 3. International Joint Recommendations to address specific needs of Undiagnosed Rare Disease Patients (2016) https://www.eurordis.org/publication/international-joint-recommendations-address-specific-needs-undiagnosed-rare- disease-patients 4. Rare disease patients’ participation in research: a report on the results of the Rare Barometer survey on rare disease patients' participation in research (2018). https://www.eurordis.org/publication/rare-disease-patients-participation- research List of relevant previous projects or activities, connected to the subject of this proposal . IRDiRC; Virginie Hivert (EURORDIS Therapeutic Development Director) is co-chair of the Therapeutic Scientific Committee and Virginie Bros-Facer (EURORDIS Scientific Director) is a member of the Patient Advocacy Constituent Committee . RD-Connect; FP7; 2013-2018- EURORDIS is WP8 leader (patient engagement), member of the Executive Management Committee and chair the Patient Advisory Council comprised of 16 rare disease patient representatives representing 15 rare diseases and European countries supporting their active involvement in the different WPs of the project (Biobanks, registries, bioinformatics tools, communication and the phenome-exome analysis platform). RD- Connect’ s resources are represented throughout the EJP in Pillar 2 and Pillar 3. . Solve-RD; H2020; 2018-2022- EURORDIS is a partner in several WPs and is responsible for the creation and animation of the Community Engagement Task Force aiming at supporting the interaction and the engagement with the different initiatives and networks currently existing in the field of diagnosis at the European and International levels. EURORDIS will also develop the first 2 editions of the Winter School (Patient Capacity Building Programme on Scientific Innovation and Translational Research in 2018 and 2019, to be developed further in Pilar 3, WP2.2 from 2020). . European Reference Networks; EC; 2017-2021-EURORDIS is responsible for the creation of all 24 European Patient Advocacy Groups (ePAGs) involved in the different ERNs. EURORDIS actively supports the activities of the 24 ePAGs communities in all ERNs and provides capacity building for these RD patient representatives within the different networks (link with future training activities in Pillar 3, WP2.3). . Connect for Children (C4C); IMI2; 2018-2023- EURORDIS is a partner involved in 6 work packages and will work together with the Sant Juan de Deu Foundation (co-leader of WP2.4 with Teddy in Pillar 3) to specifically engage 825575 – EJP RD – Part B 209 young rare disease patients in the development of the pan-European Associated with paediatric document Ref.clinical trials network Ares(2018)6091977 and - 28/11/2018 infrastructure. 78-CSO-MOH Full legal name (Acronym) – Country Chief Scientist Office, Ministry of Health (CSO-MOH), Israel Principal investigator Irit Allon Relevant Network https://www.health.gov.il/English/Pages/HomePage.aspx Description of the legal entity/department/laboratory/group: If the Beneficiary is composed of several teams (a, b, c) and you decide to replicate this table several times, there is no need to repeat the “legal entity” description in each of the tables. Main tasks in the project per Pillar/WP: Pillar 1: In WP6, we will participate in the Joint Transnational Calls In WP7, we will lead Task 7.1 Public Call document for networking scheme In WP9, we will lead the WP on Monitoring of the funded projects and be the leaders of Tasks 9.1, 9.2, 9.3 Previous experience relevant to the Tasks: In the last 14 years, CSO-MOH has been actively involved in several health- related Era-Nets and JPIs. In particular, CSO-MOH has been responsible for science to society issues, communication and dissemination and young scientists. In the last year CSO-MOH has added another field of interest, monitoring, which is currently done in the framework of E-RARE-3 and ERA-Net Per-Med. In the EJP, it will be the first time that CSO-MOH leads the entire WP and responsible for all the tasks within it. Short Profile of key Staff Members who will be undertaking the work Pr. Abraham Prof. Avi Israeli, MD, is the Chief Scientist at the Ministry of health. He is a specialist in internal Israeli medicine and the current head of the Department of Health Policy, Health Care Management and (male) Health Economics at the Hebrew University – Hadassah Faculty of Medicine. Prior to this he was the Director General of the Israel Ministry of Health (2003-2009) and the Director – General of Hadassah Medical Organization (1998 -2001).Prof. Israeli is an NSC member in several ERA- Nets, CSAs and JPIs. Dr. Irit Allon Dr. Irit Allon, DMD, Ph.D is the director of the medical research department.She is the previous (female) national coordinator of several ERA-Nets and JPIs in the CSO-MOH. She is a specialist in Oral pathology and since 2005 has gained experience in managing ERA-Nets and leading the Science to Society and Communication & Dissemination activities. She is the former national coordinator of ERA-NET PathoGenoMics, ERA-Age1 and 2, FUTURAGE and the current liaison of E- RARE, Infect-ERA, EuroNanoMed2, and JPIAMR at the CSO-MOH. Dr. Nava Dr. Nava Levine, PhD, is the national coordinator of several ERA-Nets in the CSO-MOH. She is Levin the projects manager in the Israeli association for cardiovascular research and has coordinated (female) ERA-Nets in the CSO-MOH during 2006-2013 mainly focused on the Science to Society and Communication & Dissemination activities. Ms. Elina Ms. Elina Kushnir is the- ICT director in CSO-MOH, supporting the technical and financial Kushnir aspects of ERA-NET activities. (female) 79-SNSF Full legal name (Acronym) – Country Swiss National Science Foundation (SNSF), Switzerland Principal investigator None Relevant Network ERANET E-RARE Description of the legal entity/department/laboratory/group: Mandated by the federal government, the Swiss National Science Foundation (SNSF) supports basic science in all academic disciplines, from history to medicine and the engineering sciences. The SNSF is Switzerland’s foremost research funding organisation. The SNSF was established as a private foundation in 1952. Main tasks in the project per Pillar/WP: The tasks of the SNSF is to participate in the implementation and execution of four Joint Transnational Calls for collaborative research projects. 825575 – EJP RD – Part B 210 Pillar 1: Associated with document Ref. Ares(2018)6091977 - 28/11/2018 In WP6, we will participate in: Task 6.1 Joint Transnational Call 2019 (JTC 2019): Call co-funded by the EC for three years Task 6.2 Joint Transnational Call 2020 (JTC 2020): Call co-funded by the EC for two years Task 6.3 Joint Transnational Call 2021 (JTC 2021): call not co-funded by the EC Task 6.4 Joint Transnational Call 2022 (JTC 2022): call not co-funded by the EC Previous experience relevant to the Tasks: The SNSF is a longstanding funding partner in the ERANET E-RARE and member of the E-RARE Steering Committee. Short Profile of key Staff Members who will be undertaking the work Dr. Christoph Meier Head of Section Clinical, Social and Preventive Medicine SNSF (male) Dr. Ayşim Yilmaz Head of Department Biology and Medicine SNSF (male) List of relevant previous projects or activities, connected to the subject of this proposal . The SNSF has participated in ERANET E-RARE Joint Transnational Calls since 2013. 80-BLACKSWAN Full legal name (Acronym) – Country BLACKSWAN Foundation, Switzerland Principal investigator Olivier Menzel Relevant Network E-Rare, Eurordis, NIH, RDI, UDNI, IRDiRC, ProRaris Description of the legal entity/department/laboratory/group: The BLACKSWAN Foundation was established in Switzerland in 2010 to contribute to the development of research on rare and orphan diseases worldwide. The Foundation supports research on all different types of rare and orphan disease, which makes its vision unique and helps in finding new solutions that can assist a large variety of projects. Besides its funding research mission, the Foundation organizes every two years the RE(ACT) Congress, which became an international reference point for rare disease experts. In 2014, the BLACKSWAN Foundation launched the RE(ACT) Community a crowdfunding and a knowledge sharing digital platform that connects researchers, patients and other rare disease stakeholders. Since 2015, BLACKSWAN Foundation has also started an international advocacy and awareness campaign called #RAREvolution to ensure rare diseases are recognized as an international public health and research priority. Main tasks in the project per Pillar/WP: Pillar 0: Transversal WP (WP5 external
Allikas: Sotsiaalministeerium dokumendiregister →
dokumendiregister.eeAsutusedEesti avalike dokumendiregistrite otsing · nimistu.ee andmetel